



# Acta Haematologica

International Journal of Haematology – Journal International  
d'Hématologie – Internationale Zeitschrift für Hämatologie

Official Organ of the European Division of the International Society  
of Haematology

## EDITORS

- |                              |                                 |                              |
|------------------------------|---------------------------------|------------------------------|
| A. ALDER, Aarau              | J. GUARCO, Barcelona            | W. P. MICKFET, Boston, Mass. |
| H. ALEXANDER, Santiago       | G. HINGELER, Lausanne           | E. NIELMARK, London          |
| G. BECKEL, Genève            | A. HITTMAIR, Innsbruck          | N. G. NORDSTRÖM, Stockholm   |
| R. M. von BOWENHOF, Helsinki | P. ISTRICHEL, Pavia             | A. PAYLOVSKY, Buenos Aires   |
| W. O. CRUZ, Rio de Janeiro   | F. KOLLER, Basel                | E. PÉDRAZ, Buenos Aires      |
| C. R. DAS GUPTA, Calcutta    | J. H. LAWRENCE, Berkeley Calif. | F. REDAELI, Istanbul         |
| C. JOSTOZ DIAZ, Madrid       | P. LEVON, Raritan, N.J.         | I. SHAPIRO, Brooklyn, N.Y.   |
| H. DUBOIS-FRÉCHET, Genève    | W. LÖFFLER, Zürich              | E. STORRI, Modena            |
| F. FARRERAS, Barcelona       | J. MALLARÉ, Paris               | E. UHDETTZ, Basel            |
| A. FERRI, Genova             | L. M. MEYER, Brooklyn, N.Y.     | M. VARELA, Buenos Aires      |
| L. GEOR, Brock, N.Y.         |                                 | M. C. VERHOEF, Utrecht       |

## CONTRIBUTING EDITORS

L. Hellmeyer  
Freiburg im Br.

S. Moeschlin  
Solothurn

A. Vidtsek  
København

J. Waldenström  
Malmö

## EDITORS-IN-CHIEF

H. Löfflin  
Basel

G. Rosenow  
New York, N.Y.



1968

Vol. 39

BASEL (Schweiz)

S. KARGER

NEW YORK

All rights, including that of translation into other languages, reserved.  
Photomechanical reproduction (photocopy, microcopy) of this book or parts thereof without special permission  
of the publishers is prohibited.



Copyright 1968 by B. Karger AG, Basel  
Printed in Switzerland by Buchdruckerei National-Zürcher AG, Basel  
Chicko, Schuler & Co. AG, Basel

# Contents - Inhaltsverzeichnis - Sommaire

## Vol. 39

ABBOTT, C. R. <i>vide</i> ROBERTS, B. E.	
AKSOY, M. and ERDEM, S. (Istanbul)	
The Combination of Hereditary Spherocytosis and Heterozygous Beta-Thalassemia. A Family Study	183
ALEMO, L. <i>vide</i> SCHL, E.	
ALKYIZIOU-TIOZAKI, V. <i>vide</i> KIRMI-ZILAR, S. L.	
ANTONUTS, J. I. <i>vide</i> RADIN, P. A.	
ASAI, I. <i>vide</i> MIWA, S.	
AWAI, M.; OKADA, S. TAKEKAWASU, J.; KURO, T.; IMOTO, M. and SANO, S. (Osayama)	
Studies on the Mechanism of Denaturation of the Erythroblast	193
BACCI, C.; BONI, A. M. SANTORI, S. VERIDIANO, F. and FAZIO, M. (Torino)	
Deby of Human Lymphocyte 'Blast' Transformation by Homologous RNA	270
BARTI-MAGGIORI, B. <i>vide</i> MATIASIKOTIS, N.	
BATCHMAN, MARJORIE A.; FACILIA, D. E. SCHROEDER, A. S. and VALENTINE, W. N. (Los Angeles, Cal.)	
An Unusual Hematological Syndrome with Pyruvate-Kinase Deficiency and Thalassemia minor in the Elderly	343
BEALE, D. <i>vide</i> WAK, P.	
BRACHTENDER, H. <i>vide</i> SCHWALZ, F.	
BONI, A. M. <i>vide</i> BACCI, C.	
CANTOR, G. L. (Feinberg); YAM, L. T. and MITTAL, W. J. (Boston, Mass)	
Cytochemical Demonstration of Dehydroascorbic Dehydrogenase in Blood and Bone Marrow Cells	203
CERRA, M. <i>vide</i> SCHWALZ, F.	
CORRICO, G., GONELLI, E. and PALLI, E. (Milan)	
Presence of Satellite DNA in Normal and Leukemic Human Tissues	75
DAVEY, M. G. (Perth) LAWRENCE, J. R. (Woodville); LAMONT, H. (Adelaide) and ROBERTS, H. N. (Sheffield)	
Familial Erythrocytosis. A Report of Two Cases, and Review	63
DEUTSCH, E. and FROCHER, M. (Vienna)	
Comparative Studies on Inhibitors of Fibrinolysis <i>in vivo</i> and <i>in vitro</i>	1
DEWICKST, F. and FOLLER, L. (Manchester)	
The Clotting Activity of Protein Fractions of Congenital Factor IX Deficient (Christmas) Serum	13
DUBOIS-FRANCK, H. (Geneva)	
Etude cytologique de la transformation aiguë d'une leucémie myélocytaire chronique	249
ERDEM, S. <i>vide</i> AKSOY, M.	



- FADDO, M.: vide BAGGI, C.
- FISCH, C. A. vide ROSENBERG, A. I.
- FRONZELI, G. vide SCHM, E.
- FISCHER, M. vide DEUTSCH, E.
- FORTT R. W.: vide ROSENBERG, B. E.
- FOT H.: KOTON AYIKERA (Nairobi) HARRIS, ELLIEN B. (Freiburg im Br.) and  
 PRISTON J. K. (Nairobi):  
 Isotopic and Cytological Estimations of Marrow Erythroid Activity in  
 Normal and Riboflavin Deficient Baboons 118
- GERGELY G. vide KRIZA, F.
- GERMAYO, CAR. et SCHWABER, Y. (Liestal)  
 Erythroblastopénie non mégalo-cytaire et sensible à l'acide folique chez une  
 épileptique 159
- GIROLLI, E. vide CORIOLO, G.
- GIKARD, J.-P. (Geneva)  
 Studies on Rabbit Peripheral Lymphocytes. I. DNA and Antibody Synthe-  
 sis *in vitro*, Following Antigenic Stimulation 223
- GÖTT E. und VITEL, L. (Wien)  
 Blutfremde Zellen im strömenden Blut (Leberparenchymzellen) 243
- GYTTAEL, E. vide KERR-ELLAS, M.
- HARRIS, ELLIEN B. vide FOT H.
- HEDKE, K. M. STORCK, H. HERRMANN, H. und HOFER, E. (Berlin):  
 Untersuchungen zur Korrelation von Lymphocytentransformation durch  
 Streptolysin O *in vitro* und Antistreptolysin 276
- HERRMANN, H. vide HEDKE, K. M.
- HERZ, F. KAPLAN, EUGENE and SCHWEY, ELISE S. (Baltimore Md.)  
 Differences between the Red Cell Acetylcholinesterase Defects of Paroxysmal  
 Nocturnal Hemoglobinuria and of ABO Hemolytic Disease 83
- HETWOOD, J. D. vide ROSENBERG, A. I.
- HOFER, E. vide HEDKE, K. M.
- HOFMAYR, N. MOSER, K. NEIDMANN, E. und SEIFEL, H. (Wien)  
 Untersuchungen über Erythrokinetik und Erythrozytenstoffwechsel bei  
 Thalassemia minor 333
- ISOLT, M. vide AWAI, M.
- JAIN N. C. (Davis, Calif.)  
 Adenosine Phosphatase Activity in Leukocytes of Some Animal Species 31
- KAPLAN M. H. and MAJUMDAR, H. (Frankfurt/Main)  
 Multiple Chromosomal Aberrations in Case of Malignant Myelocytoma 299
- KAPLAN EUGENE vide HERZ, F.
- KERR-ELLAS, M. GYTTAEL, E. ALEXANDROU-TERRAZI, V. and MALAMON, B.  
 (Athens)  
 F and <sup>51</sup>Cr Studies in Aplastic Anaemia and Myelocytoma 139
- KIOBOGLOU, K. A. vide MATSUDOTSU N.
- KOTON, AYIKERA vide FOT H.
- KRIZA, F. GERGELY G. and RAK, K. (Søged)  
 Megakaryocyte Response in Posthaemorrhagic Thrombocytosis of Mice 112
- KURO T. vide AWAI, M.
- LAXDER, H. vide DAVEY M. G.
- LAWRENCE, J. R. vide DAVEY M. G.
- LEHMANN, H. vide TRIDICAO, C.
- LEHMANN, H. vide WARE, P.
- LORENTZ, P. A. vide TRIDICAO, C.
- MALAMON, B. vide KERR-ELLAS, M.

- MAOCHS, F: vide MATIASOOTS, N.
- MAREKARIS, T (Turks)  
Transketolase Activity of Red Blood Cells in Conditions of Haematological Interest 321
- MARTIN, H. vide KATY, M. H.
- MARTIN DE MELO, J. vide TRINCAO, C.
- MATIASOOTS, N.; KROMOGLIOU, K. A. MAOCHS, F and BARTI-MAOCHS, B. (Athens)  
Chromosomal Study in Megaloblastic Anemia of Children 29
- MCGUIRE, P. TRICIA vide RAGAN, F. A.
- MIRANO, E. A. (Buffalo, N.Y.); MURPHY, G. P. (Baltimore Md.) STREYER, R. A. (Buffalo, N.Y.); WEBER, H. W. and RETTEF, F. P. (Belville, Cap Province)  
Extra-Renal Production of Erythropoietin in Man 359
- MITSU, W. J. vide CASTOLDI, G. L.
- MIWA, S., ARAI, I., TUCKADA, T.; SENGUO, M.; TERAMURA, K. and SCHAGA, Y. (Tokyo)  
Hageman Factor Deficiency Report of Case Found in Japanese Girl 36
- MOCHTAR, I. A. vide VAN CREVELD, S.
- MOEL VAN CHARANTE-VAN DER MEULEN, C. C. vide VAN CREVELD, S.
- MOORE, K. vide HOFSTE, N.
- MOTULSKY, A. G. vide ROSENBERG, A. I.
- MURPHY, G. P. vide MIRANO, E. A.
- NAST, J. P. and WITTEK, M. (Brussels)  
Effect of Erythroid Hyperplasia on the Disappearance Rate of Erythropoietin in the Dog 42
- NA-YAROKH, S. vide WAM, P.
- NEUMANN, E. vide HOFSTE, N.
- OKADA, S. vide ARAI, M.
- PAGE, A. vide SCHM, E.
- PAOLIA, D. E. vide BAUGHMAN, MARJORIE, A.
- PASCHIA, C. N. vide VAN CREVELD, S.
- PEDERSEN, B. (Copenhagen)  
Pb-Dosage and Prognosis in Chronic Myelogenous Leukemia 102
- POLAK, J. vide ROTTERL, B.
- POLLER, L. vide DEWITT, F.
- POLL, E. vide CORREO, G.
- POOTRAKEL, S. vide WAM, P.
- PRESTON, J. K. vide FOX, H.
- PYRAM, R. D. vide ROBERTS, B. E.
- RAGAN, F. A., MCGUIRE, P. TRICIA and ANTOSCH, J. L. (Seattle, Wash.)  
Decreased Formation of Erythrocyte Antigen A and Consistent Chromosome Abnormality in Patient with Myelomonocytic Leukemia 309
- RAK, K. vide KREIB, F.
- RETTEF, F. P. vide MIRANO, E. A.
- ROBERTS, B. E., ASHOTT, C. R. (Leeds); FORTY, R. W. (London) and PYRAM, R. D. (Leeds)  
Preliminary. A Report of Four Cases 20
- ROSBY, H. N. vide D. VRY, M. G.
- ROSENBERG, A. I. (Cleveland, Ohio); HEYWOOD, J. D.; MOTULSKY, A. G. and FINCH, C. A. (Seattle, Wash.)  
Hemoglobin H as an Acquired Defect of Alpha-Chain Synthesis. Report of Two Cases 91
- ROTTERL, B. and POLAK, J. (Olomouc)  
Nitrocatecholamines in Human Blood Platelets 129

SABERS, M. (Boston, U.S.A.) Blastoid Transformation of Rabbit Peripheral Lymphocytes by Phytohemagglutinin Using a Microculture Technique	573
SARTORI, S.: vide BACCI, C.	
SCHRYK, Elise S.: vide HIEZ, F.	
SCHMALZ, F. and BRAUNWENDER, H. (Innsbruck) On the Origin of Monocytes	177
SCHMALZ, F.; CERRA, M. und BRAUNWENDER, H. (Innsbruck) Zur Zytochemie der Drüsenfibroblasten	257
SCHNAPPAUF, H. und SCHROCK, B. (Gießen): Zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymph	282
SCHREIER, A. S.: vide BAUGHMAN, MARJORIE A.	
SCHROCK, B.: vide SCHNAPPAUF, H.	
SCHULER, Y.: vide GERMANO, GIL.	
SEIFEL, H.: vide HORETZ, N.	
SENO, S.: vide AWAI, M.	
SENETO, M.: vide MIWA, S.	
SEIDAKIRA, T. (Eibersbach an der Riss) Zur erythropoetischen Wirkung von Testosteron	368
STEEVEN, R. A.: vide MIRAND, E. A.	
STEER, J.: vide VAN CREVELD, S.	
STONE, H.: vide HIEZ, K. M.	
SOLM, E. (Cagliari); FROELICH, G.; ALIBINO, L. und FARRI, A. (Milano) G-6-PD-Mangel mit Hämoglobinopathie und alpha-Thalassaemie	167
SKRAGA, Y.: vide MIWA, S.	
TAKIYASAKI, J.: vide AWAI, M.	
TERAMURA, K.: vide MIWA, S.	
TRAILL, M. A. (Heidelberg West, Vic): The Inheritance of Leukaemia and Cancer	174
TRINCAO, C.; MARTINS DE SAID, J. (Lisbon) LORKE, F. A. and LEHMANN, H. (Cambridge): Haemoglobin J Paris in the South of Portugal (Algarve)	291
TRICKADA, T.: vide MIWA, S.	
VALENTINI, W. N.: vide BAUGHMAN, MARJORIE A.	
VAN CREVELD, S.; MOCHTAR, I. A.; MOEL VAN CHABANTE-VAN DER MEULEN, C. C. PASCHA, C. M. and STERN, J. (Hulzen) Investigation of Circulating Anticoagulants against A11F (Factor VIII) in Three Patients with Hemophilia A	214
VAN ITTERBEK, H.; VERMYLEN, J. and VERSTRAETE, M. (Leuven) High Obstruction of Urine Flow as a Complication of the Treatment with Fibrinolytic Inhibitors of Haematuria in Haemophilias	237
VERGRANO, F.: vide BACCI, C.	
VERMYLEN, J.: vide VAN ITTERBEK, H.	
VERSTRAETE, M.: vide VAN ITTERBEK, H.	
VITEK, L.: vide GOTT, E.	
WAI, P.; FOOTRAKUL, S. NAI-NARON S. (Bangkok); BRALL, D. and LEHMANN, H. (Cambridge) Haemoglobin D $\beta$ Los Angeles (D Punjab, $\alpha_2\beta_2$ 121 Glu NH <sub>2</sub> ) is a Thai Family	151
WEER, H. W.: vide MIRAND, E. A.	
WITTEK, M.: vide NAEYS, J. P.	
YAM, L. T.: vide CASTOLDI, G. L.	
Letters to the Editor	60

Libri	62, 127	381
Varia	63, 192	320, 382
Index rerum ad Vol. 39		383
Index autorum ad Vol. 39		394

## Materials and Methods

(1) AMCHA was Amikapron® (Kabi SA, Stockholm) (mixture of the active and inactive isomers).

(2) PALLBA® was supplied by Arzneimittelwerke Dresden.

(3) aACA was Epalikapron® (Kabi SA, Stockholm).

(4) Streptokinase was Streptase® (Behring Werke, Marburg)

(5) Trasylol® 3000 KIE/ml (Bayer Leverkusen) molecular weight 11,600 (15), 1 U = 0.14 µg or  $8.3 \times 10^3$  units/mole.

(6) Plasminogen enriched  $^{125}$ I labelled standard clots were prepared from fresh human plasma with labelled human fibrinogen and human plasminogen added according to DEVOX DE WIT (8). These clots were incubated 60 min in the test solutions at 37°C, the residual clot was taken out, and the activity in the solution was counted. The test solution was prepared by mixing 1.6 ml 0.9% NaCl, 0.2 ml Streptase (const. or variable concentration) and 0.2 ml of inhibitor (const. or variable concentration), 0.5 ml of the mixture were used to incubate the clot.

A blank was prepared by incubation of the clot in mixture of 1.6 ml 0.9% NaCl and 0.4 ml barbital buffer. 100% lysis was the difference of counts in the clot before incubation and the blank. The results are expressed as percent lysis corrected for activity in the blank.

$$\frac{(\text{Test sample} - \text{blank})}{(\text{Clot} - \text{blank})} \times 100.$$

In the *in vivo* test the standard clots were incubated with 0.5 ml of the patient platelet poor citrated plasma.

(7) Erythrolysis time (12)

(8) Casein test according to NOMANUS (14) was used for the determination of the factors of the fibrinolytic system during the *in vivo* experiments. Erythrolysis precipitates were used to avoid the influence of the inhibitors on the determinations. Plasminogen was determined by addition of 200 U/SK/ml, plasmin without any addition, and activator by addition of 10 U of human plasminogen.

(9) One stage prothrombin time.

(10) Partial thromboplastin time (9).

(11) Thrombin time with 5 U/ml Thrombin, normal value 8-13 sec.

(12) Fibrinogen determination. VERWEIJER's modification of the method of CLAUSS (16)

(13) The synthetic inhibitors were qualitatively determined by two-dimensional paper chromatography (courtesy of Dr. CLAUSS).

(14) Human plasminogen was prepared from Cohn fraction III according to the method of ALPER.

## Results

### *In vitro* Tests

(1) In the first series of experiments SK was kept constant with 10 U/ml and the concentration of inhibitors was varied the synthetic inhibitors between  $3 \times 10^{-3}$  M and  $5 \times 10^{-3}$  M Trasylol between 0.1 U/ml and 10 U/ml ( $1.2 \times 10^{-2}$  to  $1.2 \times 10^{-3}$  M) final concentration (Fig. 1) It was found that on a molar basis Trasylol is extremely more active than all the synthetic materials. The difference is about  $10^4$




Fig. 1 Action of inhibitors on clot lysis *in vitro*. Concentration of SK constant 10 U/ml, concentration of inhibitors variable. Ordinate: log % residual lytic activity ( $^{125}$ I labelled standard clots). Abscissa: log final molar concentration of the inhibitors.

Compared with this large difference, the differences between the synthetic inhibitors are small. PAMBA is about 2 times as active as AMCHA, and about 12 times as active as  $\epsilon$ ACA.

(2) In a second series of experiments SK concentration was varied between 1 and 100 U/ml and the concentration of the synthetic inhibitors was kept constant at  $1.25 \times 10^{-3}$  and Trasyolol at  $1.2 \times 10^{-4}$  and  $1.2 \times 10^{-3}$  M. In these experiments, residual activity (% lysis) is not calculated by referring to the maximal possible activity but to the activity obtained with the respective SK-concentration without inhibitor.

About the same relationship of the activities of the 3 synthetic inhibitors was found as in the first experiment. This relationship is independent of the concentration of SK used, whereas the absolute degree of inhibition increases with reduction of the concentration of SK. Trasyolol is extremely more active (Fig. 2).

### *In vivo* Experiments

(1) Fibrinolytic activity was induced in human volunteers by injection of 1 000 000 U SK within 30 min and sustained by 100 000 U/h for 3  $\frac{1}{2}$  h. The inhibitors were injected intravenously at the end of the infusion. The effect was tested with the standard clot method 5 and 30 min after injection.  $3.1 \times 10^{-3}$  M AMCHA caused a 60% inhibition of the fibrinolytic activity within 5 min whereas  $3.8 \times 10^{-3}$  M  $\epsilon$ ACA were necessary to induce about the same inhibition, exactly 75%.  $6.6 \times 10^{-4}$  M PAMBA caused a 20 percent inhibition and  $6 \times 10^{-4}$  M (50 000 U) Trasyolol a 87% inhibition (Fig. 3). A second





Fig. 2. Action of inhibitors on clot lysis *in vitro*. Concentration of synthetic inhibitors  $1.25 \times 10^{-4} M$ , (—) and Trasylol® 1 and 10 U ( $1.2 \times 10^{-4} M$  and  $1.2 \times 10^{-5} M$ ) final concentration constant during the experiment, Streptokinase variable. Ordinate: log % residual lysis (corrected for the lysis by streptokinase without inhibitor) Abcissa: log Units Streptokinase, final concentration.



test was performed 25 min later. The fibrinolytic activity was further reduced in the patients who received the synthetic inhibitors, whereas the fibrinolytic activity increased again from 9% lysis to 31% lysis after Trasylol. The euglobulin lysis time did not change 5 min after the injection of the inhibitors and was increased a little after 30 min. The clotting tests were not influenced by the inhibitors in this short time period (Table I).

(2) In a second series of experiments 1 000 000 U SK were injected simultaneously with the inhibitors within 30 min. The infusion was continued with 100 000 U SK/h. In the control experiment, in which SK without inhibitor was infused, fibrinogen was reduced to 14 mg% within 30 min and remained on a level of about




Fig. 4. Simultaneous application of streptokinase and inhibitors. Concentration stated in the figures. ●—● % Lysis. ○—○ mg% Fibrinogen. Time in minutes after starting the infusion.



Table I

Interruption of streptokinase-induced fibrinolytic activity  
is rise by fibrinolysis inhibitors.

## a) Clotting tests.

Treatment	Test system	Before	5 min after	30 min
$3.8 \times 10^{-3} M$ εACA	prothrombin	18%	19%	21%
	PTT	>120 sec	>120 sec	>120 sec
	thrombin time	>90 sec	>90 sec	>90 sec
	fibrinogen	<1 mg %	6 mg %	5.5 mg %
	euglobulin lysis time	no clot	no clot	180 min
$6.6 \times 10^{-3} M$ PAMBA	prothrombin	41%	36%	36%
	PTT	83 sec	84 sec	62 sec
	thrombin time	26 sec	28 sec	26 sec
	fibrinogen	87 mg %	85 mg %	75 mg %
	euglobulin lysis time	9 min	no clot	no clot
$3.1 \times 10^{-3} M$ AMCHA	prothrombin	47%	52%	51%
	PTT	100 sec	90 sec	94 sec
	thrombin time	18 sec	18 sec	18 sec
	fibrinogen	85 mg %	87 mg %	89 mg %
	euglobulin lysis time	6 min 30 sec	5 min	8 min
$6 \times 10^{-3} M$ Trasylo <sup>®</sup>	prothrombin	50%	52%	50%
	PTT	74 sec	69 sec	73 sec
	thrombin time	14 sec	13.4 sec	13.8 sec
	fibrinogen	118 mg %	132 mg %	118 mg %

10 mg % for the following period of 3 h. In correlation to this thrombin time and PTT were immeasurable and prothrombin time below 20%. The J-labelled standard clot was completely lysed. The euglobulin precipitate did not clot. Plasminogen and plasmin disappeared and a large amount of activator was found (Fig 4 Table II b).

In the experiments with simultaneous application of streptokinase and  $7.6 \times 10^{-3} M$  εACA,  $1.65 \times 10^{-3} M$  PAMBA or  $6.2 \times 10^{-3} M$  AMCHA respectively a different behaviour of the clotting factors and not very much change in the reaction of the fibrinolytic system could be observed (Fig 4 Table II). The three synthetic inhibitors behaved similarly therefore the result may be discussed together. The fibrinolytic activity measured with the <sup>125</sup>J-labelled clots reached values between 83 and 98% lysis the fibrinogen level remained between 80 and 100 mg %. In correlation prothrombin time was not reduced below 46%, thrombin time did not increase to more than 26 sec and PTT not more than to 98 sec (Fig 4 Table II a).

Table I  
b) Fibrinolysis tests. Casein units.

Treatment	Before	5 min after	30 min
Plasminogen	$3.8 \times 10^{-4}M$ $\epsilon$ ACA	0	0.084
	$6.6 \times 10^{-4}M$ PAMBA	0.204	0.222
	$3.1 \times 10^{-4}M$ AMCHA	0.15	0.28
	$6 \times 10^{-4}M$ Trasylol®	0.14	0.251
Plasmin	$5.8 \times 10^{-4}M$ $\epsilon$ ACA	0	0
	$6.6 \times 10^{-4}M$ PAMBA	0.056	0.046
	$3.1 \times 10^{-4}M$ AMCHA	0.073	0.023
	$6 \times 10^{-4}M$ Trasylol	0.24	0.167
Activator	$3.8 \times 10^{-4}M$ $\epsilon$ ACA	6.38	6.23
	$6.6 \times 10^{-4}M$ PAMBA	9.17	8.59
	$3.1 \times 10^{-4}M$ AMCHA	6.14	5.71
	$6 \times 10^{-4}M$ Trasylol	6.29	5.76

The euglobulin precipitates clotted always and were lysed within 1 to 15 min. There was no influence on the disappearance of plasminogen and plasmin and on the formation of activator (Table IIb)  $9 \times 10^{-4} M$  (75 000U) Trasylol inhibited the lysis of the standard clot much more than the synthetic inhibitors. 1 h after terminating the trasylol infusion only 52% lysis of the standard clot was observed. Fibrinogen disappeared much slower and remained on about 150 mg%. Prothrombin time was reduced from 75% to about 50%, PT and thrombin time were not significantly influenced (Table IIa). There was a higher amount of plasminogen and plasmin left after 30 min. The activator activity was the same as in the other experiments (Table IIb).

The synthetic inhibitors were traceable in the serum for 2 to 4 h after the injection with  $\epsilon$ ACA as longest.

### Discussion

The activity of the inhibitors was tested *in vitro* in a system where plasminogen was activated by SK, and human fibrin was the substrate for the plasmin formed. It acted from outside and was not incorporated into the clot. The synthetic inhibitors differed not very much in activity.  $\epsilon$ ACA, the substance longest known, had the lowest activity. AMCHA is about 6 to 8 times as active as  $\epsilon$ ACA on a molar basis and PAMBA 12 to 14 times. If one considers that AMCHA contains only 15 to 20% of the active isomere, AMCA is more potent

Table II

Simultaneous administration of streptokinase and inhibitors.

a) Clotting tests.

Treatment	Method	Before	Time after starting infusion				
			30 min	1 h	1 h 30 min	2 h	2 h 30 min
SK	Prothrombin	85%	<10%	17%	17%	20%	18%
	PTT	60 sec	>120 sec	>120 sec	>120 sec	>120 sec	>120 sec
	Thrombin time	13 sec	>90 sec	>90 sec	>90 sec	>90 sec	>90 sec
	Fibrinogen	300 mg%	14 mg%	8 mg%	6 mg%	11 mg%	<1 mg%
	ELT	12 h	no clot	no clot	no clot	no clot	no clot
SK + $7.6 \times 10^{-4}M$ $\epsilon$ ACA	Prothrombin	76%	63%	63%	63%	55%	54%
	PTT	60 sec	71 sec	74 sec	75 sec	76 sec	73 sec
	Thrombin time	12 sec	16 sec	18 sec	15.8 sec	15.4 sec	16 sec
	Fibrinogen	215 mg%	133 mg%	122 mg%	112 mg%	122 mg%	113 mg%
	ELT	12 h	15 min	16 min	11 min	13 min	11 min
SK + $1.65 \times 10^{-4}M$ PAMBA	Prothrombin	87%	48%	57%	57%	41%	41%
	PTT	54 sec	79 sec	84 sec	77 sec	74 sec	79 sec
	Thrombin time	12 sec	23 sec	24 sec	25 sec	26 sec	26 sec
	Fibrinogen	384 mg%	100 mg%	96 mg%	95 mg%	85 mg%	80 mg%
	ELT	5 h 18 min	<1 min	9 min	<1 min	8 min	9 min
SK + $6.2 \times 10^{-4}M$ AMCHA	Prothrombin	80%	56%	46%	48%	53%	52%
	PTT	68 sec	89 sec	95 sec	98 sec	76 sec	94 sec
	Thrombin time	13 sec	18 sec	17 sec	17 sec	17 sec	17.6 sec
	Fibrinogen	350 mg%	120 mg%	99 mg%	89 mg%	95 mg%	90 mg%
	ELT	>12 h	12 min	6 min	5 min	5 min	5 min
SK + $9 \times 10^{-4}M$ Trasyol®	Prothrombin	78%	50%	51%	50%	50%	50%
	PTT	75 sec	73 sec	77 sec	67 sec	76 sec	69 sec
	Thrombin time	12 sec	13 sec	14 sec	13 sec	14 sec	13.6 sec
	Fibrinogen	310 mg%	172 mg%	170 mg%	168 mg%	150 mg%	150 mg%

than PAMBA. This is in good agreement with the results of DUBBER (6) who found AMCHA 2 times as active as  $\epsilon$ ACA *in vivo* and 6 times as active *in vitro* with fibrinogen as substrate and activation of the fibrinolytic system with UK. ANDERSON (2, 3) found AMCHA 5 times as active as  $\epsilon$ ACA in the same system and 10 times as active with tissue activators. MARKWARDT (13) found PAMBA 2 times and AMCHA 4 times as active as  $\epsilon$ ACA with plasmin. For practical purposes one may conclude, that PAMBA and AMCHA are 10 times as active as  $\epsilon$ ACA on a weight basis.

Trasyol is on a molar basis  $10^3$  to  $10^4$  times more active than the synthetic inhibitor. Its mode of action differs from that of the synthetic inhibitors, which is demonstrated by the different slope of the lines in Fig. 1 and 2. This higher activity of Trasyol on molar

Table II

b) Fibrinolytic tests. Casein units.

Treatment	Before	Time after starting infusion					
		30 min	60 min	90 min	120 min	150 min	
Plasminogen	SK	5.25	0.093	0.13	0.056	0	0
	SK + $7.6 \times 10^{-4} M$ sACA	3.51	0.199	0	0	0.37	0.063
	SK + $1.65 \times 10^{-4} M$ PAMBA	4.4	0.18	0.053	0.305	0.26	0.13
	SK + $6.2 \times 10^{-4} M$ AMCHA	4.33	0.28	0.046	0	0.36	0.046
	SK + $9 \times 10^{-4} M$ Trasylol®	3.72	0.305	0.185	0.13	0.35	0.093
Plasma	SK	0	0.074	0.111	0	0.074	0
	SK + $7.6 \times 10^{-4} M$ sACA	0	0.057	0.112	0	0	0.055
	SK + $1.65 \times 10^{-4} M$ PAMBA	0	0.13	0.063	0.046	0.083	0.18
	SK + $6.2 \times 10^{-4} M$ AMCHA	0	0.26	0.057	0	0.23	0.15
	SK + $9 \times 10^{-4} M$ Trasylol	0	0.41	0.16	0.32	0.1	0.222
Activator	SK	0	6.64	6.30	6.23	4.84	6.38
	SK + $7.6 \times 10^{-4} M$ sACA	0	8.05	7.72	8.01	8.02	8.33
	SK + $1.65 \times 10^{-4} M$ PAMBA	0	8.70	8.26	8.80	8.54	8.89
	SK + $6.2 \times 10^{-4} M$ AMCHA	0	6.23	6.12	6.39	5.38	5.90
	SK + $9 \times 10^{-4} M$ Trasylol	0	5.996	6.33	6.23	6.53	6.42

basis has already been mentioned by DUNBAR (7) and is in good agreement with their results.

The *in vivo* experiments demonstrate that it is easy to interrupt the fibrinolytic activity induced by an infusion of streptokinase with the synthetic inhibitors as well as with Trasylol. The fibrinolytic activity was significantly reduced 5 min after injection of the synthetic inhibitors and declined more in the following 30 min. This reduction of activity was not a consequence of stopping the streptokinase infusion. This is demonstrated by the fact, that the euglobulin lysis time was not affected after 5 min, and only a little prolonged after 30 min. This small prolongation is the consequence of the reduction of the level of the activator by excretion of streptokinase. Trasylol was in our experiment more active than the synthetic inhibitors, but the effect was of shorter duration. The lytic activity had reached half the pre-injection value again after 30 min.

If the absolute amounts of the inhibitors used are compared, the same relation becomes evident than in the *in vitro* experiments.  $3.8 \times 10^{-4} M$  sACA were a little but more active than  $9.1 \times 10^{-4} M$  AMCHA which means again an about 6 to 8 times greater activity of AMCHA on a molar basis or a 10 times greater activity on weight basis. PAMBA had to be used in a smaller dose because not enough injectable material was available. The dose was 5 times and the

inhibition about 3 times smaller than that of AMCHA. The *in vitro* experiments have demonstrated a linear relationship between concentration of the inhibitor and inhibition. Therefore, the conclusion may be justified, that PAMBA is about two times as active as AMCHA *in vivo*.  $9 \times 10^{-7}$  M Trasylol is as active as  $3.8 \times 10^{-8}$  M  $\epsilon$ -ACA, which means that Trasylol is about 50 000 times as active as  $\epsilon$ -ACA on a molar basis, but the action is of shorter duration. The injection of Trasylol has to be repeated in intervals of 15 to 30 min if the effect should be sustained.

About the same relation of activities is found, if the inhibitors are administered simultaneously with the streptokinase to protect the patient against the effect of overabounding plasminemia.

VERSTRAETE (17) has recommended to induce streptokinase treatment with a constant dose of 1 250 000 U and to continue it with 100,000 U/h. He has three arguments in favour of this method (1) The dose is sufficient in at least 95% of the population. The determination of streptokinase resistance before treatment is unnecessary. (2) The larger the dose of streptokinase the faster the blood will be depleted of plasminogen and the shorter is the duration of plasminemia. (3) Afibrinogenemia was not noted in these experiments. VERSTRAETE, however has obviously not determined fibrinogen levels in the first hours after starting the infusion. If the streptokinase resistance of the patient is low as f.l. in our control case (50 000 U) an afibrinogenemia will result at least in the first 4 h. This is one reason why ways must be found to avoid this situation. Another point is that streptokinase in excess of plasminogen will preferably induce the formation of activator and less that of plasmin. If we could block temporarily the action of the activator by an inhibitor without interfering with its formation plasminogen should be exhausted without formation of larger amounts of plasmin. This was the reason for trying to infuse large doses of streptokinase simultaneously with inhibitors. It was expected, that plasminogen should be transformed to activator. After stopping the infusion of the inhibitor and continuing the infusion of streptokinase streptokinase will always be in excess of the newly formed small amount of plasminogen, and large amounts of activator but only negligible amounts of plasmin will continuously be found in the circulation. The excretion of the inhibitors is fast and the concentration of the activator is increasing and it will soon overcome the reduced concentration of the inhibitor. The activator will become active in the thrombus.

Under these conditions it should be possible to reduce the effects of plasminemia to a minimum.

Our experiments seem to prove this hypothesis. When a large dose of streptokinase is infused simultaneously with a synthetic fibrinolytic inhibitor and the infusion of the latter is stopped after about 30 min the fibrinogen level is not reduced to less than 100 mg and the change in clotting tests is negligible. The euglobulin lysis time is short (1-15 min) which demonstrates that activator has been formed even in the presence of the inhibitors. The casein tests with the euglobulin fraction demonstrate that plasminogen has been depleted and large amounts of activator have been formed. The lysis test on the labelled standard clot shows that the activity is lower than in the control experiment, but the activator is not completely blocked even in whole plasma.

Trasyol in the dose used interferes much more with the fibrinolytic system. The depletion of plasminogen is slower and the residual lytic activity smaller.

These experiments show that the simultaneous administration of large doses of streptokinase and moderate doses of synthetic inhibitors (about 10 g  $\alpha$ ACA or 0.5-1.0 g AMCHA or PAMBA) reduces the plasminemia and prevents the dangerous period of afibrinogenemia. In the concentrations of the inhibitor used in our experiments SK obviously was not displaced from the plasminogen SK complex as it is suggested by the experiments of HEMMERLE (10). For practical purpose, half the amount of the inhibitors will be sufficient.

Another question however remains to be solved. HEMMEYER (11) has demonstrated in cats that thrombi will not be lysed if the animals have received  $\alpha$ ACA before SK. He suggests that  $\alpha$ ACA diffuses into the thrombi and is adsorbed there interfering with the action of the activator coming later to the thrombus. Further studies will be necessary to clarify whether human thrombi and clots adsorb  $\alpha$ ACA or do not.

### Summary

The efficiency of fibrinolysis inhibitors has been compared *in vivo* on perfused  $^{125}$ I-labelled human plasma clots. *p*-Aminomethylbenzoic acid (PAMBA) is 11 to 14 times as active as  $\alpha$ -Aminocaproic acid ( $\alpha$ ACA) and 2 times as active as Amino-methyl-p-dibenzoyl-carboxylic acid (AMCHA) on molar basis. Trasyol, natural occurring polypeptide, is  $10^4$  to  $10^5$  times more active than the synthetic inhibitors. The same relationship of activities was found *in vivo*. A single injection of 3.0 g  $\alpha$ ACA or 0.5 g AMCHA or PAMBA will effectively interrupt SK-induced fibrinolysis without

activity determination, factor X activity determination, silicone clotting times, avarate activated clotting times, continuous paper curtain electrophoresis, paper strip electrophoresis, protein estimation, thromboplastin generation tests (2) using platelet substitute (1).

The serum subjected to continuous paper curtain electrophoresis was obtained from three patients known to be suffering from severe congenital factor IX deficiency. The serum from each patient was studied separately.

### Results

The distribution of the known clotting factor activities (excluding the factor IX) in serum fractions from patients suffering from congenital factor IX deficiency was found to be identical with that in normal serum (Fig 1). Factor IX deficient serum appeared to contain the same two anti-heparin activities as normal serum (Table I). The  $\alpha$ -globulin anti-heparin activity which partly overlapped the factor IX activity of normal blood was demonstrated in serum from all three patients. The fast  $\gamma$ -globulin anti




Fig 1 The relationship between the anti-heparin activity protein fractions and clotting activity in Christmas serum.

Table I

The effect of protein fractions of serum from patients suffering from severe congenital factor IX deficiency upon the heparin retarded clotting time of normal plasma.

Fraction number	Patient A		Patient B		Patient C	
	µg protein per ml	clotting time (min.)	µg protein per ml	clotting time (min.)	µg protein per ml	clotting time (min.)
1	500	7.30	250	7.15	—	8.45
2	250	7.00	100	6.30	50	8.45
3	750	7.00	100	6.30	1,700	9.00
4	2,750	7.15	50	7.00	3,650	9.15
5	6,050	8.00	2,400	7.15	4,350	12.30
6	7,000	7.30	10,250	7.30	5,150	32.30
7	6,400	6.15	12,400	4.30	4,300	41.00
8	3,900	6.30	4,100	5.15	4,100	54.00
9	4,950	6.45	2,550	7.30	4,150	15.45
10	4,800	7.30	4,800	7.00	3,200	9.30
11	3,050	7.30	6,900	8.00	4,500	9.15
12	3,500	7.30	5,350	7.30	4,150	9.15
13	4,750	6.15	6,100	5.30	5,350	8.45
14	13,800	5.45	11,500	5.00	9,770	8.15
15	23,000	6.30	35,400	6.30	26,700	7.30
16	21,250	7.00	17,800	9.00	16,350	9.15
17	9,400	7.00	800	7.30	2,000	9.30
18	2,750	7.30	350	7.30	250	8.45
Thromboplastin generation time using patient A serum 38 sec.		Thromboplastin generation time using patient B serum 27 sec.		Thromboplastin generation time using patient C serum 78 sec.		

heparin activity which has been found to be associated with contact' activation product(3) was demonstrated in two of the three patients. In patient C it was masked by the presence of an anticoagulant which made it impossible to demonstrate the fast  $\gamma$ -globulin antiheparin activity. Paper strip electrophoresis of the fractions displaying this anticoagulant activity showed that it was present in the fast  $\gamma$ -globulins (Fig. 2).

Further studies on the blood of this patient showed that serum from patient C and fractions of this serum containing fast  $\gamma$ -globulin (fractions 6, 7 and 8 in Table I) produced a marked reduction in the thromboplastin generation of normal serum and plasma (Table II). Serum and the fast  $\gamma$ -globulin fractions from patient C also produced a marked prolongation of the recalcification and heparin retarded clotting times of normal plasma. The anticoagulant activity in the serum was thermostable, not absorbed by alumina or barium






Fig. 2. Comparison of the electrophoretic pattern of JD serum with normal standard serum.

Table II

The effect of serum and protein fractions from patient C upon the thromboplastin generation of normal plasma and serum.

Material added to generation system	Minutes generation					
	1	2	3	4	5	6
0.1 ml saline	35	12	10	10	10	10
0.1 ml electrophoretic fraction 6 above diluted 1:10						90
0.1 ml electrophoretic fraction 7 above diluted 1:10	-			-		83
0.1 ml electrophoretic fraction 8 above diluted 1:10					-	86
0.1 ml serum diluted 1:10	34	31	24	23	24	20

sulphate and not removed by extraction with ether. The anticoagulant was not a heparin-like antithrombin as it did not interfere with the thrombin-fibrinogen reaction (Table III).

The anticoagulant was also non-dialyzable, being found in the electrophoretic fractions, subjected to dialysis in the course of desalting and concentration.

Paper strip electrophoresis of serum from patient C on visual examination suggested there was a slightly raised level of the fast

Table III

Some properties of serum from patient C.

Effect upon the heparin retarded clotting time of normal plasma		
	clotting time (min)	
0.2 ml saline added	6'00"	5.45
0.2 ml normal serum added	1.45	1.41
0.2 ml Patient C serum	19'00"	22'00"

Effect upon the time taken by 0.1 ml of thrombin solution (7.5 units/ml) to clot 0.2 ml of 1 percent solution of fibrinogen.		
	clotting time (sec)	
0.1 ml saline added	21	19.5
0.1 ml normal serum added	23.5	25
0.1 ml patient C serum added	23.5	24

Effect upon the recalcification time of normal plasma		
	clotting time (min)	
0.2 ml saline added	5'36	5'20"
0.2 ml normal serum added	1'57"	1'53
0.2 ml Patient C serum added	8.35	8.90
0.2 ml Patient C serum incubated at 57° C for 30 min, added	9.55	10.05
0.2 ml Patient C serum, adsorbed with 100 mg/ml Barium sulphate for 15 min, added	9.10	9.30
0.2 ml Patient C serum, adsorbed with 100 mg/ml alumina for 15 min, added	12.15	12.30
0.2 ml Patient C serum, extracted with ether added	11.00	11.15

$\gamma$ - and  $\alpha$ -globulins. Strips run, stained and scanned under identical condition using identical volumes of serum from patients C and a freeze-dried control serum of known composition confirmed this\*.

The anticoagulant activity produced a prolongation of the heparin retarded clotting time equivalent to a concentration of 12-15 units per ml of heparin in the serum of the patient.

WESSLER *et al.* (7) have shown that normal serum contains a powerful thrombogenic principle serum thrombotic acceleration (STA). This resembles antiheparin activity in some of its physical

Hyland Laboratories. Albumin 55%, globulin 40%, globulin 11%, globulin 11%, globulin 19%, and total protein 7 g/100 ml (Fig. 3)

properties, thus both are reasonably stable, both are present in factor VII deficient serum and both are absent from serum treated with simple adsorbents, e.g. alumina. Both are also unaffected by coumarin therapy. STA activity could not be equated with factor IX or factor IX but probably represents a combination of these factors (6).

The two different antiheparin activities found by us in normal blood were also found in patients with Christmas disease (factor IX deficiency). This suggests that STA activity when serum products are infused into experimental animals is different from antiheparin activities present in plasma and serum. The results also confirm that factor IX is not likely to be responsible for the antiheparin activity of normal human blood.

### Discussion

The present findings provide additional information on the antiheparin activity of blood and confirm that it is not associated with factor IX activity. The anticoagulant activity found in the serum of patient C is similar on physical properties with the circulating anticoagulants reported in the blood of haemophiles, and in cases developing anticoagulants in pregnancy.

The heparin retarded clotting time appeared to detect the circulating anticoagulant and it may be a useful method for showing the early development of anticoagulants.

*Acknowledgments.* Gratitude is expressed to the Manchester Regional Hospital Board for grant for thrombosis research and to Dr M. C. G. ISRAELS for the donation of serum from patients with Christmas disease. We are also grateful to Dr P. SEGURA for providing facilities for continuous electrophoresis.

### Summary

A review of the clinical importance of antiheparin activity in patients with thrombosis and possible relationship to factor IX (Christmas factor) study has been made of the clotting activities of protein fractions obtained from cases of congenital factor IX deficiency. The results indicate that antiheparin activity is not associated with factor IX activity. Further studies were performed on the serum of one patient, in whom circulating anticoagulant was also found. The heparin retarded clotting time was a sensitive method for the detection of the circulating anticoagulants.

### References

1. BELL, W. N. and ALYON, H. G. A brain extract as substitute for platelet suspensions in the thromboplastin generation test. *Nature Lond.* 171: 860 (1954).
2. BROS, R. and DOUGLAS, A. S. The thromboplastin generation test. *J. clin. Path.* 6: 111 (1953).

3. DEWURRY F and POLLER, L. Antiheparin activity of some human blood protein fractions and their possible relationship to thrombosis. *J. clin. Path.* **11** 339 (1963)
4. O'BRIEN, J. R. The effect of heparin on the early stages of blood coagulation. *J. clin. Path.* **13** 93 (1960).
5. POLLER, L.: The possible relationship between the anti-heparin activity and thrombosis. *J. clin. Path.* **13** 226 (1960).
6. RINDER, S. and THOMAS, D.: The role of factors XII, XI and IX in serum and plasma induced thrombosis. *Amer. J. Physiol.* **205** 1263 (1963)
7. WISSELER, S. and RINDER, S. M. The role of human coagulation factors in serum induced thrombosis. *J. clin. Invest.* **39** 262 (1960).

Authors' address: Dr F Dewurry and Dr L. Poller, Haematology Department, Withington Hospital, Manchester (England). Requests for reprints to Dr L. Poller.

Haematology Section, University Department of Pathology  
The General Infirmary, Leeds

**Prelukaemia**  
**A Report of Four Cases**

B. E. ROBERTS, C. R. ABBOTT, R. W. FORTY and R. D. PYRAN

Some cases of acute leukaemia are preceded by a variable clinical and haematological syndrome, usually related to a deficiency of at least one cell line in the peripheral blood the nature of which is obscure until a proliferation of blast cells makes the diagnosis clear. This syndrome has been termed preleukaemia and many of its features were described in a series of 12 cases by BLOCK *et al* in 1953 (4) and a further series by MEACHAM and WEISBERGER in 1954 (13). A remarkable case lasting 9 years was described by WILLIAMS (19).

The existence of this prodromal syndrome was recorded by GURZ and HUGHES (9) in their survey of 97 cases of acute leukaemia in New Zealand and accepted by BOGGS *et al* (5) in their personal study of 322 cases. However in a further series of 580 cases, ROATH *et al* (17) were unable to recognise such a phase and no attempt was made to determine its incidence or ascertain its nature. Further authors (18) having accepted this concept have applied it widely. As well as a so-called myelodysplastic group which would embrace the cases discussed here they include a variety of disorders which may be complicated by leukaemia such as aplastic anaemia and the myeloproliferative group of disorders and termed paraleukaemic by HAYHOE (10).

We wish to present 4 further cases to emphasize the existence of this prodromal syndrome and put forward a case for limiting the use of this term to the so-called myelodysplastic group.

## Case Reports

### Case 1

P.T. 15-year-old school-boy was admitted with 3 weeks' history of pyrexial illness with generalised aches and pains which became localised to the lower l. thigh. On examination there was soft swelling overlying the l. femur with enlarged tender regional lymph nodes. There was no other evidence of lymph node enlargement and the spleen was not palpable. The swelling was surgically explored and large parosteal abscess was drained of pus which on culture yielded heavy growth of *staphylococcus aureus*. Histology of the abscess wall showed inflammatory granulation tissue only. He was treated with penicillin and streptomycin and made good recovery.

Haematologically (Table I) there was pancytopenia with persistently raised reticulocyte count. Marrow (Table II) showed erythroid hyperplasia with maturation arrest at the metamyelocyte level in the granulocyte series. Megakaryocytes appeared normal. Other tests included serum bilirubin 0.2 mg/100 ml, urinary urobilinogen negative, saline osmotic fragility normal, direct antiglobulin test negative. No precise haematological diagnosis was possible at this stage.

Four months after the original presentation, however, he was re-admitted to hospital following severe nose-bleed. He had extensive purpura, generalised lymph node enlargement and splenomegaly 1 cm below the costal margin. The final haematological picture was that of marked pancytopenia. Hb. 9.4 g/100 ml, platelet count  $84 \times 10^9/\text{mm}^3$ , W.B.C.  $1.5 \times 10^9/\text{mm}^3$ , neutrophils polymorphs 3%, lymphocytes 97%. After prolonged search of the peripheral blood film, few lymphoblasts could be found but the marrow showed extensive replacement by sheets of lymphoblasts. A diagnosis of 'aleukaemic lymphoblastic leukaemia' was concluded. He was treated with prednisone 60 mg daily but after short clinical improvement died of overwhelming staphylococcal broncho-pneumonia.

### Case 2

S.B.K., retired man of 73 was admitted to hospital following the third episode of epistaxis in 3 months. There was past history of myocardial infarction 5 years previously and recent anginal pain. His main symptom for 3 months before admission had been lassitude. The findings on examination were those of sub-conjunctival haemorrhages and sparse purpuric spots. Regional lymph nodes were not enlarged and the liver and spleen were not palpable.

Haematologically (Table I) there was pancytopenia with consistently raised reticulocyte count which varied between 15-24%. Sternal marrow (Table II) showed marked erythroid hyperplasia, granulopoiesis was morphologically normal but the majority of megakaryocytes, which were present in normal numbers, showed little evidence of platelet production. The direct antiglobulin test was negative, no L.E. cells were found, serum bilirubin was 0.8 mg/100 ml, blood urea was 116 mg/100 ml, serum proteins and liver function tests showed no abnormality. No haematological diagnosis was reached at this stage when the patient had an attack of left ventricular failure and died.

*Autopsy report.* Death was due to pulmonary oedema secondary to myocardial ischaemic fibrosis. Spleen, liver and lymph nodes were normal. However both kidneys showed identical changes: the capsules were diffusely thickened, green in colour but stripping easily revealing chloromatous kidneys with granular green surface and scattered petechial haemorrhages. On section the green colour was confined to the cortex. Sternal and vertebral marrow appeared hyperplastic with red marrow extending two-thirds of the way down the shaft. *Histological findings.* The kidneys showed gross infiltration of the cortices by sheets of cells, the predominant cell type having

Table I

Preleukemic peripheral blood findings.

Case	Hb, g/100 ml	Hct, %	Retic, %	Platelets, $10^9/\text{mm}^3$	Total W.B.C. $\times 10^9/\text{mm}^3$	N	E	DIFF W.B.C. %	L	M	Film appearance	L.A.P.
1	8.2		7.0	160	2.4	49						
2	7.2		24.0	89	2.7	63			44	7	R.B.C. hypochromasia polychromasia	
3	9.6	30	2.0	normal on film	3.6	36			34	1	R.B.C.: polychromasia N.R.B.C.: 2/100 W.B.C.	-
4	7.6	24	3.0	normal on film	3.3	73			58	6	R.B.C.: anisocytosis Hypersegmented neutrophils	50
									25	2	R.B.C. hypochromasia Pelger Huët anomaly	3

Abbreviations: Hb, Hemoglobin; Hct, Hematocrit; Retic, Reticulocyte Count; Plate, Platelet Count; R.B.C., Red Blood Cells; N.R.B.C., Nucleated Red Blood Cells; W.B.C., White Blood Cells; Diff W.B.C., Differential White Blood Cells; A, Neutrophils; E, Eosinophils; B, Basophils; L, Lymphocytes; M, Monocytes; L.A.P., Leucocyte Alkaline Phosphatase (score)

Table II  
Preleukaemic marrow appearances.

Case	Principal feature	M:E ratio	Percent blast cells
1	Erythroid hyperplasia	1:2	1.5
2	Erythroid hyperplasia	1.5:1	1.0
3	Hyperplasia	5:1	2.0
4	Granulocytic hyperplasia	20:1	1.0

Abbreviations: M:E, ratio Myeloid Erythroid ratio (normal 2.5-15:1)

pale-staining and slightly indented nucleus in keeping with that of myeloblast. Similar cells were found to be involving an abdominal lymph node. Femoral marrow showed predominantly blast cell infiltration with foci of erythroblastic hyperplasia. Liver and spleen were histologically normal and not affected by the leukaemic process.

### CASE 3

H.A., a 62-year-old farmer was admitted with 6 months history of pallor, shortness of breath, cough, anorexia, loss of weight and 3 episodes of deep vein thrombosis. On examination there was moderate pallor but no other significant features, in particular no enlarged lymph nodes and no splenomegaly.

Haematologically (Table I) there was normocytic and normochromic anaemia with neutropenia. Large hypersegmented neutrophils were present and megaloblastic anaemia was suspected. Sternal marrow however showed normoblastic erythropoiesis with marked granulocytic hyperplasia serum B<sub>12</sub> and urinary excretion of FIGLU after histidine load were normal. No haematological diagnosis was possible at this stage. He subsequently developed persistent pyrexia 100° to 101° F and an E.S.R. of over 100 mm in the first hour. Many investigations were carried out to elucidate the cause of the pyrexia. Repeated blood, marrow, sputum and urine cultures were performed, but all were negative including guinea pig inoculation. Many agglutination titres were performed without significant result. Bronchoscopy, cystoscopy with retrograde pyelogram were negative. A muscle biopsy was normal, repeated L.E. cell tests were negative until finally laparotomy was carried out. This too proved completely negative and liver biopsy taken at the time was histologically normal.

The pyrexia persisted and the patient remained in the same clinical condition. A course of prednisone was given on the assumption that this was collagen disease and much symptomatic relief was obtained but an abscess developed in the laparotomy wound. Refractory anaemia persisted and repeated transfusion was needed. It was accompanied by neutropenia which varied only slightly in response to steroids or pyrogenic infection.

Repeated marrows were performed and revealed increasing granulocytic hyperplasia (Fig. 1); chromosome analysis of adequately spread mitotic cells, though small in number failed to reveal aneuploidy of the C group chromosomes or the presence of the Philadelphia chromosome. The alkaline phosphatase score of the leucocytes was not diagnostically significant, but increasingly the percentage of blast cells and promyelocytes began to climb in the marrow (Fig. 1) and 7 months after the initial presentation blast cells began to appear in the peripheral blood. He died 8 months later, never attaining remission.






Fig 1 Serial marrow counts in case 3.

## Case 4

J D T 56-year-old Irish was admitted in July 1965 with history of shortness of breath for 6 months and several hours precordial pain, the nature of which was not discovered. He had lived for 30 years in West Africa where he contracted malaria and filariasis. There was no recent exposure to drugs or chemicals. On examination the only physical sign was that of moderate pallor; there was no lymphadenopathy and no splenomegaly. Haematologically (Table I) the conspicuous features were those of a normocytic and normochromic anaemia and leucopenia associated with granulocytic hyperplasia of the bone-marrow. The neutrophils present, however, showed changes in nuclear morphology. Bi-lobed 'pince-nez' and single-lobed rounded nuclei with condensed nuclear chromatin pattern were present. They were characteristic of the Pelger-Huet anomaly. The detailed differential leucocyte count showed single-lobed Pelger-Huet cells, 26%; bi-lobed Pelger cells, 33%; polymorphs with normal morphology 12%; lymphocytes, 23%; monocytes, 2%.

A family study was possible but over the next 2 months the differential counts changed so that nearly all the neutrophils were single-lobed and normal polymorphonuclear neutrophils became absent. As this changing picture pointed to secondary acquired, rather than a primary hereditary cause many other investigations were performed in an attempt to find primary cause such as malignant lymphoma or carcinoma but all were negative. In particular liver function tests and serum protein were normal. Liver biopsy showed no abnormality, no parasites were found on examination of blood and stool.

A further diagnosis of preleukemia was considered and further investigations were performed along these lines. The leucocyte alkaline phosphatase reaction was negative in the binormal neutrophils. Cytogenetic studies were performed on direct preparations from the marrow but showed no evidence of aneuploidy of the C group chromosomes and the Philadelphia chromosome could not be identified. Repeated bone-marrow examinations showed progressive granulocytic hyperplasia with shift to the left which was emphasized by the similarity of myelocytes and single-lobed mature neutrophils. Finally 6 months after the original presentation, he was admitted with bronchopneumonia. The marrow at this time showed 12% blast cells and 25% promyelocytes which demonstrated heavy basophilic granulation and Auer rods. He failed to respond to antibiotics and died shortly afterwards.

### DISCUSSION

Clinically the cases showed neither splenomegaly nor lymphadenopathy. Symptoms were referable to the cells deficient in the peripheral blood but all cases were particularly susceptible to infection. Haematologically in all cases there was a deficiency of at least one cell line in the peripheral blood and hyperplasia of the corresponding precursors in the bone-marrow.

Cases 1 and 2 showed an anaemia with a raised reticulocyte count and erythroid hyperplasia on bone marrow examination. normoblasts were present in the peripheral blood of case 2. Reticulocytosis with or without normoblastosis was a feature at some stage in all of the 12 cases of preleukaemia published by BLOCK *et al.* (4) and is undoubtedly common in this disorder. There was no evidence that this was a regenerative reaction to haemorrhage or haemolysis in case 1 and in case 2 the reticulocytosis was out of all proportion to the severity of the nose bleed. Since localized deposits of leukaemic tissue were demonstrated at autopsy in case 2 in which death occurred during the preleukaemic phase it may be postulated that this is a reaction to marrow replacement.

The outstanding abnormalities in cases 3 and 4 were those of persistent neutropenia with abnormal leucocyte morphology and granulocytic hyperplasia of the bone marrow.

Marked hypersegmentation of the polymorphonuclear neutrophils was present in case 3 but no evidence of B<sub>12</sub> or folic acid deficiency could be found. Hypersegmented neutrophils are frequently seen in myeloproliferative disorders but it is not possible to ascertain whether these are of leukaemic origin or reactive. In this case the alkaline phosphatase reaction was normal and cytogenetic studies were inconclusive.

In contrast to case 3 some of the neutrophils of case 4 were single or bilobed and characteristic of the Pelger Huët anomaly. This is a heritable disorder but can be acquired secondary to other disorders particularly acute myeloid leukaemia (8). DARTZ *et al.* (7) demonstrated that in a case of acquired Pelger Huët anomaly secondary to myeloid leukaemia the proportion of anomalous cells increased as the disease progressed and this pattern was repeated here. For this reason acute myeloid leukaemia was suspected from the first but without a demonstrable increase in blast cells the diagnosis could not be made. This emphasizes the fact once more that

there are no established biochemical, cytochemical or cytogenetic features of acute leukaemic cells which unequivocally establishes their nature. The anomalous cells of this case had a negative alkaline phosphatase reaction and direct preparations of bone marrow revealed a normal karyotype.

These 4 cases do not fit into any established haematological diagnosis or classification at their presentation other than preleukaemia which could only be applied in retrospect when a proliferation of blast cells made the diagnosis clear.

ROWLEY *et al* (18) have classified preleukaemia into 3 groups, aplastic, myelodysplastic and myeloproliferative and the present 4 cases would seem to fit the myelodysplastic group. The inclusion of aplastic anaemia and myeloproliferative disorders within the meaning of preleukaemia is debatable however and we believe a distinction should be drawn between preleukaemic and potentially leukaemic conditions and that aplastic and myeloproliferative groups belong to the latter.

Acute leukaemic transformation in aplastic anaemia is only sporadic in published series ADAMS (1) recorded 1 in 27 cases and MOHLER and LEAVELL (15) 1 in a further 50 cases. Moreover in the 45 cases of ISRAELS and WILKINSON (11) the 60 cases of LEWIS (12) and the 102 cases of BERNARD and NAJEAN (2) this change was not seen to occur.

Again in the myeloproliferative group of disorders only a small proportion undergo leukaemic transformation and this has been related to radio-phosphorus treatment in polycythaemia rubra vera (14).

A small number of cases of sideroblastic anaemia may undergo leukaemic transformation (3). Although the true nature of this disorder is not known it is usually considered to be a primary disorder which may be complicated by acute leukaemia or a chronic myeloproliferative disorder changing into a more acute form (6) rather than preleukaemia. None of the present cases showed abnormal iron staining of the red cell precursors.

Having excluded the aplastic and myeloproliferative groups we should like to confine the term preleukaemia to cases in which there is unexplained anaemia, neutropenia or thrombocytopenia or combination of these with a hyperplastic marrow and with no clinical evidence of enlargement of spleen or lymph-nodes, ultimately merging with the full picture of acute leukaemia. The true

nature of preleukaemia so defined is not known but it probably represents the manifestations of an initially occult, slow growing acute leukaemic proliferation, which has been termed smoldering leukaemia by RHEINGOLD *et al* (16). This was revealed at autopsy in case 2 and the abnormal leucocytes in cases 3 and 4 were probably those of a well differentiated slow growing leukaemic process. But no unequivocal method of distinguishing leukaemic from normal leucocytes exists and until this is found, preleukaemia will remain a difficult diagnostic and prognostic problem.

*Acknowledgements.* We should like to thank Dr R. V. TATTERSALL, Dr O. M. TELLENG and Dr J. R. H. TOWERS for permission to publish details of their cases.

### Summary

Four cases of preleukaemia were studied from onset to death. They presented with deficiency of at least one of the cellular components of the peripheral blood, hyperplastic marrow and no enlargement of spleen or lymph nodes. Extensive investigations were not diagnostic until terminal stage was reached. The nature of preleukaemia is discussed and it is suggested that it is the manifestation of a slow growing occult, leukaemic process rather than a definite haematological condition with sporadic proclivity to leukaemic transformation.

### References

1. ADAMS, E. B. Aplastic anaemia. Review of 27 cases. *Lancet* 637 (1951).
2. BERNARD, J. and NAYLOR, V. Evolution and prognosis of the idiopathic pancytopenias. Series Haematologica 5, 1. Supplement. *J. Haemat. Munksgaard, Copenhagen* (1965).
3. BYRONUMAN, S. E. Chronic refractory anaemia with sideroblastic bone marrow. A study of four cases. *Blood* 11: 250 (1956).
4. BLOCK, M., JACOBSON, L. O. and BERNARD, W. F. Preleukaemic acute human leukaemia. *J. Amer. med. Ass.* 152: 1018 (1953).
5. BOON, D. R., WYTHOM, M. M. and CARTWRIGHT, G. E. The acute leukaemias. Analysis of 322 cases and review of the literature. *Medicine* 41: 163 (1962).
6. DAWSON, W. Sideroblastic anaemia is this malignancy? *Brit. J. Haemat.* 11: 52 (1965).
7. DART, J. M., DACE, J. V. and MCSORLEY, J. G. A. Pelger-like leucocytes in chronic myeloid leukaemia. *Acta haemat., Basel* 12: 117 (1954).
8. DICK, A. D. and MOLOVAY, W. C. Acquired pseudo-Pelger anomaly of granulocytic leukocytes. *New Engl. J. Med.* 261: 742 (1959).
9. GILL, F. W. and HODGE, R. F. Acute leukaemia over the age of fifty. A study of its incidence and natural history. *Blood* 11: 882 (1956).
10. HAYMON, F. G. J. *Leukaemia. Research and Clinical Practice* (Churchill, London 1960).
11. IMAFU, M. C. G. and WILKINSON, J. F. Idiopathic aplastic anaemia. Incidence and management. *Lancet* 63 (1961).
12. LEWIS, S. M. Course and prognosis in aplastic anaemia. *Brit. med. J.* 1: 1027 (1963).

13. MACEHAM, G. C. and WEISSBERGER, A. S. Early atypical manifestations of leukaemia. *Ann. Intern. Med.* 41: 780 (1954).
14. MODAN, B. and LIEBERFELD, A. M.: Leukaemogenic effect of ionizing irradiation treatment in polycythaemia. *Lancet* ii: 439 (1964).
15. MOSLER, D. N. and LEAVELL, R. S. Aplastic anaemia: an analysis of 50 cases. *Ann. Intern. Med.* 49: 326 (1958).
16. RUTDOWD, J. J. HALPMAN, R. ADRIAN, E. and LEAR, A. Smoldering acute leukaemia. *New Engl. J. Med.* 268: 812 (1963).
17. ROATH, S.; ISMAEL, M. C. G. and WILKINSON, J. F. The acute leukaemias: study of 520 patients. *Quart. J. Med.* 37: 237 (1964).
18. ROWLEY, J. D., BLANDFELL, R. K. and JACOBSON, L. O. Chromosome studies in preleukaemia. I. Aneuploidy of group C Chromosomes in three patients. *Blood* 27: 782 (1966).
19. WILLIAMS, A. J. Myeloblastic leukaemia preceded by prolonged haematologic disorder. *Blood* 10: 502 (1955).

Authors' addresses: R. E. Roberts, M. B., M. C. Fortin, and G. R. Abbott, M. B., B. Sc., Haematology Section, University Department of Pathology The General Infirmary at Leeds, Leeds; R. W. Forty, M. B., Departments of Medical Anatomy Postgraduate Medical School, Duane Road, Leeds, W. 1; R. D. Pyrah, M. A., M. B. Department of Pathology St. James Hospital, Leeds 9 (England).

Department of Paediatrics, University of Athens  
(Director: Prof. Dr. E. DANIPOPOULOS)

## Chromosomal Study in Megaloblastic Anaemia of Children

N. MATRANIOTIS, K. A. KIOSOGLOU, F. MAOUNIS and  
B. BASTI MAOUNI

Occasionally reports have been presented with numerical and/or morphologic chromosomal aberrations in megaloblastic anaemia of adults (2, 3, 7, 9-11, 13, 14). These are characterized by aneuploidy, namely hypodiploidy, and the presence of chromatid breaks and gaps, acentric fragments, dicentric or giant chromosomes (2, 3, 10, 11, 13, 14).

In the available literature we were unable to find any cytogenetic data in megaloblastic anaemia of children. Two cases of megaloblastic anaemia in childhood incited us to carry out a cytogenetic investigation. Both were siblings 4 and 3 years old respectively.

### *Method*

Direct bone-marrow chromosome studies were performed in both patients according to the method previously described (12). The combined Denver (1) and M<sub>1</sub> (15) system of nomenclature was used.

### *Case Reports*

The type of megaloblastic anaemia has not been determined accurately. The first patient responded promptly to parenteral vitamin B<sub>12</sub> therapy; his sister responded to oral folic acid treatment.

The clinical and laboratory data from both patients are summarized in Table I. The asterisks indicate the dates on which cytogenetic studies were performed.

In the first patient, anaemia was present since the age of 4 months; it was diagnosed as being megaloblastic at the age of 18 months, and was attributed to folate deficiency. Therapy with folic acid orally resulted in partial recovery only. Subsequent treatment with parenteral vitamin B<sub>12</sub>, however, produced an excellent response (Fig. 1).

His sister was anemic also since the age of 4 months. Folate deficiency was diagnosed at the age of 3 years. Treatment with folic acid by mouth resulted in complete remission.



Fig 1 Bone-marrow smears from the first patient studied both in relapse (left) and in remission (right). Note the abnormal white cell morphology and the megaloblastic erythropoiesis (left) and the normoblastic erythropoiesis and the normal white cell morphology (right).

### Results

The cytogenetic studies revealed the presence of both numerical and structural chromosome aberrations in the two siblings studied in relapse. During remission, however while on vitamin B<sub>12</sub> therapy the one (brother) and folic acid treatment the other (sister) these changes could not be detected any more.

The results of chromosomal studies from both siblings with megaloblastic anaemia are shown in Table II. In the first patient, in relapse pronounced hypodiploidy with random loss of chromosomes was present in 8/25 cells. Morphological aberrations were present in 19/25 cells examined. In remission the chromosome counts reverted to normal; moreover no structural anomalies were found (Fig 2).

In the second patient (sister of the previous one) during relapse, pronounced hypodiploidy with random loss of chromosomes, was present in 11/32 cells. Morphologic aberrations were present in 24/32 cells examined. In remission, the chromosome counts were normal, and no structural aberrations could be detected (Fig 3).








Fig 2. Bone-marrow metaphase plates from case 1 both in relapse (left) and in remission (right) containing 46 chromosomes each. The arrows point to chromatid breaks and gaps. In remission the chromosomes are of normal size and appearance. Both pictures were taken under the same magnification.




Fig 3. Bone-marrow metaphase plates from case 2 both in relapse (left) and in remission (right). The left cell contains 47 chromosomes (one extra in the  $D_{12-13}$  series) the right one contains 46 chromosomes. The arrows point to numerous structural aberrations (breaks, gaps and an isogap (curved arrow)). "Giant" chromosomes are also noted. In remission the chromosomes are normal. Both pictures were taken under the same magnification.

Table II

Analysis of chromosomal distribution in two cases of megaloblastic anaemia of childhood.

Case No.	Date	Clinical status	Total No. of cells counted	Chromosome number									
				-40	40	41	42	3	44	45	46	47	48
1	27-1-66	relapse	23	2				2	2	2	17		
	26-2-66	remission	6								4		2
	30-4-66	remission	14			1					12		1
2	30-4-66	relapse	32	4		3		3	1	20	1		
	19-8-66	remission	14		1					12			1

### Discussion

FORD *et al.* (7) reported a case of pernicious anaemia with pronounced hypodiploidy but subsequently these findings were attributed to technical imperfections (8) COURT BROWN *et al.* (5) and DE LA CHAPELLE and GRÅNBECK (6) in studies of 5 and 4 cases, respectively failed to find significant abnormalities.

On the other hand ASTALDI *et al.* (2, 3) portrayed numerical and morphologic chromosome changes in a woman with untreated pernicious anaemia. The abnormalities were apparently less pronounced after vitamin B<sub>12</sub> therapy (4). Similar results were reported by FORTEZA and BĄGUEWA (9) in another case of pernicious anaemia. MAC DIARMID (14) reported an increased incidence of aneuploidy and alterations in individual chromosomes in 5 patients with pernicious anaemia.

In a recent study of three patients with pernicious anaemia reported by KROSSOULOU *et al.* (13) numerical and structural aberrations of chromosomes were present. These were characterized by pronounced hypodiploidy and the presence of chromatid breaks and gaps, acentric fragments and dicentric or giant chromosomes. After vitamin B<sub>12</sub> therapy the morphologic aberrations were greatly reduced. The numerical anomalies persisted, although significantly decreased. POWNER and BERMAN (16) found abnormally long and thin chromosomes in their cases with no other numerical or structural abnormalities. Recently HEATH (10) reported on 14 cases of anaemia associated with deficiency in vitamin B<sub>12</sub> and/or folate. In 7 definite structural changes were present consisting in increased chromatid breaks, incomplete contractions (the equivalent, perhaps, of what we have termed giant chromosomes) and cen-

chromosome spreading. These anomalies were no longer present after appropriate treatment.

In the present study two cases of megaloblastic anaemia of childhood were investigated. Both patients were siblings and were studied both in relapse and in remission. In the two siblings (brother and sister) numerical and structural chromosome aberrations were found, which reverted to normal after vitamin B<sub>12</sub> therapy in one and folic acid treatment in the other.

The cytogenetic abnormalities found in megaloblastic anaemia of adults and children may be related to the metabolic role of vitamin B<sub>12</sub> and folate. It is well known that both are involved in the metabolism of the DNA. Deficiency of either of these vitamins may therefore lead to disordered DNA synthesis which may be responsible for morphologic aberrations, such as chromatid breaks and gaps, acentric fragments, dicentric or giant chromosomes.

### Summary

Cytogenetic studies were performed on two children (brother and sister) with megaloblastic anaemia. In both siblings chromosomal aberrations were found during relapse. They were no longer present while the patients were in remission on vitamin B<sub>12</sub> and folate replacement.

### References

1. A proposed standard system of nomenclature of human mitotic chromosomes. *Lancet* **i**, 1063-1065 (1960).
2. AITALDI, G.; STROMELLI, E. and R. Ricerche citogenetiche nelle emopatie osservazioni sui cromosomi dell'anemia perniciosa non trattata. 1. Alterazioni numeriche. *Boll. Soc. Ital. Biol. sper.* **38**, 111-114 (1962).
3. AITALDI, G.; STROMELLI, E. and R. Ricerche citogenetiche nelle emopatie osservazioni sui cromosomi dell'anemia perniciosa non trattata. 2. Alterazioni morfologiche. *Boll. Soc. Ital. Biol. sper.* **38**, 114-117 (1962).
4. AITALDI, G.; STROMELLI, E.; AND, R. and POLLINI, G. Recherches cytogenétiques dans l'anémie pernicieuse pré traitement. *Schwed. med. Wochn.* **82**: 1332-1334 (1962).
5. COURT BROWN, W. M., JACOB, P. A. and DOLL, R. Interpretation of chromosome counts made on bone marrow cells. *Lancet* **ii**, 160-163 (1960).
6. DE LA CRAPPELLE, A. and GILBERT, R. Normal mitotic activity and karyotype of leukocytes from pernicious anemia patients cultured in vitamin B<sub>12</sub> deficient medium. *Nature, Lond.* **197**, 607 (1963).
7. FORD, C. E.; JACOB, P. A. and LAJTHA, L. G. Human somatic chromosomes. *Nature, Lond.* **181**, 1563-1568 (1958).
8. FORD, C. E. The interpretation of chromosome counts. *Lancet* **ii**, 367 (1959).
9. FORTEZA, B. G., BACURKA, G. Análisis citogenético de un caso de anemia perniciosa antes y después del tratamiento. *Rev. clin. Esp.* **88**, 231-235 (1963).
10. HEATH, C. W. J. Cytogenetic observations in vitamin B<sub>12</sub> and folate deficiency. *Blood* **27**, 800-815 (1966).

11. KOSMOGLOU K.A. and MITTS, W.J. Cytogenetic studies in pernicious anaemia, megaloblastosis and the di-Guglielmo syndrome. *Clin. Res.* 12: 217 (1964).
12. KOSMOGLOU K. A.; MITTS, W. J. and DANKERHEIJM, W. A direct method for chromosome studies of human bone marrow. *Amer. J. clin. Path.* 41: 183-187 (1964).
13. KOSMOGLOU K.A., MITTS, W.J. and DANKERHEIJM, W.: Chromosomal aberrations in pernicious anaemia. Study of three cases before and after therapy. *Blood* 25: 662-682 (1965).
14. MACDONALD, W. D.: Personal communication (1964).
15. PATAI, K. Chromosome identification and the Denver Report. *Lancet* i: 933-935 (1961).
16. POWERS, E.R. and BERMAN, L. Human bone marrow chromosomes in megaloblastic anaemia. *Blood* 26: 784-789 (1965).

Authors' address: Drs. K. Kosmoglou, K. A. Kosmoglou, P. Mamas and B. Soti-Mamas, Department of Paediatrics, University of Athens, St. Sophia's Children's Hospital, Gouda, Athens 689 (Greece).

The Department of Hematology and the Department of Otorhinolaryngology  
Toranomon Hospital, Tokyo

## Hageman Factor Deficiency

Report of a Case Found in Japanese Girl

S. MIWA, I. ARAI, T. TSUKADA, M. SHIMIZU  
K. TERAMURA and Y. SUNAGA

Hageman factor deficiency is a rare disorder which affects both sexes and is characterized by prolonged clotting time of venous blood without abnormal bleeding tendency. The disorder is usually discovered by chance.

This is to report a case with this disorder found in Japanese, whose abnormality was detected accidentally during routine pre-operative laboratory studies.

### *Report of Case*

Y. N., a 5½-year-old Japanese girl was admitted to the Toranomon Hospital in September 1966 for tonsillectomy when she was found to have prolonged clotting time during routine pre-operative studies. She had adenoidectomy at 3 years of age without unusual bleeding. She is normally active and has never been considered by her parents as being more susceptible to bruises than her brother and other children. She had never had swollen joints, large ecchymoses, or prolonged bleeding following cuts. Family history revealed that the parents of the proband are first cousins. The family tree is shown in Fig. 1. None of the members in the family is said to have hemorrhagic diathesis.

The physical examination was entirely negative except for enlarged tonsils and hard of hearing due to adenoids.

Routine laboratory studies: Urinalysis negative; hemoglobin 12.1 g %; red blood cell count  $4.2 \times 10^6/\text{mm}^3$ ; white blood cell count  $10,000/\text{mm}^3$  with normal differential count; platelet count  $32 \times 10^3/\text{mm}^3$ ; bleeding time (Duke's) 2 min; blood clotting time (Lee White, normal 5 to 15 min) 31 min; plasma prothrombin time (Quick) 62%; serologic test for syphilis negative; blood groups B, Rh-positive.

### *Study of the Clotting Defect*

The results of routine clotting studies of patient's blood are shown in Table I. As can be seen from the table, the patient's




Fig 1 Hageman factor deficiency kindred.

Table I

Results of investigation of the hemostatic mechanism in patient Y N.

Bleeding time (normal 1 to 3 min)	2 min
Capillary resistance (Rumpel-Leede)	normal
Platelet count (normal $13-99 \times 10^4$ )	$31.6 \times 10^4$
Platelet morphology	normal
Clotting time (Lee White normal 5 to 15 min)	29 31 36 min
Silicone clotting time (normal 23 to 38 min)	34 42 min
Recalcification time (normal 100-205 )	24 min
Plasma prothrombin time (Quick, one stage; normal > 70%)	62%
Prothrombin consumption (normal > 31 )	11
Clot retraction	normal
Fibrinogen (FI-test)	normal (over 100 mg/dl)

blood exhibited greatly prolonged clotting time and recalcification time, slightly prolonged plasma prothrombin time, and abnormal prothrombin consumption. From these results, a disturbance of blood thromboplastin formation seemed most likely and further investigations on factors concerning this phase of clotting were made. As the proband is a girl, it seemed unlikely that she had either AHF deficiency or PTC deficiency and it seemed more




Fig. 2

Fig. 2. Result of thromboplastin-generation screening test.




Fig. 3

Fig. 3. Result of thromboplastin generation test.

likely that she had either PTA deficiency or Hageman factor deficiency.

Thromboplastin-generation screening test showed marked abnormality as shown in Fig 2. The results of thromboplastin generation test revealed that both the normal serum and the normal  $\text{BaSO}_4$  adsorbed plasma corrected the abnormal thromboplastin generation of the patient's blood (Fig 3).

Recalcification time using untreated tube was markedly prolonged (24 mm). When the test tube sensitized by rinsing normal diluted serum (one part of plasma in 100 of isotonic saline) followed by washing six times with isotonic saline was used (1) recalcification time of the patient's plasma was almost normalized (3 mm 24 s).

Citrated lyophilized plasma was prepared using silicon coated glassware, and was sent to Dr O D RATNOFF of Western Reserve University Cleveland, Ohio, and to Dr J P SOULIER of Centre Nationale Transfusion Sanguine, Paris, by air mail, who very kindly performed specific assay of PTA and Hageman factor. The results showed that whereas PTA activity of the patient's plasma was over 100% Hageman factor activity was less than 1%.

### Family Study

Eleven out of 14 living relatives of the probandus were available for routine coagulation study as shown in Fig 1. Hemoglobin con-

centration, red blood cell count, white blood cell count, differential count, platelet count, bleeding time, blood clotting time (LEE WHITE) recalcification time, one stage prothrombin time (QUICK) and tourniquet test were performed on these members of the family. None of them showed definite abnormality. The results of coagulation time and recalcification time are shown in Table II.

Citrated lyophilized plasmas from parents, both paternal and maternal grandparents were prepared, using siliconized glassware, and again sent to Dr O D RATNOFF for Hageman factor assay. The results obtained in his laboratory are shown in Fig 4. The father, paternal grandfather and maternal grandfather showed low Hageman factor activity, whereas that of the mother, maternal grandmother and paternal grandmother were within normal range.

### Discussion

Hageman factor deficiency is quite unique among coagulation factor deficiencies in that these individuals ordinarily do not show abnormal hemorrhagic symptoms even after trauma, surgical procedures, although blood clotting time is markedly prolonged as seen in severe hemophilia. The case reported here is not an exceptional one in this respect.

Table II

Results of clotting time and recalcification time in members of kindred N.

		Age	Clotting time (Lee-White) (normal 5 to 15 min)	Recalcifi- cation time (normal 100 to 200 s)	Comment
II	1	Paternal grandfather	70	10½	191
	2	Paternal grandmother	64	10	151
	3	Maternal grandfather	79	9½	110
	4	Maternal grandmother	69	9½	91
III	1	Father	41	8	Thromboplastin generation test normal
	2	Paternal aunt	39	10½	
	6	Paternal uncle	29	11	140
	7	Paternal uncle	25	10	130
	10	Mother	33	12	169
	11	Maternal uncle	29	9½	122
IV	1	Brother	7	10	151



Department of Paediatrics, State Hospital, Hrud

## A Survey for Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency in Rumania

J. H. SCHNEER

Hemolytic disorders following consumption of certain vegetables and drugs have long been known, but only 12 years ago it was recognized that the deficiency of erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) is in the background of these disorders [2]. The G-6-PD deficiency is prevalent amongst some ethnic groups including American and African Negroes, Caucasians of Mediterranean countries and some South-east Asian populations [6, 8, 9, 12]. In Central and Northern Europe, the G-6-PD deficiency appears too but only sporadically [3, 4, 5, 13].

In Rumania, the first case of G-6-PD deficiency – a chronic non-spherocytic anemia – was observed in 1964 by Kovacs *et al.* [7]. One year later we reported two cases of favism and the investigation of the relatives revealed other three defective subjects [10]. The absence of previous data regarding the incidence of this enzymopathy in our country prompted us to conduct a search for G-6-PD deficiency among a Rumanian population and in 1966 we exposed the preliminary results [11].

The purpose of this paper is to report the actual data of our survey.

### *Materials and Methods*

Venous blood specimens were obtained from randomly selected patients and normal individuals, from the Department of Paediatrics and the Polyclinic of Hrud (Rumania).

The qualitative G-6-PD activity was determined on freshly-drawn heparinized blood, by the methemoglobin reduction test of Beutler *et al.* [1]. Subsequently the deficient individuals and their relatives were investigated clinically, hematologically and genetically.

Table. G-6-PD deficient individuals

No.	Subject	Years	Sex	Pedigree	Diagnosis	Methemoglobin reduction test
1	G. O.	3	M	propositus	favism	complete deficiency
2	G. R.	25	F	mother	healthy	partial deficiency
3	C. V.	28	F	aunt	healthy	partial deficiency
4	C. A.	2	M	cousin	healthy	complete deficiency
5	M. D.	1	M	propositus	favism	complete deficiency
6	M. C.	29	F	mother	healthy	partial deficiency
7	B. C.	49	F	grandmother	healthy	complete deficiency
8	B. V.	11	M	uncle	healthy	complete deficiency
9	G. C.	15	M	propositus	hemophilia A, scot hemolytic anemia	complete deficiency
10	G. L.	37	F	mother	healthy	complete deficiency
11	S. V.	17	M	propositus	healthy	complete deficiency
12	S. E.	47	F	mother	healthy	partial deficiency
13	S. R.	9	M	brother	healthy	complete deficiency
14	S. F.	7	M	brother	healthy	complete deficiency
15	D. A.	64	F	grandmother	healthy	complete deficiency
16	B. E.	37	F	aunt	healthy	partial deficiency
17	A. A.	0.5	F	propositus	acute hemolytic anemia	complete deficiency
18	A. L.	43	M	father	healthy	complete deficiency
19	I. G.	66	M	propositus	thalassaemia minor	complete deficiency
20	H. M.	27	F	daughter	healthy	complete deficiency
II	D. A.	31	F	daughter	healthy	complete deficiency
II	D. V.	4	M	grandson	adactylia of the right hand	complete deficiency
23	G. A.	31	F	propositus	history of favism	complete deficiency
24	G. E.	73	F	mother	chronic anemia	complete deficiency
25	G. D.	81	M	father	healthy	complete deficiency
26	G. E.	13	F	daughter	healthy	partial deficiency
27	G. C.	9	M	son	healthy	complete deficiency
II	O. G.	3	M	propositus	favism	complete deficiency
29	O. A.	24	F	mother	healthy	complete deficiency
30	D. C.	68	M	grandfather	healthy	complete deficiency
31	M. T.	35	F	aunt	healthy	complete deficiency
32	M. P.	6	M	cousin	healthy	complete deficiency

In this study the screening test employed, did not detect as propositus, partially G-6-PD deficient females.

### Results

The methemoglobin reduction test was performed on 890 males and 792 females. Complete G-6-PD deficiency was found in 8 probands

and the survey of 94 relatives revealed other 24 deficient individuals. All the deficient subjects are of Rumanian origin between their families are no relation. The clinical and hematological data for these 32 deficient individuals are listed in the table.

### Discussions

This is the first attempt at estimating the incidence of G-6-PD deficiency in a Rumanian population, randomly selected. Considering only the test performed on males, the G-6-PD deficiency appears to attain 1.8% (gene frequency 0.0067-0.018)

It is difficult to explain the appearance of the enzymopathy. Since in our country malaria was endemic in previous years, the G-6-PD deficiency could be explained by the controversial malaria theory. Another possibility is that the genopathy was brought by the mediterranean peoples who colonized the ancient territory of Rumania (the ancient Dacia)

We suppose that the G-6-PD deficiency is not restricted to the area investigated in our survey and we think that it would be advisable to continue such studies, not only for the genetic and anthropological significance of this estimation but also for the prevention of the hemolytic states in defective subjects.

### Summary

A survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency was carried out amongst 1682 randomly selected Rumanian individuals, by the methemoglobin reduction test. 32 individuals were found to have G-6-PD deficiency. Considering only the G-6-PD deficient males, the enzymopathy appears to attain 1.8% (gene frequency 0.0067-0.018)

### References

1. BREWER, G. J., TARLOV, A. R. and ALVINO, A. S. Methemoglobin reduction test. *Bull. WHO* 22: 633 (1960)
2. CARSON, P. E.; FLAUGAR, C. L.; JONES, C. L. and ALVINO, A. S. Enzymatic deficiency in primaquine-sensitive erythrocytes. *Science* 129: 484 (1956)
3. DREYFUS, J. C.; MALSOGIA, M. et KAPLAN, J. C. Recherches sur le déficit en glucose-6-phosphate déshydrogénase en France. *Nouv. Rev. franç. Hémat.* 4: 791 (1964).
4. DULCEA, S. M., MATVEY, M. P. and SATONOVA, L. V. Skotchial ostrol gamolikt skotchial ostrol eviazhenol defitsitosa fermenta glukozo-6-fosfat dehidrogenad. *Vopr. Obr. Mater. Detstvo*, 17:81 (1967)

5. GERMANN, G.; STORM, A. JR. und AMELUNG, D. Favismus in Deutschland. *Dtsch. med. Wochr.* 89: 1863 (1963).
6. KELLERMEYER, R. W.; TARLOW A. R., BREWER, G. J., CARSON, P. E. and ALVINO, A. S.: Hemolytic effect of therapeutic drugs. *J. amer. med. Ass.* 180: 388 (1962).
7. KOWA, V.; MITEICA, N.; IACOBESCU A. and BALAN, ST. Deficienta de glucoza-6-fosfat dehidrogenaza. *Med. int. (Bucuresti)* 16: 899 (1964).
8. OMS: Hémoglobinoopathies et troubles apparentés. OMS Sér. Rapp. techn. No. 388 (1965).
9. OMS: Normalisation des techniques d'étude de la glucose-6-phosphate déshydrogénase. OMS, Sér. Rapp. techn. No. 366 (1967).
10. SCHÖDER, J. H.; SCHÖTTER, L. and CRANGANU, A. Consideratii asupra doua cazuri de favism. *Med. int. (Bucuresti)* 18: 727 (1966).
11. SCHÖDER, J. H.; SCHÖTTER, L. and BAILESCU, I. Contributii la cunoasterea deficientei de glucoza-6-fosfat dehidrogenaza. *Vista med. (Bucuresti)* 11: 151 (1967).
12. TARLOW A. R., BREWER, G. J.; CARSON, P. E. and ALVINO, A. S. Primaquine sensitivity. *Arch. intern. Med.* 109: 709 (1962).
13. WEITMAN, V. and TÖTZ, O.: Glukose-6-Phosphat-Dehydrogenase-Mangel der Erythrozyten bei drei deutschen Kindern. Nachweis einer frischen Mutation. *Klin. Wochr.* 44: 446 (1966).

Second Medical Clinic of Palacky University Olomouc, Hospital Central Laboratories  
Čadca

## Acid Phosphatases of Platelets during Coagulation and Storage of Blood

J. POLÁČEK and P. KUNUZ

Platelet factor 3 (PF3) belongs to the basic properties of platelets by which the haemostatic function of these blood elements is realized. It is evident that we can speak about lipoprotein the exact localisation of which in the ultrastructure of platelets is still open [1]

In the previous work it was shown that the acid phosphatases (APh) liberated from the platelets into serum during the coagulation of blood are probably linked to lipoprotein which is responsible for the so called platelet like activity of serum [2]

In this work we tried to find the basic correlation between activity of APh and PF3. From the point of view of lysosomal theory APh can be used as biochemical marker of lipoprotein of lysosomal origin [3]

### *Material and Methods*

Blood was taken from healthy volunteers. The serum for studying PF3 like activity was acquired from native platelet rich plasma (PRP) without use of anticoagulant as described previously as well as the settling of the activity of APh of serum or plasma without the use and with the use of detergent-analogon Triton X 100 [2].

The shortest fibrinogen time (SFT) was set as O'Brien described [4].

APS ('activité plaquettaire du sérum') was carried out according to ALAVALLE and SOULIER [5]. Results are given as differences in prothrombin consumption between 4-6 min after recalcification of test mixture. The substrate plasma without platelets was prepared for both coagulation tests according to the last mentioned method.

The fresh blood stored in ACD solution was kindly supplied by Transfusion Service Žilina. The blood was stored at 4°C and in certain intervals the samples were taken under sterile conditions. Platelets were counted by the PERRY method [6]. Plasma was separated from the samples by centrifugation at 4°C at 2,000 × g twice, each centrifugation lasting




Fig.1 Time dependence of liberation of acid phosphatase (Aph) and PF3 like activity into serum from native platelet rich plasma (PRP). SFT = shortest fibrinogen time APB = platelet activity of serum.

30 min. No formed elements could be observed in this plasma under the phase microscope. In the plasma we observed the haemoglobin content [7], the activity of Aph without and with detergent.

The thromboplastic activity by means of methods mentioned above [4-5] with modification forced by using of citrate plasma instead of serum as tested material. The basic mixture which was the same for both methods contained 0.3 ml of platelet poor substrate plasma and 0.1 ml of tested plasma. T recalcification 0.5 ml of 0.025 M  $\text{CaCl}_2$  were used.

Haemolysate was prepared by dilution of isolated erythrocytes by distilled water to desired concentration of haemoglobin [8].

### Results

The time dependence of liberation of Aph and PF3 activities into serum is given in figure 1. The curves show the correlation between both activities. The activities in serum seem to depend on the retrac

Table II. Changes in some activities in plasma from blood stored in ACD solution at 4°C

Blood No.	Day	Thrombocytes	Haemoglobin mg%	Acid phosphatase $\mu$ M/ml/h		SPT sec	APP sec
				no deterg.	with deterg.		
1	0	163 000	10	0.140	0.216	68	0
	7	132 000	20	0.274	0.714	24	3.7
	14	94 000	66	0.478	0.840	16	12.3
	21	50 000	208	1.204	2.534	15	20
2	0	223 000	14	0.250	0.420	52	2
	7	192 000	14	0.345	0.870	30	8
	14	160 000	47	0.455	0.920	22	10
	21	101 000	71	0.770	1.540	20	20
3	0	217 000	28	0.226	0.252	31	0.5
	7	188 000	48	0.546	1.172	18	18
	14	130 000	126	0.868	1.680	18	23
	21	66 000	181	0.742	1.594	18	23
4	0	186 000	16	0.084	0.112	110	0
	7	130 000	50	0.350	0.560	31	3
	14	101 000	128	0.282	1.338	20	20.2
	21	95 000	198	0.700	0.994	18	14.2
5	0	207 000	28	0.126	0.198	66	0
	7	128 000	48	0.294	1.134	17	10.5
	14	98 000	144	0.588	1.680	17	16.5
	21	48 000	226	1.148	2.072	17	22

HOROWITZ *et al.* [9] shows as for quantitative changes after ultra centrifugation the similar values as the activity of APh. About 15–20% of the activity APh liberated into serum remains also after centrifugation at  $20,000\times g$  in the supernatant. In such supernatant no thromboplastic activity could be traced by coagulation tests we used.

When following the curves showing the changes of given values in plasma obtained from the stored blood, the time correlation of the appearance of thromboplastic activity concomitantly with the activity of APh is also evident. We assume that we dealt with material of platelet origin according to WOLF [10] who described the platelet dust liberated into plasma during storage of blood. The enormously high values of APh obtained especially by means of detergent indicate that there must be a rest of the platelet lysosomes. This should prove electromicroscopical findings [11]. Even if the older samples of plasma show comparatively high values of haemoglobin, erythrocytes participated in both observed activities only very little. Haemolysate of isolated

erythrocytes the value of which was 200 mg % haemoglobin shows the activity of APh with detergent about 0.1 units of BESSEY LOWRY. No thromboplastic activity could be traced by tests used by us.

The fact that during storage of blood, except others, also the rest of platelet lysosomes is liberated into plasma is interesting both from theoretical and from practical points of view. If the correlation between by APh labeled lipoprotein and PF3 activity is proved by further experiments, it could help to solve the question of PF3 origin. We should also mention the finding of KOWALSKI *et al.* [12] that platelet APh is activated by kaolin when the values approached the values obtained by means of Triton X 100 only. On the other side the activity of PF3 was proved by means of the very kaolin [13, 14].

The fact that highly active sediment of serum acquired by ultra centrifugation is completely captured in coagulum of native PPP might mean that during retraction of coagulum a part of thromboplastic activity liberates into serum and perhaps is to ensure the perfect course of coagulation.

The increased availability of PF3 in plasma of stored blood could probably help to explain the well known clinical experience regarding the unsuitability of transfusion of stored blood to patients suffering from thromboembolic diseases.

### *Acknowledgement*

We are indebted to Mrs. L. KOWALSKA for her excellent technical assistance in the conduct of these studies.

### *Summary*

A time correlation of appearance of acid phosphatase and platelet factor 3 activities in the serum obtained from native platelet rich plasma has been found. But none of these activities was liberated from the platelets into plasma or serum close to the time when the coagulum developed *in vitro*. The liberation of both activities could be observed only after retraction of the coagulum.

Concomitantly with the liberation of acid phosphatases the platelet factor 3 activity in plasma obtained from stored blood raised. The high values of acid phosphatases in plasma give evidence to their platelet lysosomal origin.

### *References*

1. MARCUS, A. J. and ZUCKER, M. B. The physiology of blood platelets (Grune and Stratton, New York 1963).



2. POLÁK, J. Particulate nature of acid phosphatase released from thrombocytes. *Thromb. Diath. haemorrh.* (accepted for publication)
3. DE DUVE, C.: The lysosome concept; in *Lysosomes*, Ciba Foundation Symposium, p. 1 (Churchill, London 1963).
4. O'BRIEN, J. R. The platelet-like activity of serum. *Brit. J. Haemat.* 1: 223 (1955).
5. ALAÏCHE, D. et SOULIER, J. P. Le test d'activité plaquettaire du sérum. *Rev. franç. Et. clin. biol.* 2: 231 (1957)
6. PIETTE, M. et PIETTE, C.: Numération des plaquettes sanguines utilisant un liquide hypotonique basé de chlorhydrate de procaine. *Sang.* 30: 144 (1959)
7. CHERRY, W. H. and FURTH, F. W.: Modification of the Bensidine method for measurement of hemoglobin in plasma and urine. *Blood* 11: 380 (1956)
8. MEY, U. und HANZ, P.: Über den Einfluss des Erythrozytins auf die Blutgerinnung. *Blut* 13: 30 (1966)
9. HOROWITZ, H. I. and PAPADANOU, M. F.: Release of non-sedimentable platelet factor 3 during coagulation. *J. Lab. clin. Med.* 69: 1003 (1967)
10. WOLF, P. The nature and significance of platelet products in human plasma. *Brit. J. Haemat.* 13: 269 (1967)
11. PRIDICK, A. M. and ADAMS, W. R. Virus-like particles in human plasma and serum: Role of platelet lysosomes. *J. nat. Cancer Inst.* 37: 155 (1966).
12. KOWALSKI, Z.; KOPCZ, Z. WROSKYŃSKA, M. HORWIC, M. and BENETIENI, A. Z. A lysosomal concept of the platelet release reaction and viscous metamorphosis. *Thromb. Diath. haemorrh.* 16: 134 (1966)
13. HARDISTY, R. M. and HUTTON, R. A. The kaolin clotting time of platelet-rich plasma: A test of platelet factor-3 availability. *Brit. J. Haemat.* 11: 256 (1965).
14. SPART, T. H. and GERTSON, J. Studies on platelet factor-3 availability. *Brit. J. Haemat.* 11: 269 (1965).

Blood Research Laboratory, New England Medical Center Hospitals and Department of Medicine, Tufts University School of Medicine, Boston, Mass.

## Bone Marrow Injury and Repair

### *Irradiation and Mechanical Disruption<sup>1</sup>*

M. B. WEINSTEIN<sup>2</sup> and W. H. GROSSY

Exposure of the femur and tibia of the rat to 4 000 r of x irradiation results in permanent aplasia of the bone marrow [1]. Two months post irradiation, when the aplasia has been well established, autologous marrow removed from an unirradiated bone and implanted in the irradiated area can reconstitute hemopoietic activity [2]. It has been proposed that the limiting factor which determines the existence of aplasia or hemopoiesis is the condition of the microcirculation of the marrow. This sinusoidal structure is evidently uniquely capable of supporting the proliferation of hemopoietic tissue. When it is destroyed by irradiation, or otherwise, the hemopoietic marrow atrophies. The restoration of normal activity in the irradiated marrow cavity by transplantation of tissue is presumably accomplished by adventitial cells capable of proliferating to reconstitute the microcirculation. This experiment was designed to learn if normal marrow from the shielded portion of an irradiated bone could be induced by mechanical mixing to proliferate in the aplastic portion.

### *Materials and Methods*

Radiation was performed on the distal half of the tibia in groups of 10 male Wistar rats of about 400 g. The rats were placed in individual boxes and shielded by layers of lead to protect the body, upper legs and feet. The radiation source was 250 kvp-15 mA with 1/8 mm

These studies supported with funds from US Public Health Service Grant No. CA 04168-10 from the National Cancer Institute.

Trainee in Hematology supported by US Public Health Service Grant No. AM 5210-07

copper and 1 mm aluminum filter. The target-to-skin distance was 33 cm. Dose rate was 250 /min, and exposure time was 15.5 min. The half-value layer was 1.2 mm copper. The total exposure dose was 4 000. The original groups of 10 rats were reduced by 20 % because of autoamputation of irradiated legs. Shielding the feet during irradiation prevented this.

When anasthesia was required, pentobarbital was injected intraperitoneally. Mechanical disruption of tibial marrow was accomplished by introducing a 1½ in, 11 gauge needle into the marrow cavity at the femorotibial joint. Then stainless steel wire was passed through the needle into the cavity and the marrow was mixed by 20 up-and-down strokes of the wire trochar.

The marrow was disrupted at varying intervals after the irradiation (table I). In one group of animals the operation was performed before irradiation and in one group it was performed without irradiation. Only marrow of the left leg was disrupted so that the right could serve as control.

The animals were killed with ether and the tibias were removed and fixed in buffered formalin for 3 days, decalcified in Perenyi's solution for 5 days, imbedded in paraffin, sectioned at 6 µm and stained with hematoxylin and eosin.

### Results

Those bones in which the marrow was not mechanically disrupted were examined at intervals up to 8 weeks after irradiation and the typical cycle of changes was observed: sinusoidal dilation, intra medullary hemorrhages, hyperplasia and then hypoplasia [1]. In all

Table I. Recovery of hematopoiesis in hemirradiated tibia. 4000 r to distal end followed by mechanical disruption of marrow

Group (10 rats each)		Marrow disrupted after irradiation weeks	Interval from disruption of marrow until death, weeks	Interval from irradiation of marrow until death, weeks	Recovery of hematopoiesis
1	A	1	9	10	yes
	B	1	13	14	yes
	C	1	15	16	yes
2	A	2	6	8	yes
	B	2	8	10	yes
3	A	4	4	8	yes
	B	4	6	10	yes
	C	4	8	12	no
	D	4	10	14	no
4	A	6	4	10	no
	B	6	6	12	no
	C	6	10	16	no
5	A	8	2	10	no
	B	8	6	14	no

of the irradiated tibiae there was a line of demarcation by the 8th week in the distal end of the cavity the hemopoietic marrow was replaced by loose connective tissue, rare lymphocytes and plasma cells and few erythrocytes. The proximal end contained normal marrow.

The effect of mechanical disruption of marrow in the unirradiated tibia was studied after the 5th postoperative day. Marked endosteal proliferation was seen and in some areas the medullary cavity became completely filled with trabecular bone. Two, 3 and 4 weeks after disruption of the marrow some trabecular bone remained in the cavity but endosteal proliferation subsided with time.

Disruption of marrow preceding irradiation by 5 days did not modify the effects of irradiation. At 8 weeks there was fibrosis in the distal end of the cavity and in the proximal end there was normal hemopoietic marrow plus trabecular bone. The irradiated distal right tibia in every animal became fibrotic and aplastic. Results of the combined injury are shown in table I. When mechanical disruption of the left tibial marrow followed irradiation by one or two weeks (groups 1 and 2) hemopoietic cells were found in the irradiated areas 4 to 15 weeks postoperatively. Hemopoietic tissue and trabecular bone were present through the entire length of the cavity. In some bones islands of normal tissue were scattered among aplastic areas. When disruption followed irradiation by four weeks (group 3) there was recovery of hemopoiesis in the distal cavity of some animals, but not all. When disruption followed irradiation by 6 or 8 weeks (groups 4 and 5) there was only fatty and connective tissue in the distal end of the cavity 2 to 10 weeks postoperatively.

### *Discussion*

When the marrow was mechanically disrupted, the cavity quickly became filled with trabecular bone surrounded by osteoblasts. The endosteum was hypertrophic. In succeeding weeks the hypertrophy subsided. The bony replacement was complete in some bones, patchy in others. Hemopoietic marrow was present in the areas of no bone and in the spaces between the bony trabeculae.

When the marrow was mechanically disrupted after irradiation, the irradiated and unirradiated tissues were tumbled and mixed within the bony cavity. The spotty recovery of the marrow in the irradiated portions of the bone indicate that the intent of the procedure was

accomplished. Normal marrow was forced into the aplastic tissue and established itself there. But the presence of aplastic areas in the proximal cavity suggests that irradiated tissue was moved into the shielded areas and it was not invaded or converted by the adjacent normal tissue.

As the irradiation lesion matured it became more fibrotic. After four weeks the efforts to mix the marrow in the two ends of the cavity were unsuccessful, perhaps because the wire trochar only channeled the irradiated tissue and did not replace it.

It is proposed that the growth of hemopoietic marrow in irradiated portions of the tibia occurred because adventitial tissue was displaced into those areas permitting the marrow's microcirculation to be reestablished there. This would indicate that the marrow's adventitia is not aggressive—it does not propagate into irradiated areas by its own initiative. Hemopoietic tissue, on the other hand, seems to develop wherever there is adventitia to support it.

### *Summary*

Post-irradiation aplasia in the marrow of the rat's tibia developed only in the irradiated distal half. When the marrow of the unirradiated half was moved into the irradiated portion by means of mechanical disruption of the bony cavity, hemopoietic marrow developed in the irradiated portion.

### *References*

1. KROUSE, W. H.; BLOW, J. and CROSBY, W. H. Local irradiation of bone marrow I. Long term changes in the rat with particular emphasis upon vascular and stromal effects. *Blood* 48: 396 (1966).
2. KROUSE, W. H.; BLOW, J. and CROSBY, W. H. Regeneration of locally irradiated bone marrow II. Induction of regeneration in permanently aplastic medullary cavities. *Blood* 31: 400 (1968).

Authors' addresses: Dr. MORTON B. WEINSTEIN, Jackson Memorial Hospital, Dept. of Nuclear Medicine, Miami, Fla., Dr. WILLIAM H. CROSBY, New England Med. Center Hospitals, Blood Research Laboratory, Boston, Mass. (USA).

Department of Pathology St. Mary' Hospital  
Medical School, London

## Eosinophils and Dietary Histamine in the Rat

EVELYN C. BLINKINSOFF and W. K. BLINKINSOFF

Eosinophils are most numerous in the gastrointestinal tract and the skin and spend most of their life in these tissues [1]. Their function is still obscure, but ARCHER [2] considered that they inactivated histamine: this conclusion was based on the occurrence of a local eosinophilia following intradermal injection of histamine, which could be inhibited by injection of an antihistamine immediately after the injection of histamine. This hypothesis would be strengthened if the turnover or number of eosinophils altered in response to an alteration in histamine balance or in response to the continuous administration of antihistamine. In the present work, continuous infusions of tritiated thymidine were used in rats to investigate the effect of histamine-high diet, histamine-low diet and normal diet with antihistamine, on eosinophil turnover and populations. One of the authors has previously studied eosinophils in normal rats by this technique [1].

### *Material and Methods*

Seven (B 1-7) adult male black-hooded FVG/C rats (weight 300 g) and 16 (B 1-16) adult male Sprague-Dawley albino rats (weight 180-210 g) were divided into 4 groups according to diet. Each diet was given for 16 days before the rats were killed. In each group, 2, 3 or 4 rats were given 8 or 6 days continuous intraperitoneal infusion [3] of 1  $\mu$ C tritiated thymidine (specific activity 3.0 C/mole)/g/day starting 8 or 10 days after the special diets were begun and ending when the animals were killed. The detailed treatments in each group were as follows.

*Normal diet.* Six control rats (B 1-2 and B 1-4) received a normal cubed 41 B diet [4]. Three were infused with tritiated thymidine for 6 days (B 1 and B 1-2) and one for 8 days (B 2).

*Histamine-high diet.* Seven rats (B 3-5 and S 5-8) each received 15 g fresh minced raw meat daily. This diet supplies large quantities of exogenous histamine and probably also stimulates the formation of endogenous histamine [5]. Three rats (B 5 and S 5-6) were infused with tritiated thymidine for 6 days.

*Histamine-low diet.* Six rats (B 6-7 and S 9-12) each received 15 g daily of diet containing less than 0.05  $\mu$ g histamine/g [6]. One rat was infused with tritiated thymidine for 8 days (B 6) and 2 for 6 days (S 9-10).

*Antihistamine.* Four rats (S 15-16) on a normal 41 B diet each received 2.5 mg Mepyramine maleate/day. This was given in the drinking water to S 15-16 throughout, and in the drinking water to S 15-14 for 10 days, then in continuous intraperitoneal infusion for 6 days. Rats S 13-14 were infused with tritiated thymidine for 6 days.

After 10 days of the special diets, absolute eosinophil counts [7] were made on blood samples taken from 4 rats in each group (S 1-16). Blood films were taken from the tail veins of each infused rat at intervals during the infusion and fixed in 100% methyl alcohol; marrow smears (fixed in 100% methyl alcohol) and tissue blocks (fixed in formal-saline) were taken at necropsy from each infused rat. Tissue blocks were also taken at necropsy from rats B 4-5 (histamine-high diet) and B 7 (histamine-low diet). Sections (5  $\mu$ m) were prepared from the tissue blocks: those from the infused rats, and their blood films and marrow smears, were dipped in Ilford K5 nuclear emulsion or covered with Kodak AR 10 stripping film and these autoradiographs were exposed for 4 weeks at 0-4 C. All the sections, films and smears were stained with Mayer's haemalum and Heidenhain scarlet to identify the eosinophils [8]. Labelled and unlabelled eosinophil nuclei: total of between 50 and 200 were counted in each film, smear or section. Eosinophils in the marrow were not differentiated into myelocyte, metamyelocyte, stab form or mature eosinophil.

## Results

The marrow smears from each infused rat showed that cells with eosinophil granules formed 8-10% of the total cell population and the percentage labelling of these cells was 97-100%.

In the black hooded rats, differential cell counts on the blood films showed that eosinophils formed 5% of the circulating white cells, and between 100 and 120 eosinophils were present in each film. These values are within normal limits [1]. In the Sprague Dawley rats, absolute eosinophil counts on blood samples were between 122 and 288 eosinophils/mm<sup>3</sup> which is within the range given by RYTÖMÄÄ [9] for normal rats weighing 210 g. Thus the total number of blood eosinophils was within the normal range irrespective of diet.

The percentage of eosinophils labelled in each blood film was used to establish their rate of turnover. Sequential entry to and random removal from blood has been established for normal rat eosinophils [1] and this requires that

$$\log_e \left( \frac{1}{1-r} \right) = kt,$$

where  $f$  is the fraction of eosinophils labelled at time  $t$ , and  $k$  is the number of eosinophils added to the circulation in unit time, expressed as a fraction of the number normally present in the circulation. If  $\log (1/1-f)$  is plotted against  $t$  and a best fitting line is drawn, the slope of this line gives the value of  $k$ .  $k$  was determined in this way for each rat, and  $(1/2k)$  (the half life of an eosinophil in the circulation) is given in table I. The intercept of the line on the abscissa gives the time at which the eosinophils begin to leave the bone marrow and enter the blood. The time between the start of the infusion and this point is the length of time from the end of deoxyribonucleic acid synthesis of an eosinophil myelocyte to the exit from the marrow of the consequent eosinophil leucocyte (table I). The half life of eosinophils in the blood, and the time of appearance of labelled eosinophils in the blood, do not differ significantly from the normal in any dietary group.

In the tissues the distribution of eosinophils was normal in all rats [9]. No significant difference was found in either total number or percentage labelling of eosinophils between black-hooded and Sprague Dawley rats, and the values for the two strains of rat have therefore been pooled for the statistical analysis. There was also no significant difference between the percentage labelling of eosinophils in stomach, small intestine and large intestine, which have therefore also been

Table I. Half-life of eosinophils in the blood and interval between beginning of tritiated thymidine infusion and appearance of labelled eosinophils in the blood

Rat	Diet	Half-life h	Time of appearance of labelled eosinophils h
B 1	Normal	8-12	60-73
B 2			
B 3			
B 6	Histamine-high	11.5	67 ½
B 6	Histamine-low	10.1	61
S 1	Normal	10.0	51
S 2			
S 3			
S 5	Histamine-high	8.4	40
S 6			
S 7			
S 9	Histamine-low	5.9	44
S 10			
S 11			
S 12	Normal diet with antihistamine	9.8	46
S 14			

Range of normal from Foot [1].



pooled for the analysis. The mean values and the standard deviations for total number and percentage labelling of eosinophils in the tissues are given in tables II and III and comparison using the Student *t* test showed no significant differences between the dietary groups.

### Discussion

CODE [10] suggested that eosinophils contained histamine, but the amount is insignificant when compared to that in mast cells [11]

There is good evidence that the eosinophil is an antagonist to histamine. This property has been demonstrated in eosinophils from rabbits [12] from horses [13 14] and from man [14] WELSH and

Table II. Total number of eosinophils in 2 mm<sup>2</sup> of a 5  $\mu$ m section from each rat tissue: mean and standard deviation for each dietary group

Diet	No. of rats	Spleen	Stomach	Small intestine	Large intestine
Normal	4	25 $\pm$ 4	208 $\pm$ 68	130 $\pm$ 35	145 $\pm$ 52
Histamine-high	5	19 $\pm$ 3	233 $\pm$ 75	132 $\pm$ 36	139 $\pm$ 21
Histamine-low	4	23 $\pm$ 12	204 $\pm$ 64	132 $\pm$ 24	167 $\pm$ 34
Normal diet with antihistamine	2	19 $\pm$ 11	164 $\pm$ 33	111 $\pm$ 38	177 $\pm$ 40

Table III. Percentage of eosinophils labelled in rat tissues: mean and standard deviation for each dietary group

Diet	No. of rats	Spleen	Stomach and small and large intestine
<i>6-day tritiated thymidine infusion</i>			
Normal	3	79 $\pm$ 10	43 $\pm$ 21
Histamine-high	3	70 $\pm$ 4	40 $\pm$ 14
Histamine-low	2	70 $\pm$ 7	37 $\pm$ 16
Normal diet with antihistamine	2	74 $\pm$ 9	50 $\pm$ 19
<i>8-day tritiated thymidine infusion</i>			
Normal	1	88	79 $\pm$ 8
Histamine-low	1	83	83 $\pm$ 10

GREER [15] produced electron micrographs which demonstrated phagocytosis of mast cell granules by eosinophils in the peritoneal fluid of a rat.

There is also good evidence of a chemotactic effect of histamine on eosinophils in some species but not in others. When lesions of urticaria pigmentosa were stroked they showed some degranulation of the mast cells with a slight influx of eosinophils [16] and in man marked local eosinophilia followed injection of histamine in the skin of atopic individuals, although this did not occur in those who were not atopic [17-18]. Marked local eosinophilia followed injection of histamine in horses [2-19] but this effect was not seen in mice [20-21], guinea pigs [22] or dogs [23].

Mast cell granules contain most of the histamine in the body [24] and these granules may be released in the immediate hypersensitivity reaction [25] or in acute inflammation [26] thus producing a local eosinophilia. SHKIDOV and BAUER [26] showed that damage to the skin of rats produced by experimental mucormycosis caused degranulation of local mast cells within half an hour followed by a local eosinophilia in about 6 h. pretreatment with compound 48/80 (a histamine liberator) caused degranulation of the mast cells, and inflammation was then not associated with a local eosinophilia. Since local eosinophilia is an uncommon accompaniment to acute inflammation, perhaps the mechanism in this case involved a hypersensitivity reaction.

There is other evidence which suggests that the function of the eosinophil is closely related to the external environment: they are most numerous in the skin, stomach, and small and large intestine, and their number in these tissues is very small at birth but increases markedly during the first 6 months of life [9]. However if the main function of eosinophils is inactivation of histamine, it would be expected that they would be more numerous where mast cells were plentiful: this situation is found in rat skin, but in the rat tongue mast cells are numerous whereas eosinophils are few, and in the rat gastrointestinal tract eosinophils are numerous but mast cells are few. In view of this anomaly and since the rat stomach and small intestine are rich in histamine but poor in mast cells [24] the present authors considered it possible that the many eosinophils in the rat gastrointestinal tract were there because of a high local concentration of histamine derived from the food. In support of this concept, RYTÖMÄ [9] stated that a meat diet increased the number of eosinophils in the alimentary tract (though no reference to the observations was given). This point was

also made by ARCHER [27] who cited the work of BROGART [28] GODŁOWSKI [29-30] and TEIR *et al.* [31] however of these authors only GODŁOWSKI [30] used protein-rich feeding, and although he considered that two dogs on a raw meat diet had more eosinophils in the blood and intestinal tract than did the control animals, comparison of his tables I and II indicates that the values found in the test animals were within the range found in the controls. In the present work alterations in dietary histamine and probably in endogenous histamine had no effect on the number of eosinophils present in the gastrointestinal tract.

ARCHER [2] found that an antihistamine inhibited the eosinophil response to intradermal injection of histamine in horses, thus an effect on eosinophil kinetics might have been expected when an antihistamine was continuously given to rats. The absence of such an effect, the species differences in the eosinophil response to local injection of histamine, and the finding that injection of histamine into the skin in man is followed by a local eosinophilia only in atopic individuals, suggest that the main function of eosinophils is not the inactivation of histamine.

Although ROBERTS [32] has presented evidence that eosinophils rapidly take up antigen and may thus be concerned in the formation of antibody other workers have been unable to demonstrate this effect [20-33]. There is much evidence that antigen-antibody complexes are eosinotactic and are phagocytosed by eosinophils [20, 25, 33, 34, 35, 36]. Thus, the main function of eosinophils is probably related to the formation or disposal of antigen-antibody complexes.

### *Acknowledgement*

The authors are grateful to Miss J. GOSK CARR for technical assistance and to the St. Mary's Hospital Research Fund for financial assistance.

### *Summary*

The hypothesis that the main function of eosinophils is the inactivation of histamine was investigated by using continuous infusion of tritiated thymidine to estimate the turnover and number of eosinophils in rats given normal diet, histamine-high diet, histamine-low diet, or a normal diet with antihistamine. The turnover and number of eosinophils in the bone marrow, blood and tissues was not altered by any of the treatments given. These results and the known species differences in the eosinophil response to local injection of histamine suggest that the main function of eosinophils is not the inactivation of histamine.

## References

- 1 FOOT E. C. Eosinophil turnover in the normal rat. *Brit. J. Haemat.* **11** 439-445 (1963).
- 2 ARCHER, R. K. The eosinophil leucocytes, p. 60 (Blackwell Oxford 1963b).
- 3 FOOT E. C. Eosinophil turnover in the rat. *Nature, Lond.* **196** 297-298 (1963).
- 4 WORDER, A. N. I WORDER and LAKE PETER'S The U.F.A.W. Handbook on the Care and Management of Laboratory Animals, 2nd ed., p. 124 (Universities Federation for Animal Welfare, London 1957).
- 5 MITCHELL, R. G. and COOM, C. F. Effect of diet on urinary excretion of histamine. *J. ppl. Physiol.* **6** 387-392 (1954).
- 6 OCHTAROWSKI, B. KANLSON, G. and ROSENBERG, E. Biogenesis of histamine studied by its distribution and urinary excretion in germ free reared and not germ free rats fed on histamine free diet. *Acta physiol. scand.* **41** 217-228 (1957).
- 7 DACEY, J. B. and LEWIS, S. M. *Practical Haematology* 3rd ed., p. 59 (Churchill, London 1963).
- 8 SEIDER, S. H. and LILLIE, R. D. Histochemical identification of basic proteins with Bietsch's orcinol at alkaline pH. *Stain Technol.* **36** 365-370 (1961).
- 9 RYTOMAA, T. Organ distribution and histochemical properties of eosinophil granulocytes in rat. *Acta path. microbiol. scand. Suppl.* **140** 50 (1960).
- 10 COOM, C. F. The histamine-like activity of white blood cells. *J. Physiol.* **90** 485-500 (1937).
- 11 RILEY, J. F. *The Mast Cells*, p. 116 (Livingstone Edinburgh 1959).
- 12 KOVACS, A. Antihistamine effect of eosinophil leucocytes. *Experientia* **6** 349-350 (1950).
- 13 VERCAUTEREN, R. and PARTING, G. On the presence of an antihistaminicum in isolated eosinophilic granulocytes. *Arch. int. Pharmacodyn.* **89** 10-14 (1952).
- 14 ARCHER, R. K. The Eosinophil Leucocytes, p. 152 (Blackwell, Oxford 1963d).
- 15 WELSH, R. A. and GALLER, J. C. Phagocytosis of mast cell granules by the eosinophilic leucocyte in the rat. *Amer. J. Path.* **35** 103-111 (1959).
- 16 DREYER, J. M. The mast cells in urticaria pigmentosa. *J. Path. Bact.* **63** 513-520 (1951).
- 17 KLEIN, B. S. COHEN, M. B. and REDOLPH, J. A. Histologic changes in allergic and nonallergic wheals. *J. Allergy* **3** 531-541 (1952).
- 18 KNOTT F. A. and BEDE PEARSON, R. S. Eosinophilia in allergic conditions. *Guy's Hosp. Rep.* **44** 230-236 (1934).
- 19 REE, R. F. Studies on allergic dermatitis (Queensland itch) of the horse: the aetiology of the disease. *Austr. J. agric. Res.* **5** 109-129 (1954).
- 20 SEIDER, R. S. Physiological approaches to an understanding of the function of eosinophils and basophils. *Ann. N.Y. Acad. Sci.* **59** 706-731 (1955).
- 21 GOSWAMI, P. K. Lack of chemotactic effect of histamine upon mouse eosinophils. *Indian J. med. Sci.* **19** 806-808 (1963).
- 22 LITT M. Studies in experimental eosinophilia. IV. Determinants of eosinophil localization. *J. Allergy* **33** 532-543 (1962).
- 23 RODEL, J. M. and BARNHART M. I. The eosinophil as a source for pro fibrinolysin in acute inflammation. *Blood* **25** 776-794 (1965).
- 24 SELYE, H. *The Mast Cells*, p. 310 (Butterworths, Washington 1965).
- 25 ARCHER, R. K. The Eosinophil Leucocytes, p. 107 (Blackwell, Oxford 1963).
- 26 SWELLLOW, W. H. and BAKER, H. These mast cells and acute inflammation in experimental mesenteric nodes of normal, 48/80 treated and diabetic rats. *J. exp. Med.* **112** 1069-1084 (1960).
- 27 ARCHER, R. K. The Eosinophil Leucocytes, p. 56 (Blackwell, Oxford 1963).
- 28 BOGART J. H. Some observations on the eosinophilic cell. *J. Path. Bact.* **31** 799-816 (1932).

- 29 GOLDSOWSKI, Z. Z.: Prevention of hormonal eosinopenia and lymphopenia by inhibition of clotting in blood. *Brit. med. J.* : 854-855 (1951)
- 30 GOLDSOWSKI, Z. Z.: The fate of eosinophils in hormonally induced eosinopenia and its significance. *J. Endocrin.* **8**, 102-123 (1952)
- 31 TERA, H., WIKELIN, O.; SUNDELL, B., PAIVANEN, I. and KUUSI, T.: Experimental alterations in the tissue eosinophilia of the glandular stomach of the rat. *Acta med. scand.* **152**: 275-283 (1955)
- 32 ROBERTS, A. N.: Rapid uptake of tritiated antigen by mouse eosinophils. *Nature, Lond.* **210**: 266-269 (1966)
- 33 LITT, M.: Studies in experimental eosinophilia. VI. Uptake of immune complexes by eosinophils. *J. Cell Biol.* **23**, 355-361 (1964a)
- 34 LITT, M.: Eosinophils and antigen-antibody reactions. *Ann. N.Y. Acad. Sci.* **116**: 964-985 (1964b)
- 35 SPYRIDIS, R. S. and SEYMOUR, E. E.: Cellular reactions to reinjection of antigen. *J. Immunol.* **92**, 540-549 (1964)
- 36 SARTER, S. M.: A function of the eosinophil: phagocytosis of antigen-antibody complexes. *Proc. Soc. exp. Biol., N.Y.* **112**: 667-670 (1963)

Institute of Medical Clinics, University of Pavia (Director: Prof. P. Intracchi)

## Cytoplasmic Shedding as a Mode of Formation of Lymphocyte-Like Blast Cells by Newt Histiocytes

E. G. RONDANELLI, E. MAGLIULO, G. CARONI and D. DIORIO

It is well known that in haemopoietic tissues of man and animals, including amphibians, particular cells are present which, due to their small dimensions and dark staining of chromatin, are variously called 'marrow lymphocytes', 'lymphocyte-like cells', 'lymphoid blast cells' [2, 7, 8, 16, 25, 29]. INTRACCHI and DESYLLA [9], FERRATA [5], DI GUGLIELMO [3], FUSCHI [6] and ROHR [20] had included among histiocytes a type of small lymphocyte-like cells which may be easily confused with lymphocytes for having a round compact nucleus, with a badly distinguishable nucleolus and a thin rim of slightly basophilic cytoplasm and, unlike lymphocytes, the ability to perform phagocytosis of vital dyes.

FLIEDNER *et al.* [7] described lymphoid blast cells appearing during haemopoietic recovery in irradiated dogs which were transfused with nitrogen-mustard treated marrow. Such cells have a large nucleus unlike that of typical lymphocytes, with a fine nuclear structure, a thin cytoplasmic rim and the capacity to synthesize DNA, thus being presumed to be endowed with stem-cell pluripotentiality. Similar cells are easily found in circulating blood of the newt *Ambystoma Vulgaris* L. [10, 11] and are particularly numerous in early phases of the haemopoietic regeneration which ensues to refeeding the animals after a long period of starvation. Independently from any question concerning the exact role of these lymphocyte-like cells (stem cell pluripotentiality?) we have had the opportunity of observing and describing in the present paper an obsolete though not infrequent mode of formation of lymphoid cells by histiocytes which were shedding in the surrounding medium large fragments of their cytoplasm.

29. GOLLOWSKI, Z. Z. Prevention of hormonal eosinopenia and lymphopenia by inhibition of clotting in blood. *Brit. med. J.* **1**, 854-855 (1951)
30. GOLLOWSKI, Z. Z. The fate of eosinophils in hormonally induced eosinopenia and its significance. *J. Endocrin.* **2**, 102-125 (1952)
31. TAN, H.; WISSELUS, O.; SUNDELL, B.; PARVANEH, I. and KUHL, T.: Experimental alterations in the tissue eosinophilia of the glandular stomach of the rat. *Acta med. scand.* **152**, 275-283 (1953)
32. ROBERT, A. N. Rapid uptake of tritiated antigen by mouse eosinophils. *Nature, Lond.* **210**, 266-269 (1966)
33. LITT, M.: Studies in experimental eosinophilia. VI Uptake of immune complexes by eosinophils. *J. Cell Biol.* **25**, 355-361 (1964).
34. LITT, M. Eosinophils and antigen-antibody reactions. *Ann. N.Y. Acad. Sci.* **116**, 964-985 (1964b)
35. SPURK, R. S. and SPURK, E. E. Cellular reactions to reinjection of antigen. *J. Immunol.* **92**, 540-549 (1964)
36. SARTON, S. M. A function of the eosinophil: phagocytosis of antigen-antibody complexes. *Proc. Soc. exp. Biol., N.Y.* **112**, 657-670 (1963)





Fig 2. Progressive shedding of large cytoplasmic fragment by newt histiocyte. Frames from phase-contrast cine-recording.]





*Fig. 3.* Same cell as in figure 2, a-c. The progressive stretching and thinning of the connecting cytoplasmic bridge causes the loss of a large portion of cytoplasm from the histiocyte. d. Retraction of the remnant of the cytoplasmic bridge.

of migratory movement, but the customary shifting in the same direction of the remaining body of the cell does not follow. The cell itself remains fixed in its position.

Still the pseudopodium is provided with a very marked autonomous motility appearing as it was actively pulling on its connection with the cell (fig 2). As a consequence, a progressive thinning of the reunion tract is being operated, until the cytoplasmic bridge is broken and the pseudopodal mass is completely detached.

While the cell retracts back the remnant of the cytoplasmic bridge and acquires a round shape, with the remaining cytoplasm forming a thin rim around the nucleus (fig 3) the fragment of cytoplasm lost by the cell in the medium performs a rather intense but apparently uncoordinated locomotory activity (fig 4). The final step of the whole process has been the production of a small cell, with a high nucleocytoplasmic ratio still provided with histiocytic potentialities, but remarkably resembling a lymphocyte.




Fig 4 Fate of the portion of cytoplasm lost by the histiocyte. The detached fragment performs uncoordinated locomotory movements in the medium before dissolution.

### Discussion

Cytoplasmic shedding which was first described by RANVIER [19] has already been the subject of several reviews [26 12 28, 13 17 18] the phenomenon being variously related to water and food transport or plasma formation or globulin releasing by mononuclear cells [24 26] Until now the interest of investigators was primarily focused on the probable fate of released cytoplasmic droplets and only in part on the becoming of the original cell. According to DOWNEY and WEIDENREICH [4] and to SHIELDS [26] many of the cells undergoing cytoplasmic shedding may eventually differentiate into specific cell types, namely lymphocytes, plasmocytes, etc.

Our phase-contrast cinerecords have now presented the visual evidence in living cells that such a phenomenon may actually occur at least as far as the capacity of histiocytes is concerned of assuming a lymphocyte like appearance and is not an artifact of fixation and staining procedures. The resulting cells, though preserving their histiocytic pattern of nuclear chromatin may be easily confused with lymphocytes according to their dimension and the nucleo-cytoplasmic ratio. The signification of such a phenomenon is not clear but we find it very interesting that these histiocyte-derived lymphocyte-like cells were very numerous in peripheral blood of newts during early phases of post-starvation haemopoietic regeneration and immediately preceding the appearing in the blood of large undifferentiated blast cells which probably derive from them and which subsequently differentiate into actively dividing erythroblasts.

Lymphocyte like cells are in this rather similar to lymphoid blast cells which were regularly observed in haemopoietic organs by MAGLIULO [14] and MAGLIULO *et al* [15] during early phases of hemopoietic regeneration in irradiated monkeys which had been transfused with autologous and homologous marrow. More recently similar reports were presented also by THOMAS [27] and by FLIEDNER [7] strongly suggesting though not proving a genetic relationship between differentiated hemopoietic cells and those primitive lymphoid blast forms which we have demonstrated may in certain circumstances originate from histiocytes by means of cytoplasmic shedding. It is interesting enough that lymphocyte-like cells may also originate in peripheral blood cultures by means of the mechanism of cytoplasmic shedding from large polynuclear blasts [1] themselves originating from phytohemagglutinin stimulated small lymphocytes.

### Summary

In newts undergoing hemopoietic regeneration after long period of starvation, circulating histiocytes were shown to shed large fragments of their cytoplasm, eventually differentiating into lymphocyte-like cells. The present investigation which was conducted by means of phase-contrast cinematography on living cells, presents the visual evidence of an obscure morphogenetic pattern of cells which may be provided of stem-cell pluripotentiality.

### References

1. AUSTALDI, G. Personal communication (1968)
2. CUDKOWICZ, G.; BROOKS, M. L. and BREKKE, H. M. Pluripotent stem cell function of the mouse marrow lymphocyte. *Science* **144** 866 (1964)

3. DE GIOULINO G. Sistema reticolo-endoteliiale. In FERRATA's *Le emopatie* p.482 (Soc. Editrice Libreria, Milano 1933)
4. DOWNNEY H. and WEIDENREICH, F. Über die Bildung der Lymphocyten in Lymphdrüsen und Milz. *Arch. mikr. Anat.* 80-306 (1912).
5. FERRATA, A. *Le Emopatie*, pp.64 and 97 (Soc. Edit. Libreria, Milano 1933).
6. FERRATA, A. *Senologia del Midollo Osseo* (Garzanti, Milano 1946)
7. FLEISCHER, T. M. THOMAS, E. D.; FACHÉ, D. THOMAS, D. and CROVETTE, E. P. Pattern of regeneration of nitrogen-mustard treated marrow after transfusion into lethally irradiated homologous recipients. In *La greffe des cellules hématopoïétiques allogéniques*, p. 43. Colloques Internationaux du CNRS, Paris 7-9 Sept. 1964 (CNRS, Paris 1963)
8. GOODMAN, J. W. Concerning the capacity of lymphocytes to give rise to erythropoiesis. In *La greffe des cellules hématopoïétiques allogéniques*, p. 31. Colloques Internationaux du CNRS, Paris 7-9 Sept. 1964 (CNRS, Paris 1963)
9. INTRAZZI, P. DEBETTA, G. Contributo allo studio degli elementi reticolo-istocitari del sangue circolante. *Haematologica* 23, 3 (1932).
10. JOLLY J. Recherches expérimentales sur la division indirecte des globules rouges. *Arch. Anat. micr.* 6, 433 (1904)
11. JOLLY J. *Traité technique d'hématologie* (Maloine Paris 1923)
12. LEVET, W. C. and RITZMAN, S. E. Relation of abnormal proteins to formed elements of the blood. *cellular sources*. *Ann. Rev. Med.* 15, 187 (1963)
13. LOUIT J. F. Immunologic and trophic functions of lymphocytes. *Lancet* ii, 1106 (1962)
14. MAGLITTO, E. Trapianto di midollo osseo omologo in scimmie Rhesus irradiate. *Boll. Soc. Med. Chir. Pavia* 78, 173 (1964)
15. MAGLITTO, E. VAN PUTTIE, L. M. DE VRIES, M. J. Risultati del trapianto di midollo osseo omologo in scimmie Rhesus irradiate. *Haematologica* 49: 213 (1964).
16. OMBROD D. G. and EVILETT, N. B. Radiomographic studies of bone marrow lymphocytes in vivo and in diffusion chamber cultures. *Blood* 23, 1 (1964)
17. POLICARD, A. La chemoïse. *Nouv. Rev. franç. Hémat.* 2, 897 (1962)
18. POLICARD, A. Points de vue sur la dynamique de la surface cellulaire. *Nouv. Rev. franç. Hémat.* 3, 739 (1963)
19. RAVVITA, L. Des chemoïocytes. *C. R. Acad. Sci.* 110, 163 (1890)
20. ROSE, K. *Das menschliche Knochenmark* (Georg Thieme-Verlag, Stuttgart 1940)
21. RONDANELLI, E. G.; TRENTA, A.; VANNI, V.; SCOTTI-FOGLERU, C.; MAGLITTO, E.; PARMA, A.; GERNA, G. Senologia delle modificazioni citologiche da piccole dosi di raggi X in cellule eritropoietiche allo stato vitale. *Atti del VII Congr. naz. Soc. ital. Ematol.*, Pavia, 17-18 Marzo 1963
22. RONDANELLI, E. G.; TRENTA, A.; MAGLITTO, E.; VANNI, V. and GERNA, G. Giant cells produced by mitotic reversion in prophase metaphase anaphase after low doses of X-rays. *Exp. Cell Res.* 41, 1 (1966)
23. RONDANELLI, E. G.; TRENTA, A.; MAGLITTO, E.; VANNI, V.; GERNA, G. et CARONI, G. Morphogénèse des cellules à plasméus moyeux par l'action des rayons X. Etude en contraste de phase sur les cellules érythropoïétiques à l'état vivant. *Exp. Cell Res.* 47, 222 (1967)
24. SARKIS, F. R. Cellular reactions to dye-protein with concept of the mechanism of antibody formation. *J. Exp. Med.* 119, 67 (1959)
25. SCHROEDER and GEORGE, H. Autoradiographic evidence for pluripotential stem cell in the bone marrow. University of California, Lawrence Radiation Laboratory UCRL 10521, 176 (1962)
26. SKILLDS, J. W. Mononuclear cells, hyaline bodies, and the plasma. An analytic review. *Blood* 17, 233 (1961)
27. THOMAS, E. D. FLEISCHER, T. M. THOMAS, D. and CROVETTE, E. P. The problem of

- the stem cell observations in dogs following nitrogen mustard. *J Lab clin. Med.* 65: 794 (1965)
28. WATTS, A and DOUGHERTY T F : The role of lymphocytes in normal and immune globulin production and the mode of release of globulin from lymphocytes. *Ann. NY Acad. Sci.* 46: 829 (1942)
29. YORRY J III : The lymphocyte *Ann. Rev. Med.* 14: 125 (1964)

I. Medizinische Universitätsklinik (Direktor: Prof. Dr. med. A. BRUNNEN) und Pathologisches Institut der Universität Kiel (Direktor: Prof. Dr. med. K. LUDWIG)

## Panmyelose mit Panhämoozytopenie

H. LÖFFLER und L. D. LEDER

Unter dem Begriff «myeloproliferierende Mischformen» hat DI GUGLIELMO [5] solche Myelosen aus dem Komplex der myeloproliferativen Krankheiten [3] herausgehoben, bei denen mehrere Zellreihen des Knochenmarkes vom pathologischen Prozeß ergriffen sind. Die Beteiligung mehrerer Zellreihen an derartigen Hämoblastosen kann entweder konstant – also während des gesamten Krankheitsverlaufes – oder nur phasenhaft nachweisbar sein. Im einzelnen unterscheidet DI GUGLIELMO erythroleukämische, erythromegakaryozytäre, leukomegakaryozytäre und erythroleukomegakaryozytäre Myelosen.

Beim letztgenannten Krankheitsbild, welches er auch als Panmyelose bezeichnet, beschreibt DI GUGLIELMO [4, 5] zwei Formen: 1. eine über Jahre verlaufende chronische, totale, hyperplastische Panmyelose, die äußerst selten sei und die sich durch eine konstante Pansythämie mäßigen Grades (ähnlich der Polycythaemia vera rubra) und zusätzlich durch die Ausschwemmung von unreifen Erythroblasten, unreifen Granulozyten sowie kleinen Megakaryozytenfragmenten auszeichnet. 2. erwähnt er eine «fast stets akute, unvollständige, hyperplastische Panmyelose». Eine nähere Charakterisierung des letztgenannten Typus gibt DI GUGLIELMO allerdings nicht.

Die große Seltenheit derartiger Hämoblastosen veranlaßt uns, im folgenden über einen Patienten zu berichten, dessen Krankheitsbild nach den Ergebnissen zytologischer, fermentzytochemischer und auf optischer Untersuchungen einer Panmyelose entspricht.

## Kasuistik

## Klinische Befunde

66-jähriger Mann. 1918 Diphtherie und Ruhr. 1959 Operation eines Ösophagusdivertikels. Sonst keine ernsthaften Erkrankungen. Familienanamnese o.B.

Seit Januar 1962 bei körperlicher Belastung Atemnot und Schwindelgefühl. Ende Juli 1964 schwarzer Stuhl. Deutliche Verschlechterung des Allgemeinzustandes. Zunahme von Atemnot und Schwindelgefühl, mehrmals Ohnmachten.

Erste stationäre Aufnahme am 11.8.1964. Auffällige Blasse, reduzierter Allgemeinzustand. Leber Milz und Lymphknoten nicht vergrößert. Keine hämorrhagische Diathese. Im Stuhl bei mehrfacher Kontrolle kein Blut nachweisbar. Laborbefunde: RSG 23/60 mm. Serumtransaminasen, alkalische Phosphatase, Bilirubin, Serumalbuminproben, Gesamtprotein und Elektropherogramm unauffällig. Röntgenologisch zwei Divertikel im unteren Sigma; Magen-Darm-Trakt sonst o.B. Weiterhin schwere normochrome Anämie, Leukozytengammatzahl an der unteren Normgrenze. Therapie: Insgesamt 9 Bluttransfusionen zu je 500 ml. Anstieg des Hämoglobins von 3,3 auf 11,4 g%, RSG 11/38 mm. Am 11.8.1964 Entlassung.

Erneute Hospitalisierung bei im wesentlichen unverändertem klinischem Befund wegen Zunahme der subjektiven Beschwerden am 21.10.1964. Röntgenologisch an Ösophagus, Magen, Colon, Nieren, Gallenblase und Thoraxorganen kein pathologischer Befund. Hämoglobin 7,9 g%. Leukozytengammatzahl zwischen 3100 und 6000  $\text{mm}^3$  schwankend. Thrombozyten 59000/ $\text{mm}^3$ . Serum-Eisen 218–319  $\mu\text{g}\%$ . HbE 30,5. Retikulozyten 2,10 / $\%$ . Osmotische Resistenz der Erythrozyten: 0,50%–0,34%. Na Cl Gerinnungsuntersuchungen




Abb. 1 Verhalten von Hämoglobin, Leukozyten und Thrombozyten während des Krankheitsverlaufes.



Abb. 2 ( ) und (b) Junge, megaloblastare Erythroblasten mit pseudopodenartigen Plasmasanktionen. ( ) Pathologische Erythroblastennukleosen mit erkrankten Chromosomen. Links unten ein Proerythrocyt. (d) bis (g) Pathologische Erythroblastennukleosen sowie Erythroblasten mit parasukleären Chromatinbrüchen. Sternalpunktat, Pappenheim-Färbung ( $\times 1400$ ).

Quick 108%, Gerinnungszeit 2'30" Blutungszeit 15 Faktor II 70%, Faktor V 114%, Faktor VII 86%. Über das Verhalten von Hämoglobin, Leukozyten und Thrombozyten während des Krankheitsverlaufes unterrichtet die Abb. 1. Die Sternalpunktation (28.10.1964 und 7.12.1964, siehe unten) ergab die Diagnose Panmyelose. Therapie: Ab 8.12. täglich 2,5 mg Amethopterin sowie Prednison mit einer anfänglichen Dosis von 200 mg/tägliche Prednison sowie 2,5 mg/die reduziert wurde. In der Zeit vom 30.10. 14.12.1964 insgesamt 7 Bluttransfusionen zu je 500 ml. Bei der Entlassung am 15.12. Hämoglobin 9,1 g%, Leukozyten 4000/mm<sup>3</sup> Thrombozyten 42000/mm<sup>3</sup>.

Dritte stationäre Aufnahme am 2.1.1965. Hb 7,0 g% bei 2,53 Mill. Erythrozyten Leukozyten 3900/mm<sup>3</sup> Serumcreatinin 182 und 217  $\mu$ g%. Weiterbehandlung mit täglich 25 mg Prednison sowie 2,5 mg Amethopterin. Außerdem in der Zeit vom 2.1. 14.1.1965 insgesamt 4 Bluttransfusionen zu 500 ml. Entlassung am 14.1.1965.






Abb.2 (a) Klappen, Promyelocyten und einzelne sogenannte Pseudopelgerformen. (b) Klappen, Promyelocyten, darzwischen Erythroblasten mit stark verklumpten und verdichteten pyknotisch veränderten Kernen. Sternaustrich ( $\times 1400$ )

Weiter stationärer Aufenthalt in der Zeit vom 17. I. - 21. I. 1963 wegen Fieberschüben und ausgedehnten flächenhaften Hautblutungen. Schwere durch antibiotische Behandlung und Hämokreislauftherapie nicht mehr zu beherrschende Bronchopneumonie. Am 21. I. 1963 Exitus letalis.

#### Morphologische Befunde

Im peripheren Blutstrich zeigten die Erythrocyten eine hochgradige Anisocytose und Poikilocytose sowie eine ausgeprägte Hypochromasie. Häufig waren sie basophil punktiert und enthielten Cabotische Ringe. Auf 100 Leukozyten fanden sich maximal 2 Normoblasten, deren Zytoplasma vakuolisiert, zum Teil optisch leer erschien. Im weissen Differentialblutbild wurden maximal 5% Myeloblasten gezählt. Der Anteil der Lymphocyten lag im Normbereich. Die neutrophilen Granulozyten waren vermindert und zum grossen Teil pathologisch verändert. Es fanden sich sogenannte Pseudopelgerformen, weiterhin vereinzelt übersegmentierte und polyploide Neutrophile mit eigenartig verklumpten Kernen. Gelegentlich waren im Zytoplasma der stab- und segmentkernigen Neutrophilen Vakuolen und Doehle-Körperchen vorhanden. Auch die Thrombozyten waren atypisch. Sie zeigten eine erhebliche Polymorphie, und es fanden sich Riesenthrombozyten sowie ungranulierte Formen.

Bei den beiden Sternaustrichuntersuchungen, die wir am 28. 10. und am 7. 12. 1964 durchführten, wurden so weitgehend identische Veränderungen gefunden, dass wir sie zusammenfassend darstellen. Die Ausstriche waren recht zellreich. An der Zellvermehrung waren alle drei blutbildenden Zellreihen beteiligt. Am stärksten trat die Erythropoiese hervor. Es fanden sich zahlreiche Anomalien, von denen alle Reifungsstadien betroffen waren (Abb.2) megaloblastäre Formen, zwei- und mehrkernige Erythroblasten, atypische

Mitosen sowie sehr häufig Kernverklumpungen und Chromatinabhepungen. Bei manchen Erythroblasten war das Zytoplasma von kleinen runden Chromatinbrocken angefüllt. Solche Veränderungen waren manchmal kaum von pathologischen Mitosen zu unterscheiden. Manche reiferen Erythroblasten zeigten ein auffällig schmales Zytoplasma, andere eine Vakuolisierung. Auch bei den reiferen Erythroblasten waren die Kerne verändert, und zwar besaßen sie häufig ein dichtes, klumpiges, fast strukturloses Chromatin, so dass der Eindruck einer Pyknose entstand (Abb. 5b).

In der granulokytären Reihe fielen insbesondere Blasten und Promyelocyten auf (Abb. 5b) die herdförmig zusammenlagen und erhebliche Kernpolymorphismen und Granulationsanomalien aufwiesen. Die reiferen Granulocytenstadien entsprachen zum Teil sogenannten Pseudopelgerzellen (Abb. 5a) vereinzelt sah man Riesenformen, wie sie bei megakloblastärer Anämie auftreten.

Die reichlich vorkommenden Megakaryocyten (Abb. 4) ließen erhebliche Größendifferenzen erkennen. Zytologisch fanden sich zahlreiche Atypien und Abweichungen von der Norm. Neben Megakaryocyten mit stark segmentierten oder gelappten Kernen sahen wir Knochenmarkriesenzellen mit sehr stark verklumptem Chromatin, ähnlich wie bei einer Kernpyknose. Das Zytoplasma der Megakaryocyten war in den meisten Fällen basophil und nicht granuliert sowie von verschiedenen grossen Vakuolen durchsetzt. Die Zellgrenzen waren oft nicht klar erkennbar sondern stark verblüßt, so dass der Eindruck eines scholligen Plasmaserfalls entstand. Innerhalb von basophilen Zytoplasmabereichen sah man schließlich ungefärbte oder sehr rötlich gefärbte Areale. Auch bei den Megakaryocyten fielen uns zahlreiche Mitosen mit Chromosomenabhepungen und Chromatinverklumpungen auf.

#### Cytochemische Befunde

**Eisenspeicher.** 80% der Erythroblasten der Sternabschnitte enthielten freies Eisen in Form von kleinen Granula. Dabei waren die Granula gegenüber der Norm vergrößert; sie lagen meist perinukleär. Weiterhin war eine erhebliche Vermehrung von eisenspeichernden Reticulumzellen zu konstatieren.

**Peroxidase-Schiff-Reaktion (PAS)** 12% der Erythroblasten des Knochenmarkes fielen auf eine schwache diffuse positive Reaktion. Die Megakaryocyten waren dagegen häufig negativ, zum Teil auch schwach homogen positiv. Von den Zellen der Granulocytopoiese reagierten die Blasten negativ. In den Promyelocyten und den weiteren Anreifungsstadien fiel die Reaktion zwar positiv aus, aber schwächer als normal.

**Alkalische Phosphatase.** In den Sternabschnitten zeigten Kapillarendothelien sowie einzelne reife Granulocyten eine positive Reaktion. Im peripheren Blutbild (Untersuchung vom 7. 12. 1964) waren 38% der reifen Granulocyten phosphatase-positiv, wobei ein Index von 44 ermittelt wurde.

**$\alpha$ -Naphthyl-Aspartat-Esterase.** Am stärksten positiv reagierten die Reticulumzellen. Bei den Erythroblasten aller Reifungsstadien war die Aktivität ganz erheblich gesteigert, wobei das Reaktionsprodukt diffus im Zytoplasma verteilt erschien. Auch die Erythroblastennitrocyten wiesen diese Aktivierungssteigerung auf. In den Megakaryocyten war gelegentlich eine ausserordentlich grobkörnliche Ablagerung von Reduktionsprodukt vorhanden. Die Granulocytopoiese zeigte keine Besonderheiten.

#### Antoptische Befunde (Sekt. \ 73/65)

**Makroskopische Befunde.** Panmyelose: Dunkelrotes Mark im gesamten Femur. In den Wirbelkörpern und im Sternum. Geringgradige Vergrößerung von Leber und Milz. Hämorrhagische Diathese: Es rekonvaleszierungsähnliche Blutungen in der Magenschleimhaut; flächenhafte Blutungen in der Nierenbeckenschleimhaut beiderseits und im Nierenparenchym rechts; pflöckchenförmige, subintimale Blutung im Bereich der Aorta abdominalis; flächenhafte Hautblutungen im Bereich des Stammes und der Extremitäten; kleine nicht ganz frische




Abb. 4 Atypische Megakaryozyten und Megakaryozytenmyeloiden. Sterealkausstrich, Papanheim-Färbung ( $\times 1000$ )

Hirnblutungen im Putamen-Klustrumbereich links. Schwere chronische kataraktale Tracheobronchitis. Geringgradige diffuse Bronchiektasen beiderseits. Schwere fibrinöse Pneumonie beiderseits. Fibrinöse Pleuritis beiderseits, rechts stärker als links. Mäßig schweres chronisches subcutanelluläres Lungenemphysem. Dilatation der rechten Herzkammer. Leberverfettung. Lipoidentspeicherung der Nebennierenrinde beiderseits. Geringgradige Arteriosklerose der Aorta. Schwere Coronararteriosklerose mit weitgehendem Verschluss des R. interventriculärs der A. coronaria sinistra. Dilatation der linken Herzkammer. Schweres Lungenödem. Cholesteatose der Gallenblase. Adenomatische Prostatahyperplasie. Geringgradige Blasenblase.

**Histologische Befunde.** Im Knochenmark von Wirbel, Sternum und Femur verhielt sich das Spongiosa regelmäßig, die Silberfasern waren nicht vermehrt. Die Fettzellen waren fast vollständig geschwunden. Bei schwacher Vergrößerung war bereits eine merkwürdige und ungewöhnliche Vielfalt von Zellen auffällig. Neben sehr kleinen kamen sehr große, neben




Abb. 5. Schnittpriparat vom Femurmark. (a) Schwund der Fettsellen. Starker Versatzung von atypischen Megakaryozyten und zum Teil mehrkernigen Erythroblasten. Geomax. (b) Nachweis der Naphthol-AS-D-Chloroacetat-Esterase am Paraffinschnitt. Die atypischen, promegakaryozytenähnlichen Zellen der neutrophilen Granulopoiese heben sich durch ihre positive Reaktion (schwarz, im Original leuchtend rot) heraus ( $\times 350$ )

stark basophilen oxyphile Elemente mit teils runden, teils auch blasseren, gelappten Kernen vor. Viele der Zellen waren mehrkernig.

Bei starker Vergrößerung (Abb. 5a) waren Megakaryozyten, Erythroblasten und Granulopoiesenzellen zu unterscheiden. Die Megakaryozyten lagen in lockeren Gruppen und besaßen häufig sehr weites, teils basophiles, teils oxyphiles, leicht gekörnertes Plasma. Oft waren ihre Plasmaränder ausgesprochen unscharf begrenzt. Die Megakaryozytenkerne zeigten ein lockeres, helles Chromatingerüst und waren oft bizarr geformt mit Lappungen und Segmentierungen aller nur erdenklichen Formen. Nukleolen waren deutlich erkennbar, die Kernmembranen meist scharf ausgeprägt.

Die Erythropoiesenzellen standen zahlenmäßig durchaus im Vordergrund. Es waren alle Reifungsstufen bis zum oxyphilen Normoblasten in bunter Mannigfaltigkeit zu erkennen, doch bestanden erhebliche Größensunterschiede. Während die Normoblasten durch ihr oxyphiles Plasma relativ gut erkennbar waren, gelang die sichere Identifizierung von unreifen basophilen Erythropoiesenstufen selbst im Geomax-Präparat nicht in allen Fällen. Unter den unreifen Erythropoiesenzellen fielen häufig zweikernige Exemplare auf. Viele Erythropoiesenzellen waren in Mitose begriffen. Dabei fanden sich im Plasma nicht selten abgesprengte Kernteile. Besonders auffällig war das Fehlen der normalerweise immer vorhanden und für die Erythropoiese typischen betont gruppenförmigen Lagerung der Zellen.




Abb. 6. Schnittpräparate von Femurmark. (a) Nachweis der  $\alpha$ -Naphthylazet-10-Esterase: Atypische Erythroblasten stark positiv mit typischer perinukleärer Reaktion (schwarz, im Original rotbraun). Darzwischen einige sehr stark positive Plasmazellen mit von Reticulumzellen ( $\times 560$ ). (b) Nachweis der sauren Phosphatase. Im wesentlichen sind die Reticulumzellen positiv (schwarz, im Original rot), daneben wenige Proerythroblasten mit punktförmiger perinukleärer Reaktion (z.B. rechts oben) ( $\times 330$ ).

Die Granulopoiesenzellen traten im Präparat zahlenmäßig zurück. Segmentkernige, stabkernige Metamyelozyten und Myelozyten waren kaum vorhanden. Dagegen konnten clonale liegende typisch granulierte Promyelozyten identifiziert werden. Auch Vorstufen der Eosinophilen kamen gelegentlich vor.

Weiterhin waren Reticulumzellen in mäßiger Anzahl, einige Plasmazellen sowie Lymphozyten eingestreut. Gewebasmastzellen kamen nicht vor.

In der Milz fanden sich innerhalb der Sinus nur wenige Infiltrate aller drei blutbildenden Zellsysteme. Am auffälligsten stachen die Megakaryozyten hervor, die die gleichen pathologischen Veränderungen zeigten wie im Knochenmark. Im Gegensatz zu den Verhältnissen im Knochenmark waren unter den Myelopoiesezellen relativ reichlich reife Granulozyten vorhanden. Erythropoiesezellen kamen nur vereinzelt vor. Die Pulparetikulumentellen wiesen eine starke Hämosiderose auf. Plasmazellen waren reichlich vorhanden.

In der Lunge bestand eine erhebliche fibrinreiche Bronchopneumonie mit Infiltraten durch gelapptkernige neutrophile Granulozyten, von denen ein grosser Teil als Pseudopelgerformen vorlag. In den Alveolen waren ausserdem grosse Mengen einer erweichlichen Flüssigkeit im Sinne eines Lungenödems vorhanden. Vielfach traf man auf kleine Blutungs-herde.

1. Leber, Lymphknoten vom Lungenhilus, Tonsillen, Niere und Harnblase zeigten keine Besonderheiten, insbesondere keine leukämischen Infiltrate.

**Histochemische Befunde.** Im Knochenmark reagierten die Megakaryozyten bei der PAS-Färbung zunächst schwach diffus-positiv. Die Reaktion war jedoch erheblich schwächer als normalerweise. Die Megakaryozyten zeigten weiterhin eine schwache Reaktion beim Nachweis von  $\alpha$ -Naphthylazetat-Esterase, von Naphthol-AS-acetat-Esterase sowie von saurer Phosphatase. Naphthol-AS-D-Chlorazetat-Esterase und alkalische Phosphatase besaßen die Megakaryozyten nicht.

Die Erythropoiesenzellen reagierten beim  $\alpha$ -Naphthylazetat-Esterase-Nachweis außerordentlich stark positiv (Abb. 6a) und erreichten fast den Aktivitätsgrad der Reticulocyten, die die am stärksten positiven Knochenmarkszellen darstellen. Besonders intensiv färbten sich große, dem Proerythroblasten an die Seite stehende Elemente an. Sie zeigten bereits nach einer Inkubationszeit von nur 2 min eine deutliche Reaktion. Im Unterschied zum Sternalpunktat war die Fermentaktivität vor allem auf eine schmale, den Kern ummittelbar wie eine Schale umgebende Plasmaschicht konzentriert, wie dies für normale Erythropoiesenzellen hochcharakteristisch ist. Beim Nachweis der sauren Phosphatase reagierte ein kleiner Teil der besonders unreifen Erythroblasten mit einer deutlichen Anfärbung innerhalb eines parasarkulären Plasmaplasmabereiches (Abb. 6b). Naphthol-AS-acetat-Esterase, Naphthol-AS-D-Chlorazetat-Esterase und alkalische Phosphatase konnten in den Erythropoiesenzellen nicht nachgewiesen werden.

Mit dem Nachweis der Naphthol-AS-D-Chlorazetat-Esterase stellten sich die neutrophilen Granulopoiesenzellen elektiv dar. Sie kamen (Abb. 5b) nur in relativ geringer Anzahl vor und entsprachen etwa den Promyelozyten. Abweichend von den normalen Promyelozyten besaßen sie jedoch unregelmäßig gestaltete Kerne. Manchmal waren sie auch zweikernig. Beim Nachweis der  $\alpha$ -Naphthylazetat-Esterase der Naphthol-AS-acetat-Esterase der sauren und der alkalischen Phosphatase verhielt sich die Granulopoiese unauffällig.

An den übrigen Organen konnten durch die histochemischen Untersuchungen keine Befunde erhoben werden, die über denjenigen Gesichtspunkt hinausführten, die bereits durch die histologische Untersuchung gewonnen worden waren.

### Diskussion

Die klinischen Befunde unseres Patienten erlaubten zunächst ohne die Untersuchung des Sternalpunktates keine endgültige Diagnose. Zwar bestand von Beginn der Erkrankung an eine Panhämozytopenie mit Anämie, Thrombozytopenie und Leukozytenwerten, die an der unteren Normgrenze lagen oder gering erniedrigt waren, und im Differentialblutbild wurden einzelne Blasten und Erythropoiesenzellen gefunden. Doch wiesen diese Befunde, wie auch die qualitativen Veränderungen der neutrophilen Granulozyten mit Pseudopelgerformen, Übersegmentation und Polyploidie und wie die morphologischen Veränderungen der Erythrozyten und Thrombozyten lediglich auf eine schwere Schädigung der Hämatopoese hin, ohne eine sichere Diagnose zu erlauben.

Erst bei der Untersuchung des Sternalmarkes konnte die Erkrankung in ihrem Wesen klar erkannt werden. Es fand sich eine schwere Hyperplasie aller drei blutbildenden Zellreihen mit hochgradigen

Atypien in der Erythropoiese, mit atypischen Blasten und Promyelozyten in der Granulopoiese und vor allem mit reichlich polymorphen, unreifen und atypischen Megakaryozyten. Die Erythroblasten und die Megakaryozyten fielen besonders auf. Einzelne Erythroblastenkerne waren fragmentiert, neben noch erhaltenen Kernen fanden sich Ansammlungen von «Chromatinkugeln» und ausserdem sah man sowohl in den Erythroblasten als auch in den Megakaryozyten zahlreiche verschiedengestaltige Mitoseanomalien. Zytochemisch imponierte eine deutliche Vermehrung der Sideroblasten mit vergrößerten Eisen granula. Ferner war die  $\alpha$  Naphthylazetat Esterase Aktivität der Erythroblasten erheblich gesteigert. Bei der PAS-Reaktion ergab sich allerdings keine wesentliche Erhöhung des Anteiles positiver Erythroblasten gegenüber der Norm. An Hand dieser Befunde konnte die Diagnose einer Panmyelose sicher gestellt werden.

Bei der Autopsie wurde eine eindeutige Hyperplasie des Knochenmarksparenchyms mit einem fast vollständigen Schwund der Fettzellen festgestellt. Ausserdem fanden sich in der Milz Infiltrate von Megakaryozyten, von Granulopoiesezellen und von Erythroblasten. Im Knochenmarksschnitt fiel vor allem die ungewöhnliche Vielfalt der Zellen und die sehr starke Vermehrung von atypischen Megakaryozyten auf, die an manchen Stellen sehr dicht gelagert waren. Zahlenmässig beherrschte jedoch – wie im Knochenmarksausstrich auch – die hochgradig polymorphe und atypische Erythropoiese mit vielen mehrkernigen Zellen und reichlich Mitosen das Bild. Die Granulopoiese stand dagegen quantitativ zurück, war aber auch im histologischen Schnitt erkennbar pathologisch verändert und insbesondere durch die Anwendung der Naphthol AS-D-Chlorazetat Esterase Reaktion am Paraffinschnitt [10] gut darzustellen. Damit war auch in Anbetracht der autopsischen Befunde an dem Vorliegen einer Hämoblastose nicht zu zweifeln, wie aus der schweren Infiltration des Knochenmarkes mit Verdrängung der Fettzellen und aus dem Nachweis von atypischen Megakaryozyten, Granulopoiesezellen und Erythropoiesezellen in der Milz hervorgeht. Dass es sich im vorliegenden Falle zweifellos um eine Panmyelose handelt, zeigen die schweren morphologischen Veränderungen an allen drei Knochenmarkszellreihen.

Ausser morphologischen Befunden, die das Vorliegen eines malignen Geschehens bewiesen, waren auch entsprechende zytochemische Befunde vorhanden, wie sie bei anderen malignen Hämoblastosen vorkommen. So imponierte eine deutliche Vermehrung von Sidero-

blasten mit vergrößerten Eisengranula sowie eine Vermehrung von eisenspeichernden Retikulumzellen. Beide Befunde sind als Ausdruck einer Eisenverwertungsstörung zu betrachten und sie kommen – abgesehen von der sideroachrestischen Anämie – auch bei Erythrämien und Erythroleukämien vor [7 15 8]. Im übrigen ist die bei unserer Beobachtung vorliegende Eisenverwertungsstörung im Rahmen einer Abhandlung über die pathologische Anatomie der sideroachrestischen Anämie ausführlicher besprochen [12] so dass sich ein weiteres Eingehen auf diese Problematik erübrigt.

Die erheblich gesteigerte  $\alpha$ -Naphthylazetat Esterase Aktivität der Erythroblasten stützt ebenfalls die Annahme einer malignen Entartung der roten Reihe, da ähnliche Aktivitäts erhöhungen bisher nur bei Erythrämie und Erythroleukämie beobachtet wurden wenn man von der perniziösen Anämie absieht [16 13 14 11]. Offenbar ist dieser zytochemische Befund immer dann zu erheben, wenn eine in hohem Masse ineffektive Erythropoiese vorliegt.

Die PAS-Reaktion erbrachte allerdings keinen Hinweis auf das Vorliegen einer malignen Veränderung innerhalb der Erythropoiese denn der Anteil positiver Erythroblasten war gegenüber der Norm nicht wesentlich erhöht. Im allgemeinen wird eine deutlich gesteigerte PAS- positive Reaktion eines grossen Teiles der Erythroblasten als sehr charakteristischer Befund bei reiner Erythrämie und bei Erythroleukämie angesehen [1 18, 15]. Dies konnten wir bei eigenen Untersuchungen an 6 Patienten mit Erythroleukämie und an einem Patienten mit erythrämischem Terminalstadium bei chronischer myeloischer Leukämie bestätigen. Bei subakut oder chronisch verlaufenden Neoplasien der Erythropoiese kann die gesteigerte PAS-Reaktion der Erythroblasten aber auch fehlen oder nur sehr gering ausgeprägt sein [22, 7]. Daraus ergibt sich, dass nur der positive Befund als Stütze für die Annahme einer malignen Erkrankung der roten Reihe anzusehen ist, während umgekehrt ein negativer Befund wie er in unserem Falle erhoben wurde, eine solche Möglichkeit keineswegs ausschliesst.

Bei dem von uns beschriebenen Krankheitsbilde handelt es sich um eine besondere Hämoblastose die von anderen myeloproliferativen Erkrankungen, wie der Polycythaemia vera rubra der Osteomyeloidose und Myelofibrose einschliesslich der Übergangsformen zu chronischen myelösen Leukämien und von der sogenannten Panmyelopathie mit hyperplastischem Mark abgegrenzt werden kann. Von diesen Krankheitszuständen unterscheidet sich unsere Panmyelose durch die sehr schweren Zelltypen. Von der Osteomyelo-



sklerose und von der Myelofibrose ist die Panmyelose durch die fehlende Spongiosa und Faservermehrung abgegrenzt. Gegen das Vorliegen einer Polycythaemia vera rubra sprechen die klinischen Befunde. Eine Panmyelopathie mit hyperplastischem Mark, wie sie in extrem seltenen Fällen als Initialstadium einer chronischen Benzolvergiftung beschrieben ist [2] kann anamnestisch ausgeschlossen werden. Andere Fälle von Panmyelopathie, die meist etiologisch nicht zu klären sind und vielfach als Autoimmunreaktion gedeutet werden kommen ebenfalls nicht in Frage, da bei einer solchen Annahme die schweren zytologischen und zytochemischen Veränderungen unverzüglich blieben, die eindeutig auf eine maligne Proliferation der Knochenmarkszellen hinweisen. Im übrigen kann keinesfalls ausgeschlossen werden, dass sich hinter manchen Fällen von derartigen Panmyelopathien mit hyperplastischem Mark in Wirklichkeit Panmyelosen verbergen.

Die Befunde des von uns beobachteten Patienten weichen in verschiedenen Punkten von der Beschreibung des Panmyelosetypus I von DI GUOLIELMO [5] ab. So fehlt z.B. die Panrythämie, und unreife Zellen der Hämatopoiese wurden nur bei längerem Suchen in geringer Zahl im peripheren Blutbild gefunden. Schliesslich erstreckte sich der Krankheitsverlauf auch nicht wie bei den Fällen DI GUOLIELMO über mehrere Jahre, sondern war sehr kurz. Ob eine Ähnlichkeit mit der zweiten von DI GUOLIELMO erwähnten Verlaufsform der Panmyelose besteht, die er eine «fast stets akute, unvollständige, hyperplastische Panmyelose» nennt, vermögen wir nicht zu entscheiden, da DI GUOLIELMO eine genaue Charakterisierung dieses Krankheitsbildes nicht gegeben hat.

Von manchen werden unter dem Terminus Panmyelose Krankheiten verstanden, die von unserer Beobachtung in vielen Einzelheiten abweichen und die im allgemeinen auch nicht ohne weiteres als maligne Hämoblastosen angesehen werden. So belegen HERZUVAL und Mitarbeiter [9] die Osteomyelosklerose und verwandte Krankheitsbilder mit dem Ausdruck «panmyélémie» und RAPPAPORT [19] fasst unter dem Begriff Panmyelose die Polycythaemia vera und die «Myelosklerose mit myelonscher Metaplasie» zusammen. Wir sind dagegen der Meinung, dass die Bezeichnung Panmyelose solchen Hämoblastosen vorbehalten bleiben sollte, die eindeutig Zeichen einer malignen Proliferation aller drei blutbildenden Systeme in Form von schweren Zellatypien etc. aufweisen, wie das bei unserer Beobachtung der Fall ist. Im übrigen ist das von uns beschriebene Krankheitsbild

durch den völlig abweichenden klinischen Verlauf und den abweichenden pathologisch-anatomischen Befund sowohl von der Osteomyeloidose als auch von der Polycythaemia vera klar abgetrennt.

Unsere Beobachtung könnte die durch zytogenetische Untersuchungsergebnisse gestützte Ansicht von einer gemeinsamen Stammzelle für die Erythropoiese, die Granulopoiese und die Megakaryozytopoiese weiter unterbauen [20, 21, 23] eine Ansicht, die u. a. aus dem Vorkommen des für die chronische myeloische Leukämie typischen Philadelphia-Chromosoms auch in Erythroblasten und Megakaryozyten abgeleitet ist. Eine solche gemeinsame Stammzelle wird auch von HAYHOE und Mitarbeitern [6] anhand zytologischer und zytochemischer Untersuchungsergebnisse bei unreifzelligen Leukosen diskutiert. Allerdings ist auch die Möglichkeit zu erwägen, dass Knochenmarkszellen – vor allem, da sie genetisch untereinander nahe verwandt sind – gleichartig anfällig gegenüber geschwulstauslösenden Noxen sind. Damit wäre z. B. denkbar, dass ein solches Agens bei allen Zellreihen gleichartige Veränderungen hervorruft, ohne dass eine gemeinsame Stammzelle unbedingt vorliegen muss.

Zur Frage der Therapie ist zu erwähnen, dass wir mit kleinen Dosen von Amethopterin wie sie von MOZSARIV [17] zur Behandlung von Erythroleukämien empfohlen werden und wie sie auch von uns mit gutem Erfolg bei einem Fall von Erythroleukämie eingesetzt werden konnten, in Kombination mit Prednison bei unseren Patienten keinen sichtbaren Erfolg hatten. Allerdings konnten wir die Behandlung nur 14 Tage lang durchführen. LUDIN [13a] hat bereits 1950 einen deutlichen Effekt des Folsäureantagonisten Aminopterin bei Erythroleukose beschrieben.

### *Zusammenfassung*

Es wird über einen 66-jährigen Patienten berichtet, der das Krankheitsbild einer Panmyelose mit Panhämozytopenie bot. Bei der blaptischen und autaptischen Untersuchung wurde eine schwere Hyperplasie des Knochenmarkes festgestellt, an der die Erythropoiese, die Granulopoiese und die Megakaryozytopoiese beteiligt waren. Alle drei Zellreihen wiesen überdies schwere zytologische Atypien auf. In der Milz fanden sich extraskelettäre Blutbildungsherde. Die zytologischen und zytochemischen Befunde werden im Hinblick auf die allgemeine hämatologische Bedeutung solcher Fälle besprochen, und es werden diagnostische, differential-diagnostische und therapeutische Fragen gestreift.

### *Summary*

This paper reports a case of malignant panmyelosis with panhemocytopenia, which occurred in a 66-years-old patient. At biopsy and autopsy the bone marrow revealed heavy hyper-

plasma of the blood forming parenchyma including erythropoiesis, granulopoiesis, and megakaryopoiesis as well. There were in addition, many cytological atypias in each of the three bone marrow cell strata. The cytological and cytochemical observations are discussed with respect to the general hematological importance of such cases, and problems of diagnosis, differential diagnosis, and therapy are briefly mentioned.

### Literatur

- 1 BALDON, V., FUNDIGRO, H. H., FURUTAKE, K. and DAMMEKE, W.: The anemia of the Di Guglielmo syndrome. *Blood* 14: 334-363 (1959)
- 2 BRECKENRIDGE, H. und HANWORTH, H.-G.: *Praktische Hämatologie* (Thieme, Stuttgart 1967)
- 3 DAMMEKE, W.: Some speculations on the myeloproliferative syndromes. *Blood* 6: 372-375 (1931)
- 4 DE GUGLIELMO, G.: Erythroblastikämie. *Sci. med. Ital.* (durch Ausgabe) 3: 15-33 (1934).
- 5 DE GUGLIELMO, G.: Die Erythroblastosen in HÄRMAYER und HITTMANN Handbuch ges. Hämatol., Bd. III/1 (Urban & Schwarzenberg, München/Berlin 1960)
- 6 HAYMON, F. G. J.; QUAGLIANO, D. and DOLL, R.: The cytology and cytochemistry of acute leukaemia (Her Majesty Stationery Office, London 1964)
- 7 HAYMON, F. G. J. and QUAGLIANO, D.: Refractory sideroblastic anaemia and erythraemic myelosis: possible relationship and cytochemical observations. *Brit. J. Haemat.* 6: 381-387 (1960).
- 8 HÄRMAYER, L.: *Störungen der Hämsynthese* (Thieme, Stuttgart 1964).
- 9 HENRIEVILLE, R.; HENRIEVILLE, R., QUEREC, O., OUVY G. et DUBREUIL, J.: La pathologie chronique (splénomégalie avec érythroblastose, myélocytose et mégakaryocytose singulière). *Nouv. Rev. franç. Hémat.* 1: 358-360 (1961)
- 10 LÖPPEL, L.-D.: Über die selektive fermentzytochemische Darstellung neutrophiler myeloischer Zellen und Gewebestreifen im Paraffinschnitt. *Klin. Wochschr.* 42: 553 (1964).
- 11 LÖPPEL, L.-D.: Fermentzytochemische Befunde bei chronischer Erythroblastose und akuter Erythritose. *Klin. Wochschr.* 43: 795-796 (1965)
- 12 LÖPPEL, K. und OBERHOLMANN, H.: Pathologische Anatomie der sideroachrestischen Anämie (Untersuchung von 4 Fällen). *Beitr. path. Anat.* 136: 66-89 (1967)
- 13 LÖFFLER, H.: Zytochemischer Nachweis von unspezifischer Esterase in Erythroblasten. *Proc. europ. Soc. Haemat.*, Wien 1961 vol. 8, p. 475 (Karger Basel/New York 1962)
- 14 LÖPPEL, H.: Zur Klinik und Hämatologie der Erythromyelosen. *Acta haemat.* 4: 321-342 (1950).
- 15 LÖFFLER, H. und SCHMIDT, J. C. F.: Zytochemischer Nachweis von Esteraseaktivität in den „Kugelförmigen“ (Mikroglobulinen) der Megaklasten. *Klin. Wochschr.* 39: 1027-1028 (1961)
- 16 MÄRKER, H.: Zytochemische Beobachtungen von Erythropathien unter besonderer Berücksichtigung von Glykogen und freiem Eisen. *Schweiz. med. Wochschr.* 91: 1209-1211 (1961)
- 17 MÄRKER, H., TEGALINO, V. und SCHMIDT, K.: Unspezifische Esterasen bei Erkrankungen und Reaktionen des erythropoetischen Systems. *Proc. europ. Soc. Haemat.*, Wien 1961 vol. 8, p. 476 (Karger Basel/New York 1962).
- 18 MÖRCHEN, S.: Zeitgemäße Behandlung der Leukosen. *Schweiz. med. Wochschr.* 95: 263-274 (1965)
- 19 QUAGLIANO, D. and HAYMON, F. G. J.: Periodic-acid-Schiff positivity in erythroblastosis with special reference to Di Guglielmo's disease. *Brit. J. Haemat.* 6: 26-33 (1960).

19. RAFFAPORT J.L.: Panmyelose; in Tumors of the hematopoietic system. Atlas of tumor pathology Section III fascicle 8 (Armed Forces Institute of Pathology Washington, D.C. 1966).
20. TOCHU, I. M.; JACOB, P. A.; COURT BROWN, W. M.; BAIRIE, A. G. and WILLIAMSON, E. R. D. Cytogenetic studies on bone marrow in chronic myeloid leukaemia. *Lancet* **i** 844-846 (1963)
21. TRUJILLO J. M. and OWEN, S.: Chromosomal alteration of erythropoietic cells in chronic myeloid leukemia. *Acta haemat.* **29**: 311-316 (1963)
22. VERLOOF A. L. C.; BEKKING, J. and DEKKRAAD-NJOO, A. Primary or essential siderochromic erythrocytes. *Acta haemat.* **27** 129-145 (1962)
23. WYRANO, J. FREI III E. TYO, J. H.; CARROUX, P. P. and BACHER, O. The distribution of the Philadelphia chromosome in patients with chronic myelogenous leukemia. *Blood* **22** 664-673 (1963)

Department of Medicine and Department for Pathological Anatomy  
Intensive Care Unit General Hospital Masarbor

## Fatal Peroral Iron Poisoning in a Young Woman

M. ČERNELČ, V. KUŠAR and S. JEREŠIN

During recent years a considerable number of severe or fatal accidental poisonings by iron salts has been reported [1 2 3 5, 6 7 8 12 13 14]. In the USA approximately 2000 cases of iron intoxication are encountered yearly with a death rate of 45 % [4]. In most cases children ingested tablets of ferrous salts, usually coloured or coated with chocolate. The exact dose of iron ingested could only be determined accurately in 36 % of a group of 172 children [4]. The introduction of deferoxamine changed the treatment and improved the fatal outcome of iron poisoning [10]. The death rate is now lower than 10 % if proper therapy is started early enough. The normal low iron excretion in urine is increased by deferoxamine to levels exceeding one hundred times the normal values [10 15].

The majority of cases with iron poisoning reported were in children and it may be of interest to report a case of suicidal iron intoxication in an adult with a fatal outcome.

### *Case Report*

A 23-year-old woman was admitted to the Psychiatric Department with the diagnosis of psychoneurosis. Her fiancé reported that he had found her in a semicomatous state vomiting brown and black masses which were suggestive of gastric hemorrhage. Thereafter the patient admitted to have ingested approximately 100 tablets 2 days previously because of conflicts in her family. On admission the patient was semicomatous and said with weak voice that she took two bottles of antianemic tablets about 32 h before. The local physician reported later that he found two empty bottles of antianemic tablets, containing 50 mg iron each, in the patient's room. The total dose taken was 10 g iron or 166 mg/kg body weight. The clinical findings were: dark brown appearance of skin similar to sun tanning. Flows of the bds was found, but the reflexes on examinations of the extremities were normal. Skin temperature was 36.5°C, the blood pressure was not measurable, the pulse rate 130.




Fig 1 Myocardium. Sudan III Myocardial fibers with microscopic droplets of fat ( appearing as black spots).

Hb 72.2% (11.55 g %) RBC 3,830,000,  $\text{Hct}$  0.93, WBC 49,000, bands 1,  $\text{segm}$ . 81%, lymph. 12%, monocy. 6%. Blood urea 84 mg %, iron 480  $\mu\text{g}$  %. Stool examination for occult blood positive.

After infusion of Ringer solution with Dexamethasone Rheomacrodex and antibiotic therapy the blood pressure rose to 70/60 mm Hg. The patient was then transferred to the Intensive Care Unit, where she died after admission.

Investigations (Intensive Care Unit) Blood urea 84 mg %, blood sugar 110 mg %, pH 7.133; 7.163;  $\text{HCO}_3^-$  12.4 10.4 mEq/l total  $\text{CO}_2$  13.5 11.3 mEq/l, physic. bound  $\text{CO}_2$  1.12 mEq/l  $\text{pCO}_2$  38.30 mm Hg.  $\text{HCO}_3^-/\text{CO}_2$  1 10.9 1 11.6. Electrophoresis Alb. 62.5%  $\alpha$ -glob. 4.8%  $\alpha_2$ -glob. 6.4%  $\beta$ -glob. 8.8%  $\gamma$ -glob. 16.5%.

*Post mortem examination.* The body is that of an adequately nourished woman. Both lungs show considerable degree of congestion and numerous hemorrhages especially on the anterior border. In the pleural cavities approximately 100 ml of hemorrhagic fluid were found. The heart, pericardium and thymus appeared normal and so did the gallbladder and pancreas. Lateral to both adrenals and under the capsules of the kidneys extensive hemorrhages were found. The kidneys appear pale with normal ureters; the bladder which is also normal, contains no urine. The reproductive organs are normal as are the brain and meninges. The stomach shows an area of congestion containing numerous small hemorrhagic spots with some edema. The stomach contains some millilitres of dark brown coffee-ground material. In the duodenal area there are abundant hemorrhages. The small intestine contains dark tarry material especially in the ileum. The large intestine shows areas of congestion and swelling with hemorrhagic spots. The liver is pale, flabby greasy to touch, with areas of orange and yellow color. The spleen is normal in size, weight and consistence.

*Histology* The heart shows fatty degeneration (fig. 1) as do also the epithelial cells of the tubules in the kidneys (fig 2). In the liver widespread and uniform fatty change was found. The droplets of fat in the cells are confluent, so that no protoplasm can be seen (fig 3).




Fig 2. Kidney. Haematoxylin-eosine. Numerous vacuolated tubular cells after extraction of fat.

Fig 3. Liver. Haematoxylin-eosine. Heavy parenchymatous degeneration of liver cells and deposition of fat.

Staining with Sudan III shows the fatty degeneration to be of a higher degree than expected by the haematoxylin-eosine method. The main lesions occur in the gastro-intestinal tract. In the stomach minimal changes were found, but in the duodenal mucosa severe necrosis of

the epithelium edematous, so that no normal areas were encountered. In the deep layers the cell nuclei were colored pale or absent. The muscularis mucosae was edematous and thickened, the Brunner cells were weakly colored. It is of interest to note that in the tubules of kidneys and hepatic cells iron could not be demonstrated.

### Discussion

REISMAN *et al* [9] studied the mechanism of the toxic action of iron in animals. By stomach or duodenal tube or by enemas dissociable iron salts were given. The lethal dose in dogs and rabbits was found to be approximately 150 to 200 mg iron per kilogram body weight. In the majority of the animals no histologic changes were seen in the intestinal mucosa, but in some instances intestinal bleeding from congested capillaries occurred. In children who died from iron intoxication, necrosis of the intestinal mucosa was encountered, although in some cases minimal necrotic changes were found. REISMAN estimates that the heavy intestinal necrosis in children is due to the corrosive effect of iron salts in substance while in the experiments with dogs and rabbits aqueous solutions have been used.

Poisoning with iron in adults is very rare. The patient reported passed at home of the three characteristic phases of iron intoxication: 1. Acute gastro-intestinal symptoms, 2. relative wellbeing, 3. fatal termination. She entered the hospital in the terminal phase of intoxication and died shortly after admission so that no therapy could be given. It appears that once the gastric mucosa is damaged, iron escapes from the gut into the tissues and leads to thrombosis of the submucosal veins. The numerous thromboses inhibit further iron absorption so that comparatively little iron is found in the liver and kidneys. It is difficult to come to another conclusion than that the extensive fatty changes in parenchymatous organs (liver, heart, kidney) cause the rapid fatal outcome. The liver is not able to maintain its detoxicating function, the heart becomes hemodynamically insufficient because of extensive fatty degeneration of its muscle fibers and the kidneys are damaged by the low blood pressure and fatty degeneration of tubular cells.

The cause of sudden death following relative wellbeing was obviously due to fatty degeneration of parenchymatous organs. Hyperventilation and pronounced acidosis, suggesting a disturbance in oxydative metabolism, was present. In a recent investigation WITZLEBEN and CHAFFEY [11] found extensive hepatic necrosis following



Prostatahypertrophie festgestellt wurde. Diese wurde zunächst konservativ behandelt, als es im April 1965 jedoch zu einer akuten Harnverhaltung kam, wurde eine Ausschaltung des Adenoms vorgenommen. Die histologische Untersuchung des Operationspräparates ergab keinen Hinweis auf Malignität. Nach der Operation war der Patient beschwerdefrei. Im Mai 1966 traten plötzlich am ganzen Körper blaue Flecken auf, ausserdem bemerkte der Patient eine ausgedehnte Blutung unter der Bindehaut. Einige Tage später kam es ausserdem zu einer Hämaturie, die so stark wurde, dass der Patient schliesslich auf eine urologische Abteilung aufgenommen werden musste. Hier ergab die i.v. Pyelographie und die zystoskopische Untersuchung keinen Hinweis auf eine lokale Blutungsursache. Aus diesem Grund wurde nun eine Gerinnungsuntersuchung durchgeführt. Diese ergab eine schwere Gerinnungsstörung (siehe später), weshalb der Patient am 4.7. 1966 zur weiteren Abklärung und Behandlung an die I. Medizinische Klinik verlegt wurde.

Die klinische Untersuchung bei der Aufnahme an der I. Medizinischen Klinik ergab folgenden Befund: Reduzierter Allgemeinzustand, blasser Hautfarbe, an der Haut keine Zeichen einer hämorrhagischen Diathese. Herz und Lunge physikalisch unauffällig. Leber nicht vergrößert, Milz 1 QF unter dem Rippenbogen tastbar, keine Lymphknotenvergrößerung. Nierenlager nicht klopfempfindlich. Rektale Untersuchung: kein abnormer Befund an der Prostata erhebbar. RR 170/90 mm Hg. Es bestand eine leichte Hämaturie.

Laboratoriumsbefunde: Senkung 70/46 mm, Serumweis 6,7 g%, Albumin 3,1 g%, Globulin 3,6 g%, Thrombocytenreaktion I E; Elektrophorese: Alpha<sub>1</sub>- und Alpha<sub>2</sub>-Globulinvermehrung. LAP 117 mE, Serumbilirubin 0,42 mg%, Bromsulphaleinretention nach 45 min 2%, Cholesterin 240 mg%, Harnstoff-Stickstoff 311 mg%, alkalische Phosphatase 3,1 m Mol E, saure Phosphatase 1,2 m Mol E. Blutbefund: Ery 3,9 Mill, Hb 75%, FI 0,96, Leukozyten 6.350, Unsegmentierte 5%, Segmentierte 74%, Eosinophile 2%, Basophile 2%, Monozyten 1%, Lymphozyten 16%. Harnbefund: Albumen positiv, Saccharum negativ, Urobilinogen 1/4 Sulkowitsch positiv; im Sediment reichlich Erythrozyten.

Röntgenuntersuchungen: Thoraxröntgen: Linksherz mit beginnender Akkretion, vergrößerte Grundherzgröße der Lungen. Kein Hinweis für hämorrhagische Veränderungen. Magen-Darm-Passage: normaler Befund. i.v. Pyelographie: Dörtige Ausscheidung des Kontrastmittels aus beiden Nieren mit vor allem rechts unvollständiger Darstellung des Nephrosystems. Unbedingter Abfluss des Kontrastmittels in die nicht vollkommen zur Darstellung gebrachte Harnblase. Verdacht auf Anhebung des Blasenbodens bei Vergrößerung der Prostata. Skelettröntgen: Hochgradige Spondylose mit multiplex Bandscheibengenerationen und Osteochondrose im Bereich der Brustwirbelsäule. Multiple Osteoporose.

#### Gerinnungsuntersuchungen

Bei der ersten Untersuchung des Patienten konnten folgende Befunde erhoben werden (Tab. I).

Als wesentliche pathologische Befunde wurde eine schwere Fibrinogenopenie bei gleichzeitiger Thrombopenie gefunden. Ferner bestand eine leichte Verminderung des Prothrombins und von Faktor V. Es war auch eine leichte Verminderung von Faktor VIII anzunehmen, da der Thromboplastinbildungszeit unter Verdünnung von Patientenplasma leicht pathologisch war. Eine vermehrte Fibrinolyse konnte mit dem Fibrinolysestest nicht nachgewiesen werden, die Englobulinlysezeit war bei der ersten Untersuchung normal, bei späteren Untersuchungen konnte jedoch gelegentlich eine verkürzte Englobulinlysezeit gefunden werden (Abb. 2).

Das gleichzeitige Vorkommen einer Fibrinogenopenie und einer Thrombopenie deutet mit grosser Wahrscheinlichkeit auf eine Verbrauchstagulopathie. Zur Verifizierung dieser Diagnose wurde aber noch die biologische Halbwertszeit von jodmarkiertem humanem Fibrinogen bestimmt. Wie zu erwarten, war die Halbwertszeit des Fibrinogens bei dem Patienten mit 12 h deutlich verkürzt (Abb. 1). Die Halbwertszeit wurde noch kürzer (9 h)

Tabelle I Gerinnungsbefunde 24.6.1966

	Pat. H. L.	Normalwerte
Gerinnungszeit (Lee White) min	6	9
Blutungszeit (Duke) min	7 <sup>30</sup>	- 3
Thrombocytenzahl (Busecra und Cronette)	90000	150000 250000
Thromboplastinzeit (Quick), %	68	75-110
Prothrombin (F II) (Dittsch und Schaden), %	65	75-110
Protocelerin (F V) (Dittsch und Schaden), %	67	75-110
Fibrinogen (Clauss) mg <sup>100</sup>	40	200-400
Partielle Thromoplastinzeit (Lawdell) sec	77	50-70
Thromboplastinbildungsstest (Booss)		
Pat.-Pl.-Pat.-Serum	normal	
Pat.-Pl.-Normalserum	leicht path.	
Serumprothrombin nach 1 h, %	50	< 10
Englobulinhämost. h	über 8	über 12
Fibrinplatte	keine fibrinolytische Aktivität	

In die Fibrinolyse durch tägliche orale Verabreichung von 10 g Epsilon-Aminocapronsäure begrenzt wurde. Wurde hingegen eine Dauerinfusion von Heparin verabreicht, kam es sofort zu einer deutlichen Verlängerung der Fibrinogenhalbwertzeit, wobei allerdings der Normalwert nicht erreicht wurde. Damit war erwiesen, dass die beobachteten Gerinnungsveränderungen, vor allem die Fibrinogenopenie und Thrombopenie durch eine intravasculäre Gerinnung bedingt waren.

#### Beeinflussung der hämorrhagischen Diathese durch Heparin und weiterer Verlauf der Krankheit

Bei der Aszektomie einer Verbrauchskongulopathie infolge intravasculärer Gerinnung war zu erwarten, dass eine Unterbrechung des intravasculären Gerinnungsvorganges durch Heparin die Gerinnungswörung beseitigen würde. Wie aus Abb. 2 zu entnehmen ist, kam es tatsächlich schon 12 h nach Beginn der Heparintherapie (1000 E Heparin/Stunde als Dauerinfusion) zu einem deutlichen Anstieg des Fibrinogens, das am 4. Tag nach Therapie begann einen Höchstwert von 410 mg% erreichte. Die Thrombocyten stiegen ebenfalls an, aber erst nach einigen Tagen und nicht in demselben Ausmass wie das Fibrinogen. Gleichzeitig mit dem Anstieg des Fibrinogens und der Thrombocyten kam es zu einem Stillstehen der Blutungsneigung.

Der gute therapeutische Erfolg konnte bei nur so lange aufrechterhalten werden, als Heparin kontinuierlich infundiert wurde. Als aus technischen Gründen die Therapie mit Depotheparin subkutan fortgeführt wurde, kam es wiederum zu einem Abfall des Fibrinogens, wenn auch nicht auf so tiefe Werte wie vor der Therapie.

Der weitere klinische Verlauf war gekennzeichnet durch einen rasch zunehmenden Kraftverfall und Gewichtsverlust. Bei wiederholten rektalen Untersuchungen konnte schliesslich an der Prostata ein Tumorbefund erhoben werden, der dem Verdacht auf ein Prostatakarzinom nahelegte. Eine Probeexzision zur Verifizierung dieser Diagnose konnte




Abb. 1 Halbwertszeit von <sup>125</sup>I-Fibrinogen vor und während Therapie mit EACA 10 g tgl. bzw. Heparindauerinfusion (1000 E/h). Abszisse: Zeit in Tagen. Ordinate: Radioaktivität in „ des 10-Minutenwertes.




Abb. 2 Einfluss der Heparithherapie auf Fibrinogenspiegel und Thrombocytenzahl.

— Fibrinogen in mg%  
 ●—● Thrombocytenzahl

wegen der hämorrhagischen Diathese aber nicht durchgeführt werden. Die saure Phosphatase war bei wiederholten Kontrollen nur geringwertig. Der Patient verstarb plötzlich unter den Zeichen einer strengen Hämaturie am 3.8.1966.

#### Pathologisch-anatomischer Befund

Bei der Obduktion (Sekt. Prot. Nr 1146/66, Obd. Ritzsch, Aumurg) des Patienten fand sich ein Prostatakarcinom mit Befall der regionalen und paraaortalen Lymphknoten und aus-



Abb. 3. Fibrinthrombus in einem kleinen Lungengefäß. Mallory ( $\times 300$ ).

gedehnten Knochenmetastasen in der Wirbelhölze. I Leber und Lunge waren makroskopisch keine Metastasen nachweisbar. Als unmittelbare Todesursache war eine frische Massenblutung in die rechte Kleinhirnhemisphäre ausgemacht. Weitere Zeichen einer schweren hämorrhagischen Diathese lagen in Form massiver Muskelfrakturen im rechten Oberschenkel und verschiedenen subkutanen Hämatomen vornehmlich im Bereiche von Injektionsstellen vor.

Histologisch erwies sich das Prostatakarzinom als ein Adenokarzinom mit wechselndem Gehalt an doppelt-brechenden sudanophilen Tröpfchen im Plasma. Retroperitoneale Lymphknoten waren ausgedehnt von analogen Karzinomformationen durchsetzt, Nekrosen oder Fibrinabscheidungen fehlten dabei. I den makroskopisch tumorfreien Lungen war im histologischen Schnitt eine geringgradige Lymphangiosis carcinomatosa vor allem aber auch Tumorformationen in kleinsten Gefäßen und interalveolären Kapillaren zu sehen vereinzelt und dabei unabhängig von den Tumorstellen gelegentlich auch Fibrinthromben (Abb. 3). Das Myocard ohne Auffälligkeiten, insbesondere die Gefäße mit freier Lichtung. Auch die Leber zeigte keine größeren Veränderungen, in den Sinusoiden keine Fibrinthromben. Die Kupferschen Sternzellen relativ gross und mit stark eosinophilem Plasma. Dements zeigte bei der PAS-Reaktion eine deutliche Rotfärbung, die auch nach Diastasebehandlung bestehen blieb, Elastinfärbung negativ.

Der für diesen Fall wesentliche Befund war in den Nieren zu erheben. So gut wie alle Glomerula zeigten homogene eosinophile Ausgüsse in ihren Kapillarschlingen (Abb. 4). Diese gaben positive Färbung und waren stets von der Kapillarwand abgrenzbar. Sie waren dennoch als hyaline oder Fibrinthromben anzusprechen. Schlingennekrosen fanden sich nicht. Größere und kleinere Rinden- und Markgefäße waren frei von Thromben.




Abb 4: Hyaline Thromben in Schlingen von Nierenglomerula. Mallory ( $\times 400$ )

### *Diskussion*

Die grosse Häufigkeit thromboembolischer Ereignisse bei Patienten mit malignen Tumoren ist dem Kliniker und Pathologen wohl bekannt. Eine wesentliche Ursache der Thromboseneigung beim Tumorkranken stellt sicherlich die Hyperkoagulabilität dar die vor allem durch Vermehrung oder Aktivitätssteigerung verschiedener Prokoagulantien [13] (Fibrinogen Faktor V und Faktor VIII) zustande kommt.

Klinisch äussert sich diese Thromboseneigung zumeist in Form von Makrothrombosen oder der sogenannten Thrombophlebitis migrans. Bei einer kleinen Zahl von Fällen führt die Hyperkoagulabilität aus bisher noch nicht genau bekannten Gründen jedoch zu einem anderen klinischen und pathologisch anatomischen Bild. Es kommt zur Bildung zahlreicher Fibrinthromben in den Kapillaren verschiedener Organe, ein Zustandsbild, das als diffuse intravasculäre Gerinnung bezeichnet wird. Dadurch kommt es zum raschen Verbrauch von Gerinnungsfaktoren, vor allem des Fibrinogens und der Thrombozyten, so dass eine Gerinnungsstörung entsteht, die vor allem durch eine Fibrino-

genopenie und Thrombozytopenie gekennzeichnet ist und nach ihrer Entstehung als Verbrauchskoagulopathie [6] bezeichnet wird.

Der vorliegende Fall weist alle charakteristischen Befunde einer solchen Verbrauchskoagulopathie auf Fibrinogenopenie, Thrombozytopenie, Verminderung von Faktor V und von Prothrombin. Auch die zeitweise nachgewiesene Fibrinolyse gehört zum Bild der Verbrauchskoagulopathie, da der Körper versucht, die Fibrinthromben durch Aktivierung der körpereigenen Fibrinolyse wieder zu beseitigen. Erwartungsgemäß war die Halbwertszeit des Fibrinogens deutlich verkürzt. Durch Gabe von Heparin konnte die Fibrinogenhalbwertszeit zumindest teilweise normalisiert werden, was als Beweis dafür anzusehen ist, dass die intravaskuläre Gerinnung tatsächlich pathogenetisch im Vordergrund stand. Gleichzeitig führte die Heparinbehandlung, solange sie intensiv durchgeführt wurde, zur Beseitigung der ursprünglich bestehenden Gerinnungsstörung und der Blutungsneigung.

Auch das morphologische Substrat dieses Zustandsbildes konnte in diesem Fall eindeutig nachgewiesen werden. Es fanden sich Fibrinthromben in grosser Zahl in den Kapillaren der Niere und im geringeren Ausmass auch in der Lunge. Der Nachweis von Fibrinthromben bei der Autopsie gelingt auch bei sicheren Fällen von Verbrauchskoagulopathie nur selten, was wahrscheinlich darauf zurückzuführen ist, dass die aktivierte Fibrinolyse und die postmortale Autolyse die vorhandenen Fibrinthromben rasch weiter verändern.

Verbrauchskoagulopathien können prinzipiell bei jedem malignen Tumor [4 14 17] auftreten. Allerdings neigen bestimmte Karzinome, wie die Karzinome des Gastrointestinaltraktes [1 3 5 8] das Prostatakarzinom [5 15 16, 18, 19 21] und das Pankreaskarzinom [5 9] besonders häufig zu dieser Komplikation. Das Prostatakarzinom weist insofern eine Sonderstellung auf, als hier eine Defibrinierung nicht nur durch eine intravaskuläre Gerinnung, sondern auch durch eine Hyperfibrinolyse [10 20] zustande kommen kann, was durch den reichlichen Gehalt des Prostatagewebes an fibrinolytischen Fermenten erklärlich ist. Es scheint aber dass bei allen Fällen von Defibrinierungssyndrom beim Prostatakarzinom prinzipiell immer beide Vorgänge – nämlich Verbrauch und Hyperfibrinolyse – eine Rolle spielen, wobei einer der Mechanismen pathogenetisch im Vordergrund steht.

Wieso es gerade in bestimmten Karzinomfällen zur Verbrauchskoagulopathie kommt, ist noch nicht ausreichend geklärt. Es fällt aber auf dass diese Fälle gewisse pathologisch-anatomische und

klinische Gemeinsamkeiten haben. Pathologisch-anatomisch handelt es sich zumeist um Adenokarzinome. Es war in den bisher beschriebenen Fällen immer eine hämatogene Metastasierung nachzuweisen, wobei sich Metastasen stets in Knochen oder Lunge oder in beiden fanden. Lebermetastasen wurden hingegen so gut wie immer vermisst. Klinisch waren diese Fälle im allgemeinen durch einen besonders foudroyanten Verlauf charakterisiert, der wahrscheinlich als Ausdruck des Einsetzens einer massiven hämatogenen Metastasierung anzusehen ist. Innerhalb kurzer Zeit könnten aus den zirkulierenden Tumorzellen beträchtliche Mengen an thromboplastischen Substanzen freigesetzt werden, wodurch die Clearancekapazität des RES und die körpereigenen Inhibitoren überspielt werden. Damit wären die Voraussetzungen für eine intravaskuläre Gerinnung gegeben.

### *Zusammenfassung*

Es wird der Fall eines 71-jährigen Patienten mit einem Prostatakarzinom beschrieben, bei dem es akut zum Auftreten einer Blutungsneigung kam. Als Ursache wurde eine Verbrauchskoagulopathie festgestellt. Durch Gabe von Heparin konnten die Gerinnungsstörungen zeitweise beseitigt und die ursprünglich verkürzte Fibrinogenhalbwertszeit verlängert werden. Bei der Autopsie wurde ein Prostatakarzinom mit regionalen Lymphknotenmetastasen und hämatogenen Metastasen in den Knochen und der Lunge gefunden. Histologisch konnten in der Niere und der Lunge Fibrinthromben nachgewiesen werden.

### *Summary*

A 71-year-old patient with metastatic prostatic cancer suddenly developed severe hemorrhagic diathesis. Fibrinogenopenia, thrombocytopenia, reduction of the factors II, V and VIII and shortened half-life time of  $^{125}\text{I}$  labeled fibrinogen were found. Diffuse intravascular clotting was suggested and heparin by continuous infusion was administered. This led to marked increase of fibrinogen and partial correction of the shortened half-life time of fibrinogen. At autopsy adenocarcinoma of the prostate with bone and lung metastases was found. Fibrin thrombi could be detected in the capillaries of the kidney and the lung.

### *Literatur*

- 1 BUREK, R. L. and TYAN, M. L. Hemorrhagic diathesis in carcinoma of the stomach: case report. *Ann. intern. Med.* 49: 917 (1958).
- 2 DEUTSCH, E. Störungen der Blutgerinnung und ihre Behandlung. *Abhandl. für Blutkrankheiten*, 8: 183 (1962).

3. FLEISCHMACKER, H.: Über die Herkunft der Plasmaschleimkörper. *Wien. Arch. Inn. Med.* 34 96 (1941).
4. FOUSTAN, J. R. and HOLMAN, R. L.: Acquired fibrinogen deficiency associated with carcinoma of the bronchus. *Ann. Intern. Med.* 52: 439 (1960).
5. FRICK, F. G.: Acute hemorrhagic syndrome with hypofibrinogenemia in metastatic cancer. *Acta haemat.* 16: 11 (1956).
6. LARCE, H. G., ROKA, L. and HIRSH, H.: The defibrination syndrome. *Thromb. Diath. haemorrh. Suppl.* 29 97 (1966).
7. MACFARLANE, A. S.: *In vivo* behaviour of  $^{125}$ I Fibrinogen. *J. clin. Invest.* 42 346 (1963).
8. MCKAY, D. G. and WATKINS, G. H.: Disseminated thrombosis in colon cancer. *Cancer* 8: 970 (1955).
9. MCKAY, D. G.; MANNILL, H. and HERTIG, A. T.: Carcinoma of body of pancreas with fibrin thrombosis and fibrinogenopenia. *Cancer* 8: 862 (1955).
10. MAROTZKE, R. und MÖLLER, M. H.: Schwere hämorrhagische Diathese als erstes Zeichen eines metastasierenden Prostatakarzinoms. *Med. Klin.* 60 1993 (1965).
11. MERSKEY G. and JOHNSON, A. J.: Diagnosis and treatment of intravascular clotting; in KOLLER, DICKERT and STASCHLI ed., *Pathogenesis and treatment of thromboembolic diseases*, p. 555 (Schattauer Stuttgart 1965).
12. MERSKEY G.; JOHNSON, A. J.; PERT, J. H. and WORT, H.: Pathogenesis of fibrinolysis in defibrination syndrome. Effect of heparin administration. *Blood* 24 701 (1964).
13. MILLER, S. P., ALON, J. S.; STEFANO, T. and ZUCKERMAN, L.: Coagulation disorders in cancer. I. Clinical and laboratory studies. *Cancer* 28: 1432 (1967).
14. MILLER, S. P. and DAVISON, T.: The defibrination syndrome in cancer. *Treatment of cancer with heparin*. *N.Y.J. Med.* 67 432 (1967).
15. PROCT, G. R.; SELZEL, M., CLIFFORD, E. and WATSON, W. F. *J. Amer. med. Ass.* 158 840 (1956).
16. RAPAPORT, S. I. and CHAPMAN, CH. G.: Coexistent hypercoagulability and acute hypofibrinogenemia in patient with prostatic carcinoma. *Amer. J. Med.* 27 144 (1959).
17. ROYER, F. and RUTZ, V. D.: The defibrination syndrome. *Arch. intern. Med.* 117 17 (1966).
18. SEALE, R. A., JAMPORE, R. W. and BARON, J. A.: Clotting defect in the presence of metastatic carcinoma of prostate. *Surg. Clin. North Amer.* 31 1111 (1951).
19. SWAN, H. T.; WOOD, K. F. and DAMEL, O. D.: Dangerous bleeding associated with carcinoma of prostate. *Brit. med. J.* 1 493 (1957).
20. TAYLOR, H. J., SACHMAN, P., WINTHROP, W. F. and KRAVITZ, S. K.: The hemorrhagic syndrome of metastatic prostatic cancer and its treatment. *J. clin. Invest.* 31 666 (1952).
21. ZER, E. und OTT, H.: Klinische Gesichtspunkte zur Entstehung der erworbenen A-fibrinogenämie und Fibrinogenopense mit hämorrhagischer Diathese. *Acta haemat.* 12: 106 (1954).



Haematological Unit, Indian Council of Medical Research and Department of Haematology  
School of Tropical Medicine, Calcutta

## A Rapid Clinical Method for the Estimation of Activity of Aconitase in Blood

S. K. GHOSH SUSHILA SWARUP-MITRA and J B CHATTERJEA

The enzyme aconitase belongs to the class of hydrazase enzymes which add water to organic compounds without splitting. The reaction may involve an intermolecular oxidation reduction coupled with final hydration process. This is often a preliminary reaction step before starting biological oxidation.

The methods for the estimation of aconitase are based on the fact that it converts citrate to *cis*-aconitate which is further transformed into *Δ*-isocitrate. Citrate  $\rightleftharpoons$  *cis*-aconitate  $\rightleftharpoons$  *Δ*-isocitrate.

In a simple spectrophotometric method the light absorption due to *cis*-aconitate at 240 nm wave length is measured as an index of the enzyme activity in presence of citrate or *cis*-aconitate as the substrate [1]. This procedure is unsatisfactory for direct estimation of enzyme activity in presence of haemoglobin or blood protein which has a high extinction coefficient at 240 nm wave length. The enzyme activity may also be measured from the amount of citric acid produced from *cis*-aconitic acid by the enzymatic reaction and determined colorimetrically as a pentabromoacetone derivative [2]. This method is accurate but not suitable for rapid clinical assay of blood aconitase.

While exploring the possibility of obtaining a reliable method suitable for rapid evaluation of the status of aconitase in human blood a simple method was evolved. The principle of this method is as follows. The activity of the enzyme is determined colorimetrically by following the rate of reduction of the redox dye 2-6-dichlorophenol indophenol in presence of sodium citrate pig heart extract (isocitric dehydrogenase) nicotinic adenine dinucleotide phosphate (NADP)

manganese chloride and phosphate buffer pH 7.4. The rate of reduction is followed in a Leitz photoelectric colorimeter at 610 nm wavelength. A suitable substrate blank without citrate and NADP is run simultaneously to eliminate non-specific reduction of the dye. This method is modified from the spectrophotometric method employed by BARBAN and SCHULZE [3]. The unit of activity is taken as the rate of change of optical density per minute under the condition of the test.

### Material and Method

Five ml of venous blood collected using heparin as the anticoagulant are used for colorimetric determination of activity of aconitase as detailed below. The same sample is also analysed by standard spectrophotometric [4] method for the estimation of aconitase activity.

#### Colorimetric method

Immediately after collection, the blood is transferred to an ice bath; 0.5 ml of whole blood is dissolved in 4.0 ml of ice cold distilled water and kept in the ice bath for 10 to 15 min when the sample appears clear. Then 0.5 ml of 0.2 M phosphate buffer pH 6.8, is mixed with the solution and preserved in the ice bath till the end of the assay.

Into pyrex test tube (6" x 3"), the following reagents are added and maintained at 38° in water bath. Phosphate buffer pH 7.4, 0.2 M 1.0 ml, 0.06 M Sodium citrate 0.5 ml; distilled water 3.9 ml, manganese chloride 0.001 M 0.1 ml.

A blank reaction mixture tube is also prepared as follows. Phosphate buffer pH 7.4 0.2 M 1.0 ml, distilled water 4.4 ml, manganese chloride 0.001 M 0.1 ml.

Pig heart acetone powder extract in 0.1 M phosphate buffer of pH 7.4 containing 50-100 µg of protein/ml prepared and preserved at 4° C is used as source of isocitric dehydrogenase.

A NADP solution containing 2 mg of NADP (Sigma) per ml of distilled water is placed in test tube in ice bath.

A Leitz photoelectric colorimeter is adjusted to 100% transmission against distilled water at 610 nm wave length. 0.1 ml of 2-6-dichlorophenol indophenol (0.033%) is taken in 1 cm<sup>2</sup> cuvette. Pig heart extract 0.1 ml, NADP solution 0.1 ml and 0.2 ml of blood solution (1 in 10 dilution) are added in succession to reaction mixture tube maintained at 38° C in water bath. The whole mixture is then poured into the cuvette containing the dye. This procedure ensures thorough mixing of the dye and the reactants. A stop watch is started after taking the initial (zero time) reading. Subsequent readings are taken at an interval of 1 min for 4 min. The above procedure is repeated with blank reaction mixture.

The rate of change of optical density (O.D.) is calculated for both the substrate and blank reaction mixtures from the linear part of the activity curve. The corrected value 'delta' ( $\Delta$ ) is obtained by subtraction of the value for blank activity from that of substrate activity.

All estimations are done in duplicate and the unit of enzyme activity is taken as the rate of change of O.D. per minute under the condition of the test.

The final enzyme activity is calculated as follows

$$\begin{aligned} \text{Corrected } \Delta &= 0.0047 \\ \text{PVC (packed cell volume)} &= 32 \\ \text{Dilution factor} &= \frac{6 \times 10}{0.2} = 300 \end{aligned}$$

Table III. Units of aconitase activity in iron deficiency anaemia

Name	Hb g%	PCV %	Ret. %	WBC/mm <sup>3</sup>	Enzyme activity/ ml blood/min
S. D.	6.09	23	7.4	7,700	0.55
G. R.	5.8	22	6.6	5,300	1.12
D. N.	5.2	19	4.0	8,200	0.55
J. N. D.	5.2	23	0.9	7,100	0.79
R. B.	8.7	30	1.9	6,300	0.63
A. P.	9.8	31	1.1	18,400	1.15
S. B.	5.5	22	1.5	6,000	1.27
P. C.	6.38	26	1.8	7,500	0
B. J.	6.38	24	5.5	11,900	0.65
H. S.	3.19	16	12.0	5,600	0.48

Values for activity of aconitase obtained colorimetrically in normal and iron deficiency subjects are shown in tables II and III

### Comment

In the system employed the redox dye 2,6-dichlorophenol indophenol probably plays the following role: Citrate  $\rightarrow$  cis-aconitate  $\rightarrow$  *dl*-isocitrate. *dl*-isocitrate + NADP  $\rightarrow$  oxalo-succinate + NADPH. NADPH + oxydized dye  $\rightarrow$  NADP + reduced dye. The reduced dye does not undergo spontaneous oxydation and the fall in optical density is used as a measure of the enzyme activity. The dye 2,6-dichlorophenol indophenol has also been employed in enzymatic assay of oxydized and reduced forms of NADP and diaphorase in colorimetric studies [5, 6]. The reducing effects of the substrate blank solution is due to non-specific reducing substances likely to be present in blood lysates. The linearity curve shown in figure 1 is plotted after subtracting the blank value. Slope of the line or  $\Delta$  expressed as the unit of enzyme activity per minute, by both spectrophotometric and colorimetric methods, gave comparable results as shown in table I. It would appear that for rapid clinical estimations, colorimetric method may be substituted for spectrophotometric method. This method is sensitive enough to detect differences in the enzyme activity of normal and anaemic subjects particularly those with iron deficiency anaemia [7].

### Acknowledgement

Grateful thanks are due to K. K. MATHUR, All India Institute of Hygiene and Public Health, for statistical help.

### Summary

A simple colorimetric method has been standardised for the rapid determination of aconitase activity in whole blood by using redox dye 2-6-dichlorophenol indophenol in the presence nicotinic adenine dinucleotide phosphate isocitric dehydrogenase citrate and phosphate buffer pH 7.4. Comparison of the data on the same sample obtained colorimetrically and spectrophotometrically showed no statistically significant difference. Evaluation of the enzyme activity in blood of normal and iron deficient subjects showed a deficiency of aconitase in the latter group.

### References

1. RACKER, E. Spectrophotometric determination of aconitase as described by ABRAMSON, B. G. in COLOWICK and KAPLAN's *Methods in Enzymology* vol.1 pp. 695-698 (Academic Press, New York 1955).
2. NATHANSON, S., FRATES, J. B. and LUDOVIC, J. K. Microdetermination of citric acid. A new colorimetric reaction for pentabromocetone. *J. biol. Chem.* 175: 745-750 (1948).
3. BARBAX, S. and SCHUELE, H. O. Metabolism of tissue culture cells. The presence in HeLa cells of the enzymes in the citric acid cycle. *J. biol. Chem.* 222: 655-670 (1956).
4. RICHETER, D., OTTAVIANO, P. and DUBREUIL, O. F. Metabolism of erythrocyte XIII. Enzyme-activity in the reticulocyte. *Canad. J. Biochem. Phys.* 34: 222-235 (1956).
5. SLATER, T. F. and SAWYER, R. A colorimetric method for estimating the pyridine nucleotide content of small amounts of animal tissue. *Nature Lond.* 193: 454-456 (1962).
6. MARLER, H. R. Diaphorases in *methods in enzymology*. Ed. COLOWICK, S. P. and KAPLAN, N. O. vol.2 pp. 707-711 (Academic Press, New York 1955).
7. SWARUP S., GHOSH, S. K. and CRATTERJEA, J. B. Aconitase activity in iron deficiency. *Acta haemat.* 37: 53-61 (1967).

Authors address: Drs. S. K. GHOSH, SUSHILA SWARUP-MITRA and J. B. CRATTERJEA, Haematological Unit, Indian Council of Medical Research, School of Tropical Medicine Calcutta (India).

## Book Reviews

R. DYBEAER und K. JENSEN: *Quantities and Units in Clinical Chemistry* Munksgaard, Copenhagen 1967

In den letzten Jahren hat sich die klinische Chemie immer mehr zu einem selbständigen Fach entwickelt. Eine Vielzahl von körpereigenen Stoffen werden mit immer komplizierteren Apparaten unter teils komplexen Versuchsbedingungen analysiert. Ein echter Fortschritt ist aber nur dann gewährleistet, wenn eine auf der ganzen Welt einheitliche Terminologie in bezug auf die analysierten Stoffe und Ausdrucksformen in bezug auf Größen und Einheiten verwendet wird. Welche praktisch medizinischen Fortschritt die Wahl einer richtigen Einheit mit sich bringen kann, hat der Übergang von g/100 ml auf mEq/Liter bei den Plasma-Elektrolyten gezeigt. Ähnliches muss auch auf allen anderen Bereichen angestrebt werden. Das Buch von DYBEAER und JENSEN liefert nicht nur Anleiter zu einer solchen einheitlichen Terminologie der bio-Einheiten, sondern legt ein weitgehend vollständig ausgearbeitetes System vor. Das Buch sollte von jedem gelesen werden, der sich mit wissenschaftlichen Fragen jeder Art auseinandersetzt. Nur dann ist zu hoffen, dass unverständliche und zweideutige Mass-Einheiten wie g%, aus der Literatur verschwinden.

R. RECHTERICH, Bern

R. WARR: *Actualités en transfusion sanguine*. 2<sup>e</sup> cours européen de transfusion sanguine organisé par le Conseil de l'Europe, Strasbourg 1966. Masson, Paris 1967 184 S., 24 Abb., 50 Tab. Preis 46 F

Seit einiger Zeit organisiert der Zentrarat alljährlich einen Kurs für Transfusionskunde, zu welchem die Mitgliederländer des Rates jeweils 1-2 jüngere Spezialisten dieses Fachgebietes delegieren. Der zweite Kurs fand vom 3.-14. Mai 1966 unter Leitung von Prof. R. WARR im Blutspendecentrum Strasbourg statt. Die praktischen Kurseinheiten wurden von 11 Überwachern geleitet, gehalten von den führenden Fachleuten Frankreichs. Der vorliegende Band verfolgt diese Referate und versucht dadurch einen ausgezeichneten Überblick, namentlich über die immunohämatologischen Aspekte der Bluttransfusion.

A. HANSS, Bern

*Primates in Medicine*. Vol. I First Holloman Symposium on Primate Immunology and Molecular Genetics. Ed. by C. H. KRAVICH. Karger Basel/New York 1967 XVI + 99 p., 33 fig., 28 tab. Price: sfr./DM 16.50. US \$ 4.00/30 s.

The book contains contributions from eight research groups which were presented at the Symposium held on September 28/30, 1966, at the Aeromedical Research Laboratory of the Holloman Air Force Base, New Mexico (USA). Strikingly with the increase of knowledge on human immuno-genetic systems, the study of such systems in non-human primates is gaining growing interest. Six out of the eight studies are dealing with this subject. MOON-JAKOWSKI and WUNDER are giving survey on human-type x-human-type and cross-immune-type of blood groups in primates. MASOZZANI *et al.* are presenting new data on the nature of Rh-antigen, obtained with the method of I 125 anti Rh<sub>0</sub> (D) uptake on the red cells. WUNDER *et al.* are reporting on the complex relationship of the chimpanzee C-c-E-F system to the human Rh-Hr systems. POOLIN's paper is dealing with the structural similarities between immunoglobulins of human, chimpanzee and other non-human primates and ALFRA is presenting evidence that chimpanzee sera contain at least four Gm- and two Inv-factors, known to be isoenzymic determinants of human  $\gamma$ G-immunoglobulins. 1. and 2. Gm-factors occur in the immunological heterizations on proteins of primates

which – besides other interesting results – have revealed extensive transferrin polymorphisms in *Macaca mulatta*, chimpanzees and gorillas. Out of the two remaining studies, one by HOFFMAN and GOTTLEB deals with hemoglobin variants of chimpanzees and gibbons, the other by JENNALL, is an investigation on non-toxic immune-suppressive agents (performed not on primates but on mice). The Symposium has provided valuable informations on current researches in primate immunology and molecular genetics. Each of the studies gives lot of ideas and suggestions for further investigations which will also interest scientists working exclusively in human serology.

R. BÜTLER, Bern

J. GARCÉ: Das «Basal-Syndrom» im Kindesalter. VIII+133 S., 31 Abb., 14 Tab. Enke Stuttgart 1968. Preis DM 36.

Der Autor bemüht sich um eine Klärung des Begriffes «Basal-Syndrom». Neben der Aufzählung symptomatischer Formen, insbesondere bei Nierendehypertonie, hält er an der Existenz einer primären, essentialen Form fest. Er beschreibt im Detail die klinischen Symptome und den Verlauf bei 15 Patienten, die er hier darstellt. Durch Bestimmen erythrozytärer, leukozytärer und thrombozytärer Antikörper wird versucht, einen Beitrag zur Ätiologie des Syndroms zu liefern. Auch die Rolle der Milz im Sinne einer Dysplasie und die Zellphagocytose werden erörtert. Die spätere Mitbeteiligung der Leber im Sinne einer Zirrhose wird ebenfalls z.T. auf Autoaggression zurückgeführt. Trotz den vielfältigen Untersuchungen bleiben viele Theorien in dieser anregenden Betrachtung eines schwierigen Problems spekulativ.

M. VERT, Basel

J. M. COLLETTE, G. JANTET and E. SCHOFFELEERS: New Trends in Basic Lymphology. Proceedings of Symposium held at Charleroi (Belgium) on 11 to 13 July 1966. *Experientia, Supplementum* 14 Birkhäuser Basel 1967 233 S. Preis F 48.

The papers on the rather young specialty of lymphology presented in the Symposium at Charleroi are reproduced in *extenso* in this volume. They concern the structure and microstructure of the lymphatic vessels, the properties and permeabilities of the lymphatic endothelium, the contractility of human lymphatics, the problems of lymphaticovenous communications, the effects of lymphatic stasis and the various methods for exploration of lymphatic structure and function.

There is no question that such booklet serves as valuable source of information to the basic scientist as well as the clinical investigator interested in lymphology.

P. FRICK, Zürich

Proceedings of the 10th Congress of the European Society of Haematology Strasbourg 1968, Part I Hauptvorträge: 312 Seiten. Preis sFr./DM 75.– Part II Kurzvorträge (2 Teile, 814 und 774 Seiten) Preis für beide Teile: sFr./DM 570.–

Traditionsgemäss erscheinen die Beiträge des 10. Kongresses der Europäischen Gesellschaft für Hämatologie in sorgfältig ausgestatteter Buchform. Der erste, bereits vor Jahresfrist veröffentlichte Teil enthält die Hauptreferate. Der Band ist für jeden hämatologisch orientierten Arzt und Biochemiker ein wertvolles Quellenwerk, welches auf knappem Raum neuere Aspekte in sorgfältig reflektierten Übersichten über zentrale Probleme der Hämatologie zusammenfasst. Die Arbeiten von SAKOBY über Methoden der Untersuchung von Makromolekülen in Lösung und diejenige von KAMAT über Struktur und Heterogenität von Antikörpern zeigen die Bedeutung und Fruchtbarkeit interdisziplinärer Zusammenarbeit zwischen Kliniker und Biochemiker. Weiter, durchwegs originell dargestellte Beiträge behandeln die Geographie hämatologischer Erkrankungen, Probleme der Blutgerinnung, Fibrinolyse und Serologie, sowie neuere Aspekte der Leukämieforschung. Von besonderem praktischen Interesse ist die Arbeit von LAWKOWICZ und CERNES über die vergleichende Hämatologie verschiedener Tiergattungen, welche häufig für die experimentelle Forschung herangezogen werden.

or chronic renal insufficiency can be associated with a haemorrhagic disorder. In the same year SALMAN and NERI [5] and CASTALDI *et al.* [6] investigated the dynamic platelet functions in the haemorrhagic diathesis of uraemia. This paper which is a continuation of that presented in 1966 describes the haemostatic mechanism in 19 cases of uraemia and deals mainly with platelet adhesiveness.

### *Material and Methods*

**Patients.** The haemostatic mechanism was investigated in 19 uraemic patients who showed signs of a haemorrhagic disorder (tendency to epistaxis, spontaneous haematomas) at some stage of the disease. At the time of the examination 5 of these patients showed cutaneous-mucosal haemorrhages (purpura, haematomas, haemoptysis). All these patients had severe renal impairment with high blood urea levels (over 150 mg/100 ml), a markedly reduced glomerular filtration rate and haematuria. A few of them were treated by peritoneal dialysis and the others were on the waiting list for renal transplantation.

**Methods.** The platelet function was investigated using the following tests:

1. Bleeding time: Owren's method [7] was used. In our hands the normal values were between 5 and 7 min. The bleeding time is determined by the vasoconstriction, platelet adhesiveness, aggregation and viscous metamorphosis.

2. Platelet adhesiveness: We used BORCHOREVNIK's test which measures platelet adhesiveness *in vivo* [8]. Two platelet counts are made, one in venous blood and another in the blood flowing from a 1 cm long and 1 mm deep skin incision on the forearm (the same incision was also used for the bleeding time test by Owren's method). The difference between the two counts indicates the number of platelets adherent to the margin of the incision. The normal values represented as a percentage of the venous blood platelet count were, in our experience between 20% and 48%, with an average value of 34% [9].

3. The difference between the maximal amplitudes (ma) of the thromboelastographic curves in platelet-rich and platelet-poor plasma, expressed as  $ma_1 - ma_2$ . The  $ma_1 - ma_2$  value depends on the thrombodynamic function of the platelets which determines their participation in syneresis. For normal platelet counts the  $ma_1 - ma_2$  value varies between 30 mm and 35 mm.

4. Clot retraction: This test measures the retractive function of platelets.

5. Prothrombin consumption test: Normal results are more than 25 sec. Results below this limit are abnormal and, if one can be sure that there is no deficiency of any plasma factor which takes part in the generation of the intrinsic activator, they would indicate deficiency of platelet factor 3.

### *Results*

Results are shown in table 1. The prothrombin consumption test was abnormal in 17 out of 19 patients (89.4%) with an average time of 20.3 sec which is below the normal limit of 25 sec. This was, therefore, an almost constant finding. BORCHOREVNIK's test showed decreased adhesiveness in 11 out of 19 patients (57.9%). The average value of 18.8% was much below the normal value of  $34\% \pm 7\%$ , and the differ

Table 1. Chronic renal failure

Patient	No. of platelets per $\text{mm}^3 \times 1000$	Bleeding time min	TEG $\text{ma}^1\text{-ma}^2$ mm	Platelet adhesiveness in rky %	Clot retraction	Prothrombin consumption index
1 F.L.	230	4	44	30	N	-
2 D.F.	269	>20	39.5	20	N	21
3 A.A.	100	27	-	44	N	19
4 V.S.	298	15	29	8	N	-
5 D.C.	179	27	-	9	N	14
6 E.B.	90	-	-	22	N	18
7 P.S.	186	>20	45	0	N	15
8 J.T.	138	4	40	17	N	21
9 D.C.	118	5	40	13	N	16
10 A.B.	115	>20	42	11	N	15
11 J.M.	381	-	-	22	N	-
12 S.P.	310	5	-	0	N	31
13 L.B.	350	5	-	30	N	-
14 E.R.	340	15	34	15	N	30
15 J.O.	315	4	36	8	N	23
16 J.V.	283	3	28	43	N	21
17 O.D.	285	>15	46	36	N	19
18 C.C.	235	7	31	15	N	17
19 D.L.	265	>15	34.5	17	N	24
Mean	236	>12	31.2	18.8		20.3

ence was statistically significant. This difference is well represented in figure 1 where a comparison is made between normal adhesiveness and adhesiveness in uraemia. The bleeding time was prolonged (over 7 min) in 9 out of 17 cases (52.9%). The thromboelastographic index  $\text{ma}^1\text{-ma}^2$ , which represents the thrombodynamic function of the platelets, was abnormal in 2 cases. Clot retraction was always normal. The platelet count was within normal limits (average  $236,000/\text{mm}^3$  against the normal average of  $262,000/\text{mm}^3$ ) except in one case where it was below  $100,000/\text{mm}^3$ .

### Discussion

The above reported results show impairment of, at least, two platelet functions (1) deficiency in the plasma of platelet factor 3 and (2) deterioration in the dynamic function of platelet adhesiveness. In addition, CASTALDI has demonstrated impairment platelet aggrega-






Fig 1 Comparison between the platelet adhesiveness in uremia (obliquely striped area) and that in 50 normal controls (solid columns)

tion. Thus, it is logical to accept that a true 'uraemic thrombopathy' does exist and is the cause of the haemorrhagic diathesis in chronic renal insufficiency. Platelet adhesiveness and aggregation become active during the first stage of haemostasis and their failure has a serious effect on early haemostasis. This is well demonstrated by the rapid commencement of bleeding and its long duration when the bleeding time test is performed. Although the bleeding time is not always prolonged, there is another characteristic feature of the abnormal test which is always present in cases of diminished adhesiveness. In normal subjects there is a time interval of 30-45 sec between the time the incision is made and the time when bleeding begins and forms a drop of blood sufficiently large to be drawn into a pipette. In cases of diminished adhesiveness this time interval is reduced to 5-10 sec. The possible cause of this phenomenon could be either absence of adhesive platelets to occlude bleeding vessels mechanically or the fact that abnormal platelets do not carry serotonin which contributes to the early vasoconstriction. In view of this observation, the axonal reflex postulated as the earliest haemostatic response appears to be much less important than dynamic platelet functions and, especially the first of these in chronological order i.e. adhesiveness. On the other hand, deficient generation of intrinsic thromboplastin impairs coagulation of the plasma which, in normal conditions, follows and reinforces the early phase of haemostasis.

Analysis of the correlation between the platelet adhesiveness, prothrombin consumption, thrombodynamic function and bleeding time in uraemia shows that

(a) Out of 13 uraemic patients with an abnormal prothrombin consumption the platelet adhesiveness was decreased in 8 and normal in 5. Two other patients with a normal prothrombin consumption showed decreased adhesiveness. Thus, these two tests of platelet function agreed in 8 and disagreed in 7 cases. Figure 2 shows a slight correlation between deficient prothrombin consumption and decreased adhesiveness but the number of tests is too small to attempt to express it in mathematical terms as an index of correlation ( $r$ ) or covariation ( $p$ ). The average values for both prothrombin consumption (20.3 sec) and adhesiveness (18.8 %) are below the normal limit.

(b) Comparison of the platelet adhesiveness with the thrombodynamic function shows that (1) Out of 9 cases with diminished adhesiveness the thrombodynamic function was normal in 8 and abnormal in 1. (2) out of 4 cases where adhesiveness was within normal limits the thrombodynamic function was normal in 3 and abnormal in 1. Thus, there is a considerable difference in the way these two platelet




Fig. 2. Correlation between platelet adhesiveness and the prothrombin consumption. The area divided into squares represents the normal range. Circles (O) indicate 'pairs of values' of adhesiveness and the prothrombin consumption. The cross (X) represents the average 'pair of values'.

functions are affected adhesiveness is often impaired but the thrombodynamic function is usually normal.

(c) Finally the platelet adhesiveness and the bleeding time are compared in figure 3 which shows that (1) out of 11 cases of diminished adhesiveness the bleeding time was prolonged in 6 and normal in 5 (2) out of 8 cases with normal adhesiveness the bleeding time was normal in 3 and prolonged in the other 5. It is possible that decreased adhesiveness was compensated in some cases by vasoconstriction which participates in the haemostatic mechanism. The average adhesiveness was 18.8% and the average bleeding time 12 min. There was therefore some correlation between decreased adhesiveness and a prolonged bleeding time.

On the other hand, the syneresis and clot retraction which are related to the so-called thrombodynamic function of the platelets were usually normal obviously these platelet functions are independent of the others.

Very little is known about the pathogenesis of the platelet defect in uraemia. We can only report that decreased adhesiveness and aggregation are not apparently related to low haematocrit values so far




Fig. 3. Correlation between platelet adhesiveness and the bleeding time. The area divided into squares represents the normal range. Circles (o) indicate 'pairs of values' of adhesiveness and the bleeding time. The cross (x) represents the average 'pair of values'.

quently found in uraemia [10-11] and that HELLUM [12] has suggested that urea may interfere with platelet aggregation induced by ADP the meticulous investigations of SALZMAN and NERI [5] refute this hypothesis.

SALZMAN and NERI [5] and CASTALDI *et al* [6] using different techniques, obtained results similar to ours. SALZMAN investigated platelet adhesiveness *in vitro* (by this technique normal values are between 25% and 60%) in 24 patients and found marked reduction to between 0% and 19% in 21 of them. He found impaired adhesiveness in 7 out of 8 cases of gastrointestinal haemorrhage associated with uraemia. Like us, he observed some correlation but not full agreement, between deficient adhesiveness and reduced prothrombin consumption. In his opinion, deficient adhesiveness is an important factor in the uraemic haemorrhagic disorder and in the prolonged bleeding time.

CASTALDI *et al* [6] investigated the haemostatic mechanism in 19 cases of renal disease, 12 of which had haemorrhagic manifestations in 5 of the latter they found platelet adhesiveness *in vivo* of less than 20% (the normal range with their technique was between 20% and 70%). The bleeding time by Ivy's method, was more than 15 min in all patients who were bleeding, and in only one who had no clinical signs of a haemorrhagic disorder. Platelet aggregation was also abnormal in the cases with a haemorrhagic tendency.

Thus, both our investigations and those of other authors show a defect in the adhesiveness, in addition to the well known diminished prothrombin consumption, which is probably related to the haemorrhagic tendency and prolonged bleeding time in uraemic nephropathy. It seems, therefore, that a deficiency of platelet adhesiveness together with a deficiency of platelet factor 3 may possibly be an important factor in the uraemic haemorrhagic diathesis. The thrombodynamic function, on the other hand, is usually normal.

### Conclusions

In chronic renal insufficiency a decreased prothrombin consumption is the most frequent finding which indicates a deficiency of platelet factor 3. There is frequently diminished platelet adhesiveness which explains the prolonged bleeding time in some cases. The bleeding time is often prolonged. The thrombodynamic function is usually normal.

### Summary

The bleeding time, platelet adhesiveness *in vivo* thrombodynamic function of platelets, clot retraction and prothrombin consumption were investigated in 10 cases of chronic uraemia associated with a haemorrhagic diathesis at some stage of the disease. A decreased prothrombin consumption as a result of deficiency of platelet factor 3 was found in almost all the cases, as well as very frequently diminution in the platelet adhesiveness, and often a prolonged bleeding time. It is suggested that impaired platelet adhesiveness and deficiency of platelet factor 3 play an important role in the uraemic haemorrhagic disorder.

### References

1. RICHMAN, D.: Haemorrhages in the course of Bright's disease, with special reference to the occurrence of a hemorrhagic diathesis of nephritic origin. *Amer. J. med. Sci.* 134 709 (1907).
2. KOSKIMÄCK, B.: Bleeding tendency in chronic renal failure. *Acta med. scand.* 157 174 (1957).
3. ALTSCHELTER, G., MARCEA, A. J. and ULLMAN, H. C.: Platelets and platelets phospholipids in uremia. *Blood* 16 1439 (1960).
4. CASTILLO, C. y GARCIA SAN MIGUEL, J.: Plaquetopatías adquiridas secundarias a procesos no hematológicos. *Med. Clin.* 44 17 (1967).
5. SALEMAN, E. W. y NERI, L. L.: Adhesiveness of blood platelets in uremia. *Thromb. Diath. haemorrh.* 15 84 (1966).
6. CASTALDI, P. A., RODRIGERO, M. C. and STEWART, J. H.: The bleeding disorder of uremia. *Lancet* ii 68 (1966).
7. OWREN, P. A.: Physiopathologie du temps de saignement. *Nouv. Rev. franç. Hémat.* 3 280 (1963).
8. BORCHGREVINK, G. F.: A method for measuring platelets adhesiveness *in vivo*. *Acta med. scand.* 163 157 (1960).
9. GARCIA SAN MIGUEL, J.: La adhesividad plaquetaria en la clínica. Tesis (1967).
10. CASPARI, E. A.: Effect of red blood-cells and adenosine on platelets adhesiveness. *Lancet* ii 1273 (1965).
11. HARRISON, M. J. G. and MITCHELL, J. R. A.: The influence of red blood-cell on platelet adhesiveness. *Lancet* ii 1163 (1966).
12. HELLEN, A. J.: The adhesiveness of human blood platelets *in vivo*. *Scand. J. clin. Lab. Invest.* 12: suppl. 31 (1960).

Medizinische Universitätsklinik Innsbruck  
(Vorstand: Prof. Dr. H. BRÄUNSTEINER)

## Zur Diagnose monozytärer Leukämien mit zytochemischen Methoden<sup>1</sup>

F. SCHMALZL und H. BRAUNSTEINER

Neuere zytochemische Untersuchungen über die Herkunft der normalen Blutmonozyten haben die Theorie der myelogenen Abstammung dieser Zellen bestätigt [4 14 30 31]. Mit der Klärung dieses Problems eng verbunden, ist die seit SCHILLING und NAZARELL diskutierte Frage der Monozytenleukämien [3 8 22, 26, 28 35]. Dem vielfach als «typische Monozytenleukämie» bezeichneten Typ SCHILLING für den eine unmittelbare retikuloendotheliale Abstammung der leukämischen Zellen bisher angenommen wurde, steht die sogenannte «myeloische Monozytenleukämie» Typ NAZARELL gegenüber deren Zellen von zahlreichen Autoren als Paramyeloblasten aufgefaßt werden. Mischtypen [8] zwischen diesen Formen wurden beschrieben.

Diese Unterscheidungen wurden anhand panoptischer und phasenkontrastmikroskopischer Untersuchungsverfahren getroffen [3 8, 22 25 28]. Mit der Anwendung zytochemischer Verfahren ist eine einfache und klare Differenzierung der Monozytenleukämie gegenüber anderen Hämoblastosen möglich geworden [4 7 11 14 17].

### *Material and Methods*

Der vorliegenden Arbeit liegen die Ergebnisse von Untersuchungen an 5 Fällen monozytärer Leukämien zugrunde. Es wurden Ausstriche von peripherem Blut und von Knochenmarkpunktionen verwendet. Die Resultate wurden zum Teil mehrfach kontrolliert.

Diese Untersuchungen wurden mit Unterstützung des Fonds Kampf dem Krebs durchgeführt.

Zur Durchführung gelangten folgende zytochemische Reaktionen.

1. Unspezifische Esterase mit  $\alpha$ -Naphthyl-Acetat als Substrat ( $\alpha$ -N-E). Wir verwendeten hierbei die von LÖFFLER ausgegebene Methode die wir gering modifizierten [16, 20].

2. Unspezifische Esterase mit Substraten der Naphthol-AS-Reihe (N-AS-E). Es sind dies unterschiedlich substituierte Derivate des  $\beta$ -Naphthols, wie Naphthol-AS, Naphthol-AS-D- und Naphthol-AS-LC-Acetat (N-AS-4). Diese Substrate geben übereinstimmende Resultat. Für den Nachweis der Hemmbarkeit der N-AS-E wurde Natriumfluorid (NaF) in der Konzentration von 1,5 mg/ml dem Puffer zugegeben [6, 16].

3. Naphthylamidase. Wir wählten diese unspezifische Bezeichnung, um jene Fermente zu kennzeichnen, die bei zytochemischen Nachweisverfahren Amide des  $\beta$ -Naphthylamides mit  $\alpha$ -Leucin,  $\alpha$ -L-Alanin oder  $\alpha$ -L-Methionin spalten [1, 27, 29, 32] und die mit der echten Leucinaminopeptidase nicht identisch sind [5]. Geringe offenbar substratbedingte Unterschiede im Verteilungsmuster des Enzyms liessen sich bei Verwendung der verschiedenen Substrate feststellen. Wir verwendeten für die vorliegenden Untersuchungen  $\alpha$ -Leucyl- $\beta$ -Naphthylamid. HCl mit der etwas modifizierten Technik nach SCHMALZ und HATZELMANN [29, 32].

4. Die Darstellung der Naphthol-AS-D-Chloroacetat Esterase (N-AS-D-Cl-E) erfolgte nach der von MOSLEY et al. [11] angegebenen Methode.

5. Saure Phosphatase wurde in Anlehnung an die Methode von BAKER und ANDERSON [2] nachgewiesen.

6. Bei der Darstellung der alkalischen Phosphatase [9] und

7. der Myeloperoxidase [10] folgten wir den Angaben von KAPLOW.

8. Die PAS-Färbung erfolgte nach HORCHOW [25] die

9. Sodalischwarz B-Färbung nach SEIDMAN and STORVY [33]. Kernfärbungen wurden entweder mit saurem Hämalaun nach METZ oder mit der DNS-Färbung nach F. CLAY durchgeführt.

### Ergebnisse

Die Ergebnisse unserer ferment und histozytochemischen Untersuchungen an normalen Blut und Knochenmarkausstrichen stimmen mit den Ergebnissen anderer Autoren weitgehend überein [7, 11, 14, 16, 17, 21, 30]. In der Tabelle I sind die Befunde der verschiedenen zytochemischen Reaktionen an leukämischen Monozyten zusammengefasst.

Unter den aufgeführten Fermentnachweisen zeigten insbesondere die sogenannte unspezifische Esterase und die Naphthylamidase auffällige Reaktionsergebnisse in den leukämischen Zellen (Tab. I).


Die Aktivität der unspezifischen Esterase war sowohl mit dem Substrat  $\alpha$ -Naphthyl Acetat wie auch mit den Substraten der Naphthol-AS-Reihe sehr hoch. Die hohe Aktivität der N-AS-E wurde durch NaF (1,5 mg/ml) in den normalen und leukämischen Monozyten vollständig gehemmt [6, 30].

Die Naphthylamidase nachgewiesen mit den Substraten  $\alpha$ -Leucyl  $\beta$ -Naphthylamid HCl, liess in allen 5 untersuchten Leukämien eine deutliche Aktivität erkennen.

Naphthol AS-D-Chloroacetat Esterase war bei Fall 1 in mässigem Ausmass in den leukämischen Zellen nachweisbar. In den 4 anderen

Fällen fanden sich nur gelegentlich Spuren dieses Fermentes in den monozytären Zellen.

Sudanschwarz B-positive Phospholipide lassen sich in allen 5 Fällen in geringem Ausmass feststellen. Peroxydase ebenfalls nur in geringem Ausmass, fand sich nur in einem Fall, die anderen enthielten kaum Peroxydaseaktivität in den leukämischen Zellen. Wir ziehen die Sudanschwarzfärbung der Peroxydase-reaktion vor, da die Sudan-schwarzfärbung in jüngeren, weniger ausdifferenzierten Zellen der myelischen Reihe die noch keine Peroxydase enthalten, bereits eine positive Reaktion gibt.



444.1 Esteraseaktivität bei verschiedenen Leukämieformen.  $\alpha$ -N-E. ) b) und ) 1c) Fermentaktivität durch 1,5 mg/ml NaF gehemmt.  $\alpha$ -N-E d) ) und f). Stark positive Monozytenleukämie ) und d). Weniger stark positiv Promonocyten-Leukämie b) )  $\alpha$ -N-E durch NaF in den leukämischen Zellen gehemmt (selber Fall wie ) f) deutliche  $\alpha$ -N-E-Aktivität in Paraneoplasien. ) 1100 b) ), d), ) f) 1800  $\times$



*Tabelle I.* Angaben über weisses Blutbild, alkalische Neutrophilenphosphatase und Verhalten in den untersuchten Fällen von Monosytenleukämie. 0 keine ± unklare

	Leukozyten pro mm <sup>3</sup>	Monosytoide Zellen in %	Index der alkalischen Leukozyten- phosphatase	o-N-phenyl- Acetat-Leukämie
Normale Blutmonosyten				++ bis +++
Fall 1 Pat. R. 25 J	3 400	48%	108	++ bis +++
Fall 2: Pat. L. 60 J	8 100	38%	40	++ bis +++
Fall 3: Pat. B. 39 J	12 000	56%	96	++ bis +++
Fall 4 Pat. W. 44 J	187 000	93%	302	+ bis +++
Fall 5 Pat. A. 72 J	12 400	70%	43	+ bis +++

Der Gehalt an saurer Phosphatase war in allen Fällen beachtlich hoch. Alkalische Phosphatase wurde in den leukämischen Zellen nicht gefunden. Die Indices der alkalischen Phosphatase der Neutrophilen sind in Tabelle I zusammengefasst. Sie waren sehr unterschiedlich hoch. Zum Teil wurden die hohen Werte durch bestehende Infekte bedingt.

PAS-positive Substanzen waren in allen Fällen wenn auch in unterschiedlichem Ausmass feststellbar. In 4 Fällen war die Anfärbung diffus und mässig stark. Ein Fall zeigte neben einer diffusen zytoplasmatischen Anfärbung in zahlreichen Zellen Granula, die teils fein teils grob waren und sich manchmal in grossen Plaques darstellten.

Auf Grund der Anfärbung bei den zytochemischen Reaktionen liessen sich die 5 Fälle in zwei Gruppen unterscheiden. Während Fall 1

ten der leukämischen Monozyten bei den verschiedenen cytochemischen Nachweisreaktionen: + schwache ++ mäßig starke +++ sehr starke Reaktion

Naphthol-AS- Acetat Esterase	N-AS-E + 1,5 mg/ml NaF	Naphthol-AS- Esterase	saure Phosphatase	alkalische Phosphatase	Naphthol- AS-D-Chloro- Acetat Esterase	Sudan-schwarz B	PAS	Peroxidase
+++	++	+	++	0	0	0	++	0
+++	+	+++	+++		+	+	+	+
++	++	+	++	0	0	0	++	0
+++	+	+++	+++		++	+	+	+
++	/	/	++	0	0	0	++	0
+++			+++		++	++	+++	++
++	++	+	+	0	0	0	0	0
+++		++	++		++	++	+++	+++
+	++	0	++	0	0	0	0	0
+++	+	++	+++		+	+	+	+
+	++	0	++	0	0	0	0	0
+++	+	++	++		++	++	+++	+++

2 und 3 eine hohe Aktivität der unspezifischen Esterase in den leukämischen Monozyten und Monozytenvorstufen zeigen, wiesen die beiden anderen Fälle einen deutlich niedrigeren Gehalt auf. Dieser geringere Fermentgehalt kann mit einer gewissen Berechtigung als Zeichen einer mangelnden Ausdifferenzierung betrachtet werden. Tatsächlich waren in den beiden letzten Fällen zahlreiche unreife Zellen im peripheren Blut feststellbar.

Um die Reaktionsintensität in den einzelnen Zellen einer Population besser zu erfassen, wurden jeweils 500 Zellen ausgezählt und je nach der gefundenen Reaktion in 4 Klassen eingeteilt (Tab. II). Besonders bei der Esterasereaktion zeigte sich deutlich, wie in den Fällen 1, 2 und 3 die stärker positiven Formen überwiegen, während in den Fällen 4 und 5 die Mehrzahl der Zellen schwächer reagiert.

Tabelle II Reaktionsstärke in den leukämischen Monozyten bei verschiedenen Leukstein-  
0 keine, + angedeutet bis schwache, ++ mäßig starke,

	$\alpha$ -Naphthyl- Acetat Esterase				Naphthol-AS- Acetat Esterase			
	0	+	++	+++	0	+	++	+++
Fall 1 Pat. R. 25 J	0	4	21	73	0	2	40	58
Fall 2 Pat. L. 60 J	0	5	27	68	0	8	30	62
Fall 3 Pat. B. 39 J	0	2	29	69	0	5	37	52
Fall 4 Pat. W. 44 J	0	12	38	50	0	42	46	12
Fall 5 Pat. A. 77 J	0	22	63	15	0	33	42	5

### Diskussion

Normale Blutmonozyten sind auf Grund neuerer Untersuchungen in ihrer Leukstein- und Enzymzytochemischen Ausstattung weitgehend charakterisiert. Ihre eindeutige Identifizierung in Ausstrichen von Blut und Knochenmark, sowie in Exsudaten und Infiltraten ist mit verfeinerten zytochemischen Methoden möglich [4 12, 14 15 29 36]. Die Theorie der Herkunft der Monozyten aus dem Knochenmark wurde mit diesen Methoden erneut untermauert, und die Abgrenzung dieser Zellen gegenüber dem retikuloendothelialen System ermöglicht [4 14 30 31].

Es erscheint nun naheliegend, diese zytochemischen Eigenschaften auch als diagnostische Kriterien für die Erkennung der Monozyten-Leukämie heranzuziehen [11 12 14 17 20, 30]. In Tabelle I sind die wesentlichsten kennzeichnenden Befunde zusammengefasst, die bei der zytochemischen Untersuchung normaler Blutmonozyten feststellbar sind. Ein entsprechendes Verhalten der leukämischen Zellen muss verlangt werden, um die Diagnose einer Monozytenleukämie oder falls es sich um jüngere Zellen mit noch nicht so ausgeprägter zytochemischer Ausstattung handelt, - einer Promonozytenleukämie zu stellen.

### Unspezifische Esterase

Das Ausmaß der mit den Substraten Naphthol-AS-Acetat und  $\alpha$ -Naphthyl Acetat feststellbaren Esteraseaktivität in den verschiedenen


und enzymcytochemischen Nachweisverfahren. Jeweils 500 Zellen wurden klassifiziert. +++ sehr starke Reaktion, x nicht durchgeführt.

Naphthol-AS-Acetat Esterase + 1,5 mg/ml NaF	Naphthyl- amidase	Naphthol-AS-D- Chloracetat Esterase	Sudan- schwarz B
0 + ++ +++	0 + ++ +++	0 + ++ +++	0 + ++ +++
20 80 0 0	10 16 22 32	12 70 18 0	96 4 0 0
x	x		
/ / / /	/ / / /	79 21 0 0	92 8 0 0
12 83 0 0	10 44 37 9	71 29 0 0	59 41 0 0
18 82 0 0	23 34 19 4	93 2 0 0	93 5 0 0
5 93 0 0	32 47 18 3	89 11 0 0	69 30 2 0

Zellformen stimmen nicht immer überein [14-30]. Besonders ausgeprägt sind die Unterschiede bei verschiedenen hämatologischen Erkrankungen. So enthalten z. B. Plasmazytomzellen [18-24] Erythroblasten bei erythrämischer Myelose [13-30] bei Perniciose [19] und bei toxischen Knochenmarkstörungen [30] und in Einzelfällen, was vielleicht zu wenig beachtet wird, auch Paramyeloblasten mehr α Naphthylacetat Esterase als Naphthol AS-Acetat Esterase.



2a



2b

Abb. 2 Naphthylamidazereaktion: a) stark positive Monocyten b) Promonocytaleukämie mit z. T. schwach positiven Zellen. 1000

Ein spezifisches Kriterium zur Erkennung der Monozyten wurde mit der Feststellung der fast vollständigen NaF Hemmbarkeit der N AS-E in diesen Zellen und ihren Vorstufen gegeben [6]. In anderen Zellen des Blutes und Knochenmarks, mit Ausnahme ausgereifter Megakaryozyten, ist diese Esterase kaum hemmbar [30]. Für die Erkennung monozytärer Leukämien legen wir demzufolge mehr Wert auf die hohe durch NaF hemmbare Aktivität der N AS-E als auf eine hohe  $\alpha$ -N E, die auch bei anderen Erkrankungen feststellbar ist. Die von uns bisher gesehenen Monozyten und Promonozytenleukämien liessen neben einer hohen  $\alpha$ -N E tatsächlich auch eine hohe durch NaF fast vollständig hemmbare, N AS-E erkennen. Im Gegensatz dazu wurde die mässig starke N AS-E leukämischer Promyelozyten und Plasmazytomzellen durch NaF kaum gehemmt, ebenso die geringe N AS-E der Myeloblasten- und Paramyeloblastenleukämie (Tab. I).

### *Naphthylamidase*

Unter den Zellen des peripheren Blutes zeigen die Monozyten bei Verwendung des Substrates  $\alpha$ -Leucyl  $\beta$ -naphthylamid die stärkste zytochemisch nachweisbare Aktivität [32]. Diese bleibt den Monozyten auch in Exsudaten, in Hautfesterpräparaten [29] und in Ergüssen [eigene Beobachtung] erhalten. Reticulumzellen enthalten viel Promyelozyten mässig viel und die übrigen Blut und Knochenmarkszellen enthalten wenig Naphthylamidase [1, 27, 32, eigene Beobachtungen].

Bei Monozytenleukämien liess sich das Ferment unter Verwendung von Leucin  $\beta$ -naphthylamid in unterschiedlicher Intensität in den leukämischen Zellen nachweisen. Im Durchschnitt war die Aktivität mässig hoch [1]. In einigen Fällen fielen manche Zellformen durch ihren hohen Fermentgehalt auf. Sehr junge Zellformen - Monoblasten - enthielten ebenso wie Myeloblasten keine Fermentaktivität.

### *Naphthol AS-D-Chloroacetat Esterase*

Dieses Ferment ist, von den stark positiv reagierenden Gewebsmastzellen abgesehen, für die Zellen der neutrophilen Reihe spezifisch. Basophile und Eosinophile enthalten in der Regel keine entsprechende Fermentaktivität [16, 30]. Die in den Monozyten manchmal nach-



Abb. 3. Naphthol-AS-D-Chloroacetat Esterase ( ) nicht fermenthaltige leukämische Monozyten neben positivem neutrophilen Segmentkernigen; b) und ( ) z.T. deutlich positive leukämische Monozyten ( ) neben ( ) angedeutet und schwach positiven (b) sowie stark positiver Promyelozyt (b) und Neutrophile ( ) b) und ( ) selber Fall wie ( ) und ( ) der Abb. 1 1000 x

weisbare geringe Aktivität wurde ebenso wie die Peroxydasereaktion der Monozyten, als Beweis für die enge genetische Beziehung der Monozyten zu den Zellen der neutrophilen Reihe angesehen [14]

Drei der beobachteten Monozytenleukämien (Nr 3 4 5) ließen keine Aktivität des Ferments in den Zellen erkennen. Der Fall 2 enthielt nur in vereinzelten Zellen eine angedeutete Aktivität. Hingegen waren die leukämischen Zellen des Falles 1 z.T. stark positiv unterschieden sich allerdings deutlich von der sehr ausgeprägten Reaktionsintensität der wenigen vorhandenen reifen Promyelozyten, von denen sie sich im übrigen auch morphologisch völlig unterschieden. Eine positive Korrelation zwischen dem Vorkommen reifer Promyelozyten im Blut und Knochenmark und stark N AS-D-E positiven Monozyten konnten wir nicht feststellen.

Ähnlich den normalen Promyelozyten weisen auch die Zellen der Promyelozytenleukämien einen hohen Behalt an N AS-D-Cl E auf

Myeloblasten und Paramyeloblastenleukämien enthalten, wenn überhaupt eine sehr niedrige Aktivität des Fermentes.

### *Sudanschwartz B Färbung*

Übereinstimmend zeigten in allen Fällen die leukämischen Zellen einen geringen oder keinen Gehalt an Sudanschwartz-anfärbbaren Substanzen. Bei den wenigen festgestellten stärker positiven Zellen dürfte es sich um Promyelozyten gehandelt haben. Die leukämischen Monozyten stimmten in ihrem Verhalten mit normalen Blutmonozyten überein: die in der Regel eine geringe Anfärbbarkeit mit Sudan schwarz B erkennen lassen. Im Gegensatz dazu wiesen Promyelozyten leukämien eine deutlich grössere Anzahl positiver Zellen und auch einen stärkeren Reaktionsgrad der Einzelzellen auf.

Für die Auswertung zytochemischer Reaktionen an hämatologischen Präparaten wurde in Anlehnung an die score Technik zur Be-




Abb. 4. Sudanschwartz B-Färbung. (a) z.T. angedeutet positiv und (b) völlig negativ leukämische Monozyten. Eine Anfärbung zeigen in (a) ein eosinophiler Granulozyt und in (b) ein neutrophiler Myelozyt. 1000 $\times$

urteilung der alkalischen Neutrophilenphosphatase mehrfach eine ähnliche Technik verwendet [20-34]. Es scheint uns für diese Fälle allerdings zweckmäßiger die Reaktionsintensität einer bestimmten Zellpopulation aufgeschlüsselt nach Reaktionsklassen in Prozenten anzugeben wie wir es in Tab. II durchgeführt haben. Diese Darstellung gestattet eine bessere Beurteilung der gefundenen Aktivität und des Grades der Ausdifferenzierung der leukämischen Zellen unter der doch wahrscheinlichen Annahme, dass der Fermentgehalt der zunehmenden Differenzierung parallel geht. Bei reaktiven Monozyten im Rahmen von Stammzellenleukämien sind die Monozyten durch eine hohe Stammzellen durch eine fehlende oder sehr geringe Esteraseaktivität gekennzeichnet. Es fehlen Zwischenstufen, die hingegen bei Monozytenleukämien vorhanden sind. [14]. LEDER [14] entwickelte neuerdings die Theorie, die bisher als «jüngere» und deshalb fermentärmere Zellformen angesehenen leukämischen Zelltypen z. B. «Myeloblasten» im Endstadium von Monozytenleukämien, seien das Resultat einer Entdifferenzierung der ursprünglich gewucherten Monozyten, etwa analog dem Vorgang der Entdifferenzierung bei Karzinomzellen. Ein Beweis für diese Ansicht steht noch aus.

### *Zusammenfassung*

Auf Grund zytochemischer Untersuchungen lässt sich das Krankheitsbild der Monozytenleukämie eindeutig begrenzen. Die gewucherten Zellen lassen sich von im Knochenmark gebildeten Blutmonozyten ab. Die Diagnose der Monozytenleukämie erfolgt auf Grund folgender zytochemischer Kriterien: 1. Der hohe Gehalt der leukämischen Zellen an unspontischer Esterase bei der Verwendung von Naphthol-Acetat als Substrat. Substrate der Naphthol-AS-Reihe sind besser geeignet als  $\alpha$ -Naphthyl-Acetat, das erzieht auch in Paraneuroblasten eine positive Reaktion gibt. 2. Die Hemmbarkeit der starken Esteraseaktivität durch NaF (1,5 mg/ml) unter Verwendung der Substrate der Naphthol-AS-Reihe. 3. Eine mäßige bis starke Aktivität der Naphthylamidase in den leukämischen Zellen. 4. Die geringe Anfärbbarkeit mit Sodalischwarz B. 5. Eine in der Regel geringe Aktivität der Naphthol-AS-D-Chloroacetat Esterase in den leukämischen Monozyten.

### *Summary*

Monozytic leukaemia can be clearly distinguished on the basis of cytochemical studies. The hyperplastic cells are derived from monocytes formed in the bone marrow. The following cytochemical criteria determine the diagnosis of monozytic leukaemia: (1) The high level of unspecific esterase in the leukaemic cells when naphthol acetates are used as substrates. Substrates of the naphthol-AS series are more suitable than alpha-naphthyl acetate, which occasionally gives positive reaction also in paraneuroblast. (2) Inhibition



of the marked esterase activity by NaF (1.5 mg/ml) when naphthol-AS substrates are used; (3) Moderate to marked naphthyl amidase activity in the leukaemic cells; (4) Poor staining with Sudan black B; (5) Usually limited naphthol-AS chloroacetat esterase activity in leukaemic monocytes.

### Literatur

1. ACKERMAN G. A. Histochemical demonstration of aminopeptidase activity in the cells of the blood and bone marrow from various haematological disorders. *Nature, Lond.* 197 189 (1963)
2. BARKA, T. and ANDERSON, P. J. Histochemical methods for acid phosphatase using hexazonium pararosanilin as coupler. *J. Histochem. Cytochem.* 10: 741 (1962).
3. BRIDSON, H. W., DALAND, G. A. and PARKER, F. Hemocytic and monocytic leukemia. A clinical, hematological, and pathological differentiation. *Cancer* 8: 237 (1953)
4. BRAUNSTEINER, H. und SCHMALEL, F. Das Problem der Monozyten. *Dtsch. med. Wochr.* 93: 456 (1968).
5. DREBETZ, F.; SAUER, S.; SAUBERER, F. und BRAUNSTEINER, H. Spaltung von L-Leucyl- $\beta$ -Naphthylamid-HCl durch Leukozyten. *Klin. Wochr.* 42: 794 (1964)
6. FISCHER, R. und SCHMALEL, F. Über die Hemmbarkeit der Esteraseaktivität in Blut monocyten durch Natriumfluorid. *Klin. Wochr.* 42: 751 (1964)
7. FISCHER, R., LOEBACHER, P. und KÄUPER, C. Untersuchungen zur enzymzytochemischen Differenzierung von leukämischen Erkrankungen am Schnittpreparat. *Vierteljahrsschr. Anat. path. Anat.* 337: 525 (1964)
8. HIRTMAIR, A. Die myeloische Monozytenleukämie (Monozytenmyelose); in: HARTMAYER und HIRTMAIR, Handbuch der gesamten Hämatologie Bd. IV/2 (Urban & Schwarzenberg, München/Berlin 1963).
9. KARLOW L. S. A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and marrow. *Blood* 10: 1023 (1955)
10. KARLOW L. S. Simplified myeloperoxidase stain using benzidine dihydrochloride. *Blood* 26: 215 (1962)
11. LAURIG, K. und B. URS-SAO, P. Zur Zytochemie der Blutzellen. *Dtsch. med. Wochr.* 87: 1913 (1962)
12. LEDER, L. D. Zur Erkennung leukämischer Monozyten im Schnittpreparat. *Beitr. path. Anat.* 153: 202 (1963)
13. LEDER, L. D. Fermenthistochemische Befunde bei akuter Erythraemie und bronchischer Erythroblastose. *Klin. Wochr.* 43: 795 (1965)
14. LEDER, L. D. Der Blutmonozyt (Springer Berlin/Heidelberg/New York 1967)
15. LEDER, L. D. und NICOLAS, R. Fermenthistochemische Untersuchungen zur Gewinnung der Makrophagen an Hautfensterpräparaten. *Frankf. Z. Path.* 73: 228 (1963)
16. LÖFFLER, H. Zytochemischer Nachweis von unspezifischer Esterase im Ausstrich. Beiträge zur Technik und Ergebnisse im Blutaustrich des Menschen. *Klin. Wochr.* 39: 1220 (1961)
17. LÖFFLER, H. Hinweise zur Unterscheidung unreifer Leukämien mit zytochemischen Methoden. *Dtsch. med. Wochr.* 88: 1531 (1963)
18. LÖFFLER, H. Unspezifische Esterase und saure Phosphatase bei Plasmocytomen. *Blut* 15: 330 (1967)
19. LÖFFLER, H. und SCHUBERT, I. C. F. Cytochemischer Nachweis von Esteraseaktivität in den Kugelbläschen (Mörscher) der Megaloblasten. *Klin. Wochr.* 39: 1027 (1961)
20. LORTOLARY P.; LEJEUNE, P.; BONGHOMME, J.; TEILLAT, F.; TANZER, J. et BORRON, M. Contribution à l'étude cytochimique des leucémies aiguës dites à cellules monocytoïdes. *Nouv. Rev. franç. Hémat.* 7: 711 (1967)

21. MOLORCY W. C., McPHERSON, A. and FLEISCHMAN, L. Esterase activity in leukocytes demonstrated by the use of naphthol-AS-D-chloroacetate substrate. *J. Histochem. Cytochem.* 8: 200 (1960)
22. NAGELI, O. *Blutkrankheiten und Blutdiagnostik* (Springer Berlin 1973)
23. PEARSE, A. G. E. *Histochemistry Theoretical and applied* (Churchill, London 1961).
24. QUARLES, D., TORRELLI, U., SALTZ, S. and MAYER, C. Cytochemical and autoradiographic investigations on normal and myelomatous plasma cells. *Acta haemat., Basel* 38: 19 (1967)
25. RASNOVITZ, Y. and SCHERER, R. Monocytic cells of normal blood, Schilling and Nageli leukemia, and leukemia reticuloendotheliosa in slide chambers. *Blood* 29: 453 (1962)
26. REICHARD, H. und SCHILLING, V. Über eine neue Leukämie durch echt Übergangsformen (Splenomyeloleukämie) und ihre Bedeutung für die Selbstinduktion dieser Zellen. *Munch. med. Woch.* 60: 1981 (1913)
27. RUTENFRÖ, A. M. und ROSALIS, C. L. A histochemical method for the demonstration of leukocyte naphthylamidase using two substrates: alanyl- and methoxyl-4-methoxy-2-naphthylamide. *Brit. J. Haemat.* 1: 593 (1966)
28. SCHILLING, V. Klinik der Reticuloendotheliosen und Monocytozen. *Z. ges. inn. Med.* 5: 506 (1950)
29. SCHMALZ, F. und BRADSTETTER, H. Zytochemische Untersuchungen zur Entwicklung der grossen mononukleären Zellen des Häufensystems. *Acta haemat., Basel* 38: 281 (1967)
30. SCHMALZ, F. und BRADSTETTER, H. Zytochemische Darstellung von Esteraseaktivitäten in Blut und Knochenmarksmastzellen. *Klin. Woch.* 46: 642 (1968).
31. SCHMALZ, F. und BRADSTETTER, H. On the origin of monocytes. *Acta haemat. Basel* 39: 177 (1968)
32. SCHUMER, J. C. F. und MATEJOSKI, F. Der cytochemische Nachweis der Leucosarmino-peptidase in menschlichen Blut- und Knochenmarksmastzellen. In: *Zyto- und Histochemie in der Hämatologie*. 9. Freiburg Symp. (Springer Berlin/Göttingen/Heidelberg)
33. SHERMAN, H. L. and STORRY, C. W. An improved method of staining leucocyte granules with Sudan black B. *J. Path. Bact.* 39: 336 (1947)
34. SOO, R. H. Die zoenologische Bedeutung cytochemischer Untersuchungen an Leukozyten. *Schweiz. med. Woch.* 96: 634 (1966).
35. SORE, C. M. and DICK, F. W. Monocytic leukemia. *Amer. J. Med.* 20: 388 (1936)
36. WILSON, H. R. Histochemical studies of leukocytes from an inflammatory exudate. 1. Alkaline and acid phosphatases and esterases. *Acta haemat., Basel* 30: 159 (1963).

which with acute terminal blastic crisis, chronic lymphoid leukemia (6) reticular (9) and lymphoid (3) disseminated sarcomatous diseases, Hodgkin's disease (12) and plasmocytoma (6). All these patients have been studied out of phases of hematologic or clinical remissions, generally in the first days after the admission in our Clinic. Moreover 8 patients with epithelial neoplasms and 9 with systemic lupus erythematosus have been studied.

Since the anti-I serum used in our researches has been obtained from a O-group patient, all the subjects included in this study were selected belonging to this erythrocyte group.

2) *In vitro*-interaction between *Mycoplasmas* and erythrocyte I antigen. The red cells of two normal O-group I-positive subjects have been suspended, after three preliminary washings, in sterile saline 12% concentration, and incubated, respectively for 60 min to 22°C and for 24 h to 4°C with the following human *Mycoplasma* strains: *Mycoplasma pneumoniae* (Eaton agent) (FH strains) *Mycoplasma fermentans* (PG. 18) *Mycoplasma hominis* type 1 (PG. 21) and type 2 (PG. 27), *Mycoplasma orale* (Patt strain). They have been grown (3-5 days at 37°C, for *M. pneumoniae* 10 days) in PPLO fluid medium (Altucci *et al.*, 1965), then centrifuged 1 h at 12,000 rpm, and finally resuspended in saline 100-fold concentration.

At the end of these two incubation periods, the red cell suspensions have been washed three times with sterile saline, resuspended in the same medium 12% concentration, and were tested with the anti-I serum, adding 0.1 ml of the red cell suspension to 0.1 ml of the serum. The degree of the I-positivity of erythrocyte suspensions after the incubation with *Mycoplasmas* has been compared with that of the same suspensions before the addition of these micro-organisms.

3) *Interaction between Mycoplasmas and I antigen in vivo.* We have selected for this study the hamster infection with *M. pneumoniae* (7). At first, we must remember that starting researches, performed for testing the behaviour of I antigen in the normal hamster red cells, have always shown (100% of the experiments) marked I-positivity in the erythrocytes of these animals.

We have infected, in two different experiments, 4 hamsters, intranasal route (ml 0.1 x 2) previous Nembutal narcosis, with *M. pneumoniae* FH strain ( $10^6$  CFU/ml). Two animals were sacrificed in the 10th day for reisolating on agar the infecting agent; and 2 respectively in 20th day for measuring the specific complement fixing antibodies.

For all the sacrificed animals we have performed lung pathology evaluation, agar titration, at tenfold dilutions, of infecting agent, I-antigen research in the red cells, serum cold agglutinins (FELDER and HOLLERMAN) and CF antibodies measurement [5, 1], reticulocyte count and Ht determination.

## Results

All the red cells of patients suffering from leukemia or other malignancies have presented a strong I-positivity. We could not show any difference, with both types of incubation, between these erythrocytes and those from controls. As registered in table I, we have always

Coming the serum we have used from O-group patient, we have examined, both for (1) and (2) all O-group red cells. It has been said [15] that *Mycoplasmas* are more active toward I antigen from A-group subjects; nevertheless, the same A.A. admitted the possibility of an interaction (of biophysical and/or enzymatic order) [4] between *Mycoplasmas* and O-group cells.

The specificity of this phenomenon was demonstrated through the lack of agglutination of hamster red cells by both anti-A and anti-B serum.

Table I. Intensity of I-positivity of red blood cells of normal subjects, patients suffering from leukemia, malignancies and systemic *lupus erythematosus*

Groups	No. of cases	Anti-I serum agglutination	Intensity
Normal subjects	10	positive	+++
Acute leukemia	15	positive	+++
Chronic myelogenous leukemia	15	positive	+++
Chronic lymphoid leukemia	6	positive	+++
Reticulosarcoma	9	positive	+++
Lymphosarcoma	3	positive	+++
Hodgkin disease	12	positive	+++
Plasmocytoma	6	positive	+++
Epithelial neoplasias	3	positive	+++
Systemic <i>lupus erythematosus</i>	9	positive	+++

observed an I positivity with 3+ intensity comparable to that of controls. The same results were obtained in epithelial neoplasias and systemic *lupus erythematosus*.

The red blood cells of normal subjects, after the two different incubation periods with the *Mycoplasmas*, have shown neither a fall nor a loss of I positivity. The intensity of the agglutination by anti-I serum has been equal both for the red cells incubated and for those not incubated with *Mycoplasmas* (table II).

Although the infection by *M. pneumoniae* in hamster has been documented by the pathological findings in the lungs, by the isolation (in 10th day) of *Mycoplasma*, and by the content in CF antibodies (in 20th day) of the sera of the animals, we have not been able to show any change of the normally high I-positivity in the hamster red cells. The research of cold agglutinins has been negative: the reticulocyte count and the Ht value have not shown any difference in respect to the controls.

### DISCUSSIONS AND CONCLUSIONS

Our results about the eventual loss of I antigen in red blood cells of patients affected by leukemia or other systemic and malignant conditions, and about the capacity of *Mycoplasmas* to inactivate I antigen *in vitro* or *in vivo* have been negative. They do not agree with the conclusions of McGHEE *et al.* [12], SCHMIDT *et al.* [14-15] BARNES *et al.* [4]. On the other hand, during the development of our work,

Table II. I-positivity of normal red blood cells before and after incubation with *Mycoplasmas* *in vitro*

Normal red blood cells samples examined	<i>Mycoplasma</i> strains tested	Red blood cells incubated at 22° C for 60 min and at 4° C for 24 h	
		Intensity of I-positivity before incub.	after incub.
1	<i>M. pneumoniae</i> (FH)	+++	+++
	<i>M. fermentans</i> (PG. 18)	+++	+++
	<i>M. hominis</i> 1 (PG. 21)	+++	+++
	<i>M. hominis</i> 2 (PG. 27)	+++	+++
	<i>M. orale</i> (Patt)	+++	+++
2	<i>M. pneumoniae</i> (FH)	+++	+++
	<i>M. fermentans</i> (PG. 18)	+++	+++
	<i>M. hominis</i> 1 (PG. 21)	+++	+++
	<i>M. hominis</i> 2 (PG. 27)	+++	+++
	<i>M. orale</i> (Patt)	+++	+++

our data have been confirmed by the results of other authors [8, 13-10]

It is not easy actually to find an explanation for these opposite results. From the technical point of view the most accurate works appear those of DUCOS *et al.* [8] SALMON *et al.* [13] and above all, by FEIZI and HARDISTY [10] who have performed a quantitative study of I antigen in red cells, and [at least FEIZI and HARDISTY] have tested both leukemic and control red cells against three different anti-I sera (whose two with high titer)

An interesting observation [10] is related to the different capacity of the various anti-I sera to detect a partial loss of I antigen (as, for example, that of some types of newborn red cells, I-cord). However it is not probable that this explanation may also partially justify the different results. On one hand it is clear that all the anti-I sera are able to show the complete loss of I antigen and/or its lack in the rare cells in adult subjects [10]. On the other hand, the loss of I antigen in leukemic red cells [12-14] has been observed with high concentrations of anti-I serum (1-2)

In our work, we could not perform a quantitative titration of anti-I reactivity of the various red cells examined, because of the low titer of the serum. Nevertheless, the intensity in the agglutination with 1-2 serum dilution clearly showed the normal presence of I antigen in the red cells. On the other hand, the technique followed by us is the same of the authors, who, on the contrary have obtained positive results. The

Table III Behaviour of I-positivity related with other tests, in hamsters infected by *Mycoplasma pneumoniae*

Testing criteria	Normal hamsters sacrificed	Hamsters infected with <i>M. pneumoniae</i>	
		Sacrif. 10th day	Sacrif. 20th day
Lung pathology	best	1) interstitial pneumonia 2) interstitial pneumonia	1) healing lesions 2) healing lesions
Agar titration of <i>M. pneumoniae</i> (CFU/ml)	n. d.	1) $2.10^7$ ; $1.8.10^6$ 2) $1.10^7$ ; $0.5.10^6$	1) $1.5.10^6$ ; $1.10^6$ 2) 0; $2.10^6$
I-positivity	+++	1) +++; +++ 2) +++; +++	1) +++; +++ 2) +++; +++
Cold agglutination	n. d.	1) absent 2) absent	1) absent 2) absent
Specific CP antibodies	n. d.	1) <10; <10 2) 10; <10	1) 40; 80 2) 40; 40
Reticulocytes, / <sub>100</sub>	17-22%	1) 20; 20 2) 19; 23	1) 19; 18 2) 17; 18
Hematocrit, %	40-42	1) 38; 43 2) 40; 43	1) 40; 43 2) 41; 42

Expressed as the reciprocal of the highest serum dilution still able to show complete absence of hemolysis with 4-8 units of antigen and 2 full units of complement.

discrepancies with the results of these authors, obtained with *in vitro* incubation between *Mycoplasmas* and I positive red cells are - nevertheless - partial. They concern *M. pneumoniae* (active, following American authors, in determining I negativity of erythrocytes) and *M. fermentans* (only slightly active). Of other 3 strains tested by us, *M. hominis* 1 has been inactive also in their experiments, *M. hominis* 2 variably inactive or slightly active, *M. orale* not tested. Contrarily to SCHMIDT *et al.* [14] we have not previously disrupted *Mycoplasmas* in these experiments by freezing and thawing twice. It is not easy to say how this difference may have contributed to give a different result.

More recently during the writing of our work, FEIZI and DARRELL [9] have reported that the treatment of OI red cells with two different strains of *M. pneumoniae* did not affect the activity of any of three anti I sera tested either after overnight incubation at 4 C, or after incubation at 22° C. These data agree with our results.

Also the experiments concerning the behaviour of I antigen *in vivo* after a documented *Mycoplasma* infection have given conflicting results. On one hand, American authors [16-12] have recently noted

that the activity of the erythrocyte I agglutininogen was (only) transiently reduced following *M. pneumoniae* infection in 5 of 27 volunteers, without signs of hemolytic anemia. On the other hand, FAIZY and DARRILL [9] have found that the red cells from patients with *M. pneumoniae* infection (1<sup>st</sup> 3<sup>rd</sup> 7<sup>th</sup> week) reacted with the anti-I serum in a manner indistinguishable from the normal cells.

We have obtained similarly negative results in *M. pneumoniae* infection in the hamster.

However it must be stressed that we cannot say at present, whether so conflicting results, in the whole, may depend also from the eventually different antigenic distribution of various I positive red cells, and/or from the different source of anti I antibody in human sera tested (a natural agglutinin in I negative patient or a cold agglutinin from patients who had suffered or not for a *M. pneumoniae* infection). Also SMITH *et al* [16] admit that the greater sensitivity of the cold agglutinin anti I reagent than the iso-anti I reagent in detecting these antigenic changes may have been due to basic differences in molecular structure of anti I cold agglutinins found in cold agglutinin disease and iso anti-I cold agglutinins.

In conclusion, our data bring us to exclude both the changes in I positivity of leukemic red cells and the interaction between I-antigen and Mycoplasmas. It cannot be excluded that Mycoplasmas are the principal microbial candidates for the triggering of autoimmune conditions [3]. Nevertheless, our actual results bring us to consider with relative scepticism, also from this point of view the possibility of an etiological relationship between Mycoplasmas and leukemia.

### Summary

The red cells of patients affected by leukemia and other systemic or malignant diseases do not show the loss of I antigen after two different types of *in vitro* incubation with anti-I serum. Normal red cells, incubated *in vitro* with five different human Mycoplasma strains, retain their normal I-positivity.

*M. pneumoniae* infection in hamsters does not change the I-positivity of the red cells. The results of some authors, who showed the loss of I antigen in leukemic red cells and its interaction *in vitro* with Mycoplasmas, are discussed in relation with our negative results.

### References

- 1 ALTUCCI, F.; SARTO, U.; VITALE, P. e DE VARGAS, F.: I Mycoplasmi nella patologia umana. Contributo personale allo studio della caustica respiratoria. *Med. clin. sper.* **16**, 313 (1966).

2. ALTUCCI, F., CORASCO, F.; COTO, V.; DE VARGAS, F. and VARONE, G. L.: Isolation of *Mycoplasmas* from patients with leukemia and other diseases. *Acta haemat.* 40: 9-17 (1968).
3. BARTLE, M. F.: *Mycoplasmas* (PPLO) leukemia and autoimmune disease; in *Methodological approaches to the study of leukemias*, p. 171 (1965).
4. BARTLE, M. F.; SCHMIDT, P. J.; MCGOWAN, M. H.; RHOES, D. B. and GRABOWSKI, M. W.: *Mycoplasma* PPLO antigen I and leukemia. *Bact. Proc.* 110 (1965).
5. CHAIKOCK, R. M. et al.: Growth of Eaton PPLO in broth and preparation of CF antigen. *Proc. Soc. exp. Biol., N.Y.* 110: 884 (1962).
6. DACEY, S. V.: The hemolytic *Anacardium*, p. 342 (Grune & Stratton, New York 1962).
7. DAJANI, A. S.; CLYDE, W. A. and DUNN, F. W.: Experimental infection with *Mycoplasma pneumoniae* (Eaton agent). *J. exp. Med.*, p. 1071 (1963).
8. DOON, B.; RUTTER, R.; COLEMAN, P.; MASTY, J. and OTTAVOY, E.: I antigen in leukemic patients. *Nature Lond.* 206: 1329 (1965).
9. FEHL, T. and DARRILL, Y. H.: Failure to demonstrate blocking of I antigen by *M. pneumoniae* *in vivo* and *in vitro*. *Nature Lond.* 211: 1159 (1966).
10. FEHL, T. and HARDISTY, R. M.: I antigens in leukemic patients. *Nature Lond.* 210: 1066 (1966).
11. MARIN, W. C.: Anti I. A cold antibody defining the II relationship in human red cells. *Brit. J. Haematol.* 7: 200 (1961).
12. MCGOWAN, M. H.; SCHMIDT, P. J. and CARBONE, P. P.: Close association of I blood group and disease. *Nature Lond.* 202: 606 (1964).
13. SALMOY, C. H., SALMOY, D.; MACQUE, C. et BERTHEUX, J.: Etude quantitative de l'antigène I dans les érythrocytes des sujets atteints de leucémie aigüe. *Nouv. Rev. franç. Hémat.* 6: 563 (1966).
14. SCHMIDT, P. J.; BARTLE, M. F. and MCGOWAN, M. H.: The I blood group, PPLO and leukemia. *Blood* 24: 834 (1964).
15. SCHMIDT, P. J., BARTLE, M. F. and MCGOWAN, M. H.: *Mycoplasma* and blood group I association with neoplastic disease. *Nature Lond.* 215: 371 (1965).
16. SEELY, C. B.; MCGOWAN, M. H. and SCHMIDT, P. J.: Changes in erythrocyte I agglutinogen and anti I agglutinins during *M. pneumoniae* infection in man. *J. Immunol.* 99: 333 (1967).
17. WIDNER, A. S.; VOORH, L. S.; COMEN, L. and FELDMAN, S.: *Ann. Intern. Med.* 44: 221 (1956).



separately were prepared for histological and chromosomal study and the remaining tissue was then transplanted into syngeneic hosts.

2 *Thymus from mice exposed to thigh-thickened irradiation.* Eight weeks following the first in a series of thigh-thickened irradiation, mice were killed and pieces of the thymus implant prepared for histological, chromosomal and transplantation study as mentioned above.

4 *Virus-induced lymphomas.* a) Four 7 and 10 weeks after inoculation of virus into the intrarectal implant in the thymectomized and irradiated recipients the animals were killed and pieces of the thymic implant prepared for histological, chromosomal and transplantation study as mentioned above.

b) In separate set of experiments, chromosomal analysis and histological examination were performed on 11 virus-induced disseminated lymphomas. No transplantation was performed on these animals since other experiments have shown that the disseminated lymphomas are readily transplantable [unpublished data].

## Results

1 *Thymus from normal controls* The chromosome pattern of thymus cells from 7 normal control mice of various ages is shown in table I. A metaphase of a normal thymus cell is shown in figure 1. Occasional cells contain only 39 chromosomes and a few cells have an extra chromosome. Although an attempt was made to count only cells that appeared intact, the possibility cannot be excluded that the missing and extra chromosomes are artefactual, due to excessive hypotonic treatment.

2 *Thymus from mice exposed to leukemogenic whole-body irradiation* (table II) Eight weeks after irradiation the thymic lobes were very small. Two were histologically classified as atrophic, indicating lymphocytic depletion [7]. The small size of these lobes made it dif-

Table I The chromosome pattern of normal untreated mice

Sex	Age weeks	No. cells with indicated chromosome number		
		39	40	41
F	6	1	39	
F	10		42	
F	21	1	36	1
M	20	2	36	1
M	20		41	
M	20	1	29	1
M	21	1	35	

Table II. The chromosome pattern and transplantation behaviour of thymus cells during the development of radiation-induced lymphomas

Weeks after X-ray	Mouse No.	Histol. classif.	Results of transpl.	No. cells with indicated chromosome number							Structural chromosome alterations	Flasal interpretation normal	Flasal interpretation reciprocal	deficiency
				< 38	38	39	40	41	42	> 42	80			
8	1	Atrophy			2	0	1					x		
	2	LGT			1	1	8	1				x		
	3	Normal		1	1	12					+		x	
	4	Normal			2	11						x		
	5	LGT		2	2	9	1				+		x	
	6	Atrophy		2	1	8			2	2	+		x	
14	1	LGT		1	2	24	2	1						
	2	LGT			2	17	2	1	4					
	3	LGT			3	11	1	3						
	4	IL	+	1	4	17	17		2	3	++			x x x
	5	IL		2	2	13	1				+		x	
	6	IL		2	2	16	4			5			x	
20	1	LGT			1	11	2						x	
	2	IL			1	2	17	1					x	
	3	IL	+		4	7	4			2			x	
	4	IL	+	1	2	1	10			1			x	
	5	IL	+		1	4	13		1				x	
	6	IL			3	9			1	1			x	
	7	IL	+	1	2	11	2		1	1	+		x	
	8	IL		1	2	12			1	4			x	
	9	IL	+	1	2	1	16	2	1	7			x	
	10	IL		1	2	1	13	2		0			x	

LGT lymphomas confluent to thymus, IL invasive lymphoma.

difficult to obtain good chromosome preparations and only relatively few metaphases could be examined. Occasional morphological aberrations were observed and in one atrophic lobe (No. 6) 7 of 15 cells showed aneuploidy. All of the implanted thymic lobes gave a negative transplantation test at 8 weeks after irradiation.

Fourteen weeks after irradiation all the lobes exhibited histological signs of tumour either as lymphomas confined to the thymic lobe or as invasive lymphoma. Only one however gave a positive take after transplantation. All these lobes showed numerical aberrations in chromosome pattern (fig 2) and some chromatid breaks were observed. Four of the 6 animals were classified as definitely abnormal.

At 20 weeks all lobes examined were histologically lymphomatous. Though the number of metaphases examined is small in some of the lymphomas it is obvious that all tumours analyzed at 20 weeks had substantial proportions of aneuploid cells. Two out of 10 lobes were classified as definitely abnormal. Six of 36 cells from one mouse (No. 9) had chromosome numbers in the tetraploid range. Only occasional breaks were observed in these groups.

Five out of 10 lobes gave a positive transplantation test (table II). All of these were invasive lymphomas in a macroscopically and microscopically early stage. Mice No. 2 exhibited slight dissemination to distant organs. Thus no correlation was found between specific morphological features and positive transplantation tests of the thymomas developing after irradiation. Nor was there a correlation between transplantation behaviour and the first appearance of numerical or morphological abnormalities in the chromosome patterns.

*5. Thymus from mice exposed to thigh-shielded irradiation* Following irradiation with the thighs shielded the thymus undergoes characteristic histological alterations instead of the atrophy preceding the tumour development following leukemogenic whole body irradiation the thigh-shielded irradiation is attended by rapid recovery and hyperplasia of the thymus that becomes populated by small dense thymocytes [7]. Good spreading of the chromosomes is very difficult to obtain from these cells and a total of 40 acceptable metaphases could be obtained from 4 mice. The number of the chromosomes of these cells are presented in table III showing no major deviations from the mode of 40. No structural abnormalities were observed and the transplantation tests were all negative.

*4. Virus-induced lymphomas (table IV)* Four weeks after the inoculation of leukemogenic virus all of the three implants available for

Table III The chromosome pattern of thymus cells following thigh-shielded irradiation of the mice

No. cells with indicated chromosome number				Final Interpretation		
38	39	40	41	normal	equivocal	definitely abnormal
2	4	35	1		x	

The table includes the chromosome counts of thymus cells from 4 mice

histologic examination were neoplastic. Two of these gave positive transplantation tests. Occasional aneuploid cells occurred but no convincing chromosomal aberrations were encountered. One of 4 were considered equivocal.

Seven weeks after virus-inoculation all implants were neoplastic and exhibited histological evidence of invasive lymphoma although in an early stage of development. One of these, No. 1 had about 3% of the cells in the hyperdiploid range. Because of the very small size of this tumour few metaphases could be examined. The other animals in these groups showed occasional loss of chromosomes but no major numerical or morphological aberrations occurred. Because of the small number of metaphases accessible to analysis the majority of these cases were classified as 'equivocal'. All tumours gave positive takes after transplantation.

Ten weeks after virus-inoculation the tumours were histologically still in an early stage of development. Two of the lymphomas were still non-invasive. The chromosome counts indicate numerical aberrations in most of the cases, except for No. 3 and possibly No. 2. One tumour No. 5 had some missing chromosomes and one tetraploid cell and occasional chromatid breaks were observed. Four of the 5 tumours were classified as 'equivocal'. Three implants, of which 2 were histologically classified as lymphoma confined to the implant, yielded positive transplantation takes. One invasive lymphoma with 5 out of 16 cells in the hyperdiploid range was negative after transplantation.

The chromosome pattern of virus-induced, disseminated lymphomas in the terminal stage of the disease is demonstrated in table V. The counts indicate numerical abnormalities in all cases and 9 of the 11

Laboratory of Blood Coagulation, Department of Medicine and the ENT Department,  
University of Louvain

**Double Blind Evaluation of the Haemostatic Effect  
of Adrenochrome Monosemicarbazone, Conjugated Oestrogens  
and Epsilonaminocaproic Acid after Adenotonsillectomy**

VL. VERSTRAETE, J. VERMYLEN and J. TYBERGHEIN

*Evaluation of the haemostatic effect of agents designed to reduce blood loss is beset with numerous difficulties. Patients with a chronic haemorrhagic diathesis often bleed intermittently haemorrhage ceasing or diminishing regardless of the drug administered. If the alleged beneficial effect of a haemostatic agent is tested when normal haemostasis is challenged, it must be ascertained that the severity of bleeding and underlying mechanism leading to it are similar in the different individuals. This latter requirement implies that traumatized persons or patients subjected to the multiple variants of surgery cannot be considered as valid test material for this purpose.*

*A more uniform challenge to haemostasis is a well standardized bleeding time but even in the best hands it is difficult to make a uniform cut through the skin, due to the natural anatomical variations in vessel size. Because of other variables also, numerous cuts (e.g. 20 in the rabbit's ear) have to be made to ensure statistical validity [11]. Reproducible results are also very difficult to obtain in man [13].*

*In view of these drawbacks we chose adenotonsillectomy as a test situation wherein the mechanical trauma is fairly standard and large enough to permit pharmacologically induced reduction in blood-loss, if any to be measured. Furthermore a large number of individuals can be included in the trial and as only healthy children are involved, the subjects can be considered as constituting a fairly homogenous group. The type of operation selected also offers the possibility of assessing blood-loss.*

Three substances commercially available as haemostatic agents were evaluated in double blind trials using measured blood-loss as criterion in children subjected to adenotonsillectomy. The order of allocation of the test substance or placebo was randomly determined.

### Methods

The experiments reported herein were performed in collaboration with the ENT department of the University Hospital of Louvain, Belgium. The subjects involved were all patients admitted to this department the night before operation and discharged 10 h after surgery. The technique used for tonsillectomy and adenoidectomy did not vary substantially among the different surgeons of the University department where all the operations were performed. Minor variations could not influence the results as a control group was included in the series. A premedication was given, the child remained seated during the operation and was briefly anaesthetized with ethyl chloride. The adenoids were removed using the Volkman curette and tonsillectomy performed by means of the Stadeltongs. 80% of the children studied were subjected to both operations.

In the trial with adrenochrome monosemicarbazone, loss of blood through aspiration or ejection, was ascertained gravimetrically. Previously weighed dry gauze sponges, doctors' and nurses' blouses and bedlinen were used and the quantity of blood-loss determined by immediate re-weighing. The blood lost during the following 10 h was assessed using the same gravimetric method. The incidence of saliva and other ejected material in the weight difference can be disregarded because a large control group underwent similar treatment.

In the trials with conjugated oestrogens and with epilone-aminocaproic acid, total blood loss was determined by placing all the ejected blood, tampons, towels, doctors' and nurses' blouses and bedlinen used for one child in a blood-loss monitor. The instrument used was the Perdometer (A.B. Lenn Ljungberg, Stockholm). The blood containing materials were collected in a tank containing 40 l of water and haemolyzing agent. The blood was washed out by rotary washing mechanism and haemolysed. The blood-containing solution was filtered and pumped continuously through a photometer that measured the light absorption due to haemoglobin content. Since this is proportional to the amount of blood present, the quantity of blood lost can be immediately ascertained by a conversion table that takes into account the patient's preoperative haemoglobin value. The objection that swallowed blood is not taken into account can be disregarded because the same procedure was used for both the treated and control groups. The measurement of very small amounts in the Perdometer is not reliable below 10 ml of blood due to uneven distribution of fluids in the instrument (40 l) but above this figure, the correlation with the measured value is good. The average error of the instrument in test determinations of known amounts of blood was 3% (14). Haemoglobin was determined by the method of DRABKIN.

Adrenochrome monosemicarbazone (1-methyl-2,3-dihydro 3-hydroxyindole-5,6-quinone) (Adrenoxyl® Labax Adrenoxon® SE Mänsingh Co.) is one of the first derivatives produced during the oxidation of epinephrine, the semicarbazone of adrenochrome is a stable substance. Vials containing 5 mg active substance or placebo were prepared. The water soluble conjugated oestrogens (Premarin® Ayerst; Equigyn® Torrado) were used. Each vial contained 20 mg natural oestrogen in the dried state or placebo. The epiloneaminocaproic acid-vials (EACA) were Epilapron® Kabi, Stockholm, containing 5 ml active substance at 40% (w/v).

The kind cooperation of the doctors and nurses of the ENT Department (Head Prof. Dr. F. CHAMBER) is gratefully acknowledged.

## Results

### Adrenochrome

Vials with adrenochrome monosemicarbazone (5 mg) or placebo, identical in appearance, were prepared and numbered at random by the manufacturer and administered according to the double blind technique. The key indicating the content of each vial was kept in a sealed envelope which was not opened until the trial had been completed. A total number of 100 children took part in the trial of which 6 were eliminated at the end of the study because of incomplete data. Placebo was administered to 47 children and adrenochrome monosemicarbazone to the remaining 47 cases. Each patient received the night before amygdalotomy 5 mg adrenochrome intramuscularly and a second identical dose approximately half an hour before operation. This dose is considered to be high for children with an average weight of 22.3 kg.

In this trial, blood loss was measured by a gravimetric method. The mean difference in weight of the linen before and after operation was 60 g (SD 21) in the adrenochrome-treated group and 58 g (SD 28) in the placebo-treated group. Both groups were similar in weight and height (table I).

### Conjugated Oestrogens

This trial also was conducted strictly according to the double blind method, the sequence of substances given to the patients being determined by random allocation. All vials were similar in appearance. The content of one vial (20 mg) was injected intramuscularly approximately half an hour before the operation. At all 200 children were involved in this trial upon completion of the study 27 cases (15 treated with conjugated oestrogens and 12 with placebo) had to be rejected for a variety of reasons likely to invalidate the results (loss of part of the linen, spitting of blood in the toilet or children leaving the ENT department before 6 p.m.) After disclosure of the code-key it appeared that, of the remaining 173 children, 85 received the test substance and 88 the placebo material.

The results of measured blood-loss are given in table I. Both groups of patients were identical in weight and height, no difference in blood loss could be found.

Table I

	Monosemicarbazone of adrenochrome	Placebo
Number of children in the trial	47	47
Mean blood-loss	58 g (SD 28)	60 g (SD 21)
Mean height	115 cm (SD 0.12)	112 cm (SD 0.18)
Mean weight	22.2 kg (SD 7.7)	22.2 kg (SD 9.7)
	Conjugated oestrogen	Placebo
Number of children in the trial	85	88
Mean blood-loss	83.4 ml (SD 37.8 ml)	89.8 (SD 37.0)
Mean height	117 cm (SD 16.1 cm)	115 (SD 13.7)
Mean weight	22.6 kg (SD 8.4)	21.2 kg (SD 8.08)
	EACA (2 g l.)	
Number of children in the trial	25	
Mean blood-loss	89.0 ml (SD 36.6)	
Mean height	121.3 cm (SD 13.08)	
Mean weight	23.9 kg (SD 6.8)	
	EACA	Placebo
	≤ 15 kg: 4 g l.	
	> 15 < 30 kg: 8 g l.v.	
	> 30 kg: 12 g l.	
Number of children in the trial	31	36
Mean blood-loss	60.3 ml (SD 17)	67.2 ml (SD 40.6)
Mean height	119 cm (SD 16.2)	125 cm (SD 13.4)
Mean weight	22.3 kg (SD 7.2)	22.6 kg (SD 8.5)

### Epsilon-Amino-Caproic Acid

Vials containing 5 ml EACA at 40% were available. The content of one vial (2 g) was injected intravenously 30 to 60 min before operation in 25 children. There was no control group however the children involved in this trial were not preselected. The results of blood-loss are compared with the blood-loss obtained in the 88 control children, operated in identical circumstances. No difference was noted in measured blood-loss 89.0 ml (SD 36.6) in the treated group 89.8 ml (SD 37.0) in the control group of the previous trial.

As the possibility that the EACA dose was insufficient could not be excluded, it was decided to initiate a new trial whereby the EACA dose was increased and adapted to the weight of the child. The following doses of EACA were administered intravenously 30 to 60 min before the operation in children less than 15 kg 4 g EACA between



15 and 30 kg B g EACA over 30 kg 12 g EACA. A few instances of vomiting were observed after injection of the drug

As the EACA dose had to be adapted according to the weight of the child this part of our investigation was not a double blind but still a controlled not stratified study. Each patient involved in the study was allocated to the EACA or placebo group according to serial numbering before the trial started each number was listed at random in one of the two groups. As a significant difference in blood loss was observed after treatment of 67 children (31 in the EACA group, 36 in the control group) this trial was not continued with the remaining 33 of the 100 children initially envisaged. Both groups were similar with respect to weight and height. The blood-loss in the EACA treated group was 60.3 ml (SD 17) and in the control group 87.2 ml (SD 40 ll ml) this difference is highly significant ( $P < 0.001$ )

### *Discussion*

The alleged haemostatic effect of conjugated oestrogens is based on the work of SCHIFF and BURN [17]. These authors have demonstrated a progressive change from the sol to the gel state of mucopolysaccharides in the ground substance around small vessels and in the arterial walls. This polymerization of the mucopolysaccharides was observed in hamsters, monkeys and men following intravenous administration of conjugated oestrogens.

Detailed reports concerning the impact of conjugated oestrogens on blood coagulation are rare and often conflicting. An elevation of fibrinogen [12] prothrombin and factor V and a decrease of antithrombin [6] have been described but these findings could not be confirmed by other investigators [7-9]. It is possible however that capillary oozing could be shortened by action of oestrogens at the vascular or extravascular level without being influenced by the intravascular coagulation factors. An attentive study of the clinical reports is rather disappointing as the effect of conjugated oestrogens on haemostasis is based on clinical judgment only except in two trials conducted according to the double blind method which however were both negative [7-19].

It is beyond doubt that epinephrine from which monosemicarbazone of adrenochrome is derived has a vasoconstrictor effect on the microcirculation. The direct relationship between the decreased flow

of blood within these vessels and its alleged function in lessening blood loss is less clear. As epinephrine is readily oxidized to adrenochrome which itself is also unstable, a more suitable agent for clinical use was developed: the monosemicarbazone of adrenochrome which is said to be stable when administered by mouth or by injection [4].

Numerous studies have been published on monosemicarbazone of adrenochrome claiming its increased capillary resistance and usefulness in reducing haemorrhage after oral or parenteral administration. Unfortunately the enthusiastic clinical reports on its haemostatic role in man originate from clinical impressions and/or uncontrolled clinical trials. The only reported double blind clinical trial failed to confirm previous favourable reports: in this trial the observation of the duration of bleeding after dental extraction was made by the patient himself, thus exposing the evaluation method to criticism because of the ill-defined subjective criterion [5]. In another controlled trial the same drug had no statistically significant effect on capillary resistance as measured by a negative pressure method. No apparent difference in the incidence of post-operative hyphaema in a series of forty pairs of patients, one of each pair receiving monosemicarbazone of adrenochrome by mouth, was observed [18].

Different fibrinolysis inhibitors are commercially available, some of them being extracted from tissue. The polypeptide isolated from bovine lung (Trasylo<sup>®</sup> Bayer) or pancreas (Iniprol<sup>®</sup> Choay) are inhibitors of trypsin, plasmin and plasminogen activator. Synthetic fibrinolysis inhibitors are the aminoacids epsilon amino-caproic acid (EACA) Transamino-methyl-cyclohexane-carboxylic acid (AMCHA or tranexamic acid cyclocapron) and para-aminomethyl benzoic acid (PAMBA).

It has been demonstrated beyond reasonable doubt in controlled studies that synthetic fibrinolysis inhibitors can diminish bleeding from areas with increased local fibrinolytic activity as for instance in the urinary tract [1, 8, 16] and uterus [10, 15, 20]. The effective oral dose required is approximately 400 mg/kg EACA or between 60-90 mg/kg AMCHA.

Activators of the fibrinolytic system are present in almost all tissues as shown by the experiments of Astrup and Parman [3]. After adenotonsillectomy haemorrhage at the adenoid and tonsil bed may be sustained because of the local activity of tissue activators, premature dissolution of local clots prolonging bleeding or provoking renewed blood-loss. It is a fair assumption to relate the haemostatic value of

15 and 30 kg 8 g EACA over 30 kg 12 g EACA. A few instances of vomiting were observed after injection of the drug.

As the EACA dose had to be adapted according to the weight of the child this part of our investigation was not a double blind but still a controlled not stratified study. Each patient involved in the study was allocated to the EACA or placebo group according to serial numbering before the trial started each number was listed at random in one of the two groups. As a significant difference in blood loss was observed after treatment of 67 children (31 in the EACA group, 36 in the control group) this trial was not continued with the remaining 33 of the 100 children initially envisaged. Both groups were similar with respect to weight and height. The blood-loss in the EACA treated group was 60.3 ml (SD 17) and in the control group 87.2 ml (SD 40.0 ml) this difference is highly significant ( $P < 0.001$ ).

### Discussion

The alleged haemostatic effect of conjugated oestrogens is based on the work of SCHIFF and BURN [17]. These authors have demonstrated a progressive change from the sol to the gel state of mucopolysaccharides in the ground substance around small vessels and in the arterial walls. This polymerization of the mucopolysaccharides was observed in hamsters, monkeys and men following intravenous administration of conjugated oestrogens.

Detailed reports concerning the impact of conjugated oestrogens on blood coagulation are rare and often conflicting. An elevation of fibrinogen [12], prothrombin and factor V and a decrease of antithrombin [6] have been described but these findings could not be confirmed by other investigators [7-9]. It is possible however that capillary oozing could be shortened by action of oestrogens at the vascular or extravascular level without being influenced by the intravascular coagulation factors. An attentive study of the clinical reports is rather disappointing as the effect of conjugated oestrogens on haemostasis is based on clinical judgment only except in two trials conducted according to the double blind method which however were both negative [7-9].

It is beyond doubt that epinephrine from which monosemicarbazone of adrenochrome is derived has a vasoconstrictor effect on the microcirculation. The direct relationship between the decreased flow

6. JORDON, J. F. Changes in plasma prothrombin, aeglobulin and antithrombin concentration following intravenous administration of oestrogens. *Proc. Soc. exp. Biol.*, **N Y** **94** 92 (1957).
7. MCGOVERN, J. J.; DEWEER, J. E.; GOLDBERG, R. and ESTES, J. W. The effect of conjugated oestrogens in the coagulation mechanism. *J. Amer. med. Ass.* **175** 1011-1012 (1961).
8. McNICOL, G. P.; FLETCHER, A. P.; ALKJAERHO, N. and SAKARY, S. Impairment of hemostasis in the urinary tract. The role of urokinase. *J. Lab. clin. Med.* **51** 34 (1961).
9. NELSON, L. M. Intravenous promurit as a hemostatic agent. *Nord. Med.* **64** 1185 (1960).
10. NILMOR, L. and RYBO, G. Treatment of menorrhagia with epsilon aminocaproic acid. A double blind investigation. *Acta obst. gynec. scand.* **44** 467-473 (1965).
11. FURUY, L. J.; ROMAM, J.; DEMOGAUX, G. et FUMANT, A. Etude statistique du temps de saignement moyen humain. *Arch. Int. Pharmacodyn.* **67** 390 (1942).
12. PHILLIPS, L. L. Etiology of afibrinogenemia. Fibrinogenolytic and fibrinolytic phenomena. *Ann. N. Y. Acad. Sci.* **75** 676-684 (1959).
13. ROMAM, J. Arrest of bleeding (Thomas, Springfield, Ill. 1934).
14. RISTAD, H. Measurement of blood-loss during surgery. *Lancet* **i** 1304 (1963).
15. RYBO, G. Plasminogen activators in the endometrium. II. Clinical aspects. Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood-loss. *Acta obst. gynec. scand.* **45** 429-450 (1966).
16. SACK, E.; SPART, T. L.; GENTILE, R. L. and HODSON, E. Reduction of post prostatectomy bleeding by epsilon-aminocaproic acid. *New Engl. J. Med.* **268** 541 (1962).
17. SCHWARTZ, L. and BURN, H. F. The effect of intravenous oestrogens on ground substance. *Arch. Otolaryng.* **73** 44 (1961).
18. SWAN, H. T.; NUTT, A. B.; JOWETT, C. H.; FERGUSON, W. J. and BLACKBURN, E. K. Monosodium-carboxate of adrenochrome (Adrenocryl) and cataract surgery. Effect on capillary resistance and incidence of hyphema. *Brit. J. Ophthalm.* **45** 415-422 (1961).
19. TRAPER, S.; KIRACIOGLU, M. and McELFISH, A. E. Value of systemic hemostatic drugs. "Double blind" evaluation of agents used to increase coagulation during tonsillectomy and adenoidectomy. *Arch. Otolaryng.* **70** 72 (1959).
20. VERSTRAETE, J.; VERSTRAETE-DUGESACQ, M. L.; FOLLEYS, P. and VERSTRAETE, M. A double blind study of the effect of tranexamic acid in essential menorrhagia (to be published, 1968).

Department of Pathology and Clinical Laboratories, St. Barnabas Hospital, Minneapolis,  
Minn.

## Reticulohistiocyte Origin of the Blood Basophil in Human Marrow

E. M. SCHLEIGER

Since EURLICH [1] described two types of mast cells the Blutmastzelle and the Gewebsmastzelle their origin and histochemistry have been studied. Because of the structural, chemical, and functional similarities between the cells SKLYE [2] states the blood basophil represents the circulating form of the tissue mast cell system. However LEXVET and SCHUBERT [3] BRAUNSTEINER [4] BRAUNSTEINER and PAKESCH [5] SHELLEY and JULIN [6] and WENQVIST [7] showed structural differences between the blood basophil and the tissue mast cell. While the genesis of the blood basophil has remained conjectural UNGRITZ [8] derives the cell from a Basophiloblast.

It is the purpose of this communication to present morphological evidence of a direct reticulohistiocytic origin of the blood basophil in human bone marrow. For this study Hodgkin's disease was found to be particularly appropriate. Frequently the basophils are increased in the circulating blood and the bone marrow in this condition. Besides, the genesis of the blood basophil could be more easily studied than in leukemic marrows containing large quantities of undifferentiated and pleomorphic cells.

### *Material and Method*

The cell studies were made on male 28 years old, who had generalized Hodgkin's disease. The peripheral blood basophils ranged from 8 to 14% determined by the method of SCOTT-CRICK [9]. From the body of the sternum 'marrow units' (Markbröckel) were aspirated. The 'marrow unit imprint' technique was employed [10, 11]. The preparations were stained by dual staining procedure namely Wright blood stain with Toluidin blue 0.3 aqueous

solution superimposed. The latter forms chemical union with the acid mucopolysaccharides in the granules giving them the specific metachromatic appearance.



Fig 1 Reticuloendothelial syncytium. ( ) Primitive reticulolymphoid cell (kleine lymphoide Retikulumzelle of ROSS) (b) Early developmental stage of the blood basophil. ( ) Advanced developmental stage of the blood basophil.

Fig 2. ( ) Histiocyte. (b) Variants of developmental stages of the blood basophil. Note the cytoplasmic tail containing various amounts of granules of different size and degree of metachromasia.

### Results

In the reticulohistiocytic syncytium (fig. 1) the earliest recognizable developmental stage of the blood basophil is a small reticulolymphoid cell "kleine lymphoide Retikulumzelle" of ROHR (fig 1a). The nucleus is round and often slightly notched and more or less eccentrically located. It has a reddish-purple color and several various sized bluish purple nucleoli. The narrow cytoplasm ranges from light blue to colorless and may contain small metachromatic granules. The cell boundary is demarcated by a condensation of the cytoplasm. This primitive cell differentiates within the syncytium into a blood basophil without going through a blast stage (fig 1b, c). One to several basophils in various maturation stages may be present in a syncytium. The cells retain a histiocytic nucleus which becomes indented, lobulated and more or less overlaid by granules of different size and degrees of metachromasia. Various developmental stages are presented in fig 2b. The pear-shape results from a cytoplasmic tail in which the granules tend to concentrate. This morphological feature appears to be characteristic of the developing basophil. According to these morphologic findings it is inferred that the blood basophil is a histiocyte.

### Summary

The genesis of the blood basophil in human bone marrow as seen in marrow unit imprint preparations is presented. A direct origin from reticulohistiocytic syncytia could be demonstrated. The progenitor of the blood basophil is small reticulolymphoid cell "kleine lymphoide Retikulumzelle" of ROHR. It is inferred that the blood basophil is histiocyte.

### References

1. ENGLER, P. Beiträge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukocyten. Arch. Anat. Physiol. 3, 166 (1879).
2. SELYE, H. The Mast Cells, p. 361 (Butterworth, Washington, D. C. 1963).
3. LEVY, K. und SCHNEIDER, J. C. F. Untersuchungen über die sauren Mucopolysaccharide der Gewebemastzellen im menschlichen Knochenmark. Frankf. Z. Path. 9, 378 (1959).
4. BRÄUTINGER, H. Physiologie und Pathophysiologie der weissen Blutzellen (Thieme Stuttgart 1959).
5. BRÄUTINGER, H. und FÄRBER, F. Elektronenmikroskopische Untersuchungen der Granula menschlicher Leukocyten. Acta haemat., Basel 27, 156 (1967).
6. SNELL, W. B. and JENCKE, L. Functional cytology of the human basophil in allergic and physiologic reactions. Blood 19: 708 (1962).

- 7 WISSEY, G. Electron microscopy of the basophilic granulocyte. *Ann. N.Y. Acad. Sci.* 103, 332 (1963)
- 8 UNOWITZ, E. Sandoz Atlas of Hematology, p. 49 (Sandoz, Basel 1952)
- 9 SCHLICHTER, E. M. Technique for determination of the differential leukocyte ratio and total leukocyte count. *Minnesota Med.* 45, 914 (1962)
- 10 SCHLICHTER, E. M. Method for making imprints and direct smears from gross marrow units. *Amer. J. Path.* 9, 8 (1945) Techn. Sect.
- 11 ROWE, K. Das menschliche Knochenmark; 3rd ed., p. 11 (Thieme, Stuttgart 1960).



### Results

In the reticulohistiocytic syncytium (fig 1) the earliest recognizable developmental stage of the blood basophil is a small reticulolymphoid cell "kleine lymphoide Retikulumzelle" of ROSE (fig 1a). The nucleus is round and often slightly notched and more or less eccentrically located. It has a reddish-purple color and several various sized bluish purple nucleoli. The narrow cytoplasm ranges from light blue to colorless and may contain small metachromatic granules. The cell boundary is demarcated by a condensation of the cytoplasm. This primitive cell differentiates within the syncytium into a blood basophil without going through a blast stage (fig 1b-c). One to several basophils in various maturation stages may be present in a syncytium. The cells retain a histiocytic nucleus which becomes indented, lobulated and more or less overlaid by granules of different size and degrees of metachromasia. Various developmental stages are presented in fig 2b. The pear-shape results from a cytoplasmic tail in which the granules tend to concentrate. This morphological feature appears to be characteristic of the developing basophil. According to these morphologic findings it is inferred that the blood basophil is a histiocyte.

### Summary

The genesis of the blood basophil in human bone marrow as seen in marrow unit re-plant preparations is presented. A direct origin from reticulohistiocytic syncytia could be demonstrated. The progenitor of the blood basophil is a small reticulolymphoid cell "kleine lymphoide Retikulumzelle" of ROSE. It is inferred that the blood basophil is a histiocyte.

### References

1. EBERICH, H. Beiträge zur Kenntnis der granulierten Blutzugewebzellen und der eosinophilen Leukocyten. Arch. Anat. Physiol. 1: 166 (1879).
2. SELYE, H. The Mast Cells, p. 361 (Butterworth, Washington, D.C. 1963).
3. LEVYER, A. and SCHÖNBERG, J. C. F. Untersuchungen über die sauren Moxophasie der Gewebenszellen im menschlichen Knochenmark. Israel. Z. Path. 6: 578 (1959).
4. BRÄUWELDER, H. Physiologie und Pathophysiologie der weissen Blutzellen (Thieme, Stuttgart 1959).
5. BRÄUWELDER, H. und PARDECH, F. Elektronenmikroskopische Untersuchungen der Granula menschlicher Leukocyten. Acta haemat., Basel 17: 136 (1957).
6. SKELL, W. B. and JEWELL, L. Functional cytology of the basophil in allergic and physiologic reactions. Blood 19: 408 (1962).

- 7 WILQVIST G. Electron microscopy of the basophilic granulocyte. *Ann. N.Y. Acad. Sci.* 103: 352 (1963).
- 8 UNDERLITZ, E. *Sandoz Atlas of Hematology*, p. 49 (Sandoz, Basel 1952).
- 9 SCHLESINGER, E. M. Technique for determination of the differential leukocyte ratio and total leukocyte count. *Minnesota Med.* 45: 914 (1962).
- 10 SCHLESINGER, E. M. Method for making imprints and direct smears from gross marrow units. *Amer. J. Path.* 9: 8 (1945) Techn. Sect.
- 11 ROSEN, K. *Das menschliche Knochenmark*, 3rd ed., p. 11 (Thieme: Stuttgart 1960).

Istituto di Clinica Pediatrica dell'Università di Roma (II Cattedra)  
di Chimica Biologica dell'Università di Urbino

## Neonatal Hemolysis Due to a Transient Severity of Inherited Pyruvate Kinase Deficiency<sup>1</sup>

M. BOSSI, M. D'AGNÀ and G. FOMADINI

In recent years many works have shown the high occurrence and severity of the hemolytic diseases in the newborn period. In many cases, such as those due to an isosensitization to a bacterial and viral infections, to genetically determined metabolic deficiencies, to hemoglobinopathies, to morphological modifications of the cell the etiology and pathogenesis are fairly known. In other cases, the causes of the hemolytic episode are unknown. The latter forms may be ascribed to some morphological or functional transient disturbances of the cell.

However it might be that a transient state of deficiency is responsible for the hemolytic episode also in the subjects bearing an inherited defect and particularly in those cases in which some inborn errors of erythrocyte metabolism are present. Such a possibility is confirmed by the present case of hemolytic disease in a newborn infant being heterozygous for pyruvate kinase deficiency. In this subject the hemolytic state is determined by a transient severity of the genetic deficiency.

### Case Report

**M. P. Propositus.** At 4 days age the patient colouring became pallid and he demonstrated icterus, vomiting and slight splenomegaly. Examination of peripheral blood provides the

The following abbreviations have been used: *G-6-PD* glucose-6-phosphat dehydrogenase; *6-P-GD* phosphogluconat dehydrogenase; *PK* pyruvat kinase; *G-6-P* glucose-6-phosphat; *6-P-G* 6-phosphogluconate; *GSH* reduced glutathione; *APH* acetylphenylhydrazine; *ATP* adenosine 3-triphosphat; *RBC* red blood cells; *WBC* White blood cells; *HEP* Whole erythrocyt population.

The present work has been carried out with CNR funds.

following data: RBC 2,600,000, Hb 11%, reticulocytes 4%, slight anisopoikilocytosis, small number of macrocytes and normoblasts, no spherocytes, WBC 7,200, serum bilirubine 16.8%. Coombs test negative. The red cell osmotic fragility was normal before incubation and markedly increased after incubation at 37°C for 24 h. The autohemolysis was not corrected by adding glucose, and slightly decreased by adding glucose and ATP. The subject was not transfused and was treated with cortisone and albumin.

24 h after crisis RBC 2,600,000, reticulocytes 7%, bilirubine 16.6%; 48 h after crisis RBC 2,800,000, reticulocytes 9%, bilirubine 15.4%; 5 days after crisis RBC 2,800,000, reticulocytes 14%, bilirubine 12.4. 10 days after crisis both icterus and splenomegaly disappeared and the hand-feeding was well accepted. RBC. 3,900,000, reticulocytes 3%, bilirubine 9.3%; 20 days after crisis RBC 3,900,000, reticulocytes 3%, bilirubine 5.8%; 30 days after crisis RBC 4,200,000, reticulocytes 2%, bilirubine 4.1%.

The examinations of the subjects used as controls were normal, for the referred experiments, from a pathological point of view or from hematologic tests.

Researches were always been carried out parallelly on the pathological subject and on controls bearing approximately the same age.

### Materials and Methods

Blood was collected with siliconized syringe and heparin added. After centrifugation the plasma and buffy coat were removed by suction and the red cells washed three times with isotonic buffered NaCl solution at pH 7.4. The packed cell volume of these suspensions was determined by centrifugation at 3,000 rpm for 60 min in hematocrit tube. The hemolysates were prepared by treating washed cells with two volumes of cold distilled water. The ghosts were then removed by centrifugation at  $30,000 \times g$  for 30 min and the supernatant collected. All procedures were carried out at +2°C.

Young and old erythrocytes were prepared from resuspended washed cells according to MARRAS and JOHNSON's method [1], which is based on the principle that young erythrocytes are more resistant to hypotonic hemolysis than are older erythrocytes.

The glucose utilization by intact erythrocytes was determined according to previously described procedure [2] and the reduced glutathione stability according to BERTLER [3] in presence of  $5 \cdot 10^{-3}$  M glucose.

G-6-PD and 6-P-OD determinations were performed according to KORNBERG and HOMBERGER [4] and HOMBERGER and SWEETGOLD [5] following GLOCK and MCLAIRN's suggestions [6] to remove the 6-P-GD interference on 6-P-G derived from G-6-P. Pyruvate kinase determinations were performed according to BURTON and FLEISHER [7] and Trione P isoenzyme determinations according to BERNHARD [8].

Glucose was determined with glucose oxidase [9], lactic acid according to BAKER [10] GSH according to OUCHTERY and PHILLIPS [11] hemoglobin concentration with DRABKIN's method [12].

In experiments of erythrocyte separation on the basis of different osmotic resistance young-cells' are those lysed after hemolysis with 0.30% NaCl for 15 min at +2°C; old cells are those hemolyzed with 0.46% NaCl under the same conditions. The number of cells was determined by hemolysis achieved by given concentration of NaCl, taking the extent of hemolysis in water tube as equal to 100%.

In the GSH content is expressed in mg/100 ml of packed erythrocytes. The values of glucose uptake and the level of enzyme activities are referred as  $\mu$ moles of metabolized substrate per hour and per ml of packed erythrocytes.

Substrates, enzymes and coenzymes were products of Sigma and Biochemica Boehringer other chemicals of Merck. Spectrophotometric determinations were carried out with Optica

CF4 spectrophotometer; high speed centrifugations have been done on Lousis LRA refrigerated centrifuge.

### Results

We have assayed in the erythrocytes of the propositus the GSH content and stability, glucose uptake and the levels of those enzyme activities showing most frequently a genetic deficiency. The results are shown in table I and compared to normal values of newborn and adult subjects. The glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and triose phosphate isomerase activities showed normal values; the GSH content is slightly decreased, but the stability test is normal as expressed in per cent values. On the contrary, glucose uptake (46, the normal values), the synthesis of lactate (48, the normal values) and the pyruvate kinase activity (18, the normal values) are markedly decreased.

These metabolic alterations and laboratory findings indicate therefore that the hemolytic episode of the propositus is due to a PK deficiency. The slight decrease of GSH content may be referred to the marked lowering of glucose uptake.

We have assayed PK activity also in the young and old erythrocytes which were separated by hypotonic hemolysis. Also in both of these

Table I Erythrocyte metabolic activities of the propositus, and of normal newborns and adults

Metabolic activities	Propositus	Normal subjects	
		Newborn	Adults
Reduced glutathione	63	74 $\pm$ 5.8	72 4.6
{ before APH			
{ after APH	51	61 $\pm$ 7.2	59 5.7
Glucose uptake	1.8	3.4 $\pm$ 0.4	2.6 0.3
Lactate synthesis	2.7	3.6 $\pm$ 0.7	4.5 0.6
G-6-P dehydrogenase	73	72 $\pm$ 8.3	56 6.1
6-P-G dehydrogenase	60	63 $\pm$ 7.4	43
Pyruvate kinase	26	196 $\pm$ 23	153 17
Triose-P-isomerase	4600	4.00 6.0	4900 3.0

The reduced glutathione content is expressed in  $\mu$ g/100 ml packed erythrocytes. The glucose uptake, lactate synthesis and enzyme activities are referred as  $\mu$ moles of metabolized substrate/hour/ml packed erythrocytes. The values for normal subjects are the means of literature and personal data.

fractions the enzyme activity was low being 47 units in the young cells and 19 units in the old ones.

The clinical course and the very low level of PK activity of the propositus raised the possibility of an homozygous state of the defect. Therefore we have assayed erythrocyte PK activity also in the relatives of the propositus in those cases where the enzyme activity was decreased, glucose uptake also has been determined. Table II and figure 1 show the results of the investigations performed on the relatives. The defect of PK is present in the erythrocytes of the paternal branch whereas the maternal branch is unaffected. In the affected subjects the defect appears to be in the heterozygous state the PK activity ranged between 44–70% the normal values. Glucose uptake and lactate synthesis were slowly decreased in two subjects only (case No 10 and No 16)

Table II. Erythrocyte pyruvate kinase activity and glucose utilization in the family members of the propositus

Subjects Case No.	Pyruvate kinase	Glucose utilization cose uptake	lactate synthesis
1	84	2.7	4.8
2	166	—	—
3	153	—	—
4	106	2.5	4.5
4	138	—	—
5	174	—	—
5	142	—	—
6	68	2.6	4.6
7	160	—	—
8	149	—	—
9	93	2.7	4.5
10	71	2.1	3.4
11	134	—	—
12	172	—	—
13	165	—	—
15	147	—	—
16	87	2.0	3.1
17	150	—	—
18	144	—	—
19	161	—	—

The values are referred as  $\mu$ moles of metabolized substrate/hour/ml packed erythrocytes. The relationship of the reported cases is elucidated in figure 1




Fig. 1 Pedigree of propontus family in which members were tested by the pyruvate kinase activity

As it is reported in literature PK deficiency is highly heterogeneous as concerns the activity level [13-16]. Since in some heterozygous subjects the activity is much lower than in homozygous subjects, the propontus could fall within this group. However it is also possible that the severity of the defect was related to the newborn state. The results reported in figure 2 are consistent with the latter hypothesis.




Fig. 2. Pyruvate kinase activity in erythrocytic fractions of different age obtained from the propontus at different time intervals after crisis.

The erythrocyte pyruvate kinase activity of the propositus has been assayed during 40 days at different time intervals on the whole erythrocyte population and on the young and old erythrocyte fractions. The results are reported in the figure 2 as per cent of similar cell preparations obtained from newborns of the same age. In the old erythrocytes the enzyme activity is very low at every time. The enzyme from the WEP in which the reticulocyte count is very high, shows high levels of activity at the 5th and 10th day this increase is also present and progressive in the following period of observation during which blood reaches normal pictures. In the young erythrocytes the enzyme shows marked modifications with aging the activity rises rapidly during the first 20 days and then becomes stable at a level (66% the normal) which is the mean value in the heterozygous subjects.

### *Discussion*

Many authors [17-19] have demonstrated that some transitory modifications of glucose-6-phosphate dehydrogenase induce neonatal hemolysis. Our present results show that this may be also for pyruvate kinase in the propositus the transitory state of deficiency comes out to be a greater extent of the inherited trait. The low levels of the enzyme activity could account for a homozygous state. A rather long time interval is necessary for observing the disappearance of the transitory state of the defect thus, in the young cells the enzyme level reaches values which are typical for the heterozygous state only after more than 20 days from the hemolytic episode.

Few evidences have been provided that a transitory state of deficiency affecting both normal or genetically altered enzymes, may determine hemolysis. Many reasons may account for this. The hemolysis in the neonatal period has been considered only recently from a biochemical point of view. In few cases the biochemical features have been investigated during the hemolytic episode also in these cases those parameters have been examined which are usually affected by genetic mutations. In most cases, where transfusions are made, the biochemical assays are performed a long time after the crisis and therefore it is possible to detect only the metabolic inherited defects in their typical expressions.

Many authors [20-27] have incriminated some endogenous factors other than the genetic defect for the hemolytic episode in newborn



with G-6-PD deficiency. The hemolysis, which is known to affect approximately 5% of infants bearing this defect [27] has been shown to be independent of the degree of the deficiency; moreover no known hemolytic agents could be demonstrated to determine the episode. For these cases the additional, independent genetic factor might be a transient state of deficiency.

The mechanisms determining the transient states of deficiency are unknown. However the occurrence of this condition is probably related to the features of the newborn's erythrocyte which are very different from those of the adult [28]. The newborn's red blood cells, besides for the HbF, differ from the adult's ones as concerns electron microscopic appearance and chemical composition of the membrane, carbohydrate uptake and the activity levels of several enzymes. On this subject it must be remembered that the marked vulnerability of newborn's cells to damage from hydrogen peroxide [29-30] and from oxidizing agents [31-35] may be ascribed to the lowered levels of glutathione peroxidase [30] and katalase [36] activities.

As regards the mechanisms of hemolysis due to PK deficiency this may be framed in the general problem of that hemolysis which related to metabolic defects. It has been established that the process leading to sequestration and destruction of erythrocytes in the reticuloendothelial system, is determined by a progressive failure in energy production [37-43] and in the maintenance of the reductive state [44-49] of the cell. Both these processes are related to glucose utilization which is the only fully active metabolic process in the mature circulating cell. Energy production occurs by ATP resynthesis at the pyruvate kinase and phosphoglycerate kinase steps; the maintenance of the reductive state is linked with reduced pyridine nucleotides synthesis through the dehydrogenase reactions of the Embden Meyerhof Parnas pathway and of the oxidative shunt. Thus, all the erythrocyte defects leading to modifications of either process may induce the hemolytic episode.

As concerns pyruvate kinase, when the defect is partial, that is, in the heterozygous state, the damage is generally asymptomatic, probably because of two reasons: 1. Pyruvate kinase shows high levels of activity [41-42, 50] and may work sufficiently even when it is partially damaged. 2. the possible compensatory mechanism for ATP synthesis by the Rapoport Luebering cycle [51-52]. In fact the enzymes of this cycle (phosphoglycerate kinase, diphosphoglyceromutase, diphosphoglycerate phosphatase) regulate the glycolytic resynthesis of ATP. The transformation of 1,3-diphosphoglycerate into 3-phosphoglycerate may

occur through the phosphoglycerate kinase reaction with coupled ATP resynthesis or through diphosphoglyceromutase and diphosphoglycerate phosphatase reactions with release of inorganic phosphate.

In those cases where a total defect is present the pyruvate kinase activity is so low as to block the glycolytic process, as it is clear from the decreased glucose uptake. This damage leads to a decreased ATP and pyridine nucleotides synthesis and the alterations occur (cell shape, permeability phospholipid, cholesterol and coenzyme turnover allosteric properties of Hb oxidation of Hb and of structural and enzyme proteins) determining the lysis.

### Summary

A case of hemolysis in 4 days old infant is reported which is due to transient severity of heterozygous pyruvate kinase deficiency. Assays performed on the whole erythrocyte population during the crisis revealed normal levels of glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and triose-phosphate isomerase low decrease of GSH content without any modifications of its stability marked decrease of pyruvate kinase activity (18% the normal values) and of glucose uptake (50% the normal values). The pyruvate kinase activity has been followed during 40 days from the beginning of the hemolytic episode on the whole erythrocyte population and on young and old cell fractions. It has been demonstrated that in the young cells the enzyme activity increases progressively till reaching level (66% the normal values) which is peculiar of the heterozygous state of the defect.

### References

1. MAKES, P.A. and JONKOW, A.B. Relationship between the age of human erythrocytes and their osmotic resistance basis for separating young and old erythrocytes. *J. clin. Invest.* 37 1542 (1956).
2. FORMARO, G., LEONCINI, G., LUCIATTO, L. and SEGGI, G. Glucose metabolism in human erythrocytes from normal and sickle cell sensitive subjects. *J. clin. Invest.* 41 1446 (1962).
3. BRUTLER, E. The glutathione instability of drug sensitive red cells method for the in vivo detection of drug sensitivity. *J. Lab. clin. med.* 49: 87 (1957).
4. KORNBERG, A. and HORWITZ, B.L. Glucose-6-phosphate dehydrogenase. *Methods in Enzymology* vol. 1 p. 323 (Academic Press, New York 1955).
5. HORWITZ, B.L. and BARRONOW, P.Z. Phosphogluconic acid dehydrogenase from yeast. *J. Biol. Chem.* 233 371 (1958).
6. GLOCK, G.E. and MCLAREN, P. Further studies on properties and assay of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of rat liver. *Biochem. J.* 51 400 (1953).
7. BOCKR, T. and FLYNN, G. Pyruvate kinase from muscle. *Methods in Enzymology* vol. 1 p. 435 (Academic Press, New York 1955).
8. BERNHARDT, G. Triosephosphate isomerase from calf muscle. *Methods in Enzymology* vol. 1 p. 387 (Academic Press, New York 1955).

- 9 KAPLAN, A.O.: Enzymatic determination of free sugars. *Methods in Enzymology* vol. 3, p. 107 (Academic Press, New York 1957).
- 10 RABIN, S.B. and SOMMERSON, W.H.: Colorimetric determination of lactic acid in biological material. *J. biol. Chem.* 238: 535 (1941).
- 11 GARDNER, R.R. and PHILLIPS, P.H.: A modification of the nitroprusside method of analysis for glutathione. *Arch. Biochem.* 30: 217 (1951).
- 12 DRAHEIM, D.L.: A simple technique for a large scale crystallization of human oxyhemoglobin. Isomorphous transformation of hemoglobin and myoglobin in the crystalline state. *Arch. Biochem.* 21: 224 (1949).
- 13 VALENTIN, W., TANAKA, K.R. and MIWA, S.: Specific erythrocyte glycolytic enzyme defect (pyruvate-kinase) in three subjects with congenital non spherocytic hemolytic anemia. *Trans. Am. Soc. Phys.* 74: 100 (1961).
- 14 HJELM, M. and VERNER, C.H.: Non spherocytic hemolytic anemia and changes in phosphoglycerate and phosphopyruvate metabolism of the red blood cell. Xth Congr. Int. Soc. Haemat., Stockholm 1964.
- 15 KOTLER, R., BULLY, R., JONES, R.J., REIS, D. L., VAN BELLINGHOF, F. and THOMPSON, P.: Pyruvate-kinase: molecular differences between human red cell and leukocyte enzyme. *Cold Spr. Harb. Symp. quant. Biol.* 29: 215 (1964).
- 16 JURET, A., DESRAY, J., BOWEN, P., BRATY, J. et D'ANGELO, U.: cas d'anémie hémolytique par déficit en pyruvate-kinase. *Arch. franç. Pédiat.* 22: (1965).
- 17 VILLO, G., TROVATI, A.M.: Ittero neonatale con déficit transitorio della glucosa-6-fosfato deidrogenasi eritrocitaria. *Pediatrics* 69: 327 (1961).
- 18 CARCERO, E., VOLPATO, S. et SCARPA, F.: Pathologie érythrocytaire néo-natale par déficit en glucose-6-phosphate déhydrogénase. *Ann. Péd.* 33: 625 (1962).
- 19 ORDOQUE, A.: Erythrocyte glucose-6-phosphate dehydrogenase. A study of the enzyme activity in children. *Amer. J. Dis. Child* 107: 186 (1964).
- 20 FAIXON, I.: Lactère grave du nouveau-né associé à une déficience en glucose-6-phosphate déhydrogénase. *Biol. Neonat.* 1: 167 (1960).
- 21 DOXIADIS, S.A., FERAS, P., VALARI, T. and MANTHORALOS, N.: Glucose-6-phosphate dehydrogenase deficiency: a new aetiological factor of severe neonatal jaundice. *Lancet* i: 257 (1961).
- 22 DOXIADIS, S.A. and VALARI, T.: The clinical picture of glucose-6-phosphate dehydrogenase deficiency in early infancy. *Arch. Dis. Child* 39: 545 (1964).
- 23 VALARI, T., FERAS, P. and DOXIADIS, S.A.: Kernicterus in full-term infant without isoimmunization (4 cases). *Proc. roy. Soc. Med.* 54: 331 (1961).
- 24 SCHWYD, F., MIELON, T., CORRA, G. and MELA, C.: Red cell survival in jaundice newborn children with erythrocyte-enzyme deficiency. *Lancet* i: 1012 (1963).
- 25 CAMPS, F.P.A., GILES, H.M., JOLLY, H. and WOODHEAD, S.M.: Glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Nigeria. *Lancet* i: 370 (1963).
- 26 FLATZ, G., SIEGAL, S. and KROEMER, V.: Neonatal jaundice in glucose-6-phosphate dehydrogenase deficiency. *Lancet* i: 1382 (1963).
- 27 FERAS, P.H., DOXIADIS, S.A. and VALARI, T.: Neonatal jaundice in glucose-6-phosphate dehydrogenase deficient infants. *Brit. med. J.* ii: 1359 (1962).
- 28 FOURNAIS, G.: Biochemical modifications during erythrocyte lifespan (A review). *Ital. J. Biochem.* 16: 237 (1967).
- 29 GORDON, H.H., NITOWSKY, H.M. and CORUGLATR, M.: Studies of tocopherol deficiency in infants and children. I. Hemolysis of erythrocytes in hydrogen peroxide. *Amer. J. Dis. Child* 90: 669 (1955).
- 30 GROSS, R.T., BRACCI, R., REDOLPH, V., SCHROEDER, E. and KOCHER, J.A.: Hydrogen peroxide toxicity and detoxification in the erythrocytes of newborn infants. *Blood* 22: 481 (1967).
- 31 CORUGLATR, M. and HARTMANN, A.F.: Methemoglobinemia in young infants. *J. Pediat.* 33: 421 (1948).

32. GAMER, C.: Die hämolytische Frühgeburtensanämie mit spontaner Innenkörperbildung. Ein neues Syndrom, beobachtet an 14 Fällen (The hemolytic anemia of premature infants with spontaneous Heinz body formation. A new syndrome observed in 14 cases) *Helv. paediat. Acta* 8: 491 (1953).
33. ALLMON, A.C.: Danger of vitamin K to newborn (letter to the editor) *Lancet* 8: 689 (1955).
34. KRAVITZ, H., ELEGANT D.L., KAMEN, E. and JAGAN, B.M.: Methemoglobin values in premature and mature infants and children. *Amer. J. Dis. Child* 91: 1 (1956).
35. BROWN, A.K.: Peculiarities of erythrocytes of the newborn in kernicterus, p. 54. Ed. A. SALL (Kovtsak, Toronto 1961).
36. JONES, P.H.Z. and McCAMUS, R.A.: Enzyme activities in the blood of infants and adults. *Biochem. J.* 45: 464 (1949).
37. HOFFMAN, E.G. and RAPOPORT, S.: Triphospho-pyridin-nucleotid, Flavinadenin-nucleotid, Coenzym A und Thiamin-phyrophosphat im Hämolytaten von Kaninchen-Erythrocyten. *Z. physiol. Chem.* 304: 157 (1956).
38. LOWE, G.W., WALLER, H.D., HARGIS, O., SCHLESSEL, B. und MILLER, A.A.: Zur Biochemie der Alterung menschlicher Erythrocyten. *Klin. Wochs.* 35: 1008 (1958).
39. NAKAO, M., NAKAO, T. and YAMAZAKI, S.: Adenosine triphosphate and maintenance of shape of human red cells. *Nature Lond.* 187: 945 (1960).
40. NAKAO, M., NAKAO, T., YAMAZAKI, S. and YOSHIZAWA, H.: Adenosine triphosphate and shape of erythrocytes. *J. Biochem.* 49: 487 (1961).
41. TAKAKA, H.R., VALENTINE, W.N. and MIRZA, S.: Pyruvate kinase deficiency hereditary non-spherocytic hemolytic anemia. *Blood* 19: 267 (1962).
42. POWELL, R.D. and DE GOWER, R.L.: Relationship between activity of pyruvate kinase and age of the normal human erythrocytes. *Nature, Lond.* 205: 507 (1965).
43. BROCK, F., RAMOT, B., ZWANG, E. and DABOY, D.: Enzyme activities in human red blood cells of different age groups. *Israel J. med. Sci.* 2: 291 (1966).
44. JACOB, J.H., ESFELD, L.K. and ALLEN, D.W.: Oxidative hemolysis and precipitation of hemoglobin. I. Heinz body anemias as an acceleration of red cell aging. *J. clin. Invest.* 39: 1818 (1960).
45. JACOB, H.S. and JACOB, J.H.: Effect of sulphydryl inhibition on red blood cells. I. Mechanism of hemolysis. *J. clin. Invest.* 41: 779 (1962).
46. JACOB, H.S. and JACOB, J.H.: Effect of sulphydryl inhibition in red blood cells. II. Studies *in vivo*. *J. clin. Invest.* 41: 1514 (1962).
47. HILL, A.S., HART, A., CARTWRIGHT, G.E. and WITKOWSKI, M.M.: The role of non-hemoglobin proteins and reduced glutathione in the protection of Hemoglobin from oxidation *in vitro*. *J. clin. Invest.* 43: 17 (1964).
48. JACOB, H.S., INGRAM, S.H. and JACOB, J.H.: Oxidative hemolysis and erythrocyte metabolism in hereditary acatalasia. *J. clin. Invest.* 41: 1187 (1963).
49. JACOB, H.S. and JACOB, J.H.: Effects of sulphydryl inhibition on red blood cells. III. Glutathione in the regulation of the hexose monophosphate pathway. *J. biol. Chem.* 241: 4245 (1966).
50. CHAPMAN, R.G., HENNINGSEN, M.A., WALTERSDORFF, A.M., HENNINGSEN, F.M. and GARRICK, B.W.: Erythrocyte metabolism. V. Levels of glycolytic enzymes and regulation of glycolysis. *J. clin. Invest.* 41: 1249 (1962).
51. RAPOPORT, S. and LEVINSKY, J.: The formation of 2,3-diphosphoglycerate in rabbit erythrocytes the existence of diphosphoglycerate mutase. *J. biol. Chem.* 183: 507 (1950).
52. RAPOPORT, S. and LEVINSKY, J.: Glycerate 2,3-diphosphatase. *J. biol. Chem.* 189: 685 (1951).

Authors' addresses: Dr. M. BOMI, Istituto di Clinica Pediatrica, Università di Roma, Rome;  
 Prof. G. FORZANI and Dr. M. D'ACCHI, Istituto di Chimica Biologica, Università di Urbino,  
 Urbino (Italy).

---

## Libri

---

**Advances in Transplantation.** Proceedings of the 1st International Congress of the Transplantation Society Paris, 27-30 June 1967. Hrg. J. DAINOFF, J. HANSEN and G. MATRAT. Munksgaard, Copenhagen 1968. 786p. Preis \$ 18,00, DSt 145,80, dKr 270.

Die Forschungen auf dem Gebiet der Gewebe- und Organtransplantation machten in den letzten Jahren unvorstellbar grosse Fortschritte. Das neue Erkenntnis ergaben sich aus Arbeiten verschiedenster Spezialitäten, wie Immunologie, Biochemie, Genetik, Innere Medizin und Chirurgie. Es erwies sich deshalb als notwendig, dass sich die Forscher aller Spezialitäten, die an den Erregenschaften beteiligt sind, regelmässig treffen. Aus diesem Grunde fand vom 27.-30. Juni 1967 in Paris der 1. Internationale Kongress der Transplantations-Gesellschaft statt. Zuerst wurden an sieben Meetings allgemeine Themen behandelt wie: Der Mechanismus der Transplantationsabstoßung - Immunsuppressive Methoden - Genetische Probleme der Transplantation - Transplantationsantigene - Organtransplantation Knochenmarktransplantation - Krebs als Transplantation. Danach folgten verschiedene Übersichtsreferate, u.a. Betrachtungen zum Abstoßungsmechanismus - Spenderauswahl für Organtransplantationen - Biologische Probleme bei Transplantationen - Immunsuppressive Substanzen. Weitere Referate befassten sich mit Transplantationen von Niere, Leber, Herz, Lunge, Pankreas und Gehirn.

Die im Kongressband niedergelegten Ergebnisse sind nur für den Transplantationsproblemen speziell interessierten Mediziner bestimmt. Derjenige, der sich über Transplantationen allgemein orientieren möchte, sollte nicht zu diesem Buch greifen. Dem Spezialisten dagegen bietet es eine grosse Fülle von neuen Erkenntnissen.

H. THÜRKE, Basel

---

## Varia

---

### VIIth International Congress of Clinical Pathology

The VIIth International Congress of Clinical Pathology will be held in Montreal, July 13th to 19th, 1969 under the joint auspices of the Canadian Association of Pathologists, the Canadian Society of Clinical Chemists and the Canadian Association of Medical Bacteriologists.

*Tentative scientific programme.* Monday July 14 Symposium I Mycoplasmas; Symposium II Enzyme Tests. - Tuesday July 15 Symposium III Complications of Extra-Corporeal Perfusion and Cardiac Surgery; Symposium IV Standards, International Surveys and Quality Control; Symposium V Immunofluorescence in Diagnosis. - Thursday July 17 Symposium VI Restrictive Lung Disease; Symposium VII Hospital Infections; Symposium VIII Neuropathology. - Friday July 18 Symposium IX Inborn Errors in Metabolism; Symposium X Cytology; Symposium XI Haemolytic Disease of the Foetus and Newborn. - Saturday July 19 Symposium XII Future of Laboratory Medicine.

Enquiries regarding the Congress can be directed to VII International Congress of Clinical Pathology P.O. Box 8, Station G Montreal 18 (Canada)

Pathologisches Institut der Universität Köln (Direktor Prof. Dr. M. Eder) und II. Medizinische Universitätsklinik und Poliklinik Mainz (Direktor Prof. Dr. P. Schmollers)

## Über den Nachweis der Thiaminpyrophosphatase («Golgi-phosphatase») in Blut und Knochenmarkszellen<sup>1</sup>

R. FISCHER und H. H. HENCKESEN

NOVIKOFF und GOLDFISCHER [17] haben eine enzymzytochemische Methode angegeben, mit der in den Zellen zahlreicher Gewebe im Bereich der Golgzone ein deutlicher Reaktionsausfall feststellbar war. Bei diesem auf dem Gomori-Prinzip basierenden Nachweisverfahren dienten verschiedene Nukleondiphosphate sowie Thiaminpyrophosphat als Substrate, die bei annähernd neutralem pH von einer «Golgi-Phosphatase» hydrolysiert wurden. Die Annahme einer solchen spezifischen Enzymlokalisation in den lamellären und vesikulären Strukturen des Golgiapparates konnte in der Folgezeit bestätigt werden [2, 5, 13, 15, 16, 20].

Bei den vorliegenden Untersuchungen sollte das Vorkommen und die Lokalisation der Thiaminpyrophosphatase in den Zellen des Blutes und Knochenmarks geprüft werden. Die Klärung dieser Frage erschien vor allem deshalb von Interesse, weil sich gerade in jüngster Zeit wichtige Hinweise für die funktionelle Bedeutung des Golgiapparates bei der Granulabildung in den Zellen des hämatopoetischen Systems ergeben haben [3, 7, 23].

### Material und Methodik

Als Untersuchungsmaterial dienten Blut- und Knochenmarksausstriche von 30 gesunden Personen bzw. von Patienten mit nicht-hämatologischen Erkrankungen. Außerdem wurden 20 Fälle verschiedener Leukämien untersucht.

Mit Unterstützung durch die Deutsche Forschungsgemeinschaft. Anzeigen, die vorgetragen auf der 12. Tagung der Deutschen Gesellschaft für Hämatologie, Berlin 1966.

Die Ausstriche wurden luftgetrocknet und anschließend fixiert. Unter den in Vorversuchen getesteten Fixierungsmitteln ergab die Vorbehandlung mit Formalin-Calciumchlorid oder Formalin-Calciumazetat (5 Min., 4°C) die besten Resultate.

Nach der Fixierung wurden die Ausstriche in Aqua dest. gespült und erneut luftgetrocknet.

Die Inkubation erfolgte 1 Std. bei 37°C in dem von Novitsky und Goldwasser [17] angegebenen Medium: 20 ml 0,01 M Thiaminpyrophosphat, 8 ml Aqua dest., 40 ml 0,2 M Tris-Maleat-Puffer pH 7,2, 12 ml 0,03 M Bleitrat und 20 ml 0,025 M Manganchlorid.

Nach der Inkubation wurden die Präparate mehrmals in Aqua dest. gespült, anschließend für 1–2 Min. in verdünnte Ammoniumsulfidlösung eingestellt und erneut gewässert. Die Kerngegenfärbung erfolgte mit Mayers Hämalaun-Färbelösung im Glycerinobjektglas.

Die Spezifität der Thiaminpyrophosphatase-Aktivität wurde durch folgende Kontrollversuche geprüft: a) Weglassen des Substrates oder Hitzeinaktivierung, b) Zusatz von folgenden Inhibitoren zum Inkubationsgemisch: 0,01 M Uranyltriat, 0,01 M Natriumfluorid, 0,01 M Zysteinchlorid. Nach Weglassen des Substrates, Hitzeeinaktivierung sowie nach Zusatz von Uranyltriat war keine Enzymaktivität feststellbar. Dagegen blieb die Aktivität der Thiaminpyrophosphatase durch die Inhibitoren der sauren Phosphatase (Natriumfluorid) und der alkalischen Phosphatase (Zysteinchlorid) unbeeinträchtigt.

Neben der Pappenheim-Färbung kamen an Ausstrichpräparaten der untersuchten Fälle in parallel durchgeführten Untersuchungen außerdem folgende enzymzytochemischen Nachweisverfahren zur Anwendung: Naphthol-AS-D-Chloracetat-Esterase [14], Naphthol-AS-Azetat-Esterase [12], saure Phosphatase [4], alkalische Phosphatase [11].

### Ergebnisse

In der Entwicklungsreihe der *neutrophilen Granulozyten* zeigen Myeloblasten und frühe Promyelozyten nur eine geringe Aktivität der Thiaminpyrophosphatase, deren Reaktionsprodukt hier in einem kleinen umschriebenen, perinukleären Zytoplasmabereich lokalisiert ist (Abb. 1a). Mit der weiteren Differenzierung zu Promyelozyten fällt eine deutliche Vergrößerung der Aktivitätszone auf, die relativ scharf begrenzt in der Nähe der beginnenden Kerneinsenkung liegt (Abb. 1b und c). Das Reaktionsprodukt zeigt in den Promyelozyten häufig eine ring bzw. schalenförmige Anordnung, deren Mitte etwa der Lage der Zentriolen entspricht (Abb. 1b). Auch im Myelozytenstadium findet sich zumeist eine deutliche Fermentaktivität, deren Ausdehnung im Vergleich zu den Promyelozyten etwas abgenommen hat (Abb. 1d und e). Noch deutlicher wird die Abnahme der Enzymaktivität bzw. die Verkleinerung der Reaktionszone mit der weiteren Ausreifung der neutrophilen Granulozyten. Während in den Metamyelozyten häufig noch einzelne Bleisulfidniederschläge zu beobachten sind (Abb. 1f) war in den stab- und segmentkernigen Neutrophilen in der Regel keine sichere Enzymaktivität mehr nachweisbar.

Die Aktivitätszone der Thiaminpyrophosphatase in den Promyelozyten entspricht der im perinukleären Bereich des Präparates erkennbaren Lokalisation der beginnenden Azurgranula-




Abb. 1. Nachweis der Thiaminpyrophosphatase in Zellen des menschlichen Knochenmarks: a) Myeloblast, b) und c) Promyelocyten, d) und e) Myelocyten, f) Metamyelocyt, g) eosinophiler Myelocyt, h) und i) Plasmazellen. Relativ scharflokalisierte Reaktion in einem perinukleären, der Golgizone entsprechenden Bezirk.  $\times 1400$ .

tion. Eine abhebbare, zunächst auf einen perinukleären Bezirk beschränkte Reaktion zeigt in frühen Promyelocyten auch der zytochemische Nachweis der Naphthol-AS-D-Chloroazetat-Esterase (Abb. 2) oder anderer an die Leukozytengranula gebundener Enzyme (Peroxydase, Naphthol-AS-Acetat-Esterase, saure Phosphatase).

Der Reaktionsausfall in den *eosinophilen Granulozyten* stimmt im Prinzip mit den geschilderten Befunden an den Zellen der neutrophilen Entwicklungsreihe überein. Im allgemeinen fällt der Nachweis der Thiaminpyrophosphatase in den Eosinophilen jedoch etwas kräftiger aus als in den entsprechenden neutrophilen Zellen. Besonders deutlich tritt die charakteristische zirkuläre Orientierung der Aktivitätszone in den eosinophilen Promyelocyten und Myelocyten hervor.





Abb 2. Darstellung der *Saphal-AS-D-chloracetat-Reaktion* in frühen Promyelozyten mit einem zunächst auf einen perinukleären Bezirk (Golgizone?) beschränkten Reaktionsprodukt (a und b) das sich bei der weiteren Differenzierung der Zellen auf größere Abschnitte ausdehnt (c) und schließlich das Zytoplasma völlig ausfüllt (d). Promyelozyten-Leukämie.  $\times 1400$ .

(Abb 1g) Außerdem war im Gegensatz zu den ensymnegativen stab- und segmentkernigen Neutrophilen auch in den reifen eosinophilen Leukozyten gelegentlich noch eine geringe Aktivität der Thiaminpyrophosphatase in Form einzelner punktförmiger Granula zwischen den beiden Kernsegmenten nachweisbar

Durch eine besonders starke Thiaminpyrophosphatase Aktivität fallen die in den Knochenmarkausstrichen nachweisbaren *Megakaryozyten* auf. Das Reaktionsprodukt ist in den Vorstufen mit noch unsegmentiertem Zellkern in einer deutlich ausgeprägten perinukleären Zone lokalisiert (Abb 3a) Besonders bei stärkerer Vergrößerung ist hier eine lamelläre und granuläre Anordnung feststellbar Mit zunehmender Kernlappung und Ausdifferenzierung der Megakaryozyten dehnt sich die Aktivitätszone über größere Anteile des Zytoplasmas aus (Abb 3b und c) Neben unregelmäßigen Verdichtungen des Reaktionsproduktes lassen sich netzförmige Strukturen oder granuläre bzw feinvakuoläre Reaktionsniederschläge in kettenförmiger Anordnung feststellen.

Sowohl in den Zellen der *Erythrozytopenie* als auch in den *Lymphozyten* im peripheren Blut und Knochenmark war mit der von uns ange-



Abb. 3. Deutliche Aktivität der *Thiaminpyrophosphatase* in Megakaryozyten. Das Reaktionsprodukt ist in einer perinukleären Zone (a) mit zunehmender Kernleptung in einem größeren Zytoplasmabereich (b) u.T. in netzförmiger bzw. schrägknotiger Anordnung (c) erkennbar  $\times 900$

wandten Technik kein sicherer Reaktionsausfall der Thiaminpyrophosphatase nachweisbar. Eine zumeist deutliche Enzymaktivität

in einer umschriebenen etwa der perinukleären Aufhellung entsprechenden Zone fand sich dagegen in den *Plasmazellen* des Knochenmarks (Abb. 1h und i) *Monocyten* des peripheren Blutes zeigten eine insgesamt schwache Reaktion im Bereich der Kerneimbuchtung.

Bei den untersuchten *Leukosen* entsprach die Aktivitätsverteilung der Thiaminpyrophosphatase weitgehend dem Differenzierungsgrad der Zellen. So zeigten unreifzellige myeloische Leukämien je nach ihrer Differenzierungstendenz zu promyelozytären Zellen eine unterschiedlich entwickelte Golgi-phosphataseaktivität. Auch in den neutrophilen und eosinophilen Promyelozyten und Myelozyten der chronischen Myelose bestand, ähnlich wie in den entsprechenden Zellen des normalen Knochenmarks, eine deutliche Enzymaktivität. Die Zellen lymphatischer Leukämien wiesen keine zytochemisch nachweisbare Aktivität der Thiaminpyrophosphatase auf.

### Diskussion

In der seit langem geführten Diskussion über die Existenz und die funktionelle Bedeutung des in enger struktureller und funktioneller Beziehung mit dem endoplasmatischen Retikulum stehenden Golgiapparates konnte inzwischen eine weitgehende Klärung herbeigeführt werden [Übersichten 9 und 21]. Vor allem die neueren Ergebnisse der Elektronenmikroskopie haben gezeigt, dass Strukturen des Golgisystems, allerdings in sehr unterschiedlicher Ausprägung eine obliteratorische Komponente der tierischen Zellen darstellen. Zur lichtmikroskopischen Darstellung des Golgiapparates hat sich in jüngster Zeit besonders der von NOVIKOFF und GOLDFISCHER [17] eingeführte zytochemische Nachweis einer Nukleosiddiphosphatase bzw. Thiaminpyrophosphat hydrolysierenden Phosphatase bewährt, deren spezifische Lokalisation in Strukturen des Golgisystems inzwischen durch zahlreiche licht- und elektronenmikroskopische Untersuchungen an verschiedenen Geweben bestätigt worden ist [2, 5, 13, 15, 16, 20].

Die vorliegenden Ergebnisse zeigen, dass die zytochemische Lokalisation der Thiaminpyrophosphatase auch in den Zellen des hämatopoetischen Systems mit der aus elektronenmikroskopischen Untersuchungen bekannten Anordnung des Golgiapparates völlig übereinstimmt. In der neutrophilen Granulozytopoese findet sich das Maximum der Enzymaktivität im Promyelozyten- und Myelozytenstadium,

während in den reifen Neutrophilen mit der angewandten Methode keine nennenswerte Reaktion mehr nachweisbar war. Auch elektronenmikroskopisch zeigt der in Myeloblasten nur spärlich ausgebildete Golgiapparat in den Promyelozyten und Myelozyten eine deutliche Vergrößerung, um sich mit der weiteren Ausreifung bis auf einige rudimentäre Zytornen wieder zurückzubilden [1 3 6, 22]. Entsprechende Übereinstimmungen ergeben sich auch in der eosinophilen Entwicklungsreihe.

Der besonderen Ausprägung des Golgiapparates im Promyelozyten und Myelozytenstadium muss in Übereinstimmung mit den allgemeinen Vorstellungen über die funktionelle Bedeutung dieses Zellorganells eine wichtige Rolle bei der Granulabildung zugesprochen werden, die in enger räumlicher Beziehung zu Strukturen des Golgi-komplexes steht [1 3 7 23]. So entwickeln sich beispielsweise in den neutrophilen Vorstufen im Knochenmark des Kaninchens die azurophilen Granula durch Austülpung und nachfolgende Aggregation von Mikrobälchen an der konkaven, d. h. der dem Zentriol zugewandten Fläche des Golgiapparates, während die im Myelozytenstadium auftretenden «spezifischen» Granula durch Abschnürung und Konfluenz von Golgibälchen an der konvexen Begrenzung entstehen [3]. In Übereinstimmung mit diesen elektronenmikroskopischen Befunden stehen die Ergebnisse autoradiographischer Untersuchungen, bei denen nach Inkorporation von  $^3\text{H}$ -Lysin der intrazelluläre Fluss der markierten Aminosäure von Strukturen des endoplasmatischen Retikulums über den Golgikomplex in die neugebildeten Granula verfolgt werden konnte [7].

Tatsächlich lässt sich auch lichtmikroskopisch in frühen Promyelozyten im Bereich der zytochemisch darstellbaren Golgiposphatase nicht nur im panoptisch gefärbten Präparat der Beginn einer azurophilen Granulation nachweisen, sondern auch eine zunächst auf diese Zone beschränkte Aktivität bestimmter an die Leukozytengranula gebundener Enzyme wie der Peroxydase oder der Naphthol-AS-D-Chloroazetat Esterase (Abb. 2) feststellen. Eine ähnliche Lokalisation der sauren Phosphatase und anderer hydrolytischer Enzyme [1 23] liefert zudem einen weiteren Beleg für die Lysosomennatur der Leukozytengranula sowie Hinweise für die Bedeutung des Golgikomplexes bei der Entstehung «primärer» Lysosomen überhaupt. Dabei ist die saure Phosphatase jedoch im Gegensatz zu der Nukleosiddiphosphatase oder Thiaminpyrophosphat hydrolysierenden «Golgiposphatase» nicht in den lamellären Strukturen des Golgiapparates selbst lokalisiert.

sondern in den benachbarten lysosomalen Granula anzutreffen [16, 17].

Eine besonders auffällige Aktivität und Verteilung der Thiaminpyrophosphatase liess sich bei unseren Untersuchungen in den Megakaryozyten des Knochenmarks feststellen. Sie entspricht auch hier den elektronenmikroskopischen Befunden eines sehr stark ausgeprägten Golgiapparates, der bereits in den Megakaryoblasten im perinukleären Zytoplasma eine grosse, aus mehreren herdförmigen glatten Membranen und vielen Mikrobälchen aufgebaute Zone bildet. Unter wesentlicher Beteiligung des Golgiapparates entstehen in den Megakaryozyten aus Eiweissbausteinen der Grundsubstanz die verschiedenen Vorstufen des Granulomers und der Demarkationsbälchen der Thrombozyten [10, 18, 19].

Auch in den Zellen des hämatopoetischen Systems kommt somit dem Golgiapparat eine wesentliche Bedeutung im Rahmen «sekretorischer» Leistungen zu wie sie etwa von den Plasmazellen oder Geweben mit einer starken Eiweissynthese bereits seit längerem bekannt ist. Durch die Thiaminpyrophosphatase Reaktion ergibt sich nicht nur die Möglichkeit, die Struktur des Golgiapparates in den Zellen des Blutes und Knochenmarks mit einer den klassischen Imprägnationsverfahren überlegenen enzymzytochemischen Methode darzustellen sondern auch seine Variabilität unter funktionellen Bedingungen, wie etwa bei den Transformationsvorgängen der Blutlymphozyten *in vitro* [8] zu erfassen. Vor allem durch die Kombination mit anderen Enzymnachweisen werden darüber hinaus auch auf zytochemischer Basis weitere Hinweise auf die Bedeutung des Golgi-komplexes bei der zellulären Differenzierung der blutbildenden Systeme möglich sein.

### *Zusammenfassung*

Der zytochemische Nachweis der Thiaminpyrophosphatase in Zellen des Knochenmarks zeigt eine unterschiedlich starke Enzymaktivität, deren Lokalisation mit der aus elektronenmikroskopischen Untersuchungen bekannten Anordnung und Größe des Golgiapparates übereinstimmt. In der neutrophilen und eosinophilen Entwicklungsreihe zeigen Promyelozyten und Myelozyten das Maximum der Enzymaktivität. Durch eine besonders ausgeprägte Reaktion der Golgi-Phosphatase sind die Megakaryozyten gekennzeichnet. Ausserdem ist eine zumeist deutliche Enzymaktivität in den Plasmazellen feststellbar. Der Thiaminpyrophosphatase und der besonderen Ausprägung des Golgiapparates in bestimmten Knochenmarkszellen muss eine wichtige Rolle bei den «sekretorischen» Leistungen dieser Zellen, vor allem bei der Granulabildung, zugesprochen werden.

## Summary

Cytochemical demonstration of thiamine pyrophosphatase in bone marrow cells reveals different degrees of enzyme activity according to the arrangement and size of the Golgi apparatus known from electron microscopic studies. Among the neutrophils and eosinophils, maximum activity is found in the promyelocytes and myelocytes. Megakaryocytes are characterized by particularly marked Golgi phosphatase reaction. Fairly marked activity is also generally seen in the plasma cells. The presence of thiamine phosphatase and the particular development of the Golgi apparatus in certain bone marrow cells must play an important part in the secretory activity of these cells, especially formation of the granula.

## Literatur

1. ACHENBACH, G. A. Histochemical differentiation during neutrophil development and maturation. *Ann. N.Y. Acad. Sci.* 113: 537-563 (1964).
2. ALLEN, J. M.: The properties of Golgi-associated nucleoside diphosphatase and thiamine pyrophosphatase. I. Cytochemical analysis. *J. Histochem. Cytochem.* 11: 529-541 (1963).
3. BAENTZ, D. F. and FARGNAR, M. G. Origin of granules in polymorphonuclear leukocytes. *J. Cell Biol.* 22: 277-301 (1966).
4. BAREA, T. and ANDERSON, P. J. Histochemical methods for acid phosphatase using hexazonium pararosaniline as coupler. *J. Histochem. Cytochem.* 10: 741-753 (1962).
5. BAKER, K. D. and TUCKER, T. O. Histochemistry of acid phosphatase and thiamine pyrophosphatase during azan reaction. *Amer. J. Path.* 40: 637-652 (1962).
6. BESS, M. and TERRY, J. P. Electron microscopy of human white blood cells and their stem cells. *Int. Rev. Cytol.* 12: 199-241 (1961).
7. FEDORCO, M. E. and HENCK, J. O. Cytoplasmic granule formation in myelocytes. *J. Cell Biol.* 29: 307-316 (1966).
8. FISCHER, R. and GROSS, A. Zytochemie des Lymphozyten in vitro. *Klin. Wochschr.* 44: 733-738 (1966).
9. GROSSMANN, E. Funktionelle Morphologie der Zelle in HELLERER's Handbuch d. exp. Med., Bd. II/1 (Springer Berlin/Heidelberg/New York 1968).
10. JONES, O. P. Origin of megakaryocyte granules from Golgi vesicles. *Anat. Rec.* 132: 105-112 (1960).
11. KAPLOW, L. S.: A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and marrow. *Blood* 10: 1023-1029 (1955).
12. LÖFFLER, H. Zytochemischer Nachweis von unspezifischen Esterasen an Amastochen. *Klin. Wochschr.* 39: 1220-1227 (1961).
13. MECK, G. A. and BRAUNSTY, S. Localization of thiamine pyrophosphatase activity in the Golgi apparatus of mollusc, *Helix aspersa*. *J. Cell Biol.* 10: 73-85 (1963).
14. MOLONEY, W. C., MCPHERSON, K. and FLITZELMAN, L. Esterase activity in leukocytes demonstrated by the use of naphthol ASD-Chloroacetate. *J. Histochem. Cytochem.* 8: 200-207 (1960).
15. NOVICKOV, A. B. Cytochemical staining methods for enzyme activities: their application to the rat parotid gland. *Jewish med. Hosp. Bull., N.Y.* 6: 70-83 (1962).
16. NOVICKOV, A. B. and EASER, E. Pathological changes in cytoplasmic organelles. *Fed. Proc.* 21: 1130-1142 (1962).
17. NOVICKOV, A. B. and GOLDENBERG, S. Nucleosidediphosphatase activity in the Golgi apparatus and its usefulness for cytological studies. *Proc. nat. Acad. Sci.* 47: 802-810 (1961).

18. SCHULZ, H.: Schenkmikroskopische Beiträge zur Orthologie und Pathologie der Thrombocyten. *Verh. dtsch. Ges. inn. Med.* 65: 832-848 (1960).
19. SCHULZ, H.: Die Erneuerung der Thrombocyten im elektronenmikroskopischen Bild. *Verh. dtsch. Ges. Path.* 50: 239-247 (1966).
20. SMARTRAVEERAPPA, T. R. and BOCKOR, G. H.: The thiamine pyrophosphatase technique as an indicator of the morphology of the Golgi apparatus in the neuron. *Acta histochem.* 22: 155-178 (1965).
21. SÖRVER, A.: Funktion des Golgi-Apparates in pflanzlichen Zellen, in: *Funktionelle und morphologische Organisation der Zelle Bd. II Sekretion und Exkretion*, pp. 89-111 (Springer Berlin/Heidelberg/New York 1965).
22. WATANABE, Y.: Observations of white blood cells with electron microscope. *J. Electron-micro* 5: 46-57 (1957).
23. WETZEL, B. K., HORN, R. G. and SYCES, S. S.: Cytochemical localization of non-specific phosphatase activity in rabbit myeloid elements. *J. Histochem. Cytochem.* 11: 812-814 (1963).

Research Hematology Laboratory Peter Bent Brigham Hospital and Harvard Medical School, Boston, Mass.

## Serum Lactic Dehydrogenase Activity in Refractory Anemia<sup>1</sup>

D. S. ROSENTHAL, A. T. SEARIN and W. C. MOLOVEY

Serum lactic dehydrogenase activity (LDH) is markedly elevated in patients with untreated megaloblastic anemias secondary to folic acid or Vitamin B<sub>12</sub> deficiency and this activity rapidly falls with appropriate therapy [1-4]. The serum LDH levels in the anemias of iron deficiency and bone marrow aplasia are normal but levels in hemolytic anemias are frequently elevated [3]. Over the past several years we have been following a group of patients with refractory anemias, some with ineffective erythropoiesis and demonstrating sideroblasts, others presenting with Di Guglielmo's syndrome. It is often difficult to distinguish morphologically the megaloblastoid changes in these cases from that noted in pernicious anemia or folate (FA) deficiency. In this paper results of studies on the behavior of serum LDH and LDH isoenzymes will be reported.

### *Methods and Materials*

There were 9 patients in this series, all characterized by severe anemia, low reticulocytes, variable red cell morphology in the peripheral blood and bone marrow showing marked erythroid activity with reversal of the myeloid to erythroid ratio. Red cells were of varying degrees of immaturity ranging from proerythroblasts with normal maturation to population of primitive erythroid precursors associated with multi-nucleated dysplastic normoblasts. Megaloblastic like changes were frequently noted. In 7 of the 9 cases Prussian Blue stain demonstrated ringed sideroblasts and generally increased iron deposition in phagocytic histiocytes. In some cases there was an increased number of promyelocytes and myelocytes, but striking absence of mononuclear myelocytes and other myeloid changes usually associ-



ted with  $B_{12}$  or folate deficiency. Over several months, 3 patients progressed to overt acute granulocytic leukemia and expired. Six patients were refractory to therapy two of which required frequent transfusions (table I). Serum LDH activity was measured by the methods of WASSERMAN [5] and the percentage of serum LDH isoenzyme ("Heart" type) by the method of DAWSON *et al.* [6].

### Results

There were no significant differences in the LDH levels or the percent of LDH isozymes in the serum of a group of 15 normal controls compared to the patients with refractory anemia (fig 1). The mean serum LDH level for normals was 221.5 units and for the patients 241 units.

### Discussion

The extremely high serum LDH level reported in megaloblastic anemias associated with  $B_{12}$  and FA deficiency was not present in patients with refractory anemia characterized by increased iron and ringed sideroblasts. These findings are in agreement with observations made by HOFFBRAND *et al.* [7]. The elevated serum LDH activity in megaloblastosis has been presumed to come from either increased hemolysis or directly from cell breakdown in the bone marrow [2, 3].




Fig 1 Serum LDH and LDH isoenzyme activity in 9 patients with refractory anemia and 15 normal controls.

Table 1 Clinical and laboratory data in nine cases of refractory anemia

Case No	Age/Sex	L/D	Lat accn	Death	Hb g %	Hct %	WBC	Ratio %	Bone marrow	Folia acid ng %	B <sub>12</sub> ng %	F <sub>12</sub> ng	LDH w.u	Ht g %
1	67 ♂	+	11/20/64		7.5	24	2850	1.4	Ringed siderobl.	300	849	197	377	91
2	72 ♀	+	12/75/63		9.8	25	8800	2.2	Ringed siderobl.	3.5	669	120	312	91
3	74 ♂	+	6/28/66		8.2	25	3000	2.3	Ringed siderobl.	225	671	224	222	68
4	80 ♂	-	7/1/68	10/19/68	8.5	27	7200	1.8	Ringed siderobl.	30	1825	-	340	-
5	56 ♀	+	10/51/68		7.5	25	5300	2.5	Ringed siderobl.	17.2	681	249	228	84
6	67 ♂	+	11/20/66		8.8	26	4000	0.4	Ringed siderobl.	3.6	383	100	142	91
7	42 ♀	-	11/10/67	5/31/67	10.0	32	1450	5.0	Inter P	-	-	171	225	75
8	43 ♀	-	1/10/67	5/19/67	6.0	19	2000	1.8	Inter P	11.9	745	117	241	100
9	48 ♂	+	5/13/67		9.6	28	7000	3.2	Ringed siderobl.	40	2080	118	250	-
									Normal values	7-15.9	200-2000	50-150	221.5	84

+ Interf. dead  
 Converted to acid  
 Wroblewski units

This increase has been attributed to an absolute increase in LDH<sub>1</sub> and LDH<sub>2</sub>, the two electrophoretically fast LDH isoenzymes [9] found in adult red cells. In the refractory anemias there are probably two defects: an 'ineffective' type of erythropoiesis of marked degree and hemolysis resulting from increased destruction of defective red cells in the bone marrow [8]. The normal serum LDH levels in these 9 patients is of diagnostic importance and raised the question as to the source of elevated LDH activity in megaloblastic anemias.

Our observations suggest that the ineffective erythropoiesis in cases of refractory anemia may not be due to abnormal cellular proliferation, but rather to an accumulation of immature red cells with decreased destruction within the bone marrow. On the other hand, the ineffective erythropoiesis in megaloblastosis may be a result of rapid destruction of immature red cells with release of LDH from the marrow. Recent evidence of ineffective granulocytopoiesis raises the alternative possibility that much of the elevated serum LDH activity may be derived from the myeloid elements in the megaloblastic bone marrow [9, 10].

### *Acknowledgements*

The authors are grateful to Miss Ann Rimes for valuable technical assistance, and to the Hematology Laboratory (Tufts) Boston City Hospital, where these patients were followed and to the Thorndike Memorial Laboratory Boston City Hospital for performing the Serum B<sub>12</sub> and folic acid levels.

### *Summary*

Normal serum levels of LDH and its isoenzymes were found in 9 cases of refractory anemia. The red cell activity and morphology in these cases was often indistinguishable from that seen in pernicious anemia. The source of elevated LDH activity in megaloblastosis due to B<sub>12</sub> and folic acid deficiency may therefore not be derived from the increased erythroid activity but rather the increased myeloid elements which are not present in refractory anemia.

### *References*

1. ANDERSON, N. The Activity of lactic dehydrogenase in megaloblastic anemia. *Scand. J. Haematol.* 1: 212 (1964).
2. ELLIOT, B. A. and FLINNO, A. F.: Source of elevated serum enzyme activities in patients with megaloblastic erythropoiesis secondary to folic acid deficiency. *Brit. med. J.* 1: 626 (1965).
3. POLONKIN, J. A. and ISKRA, E. Serum lactic dehydrogenase activity and isoenzyme pattern in some hematological diseases. *Acta med. scand.* 117: 115 (1965).

4. STEIN, I., KOCHEW, S., ZALCNEY, R. and HOOVERSTEIN, B. Mechanism of serum LDH elevation in megaloblastic anemias. *Blood* 30: 876 (1967).
5. WROBLEWICK, F. and LADUE, J. S. Lactate dehydrogenase activity in blood. *Proc. Soc. exp. Biol., N.Y.* 90: 210 (1964).
6. DAWSON, D. M., GOODFRIEND, T. L. and KAPLAN, N. O. Lactic dehydrogenase functions of the two types. *Science* 143: 929 (1964).
7. HOFFBRAND, A. V., KRIKORIAN, S. and BUTTERWORTH, P. J. Serum lactic dehydrogenase activity and folate deficiency in myelodysplasia and other hematological diseases. *Brit. med. J.* i. 577 (1966).
8. BALDOR, M., FEDERBERG, H. J., FUTAKI, K. and DANENBERG, W. The anemia of the De Gajekins syndrome. *Blood* 11: 334 (1959).
9. LU, Y. K. and SULLIVAN, L. W. Marrow granulocyte reserve in pernicious anemia. *Clin. Res.* 14: 512 (1966).
10. FERTILE, P. E., KAPLAN, S. S. and FORD, S. C. Significance of changes in serum isoenzymic activity in megaloblastic anemia. *New Engl. J. Med.* 277: 10 (1967).

Authors' addresses: DAVID S. ROSENTHAL, M. D., Malcolm Grow USAF Hospital, Andrews Air Force Base, Washington, D.C.; ARTHUR T. SHANKS, M. D. and WILLIAM C. MOLOVEY, M. D., Peter Bent Brigham Hospital, 771 Huntington Avenue, Boston, Mass. (USA).

Departments of Clinical Pathology and Medicine,  
American University of Beirut

## Cytogenetic Studies in Acute Leukemia<sup>1</sup>

F. P. KHOURI, M. J. SHAHID and S. YENIKOMERLIAN

The discovery of a specific chromosomal abnormality in chronic myeloid leukemia [1-7, 8] has led to a revival of interest in the karyotyping of human tumors. In this respect the acute leukemias have received special attention, at least partly because of the difficulties frequently encountered in classifying them on cytological grounds alone.

The present report deals with the results of cytogenetic studies on bone marrow aspirates from 7 consecutive patients admitted to the American University Hospital with the diagnosis of acute leukemia.

### *Materials and Methods*

Six patients were males and one was female. The age range was 16-63 years, with only one patient (LCP 3) above the age of 45 years. Four had received no treatment prior to karyotyping: one (LCP 14) had prednisolone for one month; another (LCP 18) had nitrogen mustard for 7 days, 2 months prior to the examination, and third patient (LCP-7) the only female in the group, was on both prednisolone and 6-mercaptopurine at the time of the investigation.

As to the cytological type, 3 of the patients had myeloblastic, three lymphoblastic and one monoblastic leukemia. The criteria used in differentiating these types have been described in detail by HAYMON *et al.* [9]. Features of diagnostic importance were cellular and nuclear morphology, nuclear:cytoplasmic ratio, the presence of certain cytoplasmic inclusions such as Auer rods, as well as cytochemical reactions of the leukemic cells.

Sternal bone marrow aspiration was performed on every patient at the time of admission. A small portion of the aspirate was used for cytological examination following coloration with the Romanowsky stains, and for cytochemical reactions [9]. The rest was utilized in the

Aided by Grant No. 29-66 from the American University Hospital Medical School, Beirut.

cytogenetic studies using slight modification of the method of Tjio and Whang [11], without prior *in vivo* culturing (direct marrow preparations). At the same time peripheral leucocyte counts were made and smears prepared for differential counts and for cytochemical studies.

Table I contains the pertinent clinical and hematological data.

### Results

The results of the chromosome studies are shown in table II. In 4 of the patients all available plates were suitable for analysis, and all showed an entirely normal chromosome constitution. In the fifth patient (LCP 18) most of the plates were found to be normal, only 3 were hypodiploid, with a random loss of one or more chromosomes.

Distinct abnormalities were present in the marrow aspirates from 2 patients. The first, LCP 3, an 83-year-old male with myeloblastic leukemia, had not received any treatment prior to the study. Smears from his bone marrow showed numerous pleomorphic blasts with frequent mitoses, and several macroblasts and binucleate cells. Very few megakaryocytes could be seen. Cytogenetic studies revealed the presence of 2 cell-lines: a major line with a chromosome count of 41 (fig 1) and a minor near-tetraploid line of cells with 82 chromosomes. None of these latter were of adequate quality for accurate analysis.




Fig 1. Case LCP-3. Chromosome constitution of hypodiploid bone marrow cell. Note missing Y chromosome, extra D and deficiencies in groups C, E and G.

Table 1. Clinical and hematological data

Patient	Age years	Sex	Duration of symptoms prior to examination	Treatment prior to karyotyping	Leucocyte count	Peripheral blood	Sternal marrow
LCP-3 Case 211858	83	M	3 weeks	None	22,000	Myeloblasts: 73% Promyelocytes: 3% Myelocytes: 4% Monocytes: 4%	Numerous pleomorphic blast cells. Mitoses frequent. A number of monoblasts and blastlike blast-like cells. Erythropoietic markedly depressed. Very few megakaryocytes.
LCP-6 Case 211859	19	M	4 weeks	None	104,000	Myeloblasts: 82% Lymphocytes: 9%	Numerous myeloblasts and im- mature lymphocytes.  Granulopoietic and erythropoietic depressed.
LCP-7 Case 209810	30	F	8 months	Gemcitabine prednisone	8,550	Myeloblasts: 81% Promyelocytes: 1% Myelocytes: 1%	Numerous pleomorphic blast, some having Auer bodies. Mitoses frequent. Erythropoietic relatively active monoblastic. Lymphocytes common.

Table I (continued)

Patient	Age years	Sex	Duration of symptoms prior to admission	Treatment prior to biopsy/therapy	Leucocyte count	Peripheral blood	Sternal marrow
LCP-8 Case 222744	43	M	6 months	Vitamins Penicillin Streptomycin	91,000	Myeloblasts: 80% Promyelocytes: 1% Myelocytes: 1%	Numerous blast cells, many having eosinophilic granules. Mitoses of causal. Erythropoiesis markedly depressed
LCP 13 Case 225029	16	M	1 week	None	210,000	All cells classified as lymphoblasts	Numerous lymphoblasts and im- mature lymphocytes. Granulopoiesis and erythropoiesis markedly depressed.
LCP 14 Case 225010	26	M	3 months	Prednisone 1 month	2,300	Monoblasts and Promonocytes: 81% Neutrophils: 18%	Numerous monoblasts, promono- cytes and monocytes. Granulopoiesis markedly depressed. Erythropoiesis relatively active
LCP 18 Case 229125	23	M	3 months	Nitrogen mustard 7 days, 2 months earlier	1,950	Lymphoblasts: 20% Lymphocytes: 25%	Numerous lymphoblasts. Mitoses few Granulopoiesis relatively active. Erythropoiesis depressed.



Table II. Results of chromosome studies on normal marrow aspirates

Patient	Diagnosis	Total cells analyzed	Chromosome count					Marker chromosome	Remarks	
			40	41	44	45	46			
LCP 3	AML	17		13					4 (near tetraploid)	Two normal cell lines
LCP 6	ALL	12					12			Normal karyotype
LCP 7	AML	17				7	10			? No. 11
LCP 8	AML	14					14			Two abnormal cell lines
LCP 13	ALL	5					5			Normal karyotype
LCP 14	A. monocytic L.	10					10			Normal karyotype
LCP 16	ALL	12	1		1	1	10			Normal karyotype
							9			
Normal karyotype. Missing: 1C. Missing 1 No. 2 1 No. 17										
ALL Acute lymphoid leukemia, AML Acute myeloid leukemia. Missing: 1C, 1D 1 No. 16, 2P Y										

Normal karyotype. Missing: 1C. Missing 1 No. 2 1 No. 17 Missing: 1C, 1D 1 No. 16, 2P Y  
 ALL Acute lymphoid leukemia, AML Acute myeloid leukemia.

The second patient, LCP 7 was a 30-year-old female with myeloblastic leukemia. Marrow smears showed numerous pleomorphic blasts, some with Auer bodies. Mitoses were frequent among them. Cytogenetic studies showed two abnormal cell-lines, one with 46 chromosomes and the second with a count of 45. Examples of both lines are shown in figures 2 and 3.

### Discussion

To date, several hundred cases of acute leukemia have been studied cytogenetically. In some the studies were performed on direct bone marrow preparations; in others peripheral blood leukocyte cultures were used alone or in combination with the bone marrow preparations. The advantages of direct marrow methods over leukocyte cultures have been stressed by HUNOZARFORD *et al.* [4] and more recently by KROGH JENSEN [6]. Although marrow specimens in the absence of *in vitro* culturing often yielded fewer mitoses for analysis, the culturing of peripheral leukocytes has frequently resulted in the loss of abnormal cell lines, or in the preferential growth of some cell lines over others. Or if phytohemagglutinin was used in the culture, this stimulated normal lymphocytes to proliferate and predominate the cultured cell population.

Even where no culture methods were used, a variable number of patients with acute leukemia were found to have no demonstrable chromosomal aberrations. In the remaining cases, various abnormalities have been encountered. The overall incidence of these as reported in the world literature was approximately 60% [2] although REISMAN *et al.* [9] were able to demonstrate abnormal cell lines in all specimens studied during the active phase of the disease in children. In our present series only 2 of the 7 patients had karyotype changes in their marrow cells.

The chromosome groups most frequently affected were groups C and G and less commonly groups D, E and F. Both of our cases had deficiencies in group G and an extra member in group D. In addition, case LCP 3 had deficiencies in groups C and E, and one of the lines of case LCP 7 had a missing E.

In contrast with the specific abnormality present in chronic myeloid leukemia, no characteristic chromosome pattern has been established for any type of acute leukemia. In general, it has been found that in lymphoblastic leukemia the abnormal cell lines are usually hyper



Fig. 2. Case LCP-7 Chromosome constitution of the cell line with 46 chromosomes. Note abnormally short? No. 11 deficiency in group G, and extra D.




Fig. 3. Case LCP-7 Chromosome constitution of hypodiploid fac. Pattern as in figure 2, but in addition, member of pair No. 17 is missing.

diploid, while in the acute myeloid type the abnormal cells are often hypodiploid. An exception to this is the small group of elderly patients with acute myeloid leukemia in whom SANDBERG *et al.* [10] found 2 abnormal lines one hypodiploid and the other hyperdiploid. Our case LCP 3 appears to have many features in common with this group.

In conclusion, despite the small size of the series studied our findings are in agreement with the reports in the literature, namely that cytogenetic abnormalities are not demonstrable in many cases of acute leukemia, and if present, they are not of specific diagnostic significance.

### *Summary*

Cytogenetic studies are reported on direct bone marrow preparations from 7 patients with acute leukemia. Abnormalities were present in 2 patients with myeloblastic leukemia, one of whom was receiving cytotoxic drug therapy at the time of the examination. The remaining patients, including 3 with lymphoblastic leukemia, had no demonstrable chromosome changes. The above findings are compared with results of similar investigations carried out elsewhere.

### *References*

1. BAIRDE, A. G.; COCKEY-BROWN, W. M.; BOCKTON, K. E.; HARRISON, D. G.; JACOB, P. A. and TOWN, I. M. A possible specific chromosome abnormality in human chronic myeloid leukemia. *Nature Lond.* **188**: 1165 (1960).
2. HAYMON, F. G. J. and HADJIOCCA, F. Cytogenetic and metabolic observations in leukemias and allied states; in HAYMON's *Current research in leukemia*, pp. 55-76 (University Press, Cambridge 1965).
3. HAYMON, F. G. J., QUARLES, D. and DOLL, R. The cytology and cytochemistry of acute leukemias. *Spec. Rep. Ser. med. Res. Council, Lond.*, No. 304 (1964).
4. HIGGINSFORD, D. A. and NOWELL, P. C. Chromosome studies in human leukemia. III. Acute granulocytic leukemia. *J. nat. Cancer Inst.* **29**: 545 (1962).
5. KROONLOOF, K. A., MITUS, W. J. and DASTHUIS, W. Chromosomal aberrations in acute leukemia. *Blood* **26**: 610 (1965).
6. KROON JENSEN, M. Chromosome studies in acute leukemia. II. A comparison between the chromosome patterns of bone marrow cells and cells from the peripheral blood. *Acta med. acad.* **142**: 157 (1967).
7. NOWELL, P. C. and HIGGINSFORD, D. A. Chromosome studies on normal and leukemic human leukocytes. *J. nat. Cancer Inst.* **25**: 85 (1960).
8. NOWELL, P. C. and HIGGINSFORD, D. A. A minute chromosome in human chronic granulocytic leukemia. *Science* **152**: 1697 (1960).
9. REISMAN, L. E.; MITANI, M. and ZIEGLER, W. W. Chromosome studies in leukemia. I. Evidence for the origin of leukemic stem lines from aneuploid ancestors. *New Engl. J. Med.* **276**: 591 (1964).
10. SANDBERG, A. A., IMAHARA, T., KEECH, Y. and CROWWHITE, L. H. Chromosomal differences among the acute leukemias. *Ann. N.Y. Acad. Sci.* **113**: 663 (1964).
11. TRO, J. H. and WRANG, J. Chromosome preparations of bone marrow cells without prior *in vivo* culture or *in vivo* colchicine administration. *Stain Technol.* **37**: 17 (1962).

Authors' address: Drs. FARID P. KHOURI, MICHAEL J. SHARID and STEPHAN YEREMIANIAN, American University Hospital, Beirut (Lebanon).

## A Trial of Slow Release Ferrous Sulphate (Ferrogradumet®) in Prevention of Iron Deficiency in Pregnancy

R. W. BURALEM, L. POLLER and H. WACKS

We have attempted to assess the effectiveness of a slow release ferrous sulphate tablet given once daily as opposed to conventional ferrous sulphate given three times daily in the prevention of anaemia.

An ideal situation for the study of such preparations arises during pregnancy which results in iron deficiency in a considerable proportion of patients when prophylactic iron is not administered. A controlled trial has, therefore, been performed of slow-release ferrous sulphate with folic acid supplement, studied in parallel with a conventional ferrous sulphate tablet and folic acid. A large number of ante-natal patients attending a general maternity hospital has been followed.

### *Method*

The effectiveness of the slow release iron in the prevention of anaemia was evaluated by means of two large parallel groups of ante-natal patients. It was found advisable to use alternate clinics for the selection of patients for the two groups. Two booking clinics every week are held at this hospital. They were identical in all respects.

The series covered initially all patients attending the booking clinic for the first time over three-month period (September 1963–December 1963). Details were recorded of age, parity, gravidity and previous illnesses. Initial tests included haemoglobin, examination of blood film and urine bacteriology.

Routinely haemoglobin readings are expressed grams per cent. For convenience in the analysis percentage haemoglobin figures were used 100% = 14.6 g with the conventional cyanmethaemoglobin standard.

All patients were given 3 months supply of slow release ferrous sulphate (Ferrogradumet) and folic acid, or combined conventional ferrous sulphate/folic acid. The former group took one tablet daily containing 103 mg elemental iron and one 5 mg folic acid tablet, and the latter group took one tablet three times daily giving a total of 180 mg elemental iron daily and an equivalent dose of folic acid.

Normal patients were not seen again until 30 weeks in the ante-natal clinic following general practitioner care.

From the 30th week of gestation onwards each patient had regular haemoglobin check (capillary finger prick cyanmethaemoglobin) at least once every 4 weeks, although in some cases the haemoglobin was repeated weekly or fortnightly.

If the haemoglobin was below 10.2 g (70%) venous specimen was taken for absolute values. If the venous haemoglobin was found to be less than 10.2 g routine serum iron, B<sub>12</sub> and folate were advised. In some cases marrow aspiration was performed.

All patients had haemoglobin estimation just prior to delivery and, in nearly all cases within 48 h *post partum*. During the ante-natal period, not was taken of urinary infection, toxemia, bleeding, hyperemesis and various complications as well as the number of abortions, stillbirths, live births, premature and multiple births and perinatal deaths.

Finally the need for parenteral iron *pre* or *post partum* or any change in the regime of slow release ferrous sulphate to any other form of iron was noted.

Subjective data were not included, e.g. whether the patients said they were taking their tablets, whether they suffered nausea or constipation. It was assumed that with such large numbers this would be reflected in the haemoglobin level.

### Results

Of 472 patients in the trial, 228 received slow release ferrous sulphate and folic acid and 224 were given folic acid and ferrous sulphate in conventional combined form. The mean parity of the slow release group was 1.5 and 1.6 with the conventional group. The mean age was 26 years in both groups.

Ten patients were lost from each group because of confinement at another hospital, abortions, etc. The percentage of patients given parenteral iron was identical at (11.4%) in both groups. Nine additional patients were lost from the slow release iron group because they were changed to other oral iron preparations at some stage during the trial.

The effect on haemoglobin levels was as follows. The mean haemoglobin figure after delivery was 79.3% for the slow release groups and 78.7% for the other group. The weekly mean haemoglobin levels are seen in table I. Patients who were anaemic had more frequent estimations of their haemoglobin their results were analysed separately (table II). There were 54 patients with initial haemoglobin of less than 10.2 g in the slow release ferrous sulphate series and 60 patients in the conventional series. Their mean haemoglobins at delivery were 81.1% and 80.3% respectively. There was no significant difference in the speed of response of anaemic patients to the two preparations when analysed on a weekly basis using students 't test' (table II). The gross incidence of anaemia in the two groups seemed to be very close and there was no significant difference between the groups.

Table I. Mean IFb levels, %

Weeks	14	28	29	30	31	32	33	34	35	36	37	38	39	40	Post partum
Slow release ferrous sulphate	79.4	76.5	78.9	78.0	77.9	78.5	78.12	78.7	80.2	80.2	80.4	81.7	81.7	81.2	79.5
Ferrous sulphate folic acid	82.6	76.6	79.9	77.9	78.2	77.9	79.3	79.3	81.5	80.4	80.1	80.5	81.5	80.5	78.7
Mean of 37th-40th week levels = 81.5%															
Mean of 37th-40th week levels = 80.6%															

Table II. Mean IFb levels (%) of patients with 10.2 g and under at initial reading (excluding patients given parenteral iron)

Weeks	Initial	28	29	30	31	32	33	34	35	36	37	38	39	40	Post partum
Slow release ferrous sulphate	69.5	70.9	76.5	77.6	76.1	74.9	75.3	78.2	77.6	78.9	79.6	79.7	80.5	79.1	80.6
Ferrous sulphate folic acid	68.2	71.0	72.5	72.4	72.2	72.7	74.7	73.0	75.9	77.5	76.3	78.4	78.9	76.5	79.6

The incidence of complications of pregnancy was as follows. In the slow release iron group urinary infections 19 (8.3 %) antepartum haemorrhage 2, hyperemesis 1 in the conventional iron group urinary infections 17 (6.9 %) antepartum haemorrhage 4 hyperemesis 1. Premature births were 7 and 11 respectively and the number of ante-natal admissions for various causes was 38 in the slow release iron, and 45 in the other group.

### *Discussion*

At the start of the trial the two groups of patients appeared identical. Their ages and parity were similar. During the trial obstetrical complications, were similar. There was no increase in the number of premature births, abortions or stillbirths. Ante-natal admission rates were similar in the two groups and the number of patients who had hospital admission for investigation of anaemia was insignificant.

The incidence of non-responsive anaemia in patients treated with prophylactic iron and folic acid is of interest. In both series this was 11.4 %. There is thus a hard core of cases in whom anaemia was not prevented by a prophylactic regime. Similar figures have been reported in the literature. HEMMESEN [2] found that regardless of the combination of oral agent used approximately 10 % of patients remained anaemic. CHISHOLM [1] in a survey in Oxford found an incidence of anaemia of 12 % in spite of prophylactic iron therapy.

It appears that the one tablet daily regime of the administration of slow release iron is as effective clinically as giving iron three times daily in conventional form. As the amount of elemental iron is less in the slow release tablets it must be assumed that absorption is more efficient. It does not appear however that this regime is significantly better clinically in the prevention of anaemia.

If the patients' acceptability of the new preparation had been superior to conventional iron it might be assumed that the mean haemoglobin would have been maintained at a higher level or that the incidence of anaemia would have been less due to the elimination of cases unable to tolerate conventional ferrous sulphate.

The analysis of the anaemic cases showed that the two preparations were equivalent in their long term effects, no significant difference being found in the two groups at term. Although the differences were not significant the results do perhaps suggest that the response to slow release ferrous sulphate may have been more rapid and this is also



suggested by the higher number of anaemic patients in the conventional ferrous sulphate group who required parenteral iron. Similar accelerated response has been suggested by ISRAËLS and COOK [3] in the treatment of established anaemia. This trial however was not designed to assess the speed of response of established anaemias.

Conventional ferrous sulphate is used on a large scale in hospitals in this country and is consequently extremely cheap. The cost of a combined conventional ferrous sulphate/folic acid tablet for a 28 week course per patient is 4/6d. The preparations of slow release ferrous sulphate (Ferrogradumet®) used in this study is much more expensive, the current cost for a 28 week course at the best hospital price being over 30/ per patient. There might be a case for routine use of the slow release ferrous sulphate if substantial benefit could be shown. In the present study we have found no significant benefit in the prevention of anaemia in pregnancy as distinct from the treatment of established anaemias.

### *Acknowledgment*

We are grateful to Abbott Laboratories for some statistical assistance with the trial and for supplies of Ferrogradumet® and Dr A. ASHLEY, Resident Clinical Pathologist, for help in the early stages of the study.

### *Summary*

A trial of the effectiveness of slow release, once daily preparation of ferrous sulphate has been performed in the prevention of anaemia in pregnancy. The control group consisted of parallel large series of pregnant women given conventional ferrous sulphate three times daily. There was no significant difference in the incidence of anaemia, side-effects and complications in the two groups. The once daily regime was as good as, but no better than conventional ferrous sulphate in the prevention of anaemia, although there may be more rapid response in patients with established anaemia.

### *References*

1. CROSSLAND, M. A controlled clinical trial of prophylactic folic acid and iron in pregnancy. *J. Obstet. Gynaec. Brit. Comm.* 73, 191 (1966).
2. HENDERSON, P. A. Anaemia of pregnancy. *Obstet. Gynec., N.Y.* 24, 752 (1964).
3. ISRAËLS, M. C. G. and COOK, T. A. New preparations for oral iron therapy. *Lancet* ii: 634 (1963).

Authors' address: Drs R. W. BURNHAM, L. POLLER and H. WACKS, Watlington Hospital, Department of Haematology, West Didsbury, Manchester 20 (England).

I. Medizinische Klinik der Johann-Wolfgang-Goethe-Universität Frankfurt am Main  
(Direktor: Prof. Dr. W. Sasse)

## Untersuchungen über den Einfluss von Natrium-Oleat auf die Aggregation menschlicher Thrombozyten

A. M. EIRLY, H. DÖPFEN-SCHMIDT und E. BÖHLE

Die Bedeutung der Blutfette für die Entstehung von Thrombozytenaggregaten im Zusammenhang mit Störungen der Hämostase und der Mikrozirkulation ist in den letzten Jahren zunehmend diskutiert worden. Besondere Beachtung verdienen hier die unveresterten Fettsäuren des Plasmas (UFS) die sowohl unter physiologischen als auch unter pathophysiologischen Bedingungen erheblichen Konzentrationsänderungen unterliegen. Über den Einfluss erhöhter Konzentrationen von langkettigen unveresterten Fettsäuren, speziell von Ölsäure auf die Plättchenaggregation liegen allerdings widersprüchliche Angaben vor [1 & 15-16]. Nach eigenen Beobachtungen bewirken sowohl der Zusatz von Ölsäure oder Natrium-Oleat zu Blut *in vitro* als auch eine Erhöhung der Konzentration der unveresterten Fettsäuren *in vivo* eine Disaggregation von Erythrozytenaggregaten [9-10-13]. In der vorliegenden Arbeit wurde untersucht, ob der Zusatz von Natrium-Oleat zu plättchenreichem Plasma eine Aggregation der Thrombozyten *in vitro* bewirkt, und ob verschiedene Konzentrationen von Natrium-Oleat eine ADP-induzierte Thrombozytenaggregation verstärken oder abschwächen können.

### *Material und Methode*

Nüchternblut gesunder Probanden beiderlei Geschlechtes zwischen 17 und 41 Jahren wurde durch Punktion der V. can. cubitalis gewonnen, wobei die ersten ml verworfen wurden.

Herrn Prof. Dr. W. Sasse zum 60. Geburtstag

Das Blut wurde in silikonierten Gläsern aufgefangen, in denen so viel Natrium-Zitrat-Lösung vorlag, dass eine Endkonzentration von 3,8% im Blut erreicht wurde. Plättchenreiches Plasma wurde durch 20 min dauerndes Zentrifugieren des Blutes bei 300 g, plättchenfreies Plasma durch 20minütiges Zentrifugieren des plättchenreichen Plasmas bei 2000 g erhalten. Die Extinktionsmessungen wurden mit einem Eppendorf-Fotometer mit dem Filter 578 durchgeführt. In Abänderung der von Böck [4] beschriebenen Methode wurde die Durchmischung des plättchenreichen Plasmas mit Natrium-Oleat bzw. Natrium-Oleat und ADP durch Klippen der Gläsern und Küvetten ersetzt. In der Originalmethode [4] wird das plättchenreiche Plasma durch Rotation eines Schieberrings gerührt (stirring). Die infolge der verwendeten hohen Umdrehungszahl des Rührflüsschens von 1000 U/min verursachte mechanische Belastung der Thrombocyten ist gross genug, um einen Teil der Plättchen zu zerstören [3]. Die dabei freierwerdenden Substanzen, insbesondere ADP, können selbst eine Aggregation der Thrombocyten auslösen. In einer Mitteilung von Gross *et al.* [14] wurde die Bock'sche Originalmethode ebenfalls so verändert, dass keine mechanische Alteration der Thrombocyten mehr eintritt.

Nach Zusatz der einzelnen Substanzen zum plättchenreichen Plasma (PRP) wurden die Gläsern mit Parafilm verschlossen und zunächst 20mal gekippt. Die Extinktionen wurden dann in einseitigen Ablesungen gemessen, beginnend jeweils 60 sec nach Substanzzugabe. 15 sec vor jeder folgenden Ablesung wurde die Küvette wiederum 5mal gekippt. So konnte bei ausreichender Durchmischung des Plasmas eine Sedimentation der Thrombocytenaggregats vermieden werden [8]. Parallel zu jedem untersuchten plättchenreichen Plasma wurde ein Kontrollplasma des gleichen Probanden mitgeführt, dem anstelle der Testsubstanzen ein gleiches Volumen physiologischer Kochsalzlösung zugegeben wurde.

Alle Versuche wurden bei Zimmertemperatur (20 bis 22° C) und unmittelbar im Anschluss an die Blutentnahmen vorgenommen. Sämtliche Zusätze zum Plasma erfolgten in Form von 0,1 ml Lösung der entsprechenden Substanzen in physiologischer Kochsalzlösung. Dabei wurden die Konzentrationen dieser Lösungen so gewählt, dass 0,1 ml ad 5 ml Plasma die angegebenen Konzentrationen, bezogen auf Plasma, ergaben. Natrium-Oleat (Riedel-de-Haen AG, Seelze) wurde in 0,9% NaCl gelöst. Als aggregationslösende Substanz wurde das Triammoniumsalz des Adenosin-3-Diphosphats der Fa. C. F. Boehringer und Söhne, Mannheim, in einer Endkonzentration von  $2 \times 10^{-4}$  M/l verwendet. Die Lösung wurde täglich neu hergestellt. Alle Geräte, die mit Blut oder Plasma in Berührung kamen, wurden nach den üblichen Vorschriften sterilisiert. Die Genauigkeit der Extinktionsmethode ergab bei Wiederholungsmessungen eine maximale Abweichung von nur 2,63% [8]. Ein Schema der Versuchsanfänge zeigt Abb. 1



Abb. 1. Schema des Ablaufs der Versuche.

## Ergebnisse

### 1 Einfluss von Natrium-Oleat auf die Aggregation von Thrombozyten in plättchenreichem Plasma

Jeweils 8 plättchenreiche Plasmen wurden auf 10 20 40 80 und 160 mg% Natrium-Oleat Konzentration gebracht. Parallel zu jedem Messwert wurde ein Kontrollversuch mit physiologischer Kochsalzlösung mitgeführt. Die Beobachtungsdauer betrug 5 Minuten nach Zugabe von Natrium-Oleat bzw. physiologischer Kochsalzlösung zu plättchenreichem Plasma. In Vorversuchen [8] hat es sich ergeben, dass eine längere Beobachtungsdauer nicht erforderlich ist.

Die Abb. 2 zeigt den Extinktionsverlauf 8 verschiedener plättchenreicher Plasmen nach Natrium-Oleat Zusatz von 20 mg%. Die Extinktionskurven der Kontrollversuche mit physiologischer Kochsalzlösung verliefen deckungsgleich mit den eingezeichneten Kurven. Wie in allen folgenden Abbildungen sind auch hier die Extinktionen der plättchenreichen Plasmen abzüglich der Extinktionswerte der jeweiligen plättchenfreien Plasmen aufgeschrieben worden. Die unterschiedlichen Ausgangshöhen der Kurven sind Ausdruck der in den verschiedenen Plasmen der einzelnen Probanden erhaltenen verschiedenen Anzahl von Blutplättchen. Aus der Abb. 2 ist ersichtlich, dass nach Zugabe von 20 mg% Natrium-Oleat zu plättchenreichem Zitratplasma keine Extinktionsveränderung gegenüber den entsprechenden NaCl-Kontrollversuchen erfolgte. Analog dazu verliefen auch die Untersuchungen mit 10 40, 80 und 160 mg% Natrium-Oleat. In keinem der insgesamt 40 untersuchten plättchenreichen




Abb. 2. Die Wirkung von Natrium-Oleat (20 mg%) auf die Aggregation der Thrombozyten in FRP. Die Extinktionskurven der NaCl-Kontrollversuche verliefen deckungsgleich mit den eingezeichneten Kurven. Die Ziffern 1-8 bezeichnen die verschiedenen Plasmen.

Das Blut wurde in silikonierten Glaschen aufgefangen, in denen so viel Natrium-Zitrat-Lösung vorlag, dass eine Endkonzentration von 3,8% im Blut erreicht wurde. Plättchenreiches Plasma wurde durch 20 min dauerndes Zentrifugieren des Blutes bei 500 g, plättchenfreies Plasma durch 20minütiges Zentrifugieren des plättchenreichen Plasmas bei 2000 g erhalten. Die Extinktionsmessungen wurden mit einem Eppendorf-Photometer mit dem Filter 578 durchgeführt. In Abänderung der von Boser [4] beschriebenen Methode wurde die Durchmischung des plättchenreichen Plasmas mit Natrium-Oleat bzw. Natrium-Oleat und ADP durch Klappen der Glaschen und Küvetten ersetzt. In der Originalmethode [4] wird das plättchenreiche Plasma durch Rotation eines Stäbchens gerührt (stirrlog). Die infolge der verwendeten hohen Umdrehungszahl des Rührstäbchens von 1000 U/min verursachte mechanische Belastung der Thrombozyten ist gross genug, um einen Teil der Plättchen zu zerstören [3]. Die dabei freierwerdenden Substanzen, insbesondere ADP, können selbst eine Aggregation der Thrombozyten auslösen. In einer Mitteilung von Gans *et al.* [14] wurde die Boser'sche Originalmethode ebenfalls so verändert, dass keine mechanische Alteration der Thrombozyten mehr eintritt.

Nach Zusatz der einzelnen Substanzen zum plättchenreichen Plasma (PRP) wurden die Glaschen mit Parafilm verschlossen und zunächst 20mal gekippt. Die Extinktionen wurden dann in einminütigen Abständen gemessen, beginnend jeweils 60 sec nach Substanzzugabe. 15 sec vor jeder folgenden Ablesung wurde die Küvette wiederum 10mal gekippt. So konnte bei ausreichender Durchmischung des Plasmas eine Sedimentation der Thrombozytenaggregate verhindert werden [8]. Parallel zu jedem untersuchten plättchenreichen Plasma wurde ein Kontrollplasma des gleichen Probanden mitgeführt, dem ausser der Testsubstanzen ein gleiches Volumen physiologischer Kochsalzlösung zugegeben wurde.

Alle Versuche wurden bei Raumtemperatur (20 bis 22° C) und unmittelbar im Anschluss an die Blutentnahmen vorgenommen. Sämtliche Zugätze zum Plasma erfolgten in Form von 0,1 ml Lösung der entsprechenden Substanzen in physiologischer Kochsalzlösung. Dabei wurden die Konzentrationen dieser Lösungen so gewählt, dass 0,1 ml ad 5 ml Plasma die angegebenen Konzentrationen, bezogen auf Plasma, ergaben. Natrium-Oleat (Riedel-de-Haen AG, Seitz) wurde in 0,9% N Cl gelöst. Als aggregationsinduzierende Substanz wurde das Trinatriumsalz des Adenosin-5-Diphosphats der Fa. C.F. Boehringer und Söhne, Mannheim, in einer Endkonzentration von  $2 \times 10^{-4} M$  verwendet. Die Lösung wurde täglich neu hergestellt. Alle Geräte die mit Blut oder Plasma in Berührung kamen, wurden nach den üblichen Vorschriften silikoniert. Die Genauigkeit der Extinktionsmethode ergab bei Wiederholungsmessungen eine maximale Abweichung von nur 2,63% [8]. Ein Schema des Versuchsablaufs zeigt Abb. 1.




Abb. 1 Schema des Ablaufs der Versuche.

5 min nach ADP Zusatz ist im allgemeinen das Maximum der Thrombozytenaggregation erreicht (Abb. 3). So wie am Beispiel dieses Einzelversuches mit einer Natrium-Oleat Konzentration von 20 mg% gegenüber der Kontrolle mit NaCl-Zusatz zu plättchenreichem Plasma dargestellt (Abb. 3) wurden für jeden Einzelversuch entsprechende Kurven aufgezeichnet, so dass für jede Natrium-Oleat Konzentration jeweils 8 Kurvenpaare erhalten wurden. Aus diesen 8 Kurvenpaaren wurden Mittelwerte errechnet und graphisch aufgetragen (Abb. 4 und 5).

Die Abb. 4 zeigt die arithmetischen Mittelwerte der Extinktionen 8 verschiedener plättchenreicher Plasmen nach ADP Zugabe.

Bei Zusatz von Natrium-Oleat in einer Konzentration von 10 mg lagen die Extinktionswerte nach ADP Zugabe geringgradig höher als bei den Kontrollversuchen, was einer Verringerung der Thrombozytenaggregation entspricht.




Abb. 4 Kurven der arithmetischen Mittel der Extinktionswerte ( $E$ ) je 8 verschiedener PRP nach ADP-Zugabe ( $2 \times 10^{-4}$  M/l). — Plättchenreiche Plasmen mit Natrium-Oleat in einer Konzentration von 10 mg% (a) 20 mg% (b) 40 mg% (c), 60 mg% (d), 160 mg% (e). — Vergleichsproben der gleichen Plasmen, die NaCl anstelle von Natrium-Oleat enthalten. Natrium-Oleat bzw. NaCl wurden bei  $t = 0$  min cluipiert, ADP bei  $t \approx 5$  min.

Plasma wurde durch Natrium-Oleat Zusatz eine Extinktionsänderung gefunden. Auch mikroskopisch waren nach Natrium-Oleat Zusatz bis 80 mg% keine Thrombozytenaggregate nachzuweisen lediglich bei einer Plasmakonzentration von 160 mg% Natrium-Oleat waren vereinzelt Thrombozytenaggregate zu finden.

## 2. Einfluss verschiedener Natrium-Oleat Konzentrationen auf die ADP-induzierte Thrombozytenaggregation

Jeweils 11 plättchenreiche Plasmen wurden auf 10 20 40 80 und 160 mg% Natrium-Oleat Konzentration gebracht. 5 min nach dem Zusatz von Natrium-Oleat zu den plättchenreichen Plasmen wurde ADP Lösung zupipettiert. Wie sich aus Vorversuchen ergab, ist es unerheblich, ob zunächst ADP und dann Natrium-Oleat dem plättchenreichen Plasma zugesetzt wird oder ob umgekehrt vorgegangen wird [8]. Die Wirkung von Natrium-Oleat auf eine ADP-induzierte Aggregation von Thrombozyten ist aus dem Vergleich zu den in jedem Fall mitgeführten Kontrollversuchen (Zusatz von physiologischer Kochsalzlösung anstelle von Natrium-Oleat Lösung) ersichtlich. Es sollte so nachgewiesen werden, ob eine ADP-induzierte Thrombozytenaggregation durch Zusatz von Natrium-Oleat in verschiedenen Plasmakonzentrationen verstärkt oder vermindert wird.

Wie Abb 3 zeigt, kommt es innerhalb der ersten beiden Minuten nach Zusatz von ADP zu plättchenreichem Plasma zu dem bekannten Extinktionsabfall (Absinken der optischen Dichte). Gleichzeitig lassen sich schon makroskopisch Thrombozytenaggregate nachweisen.




Abb. 3 Änderung der Extinktion eines PRP nach ADP-Zusatz ( $2 \times 10^{-6}$  M). ●-●-● PRP mit Natrium-Oleat in einer Konzentration von 20 mg%. ○-○-○ PRP mit NaCl anstelle von Natrium-Oleat. Natrium-Oleat bzw. NaCl wurden zur Zeit 0 zupipettiert, ADP 5 min später.




Abb 5. Extinktionsdifferenzen zwischen Mess- (Natrium-Oleat-) und Kontroll- (NaCl-) Plasmen in Abhängigkeit von den geprüften Natrium-Oleat-Konzentrationen. Die schweren Quadrate geben die Mittelwerte der Extinktionsdifferenzen an. Ordinate: Unterschiede der optischen Dichte zwischen Mess- und Kontrollplasma, gemessen in Zinkblechen der Extinktionsdichte des benutzten Gerätes.

tistische Signifikanz sowohl für die desaggregierende Wirkung von Natrium-Oleat in Konzentrationen von 10 und 20 mg% als auch für die aggregierende Eigenschaft von Natrium-Oleat Konzentrationen über 40 mg% ist aus der Abb 5 deutlich ersichtlich (Zeichentext) eine weitergehende statistische Prüfung hatte sich deshalb erübrigt.

### Diskussion

Der Ölsäure, als einer einfach ungesättigten  $C_{18}$ -Fettsäure, kommt deswegen besondere Bedeutung zu, weil sie von den im Plasma vorkommenden unveresterten Fettsäuren den höchsten Anteil ausmacht [19]. In menschlichem Plasma, das bei einem pH von 7,4 eine grosse Pufferkapazität besitzt, sind die unveresterten Fettsäuren nahezu vollständig dissoziiert, da Fettsäuren als Essigsäure-analoge Carbonsäuren einen pK (wässrige Lösung) von 4,7 bis 5,0 aufweisen. Der Zusatz von Natrium-Oleat zu Blut in Konzentrationen bis 120 mg% verändert den pH des Blutes bzw. Plasmas nicht [12]. Die Wirkungen auf Erythrozyten [13, 12, 10] und Thrombozyten sind demnach dem Fettsäureanion zuzuschreiben.

Aus den vorliegenden Ergebnissen geht hervor, dass Zusatz von Natrium-Oleat zu Plasma in Konzentrationen bis 40 mg/100 ml eine partielle Desaggregation von Plättchenaggregaten bewirkt. Hohe Konzentrationen von Natrium-Oleat über 40 mg% verstärken demgegenüber die ADP induzierte Thrombozytenaggregation. Diese



Befunde stehen teilweise im Widerspruch zu den Ergebnissen anderer Autoren. Hierfür dürften an erster Stelle methodische Unterschiede verantwortlich sein. Von HOAK *et al.* [16] sowie MAHADEVAN *et al.* [18] wurde nachgewiesen, dass Natrium-Oleat sowohl auf gewaschene Thrombozyten als auch auf Thrombozyten in plättchenreichem Plasma aggregationsfördernd wirkt. Relativ niedrige Natrium-Oleat Konzentrationen (bis 60 mg %) aggregierten nach weiteren Feststellungen jedoch lediglich gewaschene Thrombozyten, nicht aber Blutplättchen in Plasma [16]. Die gleichen Verfasser konnten weiterhin nachweisen, dass die aggregierende Wirkung des Natrium-Oleates auf gewaschene Thrombozyten durch vorherigen Zusatz von ausreichend Albumin nahezu aufgehoben werden kann. ARDLE *et al.* [1] fanden bei niedrigen Oleat Konzentrationen weder eine aggregierende Wirkung des Natrium-Oleates in plättchenreichem Plasma noch eine Beeinflussung der ADP-induzierten Plättchenaggregation. Die Anwesenheit von Serumalbumin ist offenbar bei *in vitro*-Untersuchungen über die Plättchenaggregation von entscheidender Bedeutung, da dem Plasma zugesetzte Ölsäure bzw. Natrium-Oleat nicht frei vorliegt, sondern an Albumin gebunden wird [11, 16]. Auch die unveresterten Fettsäuren des Plasmas *in vivo* sind an Albumin gebunden. «freie» Ölsäure (ohne Bindung an Plasmaalbumin) kommt *in vivo* praktisch nicht vor. Die fehlende aggregierende Wirkung von Natrium-Oleat in Konzentrationen unter 40 mg % auf im Plasma suspendierte Thrombozyten dürfte daher Folge einer Symplexbildung zwischen dem Albumin und dem Oleat Anion sein, so dass es nicht zu einer direkten Beeinflussung von freiem, nicht an Albumin gebundenem Natrium-Oleat auf die Blutplättchen kommt.

Unter diesen Gesichtspunkten sind auch die Ergebnisse von HOAK *et al.* zu erklären, die das Auftreten von Thromben in den Lungen von Versuchstieren nach intravenösen Injektionen von Albuminlösungen mit hohen Natrium-Oleat Konzentrationen beschrieben [15, 16]. Möglicherweise bestand bei der grossen Menge von zugesetztem Natrium-Oleat zur injizierten Albumin-Lösung keine quantitative Bindung der Fettsäureanionen an das Albumin, so dass freies, nicht gebundenes Natrium-Oleat direkt auf die Plättchen einwirken konnte. Ähnliche Vorbehalte wie für die Arbeiten von HOAK *et al.* gelten auch für die Ergebnisse von ZANDEN [20] und DAY [6], die nach Natrium-Oleat Infusionen bei Tieren eine Thrombopenie beobachteten.

Intravital erfolgt der Anstieg der Konzentration der unveresterten Fettsäuren bei Stresszuständen beim Rauchen und während

des Hungers relativ langsam und auf das gesamte Plasmavolumen verteilt. Bei der therapeutischen Anwendung von Heparin und Heparinoiden kommt es zu einem relativ schnellen Anstieg der unveresterten Fettsäuren im Plasma, wobei die Fettsäuren quantitativ an Albumin gebunden sind. Die durch Heparininjektionen ausgelöste Erhöhung der Konzentration an unveresterten Fettsäuren übersteigt jedoch im allgemeinen nicht 40 mg% und liegt demnach in einem Konzentrationsbereich, der nach den vorliegenden Ergebnissen eine leichte desaggregierende Wirkung auf Thrombozytenaggregate aufweist.

Die partiell desaggregierende Wirkung von Natrium-Oleat in Konzentrationen bis 40 mg% auf ADP induzierte Thrombozytenaggregate zeigt eine auffallende Parallelität zu der früher beschriebenen desaggregierenden Wirkung von Natrium-Oleat auf Erythrozytenaggregate [13]. Während jedoch für Erythrozytenaggregate bei höheren Konzentrationen die desaggregierende Wirkung zunimmt, ist dies bei Thrombozytenaggregaten nicht der Fall (s. Abb. 5). Die Ursache der thrombozytendesaggregierenden Wirkung von Natrium-Oleat in geringen Konzentrationen und der aggregationsfördernde Effekt von hohen Konzentrationen von Natrium-Oleat konnten bisher nicht gefunden werden. Bei Erythrozytenaggregaten erfolgt die Desaggregation über eine Abrundung der Zellen (bikonvexe Erythrozyten). Der Nachweis eines entsprechenden oder ähnlichen Mechanismus für die Thrombozytendesaggregation nach Zusatz geringer Konzentrationen von Natrium-Oleat gelang mit den üblichen Methoden (Phasenkontrastmikroskop) nicht.

Der Hemmung der Aggregation der Thrombozyten kommt im Zusammenhang mit der Prophylaxe und der Therapie thromboembolischer Erkrankungen und möglicherweise auch bestimmter Schockzustände eine besondere Bedeutung zu, da die Zusammenlagerung der Thrombozyten einen massgeblichen pathogenetischen Faktor dieser Erkrankungen darstellt. Nach DEUTSCH [7] BÖHLE *et al.* [2] ZWEITLER [21] und anderen Autoren ist weiter die Möglichkeit zu diskutieren, dass arteriosklerotischen Frühveränderungen über eine Minderung der Thrombozytenaggregation zu begegnen ist. Die vorliegenden Untersuchungen mit Natrium-Oleat ergaben eine leicht desaggregierende Wirkung auf Thrombozytenaggregate bei physiologisch denkbaren Konzentrationen. Den Salzen anderer unveresteter Fettsäuren (z. B. Palmitinsäure, Stearinsäure) wird eine aggregationsfördernde Wirkung auf Thrombozyten nachgesagt [5 16 17 18]. Dabei wurden aller

dings relativ hohe Fettsäurekonzentrationen untersucht. Angesichts der Tatsache, dass Natrium-Oleat ein bivalentes Verhalten in Beziehung auf die Thrombozytenaggregation zeigt, erscheinen entsprechende Untersuchungen mit niedrigen Konzentrationen anderer Fettsäuren angezeigt.

### *Zusammenfassung*

Mit einer Modifikation der Bornschen Methode zur Messung der Thrombozytenaggregation wurde die Wirkung verschiedener Konzentrationen von Natrium-Oleat sowohl auf Thrombozyten als auch auf ADP-induziert Thrombozytenaggregate untersucht. Es ergab sich, dass Natrium-Oleat Konzentrationen bis 80 mg/100 ml Plasma keine Aggregation der Thrombozyten verursacht. Die Wirkung von Natrium-Oleat auf bereits bestehende Thrombozytenaggregate ist verschieden. Während niedrige, physiologisch denkbare Konzentrationen bei 40 mg% eine leicht Disaggregation von Thrombozytenaggregaten bewirken, führen Natrium-Oleat Konzentrationen über 40 mg% zu einer Verstärkung der bereits vorhandenen Thrombozytenaggregation.

### *Summary*

Aggregation of platelets has been studied *in vitro* by a modification of Born's method. It could be shown, that addition of sodium-oleate to platelet rich human plasma does not cause platelet aggregation in concentrations up to 80 mg%. When platelets in plasma had been aggregated by ADP before, the addition of sodium oleate in concentrations up to 40 mg% leads to a partial disaggregation of the platelet aggregates, while higher concentrations enhance the aggregation of platelets.

### *Literatur*

1. ARDRE, N. G.; KIDDOON, R. L., GLEW, G. and SCHWARTZ, C. J.: Fatty acids and *in vitro* platelet aggregation. *Austral. J. exp. Biol. med. Sci.* 44: 105-110 (1966).
2. BÖCKL, E.; BAUER, J.; HARTMUTH, E. und BRENNER, K.: Untersuchungen über die Agglutination der Erythrozyten nach Zufuhr verschiedener Nahrungsfette. *Klin. Wochschr.* 45: 555-562 (1963).
3. BORN, G. V. R.: Aggregation of blood platelets by adenosine diphosphate and its reversal. *Nature Lond.* 194: 927-929 (1962).
4. BORN, G. V. R. and CROOK, M. J.: The aggregation of blood platelets. *J. Physiol. Lond.* 159-178 (1963).
5. CORWICK, W. E., HOAR, J. G. and WARNER, E. D.: The role of lipids in thrombosis. I. Pathogenesis and treatment of thromboembolic diseases, pp. 195-206 (Schattner, Stuttgart 1966).
6. DAY, H. J.; FRIWELL, W. and SOLOVY, L. A.: Thrombosis in the dog produced by single rapid infusions of long chain saturated fatty acids. *Amer. J. med. Sci.* 233: 115-123 (1967).
7. DEUTSCH, E.: Die Antikoagulantien in der Therapie der peripheren arteriellen Durchblutungsstörungen. *Wien. klin. Wochschr.* 76: 151-153 (1964).

8. DÖRRSCHNEIDER H.: Untersuchungen über den Einfluss des Natriumoleates der Ölsäure als Vertreter der unversäeterten Fettsäuren des Plasmas auf die Aggregation menschlicher Thrombozyten. Inaug. Diss. Mainz (1968).
9. ESKILY A. M. Untersuchungen über Wirkung und Wirkungsmechanismus verschiedener oberflächenaktiver Substanzen und Pharmaka auf Erythrozytenaggregate die Blättchenperchenabsenkungsgeschwindigkeit, die Viskosität und den Hämatokrit menschlichen Blutes. *Ärztl. Forsch.* 21 323-334 (1967).
10. ESKILY A. M. Wirkung und Wirkungsweise unversäeteter Fettsäuren auf die Viskosität des Blutes. Proc. 1st int. Conf. on Hemorheology- Reykjavik/Island 1966 (Pergamon Press, im Druck).
11. ESKILY A. M., GRAMLICH, F. und MÜLLER, H. E.: Die Verteilung von <sup>125</sup>Jod-markierter Ölsäure zwischen Plasma und Erythrocyten. *Blut* 11 284-290 (1963).
12. ESKILY A. M.; GRAMLICH, F. und MÜLLER, H. E. Über den Einfluss von Lipiden, insbesondere von unversäeterten Fettsäuren auf den Mechanismus der Blättchenperchenabsenkungsgeschwindigkeit. *Klin. Woch.* 17 943-946 (1965).
13. ESKILY A. M. und MÜLLER, H. E. Aggregation und Disaggregation von Erythrocyten. *Acta haemat., Basel* 30 323-334 (1966).
14. GAGNÉ, R.; NEDERER, G. und REYTER, H. Untersuchungen über die Aggregation menschlicher Blättchen. I. Standardisierte Methoden zur quantitativen Bestimmung der Aggregation. *Klin. Woch.* 45: 931-939 (1967).
15. HOAG, J. C., CORVOIR, W. E. and WARDER, E. D. Thrombogenic effects of albumin-bound fatty acids. *Arch. Path.* 81 136-139 (1966).
16. HOAG, J. C., WARDER, E. D. and CORVOIR, W. E. Platelets, fatty acids and thrombosis. *Circulat. Res.* 20: 11 17 (1967).
17. KELL, J. W.; FLECK, R.; MACAULEY I. and BROOKE-STEWART B. Platelet-aggregation by phospholipids and free fatty acids. *Lancet* 8: 1296-1299 (1963).
18. MAHADEVAN, V.; SOVO, H. and LUDWIG, W. O. Effects of saturated and unsaturated fatty acids on blood platelet aggregation *in vitro*. *Proc. Soc. exp. Biol., N.Y.* 121 82-85 (1966).
19. SCHLADT, W.; BÖHLE, E.; BRÜCKNER, R.; TEICHER, R. und ULLRICH, B. Gaschromatographische Untersuchungen der Serumfettsäuren des Menschen. III. Die Fettsäuren der Cholesterinester der Phospholipide und Triglyceride, sowie der unversäeterten Fettsäuren bei Gesunden und Arteriosklerotikern. *Klin. Woch.* 43. 739-753 (1960).
20. ZACHARY, G. Transient thrombopenia after intravenous injection of certain fatty acids. *J. lipid Res.* 5 378-384 (1964).
21. ZWISLOCKI, A. J. Impairment of platelet function and thrombus growth in reserpin-treated rabbits. *J. Lab. clin. Med.* 70: 16-22 (1967).

Second Medical Unit, Evangelismos Hospital, Athens

## The Effect of Adrenergic Blockers on the Action of Adrenaline on the Factor VIII Activity in the Plasma

C. GARDIKAS, C. LYBERATOS, J. PYROVOLAKIS and A. PAPAYANNIS

The observation of INGRAM [4] that the intravenous infusion of adrenaline brings about a considerable elevation of the factor VIII activity in the plasma of normal subjects, was confirmed by other workers [3, 7]. According to INGRAM isopropylnoradrenaline and noradrenaline have no similar effect. The mechanism of this action of adrenaline remains unexplained.

AHLQVIST [1] has first shown that the various actions of the sympathomimetic drugs are mediated through two special receptor groups, the  $\alpha$  and  $\beta$  receptors. Adrenaline acts on both types of receptors, noradrenaline on the  $\alpha$ , whilst isopropylnoradrenaline almost exclusively on the  $\beta$  receptors. Various agents block selectively the action on the  $\alpha$  or the  $\beta$  receptors. Thus, tolazoline, phentolamine, benzodioxane, dibenamine and phenoxybenzamine are  $\alpha$ -adrenergic blocking agents, whilst dichloroisoprenaline, pronethalol and propranolol are  $\beta$ -adrenergic blocking agents.

The present paper describes investigations on the effect of  $\alpha$ - or  $\beta$ -adrenergic blocking agents on the action of the adrenaline on the factor VIII activity in the plasma.

### Material and Methods

*Experiment 1.* Ten normal adult males were used. (a) Adrenaline was administered i.v. (160  $\mu$ g in 10 ml of 5% glucose in 10 min). Before and 5 min after the end of the infusion venous blood was collected. (b) Two days later phentolamine (Regitine®), an  $\alpha$ -adrenergic blocker was given by i.v. infusion (10 mg in 200 ml of 5% glucose in 30 min). On the 20th minute of the phentolamine infusion adrenaline was administered as described above in

10 min through veins of the other arm. Five min after the end of the infusion venous blood was collected.

*Experiment II.* Ten normal adult males were used. (a) Adrenaline was administered as described in part (a) of experiment I. Before and 5 min after the end of the infusion venous blood was collected. (b) Two days later and for three consecutive days the subjects received orally propranolol (Inderal®) 60 mg daily divided into 4 six-hourly doses. On the fourth day immediately after the morning propranolol dose adrenaline was injected as described in part (a) of experiment I. Five min after the end of the adrenaline infusion venous blood was collected.

*Assay of factor VIII.* Samples of 9 ml of venous blood taken with siliconized needles and glass syringes were mixed with 1 ml of trisodium citrate ( $\text{Na}_3\text{C}_6\text{H}_5 \cdot 2\text{H}_2\text{O}$  3.8 g/100 ml) in siliconized glass test tube. After centrifugation for 15 min at 300 rpm the plasma factor VIII concentration was assayed immediately by the method described by BECK and LACFARLANE [2]. As reference standard mixed pool of plasma from 10 normal donors stored in 1 ml smoots at  $-30^\circ\text{C}$  was used.

### Results

As the tables I and II show neither Regitine® and  $\alpha$ -adrenergic blocker nor propranolol, a  $\beta$ -adrenergic blocker inhibit the effect of adrenaline on the factor VIII activity of plasma.

The present experiments support the view that the action of adrenaline on the factor VIII activity of the plasma is not mediated through the special receptor groups, as special adrenergic blockers do not inhibit this action. Thus, the mechanism of the rise of factor VIII activity in the plasma produced by adrenaline remains obscure.

Table I. The effect of Regitine® on the action of adrenaline on the factor VIII activity

Experiment	Factor VIII activity in the plasma (% of normal)		
	before adrenaline	adrenaline after administration of	adrenaline + regitine
1	98	185	197
2	102	212	208
3	114	265	253
4	84	206	220
5	108	228	222
6	115	301	307
7	96	185	194
8	101	216	209
9	100	192	202
10	107	227	220

The figures represent the mean value of 3 determinations.

Table II The effect of propranolol on the action of adrenaline on the factor VIII activity

Experiment	Factor VIII activity in the plasma (% of normal)		
	before adrenaline	adrenaline after administration of	adrenaline + propranolol
1	96	214	220
2	102	176	190
3	112	235	228
4	98	206	210
5	98	197	191
6	102	290	262
7	110	198	211
8	98	265	262
9	108	179	188
10	102	221	214

The figures represent the mean value of 5 determinations.

### Discussion

The present experiments show that neither phentolamine, an  $\alpha$ -adrenergic blocker nor propranolol, a  $\beta$ -adrenergic blocker inhibit the effect of adrenaline on the factor VIII activity. These results are in agreement with the findings of McCURE *et al.* [6] that  $\alpha$ -adrenergic blockade with phentolamine did not prevent elevation of factor VIII after adrenaline infusion. On the other hand, INGRAM [5] found that pronethalol a  $\beta$ -adrenergic blocker inhibits the elevation of factor VIII brought about by adrenaline infusion. No plausible explanation for the discrepancy of these findings can be given.

### Acknowledgement

A grant from the Royal Hellenic Research Foundation is gratefully acknowledged.

### Summary

Phentolamine an  $\alpha$ -adrenergic blocker and propranolol,  $\beta$ -adrenergic blocker do not inhibit the effect of adrenaline on the factor VIII activity in the plasma.

*References*

1. ANGLIST R. P. A study of adrenotropic receptors. *Amer. J. Physiol.* **157**: 586 (1948).
2. BOOS, R. and MACFARLANE, R. G.. Human blood coagulation and its disorders 3rd ed., p. 404 (Blackwell, Oxford 1962).
3. EOSTING, O. Changes in the activity of antihæmophilic A factor and in the bleeding time associated with muscular exercise and adrenaline infusion. *Scand. J. clin. Lab. Invest.* **15**: 539 (1963).
4. IVOGRAM, G. I. C. Increase in antihæmophilic globulin activity following infusion of adrenaline. *J. Physiol.* **156**: 217 (1961).
5. IVOGRAM, G. I. C. *Disorders in Haemostasis: Hemophilias*, p. 243. University of North Carolina (Chapel Hill 1964).
6. McCURRY, P. B. IVOGRAM, G. I. C. and JONES, R. V. Platelet changes after adrenaline infusions with and without adrenaline blockers. *Thromb. Diath. hæmorrh.* **15**: 196 (1965).
7. SOLOS, A. Observations on the effect of adrenaline and related substances on blood coagulation phenomena. Thesis, Athens (1962).





Fig. 2. Agar gel electrophoresis in citrate buffer pH 6.0. At the top and the bottom; haemoglobin of the parents of the propositus. In the center: haemoglobin of the propositus and of the other two children, homozygous carriers of  $\beta\beta$ -thalassaemia. Total absence in these three subjects of haemoglobin  $A_2$  and presence of haemoglobin F only.

S. Concetto (II 1, table I, fig. 1) the *father of the propositus* was healthy subject which showed haematologic picture typical of microcythemia and haemoglobin pattern with an elevated level of haemoglobin F (10%) and normal level of haemoglobin  $A_2$  (2.07%). Acid elution test showed quite an heterogeneous intracellular distribution of haemoglobin F.

A. Domenica (II 2, table I, fig. 1) the *mother of the propositus* and first cousin of the father was healthy woman with a haematologic microcythemic picture and a haemoglobin pattern with elevated haemoglobin F (7.50%), normal haemoglobin  $A_2$  (2.30%) and heterogeneous intracellular distribution of haemoglobin F.

A. Gregorio (II 1, table I, fig. 1) *paternal grandfather of the propositus*, was healthy macrocythemic subject with the same haemoglobin characters of the son (haemoglobin F 9.55%, haemoglobin  $A_2$  1.87%) and the same heterogeneous aspect of the intracellular distribution of haemoglobin F.

### Discussion

Both the parents and the paternal grandfather of the patient observed presented the haematologic abnormalities typical of microcythemia (or thalassemia) with high level of haemoglobin F and heterogeneous erythrocytic distribution of haemoglobin F. These data



Fig. 2. Cellulose acetate electrophoresis, glycine buffer pH 8.8. From the top to the bottom the father of the *propositus*—Cooley disease patient—the three sisters, homozygous carriers of  $\beta\delta$ -thalassaemia. Total absence of haemoglobin  $A_2$  and haemoglobin  $A_0$  in the three homozygous subjects.

are typical of F microcythaemia. The three children show a microcythaemic haematologic picture and their haemoglobin is only haemoglobin F. These data suggest that the children are homozygous for F microcythaemia. From the clinical point of view the *propositus* was the only one to present a slight anaemia with moderate hepatosplenomegaly; the other two sisters are in good health, and have no history of illness.

This is the third family reported in the literature in which cases of homozygosity for F microcythaemia have been found. In the first family [20] the *propositus* was a 31-year-old woman with slight pallor and marked hepatosplenomegaly; in the second case [22] the condition was discovered accidentally in a 9-year-old boy. Thus, all these observations agree in showing that the homozygous condition for F microcythaemia causes the subjects to be far less severely affected than the homozygous carriers of  $A_0$ -microcythaemia.

The same tendency towards a milder clinical picture is also found in the patients with double heterozygosity for  $A_2$ - and F microcythaemia.

The cases so far observed include 8 patients with severe Cooley's disease [1, 8, 16-17] and at least 7 other patients with a much less serious disease (microcytic constitutional anaemia or thalassaemia intermedia) [5, 17-19]. In another series [12, 22] most of the 21 patients were moderately affected.

These data show that the F microcythaemia is a microcythaemia variant which interacts with classical  $A_2$  microcythaemia and, besides this, they offer the documentation of new variants of genetic basis of the thalassaemia intermedia that is the homozygosity for  $\beta\delta$ -microcythaemia with high F and the double heterozygosity for this microcythaemia variant and classical  $A_2$  microcythaemia.

The present patients and the two of the literature had haemoglobin F only. Homozygosity for F microcythaemia is thus the third homozygous condition, so far described, in which there is a complete absence of haemoglobin  $A_1$  and haemoglobin  $A_2$ , the other two being homozygous condition for haemoglobin Lepore and homozygous condition for hereditary persistence of foetal haemoglobin and the second condition in which haemoglobin F only is found (the other being homozygosity for high F gene). This proves that in the three families so far described the  $\beta\delta$ -microcythaemia genes completely suppress  $\beta$ - and  $\delta$ -chain synthesis.

There are, till now, only few cases which can supply informative data on the activity of the structural genes  $\beta$  and  $\delta$  in this variant of microcythaemia. The three present and the two preceding homozygotes [10, 21, 22] and the double heterozygote for  $B_2$  haemoglobin and  $\beta\delta$ -microcythaemia [14] show a complete inactivity of locus  $\delta$ . As for locus  $\beta$  in the 5 homozygotes for F microcythaemia and in the 2 double heterozygotes for haemoglobin S and F microcythaemia [4, 6] such locus has proved to be completely inactive in 6 cases and partially functioning in 1 case [4]. It would appear that in F microcythaemia likewise in  $A_2$ -microcythaemia, locus  $\beta$  is in most instances suppressed and rarely partially functioning; as for locus  $\delta$  on the contrary the observations are not sufficient to prove a constant and complete inactivity. A larger number of cases is necessary for the final interpretation of the genic effects of this microcythaemic mutation.

In  $\beta\delta$ -microcythaemia with high F locus  $\gamma$  appears affected in a characteristic way: there is, in the heterozygote state, an evident hyperactivity which has such a constant uniformity as to appear genetically determined. On the contrary, the resulting haemoglobin F is irregularly distributed in the erythrocytes - like in the other forms of

microcythaemia — a fact that would suggest a compensatory mechanism. Therefore the compensatory hyperactivity of locus 7 is typically evident in the F microcythaemia heterozygote, but not in the  $A_2$  microcythaemia heterozygote. Moreover in the  $\beta\delta$ -microcythaemia homozygote the hyperactivity of locus 7 often reaches a much higher functional level than in the classical  $\beta$ -microcythaemia with high  $A_2$  homozygote thus considerably reducing the severity of clinical manifestations.

This consideration and the equality of the haemoglobin picture of homozygous carriers of F microcythaemia and of hereditary persistence of haemoglobin F brings to the fore the problem of relationships between microcythaemia and hereditary persistence of haemoglobin F. The similarity between the two conditions is highly suggestive. It is however clear that the two conditions cannot be based on the same genetic alteration. While in homozygous F microcythaemia state the degree of haemoglobinization is always below the normal range (so that the haematological picture of microcythaemia is always present) in homozygous state for high haemoglobin F gene the normal haemoglobin level reveals that loci 7 are both fully functioning.

Therefore in F-microcythaemia any future hypothesis on the basic genetic mechanism shall have to take into account not only the total or partial suppression of the products of the two adjacent structural genes  $\beta$  and  $\delta$  but also the partial and characteristic persistence of activity of structural gene 7 which is constant and typical in this microcythaemia variant.

### Summary

In a family of Sicilian origin the parents, who are first cousins to each other are both carriers of  $\beta\delta$ -thalassaemia (or microcythaemia) with high haemoglobin F (F-thalassaemia) and their three children are homozygous carriers of F-thalassaemia. Clinically only the propositus shows slight anaemia and moderate hepato-splenomegaly. His two sisters are apparently healthy. As the two preceding observations of literature, this family proves that the activity of normal  $\beta$  and  $\delta$  genes is completely suppressed in F-thalassaemia, and that the homozygous condition produces much less severe disease than the homozygosity for  $\beta$ -thalassaemia with high haemoglobin  $A_2$  gene.

### References

1. ZUCKER, W. W., ROSENOW, A. R. and BOOKER, C. R. Reciprocal relationship of hemoglobins  $A_2$  and F in beta chain thalassaemias. Key to the genetic control of hemoglobin F. *Blood* 17: 393 (1961).

- 2 FERAS, Ph. S. AMATOYANNOPOULOS, G. and HARAKIS, A.: Hereditary persistence of foetal haemoglobin and its combination with alpha- and beta-thalassemia. *Proc. 8th Congr. europ. Soc. Haemat.* Wien 1961 (Karger Basel/New York 1962)
- 3 SILVESTRO, E., BIANCO, I., BRANCATI, C.: Presenza di microcitemia con quota normale di emoglobina  $A_2$  e quota elevata di emoglobina F: una famiglia calabrese (Terza varietà di microcitemia). *Policlinico, Sez. prat.* 71: 1543 (1964)
- 4 RUSSO, G. and MORLICA, F.: Sickle cell haemoglobin and two types of thalassemia in the same family. *Acta haemat.*, Basel 28: 329 (1962)
- 5 POLONA, P. and MOTTA, L.: On incidence of thalassemia and normal hemoglobins in the eastern part of Sicily. First results. *Proc. 9th Congr. europ. Soc. Haemat.* Lisbon 1963, p. 530 (Karger Basel/New York 1963)
- 6 SILVESTRO, E., BIANCO, I.: Un caso di malattia microcitrinica da Hb S varietà di microcitemia con quota normale di Hb  $A_2$  e quota elevata di Hb F (Terza varietà di malattia microcitrinica). *Progr. med.*, Napoli 20: 1 (1964)
- 7 BERTETTI, A., ROSSI, U., BERGONZI, A.L.: Talassemia eterodiplo con Hb F elevata ed Hb  $A_2$  normale. *Haemat. ital.* 9: 39 (1966)
- 8 SILVESTRO, E. e BIANCO, I.: Microcitemia con abbondante Hb F ed Hb  $A_2$  normale in tre famiglie pugliesi. *Policlinico, Sez. prat.* 41: 1981 (1963)
- 9 SILVESTRO, E., BIANCO, I. e MURATORE, F.: Frequenza dei vari tipi di microcitemia di emoglobine abnormal nella provincia di Lecce. *Progr. med.*, Napoli 1: 211 (1965)
- 10 QUATTRO, N., BRANCATI, P., CONDO, R., DE ROSA, L., DIETI, E., MONTORI, R., VENTRATO, V.: Il problema sociale clinico della microcitemia e delle altre emoglobinopatie in Campania. *Atti Giornat. di Studio della microcitemia* Ferrara, 23-24 ottobre 1963. *Ist. ital. Med. Soc. Roma*, p. 3.
- 11 MALAMOS, B., FERAS, Ph. and STAMATOYANNOPOULOS, G.: Types of thalassemia-trait carriers as revealed by a study of their incidence in Greece. *Brit. J. Haemat.* 8: 5 (1962).
- 12 STAMATOYANNOPOULOS, G.; FERAS, Ph. and PAPAYANNOPOULOS, T. G.: Genetic and hematologic study of F-thalassemia. 3rd Int. Congr. hum. Genet. Chicago 1966. Abstracts, pp. 93-96.
- 13 WEATHERALL, D. J.: Biochemical phenotypes of thalassemia: the American Negro populations. *Ann. N.Y. Acad. Sci.* 129: 450 (1964)
- 14 COHEN, D. E. and MOTULSKY A. G.: Absence of  $\alpha$  delta chain synthesis in ( $\beta\beta$ ) thalassemia (F-thalassemia). *Blood* 28: 34 (1966)
- 15 FLATZ, G., PIK, C. and SERRAVALLO, S.: Haemoglobinopathies in Thailand. I. A study of patients with the thalassemia syndrome and their families. *Brit. J. Haemat.* 11: 215 (1963)
- 16 WOLFF, J. A.: Interacting thalassemia with normal  $A_2$  hemoglobin and elevated or normal fetal hemoglobin levels. 4th Ann. Meet. Amer. Soc. Hemat. *Blood* 18: 807 (1961)
- 17 WOLFF, J. A. and IGATOFF, V. G.: Heterogeneity of thalassemia major. *Amst. J. Dis. Child.* 161: 234 (1963)
- 18 GARTZDA, T. G., NATHAN, D. G. and GARDNER, F. H.: Thalassemia trait genetic combinations of increased fetal and  $A_2$  hemoglobins. *New Engl. J. Med.* 270: 1212 (1964)
- 19 FERAS, Ph.: Forms of thalassemia, in GIOSIS Symposium on Abnormal Hemoglobins in Africa, p. 71 (Blackwell, Oxford 1964)
- 20 BRANCATI, C.: Primo caso di omizigosi per la varietà di microcitemia con quota normale di emoglobina  $A_2$  e quota elevata di emoglobina F. *Progr. med.*, Napoli 1: 388 (1963)
- 21 BRANCATI, C. and BAUILLON, C.: Homozygous  $\beta\beta$ -thalassemia ( $\beta\beta$ -microcythemia). *Nature Lond.* 212: 262 (1966)
- 22 FERAS, Ph.: Thalassemia. Clinical and patho-physiological considerations. *Trans. Roy. Soc. trop. Med. Hyg.* 61: 164 (1967)
- 23 FRASER, G. R., S. AMATOYANNOPOULOS, G., NATHAN, C., LOXOPOLLOS, D. In A-

- RANOS, B.; KITHOS, C. ZA NOS-MARROUKA, I.; CHOREMIS, C. FEMAS, P. and MOTULSKY A. F. Thalassemias, abnormal hemoglobins and glucose-6-phosphate dehydrogenase deficiency in the Arta area of Greece. Diagnostic and genetic aspects of complete village studies. Ann. N.Y. Acad. Sci. 119: 415 (1964)
24. BRANCO, I.; SCHILLARO, G.; GRAZIANI, B.; DE FEO, G. Saporito, N. Ricerca sulla frequenza di beta-microcitemia di emoglobine abnormal nella popolazione della Sicilia sud-orientale. Progr. med., Napoli 23: 827 (1967).
25. SILVESTRONI, E. BRANCO, I.; MICCIZOLENI, M.; MOCIANO, G. VALLINOTTO, E. Studio biochimico, elettroforetico spettrofotometrico dell'emoglobina di malati di anemia microcitica costituzionale di morbo di Cooley. Progr. med., Napoli 13: 705 (1957)
26. ROSSIGNOL, A. R. ROSSIGNOL, M. HARRISON, A. E. and ZUCKER, A. W. A new technique for differentiation of hemoglobins. J. Lab. clin. Med. 50: 745 (1957)
27. GRAZIANI, B. DE FEO, G. La determinazione quantitativa delle emoglobine normali ed abnormal mediante elettroforesi su acetato di cellulosa. Progr. med., Napoli 23: 643 (1967)
28. SVETKEY, K. COHENLOFF A. I. and SVETKEY, L. Studies on abnormal hemoglobins. I. Their demonstration in sickle-cell anemia and other hematologic disorders by means of alkali-denaturation. Blood 6: 413 (1951)
29. KLEINHAUER, E.; BRACH, H. und BEYER, K. Demonstration von fetalem Hämoglobin in den Erythrozyten eines Blutesstrichs. J.klin. Wochs. 35: 637 (1957)
30. SILVESTRONI, E.; BRANCO, I. and GRAZIANI, B. The haemoglobin picture in Cooley disease. Brit. J. Haematol. 14: 301 (1968)
31. COHENLOFF A. I. Some important considerations in the quantitative determination of Hb F. Int. Symp. comp. Hemogl. Structure Thessalonika, 11-13 April, 1966, p. 43.

Department of Hematology (Dir. Prof. P. FARRERAS) Internal Medicine Clinic (Dir. Prof. A. PEDRO-POMA) Faculty of Medicine, University of Barcelona, Barcelona

## Complete Remission in Chronic Lymphocytic Leukemia

### Report of Case

P. PARDO, E. SIMÓ M. RIBAS-MUNDO and P. FARRERAS

Patients with chronic lymphocytic leukemia have usually a long survival either spontaneously or with treatment, but lymphocytic infiltration of the bone marrow and blood lymphocytosis persist in the majority of cases throughout the course of the disease.

We report a patient with chronic lymphocytic leukemia in whom complete clinical and hematological remission, proven by even cytochemical and lymphographic techniques, developed after therapy with cyclophosphamide and prednisone. After the complete remission it was impossible to find any feature which let us suspect the persistence of chronic lymphocytic leukemia. As this is an unusual case not often reported in the literature we think it might be worth to report it.

### Case Report

A 63 years old, married, railroad employé, born in Peñalba (Huesca) Spain. Family history was not significant. At the age of 24 he suffered pleuritis of unknown etiology. At the age of 33 ocular surgery for strabismus. Since then he has complaint of frequent upper respiratory infections.

His present illness began at the age of 63 (February 1961) with bronchitis, progressive lamtude and acute and severe pain of the left eye followed by amaurosis. A diagnosis of glaucoma was made. At this time an hemogram revealed no anemia 15,770 leukocytes with 96 lymphocytes and numerous Gumprecht cells.

Physical examination revealed an apparently healthy man with amaurosis of the left eye and generalized lymphadenopathy of medium size in cervical, axillary and inguinal regions.

Laboratory analysis (24 II.61) E.S.R. 11 mm at the first hour red blood cell count 4,565,000, hemoglobin 13.6 g%, total leukocyte count 15,770 with juvenile forms 1 %.

segmented neutrophils 3%, lymphocytes 96% and many Gumprecht cells. Myelogram hypoplastic erythropoiesis of about 8% of the total cellularity 80% of infiltrating mature lymphocytes and some lymphoblasts, scattered myelocytes and metamyelocytes. No megakaryocytes. Total proteins 3.6 g%, albumin 3.08 g%, globulin 1.24 g%. Uric acid 8.55 mg%. Platelet count 230,000. Due to the good general condition of the patient no specific treatment was given.

Three months later (3 VI.61) the leukocyte count rose to 147,070 and an enlarged spleen was detected 4 cm under the left costal margin. Treatment was started with 150 mg cyclophosphamide and 10 mg prednisone per os daily and was given for 3 months. 1 September 1961 the spleen was not palpable and the leukocyte count had dropped to 14,080. Treatment was reduced to 200 mg cyclophosphamide i.m. weekly and 5 mg prednisone per os daily.

During this time he suffered from frequent upper respiratory infections. A bacillary epithelioma infiltrating the left preauricular region and spinocellular epithelioma on the right temporal region also developed.

After 1 year of treatment (8.VI.62) with cyclophosphamide and prednisone the peripheral leukocyte count was 11,300 with 57% lymphocytes. The bone marrow aspirate revealed 20% lymphocytes. On physical examination the liver was still palpable 3 cm below the right costal margin and axillary lymph nodes were still felt. The same treatment was prescribed.

1 May 1964, three years after beginning of treatment, the patient was in good condition. On physical examination only the liver was palpable 2 cm below the costal margin neither splenomegaly nor lymphadenopathies were detected. Red blood cell count was 5,200,000, Hb 14.7 g%, and the leukocyte count was 8,250 with 22% lymphocytes. Treatment with cyclophosphamide 50 mg and prednisone 5 mg per os every other day was continued. 1 December 1964 the liver was no longer palpable. Analysis of peripheral blood was normal and treatment was stopped.

1 July 1966 physical examination was normal. The erythrocyte count was 5,300,000 with 16.1 g% Hb, the leukocyte count was 7,370 with 36% lymphocytes; only 15% of these lymphocytes presented PAS reaction. The bone marrow aspiration was normal with 5% lymphocytes.

1 July 1967 the patient was asymptomatic and physical examination was entirely normal. The hematological data remained within the normal limits. Less than 10% of the peripheral lymphocytes presented PAS reaction. The bone marrow aspiration revealed normal erythro- and leukopoiesis, presence of megakaryocytes and 12% of lymphocytes. The lymphography in July 1967 failed to reveal enlarged retroperitoneal lymph nodes.

1 March 1968 the patient is still in good clinical condition. Neither hepato-splenomegaly nor lymphadenopathies are palpable. Nevertheless, peripheral blood leukocyte count has risen to 15,560 with 52% lymphocytes. Bone marrow aspiration reveals 30% lymphocytic infiltration. Treatment with cyclophosphamide 50 mg and prednisone 5 mg every other day is recommenced.

### DISCUSSION

Chronic lymphocytic leukemia has always been considered the less malignant of all types of leukemia. Patients with long survival are common. Our case, however, has remained in complete remission for at least 3 years with no clinical or laboratory features of chronic lymphocytic leukemia.

In the available literature we have found very few cases where the complete remission of chronic lymphocytic leukemia had been satis-



factorily proven REICH [1] published in 1959 a case of complete remission after radiotherapy of the spleen (1 700 r) and blood transfusions. The patient persisted on complete remission for 5 years. DURANT and FINKELNER [2] published in 1964 a revision of 250 cases of chronic lymphocytic leukemia, lymphosarcoma and leuko-lymphosarcoma. These authors comment the difficulties encountered in some cases to differentiate chronic lymphocytic leukemia and lymphosarcoma. From the 250 cases only one achieved complete remission during 3 years after treatment with prednisone and TEM. In 1955 a case of remission in a female treated with radiotherapy was published by SCHOTT [3]. However there is no mention of the myelogram during the remission phase. Recently TSI HAN *et al* [4] have described 5 cases of complete remission among 202 patients with chronic lymphocytic leukemia and leukolymphosarcoma. The lymphocytic infiltration in bone marrow of these cases during remission ranged however between 15% and 20% which is over the upper limit for normal adults.

In our case the diagnosis of chronic lymphocytic leukemia seems unequivocal for he had generalized adenopathy, liver and spleen enlargement, white cell count of 147 000 with 96% lymphocytes and many Gumprecht cells, bone marrow infiltration with mature lymphocytes and some lymphoblasts. The leukocytosis of 13,560 with 52% lymphocytes and the 30% lymphocytic bone marrow infiltration after 3 years of clinical and hematological remission confirms the diagnosis of chronic lymphocytic leukemia.

We consider a complete remission to be present when there are no clinical or laboratory signs which could detect the disease. These criteria are consistent with the published criteria of BULL [5] for complete remission of acute leukemia. We suggest two further criteria to accept the complete remission of chronic lymphocytic leukemia: (1) The PAS reaction of the peripheral lymphocytes should be positive in less than 20% as is in normal subjects. (2) the lymphography should be normal.

In our patient complete remission during 3 years can be proved by the following data: (1) No clinical symptoms of disease. (2) no palpable adenomegaly, no hepatosplenomegaly. (3) red blood cell count 5 300 000, Hb 102, white blood cell count 7 370 with 36% lymphocytes. (4) the lymphocyte content of the bone marrow is less than 15%. (5) less than 20% of the peripheral lymphocytes show a PAS reaction. (6) the lymphography is normal.

The maintenance dose of cyclophosphamide and prednisone even when the patient was in good condition has probably played a role in the evolution of this patient, but as TIN HAN *et al* [4] comment, factors other than treatment might mediate in such cases. In accordance with these authors it is also possible that the frequency of complete remission in chronic lymphocytic leukemia might be increased significantly if patients were treated earlier and with a maintenance dosage of proven effective drugs in a long term therapy.

At the Department of Hematology of the University of Barcelona we have only seen this single case of complete remission among 68 cases of chronic lymphocytic leukemia in a period of 10 years.

### Summary

The authors report a case of chronic lymphocytic leukemia which attained clinical and hematological remission during 3 years after treatment for 3 years with cyclophosphamide and prednisone. A review of the literature has revealed very few cases of complete remission in chronic lymphocytic leukemia. The authors suggest two further criteria of complete remission in chronic lymphocytic leukemia: the PAs peripheral lymphocytes should not exceed 20% and the lymphography should be normal.

### References

1. RICHES, C. Apparent recovery in chronic lymphocytic leukemia. *J. Amer. med. Ass.* 170: 169 (1959).
2. DUKANT, J. R. and FINEBERGER, J. A. "Spontaneous" remission in chronic lymphatic leukemia? *Cancer* 17: 105 (1964).
3. SCHOTT, M. Ten-year recovery from chronic lymphocytic leukemia. *Brit. med. J.* *i*: 577 (1955).
4. TIN HAN, ESTEVE, E. Z. and SORAL, J. F. Complete remission in chronic lymphocytic leukemia and leukolymphosarcoma. *Cancer* 20: 243 (1967).
5. BAILEY, H. F. Criteria for the evaluation of response to treatment in acute leukemia. *Blood* 11: 676 (1956).

Authors addresses: Drs. F. PARDO, E. SORO and E. FARRERAS, Department of Hematology Internal Medicine Clinic, University of Barcelona, *Barcelona* (Spain). Dr. MANUEL RUIZ-MINOSO, Blood Research Laboratory, Massachusetts General Hospital, *Boston, Mass. 02114* (USA).

Second Chair of Medicine, University of Salamanca (Prof. L. ROZMAN) School of Hematology University of Barcelona (Prof. P. FARRERAS)

## Acute Erythromyelosis after Benzene Poisoning

C. ROZMAN S. WOESKYER and J. SAEZ-SERRANIA

In 1965 we published 20 cases of aplastic anemia induced by chronic benzene poisoning [1]. Malignant neoplastic disorders of the bone marrow: acute leukemia or less often chronic leukemia have been found in patients with prolonged exposure to benzene containing environments [2, 3]. There are more than 100 of such cases referred to in the literature [3]. Rare cases of erythromyelosis (erythremia in its pure form or as erythroleukemia) have been found associated with long contacts with benzene: the latter form being more common than the former [3-13]. The rarity of this cases has prompted us to report a patient with acute erythromyelosis after chronic benzene poisoning.

### Case Report

A 58-year-old varnisher was seen in January 1968, with previous history of working during 30 years in closed environment rich in benzene.

In November 1967 after a short flu with low fever the patient noticed onset of dropses after effort, lassitude and paleness. A blood count performed in early January showed normochromic anemia with 2,500,000 RBC/mm<sup>3</sup>. On examination hepatosplenomegaly was found. Chest roentgenogram was normal. In two separated occasions 500 ml of whole blood were given, without improvement in the patient's condition.

A hematological study performed on the 15th of February showed the following data: RBC 1,480,000/mm<sup>3</sup>; hemoglobin 25 Hb<sub>2</sub> 27 pg; Reticulocytes 1,500/mm<sup>3</sup>; Platelets 11,000/mm<sup>3</sup>; Leukocytes 11,000/mm<sup>3</sup>; myeloblasts 1%, promyelocytes 5%, neutrophils myelocytes %, metamyelocytes 7%, young neutrophils 24%, segmented neutrophils 41%, lymphocytes 21%, monocytes 1%, 3 erythroblasts per 100. Very marked anisopoikilocytosis: some erythrocytes with crenated edges.

Bone marrow: Proerythroblasts 1-4%, basophil erythroblasts 40.0%, polychromatophil erythroblasts 19.0%, orthochromatic erythroblasts 17.2%, myeloblasts 0.8%, prom. 1.4%, 5.8%, metamyelocytes 1.2%, reticulum cells 4.6%. Marked morphological changes of the erythroblasts were found mainly in the nuclei. Giant polyploid forms, diploerythroblasts, atypical mitoses and in some cells cytoplasmatic vacuoles were seen (fig. 1-3). There were




Fig 1 Giant and small polyploid erythroblasts with 4 and 5 nuclei.

no atypias in the white cell series. The number of megakaryocytes was scarce. Most erythroblasts showed an intense diffuse PAS-positivity of the cytoplasm. Some erythroblasts had PAS-positive granules. Perl's stain showed 78% sideroblasts without ring forms.

The course of the illness was growing worse, without response to the therapy. The patient died on the 24 of February of massive intestinal hemorrhage.

### *Comment*

Clinically and experimentally it has been shown that benzene exerts its toxicity upon the erythroblastic mitoses resulting in giant erythroblasts, polyploid mitoses and arrested mitoses in metaphase [11-12-14]. The finding of diploerythroblasts in marrow medular aplasia identifies benzene as the most probable causal agent [15].



*Fig. 2. Group of young erythroblasts with vacuoles in the cytoplasm.*

*Fig. 3. Three diploerythroblasts with nuclei arranged like coffee beans.*

The above named anomalies and the history of prolonged exposure to benzene, have lead us to consider this substance as the causative agent. On the other hand, the other clinical and hematological findings are similar to the non benzene produced erythremias. The ferrokinetic and erithrokinetic findings [1] and the PAS-positivity of the erythroblasts, as shown in our case, are similar in both types of erythremia. There are a number of blood diseases, like thalassemia, iron-deficiency anemia and hemolytic disease of the newborn which show some PAS-positivity in the erythroblasts, but this is more intense in the

acute erythremia (DE GUOLIELMO'S disease) and offers an important clue to its diagnosis [16]

### Summary

A case of acute erythromyelosis is reported after 30 years exposure to benzene. Nuclear abnormalities were found in the erythroblasts, which showed marked PAS-positivity in their cytoplasm, like in other types of erythremia.

### References

1. RODRIG, C.; RUBIA-MENDO, M.; WOLFFER, S. y GONZALEZ-LANDELL, F. Estudio clínico hematológico de 43 casos de anemia aplásica, con particular atención las de origen benzénico (20 casos). *Med. Clin.* 41: 10-22 (1965).
2. WILLIAMS, E. C. and SATTI, G. Benzene and leukemia. *New Engl. J. Med.* 271: 872 (1964).
3. GOODEL, A.; CAYROLAIS, A. et BERLAND, J. Les leucémies benzéniques de la région parisienne entre 1950 et 1963 (Etude de 50 observations). *Nouv. Rev. franç. Hémat.* 7: 463-480 (1967).
4. DEMOLE-RECHER, R. et DELCOURT, R. ■ nouveaux cas d'érythro-leucémie. Etude anatomoclinique. *Acta haemat.* 2: 350 (1949).
5. GALAVOTTI, B. and THOU, F. M. Erythroleukemic myelosis in benzene poisoning. *Brit. J. Indust. Med.* 7: 79 (1950).
6. PALLARD, F., GEORJA, P., PLANCHET, M. et F. VAL-GELY, J. Un cas d'anémie érythroblastique mortelle chez un ouvrier exposé au benzol. *Arch. mal. prof.* 11: 284 (1930).
7. ARNDT, R. et DREYER, B. Sur une observation de maladie de De Guoglielmo. *Sang.* 21: 676 (1932).
8. MARCIAL, G. A propos de la communication de R. ARNDT et B. DREYER. *Sang.* 21: 682 (1932).
9. NISSEN, N. I. and OHLIN, A. S. Erythromyelosis. Review and report of case in benzene (benzol) worker. *Acta med. scand.* 145: 56-71 (1933).
10. MARTI, H. R. and VETTER, H. Akute Erythraemie; Diagnose und Differentialdiagnose eines klinisch und autopsisch beobachteten Falles. *Schweiz. med. Woch.* 47: 1231 (1937).
11. DE GUOLIELMO, ■ and LANZACORRE, A. Inhibition of mitosis and regressive changes of erythroblasts in acute erythropathy caused by occupational benzene poisoning. *Acta haemat.* 19: 144-147 (1958).
12. MIESCHER, P., WERTHEIMANN, A. and LÖNN, H. Erythromyelose-ähnliche Hämopathie als Folge einer Benzolintoxikation. *Acta haemat.* 25: 308 (1961).
13. KOHL, P., BEYER, H. E. and SCHWITZLER, W. Erythrocytosen nach chronischer Benzolintoxikation. Untersuchung der Ferro- und Erythrocytokinetik mit radioaktivem Eisen und Chron. *Schweiz. med. Woch.* 97: 368-373 (1967).
14. ROMANELLI, E. G., GORDA, P., PECORARI, D., TROTTA, N. et COLONZI, R. Effetti del benzene sulla matrice erythroblastica. Investigazioni a la microcinematografia in corium de phos. *Acta haemat.* 26: 281-302 (1961).
15. RODRIG, C., WOLFFER, S. y DE DIEGO-SALGADO, T. Valor de los llamados diplocitoblastos en el diagnóstico de la mielocitopatía benzénica. *Sangre* 11: 203-206 (1966).
16. QUARLES, D. and HAYNES, F. G. J. Periodic-acid-Schiff positivity in erythroblasts with special reference to De Guoglielmo disease. *Brit. J. Haemat.* 6: 26 (1960).

Authors' address: Drs. C. RODRIG, S. WOLFFER and J. SARR-SERRANA, Escuela de Hematología, Clínica Médica Universitaria, Facultad de Medicina, Casanova 143, Barcelona 11 (Spain).

### Erratum

In der Arbeit SCHUAPPART-SCHNORR: Zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymphse (Vol. 39 Nr. 3, 1968) wurden leider die beiden Abbildungen vertauscht.

### Therapie der Leukosen und malignen Lymphome

In Wien findet vom 24. bis 26. März 1969 eine internationale Arbeitstagung über Chemio- und Immuntherapie der Leukosen und malignen Lymphome statt. Leitung: Prof. Dr. H. FLEISCHMACKER, Assistent: Doz. Dr. A. STACHURA, Ludwig-Boltzmann-Institut für Leukemieforschung und Hämatologie, 4-1100 Wien, Heinrich Collin-Straße 30.

### International Society of Blood Transfusion

At the meeting of the ISBT Executive Committee which took place in Moscow from the 25th February to the 1st March, it was decided that the Society could offer a few travel grants to help some young scientists to go to the 11th International Congress of Blood Transfusion, Moscow August 17-23, 1969. The total amount of money available for travel grants is \$ 2000 which will be divided among a few candidates up to the age of 35 years, actively engaged in research, to assist them in paying for their travel expenses.

Applicants shall apply to Dr. E. FARSHTEIN, Blood Bank, Rigshospitalet, 9 Ege-damvej, 2100 Copenhagen (Denmark) furnishing the Committee with 4 copies, abstracts or reprints of the paper to be submitted, a complete curriculum vitae (including the age of the applicant) and a letter of recommendation from the applicant's chief or head of the research programme, as well as some information about the applicant's possibility of obtaining financial support from other sources. The applications should be sent before the 1st of February 1969.

Department of Medicine, The University of Adelaide,  
The Queen Elizabeth Hospital, Woodville, South Australia

## Measurements of Protein Synthesis by Lymphocytes *in vitro* in Diseases of the Lymphoid Tissues

J W M. LAWTON and I. J. FORBES

In earlier studies [8, 9] measurements showed reduced globulin synthesis by lymphocytes from peripheral blood in a variety of disease states. Of particular interest were low values in a few cases of chronic lymphatic leukaemia and macroglobulinaemia, suggesting that the reduced rate of immunoglobulin synthesis commonly found in these conditions [17] may be associated with measurable metabolic deficiency in the circulating lymphocytes.

Studies were therefore undertaken to extend these preliminary observations. The activity of lymphocytes was measured in medium containing autologous plasma and in plasma-free medium, to investigate the possibility that circulating substances may inhibit protein synthesis by lymphocytes in disease states. Parallel measurements were made of the effect of phytohaemagglutinin on protein synthesis. Lymphocytes were studied from normal subjects, and from patients with chronic lymphatic leukaemia, lymphoma (unclassified) and lymphosarcoma, macroglobulinaemia, multiple myeloma and infectious mononucleosis.

### *Materials and Methods*

Normal subjects were healthy laboratory workers, medical practitioners, students, and blood donors. Diagnosis of chronic lymphatic leukaemia (CLL) was made on blood count of more than 9,000 lymphocytes/mm<sup>3</sup> and the finding of non-follicular lymphocytic infiltration of the bone marrow [3]. Multiple myeloma was diagnosed by  $\gamma$ - or  $\beta$ -2 $\mu$  band of paraproteins on serum electrophoresis which was not precipitated from the serum by rivanol [15] associated with an infiltration of the bone marrow by plasma cells. In macroglobulinaemia the paraprotein was precipitated from the serum by rivanol, and was associated with



infiltration of the bone-marrow by abnormal cells of the lymphocyte series. The category 'lymphoma (unclassified)' was made up of a small group of patients with lymphocytic infiltration of the bone marrow but without diagnostic changes in the lymph node blood or bone marrow. Diagnosis of lymphosarcoma was made from histological sections. Diagnosis of infectious mononucleosis was made in the presence of characteristic symptoms and signs, and the presence of atypical lymphocytes in the blood [6]. Heterophile agglutinins [12] were present in 6 cases, absent in 3, and not tested for in one case. The heterophile antibodies were not absorbed by guinea-pig kidney suspension [3] in 3 cases and were absorbed in one case.

**Culture of lymphocytes.** Venous blood, 40–50 ml where possible, was collected into heparin (25 IU/ml) and dextran 0.3%. After the erythrocytes had sedimented for 1 h at 37°C, the supernatant plasma was taken and centrifuged at 800 g for 15 min. The sedimented leucocytes were resuspended in half the volume of plasma and incubated at 37°C for 1 h in a glass column packed with cotton wool. The lymphocytes were eluted from the column with the other half of autologous plasma, washed twice with BSS and suspended in Eagle medium supplemented with non-essential amino acids [1]. From each blood sample  $12 \times 10^6$  ml cultures were prepared in 4 groups, so that each determination was made in triplicate. The composition of the cultures is shown in table 1. A small volume of the lymphocyte suspension was dispensed separately for the determination of the lymphocyte count (Coulter Counter Model D) and for making smear for differential leucocyte count. Cultures were incubated at 37°C for 24 h then frozen.

**Measurement of protein synthesis.** Cultures were frozen and thawed three times and centrifuged at 10,000 g for 15 min to remove cell debris. To each plasma-free supernatant was added 0.25 ml of standard human pooled serum. The protein was precipitated in 5% trichloroacetic acid, washed three times, dissolved in  $\text{NH}_4\text{OH}$  and plated as infinite thickness on 2 cm<sup>2</sup> planchets for counting in an end-window gas-flow Geiger-Müller counter.

**Total protein concentration of plasma** was estimated by the method of VOLKMAN *et al.* [20].

**Calculation of results.** Net counts per minute (CPM) were obtained by subtracting the CPM of protein in cultures containing paromycin 60 µg/ml. These samples gave counts very little above background for the counter (13–20 CPM). Mean net CPM of triplicates was converted to 'mean net CPM/ $10^6$  cells'.

The following 4 correction factors were applied:

1. Correction for the efficiency of the counter

Table 1. Composition of standard cultures

Group	Cell suspension ml	Autologous plasma ml	PHA ml	<sup>14</sup> C-leucine solution ml	Final <sup>14</sup> C-leucine concentration µCi/ml
Plasma free	0.5	0	0	0.5	0.5
Plasma free + PHA	0.5	0	0.06	0.5	0.5
25% plasma	0.5	0.25	0	0.25	0.25
25% plasma + PHA	0.5	0.25	0.06	0.25	0.25

L-Leucine <sup>14</sup>C(U) specific activity 150 mCi/m-mole Radiochemical Centre, Amersham (England)




Fig 1 Effect of increasing population density in 25% plasma medium. Simultaneous triplicates 1 ml cultures of lymphocytes from the same subject were set up with increasing numbers of lymphocytes. Protein synthesis was measured after incubation for 24 h (cpm counts per minute).

2. Correction for the  $^{14}\text{C}$ -leucine concentration to standard  $^{14}\text{C}$  concentration of 0.5  $\mu\text{Ci}/\text{ml}$ . It was shown that the CPM in newly synthesized protein were directly proportional to the concentration of radioactive substrate.

3. Correction for the amount of carrier protein to correspond to the amount (15.5 mg) in 0.25 ml of standard pooled serum, by reference to standard curve.

4. Correction for population density in plasma-containing cultures to give the theoretical incorporation in culture containing  $1 \times 10^6$  cells/ml, using the graph shown in figure 1 (No such correction was necessary for plasma-free cultures where the incorporation was directly proportional to the number of lymphocytes per ml up to density of  $16 \times 10^6$  lymphocytes per ml).

## Results

### 1 Protein synthesis in plasma free medium

*Mean total synthesis.* The basal (unstimulated) synthesis by normal lymphocytes in plasma-free medium was measured in 28 healthy adults. The mean incorporation was not significantly different from the normal in all clinical groups CLL, lymphoma, lymphosarcoma, macroglobulinaemia, multiple myeloma and infectious mononucleosis (table II)

*PHA stimulation of protein synthesis by normal lymphocytes.* The stimulation by PHA is expressed as a ratio incorporation with PHA/incorporation without PHA. The effect of PHA in increasing protein synthesis by normal lymphocytes in plasma-free medium was highly significant ( $P < 0.001$ ) The values for PHA stimulation under these culture conditions ranged from 0.7 to 3.5 with a mean of 1.87 (table II)

ing autologous plasma. Also in order to use radioactive substrate as economically as possible, the incorporation of  $^{14}\text{C}$ -leucine into all of the soluble proteins was measured rather than into the portion which was precipitated by sodium sulphate solution. The fraction of the radioactive proteins in the globulin fraction is quite variable in normal subjects and is usually substantially less than half of the total. The results in the present study are therefore not directly comparable with the previous measurements.

These studies have provided further evidence that circulating lymphocytes may have a reduced capacity to synthesize protein in diseases involving lymphoid tissues.

Measurements of protein synthesis in plasma-free medium alone showed low activity by lymphocytes from all of the disease categories studied except multiple myeloma. However the mean total synthesis in any disease group was not significantly lower than the control mean, nor was the difference significant when the data from all categories was pooled.

The addition of 25% of autologous plasma to the medium significantly enhanced protein synthesis by normal lymphocytes. This effect is probably due to better nutrition, as unidentified substances in plasma are necessary for optimal growth of other mammalian cells *in vitro* [7]. AMERSON [1] found hydrocortisone to be the factor in serum which was necessary for maximal antibody synthesis by rabbit lymph-node fragments *in vitro* but hydrocortisone has been shown to inhibit protein synthesis by human peripheral lymphocytes [16].

No evidence was found of inhibitory substances in the plasma of subjects with CLL, lymphoma and lymphosarcoma. The mean values for plasma stimulation of protein synthesis by lymphocytes in these conditions were actually higher than the normal mean although they did not reach the level of statistical significance. These findings are of interest in view of the suggestion of VON HALLAUER [19] that CLL serum contains substances which stimulate cell growth.

Although the mode of action of PHA and the significance of the response to it are not yet known, it is a useful substance to bring out differences in lymphocytes from different sources. When the adjuvant effects of plasma and PHA were both utilized it was possible to show significant deficiencies in the capacity of lymphocytes to synthesize protein. Significantly low activity was seen in lymphocytes from subjects with lymphoma, lymphosarcoma, macroglobulinaemia and infectious mononucleosis. Lymphocytes from patients with CLL showed

the same trend and when only the untreated cases were considered the mean incorporation was significantly lower than the normal.

The low total protein synthesis by the circulating lymphocytes in lymphoma, lymphosarcoma and macroglobulinaemia seems to be related to the poor immunological function reported in these so-called lymphoproliferative disorders [3 4 10 17]

Significantly low values for PHA stimulation in medium containing plasma were found in 2 cases of lymphosarcoma. In chronic lymphatic leukaemia one estimation was above the normal range and 3 were below. The degree of stimulation by PHA was found to be significantly low in infectious mononucleosis, omitting one case in which the diagnosis was doubtful. The low stimulation in infectious mononucleosis agrees well with the lack of increase of RNA synthesis in response to PHA [13]. RUSSELL also noted that unstimulated lymphocytes in infectious mononucleosis synthesized RNA at 10 times the rate of normal blood lymphocytes under the same conditions. This finding is not compatible with the results in our series where incorporation of

C-leucine into protein was not elevated. The reason for this discrepancy is not readily apparent. It may be due to a difference in the stage of the disease between the two series: more than 60% of the lymphocytes in RUSSELL's cases were morphologically atypical whereas a much lower proportion of such cells was found in the blood of the subjects of this study.

The cause and significance of these abnormalities of protein synthesis are not understood. Further qualitative characterization of the deficiencies is necessary. It is also necessary to consider the population dynamics of the disorders, for the lymphocytes are a heterogeneous population, at least with respect to immunoglobulin synthesis [18] and each immunologically competent cell normally synthesizes antibodies of only one or two specificities [11 2]. The changes in the total protein synthesis may reflect changes in the proportions of various types of cell, or changes affecting each cell of the whole population. The derangement could conceivably be initiated at the level of formation of stem cells, in the thymus, or in the peripheral lymphoid tissues. It seems likely that the disturbance in infectious mononucleosis is self limited, occurring in peripheral lymphoid tissues. The disturbance may be at a similar level in lymphosarcoma, and it has been argued that the abnormalities of immunoglobulin synthesis in CLL may also be explained by a failure of terminal immunologic determination at this level [14].

## Acknowledgements

We are grateful to Miss PEROY WOOD for skilled technical assistance. This research was supported by a grant from the National Health and Medical Research Council of Australia.

## Summary

Measurements were made of protein synthesis *in vitro* by lymphocytes from normal subjects and from patients with chronic lymphatic leukaemia, lymphoma (unclassified) and lymphosarcoma, macroglobulinaemia, multiple myeloma and infectious mononucleosis. Protein synthesis was significantly stimulated by both plasma and phytohaemagglutinin in all groups. When the lymphocytes were cultured in medium containing 25% autologous plasma and PHA, significant differences between the normal and disease groups were observed. The degree of stimulation by phytohaemagglutinin in medium containing 25% plasma was significantly low in the lymphosarcoma and infectious mononucleosis groups. In interpreting these findings it is necessary to take into account the functional heterogeneity of the circulating lymphocytes.

## References

1. ANDERSON, C. T. The requirement for hydrocortisone in antibody forming tissue cultivated in serum-free medium. *J. exp. Med.* 119: 1027-1049 (1964).
2. ATTARDE, G., COHEN, M., HOSIYA, A. K. and LERNER, E. S. Antibody formation by rabbit lymph node cells. IV. The detailed methods for measuring antibody synthesis by individual cells, the kinetics of antibody formation by rabbits and the properties of cell suspensions. *J. Immunol.* 92: 377-390 (1964).
3. BARR, M. and FARLEY, G. H. Circulating antibodies in reticuloses. *Lancet* 1305-1310 (1961).
4. BRADY, J. I. and BEZZER, L. H. Alteration of blood group antigens in leukaemic lymphocytes. *J. clin. Invest.* 44: 1582-1589 (1963).
5. DANCIGER, I. Serologic diagnosis of infectious mononucleosis. *J. Amer. med. Ass.* 78: 289-293 (1937).
6. DOWNEY, H. A. L. and MCKENZIE, C. A. Acute lymphadenitis compared with acute lymphatic leukaemia. *Arch. intern. Med.* 32: 82-112 (1923).
7. EAGLE, H. Metabolic controls in cultured mammalian cells. *Science* 119: 451-1963.
8. FORBES, I. J. and HENDERSON, D. W. Globulin synthesis by human peripheral lymphocytes *in vitro* measurements using lymphocytes from normals and patients with disease. *Ann. intern. Med.* 65: 69-79 (1966).
9. FORBES, I. J. and TUCKER, K. J. Synthesis of protein by human lymphocytes *in vitro*. I. Clinical studies. *Aust. Ann. Med.* 11: 304-310 (1963).
10. LACEY, D., PRLEY, F., KELLY, W. D. and GOODY, R. A. A comparative study of the incidence of energy in patients with carcinoma, leukaemia, Hodgkin's disease and other lymphomas. *J. Immunol.* 89: 535-548 (1962).
11. NOMAL, G. J. V. Antibody production by single cells. *Brit. J. exp. Path.* 37: 44-53 (1958).
12. RICE, J. R. and BENNELL, W. W. The presence of heterophile antibodies in infectious mononucleosis. *Amer. J. med. Sci.* 133: 90-104 (1932).
13. RITCHIE, A. D. Lymphocyte RNA synthesis in infectious mononucleosis: the response to phytohaemagglutinin *in vitro*. *Blood* 25: 602-603 (1965).

14. SAOR, R. E. and FORBES, I. J. A case of multiple autoimmune disease, lymphoid proliferation and hypergammaglobulinaemia. *Blood* 31: 536-548 (1968)
15. SAITER, A. A simple chemical test for distinguishing myeloma globulins from macroglobulins. *J. lab. clin. Med.* 63: 1054-1060 (1964)
16. SMITH, J. L. and FORBES, I. J. Use of human lymphocytes in studies of drug action. *Nature, Lond.* 215: 558-559 (1967).
17. SOLOMON, A., WALDMAN, T. A. and FAHEY, J. L. Metabolism of normal 6.6S gamma-globulin in normal subjects and in patients with macroglobulinaemia and multiple myeloma. *J. lab. clin. Med.* 62: 1-17 (1963)
18. VAN FURTH, R. The formation of immunoglobulins by lymphoid tissues *in vitro*. Doctoral thesis, University of Leiden (1964)
19. VON HALLATER, C. Über den Nachweis leukocytyler Reinstoffe im leukämischen Menschenblut. *Z. ges. exp. Med.* 76: 577-586 (1931)
20. WOLSON, W. Q., COWY, C., CALVERT, E. and ICHIDA, F. Rapid procedure for the estimation of total protein, true albumin, total globulin, globulin,  $\beta$  globulin and  $\gamma$  globulin in 1.0 ml of serum. *Amer. J. clin. Path.* 18: 723-730 (1948)

II. Anatomisches Institut der Freien Universität Berlin (Direktor: Prof. Dr. med. W. SCHWABE)

## Über den Abbau von Zellen im Knochenmark des Menschen und der Ratte

D. GRAF KEYSERLINGK

Der Abbau von Erythrozyten und Erythroblasten in den phagozytierenden Retikulumzellen des Knochenmarks ist bereits sorgfältig untersucht worden [2, 9, 4, 5]. Auch Kerne und Fortsätze von Megakaryozyten wurden in diesen Zellen gefunden [36, 38]. Es fehlen jedoch genaue Angaben darüber, welche Zellen ausserdem noch in den phagozytierenden Retikulumzellen abgebaut werden und wie dieser Vorgang morphologisch erfolgt. Bei der elektronenmikroskopischen Untersuchung dieser Frage zeigte sich darüber hinaus, dass der intrazelluläre Abbau von Zellen im Knochenmark bei Mensch und Ratte zu morphologisch verschiedenen Abbauprodukten führt.

### Material und Methode

Menschliches Knochenmark wurde durch Sternalpunktion gewonnen. Ein Teil der Patienten litt an hämatologischen Erkrankungen, während bei einer zweiten Gruppe zunächst der Verdacht auf eine solche Erkrankung bestand, der dann bei Licht und elektronenmikroskopisch nicht bestätigt wurde. Das Knochenmark der Ratte wurde am Femur von 6 Tieren eines Wistar Inzuchtstammes entnommen. Das Gewebe wurde sofort in einer 1 M  $\text{OsO}_4$ -Lösung in Michaelis-Puffer mit Saccharosezusatz bei pH 7,4 und 4°C. (für 1½ Sed.) fixiert. Stufenweise Entwässerung in Aceton und Einbettung in Mircopal. Zum Nachweis der sauren Phosphatase erfolgt die Fixierung in 2,5% Glutaraldehyd in 0,1 M Cacodylat-Puffer pH 7,4. Weitere Behandlung nach der Vorschrift von SARRIS und FARQUHAR [30]. Das Inkubationsmedium enthält 0,01 M Na- $\beta$ -Glycerophosphat, 0,004 M  $\text{Pb}(\text{NO}_3)_2$  in 0,05 M Acetatpuffer bei pH 4,9. Die Inkubationszeit betrug 1 Sed. bei 37°C. Anschließend Nachfixierung in 1 M  $\text{OsO}_4$ -Lösung in Michaelis-Puffer. Entwässerung und Einbettung wie oben. Die Schnitte wurden mit einem LKB-Ultratome hergestellt und zu Uranylacetat und Bleicitrat nachkontrastiert. Aufnahmen mit einem Siemens Elmiskop L.

*Befunde*

Bei der elektronenmikroskopischen Beurteilung von Phagozytosevorgängen muss die geringe Dicke der Schnitte berücksichtigt werden, um Fehldeutungen zu vermeiden. Die Ausläufer der phagozytierenden Retikulumzellen des Knochenmarks reichen oft weit zwischen die benachbarten Zellen. Um eine extrazellulär gelegene Zelle nicht fälschlicherweise als Phagosom anzusehen muss deshalb eine eingeschlossene Zelle nicht nur vollständig von einer Membran der phagozytierenden Zelle umgeben sein, sondern auch Veränderungen in ihrer Fernstruktur die für einen Abbau sprechen, erkennen lassen. Nur bei der Enzymreaktion unterscheidet sich diese Einschlussmembran schon durch ihren Niederschlag von der äußeren Zellmembran. In den phagozytierenden Retikulumzellen des Menschen und der Ratte konnten wir Zellen der roten Reihe, isolierte Normoblastenkerne neutrophile Granulozyten (Abb. 1a) Lymphozyten, Plasmazellen (Abb. 1b) und Thrombozyten nachweisen. Da der Abbau hämoglobinhaltiger Zellen bereits mehrfach untersucht wurde [31] braucht hier nicht näher darauf eingegangen zu werden. Das markanteste Zeichen dieses Abbaus ist das Auftreten von Einschlusskörpern mit Ferritin-Granula [24] (Abb. 2) Ferritinhaltige Einschlüsse sind auch in unserem Material häufig zu finden.

Alle Einschlusskörper enthalten das Reaktionsprodukt (Bleiphosphat) der sauren Phosphatase. Wenn eine phagozytierte Zelle noch keine deutlich ausgeprägten Zeichen des Abbaus aufweist, so liegt der Bleiphosphat Niederschlag der umgebenden Membran innen an (Abb. 2) Die äußere Zellmembran der phagozytierenden Retikulumzelle ist stets frei von Niederschlägen. Wenn deutliche Abbauerscheinungen in der eingeschlossenen Zelle erkenntlich sind, liegt das Reaktionsprodukt der sauren Phosphatase auch innerhalb des Phagosoms. Kleine Einschlüsse können vollständig von dem Niederschlag ausgefüllt sein.

Die Einschlussmembran kann der phagozytierten Zelle dicht anliegen (Abb. 1b) oder einen mehr oder weniger breiten Spaltraum zum Phagosom freilassen (Abb. 1a, 3) Dieser Spaltraum erscheint weitgehend elektronenoptisch leer (Abb. 3) oder mit einem amorphen Material geringer Elektronendichte ausgefüllt.

Im Kern der phagozytierten Zelle treten Veränderungen auf, bevor andere Abbauerscheinungen deutlich werden. Das Nukleoplasma verliert sein typisches Aussehen und wird pyknotisch (Abb. 1a)



- 37 WEDGWAY, E.: *Lymphomas*, New Engl. J. Med. 273, 1084-1090 (1965).
- 38 WETTEL, B. L.; SPICKA, S. S. and HORS, R. G.: Fine structural localization of acid and alkaline phosphatases in cells of rabbit blood and bone marrow. *J. Histochem. Cytochem.* 15, 311-334 (1967).
- 39 YAMAGAWA, I.: Glycolipids of mammalian red blood cells. In 16, *Colloq. Ges. physiol. Chem. Micabach* 1965 (Springer Berlin/Heidelberg/New York 1966).

University of Louvain, Department of Medicine (Head Prof. J. VANDERKLOOFT)  
Laboratory of Coagulation (Head Prof. M. VERSTRAETE)

## Investigations on the Fibrinolytic System in Liver Cirrhosis<sup>1</sup>

G. TYTGAT<sup>2</sup>, D. COLLEN<sup>3</sup>, R. DE VREEKE and M. VERSTRAETE

For nearly half a century various observers have reported increased fibrinolytic activity in the blood of patients with liver cirrhosis. However the fibrinolytic activity was frequently measured by the auto-digestion time of clots of total or diluted blood or plasma of the patient. This decreased lysis time, often due to low amounts of lyzable fibrin substrate, should be interpreted as 'pseudofibrinolytic activity' as long as the lytic activity cannot be measured on a standard substrate not variable from patient to patient.

Nevertheless in some well documented cases of cirrhosis, true increased plasma fibrinolytic activity has been demonstrated. This enhanced blood proteolytic activity may be a cause of spontaneous bleeding or may encourage bleeding from esophageal varices or surgical wounds [3, 8, 11]. Particularly patients subjected to portocaval shunt operations have an increased tendency to operative and postoperative bleeding [9].

According to FLETCHER *et al.* [7] the increased fibrinolytic activity in the cirrhotic patients may be due to a failure of hepatic clearance mechanisms for plasminogen activator and not to deficient plasma fibrinolytic inhibitors. This latter statement is in contradistinction with the studies of several authors [3, 11, 16, 17] indicating that the fibrinolysis in cirrhosis may also be related to decreased serum plasmin inhibitors.

This work was supported in part by the Fonds voor Geneeskundig Wetenschappelijk Onderzoek, Belgium.

Aspirant van het Nationaal Fonds voor Wetenschappelijk Onderzoek.

Navorsingsstagiair van het Nationaal Fonds voor Wetenschappelijk Onderzoek.

This discordance prompted us to study both hypotheses in a group of 25 cirrhotic patients in different stages of evolution of the disease. The present investigation involved the assay of various fibrinolytic parameters before and after activation of the fibrinolytic system by nicotinic acid.

### *Materials and Methods*

**Reagents.** Saline (0.07 M)-phosphate (0.06 M) buffer pH 7.5 (S.P. buffer) [10]. - Glycerol-phosphate buffer containing equal volumes of glycerol and S.P. buffer - Fibrinogen Bovis (Foviet, Amsterdam) lot 57 (protein 78.2%; clotable fibrinogen 62.5%; NaCl 14.9%) dissolved freshly before use in a concentration of 25 mg/7 ml S.P. buffer - Thrombin (Topostasine Roche) 20 NIH units per ml S.P. buffer stored at 20°C. - Plasma: chloroform activated bovine fibrinolysin (Parks, Davis and Co.) 1,900 Loomis units/vial, diluted in 650 ml glycerol-phosphate buffer and stored at -20°C, is diluted adequately with the same solvent before use so that 0.10 ml plasma lyses the standard clot (formed by mixing 0.55 ml S.P. buffer 0.25 ml fibrinogen solution and 0.10 ml thrombin) in a 9-11 minute range. This plasma working solution is kept on ice during the whole procedure and discarded when the lysis time of the standard clot exceeds 11 min.

**Fibrinolytic activity** was measured in the plasma and in the euglobulin fraction, on washed bovine fibrin plates, prepared according to ASTRUP and MOLLERUP [1]. For statistical evaluation the individual values of lysed surface were converted into fibrinolytic activity by reading on linear reference curve, constructed from plots of log lysed surface on bovine fibrin plate versus log sample concentration. This reference curve was obtained from pool of fibrinolytic active euglobulin precipitates, reconstituted with veronal buffer into number of 'activator' levels. Similar curves for individual cirrhotic precipitates showed slopes comparable to that of the reference curve.

**Antiplasmin assay** (according to JOHNSON [10] with slight modifications) 0.1 ml of serum dilutions (1/25, 1/50 and 1/100) in S.P. buffer are transferred to a testtube at room temperature. 0.15 ml of the plasma working solution is added. The tubes are mixed gently and kept at room temperature for 10 min.

Consecutively are added: S.P. buffer 0.40 ml, fibrinogen 0.25 ml, thrombin 0.10 ml. Immediately after adding thrombin, a time reading device is started, the reagents are mixed by mechanical swirling for about 10 sec and the tube is transferred to a water bath at 37°C. Along with each series of serum dilutions reference clot is made containing 0.10 ml plasma dilution and buffer up to 0.65 ml. Fibrinolytic endpoints, indicated by the rising of all air bubbles into the upper half of the test mixture, are read visually or in the lysis recorder [4]. All determinations are performed at least in duplicate. The antiplasmin content of the serum is calculated from a plot on log-log paper the lysis times being plotted against the reciprocal of the final serum concentrations. A line is drawn joining the two dots with lysis times adjacent to the reference time. On this line the serum dilution, producing lysis time equal to the reference time is looked for. As 0.10 ml plasma dilution contains per deflection 1 plasmin unit, the reciprocal of the serum concentration which prolongs the lysis time of 0.15 ml plasma to the time of 0.10 ml plasma (reference time) inhibits 0.5 plasmin units. Divided by two, this reciprocal of the serum concentration gives conventionally the antiplasmin content of the sample.

**Experimental groups.** Nicotinic acid was administered in two series of 25 subjects. The cirrhotic group consisted of 25 hospitalized patients, in whom the diagnosis of hepatic cirrhosis, in different stages of evolution was documented by physical examination, laboratory findings, laparoscopy and proved in all of them by liver biopsy; none of the patients was taking corticosteroids, but some were under intermittent diuretic treatment. The

control group consisted of 23 laboratory personnel and hospitalized psychosomatic patients without any known physical or biochemical abnormality. Mean age (controls 48 years; cirrhotics 50 years), mean body weight (controls 63 kg; cirrhotics 66 kg), mean cholesterol value (controls 238 mg%; cirrhotics 208 mg%), mean hemoglobin value (controls 14 g%; cirrhotics 13.2 g%) and sex ratio (3 males, 1 female) were comparable. Nicotinic acid (100 mg) was rapidly injected i.v. to the recumbent person in the mid-afternoon. Under these conditions, diurnal changes were assumed to operate uniformly [6].

Venous blood was sampled just before and 15, 30 and 60 min after the i.v. administration. The tourniquet was applied during about 15 sec before puncture of an antecubital vein. The blood was collected directly in glass tubes for preparation of serum and in pre-cooled siliconized tubes, containing potassium oxalate ( $H_2O$ ) 2.5% (1 part for 11 parts of blood) for fibrinolytic determinations. Serum was pipetted off after clotting of the whole blood for 2 h at 37°C. After centrifugation at 4°C for 10 min and 4,000 g the plasma and the serum were stored in polystyrene tubes at -20°C until used. Serum from 20 healthy donors was obtained in similar manner and mixed in equal proportions for constituting serum pool, used for preliminary investigation of the reproducibility of the antiplasmin assay.

## Results

### Determination of *in vivo* Plasminogen Activator Clearance

The fibrinolytic activity in the euglobulin fraction, measured on unheated bovine fibrin plates, will be considered according to SHERRY *et al.* as blood plasminogen activator activity [20]. Figure 1 shows the individual values of euglobulin fibrinolytic activity before (sample 0) and 15 min (sample 1), 30 min (sample 2) and 60 min (sample 3) after nicotinic acid administration.

As there is no linear correlation between lysed surface and activator




Fig. 1. Euglobulin fibrinolytic activity measured on bovine fibrin plate before and 15, 30 and 60 min after intravenous injection of 100 mg nicotinic acid, in control subjects and cirrhotic patients.

content, it is necessary for statistical analysis to compute these lysed surfaces shown in figure 1 into activator concentration by reading from a linear reference curve (plotting  $\log \text{mm}^3$  lysed surface versus  $\log$  activator activity). After calculation of the mean activator activity in the different samples of both groups, these mean data are expressed in percentage of the mean activator activity in the control group before nicotinic acid injection. These calculated mean values are for blood samples 0, 1, 2, and 3 respectively 100, 206, 152 and 137% for control subjects and 66, 403, 274 and 154% for cirrhotic patients. The lower mean value found in the cirrhotic patients, before nicotinic acid injection is not statistically different from the mean control value ( $0.05 < P < 0.10$ ). The increase in euglobulin fibrinolytic activity from sample 0 to sample 1 is statistically significant for both series ( $P < 0.001$ ) the mean increase being higher for the cirrhotic patients in comparison to the control subjects ( $P < 0.001$ ). After the 15 minute sample, the euglobulin lytic activity declined progressively to base-line values, more rapidly for the control subjects than for the cirrhotic patients.

As the *in vivo* disappearance rate of plasminogen activator is an exponential function of activator concentration with respect to time [7] the 50% *in vivo* decay time of euglobulin fibrinolytic activity can be calculated from the formula  $\log Y = \log A + bx$  and  $T_{1/2} = \log 2/b$ . The calculated mean *in vivo* 50% disappearance time of activator is 13.8 min for those control subjects, who clearly responded to nicotinic acid injection and 24.5 min for the total group of 23 cirrhotic patients ( $0.002 < P < 0.01$ ). The 50% *in vivo* activator decay is 26.2 min for the 10 cirrhotic patients exhibiting the most serious coagulation abnormalities and clinical signs of severe hepatic decompensation. These findings indicate that the *in vivo* disappearance of plasminogen activator in the cirrhotic patients is significantly longer compared to that of the control subjects.

### Antiplasmin Determination

The reproducibility of the antiplasmin assay has been preliminarily investigated. The mean of normal pool values, obtained over several weeks, is 360 antiplasmin units per ml serum, with a standard deviation of 25 units. Individual normal values vary from 210–510 units per ml,  $\bar{X} = 344$ ,  $s = 94$  and  $n = 20$ .




Fig. 2. Antiplasmin activity before and 15, 30 and 60 min after intravenous injection of 100 mg nicotinic acid in control subjects and cirrhotic patients.

The serum antiplasmin activity has been assayed before and after nicotinic acid injection in both experimental groups. The individual experimental results are summarized in figure 2, the mean values being for blood sample 0 1 2 and 3 respectively 311 263 271 and 296 units for the control persons and 192, 145 153 and 169 units for the cirrhotic patients. The mean antiplasmin content before fibrinolytic activation in the cirrhotic patients is significantly lower than in the control group ( $P < 0.001$ ). Activation of the fibrinolytic system by nicotinic acid is associated in the 15 min blood sample with a decrease in serum antiplasmin content for both series, which is highly significant ( $P < 0.001$ ) when evaluated with the method of paired comparison. The decrease in serum antiplasmin is maximal at the moment of maximal increase of euglobulin fibrinolytic activity. Subsequently the antiplasmin capacity rises steadily towards initial values, in association with a progressive decrease in euglobulin fibrinolytic activity.

In order to evaluate the importance of the decreased antiplasmin level in liver cirrhosis, a comparison was made between the fibrinolytic activity on fibrin plate in total cirrhotic plasma samples versus control plasma samples both with an identical fibrinolytic activity in the corresponding euglobulin precipitates. Indeed, the difference between plasma and euglobulin lytic activity is mainly based upon the elimination of the bulk of inhibitors (the still hypothetical anti-activator and the antiplasmins) in the euglobulin fraction. After plotting the various

plasma fibrinolytic activities versus the corresponding euglobulin fibrinolytic activities for both series, the correlation coefficient  $r_b$  between the plasma and euglobulin lytic activity measured on bovine fibrin plate, was calculated as 0.650 for cirrhotic patients and 0.268 for control subjects. The corresponding difference in slope between both regression lines is statistically significant ( $0.02 < P < 0.05$ ) confirming the importance of the decrease in fibrinolytic inhibitors in explaining the susceptibility of the cirrhotic patients for induction of fibrinolytic activity in total plasma.

### DISCUSSION

Various observers have reported increased fibrinolytic activity in liver cirrhosis, measured by the autodigestion time of clots of total or diluted blood or plasma of the patient. In our experiments, the lytic activity before nicotinic acid injection was measured on a standard lysable fibrin substrate, not variable from patient to patient, and no evidence for enhanced plasminogen activator activity in the euglobulin fraction of 25 cirrhotic plasma samples was obtained (fig. 1). Nevertheless, patients with liver cirrhosis are prone to develop increased fibrinolytic activity in certain circumstances [8, 9, 19]. Many authors relate the increased fibrinolytic activity to the release of an increased amount of plasminogen activator in the cirrhotic plasma.

Our data confirm the known susceptibility of the patients with liver cirrhosis to develop increased fibrinolytic activity after stimulation of the fibrinolytic system (fig. 1). According to FLETCHER *et al.* [7] a major factor in the abnormal fibrinolytic response to nicotinic acid, is a failure of hepatic clearance mechanisms for plasminogen activator in liver cirrhosis. Calculating the activator concentration by assessment of the euglobulin lysis time, these authors find a mean *in vivo* 50% plasma activator clearance rate of  $13 \pm 5$  min in control persons versus  $53 \pm 19$  min in cirrhotic patients.

In our experiments blood plasminogen activator precipitated almost quantitatively in the euglobulin fraction, is measured on bovine fibrin plates. From our data the calculated mean *in vivo* 50% disappearance time of activator activity is 13.8 min for the control subjects, who clearly responded to nicotinic acid injection, and 24.5 min for the total group of 25 cirrhotic patients ( $0.002 < P < 0.01$ ). Notwithstanding the methods in both studies differ the *in vivo* disappearance of plasminogen activator in the two control series is

strikingly similar. However the prolongation of the *in vivo* decay of plasminogen activator in cirrhotic patients in comparison with control subjects is less pronounced in our study. As differences in patient material (our patients being scattered over a wider range of liver insufficiency) could provide a possible explanation for this discrepancy we calculated the *in vivo* plasminogen decay in the 10 cirrhotic patients with the most seriously disturbed coagulation set and clinical signs of severe liver failure, but the 50% plasminogen decay time of 26.2 min in this group was still the half of the value found by FLETCHER [7]. The significantly longer *in vivo* disappearance time of plasminogen activator in cirrhotic patients, compared to control subjects, is according to FLETCHER [7] ascribed to insufficient hepatic clearance mechanisms of activator by the diseased liver. However it has to be kept in mind that other still hypothetical mechanisms may be involved in explaining the differences in activator disappearance time after nicotinic acid injection, such as differences in possible renal clearing of activator activity, differences in continuous activator release during the declining part of the disappearance curve, differences in nicotinic acid metabolism, and differences in level and rate of release of anti-blood activator activity. The availability of purified blood plasminogen activator is required for exact activator clearance studies and for further elucidation of the mentioned hypothetical mechanisms.

The role of the fibrinolytic inhibitors in the genesis of the increased fibrinolytic activity in liver cirrhosis and the enhanced susceptibility to stimuli capable of inducing fibrinolytic activity is debated. According to FLETCHER *et al.* [7] assays of plasma antiplasmin, performed with a caseinolytic technique, revealed no significant difference between the normal and cirrhotic group. Studies of other authors however [3, 11, 12, 17] indicate that the fibrinolytic activity in liver cirrhosis may be related to a decrease in the plasmin inhibitors in serum, this finding being in agreement with the previously stated lowered levels of alpha<sub>2</sub>-globulins in cirrhosis [18]. We performed a serum antiplasmin assay in 25 cirrhotic patients according to the fibrin clot digestion method as proposed by JOHNSON [10]. Interference in the test by residual activator activity in the serum samples was considered as negligible if not existent both for reasons of prolonged clotting at 37°C of the blood and subsequent extensive dilution (250–1 000 times) of the serum sample. As autodestruction of plasmin occurs during the test, the error may be minimized by measuring serum inhibition after a relatively short incubation time (10 min) and by adding glycerol as a



stabilizer to the plasmin solution. Although the plasmin inhibition is not fully evolved, this short preincubation time may be reliable as the bulk of serum antiplasmin activity resides in the alpha<sub>2</sub>-globulin fraction, which produces an immediate temperature independent inhibition of plasmin [13 15 16]. The mean antiplasmin content (192 U/ml serum) in the cirrhotic patients is substantially lower than the corresponding value in control subjects (311 U/ml serum) this difference being highly significant ( $P < 0.001$ ) (fig 2). The importance of the decrease in fibrinolytic inhibitors (the still hypothetical anti-activator and the antiplasmins) was evaluated by comparing the lytic activity in cirrhotic versus control plasma samples with an identical corresponding lytic activity in the euglobulin fraction where the bulk of fibrinolytic inhibitors is eliminated. Our finding of a significantly higher plasma fibrinolytic activity in cirrhotic plasma in comparison with control plasma for an identical euglobulin lytic activity supports the hypothesis that the susceptibility of the cirrhotic patients for induction of fibrinolytic activity in total plasma may be related to decrease in fibrinolytic inhibitors ( $p < 0.05$ ). Decreased antiplasmin levels in cirrhosis are probably not only due to decreased hepatic synthesis but also to increased consumption in plasmin antiplasmin complex formation. Indeed it has been demonstrated that plasmin-antiplasmin complex may form a circulating reservoir of plasmin which is innocuous to other circulating proteins but forms a ready source of plasmin when required for the lysis of fibrin. The extent of such plasmin binding may be appreciated from the work of NANNINGA and GUNST [14] who have shown that bound plasmin is present in a hundredfold greater concentration than free plasmin at a plasmin concentration of  $10^{-3}$  M.

There is a suspicion that not only the antiplasmin content but also the level of the still hypothetical inhibitor of blood plasminogen activator is decreased in liver cirrhosis. As it has repeatedly been shown that increased fibrinolytic activity is frequently the result of the presence of an activator of plasminogen and not of plasmin an inhibitor of this activator may have important physiological implications. However it has until now been impossible to measure such an inhibitor as the activator itself has not been isolated and purified.

### Summary

Patients with liver cirrhosis are prone to develop increased fibrinolytic activity after *L*-as injection of nicotinic acid. This abnormal response is due to failure of hepatic clearing of plasminogen activator. The calculated mean in vivo 50% disappearance time of activator activity is 13.8 min for 25 control subjects and 24.5 min for 25 cirrhotic patients ( $0.002 < p < 0.01$ ). Decreased antiplasmin levels in cirrhotics may potentiate the susceptibility of these patients to develop plasma fibrinolytic activity. This difference between the mean antiplasmin content (192 U/ml serum) in the cirrhotic patients and the corresponding value in the control subjects (311 U/ml serum) is highly significant. The decrease in fibrinolytic inhibitors is probably related with the finding of significantly higher fibrinolytic activity in total cirrhotic plasma in comparison with control plasma for an identical level of plasminogen activator activity in the corresponding cryoglobulin fraction of both cirrhotic and normal plasma ( $0.02 < p < 0.05$ ).

### References

1. ASTRUP T and MØLLERSTAD, S. The fibrin plate method for estimating fibrinolytic activity. *Arch. Biochem. Biophys.* 40: 346 (1952).
2. BAILEY N. T. J. Statistical methods in biology (The English Universities Press, London (1959)).
3. BRACHMONT J. L., BRACHMONT V. et DOMART A. Recherches sur l'activité fibrinolytique spontanée du plasma dans les cirrhoses du foie. *Ref. franç. Et. clin. biol.* 1: 667 (1956).
4. COLLIER, D.; TYTGA G. and VERSTRAETE, M. A semi-automated method for routine evaluation of fibrinolytic components. *J. clin. Path.* (in press).
5. DE NICOLA, P. and SOARDI, F. Fibrinolysis in liver diseases. Study of 109 cases by means of the fibrin plate method. *Thromb. Diath. haemorrh.* 2: 290 (1958).
6. FRANKLEY G. R., BALLOUTH, G. and FRANKLEY E. Evidence of diurnal fibrinolytic rhythm, with simple method of measuring natural fibrinolysis. *Clin. Sci. N.* 645 (1957).
7. FLETCHER, A. P., ROEDERMAN, O.; MOORE, E., ALQUIRRE, N. and SANCERY S. Abnormal plasminogen-plasmin system activity in patients with hepatic cirrhosis: its cause and consequences. *J. clin. Invest.* 43: 681 (1964).
8. GROSS, C. E., MORROW, A. H. and ROCHELLOT L. M. Studies on spontaneous fibrinolytic activity in patients with cirrhosis of the liver and its inhibition by epsilon amino caproic acid. *Ann. Surg.* 153: 333 (1961).
9. GROSS, C. E., ROCHELLOT L. M. and PARKER, W. F. Coagulation defects in patients with cirrhosis of the liver undergoing portacaval shunts. *Amer. J. Surg.* 104: 512 (1962).
10. JOSEPHSON, A. J. Blood coagulation, haemorrhage and thrombosis; edited by TOGANTIS, L. M., and KASAL, L. A. (Grune & Stratton, New York/London 1964).
11. KWAAR, H. C., LU, R. and MC FARLAN, A. J. S. Antifibrinolytic activity in primary carcinomas of the liver. *Clin. Sci.* 18: 251 (1959).
12. KWAAR, H. C., MC FARLAN, A. J. S. and COOK, J. Plasma fibrinolytic activity in cirrhosis of the liver. *Lancet* i: 132 (1965).
13. MARY, R. D.; COTTON, S. and JACKSON, D. Antiplasmin activity of electrophoretically separated human serum fractions. *J. clin. Path.* 19: 105 (1966).
14. MARCOWA, L. B. and OCKEY M. M. On the interaction of fibrinolysin (plasmin) with the inhibitors antithrombin and soyabean trypsin inhibitor. *Arch. Biochem.* 108: 542 (1964).
15. NORMAN, P. S. Studies of the plasmin system. II. Inhibition of plasmin by serum or plasma. *J. exp. Med.* 108: 53 (1958).

16. NORMAN, P. S. and HILL, M. B. Studies of the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma. *J. exp. Med.* 108, 639 (1958).
17. O'CONNELL, R. A.; GROSS, C. E. and ROCHOUOT, L. M. Role of inhibitors of fibrinolysis in hepatic cirrhosis. *Lancet* i, 990 (1964).
18. SATOMIAR, R. S., LEWIS, R. A. and GARTONIS, B. B. Electrophoretic studies of the plasma proteins in virus hepatitis. *J. lab. clin. Med.* 44, 349 (1954).
19. SAWYER, W. D.; FLETCHER, A. P.; ALKJAERSEN, N. and SHERRY S.: Studies on the thrombolytic activity of human plasmin. *J. clin. Invest.* 39, 476 (1960).
20. SHERRY S., LEIDMYER, R. I.; FLETCHER, A. P. and ALKJAERSEN, N. Studies on enhanced fibrinolytic activity in man. *J. clin. Invest.* 33, 810 (1959).

Central Laboratory of the Blood Transfusion Service of the Swiss Red Cross, Bern

## A Specific Inhibitor of Human Clotting Factor V

V LOPEZ, R. PFLUGSHAUPT and R. BÜTLER

In 1958 FERGUSON *et al.* [5] reported on a patient suffering from a heavy haemorrhagic diathesis due to the presence of an inhibitor of factor V. This inhibitor showed no species-specificity since it was found to inhibit bovine factor V as well. The therapeutic effect of ACTH suggested that this anticoagulant could have been of immunological origin although no direct proof for this assumption was offered.

We have observed a similar coagulation disorder in a 66-year-old woman. An inhibitor which was effective only against human factor V could be demonstrated in the plasma as well as in the serum of the patient.

### *Case Report*

M.R.L. 1899, was admitted to the hospital on September 26th, 1963 because of right-side pleurisy. Prior to hospital admission she had been treated with chloramphenicol, Tanderil® and Lederkys®. From her history it became clear that she had suffered from specific (tbc) lung infiltration already 40 years ago.

After a few days in the hospital the patient developed pericarditis. Tuberculostatic therapy was started. The treatment of thrombophlebitis of the right leg which developed early in 1963, was followed by prolonged Butaxolol® therapy. The patient's condition had improved significantly by November 13th, 1963 and she was discharged from the hospital; however 6 days later the patient had to be readmitted as an emergency with haematuria which had persisted for 2 days already. On the medial side of the right thigh and on the abdomen small to medium-size suffusions were visible. The patient was afebrile. A cystoscopy gave no evidence for mucous membrane lesions.

Laboratory findings: haemoglobin 34%, haematocrit 21%, bleeding time 3 1/2 min, clotting time 5 min, thromboplastin time determined according to Quick 33%, thrombocytes 136,000/mm<sup>3</sup>.

The patient received blood transfusions; in spite of serological compatibility she developed a temperature of 39.2° C after the fourth transfusion.

An analysis of the blood clotting system was performed on a blood sample received on November 23rd, 1963 (table I). The most striking result consists in the pronounced reduc-

tion of factor V activity as measured by the one stage assay. Correspondingly the global tests of the intrinsic system (recalcification time, hirudin tolerance time, partial thromboplastin time and prothrombin consumption test) as well as thromboplastin time were all pathological. The moderately diminished factor XI activity was probably due to the low factor V content of the factor XI-substrate used.

The patient's history gave no indication of parahaemophilia; she never had bleeding episodes before although she was allergic to penicillin. Furthermore, a hereditary coagulopathy seemed excluded by the absence of bleeding disorders in the patient's family. Thus, the presence of an inhibitor of factor V appeared probable.

The patient's blood was reexamined on December 4th, 1963 (table I). Factor V activity was still markedly reduced, and hyperfibrinogenemia had developed.

A search for *in vitro*- and *in vivo*-antibodies against red cells, for leucoagglutinins, for cell nucleus antibodies, for rheumatoid factor activity and for antibodies against immunoglobulins gave negative results.

### Special Investigations

1. *Substitution experiments in Quick's thromboplastin test.* The following incubation mixture was used: 0.1 ml citrated plasma (patient's and normal pooled plasma mixed in different ratios), 0.1 ml thromboplastin (Roche), 0.1 ml 0.4 M  $\text{CaCl}_2$ . The results of substitution experiments using the patient's plasma (AI-plasma) and normal plasma are shown in figure 1.

In second series, cross-correction experiments were performed using different incubation times of the patient's plasma with normal plasma. In these experiments the plasma was diluted 1:10 with isotonic barbital buffer (figure 2). The results obtained must be interpreted in terms of the presence of an anticoagulant inhibiting the prothrombin-conversion by the extrinsic activation mechanism. The activity of this anticoagulant appeared immediately but increased on prolonged preincubation.

2. *Effect of the inhibitor on thromboplastin generation.* As shown in figure 3, the thromboplastin generation test (TGT) [3] in which  $\text{BaSO}_4$ -adsorbed patient's plasma and normal

Table I. Clotting investigations

	23-11-63	4-12-63	5-1-66	Normal range
Recalcification time, sec	450	840	115	90-180
Hirudin tolerance time, sec	570	1,200	120	~ 300
Partial thromboplastin time (Asolectin) sec	300	510	95	70-100
Prothrombin consumption test, %	45	55	3	0-8
Thromboplastin time, sec	55	63	12	~ 13
Thrombin time, sec	11	16	14	~ 10
Fibrinogen (Schuda) mg %	400	600	300	~ 300
Factor II activity sec	19	17	18	~ 19
Factor V activity %	3	3	60	70-120
Factor VII activity %	90	-	100	70-120
Factor VIII activity %	100	100	100	70-120
Factor IX activity %	100	100	-	70-120
Factor X activity %	100	-	100	70-120
Factor XI activity %	22	-	-	70-120




Fig. 1. Substitution experiments in Quick's thromboplastin test. *A.P.L.* patient's plasma, *N.P.L.* normal plasma.




Fig. 2. Cross correcting experiments with patient's plasma and normal plasma at different preincubation times. ●—● mixture of patient plasma and normal plasma; ○—○ normal plasma alone.

serum were used, is also influenced by the inhibitor. This experiment shows, furthermore, that the inhibitor is not or only poorly absorbed by BaSO<sub>4</sub>. It proved necessary to modify the standard conditions of the TGT whereby concentrated reagents (BaSO<sub>4</sub>-absorbed plasma and serum) were used in order to demonstrate the activity of the inhibitor.




Fig 7 Activity of human and bovine factor V preparations. ●—● human factor V preparation ○—○ bovine factor V preparation.

shown in figure 5. They appear to demonstrate the presence of an anticoagulant directed against factor V. These findings also confirm that the inhibitor is present in both plasma and serum, and that it is effective upon incubation.

Patient's serum and normal plasma were preincubated for different periods of time in order to establish the interdependence of the inhibitory effect and preincubation time; the one-stage factor V assay was used. The results represented in figure 6 demonstrate that the inhibitory effect increases correspondingly with increasing incubation times.

4 *Inhibition experiments with factor V-preparations of bovine and human origin.* Factor V was prepared according to a slightly modified version of Owren's method [15]. The activity of the lyophilized product was tested as follows: 25 mg of factor V preparation of bovine origin and 100 mg factor V preparation of human origin, respectively were dissolved in 1 ml barbitol buffer. Factor V activity was determined in dilutions prepared from these solutions. Both preparations were tested for activity of other clotting factors: only factor V activity could be demonstrated.

For demonstration of inhibitor activity both, bovine and human factor V-preparations were adjusted to equal activity as based on their respective activity curves (figure 7). 0.5 ml factor V-preparation (human or bovine) was preincubated with 0.05 ml of the patient's plasma for different lengths of time; the clotting activity was measured by determination of the thromboplastin time. As a control, the patient's plasma was substituted by factor V reagents. Results are shown in figure 8, demonstrating that the inhibitor is specifically directed against human factor V but not effective against bovine factor V. Furthermore, it appears from the shape of the curve that both preparations may have lost some of their activity during the test procedure.

5 *Stability of the anticoagulant.* The inhibitor showed no loss of activity after standing at +4°C or -20°C for several weeks. Incubation at 37°C for 24 h likewise caused no loss of activity. After 1 h at 60°C no decrease of activity was discernable; whereas at 70°C the activity disappeared after 30 min.

6 *Chemical and physicochemical properties of the anticoagulant.* The inhibitor was neither absorbable on aluminum-hydroxide nor on BaSO<sub>4</sub> [2]. It is not lipophilic since after shaking with ether it was still found in the water phase.




Fig. 2. Dependence of the inhibitor's activity against factor V preparations on preincubation time.

- human factor V preparation + patient plasma
- human factor V preparation + factor V deficient plasma
- ×—× bovine factor V preparation + patient's plasma
- ×—× bovine factor V preparation + factor V deficient plasma




Fig. 3. Distribution of the inhibitor activity among electrophoretic fractions of the patient's serum.

In order to determine the electrophoretic mobility of the inhibitor 0.1 ml of the patient serum was applied to each of 15 paper strips. After electrophoresis, one strip was colored with amido black to localize the different fractions, and the 5 mm electrophoretic fractions thus localized were cut out in the remaining 14 strips. The paper cuttings were eluted during 1 h in barbital buffer at 4°C, whereby the amount of barbital buffer added was proportional to the protein content of the different fractions. Of each eluate 0.5 ml were



mixed with 0.1 ml of normal plasma, diluted 1:10 with isotonic barbitol buffer during 30 min. Factor V activity was then assayed by the one-stage test. Figure 9 shows that the inhibitory activity was contained mainly in the  $\gamma$ -globulin fraction.

**Immunohemical investigations.** The patient's serum was submitted to OUCHTERLONY immunodiffusion tests against human and bovine factor V-preparations, against normal pooled plasma, as well as against factor V-free plasma (factor V reagent). A weak but definite precipitation line formed between the patient's serum and human factor V preparation, whereas reaction of the patient's serum with normal plasma pool remained doubtful. No reaction was observed between the patient's serum and bovine factor V preparation, and no precipitation line was formed, as expected, between the patient's serum and factor V free plasma. Due to the weak appearance of the precipitation line it was not possible to obtain convincing photographic picture for reproduction.

#### Follow-up Studies

On December 18th 1963, new sample of citrated blood was tested. No alteration in the clotting defect was discernible. Factor V activity was still only 3% of normal values.

The patient's general condition was unchanged. After transfusion, haematuria stopped for a few days, but then bleeding resumed. On December 20th, 1963, ACTH-therapy was started. A daily dose of 25 mg was given until January 6th, 1966. A few days after initiation of this therapy the general condition improved both objectively and subjectively. Haematuria stopped and the thromboplastin time showed substantial improvement amounting to 60% by December 29th, 1963. On January 5th, 1966, the coagulation analysis was resumed. With the exception of a slightly reduced factor V activity (60% of normal values) blood coagulation appeared normal (table I). On January 9th, 1966, the patient went to the bathroom where she suddenly collapsed and died. An embolic obstruction of the pulmonary artery as well as thromboses of the left femoral and iliacal veins were revealed at autopsy.

#### Discussion

The appearance of haemorrhagic diathesis caused by the action of inhibitors of the clotting system is well known. This phenomenon may be due to either a raised activity of physiological inhibitors (e.g. antithrombins) or the appearance of (usually acquired) circulating anticoagulants (e.g. specific inhibitors of factor VIII). Circulating anticoagulants are most frequently directed against factors VIII and IX or against tissue thromboplastin; however specific inhibitors of most other clotting factors may be found as well [8].

Formation of circulating anticoagulants specifically directed against factor V appears to be very rare. In addition to the one case mentioned by FERROUSO *et al* [5] there exists only the observation reported by HÖRDER [9-10] in 1955. A critical evaluation of HÖRDER's case especially with regard to the genetic pattern of the haemorrhagic diathesis and to his interpretation of the experimental data leaves it very doubtful that a factor V inhibitor was present at all. We are inclined to agree with FERROUSO *et al* who concluded that HÖRDER described a case of parahæmophilia.

The case reported in this study is very similar in its characteristics to the one described by FERGUSON. As a result of the inhibition of factor V an impairment of the prothrombin-conversion by the intrinsic as well as by the extrinsic activation mechanisms occurs accordingly the recalcification time the hirudin tolerance time, the partial thromboplastin time, as well as the thromboplastin time are distinctly prolonged. Inhibition experiments with purified factor V preparations clearly demonstrate the factor V specificity of the inhibitor. However the inhibitor present in our case, contrary to the inhibitor of FERGUSON *et al.*, did not react with bovine factor V and therefore appears to be species-specific. Furthermore it may be concluded from inhibition experiments, that the inhibitor is exhibiting immediate as well as progressive activity. Evidence indicating that the inhibitor could be an antibody appears to be of particular interest. This concept is supported by the physicochemical properties (electrophoretic behaviour as a  $\gamma$ -globulin) by the effect of ACTH-therapy but mainly by the results obtained in immunochemical analyses. In fact the inhibitor behaved as a weak precipitin it must be considered, however that most precipitating antibodies form only after prolonged and powerful antigenic stimulation.

For a long time, most authors were inclined to believe that acquired circulating anticoagulants were antibodies [8]. Inhibitors found in multi-transfused haemophiliacs are classified as isoantibodies since these patients do not possess the corresponding antigens (factor VIII or factor IX, respectively). Inhibitors observed *post partum* often can be related to an iso-immunization. In this case, one must postulate group-specific differences in the antigenic structure of the clotting factor in question. However such differences have not as yet been demonstrated.

Inhibitors detectable in cases of collagen disease (e.g. in patients with *lupus erythematosus disseminatus*) but also during the course of other diseases, such as chronic glomerulonephritis, liver cirrhosis, tuberculous lymphadenitis, sepsis lenta, leuc, pemphigus vulgaris, dermatitis herpetiformis, are likewise attributed to an immunologic origin. In all these cases, an auto-sensitization must be assumed. Indirect support for the concept of the antibody character of circulating anticoagulants in most instances may be gained from the patient's history or from the physicochemical behaviour of the inhibitor. Direct serological evidence has been presented only in a few cases. Occasionally precipitating antibodies against factor VIII or factor IX could be demonstrated

[4 6 11 12, 18 19] in other cases the inhibitor activity could be removed with a specific anti immunoglobulin anti-serum [2, 16, 17]. To our knowledge, an inhibitor with antibody activity directed against factor V has never been demonstrated before. In our case the antibody may be of autoimmune origin although the question of aetiology has to remain open. Neither clinical nor serological evidence for a generalised autoimmune disease was found. The aetiological role of drugs in the induction of autoantibody formation has to be considered. As mentioned already the patient was allergic to penicillin. STEFANI and DAMENIEK [17] reported on a patient with purpura SCHÖNLEIN HENOCH who developed a circulating anticoagulant directed against factor VIII after the administration of penicillin procaine simultaneously the clinical picture deteriorated. Dysprotein aemia of the  $\gamma$ -globulin type observed in this patient was traced back by the authors to the presence of large amounts of the inhibitor although no direct proof for its antibody character was offered. An analogous case has also been described by NUSSEY and DAWSON [19].

### *Acknowledgement*

We are greatly indebted to Dr H. VORONIA, Langenau, for putting blood samples as well as the case history and clinical data of his patient at our disposal.

### *Summary*

A severe haemorrhagic diathesis in 66-year-old woman was found to be due to circulating anticoagulant directed against clotting factor V. The inhibitor was species-specific and active immediately. Immunochemical studies presented evidence for the antibody character of the inhibitor.

### *References*

- 1 ANDERSON, B. R. and TOUT S. B.  $\gamma$ G-antibody to human antithrombotic globulin (factor VIII) *J Immunol.* 100: 173 (1968)
- 2 EDWARDS, E., DIMON, K. W. E., DICK, D. W. R., AUGUSTIN, R. and LEVY, G. M. Antibody nature of the inhibitor to antithrombotic globulin (factor VIII) *Nature, Lond.* 210 746 (1966)
- 3 BAOS, R. and DOUGLAS, A. S. The thromboplastin generation test. *J. clin. Path.* 6 23 (1953)
- 4 CRADDOCK, C. G. and LAWRENCE, J. S. A report of the mechanism of the development and action of circulating anticoagulant in two cases. *Blood* 2 505 (1947)

5. FERGUSON, J. H., JOHNSON, CH. L. and HOWELL, H. A. A circulating inhibitor (anti-AcG) specific for the labile factor V of the blood-clotting mechanism. *Blood* 13, 382 (1958).
6. FROMMEYER, W. B., ERTTER, R. D. and TYLER, F. H. L. Refractoriness in hemophiles to coagulation promoting agents: Whole blood and plasma derivatives. *Blood* 5, 401 (1950).
7. GURLEY, H. J. and HONO, R. J. A circulating anticoagulant in  $\gamma$ 1A-multiple myeloma its modification by penicillin. *J. clin. Invest.* 44, 1866 (1965).
8. HÄSSLI, A., STRECHMANN, H. and BUTLER, R. Immuno-plasmopathien; in *MANOWSKI und VOLLMEIER's Immunopathologie in Klinik und Forschung*, 2nd ed., p. 270 ff. (Thieme Stuttgart 1961).
9. HÖRMER, M. H. Isolierter Faktor V Mangel, bedingt durch einen spezifischen Hemmkörper. *Acta haemat., Basel* 13, 233 (1953).
10. HÖRMER, M. H. und SOMAI, G. Inhibitorstudien bei familiärem Faktor V Mangel. *Acta haemat., Basel* 14, 63 (1955).
11. HOCOTT, C. and FRANKLEY, M. E. The nature and action of circulating anticoagulants. *Acta haemat., Basel* 12, 1 (1954).
12. MITCHELL, F. L. and JONES, H. W. The detrimental effects of frequent transfusion in the treatment of patient with hemophilia. *Amer. J. med., Sci.* 206, 710 (1943).
13. NISBET, A. M. and DAWSON, D. W. Haemophilia-like disease due to an auto-antibody. *Brit. med. J.* ii, 1077 (1957).
14. OCHSALOWY, O. Diffusion-in-gel methods for immunological analysis. *Progr. Allergy* vol. 5, p. 1 (Karger Basel/New York 1956).
15. OWEN, F. A. in *J. ROSE's Klinische Methoden der Blutgerinnungsanalyse* (Thieme, Stuttgart 1959).
16. SERRANO, S. S. The immunological character of acquired inhibitors of anti-hemophilic globulin (factor VIII) and the kinetics to their interaction with factor VIII. *J. clin. Invest.* 46, 147 (1967).
17. STEFANO, M. and DANIELLE, W. The hemorrhagic disorders; 2nd ed., p. 339 (Grune & Stratton, New York/London 1962).
18. VERTRAETE, M. et VANDEBRUGGE, J. L'hémophilie compliquée par la présence d'un anticoagulant dans le sang. *Acta clin. belge* 9, 291 (1954).
19. VERTRAETE, M. and VANDEBRUGGE, J. Occurrence and mode of action of endogenous circulating anticoagulants. *J. lab. clin. Med.* 48, 673 (1956).

G W Hooper Foundation and Department of Medicine Section of Haematology and Immunology University of California Medical Center San Francisco, Cal., Department of Medicine The Permanente Medical Group, Kaiser Hospital, Oakland, Cal.

## Another Family Showing the Interaction of the Genes for Hb G and Hb S<sup>1</sup>

L. E. LIE INJO, A. C. WANG<sup>2</sup> and R. C. BURNETT

The combination of haemoglobin G $\alpha$  and haemoglobin S $\beta$  is rare. PUGH *et al* [12] described a family in which this abnormality resulted in 4 major haemoglobins in one individual and in mild anaemia. To our knowledge no other instance of Hb G $\alpha$ -Hb S $\beta$  combination has so far been reported. More frequent are instances of Hb G $\alpha$  combined with Hb C $\beta$ , which also lead to the presence of 4 haemoglobin components and to mild haematological symptoms. SMITH and TORBERT [18] described 4 haemoglobin components in cases of Hb Hopkins 2 - Hb S, and HALL-GRAGGS *et al* [5] in cases of Hb S - Hb Stanleyville II. Hb Hopkins 2 and Hb Sta II are also abnormal in the  $\alpha$ -chains. Family studies in such cases revealed that the mutants of the  $\alpha$  and  $\beta$ -chains were inherited independently of one another. The study of such exceptional families is essential to understand the mode of inheritance of haemoglobin abnormalities and to obtain a better idea of the arrangement of the genetic loci in the chromosomes. The more families that are studied, the better one can calculate the probable relative location of the genes.

We therefore believe it important to report another case of Hb G $\alpha$  combined with Hb S $\beta$ . It provides more data on the clinical and haematological expression of such an interaction and on the chromo-

This work was supported by Research Grant HE 10486-01 by the University of California ICMRT Hooper Foundation, San Francisco Medical Center with Research Grant TV 00144 from the Office of International Research, and by Training Grant HT-05677 all from the National Institutes of Health, US Public Health Service.

Postdoctoral Fellow (No. PF-407) from the American Cancer Society

somal relationship of the genes responsible for abnormal haemoglobins in an additional family

### Methods

Haematologic examinations were conducted according to standard methods. Haemoglobin electrophoresis was performed on starch gel [19] and on agar gel [15]. Alkaline denaturation of haemoglobin followed the method of STOKER *et al.* [17] with 2% of the total amount of haemoglobin taken as the upper limit of normal. The solubility test was performed by the method of ITASO [9]. Haemoglobin components were quantitatively analyzed on diethylaminoethyl (DEAE) cellulose column chromatography by the method of HUMMAN and DORY [7]. Polypeptide chains of haemoglobin were studied on starch gel electrophoresis in an urea-barbital system at pH 8.3 [4]. Fingerprinting of peptides was performed by BAWLOWA'S [2] modification of INGRAM'S method [8].

**Isolation of peptides.** Peptides for amino acid analysis were isolated on Whatmann 33(A) filter paper by one-dimensional electrophoresis followed by descending chromatography as described by LUGGAM [6]. Additional purification was achieved by descending chromatography in butanol, acetic acid, and water solvent (4:1:5 upper layer 24 h). After each step of separation, guide strips were cut from both sides of the paper and dipped in ninhydrin to locate the position of the band containing the peptide to be isolated. This region was then eluted with solvent of ethanol, acetic acid and water (50:0.15:49.85) pH 3.8, and the eluate was evaporated to dryness in a desiccator.

**Amino acid analysis.** The isolated peptides were hydrolyzed in 6 N HCl under reduced pressure at 110°C for 20 h, and the amino acids were analyzed on Spico automatic amino acid analyzer (Model 120 C).

### Case Report

H. E., the proband, was a 45-year-old Negro man who complained of prolonged tiredness. Upon examination he was somewhat pale but nonicteric and otherwise physically normal, without enlarged spleen or liver. Repeated blood examinations revealed mild anemia with slight macrocytosis. Haematological findings, when the patient was examined again on September 21, 1967 after repeated iron therapy, were as follows: Hb 12.5 g per 100 ml, RBC 5.40 million/mm<sup>3</sup>, PCV 39.0%, MCV 72.2  $\mu$ m<sup>3</sup>, MCH 22.8  $\mu$ g, MCHC 31.5, reticulocytes 2.1%. WBC and platelet counts normal. The peripheral blood smear showed slight anisocytosis and poikilocytosis with a few target cells. Sickling of the erythrocytes took place, although not readily when they were deprived of oxygen. Alkali-resistant haemoglobin was 0.5% of the total amount of haemoglobin. Acid elution for Hb F was negative. Serum bilirubin was not increased. Haemoglobin electrophoresis revealed 4 components: (1) Hb A, (2) haemoglobin component with the mobility of Hb S, (3) component with the mobility of Hb A<sub>2</sub>, and (4) slower haemoglobin component more cathodic than Hb A<sub>2</sub> and resembling Hb B<sub>2</sub> (Fig. 1).

Examination of the patient's wife, 2 daughters, and 3 sons disclosed the following: S. E., the 32-year-old Negro wife, was physically and haematologically normal. Her haemoglobin electrophoretic pattern was also normal, she showed no increase of fetal haemoglobin and her Hb A<sub>2</sub> level was not elevated. The 2 daughters, Qd and Qs, 15 and 14 years old, were physically normal. Their peripheral blood showed slight microcytosis, anisocytosis, and poikilocytosis and contained a few target cells. Results of the sickling test were positive, but sickling did not take place readily. The pattern of haemoglobin electrophoresis in these 2 daughters was identical to the father's, again consisting of 4 haemoglobin components




Fig 1 Starch gel electrophoresis in *trans*-EDTA-boric acid buffer pH 8.6 of the haemolysates of patient and family

(fig 1) Hb F was not increased. All 3 sons were physically normal. G.E., the eldest, 17 years old, was haematologically normal and had normal haemoglobin pattern on electrophoresis, normal Hb A<sub>2</sub> level, and no increase of Hb F. K.E., the 11-year-old second son had haemoglobin pattern like that of the father and two sisters. It consisted of 4 haemoglobin components, but their quantitative distribution differed (see 'Further Haemoglobin Studies') and his erythrocytes did not sickle. M.E., the 10-year-old youngest son had normal electrophoretic haemoglobin pattern without increase of Hb F or Hb A<sub>2</sub>. The haematological findings in all members of the family are listed in table I. After prolonged oral iron therapy haematological studies were repeated in all members of the family but they were found to be essentially unchanged.

#### *Further Haemoglobin Studies*

**Electrophoresis** Haemoglobin findings on starch gel electrophoresis have already been presented (Case Report). On agar gel electrophoresis, the haemolysate of the patient and the 2 daughters, whose red blood cells




Fig. 2. Agar gel electrophoresis in citric acid-sodium citrate buffer pH 6.2 of patient haemolysate compared with that of his son K. E. and standard Hb A + S. Note that there is no separation in the haemolysate of son K. E.

showed sickling, revealed two clearly separated components, the slow er-moving one having the same mobility as a standard Hb S (fig 2). This slower component was smaller than the component with the mobility of Hb A on agar gel electrophoresis, contrary to the finding on starch gel electrophoresis. The wife and 3 sons, including K. E., who showed a component like Hb S on starch gel electrophoresis but whose erythrocytes did not sickle, each had just one band like normal Hb A, indicating that in K. E. the slow moving Hb S like component, on starch gel electrophoresis was not Hb S. This explains the inability of his erythrocytes to sickle.

**Column chromatography** Quantitative analysis of haemoglobin components of family members was made by column chromatography. These components in the proband were: Hb A 99.5%, the component with the mobility of Hb S 43.9%, the one with the mobility of Hb A<sub>2</sub> 14.6% and the slowest component 2%. Percentages for the same components in the eldest daughter were 37.0, 46.8, 14.8 and 1.4% respectively. Insufficient blood was obtained from the second daughter to perform quantitative analysis on column chromatography. Data for K. E., with a component like Hb S on starch gel electrophoresis, were: Hb A 70%, the component like Hb S 26.9%, Hb A<sub>2</sub> 2% and the slowest component 1.1%. To further demonstrate that the component like Hb S in this son was not Hb S we separated and purified it by column chromatography. A solubility test showed that this component, unlike solutions containing Hb S, was fully



Table 1 Hematological data in patient and family members

Sex	Age years	Hb g/100 ml	RBC $10^6$ / $\text{mm}^3$	Hct %	MCV $\mu^3$	MCH pg	MCHC %	Reticu- cytes %	Hb A %	Hb G or Hb O %	Hb G/g <sup>1</sup> and Hb A <sub>2</sub> %	Hb A %	Hb C <sub>1</sub> %	Hb A <sub>2</sub> rele- vant %
H. E., propositus	M	43	11.8	3.06	75.1	23.3	30.5	2.1	39.5	43.9	14.6		2.0	0.5
S. E., wife	F	32	15.6	4.80	89.6	28.9	31.6	1.4	87.6	0	-	2.4	0	1.0
G. E., son	M	17	12.7	4.95	82.8	25.7	31.0	0.5	97.5	0	-	2.5	0	1.5
Qd. E., daughter	F	15	12.2	5.25	86.0	23.2	33.9	1.6	37.0	46.8	14.8	-	1.4	0.8
Qs. E., daughter	F	14	12.6	5.70	88.5	22.1	32.7	1.0	n.c.	n.c.	n.c.	n.c.	n.c.	0.9
A. E., son	M	11	11.9	5.04	86.0	23.6	33.1	0.8	70.0	26.9	-	2.0	1.1	1.8
M. E., son	M	10	11.9	4.90	77.6	24.5	31.5	0.6	97.5	0		2.5	0	0.6

Hb A<sub>2</sub> cannot be estimated in the presence of Hb G/g<sup>1</sup>.

Not examined.




Fig. 2. Starch gel electrophoresis in urea-veronal buffer pH 8.0 of the polypeptide chains of purified haemoglobin components.

soluble in the standard phosphate buffer solution. The haemolysates of the mother and the 2 other sons separated only into Hb A and Hb A<sub>2</sub>, the Hb A<sub>2</sub> level being normal (2.4% in the mother and 2.5% in the eldest and youngest sons).

**Polypeptide chain studies.** The different components were separated by column chromatography, concentrated, dialyzed, and their purity was determined on starch gel electrophoresis. The study of globins from the purified haemoglobin samples on starch gel electrophoresis in a urea-veronal buffer at pH 8.0 revealed that the haemoglobin with the mobility of Hb A in the propositus and his 2 daughters indeed had normal  $\alpha$ - and  $\beta$ -chains. The component with the mobility of Hb S, however, had 4 polypeptide chains: normal  $\alpha$ - and  $\beta$ -chains and abnormal  $\alpha$ - and  $\beta$ -chains (fig. 3). The abnormal  $\beta$ -chains resembled those of Hb S. These findings indicate that the component with the mobility of Hb S actually consisted of 2 different haemoglobins: (1) Hb S (whose presence explained the positive sickling) and (2) a haemoglobin whose mobility was similar to that of Hb S on starch gel electrophoresis at pH 8.6 but which had abnormal  $\alpha$ -chains. The patient's haemoglobin component with the mobility of Hb A<sub>2</sub> showed a similar abnormal  $\alpha$ -chain and an abnormal  $\beta$ -chain resembling that

Table 17 Amino acid composition of the 9a and 9b peptides of the second son K.E.

Amino acid	Peptide 9			Peptide 9b (= 5b)		
	Present work	Molar ratio Literature value for Hb G	Number <sup>1</sup> of residues reported for Hb G	Present work	Molar ratio Literature value for Hb G	No. of residues reported for Hb G
Lysine	1.82	1.91	2	0.99	0.81	1
Histidine				3.04	2.28	3
Aspartic acid	1.19	1.09	1	4.39	4.01	4
Threonine	0.94	0.87	1			
Serine				1.76	1.83	2
Proline				0.90	1.04	1
Alanine	1.80	2.13	2	3.13	4.92	5
Valine	1.14	0.96	1	2.09	2.03	2
Methionine				0.16	(1)	1
Leucine	1.00	1.00	1	3.00	3.00	3

<sup>1</sup>BA LLOYD AND INGRAM [3].

The greatest portion of the methionine in our analysis was oxidized to methionine sulfoxide, which appears on the chromatogram as peak before the aspartic acid peak (11).

### Discussion

From the clinical and haematological findings for the patient and his two daughters, in all of whom the abnormal genes for Hb G and Hb S were present simultaneously we concluded that interaction between the 2 abnormal genes does not lead to significant impairment of health. However mild anaemia may be present, and their peripheral blood showed slight anisocytosis and poikilocytosis and a few target cells. In the case of simultaneous occurrence of Hb G and Hb S described by PUGH *et al.* [12] the patient, a child, had severe anaemia and clinical symptoms. However the condition in that case was complicated by homozygosity for the Hb S gene itself leading to severe anaemia. The child's mother on the other hand, was doubly heterozygous for Hb G and Hb S and had only mild anaemia and slight changes in the peripheral blood.

Biochemically our patient and his two daughters, all with the same abnormal haemoglobin pattern, again provide evidence that normal and abnormal  $\alpha$ -chains and normal and abnormal  $\beta$ -chains are produced independently as reported by other investigators. Identical peptide chains form symmetrical dimers, which combine at random and

lead to the formation of 4 major haemoglobins. As in the case of PUON *et al* [19] 2 haemoglobins besides Hb G and Hb S are formed, Hb A with normal  $\alpha$  and  $\beta$ -chains and Hb G/S with abnormal  $\alpha$ - and  $\beta$ -chains. Figure 3 shows that in our patient's component 2, which consists of Hb G and Hb S the spots indicating  $\alpha^G$  and  $\beta^A$  are more pronounced than the spots indicating  $\alpha^A$  and  $\beta^S$  which means that the amount of Hb G is higher than Hb S. This is in agreement with the observations of PUON *et al* in the only other known family with Hb G and Hb S. Using a different quantitative technique they showed in their patient's mother who carried the genes for Hb G as well as for Hb S that the amount of Hb G was higher than the amount of Hb S. They postulated that the presence of some type of non-allelic genetic regulator might have impaired the normal  $\alpha$ -chain production. The decreased availability of  $\alpha_2^A$  subunits would then result in lower proportion of Hb A and Hb S. Whether this is always the case in Hb G and Hb S combinations cannot be said since the family of PUON *et al* and the one described in this paper are the only ones available for study.

Genetically the family we have described is of interest because the proband, who had two abnormal genes, was married to a normal woman. Since 2 of his children inherited both his abnormal genes, one child inherited only one abnormal gene, and 2 inherited no abnormal haemoglobin, it can be concluded that the genes are not alleles. Hence, the 2 abnormal genes are either located in 2 different chromosomes that were inherited independently or are linked in one chromosome but one son received only one abnormal gene due to crossing over. Unfortunately descriptions of such critical matings have been too few to permit a more accurate evaluation of the chromosomal relationship of the genes. In the family reported by PUON *et al*., in which the genes for Hb G and Hb S were segregating, the observed inheritance of Hb G and Hb S was complicated because the husband was a Hb S trait carrier and therefore not normal. One child from this mating was heterozygous for Hb G and homozygous for Hb S, another was normal, and the other children were not available for study.

As already mentioned, the segregation of the genes for Hb G and Hb C $\beta$  has been described more often than the combination of Hb G $\alpha$  and Hb S $\beta$ . Since the genes for Hb C and Hb S are alleles, the mode of inheritance for Hb C also applies for Hb S and information regarding the chromosomal relationship between the Hb S $\beta$  and Hb G $\alpha$  genes can also be derived from families in which Hb C and Hb G are

segregating. Unfortunately again in the publications about such combinations, critical matings for genetic study were rarely reported. In the family described by RAPER *et al.* [13] a man doubly heterozygous for Hb G and Hb C was married to a normal woman and they produced one doubly heterozygous child and one Hb C trait carrier. Matings less suitable for genetic information have been reported by others. In the family described by WEATHERALL *et al.* [20] a man with the Hb C trait married a woman heterozygous for Hb G. Of the 5 offspring of this mating who were examined, one was normal, one heterozygous for Hb G and 3 were doubly heterozygous for Hb G and Hb C. In the family reported by RIEDER and NAUGHTON [14] a man homozygous for Hb C married a woman heterozygous for Hb G and they produced one child who was doubly heterozygous for Hb G and Hb C. In this case the Hb G was Hb G Baltimore instead of Hb G Philadelphia. In the family with Hb G and Hb C described by ATWATER *et al.* [1] the husbands of the women reported were not examined. Another combination of an  $\alpha$ -chain abnormality with a  $\beta$ -chain abnormality was reported by HALL-CRAIGS *et al.* [5] in a family in which the genes for Hb S and for Hb Sta II were segregating. On starch gel electrophoresis the Hb Sta II had the same mobility as Hb S and was shown to be an  $\alpha$ -chain abnormality, but the fingerprints revealed that it differed from Hb G. Three matings in this family were available for study. In one, the husband and wife, both doubly heterozygous for Hb S and Hb Sta II produced 2 children: one heterozygous for Hb S and one for Hb Sta II. In the second mating a Hb S trait carrier married a woman doubly heterozygous for Hb S and Hb Sta II. Five children resulted from this marriage: two were heterozygous for Hb S, one was homozygous for Hb S and one doubly heterozygous for Hb S and Hb Sta II while the fifth was homozygous for Hb S and heterozygous for Hb Sta II. In the third mating, a man doubly heterozygous for Hb S and Hb Sta II who was twice married to normal women, fathered 4 children: two were Hb Sta II trait carriers, one was normal, and one was doubly heterozygous for Hb S and Hb Sta II.

In another family in which abnormal  $\alpha$ -chain and abnormal  $\beta$ -chain haemoglobins were found together Hb S was combined with Hb Hopkins-2 [18] a fast moving haemoglobin that later was shown to be abnormal in the  $\alpha$ -chains. In the second generation of this family a critical mating took place between a woman doubly heterozygous for Hb S and Hb Hopkins-2 and a normal man, resulting in 7 children. Of 6 of them studied, one was doubly heterozygous for Hb S and

Hb Hopkins-2, 3 were heterozygous for Hb S and  $\square$  for the fast moving Hb Hopkins-2.

From the findings so far reported and from the additional family described in this paper a close chromosomal linkage between the genes for Hb G $\alpha$  and Hb S $\beta$  is indeed unlikely

### *Acknowledgment*

We wish to thank Mr ROBERT MONTAGNA of the Hooper Foundation for technical help in this study

### *Summary*

A second family with Hb G Philadelphia (an  $\alpha$ -chain abnormality) and Hb S is described, in which the proband, a Negro man, was doubly heterozygous for Hb G Philadelphia and Hb S and had 4 major haemoglobins: Hb G, Hb S, Hb A, and Hb G/S. His wife was normal. Two of his five children were doubly heterozygous for Hb G and Hb S and had the same haemoglobin pattern as the father; two others were normal, and another child inherited only the gene for Hb G Philadelphia. In this family the interaction between the genes for Hb G Philadelphia and Hb S led to mild anaemia and slight changes in the peripheral blood.

### *References*

1. ATWATER, J.; SCHWARTZ, L. R. and THORNTON, L. M. A variety of human haemoglobin with 4 distinct electrophoretic components. *Blood* 15: 901-908 (1960).
2. BAGLIOLI, C. An improved method for the fingerprinting of human haemoglobin. *Biochem. Biophys. Acta* 48: 392-396 (1961).
3. BAGLIOLI, C. and LUGRAM, V. M. Four adult haemoglobin types in one person. *Nature, Lond.* 189: 463-467 (1961).
4. CHERNOFF, A. L. and PETTIT, N. M. J. The amino acid composition of haemoglobin. III. A qualitative method for identifying haemoglobin variants of the polypeptide chains of haemoglobin. *Blood* 24: 750-756 (1964).
5. HALL-CRAIG, M.; MARSDEN, P. D.; RAPER, A. B. LEHMANN, H. and BRALL, D. Homozygous sickle-cell anaemia arising from two different haemoglobins S. Interaction of haemoglobins S and Stanleyville-II. *Brit. med. J.* 4: 87-89 (1964).
6. HILL, R. L. and SCHWARTZ, H. C. A chemical abnormality in haemoglobin G. *Nature, Lond.* 184: 641-642 (1959).
7. HUBMAN, T. H. J. and DORF, A. M. Studies on the heterogeneity of haemoglobin. IX. The use of Tris (hydroxymethyl) aminomethane-HCl buffers in the anion-exchange chromatography of haemoglobins. *J. Chromatogr.* 29: 160-169 (1963).
8. LUGRAM, V. M. Abnormal human haemoglobins. I. The comparison of normal human and sickle-cell haemoglobins by fingerprinting. *Biochem. Biophys. Acta* 20: 539-545 (1958).
9. IYANO, H. A. Solubilities of naturally occurring mixtures of human haemoglobin. *Arch. Biochem.* 47: 148-185 (1953).

- 10 McCURDY P R.; PEARSON, H. and GERALD, P S. A new haemoglobinopathy of unusual genetic significance. *J lab. clin. Med.* 58: 86-94 (1961)
- 11 MOORE, S. and STEIN, W H.: Chromatographic determination of amino acids by the use of automatic recording equipment; in COLLOWICK and KAPLAN's *Methods in enzymology* Vol. 6, pp. 819-831 (Academic Press, New York 1963)
- 12 PUGH, R. P.; MONICAL, T V and MORGAN, V. Sickle cell anaemia with two adult haemoglobins - Hb S and Hb G Philadelphia. *Blood* 23: 206-215 (1964)
- 13 RAPEL, A. B.; GAMMAGE, D. B. HURON, E. R. and SMOOT, E. M.: Four haemoglobins in one individual. A study of the genetic interaction of Hb-G and Hb-C. *Belt. med. J.* 1257 1261 (1960).
- 14 RUDER, R. F. and NAUGHTON, M. A.: Haemoglobin G (Baltimore): A new abnormal haemoglobin and an additional individual with four haemoglobins. *Bull. Johns Hopk. Hosp.* 116 17 32 (1963)
- 15 ROMONOW, A. R.; ROMON, M.; HARRISON, A. P. and ZUKLER, W W. A new technique for differentiation of haemoglobins. *J lab. clin. Med.* 50 745-752 (1957)
- 16 SCHWARTZ, H. G.; SPART, T H.; ZUKLER, W W.; NERI, J V.; ROMONOW, A. R. and KAUFMAN S. F. Combinations of haemoglobin G, haemoglobin S and thalassaemia occurring in one family. *Blood* 12: 238-250 (1957)
- 17 SINGER, L.; CHERKOVY A. I. and SINGER, L. Studies on abnormal haemoglobins. I. Their demonstration in sickle cell anaemia and other haematologic disorders by means of alkali denaturation. *Blood* 6: 413-428 (1951)
- 18 SMITH, E. W. and TOMASKI J. V.: Study of two abnormal haemoglobins with evidence for new genetic locus for haemoglobin formation. *Bull. Johns Hopk. Hosp.* 107 38-45 (1958)
- 19 SERRAVALLO, O. An improved procedure for starch-gel electrophoresis. Further variations in the serum proteins of normal individuals. *Biochem. J.* 71 585-587 (1959)
- 20 WEATHERALL, D. J.; SAGLER, A. T. and BAERSON, C. Four haemoglobins in each of three brothers. Genetic and biochemical significance. *Bull. Johns Hopk. Hosp.* 111 143-156 (1962)

Authors' addresses: Dr L. E. Lai Injo, G.W Hooper Fdn. Institute for Medical Research, Kuala Lumpur (Malaysia); Dr A.C. Wang, Dept. of Medicine, Section of Haematology University of California Med. Center San Francisco Cal. (USA), and Dr. RICHARD G. BURGERTT Dept. of Medicine, The Permanente Medical Group, Kaiser Hospital, Oakland, Cal. (USA)

The Second Department of Internal Medicine, Gama University School of Medicine,  
Machushi

## Effect of Androgen Antagonist on Erythropoietic Action of Testosterone

T. SHIRAKURA, M. AZUMA and T. MAEKAWA

It has already been established that the prolonged administration of androgen results in an increase in erythropoiesis either in experimental animals or in patients with various types of aplastic anemia or with breast cancer [1-4] although the exact mechanism remains unknown. Some investigators have recently suggested that androgenic steroid exerts its stimulatory effect on erythropoiesis through increased production of erythropoietin in the kidney [5,6]. One of the authors has pointed out the fact that this steroid has an ability to enhance a response of the erythroid tissue to hypoxic stimuli [7]. It is well known that androgen has both anabolic and virilizing activity.

The experiments presented in this paper were carried out in order to clarify the following questions: Which activity is responsible for an increase in erythropoiesis? What relationship exists between erythropoiesis stimulating activity and these two main activities of androgen?

### *Materials and Methods*

**Experiment 1.** Female rats of Wistar strain weighing 120 g were used as experimental animals, and divided into the following 5 groups. Each rat of group 1 received an intramuscular injection of 12.5 mg of testosterone as a mixture of enanthate and propionate in 0.1 ml of sesame oil (Korinosei depot® Teikoku-yokai Co.). Each rat of group 2 was injected with 12.5 mg of methenolone acetate (Promobolan depot® Schering AG) intramuscularly. Each rat of group 3 or group 4 received an intramuscular injection of 12.5 mg of testosterone or methenolone respectively and thereafter 10.0 mg of antiandrogenic agent, cyproterone acetate (1,2a-methylene-6-chloro-4 $\alpha$ -pregnandene 17 $\alpha$ -ol-3,20-dione 17 $\alpha$ -acetate) in

This compound was generously supplied by Dr. F. NEUMANN, Schering AG, Berlin.



0.2 ml of a benzyl-benzoate-castor oil mixture [1:3 (v/v)] was injected intramuscularly for week. Group 5 was served as control, which received an intramuscular injection of both 0.1 ml of sesame oil and 0.2 ml of a mixture of benzyl-benzoate-castor oil for week.

**Experiment 2.** Female mice of ddN-strain weighing 20 to 25 g were made plethoric by two daily intraperitoneal injection with 0.6 ml of an 80 percent suspension of washed homologous erythrocytes. The plethoric mice were divided into 9 groups. Each mouse of group A, B, C, or group D, E, F was given the following experimental procedures 6 days after single intramuscular injection with 2.5 mg of testosterone or with both similar dose of testosterone and 10 mg of cyproterone acetate, respectively: intramuscular administration of p-3 Co-units of purified erythropoietin (Ep) to group A and D, exposure to hypoxia of  $\frac{1}{2}$  atmosphere for 12 h to group B and E, and intramuscular injections with 0.3 ml of normal saline to group C and F. This injection with testosterone or with both testosterone and cyproterone acetate was carried out on the day of the last infusion of erythrocyte suspension. Six days after the last infusion of erythrocyte suspension, each mouse of group G, H or I was given the above described experimental procedures except the injection with testosterone or with both testosterone and cyproterone acetate.

**Experiment 3.** Seventeen plethoric mice similar to those used in experiment 2 were divided into 4 groups consisting of 4 to 6 mice. Each mouse of group J, K, L or M was injected with 0.6 Co-units of Ep, both 0.6 Co-units of Ep and 10 mg or 5 mg of cyproterone acetate, 0.6 ml of normal saline, respectively.

Quantitative determination of erythropoiesis was done as follows: rats were injected with 0.5  $\mu$ Ci of radioiron ( $^{59}\text{Fe}$  Cl<sub>3</sub>) intravenously 24 h after the last injection of mixture of benzyl-benzoate-castor oil or cyproterone. Mice were similarly injected with 0.5  $\mu$ Ci of radioiron intraperitoneally 36 h after the last injection of normal saline, Ep, hypoxic stimulation. The percentage of  $^{59}\text{Fe}$  incorporation into red cell mass was determined from the radioactivity of the blood sample taken by cardiac puncture on 24th h in rats and 72nd h in mice after the injection of radioiron, assuming the total blood volume of test animal is 5.0% (in rat) or 7.0% (in plethoric mouse) of the body weight.

Bioassay for erythropoietin was carried out by MURRAY's method [8]. Plasma samples obtained from each animal of the same experimental group were pooled and stored at -20°C until bioassay for erythropoietin activity was done. Activity of the erythropoietin in the pooled plasma sample was expressed as percentage of  $^{59}\text{Fe}$  utilized by red cell mass of bioassay mice in 24 h.

## Results

**1 Effect of androgen antagonist on  $^{59}\text{Fe}$  incorporation into red cell in testosterone or anabolic hormones treated rats.** As shown in table I significant increase in both  $^{59}\text{Fe}$  incorporation and reticulocyte counts was noted in rats injected either with testosterone (group 1) or with methenolone (group 2). The activity of erythropoietin in pooled plasma obtained from these animals was evidently elevated, as compared with control rats of group 3. There was, however, no significant difference in these values between group 1 and 2. Cyproterone administration did not suppress the enhancing effect of testosterone or methenolone both on  $^{59}\text{Fe}$  incorporation into red cell and on erythropoietin activity in

**Table I.** Effect of androgen antagonist on erythropoiesis and plasma erythropoietin level of female rats treated with testosterone or anabolic hormone

Experimental group	No. of animals	% <sup>59</sup> F incorp. into RBC	Reticulocyte count, %	Plasma erythropoietin level, %
Rats injected with Testosterone (group 1)	5	34.6 ± 5.9	6.36 ± 1.18	4.53 ± 1.38
Methenolone (group 2)	5	31.6 ± 4.5	5.06 ± 0.29	2.21 ± 0.81
Both Testosterone and Cyproterone (group 3)	5	29.6 ± 4.0	5.02 ± 1.44	3.18 ± 1.09
Both Methenolone and Cyproterone (group 4)	5	28.5 ± 5.4	4.30 ± 1.56	2.71 ± 1.02
Normal control (group 5)	8	23.6 ± 4.8	3.5 ± 1.30	0.62 ± 0.21
Mean ± S.D. of the mean.				

**Table II.** Effect of androgen antagonist on erythropoietic synergism of testosterone with erythropoietin or hypoxia

Experimental group	No. of animals	% <sup>59</sup> F incorporation into RBC
Mice pretreated with testosterone		
Erythropoietin (group A)	5	16.20 ± 3.15
Hypoxia (group B)	4	12.38 ± 2.48
Saline (group C)	5	3.65 ± 1.83
Mice pretreated with both testosterone and cyproterone		
Erythropoietin (group D)	5	13.49 ± 2.18
Hypoxia (group E)	4	9.15 ± 2.35
Saline (group F)	5	2.76 ± 1.67
Normal mice		
Erythropoietin (group G)	5	9.50 ± 2.24
Hypoxia (group H)	6	3.44 ± 1.12
Saline (group I)	5	0.42 ± 0.13
Mean ± S.D. of the mean.		

Table III. Effect of androgen antagonist on an enhancing  $^{59}\text{Fe}$  incorporation into RBC in plethoric mice induced by exogenous erythropoietin

Experimental group	No. of animals	Hematocrit %	% $^{59}\text{Fe}$ incorporation into RBC
0.6 Co-U of erythropoietin (group J)	4	$63.2 \pm 3.7$	$18.20 \pm 2.21$
Both 0.6 Co-U of erythropoietin and 10 mg of Cyproterone (group K)	4	$59.2 \pm 4.4$	$19.00 \pm 2.26$
Both 0.6 Co-U of erythropoietin and 5 mg of Cyproterone (group L)	4	$58.5 \pm 3.5$	$16.27 \pm 4.00$
Saline (group M)	5	$62.0 \pm 3.0$	$0.86 \pm 0.22$

$\Delta$  mean  $\pm$  S.D. of the mean.

plasma. Similarly cyproterone exhibited no inhibitory effect on an erythropoietic action of methenolone, as seen in table I.

2 *Effect of androgen antagonist on erythropoietic synergism of testosterone with erythropoietin or hypoxia.* The results obtained are shown in table II. The combined effect of administration of testosterone with an erythropoietin injection (group A) or exposure to hypoxia (group B) on  $^{59}\text{Fe}$  incorporation into red cell exceeded the value calculated from the sum of each stimulus (group C, G and H). From the results obtained in mice of group A and D or group B and E, it was evident that the treatment with cyproterone did not change the synergistic effect of testosterone with erythropoietin or hypoxia on erythropoiesis.

3 *Study of the inhibitory effect of androgen antagonist on erythropoiesis.* The results obtained in experiment 3 are listed in table III. Administration of 50 or 100 mg of cyproterone did not exert influence upon the enhancing  $^{59}\text{Fe}$  incorporation into red cell induced by an exogenous erythropoietin given simultaneously.

### Comment

It is noteworthy that methenolone has the same erythropoietic activity as testosterone at an equal dose level, despite the fact that the virilizing effect was one fourth of that of testosterone. This finding indicates that an erythropoietic stimulating activity of testosterone may not directly related to its virilizing effect. DUARTE *et al.* have also reported similar

results [9] Cyproterone acetate used in these experiments has no estrogenic effect but blocking activity of androgen receptor in target organ [10-11]. The results obtained hereabout reveal that cyproterone has no inhibitory effect on erythropoiesis stimulating action of either testosterone or methenolone. An increase in erythropoiesis induced by testosterone should be prevented by this androgen antagonist, if an erythropoietic action of testosterone is related directly to its androgenic effect. There are some evidences indicating that increase in erythropoiesis by testosterone results from an elevation in endogenous erythropoietin activity. Cyproterone did not affect the action of exogenous erythropoietin. Thus, it is indicated from the results presented here that the erythropoietic activity of testosterone is at least independent of its virilizing effect. Administration of androgen antagonist could not inhibit a synergistic effect of testosterone with hypoxia or erythropoietin on erythropoiesis. It is also possible to say that these synergism might not be based upon the virilizing effect of testosterone, although mechanism on these synergism remains to be clarified.

### Summary

The mechanism of erythropoietic action of testosterone, especially its relation to virilizing effect was studied, and the following results were obtained. (1) At an equal dose level methenolone has the same erythropoietic activity as that of testosterone. (2) Treatment with sufficient amount of cyproterone acetate failed to suppress an erythropoietic effect of testosterone, methenolone or exogenous erythropoietin. Cyproterone acetate did not prevent significant increase in erythropoietin level in plasma by injecting testosterone or methenolone. (3) Synergistic effect of testosterone with exogenous erythropoietin or hypoxia on radioiron utilization was not affected by cyproterone acetate. From these results it is suggested that the erythropoietic action of testosterone is independent of its virilizing effect.

### References

1. SUGIYAMA, T., AIZUMI, M. and MAKIYAMA, T. Studies on erythropoietic action of testosterone. *Acta haemat.*, Basel 30: 49 (1967).
2. BRADSHAW, N. T. and DRAMMOND, L. K. Testosterone-induced remissions in splenic neoplasms of both acquired and congenital types. *New Engl. J. Med.* 264: 933 (1961).
3. GARBER, E. H. and FENWICK, J. C., Jr. Androgens and erythropoiesis. II. Treatment of myeloid metaplasia. *New Engl. J. Med.* 264: 103 (1961).
4. KENNEDY, B. J. and GILBERTSON, A. S. Increased erythropoiesis induced by androgenic hormone therapy. *New Engl. J. Med.* 235: 719 (1957).
5. FRIED, W. and GORMLEY, C. W. The erythropoietic response to testosterone in male and female mice. *J. lab. clin. Med.* 67: 420 (1966).
6. ALIKHAN, R., VAUGHN, W. K. and RUDOLPH, M. W. Erythropoietin excretion in man following androgens. *J. lab. clin. Med.* 70: 777 (1967).

- 7 SHIRAKURA, T. Zur erythropoetischen Wirkung von Testosteron. *Acta haemat., Basel* 39: 366 (1968).
- 8 MIRAND, E. A.; GORDON, A. S. and WENGO, J. Mechanism of testosterone action in erythropoiesis. *Nature, Lond.* 206: 270 (1965).
- 9 DUARTE, L., MEDAL, L. S.; LABARONNE, J. and ARRIAGA, L.: The erythropoietic effects of anabolic steroids. *Proc. Soc. exp. Biol., N.Y.* 125: 1030 (1967).
- 10 RAYHAUD, A.: Morphogenesis of the mammary gland; in Koss and Cowpe's (eds.) *The mammary gland and its secretion*, p. 3 (Academic Press, New York/London 1961).
- 11 NEIMANN, P. and ELGER, W. The effect of the anti-androgen 1,2a-methylene-6-chloro- $\Delta^4$ -pregnadiene-17 $\alpha$ -ol-3,20-dione 17 $\alpha$ -acetate (cyproterone acetate) on the development of the mammary glands of male foetal rats. *J. Endocrin.* 36: 547 (1968).

Departments of Clinical Chemistry and Internal Medicine, University of Uppsala, University Hospital, Uppsala

## Maintenance Therapy of Pernicious Anaemia

Comparison of Cyanocobalamin, Hydroxocobalamin and a Cyanocobalamin-Zinc-Tannate Complex

A. KILLANDER and I. WERNER

The proper evaluation of different compounds for maintenance therapy in pernicious anaemia has always been difficult. It is well known that following interruption of treatment the time at which a relapse occurs may vary considerably in different patients [19 15, § 4]. In a previous communication we reported the serum  $B_{12}$  levels in 45 patients after discontinuation of  $B_{12}$  therapy [12]. Twenty patients reached low levels (100 pg/ml and less) within the first year and a further 20 within the second year. One patient was still normal after 26 months whereas the remaining 4 cases did not show low values until 44 months or more after the specific treatment had been discontinued. The reasons for this large individual variation are incompletely known.

The earliest sign of  $B_{12}$  deficiency is a subnormal serum level of this vitamin [13 10]. By taking serial blood samples different  $B_{12}$  compounds can be compared, using the patient as the control. The results of such a study are presented in this paper. The substances tested were cyanocobalamin (CN  $B_{12}$ ), hydroxocobalamin (OH  $B_{12}$ ) and cyanocobalamin-zinc tannate complex (Zn  $B_{12}$ ). These abbreviations are used throughout the paper.

### Material

The series consisted of 22 patients with untreated pernicious anaemia. In all cases positive diagnosis was indicated by the presence of the following criteria: macrocytic anaemia, megaloblastic bone marrow, histamine-fast achlorhydria, serum  $B_{12}$  concentration of 100 pg/ml and less and typical response to  $B_{12}$  therapy. In 17 cases all 3  $B_{12}$  preparations

were studied consecutively at least once. The remaining 5 patients for different reasons were given only 2 of the compounds. All vitamin B<sub>12</sub> compounds used contained 1 mg/ml. The following preparations of the above mentioned substances were used: Hepagon forte® (cyanocobalamin) Redisol® Hepagon novum® (hydroxycobalamin) Depintr® (cyanocobalamin-di-n-o-tannate)<sup>1</sup>

### Methods

Routine haematological methods were used. The assay of vitamin B<sub>12</sub> activity in serum and urine was performed microbiologically using *Escherichia gracilis* strain 8 [8]. In our laboratory values of 100 pg/ml or less are defined as being abnormally low and indicating B<sub>12</sub> deficiency. Values between 100 and 150 pg/ml are regarded as borderline and those between 150 and 900 pg/ml as normal. Urine was collected for 24 hour periods, kept in refrigerator at +4°C for not more than 48 h. Frozen aliquots were stored at -20°C until assayed. In some cases <sup>57</sup>Co- or <sup>58</sup>Co-labelled vitamin were used in the excretion studies. The radioactivity was measured in 1,000 ml volumes in scintillation counter. The rate of absorption of the different compounds from the site of injection was studied using radioactive vitamin and surface counting.

Each patient received an initial injection of 1 mg of either CN B<sub>12</sub>, OH B<sub>12</sub> or Zn B<sub>12</sub>. Haemoglobin concentration, red cell count, reticulocyte count and serum B<sub>12</sub> levels were estimated at frequent intervals following the initial injection until normal blood levels were seen. After this period haemoglobin or haematocrit determinations and serum B<sub>12</sub> levels were performed monthly or in some cases every second month. The interval from the injection to the first low serum B<sub>12</sub> value was taken as a measure of the duration of the therapeutic effect of the substance tested. After the second consecutive low value a second injection of another type of B<sub>12</sub> was given. The haemoglobin or haematocrit values as well as the serum B<sub>12</sub> levels were followed monthly as before. A third injection again of a different substance was given following the finding of two further consecutive subnormal values. In some cases the experiment was continued for up to 3 more injection-relapse cycles.

### Results

All 3 preparations were studied in 17 patients. Five of these had CN B<sub>12</sub>, 5 had OH B<sub>12</sub> and 7 had Zn B<sub>12</sub> as their first injection. A full haematological remission was obtained in all patients by this initial injection of 1 mg of vitamin B<sub>12</sub>. No differences were found between the groups of patients with regard to the time and height of the reticulocyte peak or the rate of increase in the number of red cells. Haematological remission was also maintained during the following experiments and no neurological symptoms or signs developed in any patient. Nor were any other symptoms encountered which could be attributed to B<sub>12</sub> deficiency.

We are greatly indebted to AB Astra, Sweden, Merck, Sharp & Dohme Inc., Rahway N.J., USA and Armour Pharmaceutical Company, Kankakee, Ill., USA for the gift of these preparations.




Fig 1 Seventy-two hour urinary excretion of vitamin B<sub>12</sub> after single injection of 1 mg of CN B<sub>12</sub>, OH B<sub>12</sub> and Zn B<sub>12</sub>. Each block represents 72 hour period in one patient.

### Urinary Excretion

The 72 hour urinary excretion of CN B<sub>12</sub>, OH B<sub>12</sub> and Zn B<sub>12</sub> was studied in 9, 13 and 11 patients respectively. Nine patients were subjected to 2 or 3 excretion studies. The excretion of CN B<sub>12</sub> and OH B<sub>12</sub> is negligible after 72 h. In the case of Zn B<sub>12</sub> the situation is variable. Usually there is a protracted excretion between 72 h and 168 h, in some cases amounting to 5–10%. The results are presented in figure 1. The mean and range of excretion for the 3 substances were CN B<sub>12</sub> 746 µg (543–1 000), OH B<sub>12</sub> 284 µg (99–647) and Zn B<sub>12</sub> 112 µg (3–535). Although there was considerable variation between the different patients it was evident that much more was lost after a single injection of 1 mg of CN B<sub>12</sub> than of the other 2 compounds tested. About 75% of the CN B<sub>12</sub>, 30% of the OH-compound and 10% of the Zn B<sub>12</sub> was lost in the urine during the first 3 days.

In a few cases excretion studies were performed using both an isotope technique and microbiological assay. In the case of CN B<sub>12</sub> alone or in the zinc-tannate complex there was good agreement between the results obtained from the two methods. In some cases that were given OH B<sub>12</sub> the excretion of radioactivity was considerably higher than the corresponding microbiological activity. The reason for this discrepancy was most probably that the urine had been left at room temperature. We have found that urine samples left at room temperature will at times cause a fall in B<sub>12</sub> activity when OH B<sub>12</sub> is present but not with solutions of CN B<sub>12</sub>. The figures given for OH B<sub>12</sub> excretion thus






Fig. 2. Rate of absorption of 1 mg radioactive CN B<sub>12</sub> (—○—) OH B<sub>12</sub> (---○---) and Zn B<sub>12</sub> (—○—) from the site of injection.

represent minimum values as it cannot be excluded that some of the urine samples may have been subjected to mishandling as mentioned above.

### Rate of Absorption

This was studied in 7 patients. A possibility of a difference between subcutaneous and intramuscular administration was investigated in one patient. One mg of radioactive CN B<sub>12</sub> was injected intramuscularly in the gluteal region and subcutaneously in the thigh on 2 consecutive days. There was a slight difference in the absorption rate between the 2 routes of administration. Fifty % of the dose had disappeared 42 min after the intramuscular injection and 48 min after the subcutaneous injection. In the other 6 patients the radioactive compounds were only given intramuscularly. The absorption rate of the 3 compounds differed considerably as illustrated in figure 2. Thus, 50% of the injected dose of CN B<sub>12</sub> disappeared 26 and 42 min after the injection (2 cases). The corresponding figures for OH B<sub>12</sub> was 2.5 h (one case) and for Zn B<sub>12</sub> 1.6 to 2.4 days (4 cases).

### The Serum B<sub>12</sub> Levels

The time from the injection to the first serum B<sub>12</sub> level found to be 100 pg/ml and below was considered as the duration of the therapeutic




Fig. 3. The serum  $B_{12}$  values of case H.F.

effect. This level was chosen since all patients, when started on therapy had serum  $B_{12}$  values below this level. In order to ascertain that a stable subnormal  $B_{12}$  level had been reached the next injection was not given until a second low value had been obtained. In this way the conditions at the time of injection were considered to be as standardized as possible without exposing the patients to the risks of a relapse. It is reasonable to believe that the  $B_{12}$  deficiency was most pronounced at the time of the first injection. For this reason the 3 compounds were injected in random order. In this way other possible systematic errors were also avoided.

The results showed a considerable individual variation, the extremes are represented by patient H. F. and K. J. Their serum  $B_{12}$  levels after the injection of the different compounds are illustrated in figure 3 and 4. In the case of H. F. the effect of the first CN  $B_{12}$  injection did not even last one month. The effect of the long-acting preparations was 2 to 3 months. In the case of K. J. the effect of CN  $B_{12}$  lasted 2.5 months. After the injection of Zn  $B_{12}$  the serum  $B_{12}$  level remained above 100 pg/ml for 18 months. After the same amount of OH  $B_{12}$  the  $B_{12}$  levels were above 100 pg/ml for more than one year when the patient died from a cerebral haemorrhage.

The data from all 22 patients are shown in figure 5. The mean values are given in table I. It is evident that the duration of the therapeutic effect of OH  $B_{12}$  and Zn  $B_{12}$  is considerably longer than




Fig. 4 The serum  $B_{12}$  values of case K.J.




Fig. 5. The duration of serum  $B_{12}$  levels above 100 pg per ml following injections of 1 mg of CN  $B_{12}$ , OH  $B_{12}$  and Zn  $B_{12}$ . The preparations are pictured in the order of administration.

Table 1

Substance	No. of injection-relapse-cycles	Duration of cycle in months	
		mean	range
Cyanocobalamin	21	2.1	1- 7
Hydroxycobalamin	20	7.1	2-22
Cyanocobalamin-zinc-tannate	22	6.3	2-18

that of CN B<sub>12</sub>. The results also suggest that the effect of CN B<sub>12</sub> given as the first injection was much shorter (1 to 2 months) than the effect of the same compound given as second or third injection (1 to 7 months). No significant difference related to the order of injections was found between the other two preparations. The explanation for this prolonged effect of cyanocobalamin was that there probably remained a certain depot effect of the previously given OH B<sub>12</sub> or Zn B<sub>12</sub>. A depot effect of this kind might well influence the short period of normal B<sub>12</sub> level after injections of CN B<sub>12</sub> but be of no significance in the longer periods following injections of OH B<sub>12</sub> or Zn B<sub>12</sub>. However the number of the observations was too small to permit any definite conclusions. No significant differences could be observed between the duration of the effects of OH B<sub>12</sub> and Zn B<sub>12</sub>.

### Discussion

During the last few years several reports on the therapeutic effect of so-called long acting B<sub>12</sub>-preparations have been published. The preparations studied are in principle of two types. One is the OH B<sub>12</sub> the protracted effect of which is due to its affinity to both specific and unspecific binding proteins in blood and tissues [7]. The other type is represented by preparations in which either zinc-tannate [18] or tannate in a sesame oil/aluminium monostearate gel [16] have been added to CN B<sub>12</sub> in order to decrease its solubility. In this study only the zinc-tannate-cyanocobalamin complex was used. The cyanocobalamin tannate complex in aluminium monostearate/sesame oil gel (B<sub>12</sub> TAM-a-Dumex) was not available when this investigation was started.

Several reports have been published comparing the effect of OH  $B_{12}$  with that of CN  $B_{12}$ . It is evident that the urinary excretion of OH  $B_{12}$  is much lower than that of CN  $B_{12}$  [5, 11-6]. The large individual variation found by us has been reported by several authors and there are also considerable differences in the excretion data reported by different laboratories.

The absorption rate from the injection site was studied by GLASS *et al.* [5] and by KILLANDER and SCHILLING [11]. They found a slower rate of absorption with OH  $B_{12}$  compared to CN  $B_{12}$ . Our results agree with their findings. In our 4 cases that were given Zn  $B_{12}$ , 50% of the radioactivity had disappeared by about 2 days. No other reports on the absorption rate of Zn  $B_{12}$  seem to have been published. KANTZENBERG *et al.* [14] working with  $B_{12}$  TAM found an appreciable activity at the site of injection 2 months after the administration of 1 mg. The absorption rate measured as the disappearance of 50% of the radioactivity was about 20 days. The absorption rate for the TAM preparation thus seems to be extremely slow compared to that of the substances studied in the present investigation.

Serum  $B_{12}$  levels after single injections of OH  $B_{12}$  have been reported by several authors. They all found much higher levels both initially and after several weeks when compared with CN  $B_{12}$  in pernicious anaemia patients [2, 20, 3]. After a single injection of 1 mg of OH  $B_{12}$  normal values of serum  $B_{12}$  were observed in several patients for periods of 6 to 13 months. The present study clearly demonstrates these differences between the hydroxo- and cyanofarms of the vitamin, although the individual variation is considerable (fig 5). No other reports are available of the effect of Zn  $B_{12}$  on the serum  $B_{12}$  levels in pernicious anaemia patients. Our results indicate an effect quite similar to that of OH  $B_{12}$ . Studies on the  $B_{12}$  TAM have also shown a protracted effect of the same order of magnitude [1].

It is evident that the urinary excretion of vitamin  $B_{12}$  is much less after the injection of OH  $B_{12}$  and Zn  $B_{12}$  than after CN  $B_{12}$ . Both OH  $B_{12}$  and Zn  $B_{12}$  are able to maintain a normal serum  $B_{12}$  level for a much longer time than CN  $B_{12}$ . These two points indicate that better results can be obtained with these 2 preparations than with CN  $B_{12}$ .

The close similarity of the effects of OH  $B_{12}$  and Zn  $B_{12}$  is somewhat surprising. To judge from the low disappearance rate and the urinary excretion figures a much longer duration of the zinc-tannate compound would have been anticipated. A prolonged urinary excretion of Zn  $B_{12}$  observed in a few patients might be one explanation. A defect utiliza-

tion of the compound would also explain the above findings. The OH B<sub>12</sub> represents a more physiological form of the vitamin and it can be assumed that what is retained is also used and metabolized normally in the body. Zn B<sub>12</sub> is an artificial, non-physiological compound of the vitamin and zinc tannate. Without further evidence it cannot be assumed that this highly insoluble material will be completely utilized by the body.

### Summary

A comparative study was performed on 3 types of vitamin B<sub>12</sub>: cyanocobalamin (CN B<sub>12</sub>), hydroxocobalamin (OH B<sub>12</sub>) and cyanocobalamin-dioc-tannate complex (Zn B<sub>12</sub>). The rate of absorption from the site of injection of CN B<sub>12</sub>, OH B<sub>12</sub> and Zn B<sub>12</sub> measured as the disappearance of 50% of the radioactivity was approximately 40 min, 2.5 h and 2 days respectively. The 72-hour urinary excretion rate after injection of 1 mg of the B<sub>12</sub> preparation was on the average 73% for CN B<sub>12</sub>, 30% for OH B<sub>12</sub> and 10% for Zn B<sub>12</sub>. A complete haematological remission was obtained in all cases after single injection of 1 mg of all three substances. The serum B<sub>12</sub> level was maintained above 100 µg/ml for an average time of 2.1 months with CN B<sub>12</sub>, 7.1 months with OH B<sub>12</sub> and 6.3 months with Zn B<sub>12</sub>. It is concluded that the effect of OH B<sub>12</sub> and Zn B<sub>12</sub> is superior to that of CN B<sub>12</sub>.

### References

1. BARTHELEMY-MADSEN, P.; NIELSENBAARD, S.; SCHWARTZ, M., HANSEN, T. and MIELKE-GRACEY, E. Serum-vitamin B<sub>12</sub> during maintenance therapy in pernicious anaemia with depot preparation of vitamin B<sub>12</sub>. *Lancet* ii: 739 (1966).
2. BOCKHE, M. S., BOTTOMLEY, A. C. and ISRAELI, M. G. G. Hydroxocobalamin for pernicious anaemia. *Lancet* ii: 173 (1964).
3. CHALKINS, J. N. M. and SEWTON, N. K. Comparison of hydroxocobalamin and cyanocobalamin. In the treatment of pernicious anaemia. *Lancet* ii: 1305 (1965).
4. DANNY, W. J.; JONES, E.; CLARK, S. L., J.; MCQUARTY, W. J.; DE OLIVEIRA, J. D.; PERES, C.; KEVART, J. and LE BROUQUY, J. The development of vitamin B<sub>12</sub> deficiency by untreated patients with pernicious anaemia. *Amer. J. clin. Nutr.* 6: 513 (1956).
5. CLARK, G. B. J.; SKELTON, N. R.; LEE, D. H.; JONES, E. L. and HARDY, W. W. Hydroxocobalamin. I. Blood levels and urinary excretion of vitamin B<sub>12</sub> in man after single parenteral dose of aqueous hydroxocobalamin, aqueous cyanocobalamin and cyanocobalamin-dioc-tannate complex. *Blood* 18: 511 (1961).
6. HEDERICH, H. L. and GABER, E. Z. Intravenöse Retention und Excretion des Aqueocobalmins, einer für die Therapie geeigneten natürlichen Vitamins B<sub>12</sub>-Depotform. *Klin. Wochs.* 39: 685 (1961).
7. HERTZ, H.; KONTHEIM, H. P. and HOFF-JENSEN, E. Studies on vitamin B<sub>12</sub> retention: comparison of retention following intramuscular injection of cyanocobalamin and hydroxocobalamin. *Scand. J. Haemat.* 1: 5 (1964).
8. HUTCHES, S. H.; BACH, M. E. and ROW, O. I. M. A sugar-containing basal medium for vitamin B<sub>12</sub> assay with Euglena: application to body fluids. *J. Protoc.* 3: 101 (1956).
9. JONES, E.; TILMAN, C. G. and DANNY, W. J. Observations on relapse in pernicious anaemia. *Ann. intern. Med.* 30: 374 (1949).

10. KILLANDER, A. Oral treatment of pernicious anaemia with vitamin B<sub>12</sub> and purified intrinsic factor. *Acta med. scand.* 160-339 (1938)
11. KILLANDER, A. and SCHILLING R. F. Studies on hydroxocobalamin. *J. Lab. clin. Med.* 57 533 (1961)
12. KILLANDER, A. and WERNER, I. Studies on maintenance treatment of pernicious anaemia; in HEDGECOCK Vitamin B<sub>12</sub> and Intrinsic Factor 2. europ. Symp. über Vitamin B<sub>12</sub> und Intrinsic Factor p. 663 (Enke, Stuttgart 1962)
13. KRISTENSEN, H. P. Ø. LUND, J. ØRSKOV, A. S. and PEDERSEN, J. Maintenance therapy in pernicious anaemia. *Lancet* i. 1266 (1957)
14. KRISTENSEN, K.; BASTRUP-MADSEN, P.; NØRREGAARD, S. og SCHWARTZ, M. Et injicerbart B<sub>12</sub>-vitamin-præparat (Bictolven) med retarderet absorption. *Ugeskr. Læg* 124 1681 (1962)
15. SCHWARTZ, S. O. and LØRSEN, H. Relapses in pernicious anaemia. *J. amer. med. Ass.* 124 637 (1944)
16. SCHWARTZ, M. BASTRUP-MADSEN, P. NØRREGAARD, S. and KRISTENSEN, K. A vitamin-B<sub>12</sub> preparation with retarded absorption. *Lancet* ii. 1181 (1962).
17. SKOUDT A. P. Retention, distribution og forbrug af B<sub>12</sub>-aktivitet efter parenteral indgift af hydroxocobalamin (Vibeden) *Ugeskr. Læg* 126 253 (1966)
18. THOMPSON R. E. and HECHT R. A. Studies on long-acting vitamin B<sub>12</sub> preparation. *Amer. J. clin. Nutr.* 7 311 (1939).
19. WALDENSTRØM, J. Remissioner vid leverbehandlad perniciose. *Nord. Med.* 26 3208 (1942)
20. WHITEY J. and KELPATRICK, G. E. Hydroxocobalamin and cyanocobalamin in Addisonian anaemia. *Lancet* i. 16 (1964)

Laboratory of Experimental and Clinical Hematology Pavlov Institute of Physiology of the  
USSR Academy of Sciences, Leningrad

## DNA Synthesis by Erythroblasts in Normal Man and in Some Disorders of Erythropoiesis

A. J. JAROSHEVSKY V. J. PLOTKIN and G. J. SNEKTER

At present H-thymidine, a specific precursor of DNA, is generally used for the study of the proliferation of the bone marrow cells. Our paper presents investigations on the proliferative activity of the erythroblasts in 13 normal subjects and in 20 patients with marked disorders of erythropoiesis.

### *Materials and Methods*

Bone marrow samples were obtained by sternum puncture and were cultivated in liquid medium containing the patient's own plasma and Haeck isotonic solution with heparin. H-thymidine (specific activity 3.6 c/g) was added to the medium in the end concentration equal to 0.1  $\mu$ Ci/ml. The bone marrow suspension in the nutrient medium was carried in 4 tubes in 1 ml and cultivated in shaking incubator at 37°C. In the first tube the incubation was stopped after 15 min, in the other tubes after 1/2, 1 and 2 h. After the incubation the tubes were centrifugated and smears were prepared from the sediment and fixed with methanol during 10 min. Autoradiography was carried out by the method of Zamojski [21]. A liquid nuclear emulsion of the R-type was used.

The smears were stained using Borro's technique [5]. Thirty to 40 young cells (pronormoblasts and basophilic normoblasts) 100 polychromatophilic normoblasts and 50 orthochromic normoblasts were calculated. The percentage of labeled cells was calculated in each group of cells.

The generation time of cells was calculated using the formula of Dornau and Dornau [8] for the exponentially growing population

$$T = \frac{\ln 2}{\lambda} \quad \text{where} \quad \lambda = \frac{\Delta N}{(N + N_p) \Delta t}$$

T = generation time.  $\ln = 0.693$ .  $\Delta N$  = accretion of the number of cells during time  $t$ .  
N = number of cells in period of DNA synthesis.  $N_p$  = proliferative pool, i.e. the ration of cells capable for division and all cells of the given species.

Emulsion "R" is produced at the Research Chemo-photographic Institute, Moscow (USSR).



Table 1 Clinical and hematological data of 15 patients with hypoplastic and iron deficiency anemia

Pat. No.	Diagnosis	Age years	Sex	Length of disease, years	Leucocytes %										
					RBC/mm $\times 10^6$	Hb, g%	PT	WBC/mm $\times 10^6$	staf cells	squashed neutrophils	lymphocytes	Sedimentation rate mm/h	Reticulocytes, %	Thrombocytes mm <sup>3</sup> $\times 10^6$	Serum iron, mg%
1	Hypoplastic anemia	48	F	0.3	3.1	11.7	1.1	3.3	2.5	38	■	11	1.8	93	-
2	Hypoplastic anemia	51	M	0.3	3.0	10.6	1.0	4.6	14.5	20	57.5	10	1.2	20	-
3	Hypoplastic anemia	27	F	0.5	1.4	4.35	0.92	2.0	22	17	53	8	-	10	
4	Hypoplastic anemia	19	F	1.2	2.5	8.53	1.0	2.0	10	29	49	20		10	
5	Hypoplastic anemia	14	M	0.2	3.0	11.33	1.1	3.26	1	8	82	20	-	37.5	
6	Chronic posthemorrhagic anemia	29	F	0.75	4.46	9.8	0.67	5.5	0.5	72.5	15	16	■	3.79	13
7	Chronic posthemorrhagic anemia	31	M	5	3.9	9.5	0.73	4.7	2	63	25	-	-		
8	Chronic posthemorrhagic anemia	47	F	1	3.5	9.5	0.81	3.5	1.5	51	32	22		318	10
9	Chronic posthemorrhagic anemia	48	F	1	4.8	8.2	0.5	5.5	1	74	11.5	11	0.8	526	
10	Chronic posthemorrhagic anemia	40	F	0.8	4.0	9.2	0.68	6.33	6	63.5	22.5	11	1.2		50
11	Chronic posthemorrhagic anemia	50	F	2	4.4	9.8	0.63	4.6	0.5	69.5	21.5	17			23
12	Chronic posthemorrhagic anemia	54	M	3	5.2	10.5	0.6	3.1	2.5	33.5	32.5	12	1	296	40
13	Essential hypochromic anemia	37	F	1	4.7	10	0.6	5.1	1	59	34	12	0.7	220	70
14	Essential hypochromic anemia	41	F	0.5	4.4	9.4	0.73	4.7	0.5	60.5	30.5	12		240	50
15	Essential hypochromic anemia	46	F	16	3.6	8.5	0.7	4.7	0.5	70	21.5	12	0.2		20

Table II. Clinical and hematological data of patients suffering from polycythemia vera

Age years	Sex	Length of disease years	RBC/ mm <sup>3</sup> × 10 <sup>9</sup>	Hb, g% g/dl	WBC/ mm <sup>3</sup> × 10 <sup>9</sup>	Thrombo- cytes/mm <sup>3</sup> × 10 <sup>9</sup>	Sedim. rate mm/h	Viscosity of blood	Hematocrit %	Increase of liver spleen	
39	M	1	6.44	21.0	13.0	520	2	16.6	63/17	+	+
48	M	14	8.1	18.3	7.2	190	1.5	8.3	70/30	+	+
42	F	2	6.08	17.6	14.2	600	2	10	80/20	+	+
58	M	3	6.95	21.0	29.2	400	2	12.5	79/21	+	+
54	F	5	7.25	23.6	4.4	170	1	16.6	68/12	+	+

It was assumed in the calculations that the constant concentration of <sup>3</sup>H-thymidine is equal to 1 i.e. all cells after period of DNA synthesis are divided and their destruction is minimal.

Control subjects were donors selected for bone marrow transplantations. Among the patients 5 had hypoplastic anemia, 5 polycythemia vera and 10 iron-deficiency anemia (7 chronic posthemorrhagic and 3 essential hypochromic anemias). The clinical and hematological data of the patients are shown in tables I and II.

## Results

**1 Normal subjects** After 15 min incubation of bone marrow in the presence of <sup>3</sup>H-thymidine the percentage of the label in pronormoblasts and basophilic normoblasts was  $76.6 \pm 0.73$  and in polychromatophilic normoblasts  $23.0 \pm 0.86$ . After 2 h incubation there was a significant increase of the label ( $p < 0.01$ ) up to  $88.8 \pm 1.1$  and  $37.6 \pm 2.4$  correspondingly (orthochromic normoblasts did not incorporate <sup>3</sup>H thymidine).

The generation time of pronormoblasts and basophilic normoblasts was  $17.8 \pm 0.94$  h, and that of polychromatophilic normoblasts  $11.2 \pm 1.1$  h.

**2. Hypoplastic anemia.** After 15 min of cultivation the percentage of the label was  $31.5 \pm 6.06$  in pronormoblasts and basophilic normoblasts and  $8.2 \pm 2.04$  in polychromatophilic normoblasts. After 2 h the percentage increased up to  $66.5 \pm 5.03$  and  $14.6 \pm 1.34$  correspondingly.

The generation time of pronormoblasts and basophilic normoblasts was  $4.9 \pm 0.6$  and that of polychromatophilic normoblasts  $17.6 \pm 3.72$  h.

3 *Polycythaemia vera*. After 15 min cultivation the percentage of the label was  $68.2 \pm 1.87$  in pronormoblasts and basophilic normoblasts and  $19.7 \pm 2.45$  in polychromatophilic normoblasts. After 2 h it was  $85.5 \pm 2.93$  and  $33.3 \pm 4.1$  correspondingly

The generation time of pronormoblasts and basophilic normoblasts was  $11.7 \pm 1.2$  h, and in polychromatophilic normoblasts it was  $11.6 \pm 0.9$  h.

4 *Chronic posthemorrhagic anemia*. After 15 min cultivation the percentage of the label was  $69.8 \pm 3.66$  in pronormoblasts and basophilic normoblasts and  $24.3 \pm 3.65$  in polychromatophilic normoblasts. After 2 h incubation the label was  $86.9 \pm 1.9$  and  $32.3 \pm 2.6$  correspondingly

The generation time of pronormoblasts and basophilic normoblasts was  $12.7 \pm 1.5$  h and that of polychromatophilic normoblasts  $17.5 \pm 3.39$

5 *Essential hypochromic anemia*. After 15 min incubation the percentage of the label was  $76.3 \pm 2.0$  in pronormoblasts and basophilic normoblasts and  $22.0 \pm 0.26$  in polychromatophilic normoblasts. After 2 h it was  $87.6 \pm 3.9$  and  $31.6 \pm 1.2$  correspondingly




Fig. 1 Uptake of  $^3\text{H}$ -thymidine in erythrocytic precursors of healthy subjects and patients with some disorders of erythropoiesis. ● normal subjects, ■ hypoplastic anemia, ○ polycythaemia vera, ▲ essential hypochromic anemia, ▲ chronic posthemorrhagic anemia, — pronormoblasts and basophilic normoblasts, — polychromatophilic normoblasts.

The generation time of pronormoblasts and basophilic normoblasts was  $22.7 \pm 5.83$  h and in polychromatophilic normoblasts  $16.0 \pm 4.16$  h.

All results are demonstrated graphically in figure 1

### Discussion

The results of the present study in normal subjects are in agreement with those of other authors [1-3 6 7 11 13 16 19 20]

There are only few publications on the DNA synthesis of bone marrow cells in hypoplastic anemia [1 9 10 12, 14 15 17]. According to these results our studies indicate a decrease of the cells synthesizing DNA and of the intensity of DNA synthesis. The marked fall of labeled cells after 15 min incubation also illustrates the decrease of DNA producing cells in the bone marrow of patients with hypoplastic anemia. The observation during 2 h shows that in these patients the increase of the label of pronormoblasts and basophilic normoblasts is 3 times greater than in normal subjects. However the label does not reach the normal values by the end of incubation. The high increase of the labeled pronormoblasts and basophilic normoblasts can be explained by a shortened presynthetic period G<sub>0</sub> in the mitotic cycle of these cells, that is followed by an increased proliferative possibility of a small part of pronormoblasts preserving their ability for DNA synthesis. A marked shortening of the generation time confirms this assumption.

In hypoplastic anemia the slight increase of labeled polychromatophilic normoblasts and the more prolonged generation time may signify a prolongation of the presynthetic G<sub>0</sub> period and, possibly of DNA synthesis.

The significant decrease of the label ( $p < 0.01$ ) after 15 and 30 min incubation of the bone marrow of patients with polycythaemia vera confirms a diminution of the cells taking part in proliferation. It is evident that a considerable part of cells is in the 'rest period' (G<sub>0</sub>-period). The appearance of substances like inhibitors [8] or chalones [4] in the bone marrow of these patients cannot be excluded. These substances are contained in mature erythrocytes and prevent an entry of young cells into the mitotic cycle. By the end of the incubation the percentage of the label is almost normalized, that indicates the accelerated passing of cells through all periods of the mitotic cycle. This is

confirmed by a shortening of the generation time of pronormoblasts and basophilic normoblasts. The shortening of the mitotic cycle of pronormoblasts and basophilic normoblasts may be one of the factors that lead to the pathological increase of erythrocytes in polycythemia vera.

There is no significant difference in the percentage of labeled cells between normal subjects and patients with iron deficiency. Thus there is no disturbance of DNA synthesis of the erythroid cells of patients with iron deficiency anemias. At the same time the generation time of polychromatophilic normoblasts is increased.

It is evident that the latter depends on the delay of polychromatophilic normoblasts in the presynthetic period ( $G_1$ ) that may be stipulated by the disturbance in hemoglobinizations. It is of interest, that the generation time of pronormoblasts and basophilic normoblasts in essential hypochromic anemia was 10 h longer than in chronic posthemorrhagic anemia.

### Summary

The DNA synthesis of the erythroid cells was investigated in bone marrow cultures by an autoradiographic method using  $^3\text{H}$ -thymidine. A decrease of the label was found in hypoplastic anemia indicating a considerable diminution of the proliferative pool of erythroid cells. There was a slight decrease of labeled cells in polycythemia vera at the beginning of incubation indicating some diminution of proliferation. However by the end of incubation period the percentage of the labeled cells was normalized. In iron deficiency anemias the  $^3\text{H}$ -thymidine incorporation did not differ from that in normal subjects.

### References

1. ASTALDI, G. Differentiation, proliferation and maturation of haematopoietic cells studies in tissue culture. In WOUTERMANS and O'CONNOR's Cells Found. Symp. on Haematopoiesis. Cell production and its regulation, p. 99 (Churchill, London 1960).
2. BORD, J. P. FLOTROU, T. M. CHAMBERS, E. P. RICHES, J. R.; BOURGAIN, G. and SCHOUK, P. K. Proliferative potentials of bone marrow and blood cells studies by *in situ* uptake of  $^3\text{H}$ -thymidine. Acta haemat., Basel 27: 1 (1959).
3. BORD, J. P. FLOTROU, T. M. CHAMBERS, E. P. RICHES, J. R. and ROBINSON, L. S. Cell turnover in blood and blood-forming tissue studied with tritiated thymidine. In STOKESMAN's The Kinetics of Cellular Proliferation, p. 118 (Grune & Stratton, New York 1959).
4. DOCLACUS, W. S. Mitotic and functional homeostasis: speculative review. Cancer Res. 25: 1684 (1965).
5. BORD, J. Autoradiography in Biology and Medicine (Moscow 1958).
6. CHAMBERS, E. P. BORD, J. P. FLOTROU, T. M. and KILLMAN, S. A. The use of tritiated thymidine in the study of haematopoietic cell proliferation. In WOUTERMANS and

- O'Connor's Ciba Found. Symp. on Haematopoiesis. Cell proliferation and its regulation, p. 70 (Churchill, London 1960).
7. CACCIOTTI, F. P.; FLEISHER, T. M.; RUDOLPH, J. R.; BOND, V. P. and HOOVER, W. L.: Dynamics of proliferating system of man studied with tritiated thymidine. *J. clin. Invest.* 37: 887 (1958).
8. DORVLA, A. K. and DORVLA, O. K.: The analysis of mitotic cycles; in *The studies in cells cycles and metabolism of nuclear acids in cells differentiation*, p. 5 (Leningrad 1964).
9. FEDOTENKO, F. F.: *Aplastic and Hypoplastic Anemia* (Moscow 1965).
10. FEDOTENKO, F. F.; KOZDRETZ, G. I. and KARASOVA, L. I.: Autoradiographic and cytochemical studies of blood cells in aplastic and hypoplastic anemia patients. *Probl. Hematol. pereliv Krovi* 8: 19 (1963).
11. GROSSER, G.: Proliferative capacity of normal bone marrow (radioautographic study with tritiated thymidine). *Scand. J. Med. Intern.* 6: 165 (1965).
12. KARPOV, A. P.: Autoradiographic studies of hematopoiesis in hypo- and aplastic anemias. 43 *Plenum Utchenogo Soveta of Central Institute of Hematology and Blood Transfusion*, vol. 11, p. 329 (Moscow 1967).
13. KENN-ELLAM, M.; HARRIS, F. B. and GYFFAI, F.: *In vivo* study of DNA-synthesis time and cell cycle time in erythrocyte precursors of normal and thalassaemia subjects using  $^3\text{H}$ - and  $^{14}\text{C}$ -thymidine double labeling technique. *Acta haemat., Basel* 38: 170 (1967).
14. KILLMANN, S. A.: Effect of deoxyuridine on incorporation of tritiated thymidine. Difference between normoblasts and megaloblasts. *Acta med. scand.* 175: 483 (1964).
15. LAJTHA, L. G.: On DNA labeling in the study of the dynamics of bone marrow cell proliferation in STURLMAN. *The Kinetics of Cellular Proliferation*, p. 173 (New York 1959).
16. LAJTHA, L. G. and OLIVER, R.: Studies on the kinetics of erythropoiesis—model of the erytron; in WOLSTENHOLTE and O'Connor's Ciba Found. Symp. on Haematopoiesis. Cell production and its regulation, p. 289 (Churchill, London 1960).
17. MORSCHLER, S. and SPACK, B.: Experimental studies on the mechanism of action of benzene on the bone marrow (Radioautographic studies using  $^3\text{H}$ -thymidine). *Acta haemat., Basel* 38: 104 (1967).
18. OSGOOD, F. F.: A unifying concept of the etiology of the leukemias, Erythromas and cancers. *J. nat. Cancer Inst.* 18: 155 (1957).
19. SCHON, J. R.; KELLY, J. M.; OWEN, G. A. and TOWSE, W. N.: DNA and RNA synthesis of marrow cells of normal subjects and patients with plasmocytic disorders. *Blood* 20: 790 (1962).
20. SCHON, J. R.; KELLY, J. M.; TOWSE, W. N. and OWEN, G. A.: *In vivo* DNA and RNA synthesis in human bone marrow cells—study of 12 normal and 12 patients with plasmoplasmocytic disorders. *Blood* 27: 310 (1966).
21. ZIMKINA, L. N.: Application of radioactive isotopes in cytology. In *The Radioactive Isotopes in cytology*, p. 5 (Leningrad 1959).

Department of Biology and Genetics, Medical College of Virginia, Richmond, Va.

## Change from Fetal to Adult Hemoglobin in Relation to Changes in the A Antigen of Human Erythrocytes

F J GRUNDBACHER

Fetal erythrocytes differ from those produced in adult individuals not only in size and in the type of hemoglobin, but also in antigenic properties of the cell membrane. Fetal erythrocytes possess an antigen that is no longer present in red cells of adults [6] and the ABH antigens are weaker in fetal red cells than in those of adults. Strength or reactivity of the A antigen increases during fetal life and infancy until adult values are reached at 2 to 3 years of age, thereafter remaining relatively unchanged for the rest of the individual's life [2]. Change of the A antigen therefore overlaps the change from fetal to adult hemoglobin that takes place during the last trimester of gestation and early infancy. At birth, both the A antigen and hemoglobin are in process of undergoing change.

The question arose as to whether change in the A antigen and change in hemoglobin are closely interrelated. This was determined by utilizing blood samples of newborn infants and multivariate analyses. Results on the interrelation between strength of the A antigen and percentage of adult hemoglobin, as well as findings on effects of the infant's sex and birth weight are presented in this report.

### *Materials and Methods*

Freshly collected samples of blood from the umbilical cord were used. Strength of the A antigen and blood group subtypes of A were determined as previously described [3, 4].

A modification of the technique of *Smestad et al.* [8] was used for determining fetal hemoglobin. KOH solution was used at 1/10 M, and the 1 M solution was stored at 4°C. The  $(\text{NH}_4)_2\text{SO}_4$  solution was saturated at 25°C, diluted to 75% saturation, and also stored at

4 C. Washed and packed red cells were hemolysed with distilled water and toluene. After centrifugation, the 2 upper layers were discarded and the red solution filtered through double Whatman No. 2 paper filter. With the filtrate and distilled water hemoglobin solutions were prepared that gave reading of exactly 500 units in Klett-Summerson colorimeter with green filter (corresponding to O.D. = 1.00). Three test tubes (size  $13 \times 100$  mm) each with 1.3 ml of the standardized hemoglobin solution, were prepared from each sample of blood. Temperature was standardized to  $25^{\circ}\text{C}$  in constant temperature water bath. To each tube 1.0 ml of  $1/10 \text{ N } \text{NaOH}$ , which had been prewarmed to  $25^{\circ}\text{C}$ , was added at determined intervals. After exactly 5 min of incubation, 2.0 ml of cold  $(\text{NH}_4)_2\text{SO}_4$  solution was added to each tube. The tubes were inverted twice and the content filtered through dry No. 2 Whatman paper filter. Filtration was repeated through the same filter at 15 min after the addition of  $(\text{NH}_4)_2\text{SO}_4$ . Optical density was determined twice: first, after the second filtration + 30 min after the addition of  $(\text{NH}_4)_2\text{SO}_4$  and again, after the third filtration at 45 min after the addition of  $(\text{NH}_4)_2\text{SO}_4$ . Percentage of fetal hemoglobin of sample was computed from the mean of the 6 readings (3 tubes measured twice) and the values converted to adult hemoglobin (100 minus percentage of fetal hemoglobin = adult hemoglobin).

Correlation coefficients were used, as more meaningful presentation of the relative magnitude of association between variables is possible than with regression coefficients. Partial correlation coefficients, form of multivariate analysis, have been described, for example, by KENDALL and STEUART [7].

Percentage of fetal hemoglobin was determined in cord blood samples of 97 infants. Only 86 infants, however, could be included in the analysis as 6 mothers were uncertain about their estimated date of conception; 5 non-Caucasians were not included because of known racial differences in birth weight and development [5]. The strength of the A antigen was determined in 54  $\text{A}_1$  Caucasian infants born to mothers of blood type A. Two girls, one resulting from 250 and an other from 297 day pregnancy represented the extremes in duration of pregnancy among the infants in whom strength of the A antigen had been determined. Duration of gestation ranged from 210 days (boy) to 305 (girl) among the infants in whom fetal hemoglobin had been determined.

### Results

Figure 1 shows the frequency distribution for percentage of adult hemoglobin in the 86 infants and strength of the A antigen in the 54  $\text{A}_1$  infants. The figure reveals wide variation between infants. By coincidence the values for percentage of adult hemoglobin and strength of the A antigen are of similar magnitude.

In 24 infants, both strength of the A antigen and percentage of adult hemoglobin were determined. The results, illustrated in figure 2 reveal a positive association between the two variables. The simple correlation coefficient between strength of the A antigen and percentage of adult hemoglobin was  $r = 0.52 \pm 0.12$  which, for 22 DF is highly significant ( $P < 0.01$ ). Part of this association might result from a common effect of duration of gestation or a common effect of weight. These effects were corrected with partial correlation analysis.






Fig. 1 Frequency distribution of strength of the A antigen and percentage of adult hemoglobin in newborn infants.




Fig. 2 Association in infants in whom both strength of the A antigen and percentage of adult hemoglobin were determined. The dots represent individual values.

The partial correlation coefficient (holding both birth weight and duration of gestation constant) was  $r_{AHWD} = 0.44 \pm 0.18$  for 20 DF this is significant ( $P < 0.05$ ). Thus, there remains a significant association between strength of the A antigen and percentage of adult

Table I Mean percentage of adult hemoglobin and mean strength of the A antigen in newborn infants

Sex	Number of infants	Mean duration of gestation days	Mean birth weight kg	Mean percentage of adult hemoglobin
Boys	50	278.4 $\pm$ 1.9	3.36 $\pm$ 0.35	27.49 $\pm$ 0.80
Girls	36	283.8 $\pm$ 1.7	3.34 $\pm$ 0.43	29.54 $\pm$ 1.00
				Mean strength of the A antigen
Boys	31	280.9 $\pm$ 1.3	3.40 $\pm$ 0.48	24.78 $\pm$ 1.11
Girls	23	278.3 $\pm$ 2.4	3.44 $\pm$ 0.44	28.62 $\pm$ 1.32

Strength determined in immunohemolytic test

hemoglobin that is independent of birth weight and of duration of gestation.

Means and standard errors for percentage of adult hemoglobin and strength of the A antigen are presented in table I for boys and girls separately. Percentage of adult hemoglobin was slightly higher in girls than in boys but the difference was not statistically significant ( $P > 0.05$ ). Duration of gestation was significantly lower in boys than in girls and this accounts in part for the observed higher mean percentage of adult hemoglobin in girls than in boys. A slight difference, however, was still discernible among the infants resulting only from pregnancies of 270 to 290 days duration: the mean percentage of adult hemoglobin for girls was  $29.7 \pm 1.23$  and that for boys was  $28.0 \pm 0.96$ .

Strength of the A antigen, on the other hand, was significantly higher in girls than in boys ( $P < 0.05$ ). As table I shows, the average duration of gestation was slightly higher for the 31 boys than for the 23 girls, i.e., an even larger difference in antigen strength may be expected for equal duration of gestation.

Simple and partial correlation coefficients are presented in table II. The table shows that the simple correlation coefficient between percentage of adult hemoglobin and duration of gestation was slightly higher than that between percentage of adult hemoglobin and birth weight. Both were highly significant ( $P < 0.01$ ). The partial correlation coefficients, holding either duration of gestation or birth weight constant, were markedly lower than the corresponding simple correlation coefficients.

Table II. Simple and partial correlation coefficients of percentage of adult hemoglobin and strength of the A antigen with birth weight and duration of gestation

		Birth weight (W)	Duration of gestation (G)
Percentage of adult hemoglobin (H)	Simple corr. coeff.	$r = 0.34^{\circ} \pm 0.10$	$r = 0.58^{\circ} \pm 0.09$
	Partial corr. coeff.	$r_{HW,G} = 0.18 \pm 0.11$ (holding duration of gestation constant)	$r_{HG,W} = 0.24^{\circ} \pm 0.10$ (holding birth weight constant)
Strength of the A antigen (A)	Simple corr. coeff.	$r = 0.42^{\circ} \pm 0.11$	$r = 0.21 \pm 0.15$
	Partial corr. coeff.	$r_{AW,G} = 0.51 \pm 0.13$ (holding duration of gestation constant)	$r_{AG,W} = 0.03 \pm 0.14$ (holding birth weight constant)
P < 0.05      P < 0.01			

Table II further reveals that strength of the A antigen is more closely correlated with birth weight than with duration of gestation, the partial correlation coefficient between strength of the A antigen and duration of gestation being close to zero. The partial correlation coefficients thus show a trend in the opposite direction: strength of the A antigen was closer correlated with birth weight than with duration of gestation, while percentage of adult hemoglobin showed a slightly closer association with duration of gestation than with birth weight.

### Discussion

Newborn infants revealed wide variation in strength of the A antigen of red cells and in percentage of adult hemoglobin. The analyses disclosed that part of this variation resulted from variation in duration of gestation and variation in birth weight. However, holding duration of gestation and birth weight constant in partial correlation analysis, still revealed a significant association between strength of the A antigen and percentage of adult hemoglobin. An association between strength

of the A antigen and percentage of adult hemoglobin was thus demonstrated that is independent of variation in duration of gestation and variation in birth weight. Despite this association, the results have also provided evidence that change in the A antigen and change in hemoglobin are not fully interdependent. This was demonstrated by the following findings (a) the correlation between strength of the A antigen and percentage of adult hemoglobin was less close than could be expected if the change were fully synchronized (fig 2) (b) strength of the A antigen was much closer correlated with birth weight than with duration of gestation, while percentage of adult hemoglobin was slightly closer correlated with duration of gestation than with birth weight (c) an apparent effect of sex was more marked for strength of the A antigen than for percentage of adult hemoglobin (d) change in hemoglobin is completed at an age before strength of the A antigen has reached adult values [2] These findings suggest that change in the A antigen and change in hemoglobin may be controlled by different factors.

The partial correlation coefficients determined in the present study may be used to provide a measure of the causes that affect the change in hemoglobin and the change in the A antigen, in particular to determine whether change is predominantly a function of chronological age or of the infant's development (expressed in birth weight) Either of the two might be feasible. Duration of gestation, however was found to be an almost negligible determinant for the A antigen when compared with the effects associated with birth weight. The significant partial correlation coefficient between strength of the A antigen and birth weight (holding duration of gestation constant) suggests that relative development of the infant (expressed in weight) has a marked effect on the change in the A antigen. In general, rapidly developing infants (expressed in birth weight) are expected to show a relatively faster increase in strength of the A antigen than slower developing infants. This conclusion is further supported by the finding of a higher strength of the A antigen in girls than in boys. Girls are known to develop faster than boys (physiologic, skeletal) despite the fact that boys exceed girls in size and weight [1-9] In connection with properties of the erythropoietic system, the faster skeletal development in girls than in boys, as reported by CHAMPEL [1] is of particular interest.

In contrast to the A antigen, percentage of adult hemoglobin was found to occupy more an intermediate position in its association with duration of gestation and birth weight. The significant partial correlation coefficient between duration of gestation and percentage of adult

hemoglobin indicates that the change from fetal to adult hemoglobin is markedly influenced by chronological age of the infant. Thus, change in hemoglobin seems to be more dependent on time than on the infant's weight, while for the A antigen the reverse is the case.

The significant partial correlation coefficient between strength of the A antigen and birth weight indicates also that weight is not merely an expression of size, but may provide information on the relative development of the infant. This has long been known to be valid in cases of prematurity. The present results reveal, however, that this is applicable even for infants resulting from pregnancies of the same duration.

### Summary

Strength of the red cell A antigen and level of adult hemoglobin were found to be significantly correlated in newborn infants, even after correction for variation in birth weight and duration of gestation. Furthermore, strength of the A antigen was significantly higher in girls than in boys and much closer associated with birth weight than with duration of gestation. On the other hand, percentage of adult hemoglobin was somewhat closer associated with duration of gestation than with birth weight. The results indicated that relative development of the infant (expressed in birth weight) has marked effect on the change in the A antigen, while the change in hemoglobin is more dependent on chronological age of the infant.

### References

1. CHERRY, A. Prevalence and distribution of ossification centers in the newborn infant. *Amer. J. Dis. Child* 77: 355-361 (1949).
2. GREINERACKER, F. J. Changes in the human A antigen of erythrocytes with the individual's age. *Nature, Lond.* 209: 192-194 (1966).
3. GREINERACKER, F. J. Immunochemistry as a method for quantitation of the A antigen of human erythrocytes. *J. Immunol.* 93: 205-12 (1964).
4. GREINERACKER, F. J. Quantitative variation of the A antigen at birth: its significance in ABO hemolytic disease and in the infant's development. *Acta paediat. scand.* 54: 550-556 (1965).
5. HOLMAN, G. H. Studies on physiologic hyperbilirubinemia of Negro and White premature infants. *Pediatrics* 22: 1115-1123 (1958).
6. LEE, E. W., LEHMANN, H. and MORTLEY, A. E. A rabbit serum containing specific agglutinin for the red cells of the newborn. *Brit. med. J.*, at: 602-604 (1953).
7. KENDALL, M. G. and STUART, A. The advanced theory of statistics Vol. 2. Inference and relationship (Griffin, London 1961).
8. SINGER, R., CHENOWETH, A. L. and SINGER, L. Studies on abnormal hemoglobin. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* 6: 413-428 (1951).
9. TAYLOR, J. M. Growth at adolescence. 2nd ed. (Blackwell, Oxford 1962).

Department of Experimental Hematology Instituto Venezolano de Investigaciones Científicas, Hematology and Blood Bank Section and Medical Department University Hospital, Caracas

## Congenital Deficiency of Fibrin Stabilizing Factor (Factor XIII)

*A Report of the First Case from Latin America*

T. ARENDS, J. M. GUEVARA and J. R. RANGEL

The cases of congenital deficiency of the fibrin stabilizing factor (FSF) (synonyms factor XIII Laki and Lorand factor fibrinase, Atoka diathesis) described to date have been found in Europe, Switzerland [1] Finland [2, 3] France [4, 5] Italy [6, 7] England [8] Greece [9] and Denmark [10]. It has also been reported in Israel [11] in the United States [12-13] and Canada [14]. No cases have been previously reported in Latin America.

The case reported here concerns a FSF deficiency studied in a Venezuelan native which was classified as congenital by the results obtained from clinical and laboratory tests.

### *Methods*

The coagulation tests were performed by the standard methods [15], and the plasma clot solubility in 5*M* urea was done according to Losowsky *et al.* [8]. The defect of these patients being in the clot, it was thought that re-dissolving it with trypsin and studying electrophoretically difference might be observed when compared with the normal subjects. The following method was used: 0.5 ml of ovalated plasma mixed with 0.5 ml of 0.025 *M* of  $\text{CaCl}_2$ , incubated 30 min at 37°C, the clot was tapped loose and washed 3 times with *N*  $\text{Cl}$  0.85 *M*, and then trypsin digested with 1 drop of commercial trypsin (NBCo) 4 mg/ml at 37°C for 2 h, shaking gently at intervals 2 or 3 times. Trypsin digestion was stopped adjusting to pH 6.4 with 0.5 *N* acetic acid, and centrifugated at 2000 rpm. Acetate cellulose electrophoresis of the supernatant liquid was made applying the sample 6 times.

hemoglobin indicates that the change from fetal to adult hemoglobin is markedly influenced by chronological age of the infant. Thus, change in hemoglobin seems to be more dependent on time than on the infant's weight, while for the A antigen the reverse is the case.

The significant partial correlation coefficient between strength of the A antigen and birth weight indicates also that weight is not merely an expression of size, but may provide information on the relative development of the infant. This has long been known to be valid in cases of prematurity. The present results reveal, however, that this is applicable even for infants resulting from pregnancies of the same duration.

### Summary

Strength of the red cell A antigen and level of adult hemoglobin were found to be significantly correlated in newborn infants, even after correction for variation in birth weight and duration of gestation. Furthermore, strength of the A antigen was significantly higher in girls than in boys and much closer associated with birth weight than with duration of gestation. On the other hand, percentage of adult hemoglobin was somewhat closer associated with duration of gestation than with birth weight. The results indicated that relative development of the infant (expressed in birth weight) has marked effect on the change in the A antigen, while the change in hemoglobin is more dependent on chronological age of the infant.

### References

1. CANNES, A. Prevalence and distribution of ossification centers in the newborn infant. *Amer. J. Dis. Child* 77: 355-381 (1949).
2. GERSHBERGER, F. J. Changes in the human A antigen of erythrocytes with the individual's age. *Nature, Lond.* 204: 192-194 (1964).
3. GERSHBERGER, F. J. Immunohemolysis as a method for quantitation of the A antigen of human erythrocytes. *J. Immunol.* 93: 205-212 (1964).
4. GERSHBERGER, F. J. Quantitative variation of the A antigen at birth: its significance in ABO hemolytic disease and in the infant's development. *Acta paediat. scand.* 54: 550-556 (1965).
5. HOLMAN, G. H. Studies on physiologic hyperbilirubinemia of Negro and White premature infants. *Pediatrics* 22: 1115-1123 (1958).
6. LEEK, E. W., LIEBERMAN, H. and MOURANT, A. E. A rabbit serum containing specific agglutinin for the red cells of the newborn. *Brit. med. J.* 41: 602-604 (1933).
7. KIDWELL, M. G. and STUART, A. The advanced theory of statistics. Vol. 2. Interference and relationship (Griffin, London 1961).
8. SEIGLER, R., CHERNOWY, A. L. and SWEENEY, L. Studies on abnormal hemoglobin. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* 6: 415-428 (1931).
9. TANNER, J. M. Growth at adolescence; 2nd ed. (Blackwell, Oxford 1962).

Author's address: Dr. F. J. GERSHBERGER, Department of Biology and Genetics, Medical College of Virginia, Richmond, Va. 23298 (USA).

Table 2. Effect of the mother's plasma on the patient's clots. Incubation of the clots in 5M urea, expressed after B and DELAHE [14]

Subject studied	Correction power of plasma added <i>in vitro</i>							
	Pure	1:2	1:4	1:8	1:16	1:32	1:64	1:28
Control	++	+-	---	-	---	-	=	0
Mother	++	+-	---	-	-	0	0	0

and indirect platelet count were all normal. The solubility of the recalcified plasma clot was demonstrated in 5M urea solution. Other kinasologic and biochemical tests were normal, except the hemoglobin which was somewhat low (10.1 g/100 ml). Peripheral blood smear showed mild hypochromia of the red cell.

Physical therapy was instituted, consisting of moderate exercises and electrostimulation of the right anterior tibial muscles.

A year after she was discharged, the patient was hospitalized in coma in her home town and died within 24 h. Post mortem examination revealed intraparenchymatous cerebellar hemorrhage with rupture of the upper wall of the right cerebellar lobe.

*Electrophoresis of the recalcified plasma.* In the electrophoresis of the trypsin digested clot revealed, in addition to the albumin and fibrinogen, 2 other fractions migrating ahead of the albumin. Other minor fractions, slower than albumin, were not identified (Fig. 1). The patient's trypsin digested clot and that of her mother's, did not show difference when compared with the results obtained in normal subjects.

*Family studies.* The solubility of the plasma clot in 5M urea was done to the mother and maternal uncle, not finding abnormalities in either one. The capacity of correction of the mother's diluted plasma, done according to Jones *et al.* [5] was slower than the normal control (table 1). This method has been used to determine heterozygous subjects.

### Discussion

MacFarlane [16] estimated the probable incidence of FSF deficiency to be  $0.1 \times 10^{-6}$  inhabitants, which makes it one of the coagulation inborn errors of lowest frequency. Nevertheless, the possibility of mistaking it with the hemophilias should be kept in mind when dealing with hemophiloid states. The fact that to this writing only one case has been found in Venezuela - with a population of more than 9,500,000 - apparently confirms the reported low incidence of this disorder.

The genetic mechanisms of this condition has been considered as determined by a recessive autosomal gene although abnormal results found in the plasma of parents of some patients with congenital deficiency of FSF [1, 5, 13, 14, 17] allows the postulation of a possible



Table II Clinical characteristics of the published

Case	Sex	Age years	Country	Parents consangu.	Other family memb. studied deficients	non- deficients
1	M	7	Switzerland	yes	1 brother (case 2) 1 cousin	2 grand-mothers 2 cousins
2	M	18m	Switzerland	yes	case 1	-
3	M	2	Finland	no	?	?
4	M	6	France	no		1 brother
5	F	2	Italy	yes	case 18	-
6	M	14m	France	no	mother	-
7	M	4	France	yes	parents <sup>a</sup>	
8	F	32	Finland	yes	-	
9	M	26	USA	no	1 brother (case 10)	
10	M	23	USA	no	case 9	
11	M	12	Canada	no	parents	
12	M	28	England	no	-	
13	M	4	England	no	-	
14	M	3	England	no		
15	M	24	Greece	?		
16	M	12	Denmark	no		parents
17	F	29	Israel	yes	-	
18	F	1	Italy	yes	1 sister (case 5)	parents
19	M	3	USA	no	2 siblings parents grand-mother <sup>a</sup>	maternal grand-father <sup>b</sup>
20	F	3	USA	no	parents 2 sisters 1 brother <sup>d</sup>	
21	F	20	Venezuela	no	mother <sup>b</sup>	

Age at the time of diagnosis

Plasma clot was soluble in 5% citrate

## cases of congenital deficiency of FSF (Factor XIII)

ambly- local	Bleeding manifestations				Hemostat. Clot- ting	eff. of transf.	Authors
	ecchy- moses	hema- tomas	dental	other			
+	+	+	—	Post wounds, subdural hematomas	slow	yes	DICKERT <i>et al.</i> , 1961 [1]
+	+	+	—			?	
—	—	—	—	post wounds			IKKALA and NEVANLINNA, 1962 [2]
+	+	—	—	post wounds		yes	MAHRE, 1963 [4]
—	+	—	+	post wounds		yes	MADELLI, 1963 [6]
—	—	+	—	otorrhagia, cerebro- meningeal		yes	JOMO <i>et al.</i> , 1964 [5]
—	+	+	—	post wounds		yes	
+	—	—	—	hemoperi- toneum, hemarthrosis		yes	IKKALA <i>et al.</i> , 1964 [3]
?	—	+	+	epistaxis	slow	yes	HAMPTON <i>et al.</i> , 1965 [12]
—	+	+	+	epistaxis		yes	
—	+	+	—	hemarthrosis, subdural hematoma		yes	BARA and DELAGE, 1965 [14]
—	—	+	—	hemoperi- toneum		yes	
+	+	+	—			yes	LOEWEN <i>et al.</i> , 1965 [8]
+	+	+	—			yes	
—	—	—	—	post pen- ectomy	slow		TEVERICH <i>et al.</i> , 1965 [9]
—	—	—	—	post wounds, hemarthrosis, subdural hematoma	slow	yes	AMER and RAMECK, 1965 [10]
+	+	—	—	hirsutism, hematoma	slow	yes	FINKER <i>et al.</i> , 1966 [11]
—	+	+	—	post wounds		yes	OTT and <i>et al.</i> , 1966 [7]
—	+	+	—	post wounds, hemarthrosis		yes	BRYTER, 1967 [13]
+	+	—	—	post wounds		yes	BOCHARD and ALTA, 1968 [17]
+	+	+	—	post wounds, cerebellar hemorrhage		es	this report

Partial deficiency of FSF demonstrated by thromboelastography  
Platelets transaminase test  
FSF levels

## Libri

J. H. P. JONES and P. H. J. HUMMANT: *A Laboratory Manual on Abnormal Haemoglobins*. 2nd ed. Blackwell, Oxford/Edinburgh 1968. 126 p. Price 30 s.

This manual was, as stated by the authors, 'primarily written for the medical pathologists and the laboratory workers receiving samples of blood for investigation, but who have not made special study of this field'. Indeed the book is clearly and concisely written, both in its initial part on clinical data and in the subsequent chapters on biochemical evaluation of abnormal haemoglobins. Much practical information reflects the *not* personal experience of the authors, and many useful details are given which cannot be easily found in the original literature. The procedures include only few and important references to original publications which facilitates reading. In the reviewer's opinion, there is too much referring from one chapter to another. On page 48 the authors state that 'the elution rates (on DEAE-Sephadex) are similar to those seen in DEAE cellulose chromatography' but in the corresponding section the reader again is referred to CM-chromatography concerning the same question. The reader is also supposed to be familiar with migration patterns of abnormal haemoglobins on electrophoresis (cf. plates 3 and 4). The later chapters cannot be well understood without the complete reading of the earlier parts of the book. In general, the second edition of the *Laboratory Manual on Abnormal Haemoglobins* is most welcome gift to every investigator interested in haemoglobinopathies. R. Beck, Basel

H. S. COX: *Medical Cyto-Technology*. Butterworth, London 1968. 63 p. Price 10 s.

The small monograph is concerned exclusively with exfoliative cytology and describes the current diagnostic methods including the technique for obtaining and preparing specimens of vaginal, cervical and endometrial smears, bronchial aspirates, gastric washings and sputum fluids. The staining techniques are reported and the characteristics of normal and malignant cells as well as the problems of cyto-screening are briefly discussed. Some recommendations for laboratory training are given at the end of the booklet, which offers concise introduction in cytology for students, general pathologists and technicians and also stimulates more detailed studies necessary for the specialized cytologist.

H.R. MARTI, Aarau

L. H. R. WALLEY and J. R. ROBERTSON: *Human Haemoglobin Variants and their Identification*. Butterworth, London 1968. 56 p. Price 10 s.

The booklet contains in its first 15 pages a brief introduction in the field of haemoglobinopathies with summaries on the haemoglobin molecule, the genetic code, the abnormal haemoglobins, the thalassaemias, the Hb M variants and the inheritance and geographical distribution of the most frequent abnormalities. In these short chapters many details had to be omitted, only a small selection of abnormal haemoglobins are mentioned and the heterogeneity of thalassaemia is incompletely reported. In the main part of the booklet the current laboratory techniques are described. With details necessary to perform the methods. Different techniques for detection of inclusion bodies, the sickle cell test, several methods of haali denaturation, the technique of electrophoresis on cellulose acetate, starch gel and block, agar gel, polyacrylamide gel and paper, the ion exchange chromatography, the heat denaturation, Hb S solubility test and the stain for Hb F in red cells are given. This small volume is certainly a valuable help for pathologists and technicians.

H. R. MARTI, Aarau

S. 300. Die Thrombocytentransfusionen. Untersuchungen mit radioaktiv markierten Thrombocyten. Fischer Stuttgart 1968. 119 u., 31 Abb. Preis DM 29.50.

Plättchentransfusionen haben im Laufe der letzten Jahre an Bedeutung gewonnen, da von klinischer Seite her besonders im Zusammenhang mit der intensiven zytostatischen Behandlung der Neoplasien, die Nachfrage stark gestiegen ist. Das erweckte Interesse spiegelt sich auch in der rasch wachsenden Flut der diesem Thema gewidmeten Literatur. Ein Überblick in der Art der vorliegenden Monographie kommt deshalb sicher einem allgemeinen Bedürfnis entgegen. Dabei hat der Autor sich die Sache nicht leicht gemacht: er begnügt sich nicht mit der Zusammenstellung der Literatur, sondern er hat versucht, die verschiedenen Ansichten und die noch offenen Fragen — und es sind deren viele — selbst zu überprüfen und mit besonderen Versuchsarrangierungen einer Lösung näher zu bringen. Mit Recht legt der Autor für die Beurteilung der Funktionstüchtigkeit der Plättchen das Hauptgewicht auf die Überlebenszeit radioaktiv markierter Thrombocyten. Ein ausführlicher erster Teil ist der Methodik der Thrombocytenmarkierung ( $^{51}\text{Cr}$  und DFPP) und allen damit zusammenhängenden Problemen gewidmet. Unter dem für die Beurteilung der Thrombocytenfunktion herangezogenen *in vivo*-Methoden verdient vor allem die vom Autor erstmals auf Thrombocyten angewandte Zellelektrophorese Beachtung. Im Zusammenhang mit der Herstellung von Thrombocytenkonserven hat der Autor die wichtige Frage des geeigneten Antikoagulans noch einmal aufgegriffen und zur Hälfte der *in vivo*-Methoden überprüft. Dabei konnte er die Überlegenheit der ACD-Lösungen mit niedrigem pH bestätigen. Zur Konservierung der Thrombocyten wird anhand eigener Versuche Stellung bezogen. Die Besprechung der klinischen Indikationen der Plättchentransfusion wird zum Auslass genommen, um Fragen des Thrombocytenmasses bei den verschiedenen Thrombopoenformen eingeblend zu diskutieren. Im Abschnitt über die Thrombopoenien als Folge eines vermehrten Verbrauchs finden sich interessante Beiträge zu den postoperativen Thrombopoenien; die eigentlichen Verbrauchsagopathien, die regelmäßig mit einer Thrombopoenie einhergehen, finden jedoch keine Erwähnung. Der letzte Abschnitt ist immunologischen Aspekten der Thrombocytentransfusion gewidmet, wobei der Kreis so weit gezogen ist, dass fast das ganze Gebiet der Thrombocyten-Immunologie Berücksichtigung findet. Neben der Gegenüberstellung (und Wertung) der verschiedenen Methoden zum Antikörpernachweis scheitern uns die Untersuchungen zur Frage der Spezifität der Isoantikörper besonders wertvoll. Beachtung (und Nachprüfung) verdient sodann die Feststellung, dass das Serum von TTP-Patienten die elektrophoretische Beweglichkeit normaler Thrombocyten regelmäßig zu vermindern vermag. Der (hypothetische) Antikörperselektionsverlauf ist offenbar in dieser Hinsicht anders als die Isoantikörper, welche in der Regel nicht zu einer Beeinträchtigung der elektrophoretischen Beweglichkeit führen. Im übrigen hat der Autor die Erfahrung anderer bestätigt, dass die Überlebenszeit der Plättchen den nur Zeit schwachen Hinweis auf das Vorliegen von Antikörpern zu geben — einmal von praktischer Bedeutung ist schließlich der Nachweis, dass Hämolyse oder Agglutination des ABO-Systems mit erhöhtem Titer zum beschleunigten Abbau ABO-inkompatibler Plättchen führen.

Die Monographie vermittelt eine Fülle von höchst interessanten und wichtigen Daten aus dem Kapitel der Thrombocytenphysiologie und -pathologie. Bei der Vielseitigkeit des Gebotenen mag der Titel des Buches sogar etwas zu bescheiden angeden sein. Andererseits vermisst der punktierte orientierte Leser vielleicht eine verbindliche Empfehlung, wie im Einzelfall für die Thrombocytentransfusionen vorzugehen sei, z.B. in Bezug auf Wahl des Präparates (PRP oder Konsentrat), technische Durchführung der Konzentration unter Berücksichtigung aller dokumentierten Erkenntnisse, Anzahl der benötigten Spender, Möglichkeiten der Thromboprophylaxe, usw. Das Buch wird aber von jedem, der sich mit den Thrombocyten beschäftigt und der sich über die Möglichkeiten der Plättchentransfusion orientieren möchte, mit Gewinn gelesen werden. Die klare Gliederung erleichtert die Lektüre, wobei wir die am Ende jedes Abschnittes gegebene Zusammenfassung als besonders angenehm hervorheben möchten.

U. BOCKMANN, Bonn

Age, v. Murine virus-induced leukaemia, Pathogenesis... (leukaemia)

Agglutination (haemagglutination) electron microscopic examination of haemagglutination produced by iodinated Coombs serum, 38, 388

- v. Isohaemagglutination

Agglutinin synthesis regulation independent of antigen, 37 62

Agglutinins ABO blood group agglutinins in saliva, 38, 351

- v. Phythaemagglutinin, Phythaemagglutinin

Aggregation und Desaggregation von Erythrocyten, 36, 323

Aggregation, erhöhte, der Thrombocyten, bei essentieller Hyperlipidämie, 38, 95

Aggregation menschlicher Thrombocyten, Untersuchungen über den Einfluss von Natrium-Oleat, 40 205

AHF (= Antihäemophilic factor = AHG A) v. Factor VIII

AHG A (= Factor VIII = Antihäemophiles Globulin A), v. Adrenergic blockers, Factor VIII

AKR (strain of mice) leukaemia, prevention by thymectomy at varying ages, 38, 317

Algiers (= Portugal province) haemoglobin J Paris is the South of Portugal (Algiers) 39 291

Alkaline phosphatase activity in leucocytes of some animal species, 39 51

Alpha-chain synthesis; haemoglobin H as an acquired defect of alpha-chain synthesis (Report of two cases) 39, 91

Alpha and beta chains (polypeptide chains of haemoglobin) v. Thalassemia

Alpha Naphthyl-Acetas-Esterase, Esterase, unspezifische Monocytes

Alpha-Thalassaemie G-6-PD-Mangel mit Häemoglobinopathie und alpha-Thalassaemie, 39 167

Aminocaproic acid ( $\epsilon$ -aminocaproic acid) Fibrinolysis, Fibrinolysis inhibitors, Haemostatic effect

p-Aminomethylbenzoic acid, Fibrinolysis

Aminomethylcyclohexane-carboxylic acid, Fibrinolysis, Fibrinolysis inhibitors

Anaemia, aplastic, and myelodysplastic, Fe<sup>59</sup> and Cr<sup>51</sup> studies, 39 139

- - - Hexachlorocyclohexan

Anaemia, aplastic idiopathic; paroxysmal

nocturnal haemoglobinuria following aplastic anaemia 38, 57

- associated with trisomy-21 and partial endoreduplication, case, 37 137

Anaemia, Cooley's anaemia, Thalassemia major

Anaemia, haemolytic, congenital nonspherocytic characterisation of glucose-6-phosphat dehydrogenase in Swedish children with congenital nonspherocytic congenital haemolytic anaemia, 37 198

Anaemia, haemolytic, v. Sickle cell.

Anaemia, mediterranea, Alpha-Thalassaemia, Beta-thalassaemia, Haemoglobin Lepore in Campania, Thalassemia, Thalassemia (B) Thalassemia major Thalassemia minor Thalassemia subjects, Thalassemic syndrome

Anaemia, megaloblastic, of children, chromosomal study 39, 29

Anaemia, pernicious maintenance therapy of pernicious anaemia (Comparison of Cyanocobalamin, Hydroxycobalamin and Cyanocobalamin-ethyl-tartrate complex), 40 305

Anaemia, refractory serum lactic dehydrogenase activity in refractory anaemia, 40, 187

Anaemia, sickle cell anaemia, v. Sickle cell.

Anaemia, sideroblastic; reversible sideroblastic anaemia caused by chloramphenicol, 38, 1

Anaemia, v. Erythroblastopenie

Anämie, hämolytische, chronische, Übergang einer artemisininempfindlichen Erythropathie bei Glukose-6-Phosphat-dehydrogenase-Mangel in eine chronische hämolytische Anämie, 37 206

Anämie, hämolytische, bei Sarkoidose der Milz, 37 194

Anämie, hypochrome, therapie-resistente, Atransfusionsanämie

Androgen antagonist, effect on erythropoietic action of testosterone, 40, 299

- v. Testosterone

Anämie, Anaemia Erythroblastopenie

Anephric state, Erythropoietin

Aneuploidy Spleen cells, Trisomy-21

Animal species alkaline phosphatase activity in leucocytes of some animal species, 39 51

Animals, laboratory comparative haematology (Selected aspects), 36, 19 (C)

- Antibiotikum, Chloramphenicol
- Antibodies; study of various antibodies and genetically determined serum groups among aborters producing anti-T<sub>J</sub>-like haemolysis and non-aborters in *Western Australia*, 33, 231
- ; structure and heterogeneity 36, 198 (C)
- ; Antigen
- Antibody and DNA synthesis *in vitro*, following antigenic stimulus (Studies in rabbit peripheral lymphocytes I.) 39 223
- v. 'Blast' transformation, Blastoid transformation, Lymphocytentransformation
- Anticoagulants, circulating; investigation of circulating anticoagulants against AHP (= factor VII) in three patients with haemophilia A, 39, 214
- Anticurvular drug therapy Erythroblastopénie
- Anticorps, Antibodies
- Antigen; agglutinin synthesis regulation independent of antigen, 37 62
- ; I antigen
- Antigenic changes, multiple, in case of acute leukaemia, 37 150
- Antigenic stimulus; DNA and antibody synthesis *in vitro* following antigenic stimulus (Studies in rabbit peripheral lymphocytes I.), 39 223
- 'Blast' transformation, Blastoid transformation, Lymphocytentransformation
- Antigens, Antibodies
- Antihemophilic globulin A (= AHG A)
- Adrenergic blockers, Factor VIII
- Antihemophilic globulin B (= Factor IX = FIC), Christmas factor
- Antipeptin activity Christmas factor
- Antikörper Antibodies
- Antistreptolysin; Untersuchungen zur Korrelation von Lymphocytentransformation durch Streptolysin O *in vitro* und Antistreptolysin 33, 276
- Antibody 'Blast' transformation, Blastoid transformation
- Anti-T<sub>J</sub>-like haemolysis study of various antibodies and genetically determined serum groups among aborters producing anti-T<sub>J</sub>-like haemolysis and non-aborters in *Western Australia*, 33, 231
- Aplastic anaemia paroxysmal nocturnal haemoglobinuria following aplastic anaemia 38, 57
- ; and myeloclerosis, Fe<sup>59</sup> and Cr<sup>51</sup> studies, 39 139
- v. Hexachlorocyclohexan
- Arzneimittelsensibilisierende Erythropathie bei Glukose-6-Phosphatdehydrogenase Mangel, Übergang in eine chronische hämolytische Anämie, 37 206
- Atransferrinämien (kongenitale und erworbene Formen), 35, 40 (C)
- Australie, v. *Western Australia*
- Autohaemolysis, v. Haemolytic syndrome, unusual
- Automation in haematology (Symposium at the XI Congress of the International Society of Haematology) 39 581 (B)
- Autoradiographie, Technik, 39 127 (B)
- Autoradiography Benzene Chromatinstrukturen; Double labelling technique; Erythroblast; Leukemia, cell proliferation Leukemia, lymphatic, acute Megakaryocytes Microradiostereography; Mononucleosis Plasma cells Proliferation activity
- Aviannose B<sub>12</sub> Baboons
- Baboons isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 38, 116
- Baboun, Baboons
- Bacterial endotoxins early appearance of blast-like cells in the thoracic duct lymph of rats given bacterial endotoxins, 37 301
- 'Barro-Syndrom' im Kindesalter 40 111 (B)
- Basic lymphology new trends (Symposium Charleroi, 1966) 40 111 (B)
- Basophile Zellen zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymph, 38, 282
- Basophilic reticulohistiocytic origin of the blood basophil in human marrow 40, 162
- B<sup>+</sup> blood group; an example of aberrant blood group (B7) 38, 332
- Bence Jones Protein, zu seiner Struktur, 38, 147
- Benzene, mechanism of action on the bone marrow experimental studies (Radioautographic studies using H<sup>3</sup>-thymidine) 38, 101
- Benzene poisoning erythrosisleukia after benzene poisoning, 40, 234
- Benzidine-positive protein fraction, peculiar in the plasma of newborns and children with various haemolytic conditions, 35, 361

Benzol, Benzene

Benzene, v Sarkoidose

Beta and alpha chains (polypeptide chains of haemoglobin) Thalassemia

Beta-thalassemia, heterozygous, and hereditary spherocytosis (A family study) 39 185

- v Pyruvate-kinase deficiency

Biological fluids, proteins, v Proteides

Biology v Experimental biology

'Blast cells' cytoplasmic shedding as a mode of formation of lymphocyte-like blast cells by newt histiocytes, 40 67

Blast-like cells in the thoracic duct lymph of rats given bacterial endotoxins, early appearance, 37 301

Blast population (leukaemia) v Proliferative activity

'Blast' transformation of lymphocytes: delay of human lymphocyte 'blast' transformation by homologous RNA, 39 270

Antibody Blastoid transformation, Lymphocytentransformation

Blastic crisis of a granulocytic leukaemia, two Ph 1 chromosomes, 38 391

Blastoid transformation of rabbit peripheral lymphocytes by phytohaemagglutinin using microculture technique, 39 373

Antibody 'Blast' transformation, Lymphocytentransformation

Blutung, Thrombocytole, posthaemorrhagisch

Bleeding, arresting, Haemostase, Hemorrhagische disorders, Hämostase

Blood basophil in human marrow reticulohistiocytic origin, 40 162

Blood cells cytochemical demonstration of dihydroorotic dehydrogenase in blood and bone marrow cells, 39 203

Blood coagulation, Adrenergic blockers, Aggregation (Thrombocyten) Blutgerinnungsfaktoren, Christmas disease, Christmas factor Coagulation, Factor V

Factor VIII Fibrinolysis, Fibrinolyse, Fibrinolysis inhibitors, Fibrinolytic system, Fibrin-stabilizing factor Haemostase, Haemostatic effect, Hageman factor deficiency Hemorrhagic disorders, Hämostase, Phosphataase, Retraktionsvorgang, Thromboembolische diseases (B)

Uraemic thrombopathy Verbrauchskoagulopathie

Blood grouping tests, 40 336 (B)

Blood groups: an example of aberrant blood group (B?) 38 532

an introduction to blood group serology (3rd ed.) 39 127 (B)

- v A antigen, ABO blood group, ABO hemolytic disease, Antigenic changes, Anti-Tj-like haemolysis, (Haemagglutination) I antigen, Isohaemagglutination, Rhæsusfactor

Blood transfusion in clinical medicine (4th ed.) 37 407 (B)

Blood transfusion; International Society of Blood Transfusion, XIIIth International Congress, Moscow 1969 (travel grants) 40 240

Blood from the umbilical cord, : A antigen Blut und Knochenmark, Untersuchungen (Methoden) 40 258 (B)

Blut Proaktivator v Proaktivatorgehalt

Blutfreund Zellen im artemischen Blut (Leberparenchymszellen) 39 243

Blutgerinnungsfaktoren und essentielle Hyperphosphämie, 38 219

Blutgruppen, Blood grouping tests (B) Blood groups

Blutlymphocyten, funktionsfähige, Isolierung, 38 300

Blutmastzellen, Basophils

Blutplättchen, Platelet transfusion, Platelets, Thrombocyten, Thrombocytentransfusion (B)

Blutplasmaaggrusion, Retraktionsvorgang, 38 571

Blutplättchen, v Hemorrhagic disorders, Hämostase, Retraktionsvorgang

Bluttransfusion, Blood transfusion (B) Transfusion (B)

Blutzellen; über den Nachweis der Thionopyrophosphatase (Colorophosphatase) in Blut- und Knochenmarkszellen, 40 177

BORCK-BERGER-SCHMIDMANN, Moritz, Sarkoidose

Bone marrow; cellular changes in the bone marrow following chronic treatment of rats with cortisol, 38 250

: cytochemical demonstration of dihydroorotic dehydrogenase in blood and bone marrow cells, 39 203

: experimental studies on the mechanism of action of benzene on the bone marrow (Radioautographic studies using  $^{32}\text{P}$  thyroidase) 38 104

- failure of shielding the thymus to induce recovery of bone marrow after radiation, 37 109  
 injury and repair (Irradiation and mechanical disruption) 40 35  
 isotypic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 39 118  
 reactions, 38, 403 (B)  
 reticulohistiocytic origin of the blood basophil in human marrow 40 162  
 in rib- cell proliferation in leukaemia during relapse and remission (L. DNA and RNA synthesis of leukaemic cells in the bone marrow *in vitro*) 38, 313  
 Eosinophil granules Erythroblast( ) Erythrocyte precursors; Erythroid hyperplasia Gamma-Hexachlorocyclohexan Gartner cells Knochenmark; Knochenmark (B); Knochenmarkzellen Leukaemia, myeloid, chronic Megakaryocytes; Monocytes; Myelodysplastic Pancytopenia; Proliferative activity Typhus abdominalis  
 Book reviews, 37 159 (B); 38, 64 (B) 403-407 (B); 39 62 (B), 127 (B) 381 (B) 40 110-112 (B), 176 (B) 258-259 (B), 336-338 (B)  
 Brugs, colloquium, (XXth, may 3-7 1967)  
 Protides of the biological fluids, 37 224  
 — (XXVth, may 1-5, 1968) Protides of the biological fluids, 37 192  
 Buchbesprechungen, 37 159 (B) 38, 64 (B) 403-407 (B); 39 62 (B), 127 (B) 381 (B); 40, 110-112 (B) 176 (B) 258-259 (B) 336-338 (B)  
 C<sup>14</sup> Carbon, radioactive  
 Caesium chloride density gradient centrifugation, DNA, satellite  
 Campese, Haemoglobin Lepore in Campese  
 Cancer; the inheritance of leukaemia and cancer 38, 174  
 Cancer chemotherapy two week course (Houston, Texas, 13-24th May 1968), 39 63  
 Cancer detection Uno Internationals contra Cancerum (UICC) monograph series, vol. 4 (Prepared by the Cancer Detection Committee of the Commission on Cancer Control) 38, 406 (B)  
 Cancer research, Erythropoiesis (B) Thymus (B)  
*Canis familiaris*, Dog  
 Capillaries, Haemostasis, Hemorrhagic disorders, Hemostasis  
 Carbamazepine, v Erythroblastopenia  
 Carbamyl-SH-dibenzos (b, f) aspartic (= Tetratol®) v Erythroblastopenia  
 Carbon, radioactive, Erythrocyte precursors; Haemoglobin, *in vitro* synthesis Mononuclear infection; Protein synthesis  
 Carcinoma, Cancer detection (B), Erythropoiesis (B) Thymus (B), v branchaoligulopathy  
 Carle, Jovell, Eosinophil granules, Thymus  
 C57Bl mice, Leukaemogenesis  
 Cell, Elektrolytic (B)  
 Cell cultures, Antibody; Blast transformation; Blastoid transformation, Cell proliferation; Leukocytes, kultiviert; Lymphocytes (derivative cells); Lymphocytes and their derivative cells Lymphocytes from patients; Lymphocyte transformation Mononuclear cells Mononuclear leukocytes Mononuclear infection; Ph 1 chromosomes Spleen cells; T-mu-21  
 Cell cycle time, Erythrocyte precursors  
 Cell kinetics and thymidine metabolism (Frontiers in biology vol. 6) 39 381 (B)  
 Cell maturity and eosinophil granules electron microscopic observations on guinea-pig marrow 38, 350  
 Cell proliferation in leukaemia during relapse and remission (L. DNA and RNA synthesis of leukaemic cells in the bone marrow *in vitro*) 38, 313  
 — (II. DNA synthesis of leukaemic cells in the peripheral blood *in vitro*), 37 18  
 Centrifugation comment on the method of determining the trapped volume of plasma after centrifugation based on the correlation between trapped volume and electrical conductivity 38, 253  
 Cpln, thalassaemia in Cpln, 38, 209  
 C<sup>14</sup> format, Mononuclear infection  
 C3H(f) mice, Mouse leukaemia  
 Chains, polypeptide chains, Bence Jones protein, Haemoglobin H, Thalassaemia Chemistry Clinical chemistry (B)  
 Chemotherapy; two week course in cancer chemotherapy (Houston, Texas 13-24th May 1968) 39 63



- Chicken, v. Myeloblastosis virus
- Chien, v. Dog
- Children; chromosomal study in megaloblastic anaemia of children, 39 29
- v. Erythrocytosis, Kindemalter (B) Protein fraction
- Chindinhaltiges, Kombinationspräparat (Eucard  $\otimes$ ) v. Erythropathie
- Chloramphenicol induced haemolysis *in vitro* and survival of chloramphenicol treated cells *in vitro*, 38, 11
- reversible sideroblastic anaemia caused by chloramphenicol, 38, 1
- Chloramphenicol-Präparat (Parasin  $\otimes$ ) Erythropathie
- Christmas disease in girl with female karyotype, 37 217
- Christmas factor; the clotting activity of congenital factor IX deficient (Christmas) serum, 39, 13
- Chromatinstrukturen die Zertfolge der DNS-Vervielfachung der Chromatinstrukturen in Interphasen von kultivierter Leukocyten, 38, 351
- Chromatography v. Bence Jones Protein
- Chromes (radiochromes) v. Erythrokinetic studies
- Chromes, radioactive, Haemolysis *in vitro*
- Chromes, radioactive, v. Aplastic anaemia, Thalassemia minor
- Chromosomal abnormalities chromosomal aberrations and neoplastic potentialities of thymus cells during leukemogenesis, 40 142
- decreased formation of erythrocyte antigen A and consistent chromosome abnormality in a patient with myelomonocytic leukaemia, 39 309
- multiple chromosomal aberrations in case of malignant myelodysplasia, 39 299
- two Ph 1 chromosomes in blastic crisis of granulocytic leukaemia, 38, 391
- Ph 1-dosage and prognosis in chronic myelogenous leukaemia, 38, 102
- of spleen cells in osteomyelodysplasia, 38, 397
- Chromosome( ) G 21 trisomy-Leukemia, acute Leukemia, myeloid, chronic Macroglobulinemia; Trisomy-21
- Chromosomal factors, Pathogenesis (leukaemia)
- Chromosomal study in megaloblastic anaemia of children, 39 29
- Chromosome studies, v. Haemoglobin H
- Chromosomes and leukaemia, 38, 157 (C)
- Chromosomes, Christmas disease
- Chronic lymphocytic leukaemia, Leukaemia, lymphocytic
- Circulating anticoagulants investigating of circulating anticoagulants against AHF (= factor VIII) in three patients with haemophilia A, 39 214
- Cirrhotic of the liver- investigations on the fibrinolytic system in liver cirrhosis, 40, 265
- C<sup>14</sup>-leucine, Haemoglobin, *in vitro* synthesis Protein synthesis
- Clinical chemistry quantities and units, 40, 110 (B)
- Clinical medicine blood transfusion in clinical medicine (4th ed.) 38, 407 (B)
- Clinical method, rapid, for the estimation of activity of ascorbic acid in blood, 40 104
- Clinical pathology VIIth International Congress of Clinical Pathology (Montreal, 1969) 40, 176
- Clotting activity of protein fractions of congenital factor IX deficient (Christmas) serum, 39 13
- Co<sup>57</sup> (Co<sup>60</sup>) v. Pernicious anaemia (maintenance therapy)
- Co<sup>57</sup> Thymus
- Coagulation; importance of coagulation besides haemostasis, 38, 133 (C)
- Coagulation of blood, v. Adrenergic blockers, Aggregation (Thrombocytes), Blutgerinnungsstörungen, Christmas disease, Christmas factor Coagulation, Factor V Factor VIII Fibrinolytic, Fibrinolysis, Fibrinolysis inhibitors, Fibrinolytic system, Fibrin-stabilizing factor Haemostasis, Haemostatic effect, Hageman factor deficiency Hemorrhagic disorders, Hemostasis, Phosphatases, Retraktionsvorgang, Thromboembolic diseases (B) Uraemic thrombopathy v. Thrombozytopenie
- Cobalt, radioactive, Pernicious anaemia (maintenance therapy), Thymus
- Lobay, Eosinophil granulosa, Thymus
- Colcemid, Chromatinstrukturen
- Collagen, abnormal, Hemorrhagic disorders
- Colloquium, Bruges (Protocols of the biological fields) XVth, may 3-7 1967, 37 224
- XVth, may 1-3, 1968, 38, 192

- Come for over 5 weeks, 39 320
- Committee, International, for Standardization in Haematology 3rd Transactions, Strasbourg 22./27.8.1965 (Standardization in Haematology III) 39, 404 (B)
- Normierung
- Comparative haematology of laboratory animals (Selected aspects) 36, 13 (C)
- Comparative leukaemia research (Proceedings of an International Vassalli-Gross symposium, Stockholm, September 1965) 39, 405 (B)
- Coomes rendus, Comparative leukaemia (B) Congress, Standardization (B)
- Thromboembolic diseases (B)
- Conductivity electrical, Electrical conductivity
- Conference of experimental biology and medicine in Switzerland (September 1966), 37 322
- Colloquium, Symposium
- Congenital deficiency of fibrin-stabilizing factor (= factor XIII) (A report of the first case from Latin America), 40 329
- Congenital erythrocytosis, Erythrocytosis
- Congenital factor IX deficient (Christmas) serum, clotting activity of protein fractions, 39 13
- Congenital methaemoglobinemia (Bibliotheca haematologica Vol. 28) 40 230 (B)
- Congenital nonspherocytic haemolytic anaemia characterization of glucose-6-phosphate dehydrogenase in Swedish children with congenital nonspherocytic congenital haemolytic anaemia, 37 196
- Congress, European Society of Haematology: Proceedings of the 10th Congress (Strasbourg, 23. 26.8.1965) (part I: main lectures) 36, 1 296 (C)
- , Proceedings part I and II 40 111 (B)
- 11th Congress (Athens, 10. 14.9.1967), 36, 417
- Congress, XIIth, of the International Society of Haematology Sydney (21. 26. August, 1966) (Amalgamation of the International Society the European Society and the Asian-Pacific Society of Haematology), 37 323
- Congress, XIIth, of the International Society of Haematology (New York September 1-6, 1968), 37, 320
- Congress, International, VIIth, of Clinical Pathology (Montreal, 1969) 40 17
- Congress, Blood transfusion Colloquium, Microcirculation, Symposium, Therapy, Transplantation (B)
- Conjugated oestrogens, Haemostatic effect Cooley's anaemia, Alpha Thalassemic, Beta-thalassemia, Thalassemia, Thalassemia major
- Coovum serum, iodinated, Electron microscopic examination
- Corrigendum (ad Vol. 39 [1968] S. 282) 40 240
- Cortisol; cellular changes in the bone marrow following chronic treatment of rats with cortisol, 36, 250
- Coverslip cultures, Mononuclear cells, Mononuclear leukocytes
- Cr<sup>51</sup> and Fe<sup>59</sup> studies in aplastic anaemia and myeloclerosis, 33, 190
- Cr<sup>51</sup> Erythrokinetic studies, Haemolysis *in vitro*, Thalassemia minor
- CaCl<sub>2</sub> (density gradient centrifugation) DNA, satellite
- Cr<sup>51</sup>-chromidine, Erythrocyte precursors, Mononucleosis
- Culture des cellules, Antibody Blast transformation Blastoid transformation Lymphocyten transformation
- Cultures de tissus, Cell proliferation Culture des cellules; Leukocytes, kultiviert; Lymphocytes; Lymphocytes (derivative cells) Lymphocytes and their derivative cells; Lymphocytes from patients; Mononuclear cells Mononuclear leukocytes; Mononuclear leukocytes Ph 1 chromosomes; Splice cells; T-met-21
- Cyanoalbumin, Pernicious anaemia (maintenance therapy)
- Cyanoalbumin-iodo-tinctoria complex, Pernicious anaemia (maintenance therapy)
- Cyanoide hereditary methaemoglobinemia cyanosis due to diaphanous deficiency in three successive generations, 37 276
- Methaemoglobinemia
- Cytidin (TP-cytidine) Elastoid transformation, Plasma cells
- Cytochemical demonstration of dehydrogenase activity in blood and bone marrow cells, 37 203
- Cytokinetic; cytochemische Untersuchungen zur Entwicklung der grossen

- mononukleären Zellen des Hautfensters, 38, 281
- Diagnose monosytärer Leukämien mit zytochemischen Methoden, 40, 121
  - v Acetylcholinesterase, Alkaline phosphatase, Cytology Dreischnitzellen, Enzyme analysis, Erythroblasts, Foetal Erythrocytes, G-6-PD  $\rightarrow$ , Lymphocytes (derivative cells) Lymphocytes and their derivative cells, Monocytes, Mononuclear infections, Myelosclerosis, Plasma cells, Reticulocytes, Sickle cell disease, Thiaminpyrophosphatase
- Cytogenetic studies in acute leukaemia, 40, 192
- Cytogenetic studies, in unusual forms of chronic myeloid leukaemia, 38, 129
- v G 21 trisomy Haemoglobin H, Leukaemogenesis, Megaloblastic anaemia, Myelosclerosis, Ph 1 chromosomes, Spleen cells, Trisomy 21
- Cytological and karyotypic estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 39, 118
- Cytologie: étude cytologique de la transformation aigue d'une leucémie myélocytaire chronique, 39, 249
- Cytology: contribution of cytology to the study of lymphopathies, 36, 296 (C)
- Cytoplasmic shedding as a mode of formation of lymphocyte-like blast cells by new histiocytes, 40, 67
- Cyto-technology technique, 40, 336 (B)
- Cyto Zyto
- D<sup>+</sup> anti-D serum, v Haemagglutination
- Deckgläschen (Leukocyten-Kulturen) v Mononuclear leukocytes
- Defect of glucose-6-phosphate dehydrogenase, v Sickle cell disease
- Defects in haemorrhagic disorders, their nature, 36, 141 (C)
- Delta thalassaemia a new thalassaemic syndrome: Homozygous haemoglobin S disease delta thalassaemia, 36, 41
- Density gradient centrifugation, analytical, DNA, satellite
- Denudation of the erythroblast, studies on the mechanism, 39, 193
- Depression of the megakaryocyte-platelet system in rats by transfusion of platelets, 38, 34
- Desaggregation and Aggregation von Erythrocyten, 36, 323
- Desoxyribonucleic acid, satellite: presence of satellite DNA (= desoxyribonucleic acid) in normal and leukaemic human tissues, 39, 75
- Desoxyribonucleic acid (= DNA) synthesis, by erythroblasts in normal man and in some disorders of erythropoiesis, 40, 315
- DNA and antibody synthesis in *in vitro*, following antigenic stimulus (Studies on rabbit peripheral lymphocytes L), 39, 273
  - *in-vitro* study of DNA-synthesis time and cell-cycle time in erythrocyte precursors of normal and thalassaemic subjects using a  $H^3$  and  $C^{14}$ -thymidine double labelling technique, 38, 170
  - ; the infectious mononuclear cell (L. DNA synthesis) 36, 257
  - division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 38, 163
  - the proliferation of infectious mononuclear lymphocytes *in vitro*, 38, 19
- Desoxyribonucleic acid (=DNA) v Benzene; Blast transformation Blastoid transformation Erythroblast; Leukemia, cell proliferation... Lymphocyten-transformation Plasma cells Reticulocytes Thymidine metabolism (B)
- Desoxyribonukleinsäure (= DNS) v Doppelung der Chromatinstrukturen in Interphasenkerne kultivierter Leukocyten, 38, 361
- Deutsche Gesellschaft für Hämatologie, 14. Tagung, Kiel, September 1969, 38, 382
- Development of eosinophil leukocytes, Eosinophil granules
- Dextran, hochmolekulares, Aggregation
- Di Goussano's syndrome, v Haemoglobin H
- Diagnose monosytärer Leukämien mit zytochemischen Methoden, 40, 121
- Dialyzing membrane, Erythropoiesis
- Disphorose deficiency; hereditary methemoglobinemic cyanosis due to disphorose deficiency in three successive generations, 37, 276
- DPHN-
- Dietary histamine and eosinophils in the rat, 40, 59
- Diffusion de la lumière (Diffusion de champs électromagnétique) Macromolécules

- Dihydropyruvic acid dehydrogenase, cytochemical demonstration in blood and bone marrow cells, 39 203
- Diphosphopyridine nucleotide, reduced, DPNH ..
- Diploid metaphases, Spleen cells
- Diseases of the lymphoid tissue, Protein synthesis
- Division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 39, 163
- DNA, Deoxyribonucleic acid Deoxyribonucleic acid
- DNS, Deoxyribonucleic acid Deoxyribonucleic acid
- Dog: effect of erythroid hyperplasia on the disappearance rate of erythropoietin in the dog, 39 4
- Double blind evaluation of the haemostatic effect of adrenochrome monomelicarbinone, conjugated oestrogens and epalrestinacetic acid after adenotomylectomy 49 134
- Double emulsion technique, Double labelling technique
- Double labelling technique *in vivo* study of DNA-synthesis rate and cell-cycle time in erythrocyte precursors of normal and thalassaemic subjects, using  $^3\text{H}$  and  $\text{C}^{14}$ -thymidine double labelling technique, 39, 170
- DPNH (= Diphosphopyridine nucleotide, reduced)-methaemoglobin reduction deficiency hereditary methaemoglobinemia due to DPNH-methaemoglobin reduction deficiency (Report of family) 37 284
- Diaphorase
- Drepanocytosis, Sickle cell
- Drüsenfaserzellen, Zytoblasten, 39 237
- Drug-sensitive erythropathy Erythropathic
- Ductus thoracicus-Lymphæ zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymphæ, 39 202
- Thoracic duct lymph, Thoracic duct lymphocytes
- Eisen, Acetate Acetate Anemia anemia
- Baboon Erythrokinetic studies Erythropoiesis Erythropoiesis; Ferritin Ferritin Ferric sulphate; Haemoglobin H Haemoglobin, *in vitro* synthesis Häm-synthese Iron deficiency Iron poisoning Iron sorbitol; Sideroblastic anemia; Thalassemia minor
- Elektrostoffwechsel, Atransferrämien
- Electrical conductivity: comment on the method of determining the trapped volume of plasma after centrifugation based on the correlation between the trapped volume and the electrical conductivity 39, 233
- Electrical resistance, Electrical conductivity
- Electron microscopic examination of haemagglutination produced by iodized Coombs serum, 39, 289
- Electron microscope, Basophile Zellen, Eosinophil granules, GLANZ cells, Hertz body Lymphocytes, Blasse Leukämie, Phagocytose
- Electrophoresis: simple method for the quantitation of haemoglobin fractions obtained by starch-gel electrophoresis, 39, 306
- Electrophoresis, Alpha-Thalassämie; Antibodies Anti-Tp-like haemolysis Black Joints Protein Congenital nonspherocytic haemolytic anemia; Delta thalassaemia Fibrin-stabilizing factor; Haemoglobin D Haemoglobin G (Philadelphia) Haemoglobin H; Haemoglobin J Para Haemoglobin Koefler Haemoglobin Lepore in *Camponotus*, Hämoglobine, menschliche Macroglubulinasen Methaemoglobinemia cyanosis Macrocythemia Paraproteinämie-Protein fraction Schick cell; Spherycytosis; Thalassemia (Cyte) Thalassemia syndromes
- Elektrolyte, intracelluläre, Transport und Funktion (Symposium in Schürze, 1967), 49 112 (B)
- Emboly Thromboembolische dromen (B)
- Embryonales Hämoglobin in roten Blutzellen menschlicher Embryonen, intracelluläre Verteilung (Ein Beitrag zur Ontogenese menschlicher Hämoglobine), 39, 264
- Ence de chate, Macrophages
- Endoduplication, parval, Tricory-21
- Enfant, Erythrocytosis, Kundershter (B), Megaloblastic anemia, Protein fraction
- Endotoxine, bacterial, Bacterial endotoxins

England; sickle cell haemoglobin *Punjab* disease S from Ghana and D from England, 38, 324

Entkernung der Erythroblasten, v Erythroblast

Entwicklungstadien eosinophiler Leukozyten, v Eosinophil granules

Entzündungs-Makrophagen, v Macrophages

Enzyme analysis, histochemical, of peripheral blood changes in murine virus-induced leukaemia, 38, 112

Enzyme cytochemistry v Lymphocytes and their derivative cells

Enzymes, v Ferments

Eosinophil granules and cell maturity: electron microscope observations on guinea-pig marrow 36, 330

Eosinophilen-Leukämie, akute: kasuistischer Beitrag zum Krankheitsbild der akuten Eosinophilen-Leukämie, 37 143

Eosinophils, and dietary histamine in the rat, 40, 59

- the nuclear segmentation of eosinophils under normal and pathological conditions, 37 120

Epidemiology Human leukaemia

Épileptique erythroblastopénie non mégalo-cytaire et sensible à l'acide folique chez un épileptique, 39 159

Epilone-aminocaproic acid, Fibrinolysis, Fibrinolysis inhibitors, Haemostatic effect

Ernährung, Dietary histamine

Erratum (ad V. of. 39 [1968] S. 283), 40, 240

Erythraemia, v Erythromyelosis

Erythroblasts studies on the mechanism of denaturation of the erythroblast, 39 193  
in man DNA synthesis by erythroblasts in normal man and in some disorders of erythropoiesis, 40 313

PAS-positive erythroblasts in kidney diseases, 37 225

Erythrocyte precursors

Erythroblastopénie non mégalo-cytaire et sensible à l'acide folique chez un épileptique, 39, 159

Erythrocyte antigen A, decreased formation, and consistent chromosome abnormality in patient with myelomonocytic leukaemia, 39 309

Erythrocyte glucose-6-phosphate dehydrogenase deficiency in *Hawaii*, survey 37 94

Erythrocyte glucose-6-phosphate dehydrogenase deficiency in *Romania*, a survey 40, 44

Erythrocyte I group I antigen of red cells in leukaemia and its interaction with *Mycoplasma in vivo* and *in vitro*, 40, 134

Erythrocyte precursors *in-vivo* study of DNA-synthesis time and cell-cycle time in erythrocyte precursors of normal and thalassaemic subjects, using  $H^3$  and  $C^{14}$ -thymidine double labelling technique, 38, 170

Erythrocyten; Aggregation und Disaggregation, 36, 323

- fetale, und fetales Hämoglobin. Vergleichende Untersuchungen über strukturelle und funktionelle Besonderheiten der roten Blutzelle Neugeborener und junger Säuglinge, 38, 64 (8)

- die intrazelluläre Verteilung von embryonalem Hämoglobin in roten Blutzellen menschlicher Embryonen (Ein Beitrag zur Ontogenese menschlicher Hämoglobine), 38, 264

- die Lokalisation der unspezifischen Esterase in foetalen Erythrocyten und deren Vorstufen, 37 240

- Resorptionfunktion (Bibliotheca Haematologica, fasc. 25) 38, 404 (8)

- Untersuchungen über die Hämynthese in roten Erythrozyten (II.: Die Bildung von  $Fe^{2+}$ -Hämoglobin in peripheren menschlichen Erythrocyten *in vitro*) 38, 63  
v Polycythaemia vera, Renklozyten

Erythrocytenstoffwechsel und Erythrokinetik bei Thalassaemia minor I. Untersuchungen, 39 333

Erythrocyten (Stoffwechsel und Membranpermeabilität), Synopsen

Erythrocytes; change from fetal to adult haemoglobin in relation to changes in the A antigen of human erythrocytes, 40, 322  
- differences between the red cell acetylcholinesterase defects of paroxysmal nocturnal hemoglobinuria and of ABO hemolytic disease, 38, 65

reticulocyte and normoblast labelling with leucine- $H^3$  in thalassaemic and non thalassaemic subjects, 40, 37

- studies of Hantz body formation, 37 1

- transketolase activity of red blood cells in conditions of haematological interest, 39 321

- in *in vivo* synthesis of haemoglobin from  $\text{Fe}^{55}$  and leucine- $\text{C}^3$  by normal, sickle cell and thalassaemic immature red cells, 33, 200
- 1 Agglutinin, Chloramphenicol, Electrical conductivity Erythroblasts, Erythropoietic, Erythropoiesis, Glucose-6-phosphate dehydrogenase, Glucose-6-phosphate dehydrogenase, G-6-PD, Pyruvate kinase deficiency Sickle cell-beta, Spherocytosis
- Erythrocytosis, familial (A report of two cases, and a review) 39 63
- Erythroid activity of bone marrow Erythropoiesis
- Erythroid hyperplasia, effect on the disappearance rate of erythropoietin in the dog, 39 42
- Erythrokinetic studies in thalassaemia with simultaneously radioactive tracers ( $\text{Fe}^{55}$  and  $\text{Cr}^{51}$ ) 37 63
- Erythrokinetik und Erythrozytenstoffwechsel bei Thalassaemia minor U tersuchungen, 39 333
- Erythroleukaemia, v Erythromyelosis, Haemoglobin H
- Erythrocytosis, acute, after benzene poisoning, 40 234
- Erythropoietic, aneukleotempfindliche, bei Glukose-6-Phosphatdehydrogenase Mangel, Übergang in eine chronische hämolytische Anämie, 37 206
- Erythropoiesis DNA synthesis by erythroblasts in normal man and in some disorders of erythropoiesis, 40, 315
- ; effect of androgen antagonist on erythropoietic action of testosterone, 40, 297
- ; erythropoietic action of testosterone, 38, 49
- the effect of testosterone, adrenal steroids and prolactin on erythropoiesis, 38, 292
- ; zur erythropoietischen Wirkung von Testosteron, 39 366
- isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 39, 118
- ; production cellulaire érythropoietique (Progrès dans les recherches sur le cancer Vol. 14), 40, 238 (B)
- 1 Erythrocyte precursors, Erythrokinetic studies, Reticulocytes, Aueroblastic anaemia
- Erythropoiesis, disturbance Haemoglobin H
- Erythropoietin; effect of erythroid hyperplasia on the disappearance rate of erythropoietin in the dog, 39 42
- ; extra-renal production of erythropoietin in man, 39, 339
- fractionation of erythropoietin by selective membrane permeability 38 372
- Especies d'antimex (phosphatase des leucocytes) v Animal species
- Esterase, nonspecific (NaF sensitive) Monocytes
- Esterase unspezifische; die Lokalisation der unspezifischen Esterase in sortalen Erythrocyten und deren Vorstufen, 37 240
- Eucard® (= chitidomhaltiges Kombinationspräparat) Erythropoietin
- European Society of Haematology Proceedings of the 10th Congress (Strasbourg, 23-28.8.1963) (part I main lectures) 36, 1 296 (C)
- ; 11th congress (Athens, 10-14.9.1967), 36, 417
- Proceedings of the 10th Congress, Strasbourg, 1963 (Part I and II), 40, 111 (B)
- European Society for Microcirculation, 5th Conference (as an International Conference) Gothenburg, June 24-29 1968, 39 19\*
- Evolution des leucocytes éosinophiles, v Eosinophil granules
- Experimental biology and medicine, conference in Switzerland (September 1966) 37 322
- Extirpation du rein, Erythropoietin
- Extra-renal production of erythropoietin in man, 39 339
- Extraction of the spleen, Erythroblast
- Facteurs locaux du premier temps de l'hémostase, 36, 109 (C)
- Factor V (= Prothrombin); specific inhibitor of human clotting factor V 40 273
- Factor VIII (= AHF = Antihæmophilic globulin A = AHG A) investigation of circulating anticoagulants against AHF (= Factor VIII) in three patients with hæmophilia A, 39 214
- ; pitfalls of factor VIII assay 38 383
- ; Adrenergic blockers
- Factor IX (= PTO factor); the clotting

- activity of protein fractions of congenital factor IX deficient (Christmas) serum, 33, 13
- v Christmas disease
- Factor XII Hagensen factor deficiency (Report of case found in Japanese girl) 33, 36
- Factor XIII (= fibrin-stabilizing factor); congenital deficiency of fibrin-stabilizing factor (= factor XIII) (A report of the first case in Latin America) 40, 329
- Factors (blood coagulation) Blutgerinnungsfaktoren
- Familial erythrocytosis (A report of two cases, and review) 39, 63
- Family (families) study on three families with haemoglobin Lepore in *Campesina* (Hb Lepore trait, heterozygosity for Hb Lepore and  $\beta$ -thalassaemia, heterozygosity for Hb Lepore) 37, 266
- another showing the interaction of the genes for Hb G (Philadelphia) and Hb S, 40, 286
- Family with delta thalassaemia, v Delta thalassaemia
- Family (families) v Alpha-Thalassaemia
- Factor XII, Fibrin-stabilizing factor Haemoglobin J Paris, Macrolobulinæmia, Methaemoglobinæmia, Methaemoglobinæmic cyanosis, Microcythæmia, Pyruvate kinase deficiency Spherocytosis
- Fatty acids, non esterified, v Demargination
- Ferritin, Alpha-Thalassaemia
- Fe<sup>59</sup> and Cr<sup>51</sup> studies in aplastic anaemia and myelocytosis, 33, 139
- Fe<sup>59</sup>-Haemoglobin; Untersuchungen über die Hämsynthese in roten Blutkörperchen (II. Die Bildung von Fe<sup>59</sup>-Haemoglobin in peripheren menschlichen Erythrocyten *in vivo*) 33, 65
- Fe<sup>59</sup> Baboon Erythroid hyperplasia Erythrokinetic studies; Erythropoiesis; Erythropoietin; Haemoglobin II Haemoglobin, *in vivo* synthesis; Iron sorbitol, Thalassaemia minor
- Feinstruktur Basophile Zellen, Eosinophil granules, GAUCHER cells, Haemagglutination, Hirtz body Lymphopathia, Mönse leukaemia, Phagocytosis
- Female karyotype Christmas disease in girl with female karyotype, 37, 217
- Fœtal cutaneæ, Mononukleäre Zellen
- Fer v Aconitase; Aplastic anaemia; Baboons; Erythrokinetic studies Erythropoiesis; Erythropoietin; Ferritin; Ferrous sulphate Haemoglobin H Haemoglobin, *in vivo* synthesis; Hämsynthese; Iron deficiency Iron poisoning Iron sorbitol; Sideroblastic anaemia; Thalassaemia minor
- Fer metabolisme, v Atransferridinæmia
- Ferment cytochemistry, Lymphocytes and their derivative cells
- Ferments; histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 35, 112
- Ferments, v Acetylcholinesterase; Aconitase Alkaline phosphatase Diaphorase Dihydroorotic acid dehydrogenase: Dehydrogenasen; Esterase, unspezifische Glucose-6-phosphate dehydrogenase: Glucose-6-Phosphatdehydrogenase: G-6-PD Isoenzyme variations (B); Monocytes Mononukleäre Zellen Nitrate cholinesterase; Pyruvate kinase deficiency Reductase Retikulozyten; Serum lactic dehydrogenase Sickle cell, Thalassaemia minor; Thiamidopyrophosphatase; Transketolase
- Ferritin; identification of ferritin within GAUCHER cells (An electron microscopic and immunofluorescent study) 37, 189
- Ferrogradomet® Ferrous sulphate
- Ferokinetic studies, Haemoglobin H
- Ferrous sulphate, slow release ferrous sulphate tablets; trial of slow release ferrous sulphate (Ferrogradomet®) in prevention of iron deficiency in pregnancy 40, 200
- Fœtal haemoglobin change from fœtal to adult haemoglobin in relation to changes in the A antigen of human erythrocytes, 40, 322
- Fœtal Haemoglobin and fœtal Erythrocytes. Vergleichende Untersuchungen über strukturelle und funktionelle Besonderheiten der roten Blutkörperchen Neugeborener und junger Stuglinge, 33, 64 (B)
- v Embryonales Haemoglobin
- Fibrin über den Retraktionsvorgang beim Blutplasmaerinnel, 36, 371
- Fibrinase, v Factor XIII
- Fibrinogen, Aggregation
- Fibrinolysis; comparative studies on inhibitors of fibrinolysis *in vivo* and *in vitro* 39, 1

- essentielle Hyperlipämie und erniedrigte Fibrinolyse-Aktivität, 33, 178
- der Proaktivatorgehalt im fibrinolytischen System von Hyperlipämiern, 33, 377
- therapeutische Fibrinolyse, 36, 89 (C)
- Fibrinolyse inhibitors: high obstruction of urine flow as a complication of the treatment with fibrinolytic inhibitors of haematuria in haemophilias, 33, 237
- Fibrinolytic system in liver cirrhosis, investigations, 40, 265
- Fine structure: Basophile Zellen, Eosinophiler granules, Gaucher cells, Haemagglutination, Hürter body, Lymphoplastic, Mouse leukaemia, Phagocytosis
- Finger prints: Alpha-Thalassaemia, Haemoglobin J Paris, Haemoglobin Koehler Sickle cell
- Fluorescent antibody technique, Gaucher cells
- Foetale Erythrozyten: die Lokalisation unspezifischer Esterasen an foetalen Erythrozyten und deren Vorstufen, 37, 240
- Foetal, Fetal...
- Feto-Maternal Incompatibility Symposium, 11th International (Brussels, 15. 11. 1968) 33, 382
- Fove, Leberparenchymsellen Liver cells
- Folique, acide - erythroblastopoenie non mégalocytaire et sensible à l'acide folique chez un épileptique, 37, 159
- Formes (C<sup>4</sup>-formes) Mononucleose infections
- Fortschrittsberichte, Thyssen (B)
- Fowl, Myeloblastosis virus
- Fractionation of erythropoietin by selectin membrane permeability 38, 372
- FXF v. Fibrin-stabilizing Factor
- Reaktion und Transport intrazellulärer Elektrolyte (Symposium, Schüren, 1967) 39, 382 (B)
- Cells desmoplasia, Myeloblastosis virus
- Gamma G globulin, Antibodies
- Gamma globulin, v. Agglutinin
- Gamma globulin (Hypergamma globulinemia), Macroglubulinemia
- Gamma-Haemachlorocyclobeta Knochenmarkschäden nach beruflicher Einwirkung des Insektenblut Gamma-Haemachlorocyclobeta (Lindan) 36, 337
- Ganglions lymphatiques, position, Lymphopapules
- Gaucher cells; identification of ferritin within Gaucher cells (An electron microscopic and immunofluorescent study), 37, 189
- Gefäße, v. Hemorrhagic disorders, Hémorragies
- Geldrollenaggregation Aggregation
- Genetically determined serum groups, Anti-T<sub>1</sub>-like haemolysis
- Genetics, v. Alpha-Thalassaemia Anti-T<sub>1</sub>-like haemolysis, Delta thalassaemia, Erythrocytosis, Fibrin-stabilizing factor: Haemoglobin D Haemoglobin G (Philadelphia), Haemoglobin J Paris, Hageman factor deficiency Leucocyte variations (B) Macroglubulinemia, Methaemoglobinemia (B) Microcythemia, Primates in medicine (B) Pyruvate kinase deficiency Salvia, Sickle cell - Spherocytosis, Thalassaemia
- Genetics, human, isotype variations (B)
- Genotype, Isohemagglutination
- Geographical haematology 40e Zealand symposium, proceedings, 37, 372
- Geographie remarques sur l'hématologie géographique, 36, 1 (C)
- Gerinnung (Blutplasmaerinnung) Reaktionsvorgang
- Gesellschaft Deutsche Gesellschaft für Hämatologie, 14. Tagung, Kiel, September 1969, 39, 382
- Gesellschaften, European Society of Haematology International Society of Haematology Microcirculation
- Gewebeulturen, Cell cultures, Tissue cultures
- Gewebestellen, Basophils
- γG Globulin, Antibodies
- Glanz: sickle cell haemoglobin D Paraglobulin 5 from Glanz and D from England, 38, 324
- Glanz beads, Eukaryocytes
- Glasperlen, Eukaryocytes
- Globulin (gamma globulin) Agglutinin, Gamma G globulin, Gamma globulin
- Globulin, Antibodies
- Glucose-6-phosphate dehydrogenase (= G-6-PD) survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency in Hawaii, 37, 94
- 1 survey for erythrocyte glucose-6-de-



- hydrogenase deficiency in *Ruminants*, # 44  
 — characterization in *Serfolow* children with congenital nonspherocytic haemolytic anaemia, 37 193  
 — and sickle cell disease, 36, 399  
 — v *Acetylcholinesterase*  
*Glucose-6-phosphatidehydrogenase-Mangel mit Hämoglobinopathie und alpha-Thalämie*, 39 167  
 — Übergang einer arzneimittelempfindlichen Erythropathie bei Glucose-6-Phosphatidehydrogenase-Mangel in eine chronische hämolytische Anämie, 37 206  
*G-6-PD (= Glucose-6-phosphat dehydrogenase) - Mangel mit Hämoglobinopathie und alpha-Thalämie*, 39, 167  
*Glycolytic des leucocytes humaine, mesurée in vitro, effet de l'azulane et de quelques autres facteurs*, 37 181  
*G-6-PD v Glucose-6-phosphat dehydrogenase, Glucose-6-Phosphatidehydrogenase*  
*Glucosephosphatase v Thiamopyrophosphatase*  
*Granules, eosinophil, and cell maturity-electron microscopic observations on guinea-pig marrow*, 36, 350  
*Granulocytic leukaemia, chronic; two Ph 1 chromosomes in blastic crisis of granulocytic leukaemia*, 36, 391  
*Granulinsynthese unter physiologischen und pathologischen Bedingungen (Experimentelle Medizin, Pathologie und Klinik, Bd. 17)*, 38 403 (B)  
*Gravidity Aborters, Iron deficiency*  
*Grupe, v Rizin*  
*Grosses, Aborters, Iron deficiency*  
*Groupes sanguins, v A antigen, ABO blood group, ABO hemolytic disease, Aberrant blood group, Antigenic changes, Anti-Ty-like haemolysis, Blood grouping tests (B), Blood groups (B), (Haemagglutination) I antigen, Isohaemagglutination*  
*G 21 trisomy as: case of acute myeloblastic leukaemia*, 38, 142  
*Guinea-pig, Eosinophil granules, Thymus*  
*Haemagglutination electron microscopic examination of haemagglutination produced by admixed Coombs serum*, 38, 333  
*Isohaemagglutination*  
*Haemagglutinin, Agglutinin*  
*Haematological disease, unusual as un-*  
*usual haematological syndrome with pyruvate-kinase deficiency and thalassemia minor in the kindred*, 39, 345  
*Haematological diseases transketolase activity of red blood cells in conditions of haematological interest*, 39, 321  
*Haematological and serological behaviour of chicks inoculated with myeloblastosis virus*, 37 311  
*Hämatologie Strahlenchäden und Strahlenhämatologie (Schriftenreihe der ärztlichen Fortbildung, Bd. 31)*, 39 381 (B)  
 — v *Hämatologie (B)*  
*Haematokrit, v Electrical conductivity*  
*Haematology automation in haematology (Symposium at the 11th Congress of the International Society of Haematology)*, 39, 381 (B)  
 — comparative, of laboratory animals (Selected aspects), 36 13 (C)  
 — *European Society of Haematology Proceedings of the 10th Congress (Strasbourg, 23-28.8.1963) (part I main lectures)*, 36, 1 296 (C)  
 — *Proceedings part I and II*, #3, 111 (B)  
 — *11th Congress (Athens, 10.14.9.1967)*, 36, 417  
 — *11th Congress of the International Society of Haematology (Sydney August 21-26, 1966) (Amalgamation of the International Society the European Society and the Asia-Pacific Society of Haematology)*, 37 232  
 — *11th Congress of the International Society of Haematology (New York, September 1-6, 1968)*, 39 370  
*Geographical haematology Hematologia (B) Versierung, Standardization (B)*  
*Haematopoiesis, Eosinophil granules*  
*Haematopoietic cells, Bone marrow cells*  
*Haematopoietin, Erythropoiesis, Erythropoiesis*  
*Haematuria high obstruction of urine flow as complication of the treatment with fibrinolytic inhibitors of haematuria in haemophilic, 39, 257*  
*Haemoglobin, Methaemoglobinemia, Methaemoglobinemic cyanosis*  
*Haemim, Hémos*  
*Haemoglobin change from fetal to adult haemoglobin in relation to changes in the*

- A antigen of human erythrocytes, 40 322  
 Untersuchungen über die Hämoythese  
 in roten Blutzellen (II: Die Bildung von  
 $Fe^{2+}$ -Hämoglobin in peripheren menschen-  
 lichen Erythrocyten *in vitro*) 33, 63
- Haemoglobin fractions; simple method for  
 quantitation of haemoglobin fractions  
 obtained by starch-gel electrophoresis,  
 33, 306
- Haemoglobin, *in vitro* synthesis, from  $Fe^{2+}$   
 and leucine- $-C^3$  by normal, sickle-cell  
 and thalassaemic human red cells, 33,  
 200
- Haemoglobin-Synthese Atransferrin-  
 ksenin, Hämoythese, Reticulocyten
- Haemoglobin A, Adult haemoglobin,  
 Haemoglobin fractions; Haemoglobin  
 Koefliker Haemoglobine, menschliche  
 Thalassaemia
- Haemoglobin A<sub>2</sub> (derivative from haemo-  
 globin A) Protein fraction
- Haemoglobin D; sickle cell haemoglobin D  
*Punjab disease*: S from Ghana and D from  
 England, 33, 324
- Haemoglobin D $\beta$  Los Angeles (D *Punjab*  
 $\alpha_2\beta_2$  121 Glu NH<sub>2</sub>) in The family 33,  
 151
- Haemoglobin E, Thalassaemia (Ceylon)
- Haemoglobin F Fetal haemoglobin;  
 Fetales Hämoglobin (B) Haemoglobin  
 fractions; Hämoglobine, menschliche  
 Microcythaemia
- Haemoglobin III (Philadelphia); another  
 family showing the interaction of the  
 genes for Hb G (Philadelphia) and Hb S,  
 40 206
- Haemoglobin Gower 1 and 2, Häm-  
 globine, menschliche
- Haemoglobin H as an acquired defect of  
 alpha-chain synthesis (Report of two  
 cases) 39 91
- Haemoglobin H, Alpha-Thalassaemia,  
 Thalassaemia, Thalassaemia (Ceylon)
- Haemoglobin J Para in the South of  
 Portugal (Algarve), 32, 231
- Haemoglobin Koefliker new acquired  
 haemoglobins appearing after severe  
 haemolytic  $\alpha_2$  mara 141 Arg  $\beta_2$  37 17
- remarks on the so-called Haemoglobin  
 Koefliker' 39 60
- answer to the remarks on 'Haemoglobin  
 Koefliker' of Bates, Fudge, Lucci and  
 Maggioni, 39 61
- Haemoglobin Lepore in *Campania*, study on  
 nine families (Hb Lepore trait, hetero-  
 zygosity for Hb Lepore and  $\beta$ -thalas-  
 saemia, homozygosity for Hb Lepore) 37  
 266
- Haemoglobin 'Typ Mexico Alpha  
 Thalassaemic
- Haemoglobin plasma modified (HbPSM)  
 Haemoglobin Koefliker'
- Haemoglobin S; sickle cell *Punjab disease*:  
 S from Ghana and D from England, 33, 324  
 ; disease delta thalassaemia, homozygous;  
 new thalassaemic syndrome, 35, 412  
 ; Haemoglobin O (Philadelphia)
- Haemoglobin Th, Haemoglobin frac-  
 tions
- Hämoglobine, menschliche die intrazell-  
 kuläre Verteilung von embryonalem  
 Hämoglobin in roten Blutzellen menschen-  
 licher Embryonen (Ein Beitrag zur  
 Oxygenase menschlicher Hämoglobine)  
 33, 264
- Haemoglobins
- Hämoglobinopathie; G-6-PD-Mangel mit  
 Hämoglobinopathie und alpha-Thalasse-  
 mie, 33, 167
- Hämoglobin Koefliker Haemoglobin  
 Lepore in *Campania*, Haemoglobins (B)  
 Thalassaemia, Thalassaemia syndrome
- Haemoglobin basiss haemoglobin va-  
 rients and their identification, 40 336 (B)  
 laboratory manual on abnormal haem-  
 oglobins, 40 336 (B)  
 man haemoglobins including the haem-  
 oglobinopathies and their investiga-  
 tion, 37 1/1 (B)
- Hämoglobinurie differences between the  
 red cell acetylcholinesterase defects of  
 paroxysmal nocturnal haemoglobinuria  
 and ABC hemolytic disease 39 83  
 paroxysmal nocturnal haemoglobinuria  
 following aplastic anaemia 38, 57  
 relationship of paroxysmal nocturnal  
 haemoglobinuria to other pili-depressed  
 hemolytic syndromes of acetylcholin-  
 esterase 37 88
- Haemoglobin Koefliker
- Hämolyse perpetua d'origine exogene  
 mara, 33, 273
- Hämolyse, hereditäre due to transient  
 activity of inherited pyruvate kinase de-  
 ficiency 40 11
- Hämolyse, severe haemoglobin Koefliker

- a new acquired haemoglobin appearing after severe haemolysis:  $\alpha_2$  minus 141 Arg  $\beta_2$ , 57 174
- Haemolysis in vitro; studies on chloramphenicol induced haemolysis in vitro and survival of chloramphenicol treated cells in vitro 33, 11
- Haemolysis, v ABO haemolytic disease, Anti-Tp-Eko haemolysis
- Haemolytic anaemia, v Sick cell..
- Haemolytic anaemia, congenital non-spherocytic, v Anaemia, haemolytic, congenital, nonspherocytic
- Haemolytic diseases a peculiar benzidine-positive protein fraction in the plasma of newborns and children with various haemolytic conditions, 36, 361
- Haemolytic syndrome, unusual an unusual haematological syndrome with pyruvate-kinase deficiency and thalassemia minor in the kindreds, 59 345
- Haemolytic systems, pH-dependent, relationship of paroxysmal nocturnal haemoglobinuria to other pH-dependent haemolytic systems role of acetylcholinesterase, 57 68
- Hämolytische Anämie bei Sarkoidose der Milz, 126
- Hämolytische Anämie, chronische, v Anämie, hämolytische, chronische
- Hämometerprüfung; Normierung in der Hämatologie (Einstufungen der Hämometerprüfstelle) 33, 63
- Haemophilia high obstruction of urine flow as complication of the treatment with fibrinolytic inhibitors of haematuria in haemophilias, 39 237
- an origination of circulating anticoagulants against AHF (= factor VIII) in three patients with haemophilia A, 39, 214
- World Federation of Hemophilia. International Symposium (Montreal, 26-28th August 1968), 39 65
- Christmas disease, Factor VIII
- Haemorrhagic disorders the nature of the defect in hemorrhagic disorders, 36, 141 (C)
- Haemorrhagic symptoms, v Christmas disease
- Haemorrhagy v Thrombocytosis, post haemorrhagic
- Haemostasis importance of coagulation besides haemostasis, 36, 153 (C)
- ; v Hemorrhagic disorders, Hémorragie
- Haemostatic effect double blind evaluation of the haemostatic effect of adrenochrome monosuccinylbarbitone, conjugated oestrogens and calcium-aminocaproic acid after adonotomectomy 40 154
- Hämsynthese in roten Blutzellen, Untersuchungen. (II. Die Bildung von  $\text{Fe}^{2+}$  Häemoglobin in peripheren menschlichen Erythrocyten in vitro), 33, 63
- Hämsynthese, Atransferrinkrise, Retikulozyten
- Haem v Hem. (Hém.)
- Hageman factor (= Factor XII) deficiency (Report of one found in a Japanese girl) 39, 36
- H antigen, ABO blood group
- Hautfärbung; cytochemische Untersuchungen zur Entwicklung der grossen mononukleären Zellen des Hautfärbens, 33, 281
- Hautfärbungsreaktionen, v Macrophages
- Haasell, survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency in Haasell, 57 94
- Hb A<sub>2</sub> v Adult haemoglobin, Haemoglobin A<sub>2</sub>, Thalassemia
- Hb A<sub>2</sub> (derivative of Hb A) v Protein fraction
- Hb D v Haemoglobin D
- Hb E, Haemoglobin E
- Hb F v Fetal haemoglobin, Haemoglobin F Microcythaemia
- Hb G, v Haemoglobin G (Philadelphia)
- Hb Gower I und 2, Hämoglobine Gower I und 2
- Hb H, Haemoglobin H
- Hb J Para, v Haemoglobin J Para
- Hb Koefüster Haemoglobin Koefüster
- Hb Lepore, v Haemoglobin Lepore in Compere
- Hb Typ Mexico v Haemoglobin Typ Mexico
- HbPM, Haemoglobin Plasma Modified
- Hb S, Haemoglobin S
- Hb Th, Haemoglobin Th
- HCCH, Hexachlorcyclohexan
- H<sup>3</sup>-cytidine, v Blastoid transformation, Plasma cells
- H<sup>3</sup>-deoxycytidine-3-monophosphate, Mononucleoside
- Hazut body studies of Hazut body formation, 57 1
- Hémagglutination, v Isohémagglutination

- Hematologia (Propedeutica médica Vol. I) (portugiesisch) 38, 403 (B)
- Hématologie géographique, remarques, 36, 1 (C)
- Hématologie; Société Européenne d'Hématologie: 10<sup>e</sup> congrès (Strasbourg 23. 28. 8. 1965) comptes rendus (1<sup>re</sup> partie rapports principaux) 36, 1 296 (C)
- comptes rendus (1<sup>re</sup> et 2<sup>e</sup> partie), 40, 111 (B)
- 11 congrès (Athènes, 10. 14. 9. 1967) 36, 417
- actes des hématologues, 38, 62 (B)
- Hæmatology
- Hémine; l'index H<sup>2</sup>-dymidine des mégarocytes de la souris intacte et injectée d'hémine, 38, 43
- Hemoglobin H as an acquired defect of alpha-chain synthesis (Report of two cases) 39 91
- Hemoglobin H, Hæmoglobin H
- Hemophilia, Hæmophilia
- Hemorrhagic disorders; the nature of the defects in hemorrhagic disorders, 36, 141 (C)
- Hémostase; facteurs locaux du premier temps de l'hémostase, 36, 109 (C)
- Hæmostasis, Hemorrhagic disorders
- Hem. (Hém.), Hæm
- Hepa Leberparenchymentellen, Liver cirrhosis
- Hepatic (antibepan activity) Christmas factor
- Hereditary methaemoglobinæmia cyanosis due to diaphorase deficiency in three successive generations, 37 276
- Hereditary methaemoglobinæmia due to DPGH-methaemoglobin reductase deficiency (Report of family) 37 284
- Hereditary spherocytosis and heterozygous beta-thalassaemia (A family study) 39 183
- Heredity v Isosync variations (B)
- Hereditary Alpha-Thalassaemic, Beta-thalassaemic, Christmas factor Congenital nonspherocytic haemolytic anaemia, Delta thalassaemia, Erythrocytosis, Fibrin-stabilizing factor Hæmoglobin D, Hæmoglobin G (Philadelphia) Hæmoglobin J Paris, Hæmoglobin Koefiker Hæmoglobin Lepore in Camponia, Hæmoglobin factor deficiency Hereditary Macrolobulæmæmia, Methaemoglobinæmia (B) Microcythaemia, Pyruvate kinase deficiency Sick cell Thalassemia, Thalassemia major Thalassemia
- Hermaphrodit, true Aberrant blood group
- Heterogeneity and structure of antibodies, 36, 198 (C)
- Heterozygosity for Hb Lepore and  $\beta$ -thalassaemia, homozygosity for Hb Lepore, Hæmoglobin Lepore in Camponia
- Heterozygous beta-thalassaemia, Hereditary spherocytosis
- Hemichloro lobocin (Gamma-Hemichlorocyclobicin) Knochenmarkschiden nach herofflicher Einwirkung des Insektizids Gamma-Hexachlorcyclobicin (Lindan), 38, 337
- Histamine, dietary and eosinophils in the rat, 40 59
- Histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukemia, 38, 112
- Histochemistry Acetylcholinesterase, Alkaline phosphatase, Cytology Dihydroorotic acid dehydrogenase, Drüsen fieberzellen, Enzyme analysis, Erythroblast, Foetale Erythrocyten, G-6-PD Lymphocytes (derivative cells) Lymphocytes and their derivative cells, Lymphopathia, Monocytes, Mononucleosis infectiosa, Mononukleäre Zellen, Monocytaire Leukämien, Myelocytosis, Plasma cells, Reticulocytes, Sick cell disease, Thiaminepyrophosphatase
- H<sup>2</sup>-leucine, Plasma cells, Reticulocyte
- Hochpolymere Substanzen, Macromoleculars
- HODOKI, mortus: Reticulosis
- Homme, Hämoglobine, menschliche Isosync variations (B) Human Mac (C)
- Hormonæ, immunologische Lymphocyten
- Homologous RNA, Ribonucleic acid, homologous
- Homotransplantation, Erythropoietin (extra-renal)
- Homotransplantation reactions, Lymphocytes
- Homotransplantation reaction, Lymphocytes
- Homozygosity for Hb Lepore, heterozygosity

- for Hb Lepore and  $\beta$ -thalassaemia, v Haemoglobin Lepore in *Compens*
- Homozygous haemoglobin S disease delta thalassaemia new thalassaemic syndrome, 36, 412
- Homozygous  $\beta\delta$ -thalassaemia (or microcythemia) with high haemoglobin F in *Sick* family three cases, 40, 220
- Hormones, v Erythropoiesis, Erythropoietin, Testosterone
- HP-thymidine Index HP-thymidine des mégakaryocytes de la souris intacte et injectée d'hémoc, 38, 43
- HP-thymidine, (HP-uridine) v Benzene, Blastoid transformation Chromatin-structure DNA synthesis Eosinophils; Erythroblast; Erythrocyte precursors Leukemia, acute Leukemia, cell proliferation Metabolism of leukocytes Macrophages Mononuclear Plasma cells Proliferative activity; Thoracic duct lymph Thymidine metabolism (B)
- Hühnerchen, v Myeloblastosis virus
- Human, leukocytes - v Leukocytes human
- Human blood platelets, nitrocathecolamine, 39, 129
- Human clotting factor V a specific inhibitor 40, 273
- Human erythrocytes, v A antigen
- Human genetics, v Isotype variations (B)
- Human haemoglobin variants and their identification, 40, 338 (B)
- Haemoglobins
- Human leukaemia, pathogenesis, 36, 189 (C)
- Human leukaemia, viral theory 36, 174 (C)
- Human lymphocyte; delay of human lymphocyte blast transformation by homologous RNA, 39, 270
- Antibody Blastoid transformation, Lymphocytransformation
- Human marrow v Basophils
- Human mononuclear leukocytes, *in vitro* transformation, (I. Comparison of cells in suspension and attached to coverslips) 36, 333
- (II) Precursors of large mononuclear cells on coverslips 37, 32
- Human tissues (normal and leukemic), v DNA, satellite
- Hund, Dog
- HP-uridine, Leukemia, cell proliferation, Plasma cells, (HP-thymidine)
- Hydrocortisone, v Peritoneal ascites (maintenance therapy)
- Hypergammaglobulinemia, v Macroglobulinemia
- Hyperlipaemic erhöhte Aggregation der Thrombozyten bei essentieller Hyperlipämie, 38, 311
- essentielle, und Blutgerinnungsfaktoren, 38, 219
- ; essentielle, und verminderte Fibrinolyse-Aktivität, 38, 178
- der Proaktivatorgehalt im fibrinolytischen System von Hyperlipämikern, 38, 377
- Hypophysectomy, v Prolactin
- Hypotransferrinemia, v Atransferrinemia
- Hypoxia, v Erythropoiesis
- I antigen of red cells in leukemia and its interaction with Mycoplasmas is new and is also 40, 154
- Idiopathic aplastic anaemia, associated with trisomy-21 and partial endoreduplication, case 37, 157
- v Aplastic anaemia
- Ikterus, hämolytischer v Sarkoidose
- Immunoelectrophoresis, v Paraproteinaemia
- Immunoblasts, v Lymphocytes
- Immunochromatography v Antibodies
- Immunoelectrophoresis, Antibodies, Macroglobulinemia
- Immunofluorescent technique, Cancer cells
- Immunoglobulins, v Antibodies
- Immunologische Homöostase Lymphocyten
- Immunology v Human leukaemia, Primates in medicine (B)
- Immunreaktionen, Thymus (B)
- Inclusion de Huxley Huxley body
- Index HP-thymidine des mégakaryocytes de la souris intacte et injectée d'hémoc, 38, 43
- India ink, v Macrophages
- Infectious mononucleosis division of leukocytes already in DNA synthesis from patients with acute leukemia and infectious mononucleosis, 38, 163
- ; infectious mononucleosis cell (I: DNA synthesis) 38, 157
- the proliferation of infectious mononucleosis lymphocytes *in vitro*, 38, 19

- zur Zytochemie der Drüsenleberzellen, 39 257
- Inflammation (macrophages of inflammation), Macrophages
- Inheritance of leukaemia and cancer 39, 174
- Inherited pyruvate kinase deficiency v Pyruvate kinase deficiency
- Inhibitor specific, of human clotting factor 1 49 275
- Inhibitors, v Fibrinolysis inhibitors
- Injury of bone marrow and repair (irradiation and mechanical disruption) 40 55
- Inoskörper v Hainc body
- Insektizid Knochenmarkschäden nach beruflicher Einwirkung des Insektizids Genotoxizität, clobenon (Lindan) 39, 337
- Insuline effet de l'insuline et de quelques autres facteurs sur la glycolyse des leucocytes humains, examinée *in vitro*, 37 161
- Integumentation cutanée, v Hämifester
- International Committee for Standardization in Haematology 3rd Transactions, Strasbourg, 22-27 8. 1965 (Standardization in haematology III) 39, 404 (B)
- Normierung
- International Conference on Microcirculation (5th Conference of the European Society for Microcirculation), (Gothenburg, June 24-29, 1968), 39 192
- International Congress, VIIth, of Clinical Pathology (Montreal, 1969) 40 178
- International Congress, 1st, of the Transplantation Society (Paris, June 1967) 37 322
- Proceedings (Advance in transplantation), 40 178 (B)
- International Council of Nurses, 39 362
- International Society of Blood Transfusion, XIIth Congress, Moscow 1969 (travel grants) 40 240
- International Society of Haematology XIIth Congress, Sydney 21-26 August 1966 (Amalgamation of the International Society the European Society and the Asian-Pacific Society of Haematology) 37 325
- International Society of Haematology XIIth Congress, New York, 1-6. 9. 1968, 39, 320
- International Symposium, IIth, on Feto-Maternal Incompatibility (Brussels, 15. 16. 11. 1968) 39 582
- International Symposium on Hemophilia, Montreal (26-29th August 1968) (World Federation of Hemophilia), 39, 63
- International Symposium sur la recherche comparée dans les leucémies (IIIème) Paris 11-13 juillet 1967 37 323
- International Workshop-Gate symposium, Leukaemia research (B)
- Internationales, (I.) Symposium über Stoffwechsel und Membranpermeabilität von Erythrozyten und Thrombozyten, Wien (17.-20. Juni 1968) 39, 63
- Interphascherne; die Zeitfolge der DNA-Verdopplung der Chromatinstrukturen in Interphascherne inhibierter Leukozyten, 39, 361
- Intoxikation, Benzene, Benzene poisoning, Iron poisoning
- Intrazelluläre Elektrolyte, Transport und Funktion (Symposium in Schönen, 1967) 40, 112 (B)
- Iode, radioactive, Fluoridolym
- Iodized Cocoon serum, Electron microscopic examination
- Iron deficiency; acronitase activity 37 III trial of slow release ferrous sulphate (Ferrogardmet®) in prevention of iron deficiency in pregnancy 40, 200
- Iron, metabolism, Atransferrinämien
- Iron poisoning fetal peroral iron poisoning in young women, 40, 90
- Iron sorbitol, studies on this metabolism, 37 253
- Iron, Aplastic anaemia Baboon Erythroid hyperplasia; Erythropoiesis Erythropoietin Ferritin; Haemoglobin H; Haemoglobin, *in vivo* synthesis Häm-synthese Sideroblastic anaemia (Thalassemia minor
- Irradiation, Bone marrow injury Leukemogenesis, Pathogenesis (leukemia), StrahlenhämatoLOGIE (B), Strahlenchancen (B), Thymus
- Isoczymes, Isozyme variations (B)
- Isobömsagglutination; études quantitatives de l'isobömsagglutination, 36, 239 (C)
- Isolierung funktionstüchtiger Blastophoren, 39, 300
- Isotope, radioaktive, Aplastic anaemia; Autoradiographie (B); Baboon; Benzene Blastoid transformation Chromatinstrukturen DNA synthesis; Eosinophils; Erythroblast; Erythrocyte precursor

- non Erythroid hyperplasia Erythrokinetic studies; Erythropoiesis; Erythropoietin Fibrinolysis; Haemoglobin H Haemoglobin, *in vivo* synthesis Haemolysis *in vivo*; Haemorrhage H<sup>2</sup>-cytidine; Iron sorbitol; Leukaemia, acute Leukaemia, cell proliferation; Leukocytes, leukaemic Macrophages Megakaryocytes Metabolism of leukocytes Mononuclear; Pernicious anaemia (nutritional therapy) Plasma cells Platelets Proliferative activity Protein synthesis Reticulocyte Thalassemia minor Thoracic duct lymphocytes Thrombocytes-transfusion (B)
- Isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 39 118
- Isozyme variations in man (Monographs in human genetics, Vol. 1) 38, 404 (B)
- Italian ancestry (partial) v Pyruvate-kinase deficiency
- Ju Fibrinolysis
- Japanese girl, v Hageman factor deficiency
- Jay-system, v Anti-T<sub>2</sub>-like haemolysis
- Jones, v Bruce Jones Protein
- JULLARD JEAN JULLARD prize, 39 320
- Kaninchen, Rabbit
- Kapillaren, v Capillaries
- Karyogram, v G 21 trisomy Idiopathic
- Karyotype Leukemia, acute Leukemia, myeloid, chronic Leukemogenesis Macroglobulinemia; Megakaryoblastic anaemia Myelomonocytic leukaemia Myelodysplasia Osteomyelodysplasia Ph 1 chromosomes Spleen cells Trisomy-21
- Karyotype, female Christmas disease in girl with female karyotype, 37 217
- Karzinom, v Cancer detection (B) Thymus (B)
- Kerne (Zellkerne) Chromatinstrukturen, Chromosomen, Erythroblast (Entkernung) Karyogram
- Kernsegmentierung, Eosinophil
- Ketten (Polypeptidketten  $\alpha$ - und  $\beta$ -Ketten am Haemoglobin) v Thalassemia
- Ketten (Polypeptid-Ketten) Bruce Jones Protein
- Kidney Erythropoietin (extra-renal) Uraemic thrombopathy
- Kidney blockade, Fibrinolysis inhibitors
- Kidney diseases PAS-positive erythroblasts in kidney diseases, 37 225
- Klador v Erythrocytosis, Megakaryoblastic anaemia, Protein fraction, Pyruvate-kinase deficiency
- Kindesalter des Kruer-Syndrom im Kindesalter 40 111 (B)
- Klinisch, Clinical (B)
- Knochenmark über den Abbau von Zellen im Knochenmark des Menschen und der Ratte, 40, 252
- Knochenmark und Blut, Untersuchungen, (Methoden) 40 258 (B)
- Knochenmark, v Bone Bone marrow Bone marrow injury; Bone marrow reactions (B); Cortical; Eosinophil granules Erythroblast(s) Erythrocyte precursors, Erythroid hyperplasia; Gaucher cells Knochenmarkveränderungen Leukemia, cell proliferation; Leukemia, myeloid, chronic Megakaryocytes Monocytes Myelodysplasia Panmyelosis Proliferative activity
- Knochenmarksbildung nach beruflicher Einwirkung des Ionisierendes Gamma-Hexachlorcyclobenzol (Linden), 38, 557
- Knochenmarkzellen über den Nachweis der Thiaminpyrophosphatase (G6P-phosphatase) in Blut und Knochenmarkszellen, 40 177
- Knochenmarkveränderungen bei Typhus abdominalis, 37 11
- Knochelopathie Vererbungsgenopathie bei metastasierendem Prostatakarzinom, 40, 95
- lokal<sup>9</sup> Thymus
- Kohlenstoff, radioaktiver Erythrocyte precursors Haemoglobin, *in vivo* synthesis Mononuclear
- Kollagen, anormales, v Hemorrhagic disorders
- Koma, v Coma
- Kongenital v Congenital
- Kongress, Blood transfusion, Colloquium, Congress, Haematology (B), Microcirculation, Symposium, Therapy
- Krebs, Cancer detection (B) Thymus (B)
- Krebsforschung, Fortschritte Erythropoiesis (B)
- Labelling index (leukaemia blast cells), Proliferative activity
- Laboratory animals, comparative haematology (Selected aspects) 36, 15 (C)

- Laboratory manual on abnormal haemoglobins, # 336 (B)
- Lactic dehydrogenase (= LDH); serum lactic dehydrogenase activity in refractory anaemia, # 187
- ; Virus-induced leukaemia
- Lapla, Rabbit
- Latin America, v Fibrin-stabilizing factor
- LDH, v Lactic dehydrogenase
- Lebensdauer der Erythrozyten, Erythrokinetik
- Leber Liver cirrhosis
- Leberparenchymszellen im Leukorytenkonzentrat. Blutfremde Zellen im strömenden Blut, # 243
- Leitfähigkeit, elektrische Electrical conductivity
- Letters to the editor (Haemoglobin boehlin) # 60
- Leucémie, myélocyttaire; étude cytologique de la transformation aigue d'une leucémie myélocyttaire chronique, # 49
- Leucémies IIIème Symposium International sur la recherche comparée dans les leucémies, Paris 11-13 juillet 1967 # 323
- Leucine ( $C^{14}$ -leucine) Haemoglobin, *in vivo* synthesis; Plasma cells; Protein synthesis
- Leucine- $H^3$ ; reticulocyte and normoblast labelling with leucine- $H^3$  in thalassaemic and non thalassaemic subjects, # 37
- Plasma cells
- Leukaemia, cell proliferation during relapse and remission; (I) DNA and RNA synthesis of leukaemic cells in the bone marrow *in situ*, # 5, 515
- (II) DNA synthesis of leukaemic cells in the peripheral blood *in vivo*, # 16
- Leukaemia and chromosomes, # 157 (C)
- Leukaemia on the I antigen of red cells in leukaemia and its interaction with Mycoplasma *in vivo* and *in vitro*, # 134
- Leukaemia; isolation of Mycoplasmas in leukaemia and other diseases, # 9
- presence of satellite DNA in normal and leukaemic human tissues, # 75
- Leukaemia, acute; cytogenetic studies, # 192
- ; division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, # 103
- ; proliferative activity of the cells of acute leukaemia in relapse and in steady state, # 193
- Leukaemia, granulocytic, chronic two Ph 1 chromosomes in blastic crisis of granulocytic leukaemia, # 391
- ; (Philadelphia chromosome) Leukaemia and chromosomes
- Leukaemia, lymphocytic, acute; metabolism of leukocytes in case of acute leukaemia, # 294
- Leukaemia, lymphocytic, chronic: the potential of lymphocytes from patients with leukaemia and reticuloses to transform under influence of phytohaemagglutinin, # 100
- ; complete remission (Report of case) # 230
- the inheritance of leukaemia and cancer # 174
- Leukaemia, human, pathogenesis, # 185 (C)
- Leukaemia, human, viral theory # 174 (C)
- Leukaemia, mouse leukaemia; transmission of mouse leukaemia by oral route, # 1
- Leukaemia, myeloblastic, acute multiple antigenic changes in case of acute leukaemia, # 150
- ; O 21 transcy in case of acute myeloblastic leukaemia, # 142
- Leukaemia, myeloblastic, Myelocytosis
- Leukaemia, myeloid, chronic cytogenetic studies in unusual forms of chronic myeloid leukaemia, # 129
- Leucémie myélocyttaire
- Leukaemia, myelogenous, chronic Ph<sup>1</sup> diagnosis and prognosis in chronic myelogenous leukaemia, # 102
- Leukaemia, myeloid, Myeloblastic virus
- Leukaemia, myelomonocytic; decreased formation of erythrocyte antigen A and consistent chromosome abnormality in patient with myelomonocytic leukaemia, # 309
- Leukemia, plasma cell leukaemia, Plasma cells
- Leukaemia preleukaemia (A report of four cases) # 20
- Leukaemia, relapse, Leukaemia, cell proliferation
- Leukaemia, remission, Leukaemia, cell proliferation
- Leukaemia research, comparative (Pro-



- ceedings of an International Workshop-Gauter symposium, Stockholm, September 1963), 38, 405 (B)
- IIIème Symposium International sur la recherche comparée dans les leucémies, Paris, (11-13 juillet 1967) 37 323
- Leukaemia, therapy; platted transfusion therapy film, 37 160
- Leukemia, virus histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 38, 112
- prevention of AKR (strain of mice) leukaemia by thymectomy at varying ages, 38, 317
- Leukaemia, v Leukaemogenesis
- Leukemic cell the mononucleoside and leukemic cell (IL RNA synthesis) 40 28
- Leukemia, cell proliferation
- Leukemic leukocytes *in vivo* uptake of  $^3\text{H}$ -methionine by normal and leukemic leukocytes, 40, 118
- Leukemia, eosinophile, akute hämatologische Beitrag zum Krankheitsbild der akuten Eosinophilen-Leukämie, 37 143
- Leukämien, monocytäre, Diagnose mit zytochemischen Methoden, 40, 121
- Leukemogenesis chromosomal aberrations and neoplastic potentialities of thymus cells during leukemogenesis, 40, 142
- Leukemia, v Leukemia
- Leukemogenesis, Leukemogenesis
- Leukocyte culture, v Cell cultures Leukocytes, mononuclear
- Leukocyten, kultivierter die Zeitfolge der DNA-Verdopplung der Chromatinstrukturen in Interphasen kultureller Leukocyten, 38, 361
- Leukocyten, neutrophile, v Granulocytopoese (B)
- Leukocytenkonzentrat blutfreie Zellen im strömenden Blut (Leberparenchymzellen) 38, 245
- Leukocytes, blood leukocytes, peripheral, Spleen cells
- Leukocytes division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 38, 163
- Leukocytes of some animal species, activity of alkaline phosphatase, 39 31
- Leukocytes, eosinophil, Eosinophil granules
- Leukocytes humans, glycolytic, measured *in vivo*, effect of insulin and de quelques autres facteurs, 37 161
- Leukocytes, leukemic (and normal) *in vivo* uptake of  $^3\text{H}$ -methionine by normal and leukemic leukocytes, 40 18
- Leukocytes, metabolism in a case of acute leukaemia, 37 294
- Leukocytes, mononuclear human, transformation (I. Comparison of cells in suspension and attached to coverslips), 36, 335
- the transformation of human mononuclear leukocytes *in vivo* (II: Fixations of large mononuclear cells on coverslips), 37 32
- Leukocytes, v Lymphocytes (derivative cells)
- Leukem, v Therapie
- Libri, 37 159 (B) 38, 64 (B) 403-407 (B) 39 62 (B) 127 (B) 381 (B) 40, 110-112 (B) 176 (B), 238-239 (B), 336-338 (B)
- Lichtstreuung, Macromolécules
- Lien, Gargous cells, Miltz, Splenomegaly Spleen cells
- Light scattering, v Macromolécules
- Linden Knochenmarkschäden nach beruflicher Einwirkung der Insektizide Gamma-Hexamethylcyclodextran (Linden) 38, 337
- Lipämie (Hyperlipämie); erhöhte Aggregation der Thrombocyten bei essentieller Hyperlipämie, 38, 95
- essentielle Hyperlipämie und Blutgerinnungsfaktoren, 38, 219
- essentielle Hyperlipämie and erodierte Fibrinolyse-Aktivität, 38, 178
- der Proaktivatorgehalt im fibrinolytischen System bei Hyperlipämie, 38, 377
- Liver cirrhosis investigations on the fibrinolytic system in liver cirrhosis, 40 263
- Liver Leberparenchymzellen
- Livres nouveaux, 37 159 (B); 38, 64 (B), 403-407 (B); 39, 62 (B), 127 (B), 381 (B) 40, 110-112 (B) 176 (B) 238-239 (B)
- Lösungen, v Macromolécules
- Los Angeles, v Haemoglobin D
- Lumière, diffusion, v Macromolécules
- Lymph node puncture, Lymphopathies
- Lymphatic leukaemia, v Leukemia, lymphocytic
- Lymph der Ductus thoracicus zur Natur der stark eosinophilen Zellen in der Ductus thoracicus-Lymph, 38, 282

- ; Thoracic duct lymph
- Lymphocyte culture delay of human lymphocyte "blast" transformation by homologous RNA, 39 270
- Antibody Blastoid transformation, Lymphocytentransformation
- Lymphocyte-like blast cells; cytoplasmic shedding as mode of formation of lymphocyte-like blast cells by newt histiocytes, 40 67
- Lymphocyte stimulation, 40 239 (B)
- Lymphocyten Isolierung funktionsfähiger Eukaryocyten, 33, 300
- Lymphocyten und Proteine 36, 30 (C)
- Lymphocytentransformation durch Streptolysin II *in vitro* und Antistreptolysinischer Untersuchungen zu deren Korrelation, 39, 276
- Lymphocyte culture, Lymphocytes
- Lymphocytes; division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 38, 163
- Lymphocytes, "blast" transformation; delay of human lymphocyte "blast" transformation by homologous RNA, 39 270
- Antibody- Lymphocytes, blastoid transformation; Lymphocytentransformation
- Lymphocytes, blastoid transformation blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 39 373
- Antibody; Lymphocytes, "blast" transformation Lymphocytentransformation
- Lymphocytes; measurements of protein synthesis by lymphocytes *in vitro* in diseases of the lymphoid tissues, 40, 241
- ; the proliferation of infectious mononucleosis lymphocytes *in vitro*, 38, 19
- Lymphocytes of thoracic duct; the types of rat thoracic duct lymphocytes which respond to phytohemagglutinin *in vitro*, 38, 121
- Lymphocytes from patients with leukaemia and reticulosos, potential to transform under the influence of phytohemagglutinin, 37 100
- Lymphocytes, peripheral blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 39, 373
- Antibody Lymphocytes, "blast" transformation, Lymphocytentransformation
- Lymphocytes, peripheral, of rabbit, studies (I. DNA and antibody synthesis *in vitro*, following antigenic stimulus), 39, 223
- "Blast" transformation, Blastoid transformation, Lymphocytentransformation
- Lymphocytes and their derivative cells *in vitro*, studies; (II: Biochemical constituents) 36, 344
- ; (II. Enzyme cytochemistry), 37 42
- Lymphocytes, Drüsenförmigen, Macrophages, Mononuclear leukocytes
- Lymphocytic leukaemia, Leukämie, lymphocytic
- Lymphogranulomatosis, Reticulosos
- Lymphoid blast cells, v Lymphocyte-like blast cells
- Lymphoid tissues, diseases, Protein synthesis
- Lymphology new basic trends (Proceedings of symposium held at Charleroi (Belgium) 1966 [Experientia Suppl. 14]), 40, 111 (B)
- Lymphomas, Leukämien, Therapie
- Lymphopathies; contribution of cytology to the study of lymphopathies, 36, 296 (C)
- Lysokinas, Proaktivität
- Macroglobulinämie VALLEY-WATKINS macroglobulinämie (A family study) 36, 184
- Macroglobulinämien, african, 36, 26 (C)
- Macromolecules; configurations des macromolécules en solution méthodes d'étude, 36, 63 (C)
- Macrophages on the origin of the skin window macrophages, 36, 386
- Lymphocytes (derivative cells) Mononukleäre Zellen
- Maintenance therapy of pernicious anaemia (Comparison of Cyanocobalamin, Hydroxycobalamin and Cyanocobalamin-Zinc Tartrate Complex) 40 303
- Makro Makro
- Maladie de sommeil, Macroglobulinämie
- Malignant myelodysplasia multiple chromosomal aberrations in case of malignant myelodysplasia, 39 299
- Man extra-retinal erythropoietin production in man, 39, 339
- isozyme variations in man (Monographs in human genetics, Vol. 1) 36, 404 (B)
- Man, A antigen; Haemophil; Erythropoietin Hämoglobin, menschliche

- Hämsynthese; Human... Leukocytes  
humains Platelets Thrombocytes
- Man haemoglobins including the haemo-  
globinopathies and their investigation,  
37 159 (B)
- Haemoglobin
- MARCHAPPAVA-MICHELL, v Paroxysmal noc-  
turnal hemoglobinuria
- Marrow erythroid activity in normal and  
riboflavin deficient baboons, isotopic and  
cytological estimations, 39 118
- Mastzellen (Mastmastzellen und Gewebe-  
mastzellen) Basophil
- Materials, exogenous haemolysing prop-  
erties of some exogenous materials, 38 273
- Maturation of erythrocytes, v Erythro-  
blast, Reticulocytes
- Maus, Leukaemia virus, Leukaemogene-  
sis, Mice, Mouse leukaemia, Souris
- Mechanical disruption, Bone marrow  
injury
- Mechanism of denaturation of the erythro-  
blast, studies, 39 193
- Medical cyto-technology 40 336 (B)
- Médicamentouse, erythropathie médica-  
mentouse, v Erythropathie
- Medicine, experimental, v Experimental  
biology
- Mediterranean anaemia, Alpha-Thalae-  
mia, Beta-thalassaemia, Haemoglobin  
Leptore in *Camponotus*, Thalassemia, Thal-  
saemia (B) Thalassemia major Thal-  
saemia minor Thalassemic subjects,  
Thalassemic syndrome
- Medulla osseus, Benzene Bone marrow  
Bone marrow injury Bone marrow re-  
actions (B) Cortisol Eosinophil gran-  
ules Erythroblast( ) Erythrocyte pre-  
cursors Erythroid hyperplasia Gamma-  
Hexachlorocyclohexan GAUCHER cells  
Knochenmark Knochenmark (B)  
Knochenmarkszellen Leukaemia, cell  
proliferation Leukaemia, myeloid, chro-  
nic Megakaryocytes Monocytes Mye-  
locytosis Panmyelosis Proliferative  
activity Typhus abdominalis
- Meerschweinchen, Eosinophil granules,  
Thymus
- Méring, Haematology
- Megakaryocyte response in posthaemor-  
rhagic thrombocytes of mice, 39 112
- Megakaryocytes depression of the mega-  
karyocyte-platelet system in rats by  
transfusion of platelets, 39 31
- Floures H<sup>3</sup>-thymidine des mégakaryo-  
cytes de la souris intacte et injectée d'hé-  
mine, 38 43
- Megaloblastic anaemia of children, chro-  
mosomal study 39 29
- Mégalozytes, v Erythroblastopénie
- Membranpermeabilität (Erythrocyten und  
Thrombocyten) v Symposium
- Mensch, v Isocyste variations (B) Man(n)
- Menschliche Häoglobine, Hämoglo-  
bine, menschliche
- Menschliche Thrombocyten, Thrombo-  
cyten
- Menschliches Knochenmark; über den Ab-  
bau von Zellen im Knochenmark des  
Menschen und der Ratte, 40 252
- Mercaptoethanol, effect on antibodies,  
Antibodies
- Metaphases, diploid, v Spleen cells
- Metabolism of iron sorbitol, studies, 37 253
- Metabolism of leukocytes in a case of acute  
leukaemia, 37 294
- Metabolismus, v Erythrocytes (Stoffwech-  
sel ) Erythrocytenstoffwechsel
- Methaemoglobinemia, congenital (Biblio-  
theca haematologica, Vol. 25), 40 229 (B)
- Methaemoglobinemia, hereditary due to  
DPNH-methaemoglobin reductase de-  
ficiency (Report of family) 37 284
- Methaemoglobinemia cytosol, hereditary  
due to diaphorase deficiency in three  
successive generations, 37 276
- Methionine (S<sup>35</sup> L-methionine) in the  
uptake of S<sup>35</sup> L-methionine by normal  
and leukaemic leukocytes, 40 18
- Méthode, v Acoustase, Automation (B)  
Autoradiographie (B), Blastoid trans-  
formation (microculture), Blood grouping  
tests (B) Eosinophocytes, Cyto-techno-  
logy (B) Double labelling technique,  
Erythropoietin, Factor VIII, Haemoglo-  
bin fractions, Haemoglobins (B), Kno-  
chenmark (B) Monocytic Leukemia
- Mice; histochemical enzyme analysis of  
peripheral blood changes in murine virus-  
induced leukaemia, 38 112
- prevention of AKR (strain of mice) leukaemia  
by thymectomy at varying ages, 38 317
- ; megakaryocyte response in posthaemor-  
rhagic thrombocytes of mice, 39 112
- Leukaemogenesis, Mouse leukaemia  
Souris

MICHELL, v MARCIANAS A.

MICHELL, v RUTTI-

Microangiography Autocardiographic (B); Benzene Chromatinstruktur; Double labelling technique Erythroblast Leukaemia, cell proliferation; Megakaryocytes Metabolism of leukocytes Mononucleosis; Plasma cells Proliferative activity

Microcirculation; European Society for Microcirculation, 5th Conference (as an International Conference) Gothenburg June 24-29 1968, 39 192

Microculture; blastoid transformation of rabbit peripheral lymphocytes by phytohaemagglutinin using microculture technique, 39 373

- Antibody 'Blast' transformation, Lymphocyten transformation

Microcythaemia (three cases of homozygous  $\beta\delta$ -thalassaemia (or microcythaemia) with high haemoglobin F in Sanhes family 40, 220

Microcytic type of sickle cell-beta thalassaemia disease, Sickle cell-beta

Microscope Electronique, Basophile Zellen, Eosinophil granules, Gartner cells, Haemagglutination, Hartz body Lymphopathies, Mouse leukaemia, Phagocytes

Microscope en contrast de phase, Lymphocyte-like blast cells

Milz histolytische Analyse bei Sarkomose der Milz, 37 126

GADGERS cells, Spleen cells, Splenomegaly

Mitochondrien, Reinkleocyten

Mitosis, Proliferative activity Trisomy-21

Mitotic activity Mononucleosis infectiosa

Moelle osseuse, Benzene Bone marrow-Bone marrow injury Bone marrow reactions (B) Cortisol Eosinophil granules Erythroblast(s) Erythrocyte precursors; Erythroid hyperplasia Gartner Heterochlorocyclobenz Gartner cells Knochenmark; Knochenmark (B); Knochenmarkzellen Leukemia, cell proliferation Leukemia, myeloid, chronic; Megakaryocytes; Monocytes; Myelomonocytic Panniculitis; Proliferative activity; Typhus abdominalis

Molecular genetics, Primates in medicine (B)

Molge vulgaris Lymphocyte-like blast cells Monocytes; on the origin of monocytes, 32, 177

Monocytes (transformed in macrophages) Macrophages

Monocytic leukaemia, Myelomonocytic leukaemia

Mononuclear leukocytes, human, transformation *in vitro* (I. Comparison of cells in suspension and attached to coverslips) 36, 335

— (II. Precursors of large mononuclear cells on coverslips) 37 32

Blast-like cells

Mononucleosis infections; division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 39 163

- the infectious mononucleosis cell (L. DNA synthesis) 38, 257

the mononucleosis and leukaemic cell (II. RNA synthesis) 40 28

the proliferation of infectious mononucleosis lymphocytes *in vitro*, 32, 19

zur Zytiochemie der Drüsenleberzellen, 39 257

Mononukleäre Zellen, grosse, des Harnseners, cytochemische Untersuchungen zu ihrer Entwicklung, 39 281

Monocytaire Leukämien, Diagnose mit cytochemischen Methoden, 40, 121

Morbus GADGERS, GADGERS cells

Morbus HODGKIN, Reticuloses

Morbus WALDENSTRÖM, Macrocytosis leukaemia ( )

Mouse leukaemia, transmission by oral route, 40 1

Leukaemogenesis, Mice, Murine virus-induced leukaemia, Souris

Murine virus-induced leukaemia; histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 38, 112

prevention of AHR (strain of mice) leukaemia by thymectomy at varying ages, 38, 317

Leukaemogenesis, Mice, Mouse leukaemia, Souris

Mice murinus, Leukaemogenesis, Mice, Mouse leukaemia, Murine virus-induced leukaemia, Souris

Mycoplasma fermentans (M. ewingii); isolation of mycoplasmas in leukaemia and other diseases, 40 9

- Hämsynthese Human... Leukocytes  
humains Plattelets Thrombocyten
- Man haemoglobins including the haemo-  
globinopathies and their investigation,  
57 159 (B)
- v Haemoglobins
- MARCHIAFAVA-MICHELLE, v Paroxysmal noc-  
turnal hemoglobinuria
- Marrow erythroid activity in normal and  
riboflavin deficient baboons, isotopic and  
cytological estimations, 59 118
- Mastzellen (Blutmastzellen und Gewebe-  
mastzellen) v Basophils
- Materials, exogenous haemolysing prop-  
erties of some exogenous materials, 58, 273
- Maturation of erythrocytes, v Erythro-  
blast, Retikulozyten
- Mice, v Leukaemia virus, Leukaemogene-  
sis, Mice, Mouse leukaemia, Souris
- Mechanical disruption, v Bone marrow  
injury
- Mechanism of demarcation of the erythro-  
blast, studies, 59, 193
- Medical cyto-technology #0 536 (B)
- Médicamenteuse, érythropathie médica-  
mentouse, v Erythropathic
- Medicine, experimental, v Experimental  
biology
- Mediterranean anaemia, Alpha Thalas-  
saemie, Beta-thalassaemia, Haemoglobin  
Lepore in *Campheria*, Thalassaemia, Thal-  
assaemia (B) Thalassaemia major Thal-  
assaemia minor Thalassaemic subjects,  
Thalassaemic syndrome
- Medulla osseum, v Bone Bone marrow  
Bone marrow injury Bone marrow re-  
actions (B) Cortisol Eosinophil granu-  
les Erythroblast( ) Erythrocyte pre-  
cursors Erythroid hyperplasia Gamma-  
Hexachlorocyclohexan GAUCHER cells;  
Knochenmark Knochenmark (B)  
Knochenmarkzellen; Leukaemia, cell  
proliferation Leukaemia, myeloid, chro-  
nic Megakaryocytes; Monocytes Myo-  
sclerosis Panmyelose Proliferative  
activity Typhus abdominalis
- Meerschweinchen, v Eosinophil granules,  
Thymus
- Meeting, Haematology
- Megakaryocyte response in posthaemor-  
rhagic thrombocytosis of mice, 59 112
- Megakaryocytes depression of the mega-  
karyocyte-platelet system in rats by  
transfusion of platelets, 58, 34
- l'index H<sup>3</sup>-thymidine des mégakaryo-  
cytes de la souris intacte et injectée d'hé-  
mine, 58, 43
- Megaloblastic anaemia of children, chro-  
mosomal study 59, 29
- Mégulocytes, v Erythroblastopénie
- Membranpermeabilität (Erythrocyten und  
Thrombocyten) v Symposium
- Mensch, v Isosyme variations (B), Man( )
- Menschliche Hämatoblaste, Hämatoglo-  
bine, menschliche
- Menschliche Thrombocyten, Thrombo-  
cyten
- Menschliches Knochenmark, über den Ab-  
bau von Zellen im Knochenmark des  
Menschen und der Ratte, #0, 252
- Merepactoanod, effect on antibodies,  
Antibodies
- Metaphases, diploid, Spleen cells
- Metabolism of iron sorbitol, studies, 57 253
- Metabolism of leukocytes in case of acute  
leukaemia, 57 294
- Metabolismus, v Erythrocyten (Stoffwech-  
sel) Erythrocytenstoffwechsel
- Methaemoglobinemia, congenital (Biblio-  
theca haematologica, Vol. 28) #0, 239 (B)
- Methaemoglobinemia, hereditary due to  
DPNH-methaemoglobin reductase de-  
ficiency (Report of family) 57 284
- Methaemoglobinemic cyanosis, hereditary  
due to diaphorase deficiency in three  
successive generations, 57 276
- Methionine (5<sup>m</sup> L-methionine) in vivo  
uptake of 5<sup>m</sup> L-methionine by normal  
and leukaemic leukocytes, #0, 18
- Methode, v Acanthase, Automation (B),  
Autoradiographie (B), Blastoid transfor-  
mation (microculture), Blood grouping  
tests (B), Blutlymphocyten, Cyto-techno-  
logy (B) Double labelling technique,  
Erythropoietin, Factor VIII, Haemoglo-  
bin fractions, Haemoglobins (B) Kno-  
chenmark (B) Monocytäre Leukämie  
Mice; histochemical enzyme analysis of  
peripheral blood changes in murine virus-  
induced leukaemia, 58, 112
- ; prevention of AKR (strains of mice) leuka-  
emia by thymectomy at varying ages, 58, 517
- megakaryocyte response in posthaemor-  
rhagic thrombocytosis of mice, 58, 112
- v Leukaemogenesis, Mouse leukaemia  
Souris

- Origin of monocytes, 39, 177
- Orotic acid, Dihydroorotic acid dehydrogenase
- Oryzopsis amabilis, Rabbit
- Osmotic fragility Spherocytosis
- Osteomyelocytosis; chromosomal translocation of spleen cells in osteomyelocytosis, 39, 397
- Panbilmorytopenie mit Panmyelose, 40 75
- Panmyelopathie, Hexachlorcyclohexan
- Panmyelose mit Panbilmorytopenie, 40 75
- PAP-NICOLAOU technique v. Cyto-technologie (B)
- Papio cynophthalmus, Baboon
- Paraproteinkämie und plasmazelluläre Zellproliferation bei Polycythaemia vera, 38, 240
- Parvixin® (= Chloramphenicol-Präparat), Erythropathie
- Paroxysmal nocturnal haemoglobinuria differences between the red cell acetylcholinesterase defects of paroxysmal nocturnal hemoglobinuria and of ABO hemolytic disease, 39 83
- following 'aplastic anaemia', 39 37
- ; relationship to other pH-dependent hemolytic systems: role of acetylcholinesterase, 39 86
- ; Haemoglobin Koeflikker
- PAS (= periodic acid Schiff)-positiv erythroblasten in kidney diseases, 37 225
- Pathogenesis of human leukaemia, 36, 183 (C)
- Pathogenesis and treatment of thromboembolic diseases (International Symposium, Basel, 25. II. 1963) 36, 407 (B)
- Pathology Clinical pathology Granulocytopenia (B)
- Pavian, Baboon
- Peku (scénère certains), Macrophages, Mononukleäre Zellen
- Peptid chains, Bovine Jeron Protein
- Periodic acid Schiff positivity PAS
- Peripheral lymphocytes, Lymphocytes, blastoid transformation
- Periphere Blut, Leberparenchymzellen
- Perle de verre, Blutlymphocyten
- Pernicious anaemia maintenance therapy of pernicious anaemia (Comparison of Cyanocobalamin, Hydroxocobalamin and Cyanocobalamin-ethio-tannate complex), 40, 305
- Pestizid, Insektizid
- PHA, Phytohaemagglutinin
- Phagocytose; über den Abbau von Zellen im Knochenmark des Menschen und der Ratte, 40 252
- Phase contrast microscope, Lymphocyte-like blast cells
- Ph<sup>1</sup> chromosomes (= Philadelphia chromosomes); Ph<sup>1</sup>-diagnosis and prognosis in chronic myelogenous leukaemia, 39 102
- two in blastoid crisis of granulocyte leukaemia, 39 391
- Chromosomes, Myelocytosis
- pH-dependent haemolytic systems, Haemoglobinuria
- Philadelphia chromosomes, Ph<sup>1</sup> chromosomes
- Phosphatase, alkaline, activity in leukocytes of some animal species, 39, 51
- Phosphatases, acid, of platelets during coagulation and storage of blood, 40 48
- Phytohaemagglutinin (= PHA); blastoid transformation of rabbit peripheral lymphocytes by phytohaemagglutinin using microculture technique, 39, 373
- ; Lymphocytes and their derivative cells in vivo, studies (I. Biochemical constituents), 36 344
- ; the potential of lymphocytes from patients with leukaemia and reticuloses to transform under influence to phytohaemagglutinin, 37 100
- the types of rat thoracic duct lymphocytes which respond to phytohaemagglutinin *in vitro* 38, 121
- Agglutinin, Antibody 'Blast transformation, Lymphocytenmetamorphosen, Lymphocytes and their derivative cells
- Pitfalls of factor VIII assay 38, 383
- Pituitary Prolactin
- Placcho, Haemostatic effect
- Plaquettes sanguines, Haemorrhagic disorders, Hémostase, Plättchen transformation, Plättchen, Retraktionsvorgang, Thrombocyten, Thromocytentransfusion (B)
- Plasma; peculiar benzidine-positive protein fraction in the plasma of newborns and children with various haemolytic conditions, 36 381
- Atransferrinase
- Plasma cells; cytochemical and autoradiographic investigations on normal and myelomatous plasma cells, 38 79

- Plasma**, trapped volume of plasma; comment on the method of determining the trapped volume of plasma after centrifugation based on the correlation between the trapped volume and the electrical conductivity 39 235
- Plasmaretikuläre Zellproliferation und Paraproteinkämie bei Polycythaemia vera**, 38, 240
- Plasmin** (Fibrinogen) v Fibrinolyse, Fibrinolyse
- Plasminogen activation, inhibitors**, v Fibrinolyse inhibitors
- Plasmocytom**, Plasmaretikuläre Zellproliferation
- Plastic substances**, new haemolyzing properties of some exogenous materials, 38 275
- Plated transfusion therapy (leukaemia) film**, 39 160
- Platelets and phosphatases of platelets during coagulation and storage of blood**, 40 48
- depression of the megakaryocyte-platelet system in rats by transfusion of platelets, 38, 34
- microcatechol-sulfatase in human blood platelets**, 39 129
- Hemorrhagic disorders, Hämorrhagie, Plated transfusion, Retraktionsvorgang, Thrombocyten, Thrombocytentransfusion (B)
- Poisoning (benzene) erythromyelosis, acute**, after benzene poisoning, 40 234
- Poisoning (iron) fatal peroral iron poisoning in young women**, 40 90
- Polycythaemia vera Paraproteinkämie und plasmaretikuläre Zellproliferation bei Polycythaemia vera**, 38, 240
- Erythrocytosis**
- Polypeptide chains**, Haemoglobin H
- Polypeptide chains (alpha and beta chains of haemoglobin) Thalassemia**
- Polyploidy (endoreduplication) partial**, v Trisomy-21
- Populations of molecules**, Antibodies
- Portugal**, haemoglobin J Fane in the South of Portugal (*Algarve*) 39 291
- Poovins**, v Myxobolus virus
- Pregnancy** Iron deficiency
- Preleukaemia (A report of four cases)** 39 20
- Preleukaemia states**, Pathogenesis (leukaemia)
- Primary macroglobulinaemia**, Macroglobulinaemia
- Primates in medicine (Vol. 1) (First Holloman symposium on Primate Immunology and molecular genetics)** 40 110 (B)
- Price**; JEAN JULLIARD prize, 39 320
- Proaccelerin**, Factor V
- Proaktivatorgehalt im fibrinolytischen System von Hyperlipämikern**, 38, 377
- Proceedings of the 10th congress of the European Society of Haematology (Strasbourg, 23. 28. 8 1965) (part I: main lectures)** 36 1 296 (C)
- Proceedings of the 10th Congress of the European Society of Haematology Strasbourg, 1965 (Part I and II)** 40, 111 (B)
- Proceedings of the 1st International Congress of the Transplantation Society 1967 (Advances in transplantation)** 40 176 (B)
- Proceedings**, Geographical haematology Leukaemia research (B) Lymphology (B) Standardization (B) Thromboembolic diseases (B) Transplantation (B)
- Production cellulaire érythropoïétique (Progrès dans les recherches sur le cancer Vol. 14)** 40 238 (B)
- Proerythrocyten**, Foetale Erythrocyten
- Progrès**, v Thymus (B)
- Prohormones**, testosterone and adrenal steroids, effect on erythropoiesis, 38, 292
- Proliferative activity of the cells of some leukaemia in relapse and in steady state**, 38, 193
- Proptética médica**, Vol. I Hematología (portugolisch) 38 403 (B)
- Prophylaxis**, Rhesus factor
- Prostatokarzinom**, metastaserendes, 1 er bruchakozgalopatie
- Protein zur Struktur des Bence Jones Proteins**, 38, 147
- Protein fraction** peculiar benzidine-positive protein fraction in the plasma of newborns and children with various haemolytic conditions, 36, 361
- Protein fractions**, clotting activity of congenital factor IX deficient (Chromas) serum, 39 13
- Protein synthesis by lymphocytes in vivo in diseases of the lymphoid tissues, measurements**, 40 241
- Protein and Lymphocytes**, 38, 50 (C)

- Proteins, v. Macromolecules, Paraproteinaemic
- Proteins, iodinated, v. Electron microscopic examination
- Protides of the biological fluids XVIth colloquium, Bruges, (May 3-7 1967) 37 224
- Protides of the biological fluids XVIIth Colloquium, Bruges, (May 1-5 1968) 39 192
- PTC factor (= Plasma thromboplastic component = Antithrombophilic globulin B = Factor IX) Christmas disease, Christmas factor
- Poissé disease; sickle cell haemoglobin
- Poissé disease: S from Ghana and D from England, 32, 324
- Poissé Haemoglobin D
- Funktion der Lymphknoten, Lymphopathien
- Pyronophils Zellen, v. Basophile Zellen
- Pyruvate kinase deficiency; neonatal haemolysis due to transient severity of inherited pyruvate kinase deficiency 40, 166
- ; an unusual haematological syndrome with pyruvate-kinase deficiency and thalassaemia minor in the kindreds, 39 343
- Quantitation of haemoglobin fractions obtained by starch-gel electrophoresis, simple method, 32, 306
- Quantitative études quantitatives de l'hémoagglutination, 36, 219 (C)
- Quantities and units in clinical chemistry, 40 110 (B)
- Quantifizierung des Fibrins, Retraktionsvorgang
- Rabbit blood transformation of rabbit peripheral lymphocytes by phytohaemagglutinin using microculture techniques 39 373
- Antibody 'Blast' transformation, Lymphocyten transformation
- Rabbit peripheral lymphocytes, studies (I DNA and antibody synthesis *in vitro*, following antigenic stimulus) 39, 223
- 'Blast' transformation, Blastoid transformation, Lymphocyten transformation
- Radiation; failure of shielding the thymus to induce recovery of bone marrow after radiation, 37 109
- Leukaemogenesis, Pathogenesis... (leucemia) Strahlentherapie (B)
- Radioactive tracers, Isotope, radioaktive
- Radioautography Microautoradiography
- Radio-carbon, Erythrocyte precursors; Haemoglobin, *in vivo* synthesis Mononuclear Protein synthesis
- Radio-chrome, v. Aplastic anaemia, Erythrokinetic studies, Haemolysis *in vivo*, Thalassaemia minor
- Radio-cobalt, Pernicious anaemia (maintenance therapy) Thymus
- Radio-iodine, Fibrinolysis
- Radio-iron, Aplastic anaemia; Baboon; Erythroid hyperplasia; Erythrokinetic studies; Erythropoiesis Erythropoietin Haemoglobin H Haemoglobin, *in vivo* synthesis Hämsynthese Iron sorbitol Thalassaemia minor
- Radio-sulfur Leukocytes, leukaemic-Platelets
- Rat über den Abbau von Zellen im Knochenmark des Menschen und der Ratte 40 252
- cellular changes in the bone marrow following chronic treatment of rats with cortisol, 32, 250
- depression of the megakaryocyte-platelet system in rats by transfusion of platelets, 39 34
- eosinophils and dietary histamine in the rat, 40, 59
- thoracic duct lymphocytes, which respond to phytohaemagglutinin *in vivo* types, 32, 121
- Agglutinin, Thoracic duct lymph
- Rat, GAUCHER cells, Milz, Spleen cells, Splenomegaly
- RAUSCHER murine leukaemogenic virus, Virus-induced leukaemia
- REBOCKsche Methode, Hautfenster Macrophages
- Red cells transketolase activity of red blood cells in conditions of haematological interest, 39, 321
- red cell acetylcholinesterase defects of paroxysmal nocturnal haemoglobinuria and of ABO hemolytic disease, differences, 39, 85
- 1 Erythrocyt—
- Reductase; hereditary methaemoglobinemia due to DPNH-methaemoglobin reductase deficiency (Report of family) 37 284



- Reduplikation, Chromatinstrukturen  
 Refractory anaemia, v. Aneuploia, refractory  
 Reifung der Reticulocyten, 36, 273 (C)  
 Relapse of leukaemia, v. Leukaemia; cell  
 proliferation Proliferative activity  
 Remission, complete, in chronic lympho-  
 cytic leukaemia (Report of a case) 40 230  
 Remission of leukaemia, v. Leukaemia cell  
 proliferation ; Proliferative activity  
 Ren extra-renal production of erythro-  
 poietin in man, 39, 359  
 Fibrinolysis inhibitors, Kidney dis-  
 eases, Uraemic thrombopathy  
 Renoprol state, v. Ren  
 Repair; bone marrow injury and repair  
 (Irradiation and mechanical disruption)  
 40, 55  
 Replication, v. Chromatinstrukturen  
 Resistance, electrical, Electrical conduc-  
 tivity  
 Reticulocyte and Normoblast labelling with  
 leucine- $^{14}$ C in thalassaemic and non  
 thalassaemic subjects, 40 57  
 Reticulocytes, Reifung, 36, 273 (C)  
 Reticulohistiocytic origin of the blood baso-  
 phil in human marrow 40 162  
 Reticuloses, lymphocytes the potential of  
 lymphocytes from patients with leu-  
 kemia and reticuloses to transform under  
 the influence of phytohemagglutinin,  
 37 100  
 Reticulomacrien, phagocytkernende, im  
 Knochenmark, v. Phagocyten  
 Retraktionsvorgang beim Blutplasmagetren-  
 nung, 36, 371  
 Reversible adrenergic anaemia caused by  
 chloramphenicol, 38, 1  
 Rezeptorfunktion der Erythrocyten (Bibli-  
 otheca Haematologica, fasc. 25) 38, 404  
 (B)  
 Rhomfactor anti-Rh serum, Haemag-  
 glutination  
 Rhom factor 11th International Sympo-  
 sium on Feto-Maternal Incompatibility  
 (Brussels, 15. 16. 11 1968), 39 362  
 Riboflavin isotopic and cytological estima-  
 tions of marrow erythroid activity in  
 normal and riboflavin deficient baboons,  
 39 118  
 Ribonucleic acid (= RNA) homologous;  
 delay of human lymphocyte blast trans-  
 formation by RNA interference 39 400  
 Ribonucleic acid (= RNA) synthesis the  
 mononucleoside and leukemic cell (IL  
 RNA synthesis), 40, 28  
 Ribonucleic acid (= RNA) *in vivo* syn-  
 thesis, Leukemia, cell proliferation  
 Ribonucleic acid (= RNA) v. Antibody  
 Blastoid transformation, Lymphocyte-  
 transformation, Plasma cells, Reticu-  
 locytes, Thalassemia  
 Ribosomes, v. Reticulocytes  
 Risti-Gutwein-Micetti, Thalassemia  
 minor  
 Ring chromosome, Leukemia, granulo-  
 cytic, chronic  
 RNA, Ribonucleic acid..  
 Rotationsdispersion, optische, Debye  
 Jones Protein  
 Rose Eristellen, Erythrocyten, Erythro-  
 cytes  
 Rousseau-aggregates Aggregation  
 Rousseau, a survey for erythrocyte glucose-6-  
 dehydrogenase deficiency in Roumania, 40,  
 44  
 5 $^{th}$  v. Platelets  
 Sauglinge, junge, v. ABO haemolytic dis-  
 ease, Fetales Hämoglobin (B), Neu-  
 natal Protein fraction  
 Saliva; ABO blood group agglutinins in  
 saliva, 39, 351  
 Salmonele enteritidis, Bacterial endotoxins  
 Sardinian children; glucose-6-phosphate de-  
 hydrogenase, characterization, in Sardinian  
 children with congenital nonsphero-  
 cytic haemolytic anaemia, 37 198  
 Sardinian families, G-6-PD  
 Sarkoidose der Milz; hämolytische Anämie  
 bei Sarkoidose der Milz, 37 126  
 Satellite DNA; presence of a satellite DNA  
 in normal and leukemic human tissues,  
 39, 75  
 Scattering, light scattering, Macromole-  
 cules  
 SCHALZMANN, Sarkoidose  
 Schlafkrankheit, v. Macroglobulinaemia  
 Schwangerschaft, Abortion, Iron defi-  
 ciency  
 Schweiß, radioaktiver Platelets  
 Schüttelzählung Leukemia, lym-  
 phatic, acute  
 Sedimentations-Diagramm, Debye Jones  
 Protein  
 Sedimentation, retard, of eosinophils under

- normal and pathological conditions, 37  
120
- Selective membrane permeability Erythropoietin
- Serological and haematological behaviour of chicks inoculated with myeloblastosis virus, 37 311
- Serology as introduction to blood group serology (3rd ed.) 33, 127 (B)
- Serum lactic dehydrogenase activity in refractory anaemia, 40, 187
- Serumcin, Atranserrinlösung
- Sex hormones, Testosterone
- Sex (true hermaphrodit) Aberrant blood group
- Sickle cell anemia v. Microcythemia
- Sickle-cell anaemia; as *in vitro* synthesis of haemoglobin from Fe<sup>2+</sup> and locoine-C<sup>14</sup> by normal, sickle-cell and thalassaemic immature red cells, 38 200
- Sickle cell-beta thalassaemia disease, two subtypes a) Normocytic type of sickle cell-beta thalassaemia disease b) Microcytic type of sickle cell-beta thalassaemia disease (Thalassaemia syndromes VI.) 37 181
- Sickle cell disease and glucose-6-phosphate dehydrogenase, 38 330
- Sickle cell haemoglobin II Papez disease B from Ghana and D from England, 38 324
- Siderachronische Störung der Erythropoese, Sideroblastic anaemia
- Sideroblastic anaemia, reversible, caused by chlorzaphenicol, 38 1
- Strangiferische, Leukaemia research (B) Proceedings (B) Standardisation (B) Thromboembolic diseases (B) v. handlungen
- S<sup>35</sup>-L-methionine, Methionine
- Still window macrophages, origin, 38 386
- Mononukleäre Zellen
- Sleeping sickness, Macroglobulinaemias
- "Jugged blood" phenomenon, Aggregation
- Society Deutsche Gesellschaft für Hämatologie, 14 Tagung, Kiel, September 1969 37, 382
- European Society of Haematology Proceedings of the 10th Congress (Strasbourg, 23. 26. 8. 1965) (part I main lectures) 36, 1 296 (C)
- ; Proceedings (part I and II) 40 111 (B)
- 11th Congress (Athens, 10. 14. 9. 1967) 36, 417
- 11th Congress of the International Society of Haematology (Sydney August 21-26, 1966) (Amalgamation of the International Society the European Society and the Asian-Pacific Society of Haematology), 37 232
- 12th Congress of the International Society of Haematology (New York, September 1-6 1968) 37, 320
- Transplantation Society 11th International Congress (Paris, June 1967), 37 322
- Transplantation Society 1st International Congress, 1967 Paris, proceedings (Advance in transplantation) 40, 176 (B)
- v. Blood transfusion, Microcirculation, Standardisation (B)
- Sodium fluoride sensitive esterase, Monocytes
- Solutions, Macromolecules
- Soufre, radioactive, Plaquettes
- Souris l'index H<sup>3</sup>-thymidine des mégalocaryocytes de la souris intacte et injectée d'hémie, 38 43
- Leukemia virus, Leukemogenesis
- Slice, Mouse leukaemia
- Southern Portugal Portugal
- Species, animal, Animal species
- Speichel, Saliv
- Spherocytes, hereditary and heterozygous beta-thalassaemia (A family study), 37 189
- Congenital nonspherocytic hemolytic anaemia
- Spleen cells chromosomal abnormalities of spleen cells in osteomyelocytosis, 38 39
- Gaucher cells, Mice
- Splenomegalies, tropical, Macroglobulinaemias
- Standardisation in haematology III (3rd Transactions of the International Committee for Standardisation in Haematology Strasbourg 22/27. 8. 1965) 38, 404 (B)
- Normierung
- Starch-gel electrophoresis simple method for the quantitation of haemoglobin fractions obtained by starch-gel electrophoresis, 38 306
- Statistische Auswertung, A antigen ABO hemolytic disease Aggregation (Throm-

bocytin) Anti-Tj<sup>a</sup>-like haemolysis  
 Rhetzerinnungsfaktoren; Cortisol Eosinophil granules Erythroid hyperplasia  
 Factor VIII Fibrinolytic Glycolytic  
 Haemoglobin, *in vitro* synthesis Haemolysing properties ; Haemostatic effect;  
 Haemorrhage Index H<sup>a</sup>-thymidine; Isohaemagglutination Lymphocytoconformation Metabolism of leukocytes  
 Proliferative activity; Protein synthesis  
 Saliva; Transketolase

Steady state of leukaemia, v Proliferative activity

Steroids, Adrenal steroids, Cortisol, Testosterone

Stimulation lymphocyte stimulation # 239 (B)

Stoffwechsel, Erythrocytenstoffwechsel, Metabolism

Stoffwechsel (Erythrocyten und Thrombozyten) Symposium

Storage of blood acid phosphatases of platelets during coagulation and storage of blood, # 48

Strahlenschaden und Strahlenhämatologie (Schriftenreihe der ärztlichen Fortbildung Bd. 31) 39 381 (B)

Strahlenwirkung, v Leukaemogenesis, Pathogenesis (leukemia) Thymus

Streptokinas, Fibrinolyse

Streptolysin O Untersuchungen zur Beziehung von Lymphocytoconformation durch Streptolysin O *in vitro* und Antistreptolysin # 276

Antibody 'blast' transformation, Blastoid transformation

Structure and heterogeneity of antibodies, 35, 198 (C)

Submicroscopical structure, v Basophile Zellen, Eosinophil granules, GARDNER cells, Haemagglutination, Hairy body Lymphopachia, Mouse leukaemia, Phagocytosis

Substances tissue-actives, Desaggregation Suckling, Fetales Hämoglobin (B)

Sulfatase, Nitroreductase/sulfatase

Sulfur radioactive, Leukocytes, Leukemic Platelets

Surface-active substances, Desaggregation

Survival of chloramphenicol treated cells *in vitro* and chloramphenicol induced haemolysis *in vitro*, 36, 11

Survival time, v Erythrokinetik

Symposium, International, on Hemophilia, Montreal, 26-28th August 1968 (World Federation of Hemophilia) 39 63

- 11th, International on Foeto-Maternal Incompatibility (Brussels, 12, 13, 11 1968) 39, 382

- 11th, International sur la recherche comparée dans les leucémies, Paris, 11, 13 juillet 1967 37 323

- 1 International Symposium über Stoffwechsel und Membranpermeabilität von Erythrocyten und Thrombozyten (Wien, 17-20. Juni 1968) 39 63

Symposium, v Automation (B), Electrolyte (B) Experimental biology Geographical haematology Leukemia research (Wasser-Gass) (B), Lymphology (B), Primates in medicine (B), Thromboembolic diseases (B)

Tagungsberichte, v Verhandlungen Technik der Autoradiographie, 39 127 (B)

Technique, v Automation (B), Cyto-technology (B)

Tégrenol® v Erythroblastopénie

Tissue-actives, substances tissue-actives, Desaggregation

Testosterone, adrenal steroids and probo tin, effect on erythropoiesis, 36, 232

- effect of androgen antagonist on erythropoietic action of testosterone, # 239

- zur erythropoietischen Wirkung von Testosteron, 39 366

- studies on erythropoietic action of testosterone, 36, 49

The family haemoglobin D<sup>a</sup> Los Angeles (D Punjab,  $\alpha_2\beta_2$ , 121 Gln NH<sub>2</sub>) in The family 39 151

Thalassemia, 35, 256 (C)

- 1 ( $\beta$ -thalassaemia) Haemoglobin Lepore in *Campania*

- in *Cyprus*, 39 209

- 1 G-6-PD-Mangel mit Hämoglobinopathie und alpha-Thalassaemie, 39, 167

- hereditary spherocytosis and hereditary beta-thalassaemia (A family study), 39 183

; reticulocyte and normoblast labelling with leucine-<sup>14</sup>C in thalassaemic and non thalassaemic subjects, # 37

- three cases of homozygous  $\beta\delta$ -thalassaemia (or microcythaemia) with high

- haemoglobin F in *Sickle cell* family # 220  
*in vitro* synthesis of haemoglobin from  $Fe^{59}$  and leucine- $C^{14}$  by normal, sickle-cell and thalassaemic immature red cells, 37 200
- Thalassaemia major; erythrokinetic studies in thalassaemia with simultaneous radioactive tracers ( $Fe^{59}$  and  $C^{14}$ ) 37 63  
 —; *in-vitro* study of DNA-synthesis time and cell-cycle time in erythrocyte precursors of normal and thalassaemic subjects, using  $H^3$  and  $C^{14}$ -thymidine double labelling technique 37, 170
- Thalassaemia minor: modes of presentation, # 34  
 ; Untersuchungen über Erythrokinetik und Erythrozytenstoffwechsel bei Thalassaemia minor 39 353  
 an unusual haematological syndrome with pyruvate-kinase deficiency and thalassaemia minor in the kindreds, 37 345
- Thalassaemia syndromes, 38, 405 (B)  
 —; (VL Two subtypes of sickle cell beta thalassaemia disease ) Normocytic type of sickle cell - beta thalassaemia disease; b) Microcytic type of sickle cell-beta thalassaemia disease) 37 181
- Thalassaemic syndrome new Homozygous haemoglobin S disease delta thalassaemia, 38 412
- Therapeutische Fibrinolyse 36 89 (C)
- Therapie der Leukosen und malignen Lymphome (Internationale Arbeitstagung Wien, 1969) # 240
- Therapy Erythroblastopenie, Iron deficiency Leukaemia, lymphocytic (complete remission), Pernicious anaemia (radiation therapy), Placental transfusion therapy Transfusion (B), Thrombocytentransfusion (B) Thromboembolic diseases (B)
- Thermodynamic approach, Isothermization
- Thiaminpyrophosphatase ("Gluco-phosphatase") in Blut- und Knochenmarkszellen, ihr Nachweis, # 177
- Thoracic duct lymphocytes; the types of rat thoracic duct lymphocytes which respond to phytohemagglutinin *in vitro*, 38, 121  
 —; early appearance of blast-like cells in the thoracic duct lymph of rats given bacterial endotoxins, 37 301
- Thrombocyten erhöhte Aggregation der Thrombocyten bei essentieller Hyperlipämie 38, 95  
 Untersuchungen über den Einfluss von Natrium-Oleat auf die Aggregation menschlicher Thrombocyten, # 1, 205  
 Hemorrhagic disorders, Hemostatic, Platelets, Retraktionsvorgang Transfusion; platelet
- Thrombocyten (Stoffwechsel und Membranpermeabilität) Symposium
- Thrombocytentransfusion (Untersuchungen an radioaktiv markierten Thrombocyten) # 337 (B)  
 —; Transfusion platelet
- Thrombocytosis, posthaemorrhagic in mice, megakaryocyte response, 39 112
- Thromboembolic diseases, pathogenesis and treatment (International Symposium, Basel, 29. 8. 1965) 38, 407 (B)
- Thrombolytic, Fibrinolytic
- Thrombopathy uremic, investigation, # 119
- Thrombopoietin, : Thrombocytosis, post-haemorrhagic
- Thymectomy; prevention of ALR (strain of mice) leukaemia by thymectomy at varying ages, 38, 317
- Thymidine metabolism and cell kinetics (Frontiers in biology vol. 6) 39, 381 (B)
- Thymidine ( $C^{14}$ -thymidine,  $H^3$ -thymidine) Erythrocyte precursors, Mononucleosis
- Thymidine ( $H^3$ -thymidine) Benzene Blastoid transformation Chromatinstrukturen DNA synthesis Eosinophils; Erythroblast; Erythrocyte precursors Index  $H^3$ -thymidine Leukaemia, acute Leukaemia, cell proliferation; Macrophages Metabolism of leukocytes Mononucleosis Plasma cells Proliferative activity Thoracic duct lymphocytes
- Thymus (Recent results in cancer research, vol. 5) 38 406 (B)  
 failure of shielding the thymus to induce recovery of bone marrow after radiation, 37 109  
 (thymomas) chromosomal aberrations and neoplastic potentialities of thymus cells during leukaemogenesis, # 142
- Tiere, Laboratorientiere. Comparativ haematology
- Tierarten (Phosphatase in Leukozyten) Animal species

- Tissue cultures, v. Antibody Blast transformation; Blastoid transformation Cell proliferation Leukocytes, kultivierte Lymphocyten transformation Lymphocytes; Lymphocytes (derivative cells) Lymphocytes and their derivatives; Lymphocytes from patients Lymphocytes, peripheral Mononuclear cells Mononuclear leukocytes Mononucleosis Ph 1 chromosomes Spleen cells; Trisomy-1
- Tp<sup>+</sup> v. Anti-Tp<sup>+</sup>-like haemolysis
- Tonillectomy v. Haemostatic effect
- Toxines, v. Bacterial endotoxins
- Trabecular acid (= active isomer of aminomethylcyclohexane-carboxylic acid) Fibrinolysis, Fibrinolysis inhibitors
- Transactions, (3rd) of the International Committee for Standardization in Haematology Strasbourg, 22-27.8.1963 (Standardization in haematology III) 38 404 (B)
- Transfusions, Leukaemia research (B) Normierung Proceedings, Proceedings (B) Thromboembolic diseases (B)
- Transferrin Atransferrinkomplex (kongenitale und erworbene Formen) 38 40 (C)
- Transformation of human mononuclear leukocytes (L. Comparison of cells in suspension and attached to coverslips) 36, 335
- (II. Procurement of large mononuclear cells on coverslips) 37 32
- Transfusion blood transfusion in clinical medicine (4th ed.) 38, 407 (B)
- International Society of Blood Transfusion, XIIIth International Congress, Moscow 1969 (travel grants) 40 240
- sanguine, actualités (2<sup>e</sup> cours européen de transfusion sanguine organisé par le Conseil de l'Europe, Strasbourg, 1966) 40 110 (B)
- placoid transfusion therapy (leukaemia) film, 37 160
- Thrombocytentransfusion (B) Placids
- Transferrase activity of red blood cells in conditions of haematological interest, 38 321
- Transmission of mouse leukaemia by oral route, 40 1
- Transplantation, advances (Proceedings of the 1st Congress of the Transplantation Society Paris, 1967), 40, 176 (B)
- 37 322
- Transplantation, Erythropoietin (extrarenal)
- Transplantation reactions, Lymphocytes Transport und Funktion intrazellulärer Elektrolyte (Symposium in Schöna, 1967) 40 112 (B)
- Trapped volume of plasma; comment on the method of determining the trapped volume of plasma after centrifugation based on the correlation between the trapped volume and the electrical conductivity 38, 255
- Trasylol® Fibrinolysis
- Treatment and pathogenesis of thromboembolic diseases (International Symposium, Basel, 29.8.1.9.1963) 38, 407 (B)
- Trisomy-21; case of idiopathic aplastic anaemia associated with trisomy-21 and partial endoreduplication, 37 137
- G 21 trisomy in a case of acute myeloblastic leukaemia, 38, 142
- Trithium, v. Cytidine DNA synthesis Eosinophils H<sup>3</sup>-cytidine H<sup>3</sup>-leucine H<sup>3</sup>-uridine Leucine H<sup>3</sup> Leukaemia, cell proliferation, Macrophages Thymidine (H<sup>3</sup>-thymidine)
- Tumoren, v. Cancer Cancer chemotherapy Cancer detection (B) Erythropoietin (B) Leukaemogenesis, Thymus (B), v. v. brachycephalopneumonia
- Turkish family Spherocytosis
- Touche, Macrophages
- Typhus abdominalis, Knochenmarkserkrankungen, 37 11
- UICC, v. Union Internationale contre le Cancer
- Ultracentrifuge, Barven Jovan protein, Macroglobulinämien
- Ultracentrifuge, analytical, D.V.A. and lit
- Ultrastructure, Basophile Zellen, Zosterophil granules, GLASSER cells, Haemagglutination, Haez body Lymphocytes, Mouse leukaemia, Phagocytes
- Umbilical cord blood from the umbilical cord, v. A antigen
- Units and quantities in clinical chemistry 40 110 (B)
- Union Internationale contre le Cancer Monograph series, vol. 4 Cancer dect

sonian pernicious anaemia also showed a normal TKA of the red cells. It has been found earlier that carriers of broad fish tapeworm may exhibit disorders of folic acid metabolism [8, 12, 14-22]. This might be the reason why the enzyme metabolism of the red cells, in at least some anaemic tapeworm carriers, does not follow the same course as in Addisonian pernicious anaemia. The same might also be suggested by the results obtained from the folic acid deficiency patients of the present series (table IV No. 1-3). LEVITAN *et al.* [10] found on serum lactate dehydrogenase, that its activity is increased in Addisonian pernicious anaemia but in no other megaloblastic anaemias. It is true that later observations have shown increased lactate dehydrogenase values both in vitamin B<sub>12</sub> and folic acid deficiency anaemias [4-9].

In azotemia the glucose-6-phosphate dehydrogenase activity of red cells has been found to be increased [3-6, 24]. This has been attributed to increased erythropoiesis or reduced mean age of the cells. In the present study the TKA of red cells remained largely within the normal variation range, and did not differ statistically significantly from the controls. Figure 1 shows, however that 3 of the 13 patients had TKA values distinctly higher than the control subjects.

The thyroid hormone is known to stimulate the oxygen consumption of the red cells. This especially seemed to be the case in hexose monophosphate shunt [17]. As a possible result it has been found that the glucose-6-phosphate dehydrogenase activity of the red cells is increased [18-21, 27] in thyrotoxic patients. A similar result has been obtained on healthy subjects after administration of thyroxin [20]. It might be expected that activities of several enzymes of hexose monophosphate shunt should be increased. Figure 4 shows, however that the TKA of red cells is largely within the range of normal variation in about 20% the TKA was even below the normal range. In one patient, a man of 60 the TKA was only 31 units. Simultaneously he had a very violent hyperthyroidism and peripheral neuritis in the lower limbs. It is quite possible, theoretically that the need of cocarboxylase is increased in hyperthyroidism while its deficiency might lead to reduced TKA values. The values of six patients with hypothyroidism must be considered completely normal.

A few cases of the group of 'Various Haematological Conditions' (table IV) deserve attention. Case No. 6 with polycythaemia vera

I. Medizinische Universitätsklinik Wien (Vorstand: Prof. Dr. E. Dornick)

# Untersuchungen über Erythrakinetik und Erythrozytenstoffwechsel bei Thalassaemia minor<sup>1</sup>

N. HONETZ, K. MOSER, E. NEUMANN und H. SEIFEL

Während die homozygote Form der Thalassämie eine meist zum Tode führende, schwere Erkrankung darstellt, weist die heterozygote Form nicht nur eine außerordentliche Variabilität, sondern auch einen sehr unterschiedlichen Intensitätsgrad der Symptomatik auf, deren Ursache bis heute noch nicht geklärt erscheint. Es ist daher verständlich, dass Versuche unternommen wurden, weitere Unterteilungen nach verschiedenen Gesichtspunkten vorzunehmen [10-34]. Dabei hat sich die Einteilung der heterozygoten Form der Thalassämie in jene Fälle, die lediglich am Vorliegen von Thalassämiemerkmalen, wie Facies microcythaeica, Mikrozytose mit vermehrter osmotischer Resistenz, Hämoglobin-A<sub>2</sub>-Vermehrung zu erkennen sind (Thalassaemia minima oder Thalassaemia trait) und solche Fälle, die mit Krankheitserscheinungen einhergehen (Thalassaemia minor) allgemein durchgesetzt. Nur bei einem Teil dieser heterozygoten Formen lassen sich Zeichen eines vermehrten Erythrozytenabbaues feststellen für den die verstärkte mechanische Zerbrechlichkeit der Erythrozyten verantwortlich gemacht wird. Die Ursache derselben ist allerdings bis heute nicht bekannt und wird mit der defekten Erythropoese in Zusammenhang gebracht [14]. Zur weiteren Klärung der Pathogenese wurden daher in letzter Zeit Stoffwechseluntersuchungen an Erythrozyten Thalassämiekranker durchgeführt. So konnten GRIGNANI *et al.* [18] bei drei Fällen von Thalassaemia major eine deutliche Aktivität der Glycerophosphatdehydrogenase Aktivität in den Erythrozyten nachweisen, während bei Gesunden und bei an Thalassaemia minor Erkrankten die Aktivität dieses Fermentes in den Erythrozyten

<sup>1</sup>Herrn Prof. Dr. F. BENECKE zum 60. Geburtstag gewidmet.

6. v DETTRICK, F.: Glucose-6-Phosphat-Dehydrogenase in den Erythrocyten bei nephrogenen Anämien. *Klin. Wochr.* 40: 1075 (1962).
7. FINGELLY J.; FRANK, O.; BAUER, H. and LERIVY C. M. Transketolase activity in experimental thiamine deficiency and hepatic necrosis. *Proc. Soc. exp. Biol., N.Y.* 116: 875 (1964).
8. GRÄNICK, R., BJÖRCKEN, F. and NYSSAN, W. Formilungstutaminoseyca i urm vid solrytblast. *Nord. Med.* 66: 1343 (1961).
9. HOFERAND, A. V.; KRIMENCHENSKY S.; BUTTERWORTH, P. J. and MOLLIN, D. L.: Serum lactic dehydrogenase activity and folate deficiency in myelodysplasia and other hematological disorders. *Brit. med. J.* 1: 577 (1966).
10. LEVITAN, R., WASSERMAN, L. R. and WADSWORTH, F. Clinical significance of serum enzyme alterations in hematologic diseases. *Clin. Res.* 7: 217 (1959).
11. MARIKÄNEN, T.: Studies on the urinary excretion of thiamine riboflavin, nicotinic acid, pantothenic acid and biotin in achlorhydria and after partial gastrectomy. *Acta med. scand.* 169 suppl. 360 (1960).
12. MARIKÄNEN, T.: Tapeworm anaemia and the economy of vitamins B in man. *Ann. Med. intern. fenn.* 51: 229 (1962).
13. MARIKÄNEN, T.: Riboflavin content of blood in carriers of fish tapeworm (*Diphyllobothrium latum*). *Acta med. scand.* 171: 195 (1962).
14. MARIKÄNEN, T., BÄCKSTRÖM, P. and SAVOLA, P. Urinary excretion of folic acid in endemic and non-endemic carriers of the fish tapeworm (*Diphyllobothrium latum*). *Acta med. scand.* 176: 361 (1961).
15. MARIKÄNEN, T., LEVANTO, A., VIRTANEN, S. and SALLINEN, V.: Folic acid and vitamin B<sub>12</sub> in tuberculosis. *Scand. J. Haemat.* 4: 283 (1967).
16. MARIKÄNEN, T. and KALLIOWALJA, J. L.: Transketolase activity of blood cells in various clinical conditions. *Amer. J. med. Sci.* 252: 564 (1966).
17. NICKELLS, T. and BEUTLER, E.: The effect of Tet-iodothyronine on the oxidative metabolism of erythrocytes. I. Cellular studies. *J. clin. Invest.* 38: 788 (1959).
18. NICKELÄ, E. A. Bestämning av enzymet i erythrocyter. *Nord. Med.* 68: 1944 (1962).
19. NICKELÄ, E. A., PITKÄNEN, E., VUONO, P. and FOSSILL, O.: Erythrocyte enzymes in species of different ecology. *Ann. Med. intern. fenn.* 49: 187 (1960).
20. PEARSON, H. A. and DUTAY, R. Erythrocyte glucose-6-phosphate dehydrogenase activity related to thyroid activity. *J. Lab. clin. Med.* 57: 943 (1961).
21. PITKÄNEN, E. and NICKELÄ, E. A. Erythrocyte enzymes in thyrotoxicosis. *Ann. Med. intern. fenn.* 49: 197 (1960).
22. OIKARINEN, B.; HANSEN, H. A. and LARSEN, L. O. Megaloblastic bositriocrophalus anemia mainly due to folic acid deficiency. *Acta med. scand.* 174: 155 (1963).
23. RAAB, W. and FRIEDENBERG, H. Serumenzymaktivitäten bei hepatischen Porphyrien. *Klin. Wochr.* 45: 587 (1967).
24. TREIL, G. B.; BRODICK, O. E. and DOOLAR, P. D. Red cell glutathione content and stability in renal insufficiency. *J. Lab. clin. Med.* 58: 736 (1961).
25. VAN THIECKER, O. J. Die perniziöse Anämie als eine selbständige Krankheit. *Dtsch. Arch. klin. Med.* 131: 113 (1920).
26. VARTANIAN, I. Clinical significance of blood catalase. *Ann. Med. intern. fenn.* 36: suppl. 5 (1947).
27. VUONO, P. Red cell enzymes in anemia. *Scand. J. clin. Lab. Invest.* 15: suppl. 72 (1963).

Author address: Docent T. MARIKÄNEN, M.D. Department of Medical Microbiology University of Turku, Turku (Finland)



nicht vorhanden war. Eine Aktivitätszunahme fast aller Enzyme in den Erythrozyten mit Ausnahme der Phosphofruktokinase, die bei Thalassämie vermindert ist, fanden BELFIORE *et al.* [5]. Weiter konnten ZÜRCHER *et al.* [41] wechselnde Befunde über den Nukleotidgehalt der Erythrozyten und CORAINI *et al.* [11] eine Verminderung der Adeninnukleotide in den Erythrozyten thalassämischer Kinder nachweisen.

Wir hatten nun bei einer Patientin mit Thalassaemia minor bei der mittels  $^{51}\text{Cr}$  und  $^{59}\text{Fe}$  Aufschluss über Ort und Ausmass der Erythrozytenbildung und des Erythrozytenabbaues erhalten werden konnte, sowie bei deren Tochter die Thalassämieerkmale ohne Krankheitssymptome aufwies, Gelegenheit, Untersuchungen des Erythrozytenstoffwechsels durchzuführen.

### Kasuistik

Pat. T II eine aus Serbien gebürtige, 34 Jahre alte Fremdarbeiterin wurde mit Hepatitisverdacht an die Klinik gewiesen. Anamnestisch wird das Vorkommen von Gelbsucht und Bluterkrankungen in der Familie berichtet. Nach einem fieberhaften Infekt 2 Monate vor der Klinikaufnahme wurde ein Stöhrabitus bemerkt, der in der Folgezeit immer wieder auftrat. Die Pat. fühlt sich matt, schwindlig und appetitlos. Status: Mit Ausnahme eines den Rippenbogen um 3 QF überragenden, linken Milztumors und der bläulichen Hautfarbe keine Besonderheiten. Schädelform unauffällig, Leber nicht vergrößert. Laborbefunde: Blutsenkung n.V. 2/4 mm, WAR negativ. Serumbilirubinproben, Eiweißwerte und Elektrophorese unauffällig. SGOT 16 mE, LAP 9,7 mE, LDH 133 mE, Gesamtbilirubin 2,9 mg%, davon 2,3 mg% indirektes Bilrubin, Serumseifen 80 µg%, Bromsulphthaleinretention nach 45 min normal, Harnbefund chemisch und morphologisch unauffällig, Cholezystographie nach peroraler Füllung o.B., Röntgenaufnahmen des Skelettes mit Ausnahme einer grobporigen Struktur der Schädeldecke ohne Besonderheiten. Hämatologische Befunde: Ery 446  $\mu\text{Ml}$ , Hb 8,9 g%, Hk 23%, FI 0,62, Retikulozyten 18‰, Hbz 20 ng, Volz 64  $\mu\text{m}^2$ , Hb-Index 29%, Leuko 4500 bei unauffälliger Verteilung, Thrombozyten 220000.

Vermehrte Anis- und Poikilozytose, basophile Tüpfelung und Targetzellen in einem höheren Prozentsatz. Osmotische Resistenz deutlich verbreitert. Im Alkalidenaturierungstest nach Seewitz und Matarb, 3,5% Hb-F, Hb-A<sub>2</sub> war in einer Menge von 5,2% vorhanden. Direkter Coombs-Test, Blockingtest und indirekter Coombs-Test negativ. Kälteagglutininstitier 1/8, A bzw. Hypohaptoglobulinämie, Storchimolytest negativ. Sternmark, 80% Zellen der erythropoetischen Reihe, davon 85% Sideroblasten. Siderozyten 3%. Zahlreiche basophil getüpfelte Normoblasten. Granulopoese unauffällig.

Pat. M. S., 16 Jahre Tochter der Pat. T. D. Die Anamnese ist unauffällig und die Pat. beschwerdefrei. Kein Milztumor, kein Ikterus und keine auffällige Schädelform. Keine sicheren Zeichen für eine gesteigerte Hämolyse. Serumbilirubin und Serumseifen im Normbereich, Haptoglobulin nicht vermindert. Ery 587  $\mu\text{Ml}$ , Hb 11,0 g%, Hk 57%, FI 0,63, Hbz 16,4 ng, Volz 62  $\mu\text{m}^2$ , Hb-Index 34%, Retikulozyten 14‰.

Wir danken Herrn Dozent KLEINHAUER, Kinderklinik München, für die quantitative Hb-A<sub>2</sub>-Bestimmung.

keine basophile Tüpfelung der Erythrozyten. In der Stärkgelelektrophorese zeigte sich die Vernehrung von Hb-A<sub>2</sub>, allerdings wurde eine quantitative Bestimmung nicht durchgeführt.

### Methodik

2. *Erythrokinetik.* Die Untersuchungen mit <sup>51</sup>Cr und <sup>59</sup>Fe erfolgten nacheinander so, dass das mit <sup>59</sup>Fe markierte Plasma erst unmittelbar nach Abschluss der Chromoberflächenaktivitätsmessungen injiziert wurde. Die Messungen wurden mittels eines Szintillationszählers durchgeführt, wobei zur Trennung der Energiebereiche lediglich für die Blutmessung ein Elektronenanalysator zur Verfügung stand. Bei den Eisenoberflächenaktivitätsmessungen wurde die energiereichere Chromstrahlung durch entsprechende Einstellung des Diskriminators ausgeschaltet. Die Markierung von autologen Patientenplasma und autologen Patientenerthrozyten erfolgte *in vivo* mit etwa 20 µC <sup>59</sup>Fe-Chlorid bzw. mit 100 µC Na-Chromat (<sup>51</sup>Cr). Bestimmt wurden Erythrozytenvolumen, Plasmachemieanalyse, Eisenzufuhr und scheinbare Chromüberlebenszeit der Erythrozyten. Ausserdem wurden Oberflächenaktivitätsmessungen über Leber, Milz, Herz und Spleen durchgeführt.

2. *Stoffwechselmessungen in den Erythrozyten.* a) Enzymaktivitätsbestimmungen. Ziträtsäure wird 5 mal in isotoner NaCl-Lösung gewaschen. Die Erythrozyten werden in Phosphat-Ringer Lösung (pH 7.4) suspendiert und auf 2,5 bis 3 Mill. Erythrozyten/µl eingestellt. Ein ml der Suspension wird mit 1 ml Aqua bident., 0,7 ml m/20 Tris-Hensolepuffer (pH 7,5) und 0,3 ml gesättigter und filtrierter Digitoninlösung versetzt, 15 min im Kühlenschrank stehen gelassen und anschließend 15 min bei 350 U/min zentrifugiert und dekantiert. Alle Enzymbestimmungen wurden bei pH 7,5 und +25 °C in einer durchströmten Testkammer bei einer Wellenlänge von 366 nm im Photoscanner Eppendorf durchgeführt. Die Fermentaktivität wurde nach Büchner durch Bestimmung der Laufzeit der Reaktion nach einem Vorlauf zwischen 2 Extinktionsmarkern gemessen. Die Angabe der Enzymaktivität erfolgt in internationalen Einheiten (IU). 1 IU wird als die Enzymmenge definiert, die 1 Mikromol Substrat/Zehneinheit umsetzt.

Die Bestimmung der Hexokinase erfolgte nach GRUBB und LÖWEN [19], die der Hexosphosphatkinase nach SLICK [38], der Fruktose-6-Phosphatkinase nach LEO [27], der Dephosphofruktose-Aldolase nach BUCHNER [8], der Triosephosphatisomerase nach BUCHNER [4], der Glycerinaldehyd-3-phosphat-dehydrogenase nach DILLON und BUCHNER [15], der 3-Phosphoglycerat 1-Kinase und der Phosphoglyceromutase nach BUCHNER [8], der Enolase nach BUCHNER [7], der Pyruvatkinase nach BUCHNER und FRIEDL [9], der Laktatdehydrogenase nach KENOWITZ und OTT [26], der Malatdehydrogenase nach ZINN [15], der Glukose-6-Phosphatdehydrogenase nach KORNBERG und HORRIGER [25], der 6-Phosphoglukonat-Dehydrogenase nach HORRIGER und BARRACLOUGH [25], der Glutathionreduktase nach RACER [33], der Myokinase nach ADAM und BUCHNER [7], der Mg<sup>++</sup>-aktivierten ATP-ase nach LÖWEN und GRUBB [26].

b) Substratbestimmungen. Zur Bestimmung von Adenosintriphosphat (ATP), Adenosindiphosphat (ADP) und Adenosinmonophosphat (AMP) wurde Vollblut entnommen und sofort in eiskaltete 6%ige Perchlorsäure eingebracht. Der entzuckerte Niederschlag wurde abzentrifugiert, anschließend erfolgt die Neutralisierung mit 1-N KOH und Abtrennung des Kaliumperchlorates. ATP, ADP und AMP wurden enzymatisch nach ADAM [1] bestimmt. Die enzymatische Laktatbestimmung erfolgte nach HOGGER [22] und die Pyruvatbestimmung nach CLARK und BUCHNER [13]. Das reduzierte Glutathion wurde nach der Methode von GRUBB und PHILLIPS [20], die Glutathionstabilität nach BERTLEY [6] bestimmt. Der Kalium- und Natriumgehalt der Erythrozyten wurde mit dem Flammenphotometer gemessen.

c) Manometrische Bestimmungen. Zur Erfassung des Gasaustauschs der Erythrozyten wurde die Sauerstoffaufnahme und die Kohlendioxidbildung nach WAR-

zurück [40] mit der Gefäßpaarmethode bestimmt. Gleichzeitig wurde auch die Laktat und Pyruvatbildung pro Stunde gemessen. Dazu wurden die Erythrozyten in der vorher beschriebenen Weise gewaschen und in Bicarbonat-Ringer-Lösung mit Glukoseansatz suspendiert. Die Konzentration der Erythrozyten in dieser Suspension betrug 3 Mill./ $\mu$ l. Hämoglobin und Methämoglobinbestimmungen wurden nach dem Prinzip der Kohlenoxydhämoglobinmethode von Katus [29] durchgeführt.

### Ergebnisse

**Erythrokinetik.** Es findet sich bei Pat. T D eine deutlich beschleunigte Plasmasensenclearance von 23 min, woraus sich bei einem Eisenspiegel von 80  $\mu$ g % ein mit 24 mg/100 ml Blut die auf etwa das Vierfache der Norm erhöhte Plasmasensenturnoverwert ergibt. Im Gegensatz zu diesem erhöhten Plasmasensenturnoverwert ist jedoch die Eisenuutilisation mit nur 35,6 % sehr niedrig (Abb. 1). Wie in der Abbildung ersichtlich, erfolgt der Eisenanstieg über dem Sacrum rasch und hat bereits nach 4 Stunden seinen maximalen Wert erreicht, der allerdings infolge der starken Ausdehnung des blutbildenden Markraumes nicht hoch ist. Der Aktivitätsabfall geht nur langsam vor sich, ohne dass nach 13 Tagen der Ausgangswert erreicht wurde. Die Leberaktivität nähert sich nach anfänglichem Abfall etwa am 10. Tag wieder dem Ausgangswert, während die Milzaktivität nach vorübergehendem Abfall den Anfangswert bald übersteigt. Bis zum 3. Tag nimmt die Aktivität hier rasch und darnach nur mehr langsam zu. Die Untersuchungen mit  $^{54}\text{Cr}$  ergeben eine Verkürzung der scheinbaren halben Erythrozyten lebensdauer auf 16 Tage, ohne dass sich eine nennenswerte Aktivitätszunahme über einem der gemessenen Organe feststellen lässt.

**Erythrozytenstoffwechseluntersuchungen.** Aus der Tab. I ist zu erkennen, dass von den Erythrozytenenzymen bei Pat. T und ihrer Tochter M. eine deutlich nachweisbare Glycerophosphatdehydrogenase-Aktivität in den Erythrozyten vorhanden ist. Es fällt weiter die deutlich verminderte  $\text{Mg}^{++}$  abhängige ATP-ase Aktivität in den Erythrozyten beider Patientinnen auf. Von den übrigen Enzymaktivitäten sind die D-1 Phosphofruktose Aldolase, die Pyruvatkinase und Glukose-6-Phosphatdehydrogenase-Aktivität in den roten Blutzellen beider Patientinnen etwas erhöht, die Fruktose-6-Phosphatkinase und die Laktatdehydrogenase Aktivität und bei der Pat. T in den Erythrozyten erhöht, während bei ihrer Tochter keine Vermehrung der Aktivität gefunden wurde. Die Enolase-Aktivität ist bei beiden Patientinnen in den roten Blutzellen etwas vermindert. Bei der Tochter von Pat. T ist die Hexokinase und die




Abb. 1

Malatdehydrogenase Aktivität in den Erythrozyten geringfügig erhöht. Die Substratuntersuchungen (Tab. II) zeigten, dass der ATP und ADP-Gehalt der Erythrozyten bei Pat. T deutlich vermindert ist, der AMP-Gehalt ist unauffällig. Auch die Tochter M. weist in den Erythrozyten einen verminderten ATP-Gehalt auf, ADP und AMP sind unauffällig. Bei Pat. T ist das reduzierte Glutathion in den Erythrozyten etwas vermindert, das Methämoglobin leicht erhöht. Die Untersuchung des Natrium- und Kaliumgehaltes der Erythrozyten ergab bei beiden Patientinnen eine Verminderung des Kaliumgehaltes, während der Natriumgehalt

*Tabelle I* Normalwerte der Enzymaktivitäten mit Streubreiten in IU/10<sup>12</sup> Erythrozyten und Werten von Patientin T D. und M. S.

	Normalwerte	±	Pat. T	Pat. M.
Hexokinase	1,84	0,98	1,63	3,84
Glukose-P Isomerase	83,0	8,0	96,6	90,0
Fructose-6-P-Kinase	15,0	2,5	19,1	17,2
D-6-P-Fructose-Aldolase	5,5	0,5	10,6	10,5
Triose P Isomerase	626,0	89,0	581,0	629,0
Glycero-phosphat DHG			4,8	4,9
Glycerinaldehyd-3-P-DHG	225,0	94,2	217,0	273,0
3-P-Glycerat-1 Kinase	303,0	36,5	334,0	323,0
P-Glycerat Mutase	72,5	10,5	66,5	68,9
Enolase	28,5	3,4	30,7	18,3
Pyruvatkinase	40,7	6,1	59,1	53,6
Laktatdehydrogenase	283,0	41,5	381,0	232,0
Glukose-6-P DHG	13,9	1,54	20,4	17,3
6-P-Glukonat DHG	5,7	1,2	6,45	7,4
Glutathionreduktase	6,1	2,1	8,45	8,06
Malatdehydrogenase	244,0	36,2	180,0	359,0
Mg <sup>++</sup> -abhängige ATP-ase	33,0	3,7	5,9	11,3

*Tabelle II* Stoffwechselleistungen der Erythrozyten, Substrate in Mikromol/10<sup>12</sup> Erythrozyten (37°C, pH 7,4 Bikarbonat Ringer Lösung 0,01 M Glukose) Glutathionstabilität (Abfall) % und Methämoglobingehalt in % sowie Kalium und Natriumgehalt der Erythrozyten von Gesunden und Patientin T und M.

	Normalwert	±	Pat. T	Pat. M.
O <sub>2</sub> -Aufnahme/h	4,20	0,4	2,93	
CO <sub>2</sub> -Bildung/h	7,68	1,0	11,3	
Pyruvatbildung/h	0,9	0,3	0,69	
Laktatbildung/h	28,2	8,6	36,50	
Glukoseverbrauch/h	12,1		25,23	
ATP	20,8	1,8	8,13	15,2
ADP	2,2	0,2	0,69	1,14
AMP	1,1	0,4	1,22	0,7
Reduziertes Glutathion (GSH)	20,0	3,9	15,7	16,0
GSH-Stabilität (Abfall) %	bis 75%		9,3	11,3
Methämoglobin (%)	1,0		1,8	0,3
K <sup>+</sup> (mval/l)	92,0	4,7	78,0	83,4
N <sup>+</sup> (mval/l)	19,0	4,2	29,0	26,3

vermehrt war. Die Untersuchung der Stoffwechselleistungen der Erythrozyten von Pat. T zeigte, dass die Erythrocyten einen doppelt so hohen Glukoseverbrauch und eine erhöhte Laktatbildung auf

wissen. Die Pyruvatbildung ist unauffällig. Die Sauerstoffaufnahme ist geringfügig vermindert, die Kohlendioxidbildung etwas erhöht.

### Diskussion

Bei der Untersuchung der Erythrozytenenzyme unserer beiden Patientinnen fällt die nachweisbare Aktivität der Glycerophosphatdehydrogenase auf die normalerweise, wie LOHR und WALLER [29] zeigen konnten, in den Normozyten fehlt. Die Autoren konnten bei 3 Kranken mit Thalassaemia major eine erhöhte Aktivität dieses Enzymes in den Erythrozyten nachweisen, bei einem Fall von Thalassaemia minor war die Aktivität der Glycerophosphatdehydrogenase nicht vorhanden. Die Glycerophosphatdehydrogenase, die im Nebenweg der Glykolyse wirksam ist, benötigt für die Reaktion mit dem Substrat Dihydroxyazetonphosphat NADH<sub>2</sub> als Co-ferment (Abb 2). Es konkurriert die Glycerophosphatdehydrogenase in den Erythrozyten bei der Thalassaemia minor mit der Laktatdehydrogenase und der Methämoglobinreduktase um das bei der oxydierenden Gärungsreaktion gebildete NADH<sub>2</sub>. Damit könnte der leicht erhöhte Methämoglobingehalt der Erythrozyten unserer Patientin erklärt werden. Dass die Laktatbildung wie erwartet, nicht vermindert, sondern eher leicht erhöht gefunden wurde, könnte mit dem hohen Glukoseverbrauch der Erythrozyten erklärt werden. Eine verminderte ATP-ase-Aktivität in den Erythrozyten ist bisher erst von HARVALD *et al.* [21] bei 3 Fällen von nicht sphärozytärer hämolytischer Anämie beschrieben worden. Bei der Thalassaemia minor ist bisher eine Aktivitätsverminderung dieses Enzymes nicht gefunden worden. Die Bedeutung der Mg<sup>++</sup> ATP-ase für den aktiven Transport von Kalium und Natrium durch die Zellmembran ist bekannt [32, 36–37]. Wahrscheinlich ist die Elektrolytstoffwechselstörung der Erythrozyten und damit auch die vermehrte Hämolyse damit in Verbindung zu bringen.

Der verminderte ATP-Gehalt, der verminderte bzw. unauffällige ADP und AMP-Gehalt der Erythrozyten bei uneingeschränkter Pyruvat und Laktatbildung sprechen eher für eine Nukleotidbildungsstörung bei uneingeschränkter Glykolyse. Auch die Verminderung des Nukleotidgehaltes der Erythrozyten könnte für die Elektrolytstoffwechselstörung und verstärkte Hämolyse verantwortlich gemacht werden. Die von uns teilweise erhöht gefundenen Enzymaktivitäten in den Erythrozyten weisen auf eine jüngere Zellpopulation hin wie es im Rahmen der Hämolyse erwartet wird.

21. HARVALD, R.; HASEL, K. H., SÖDERB, R. and TRAP-JENSEN, J. Adenosinetriphosphatase deficiency in patients with non-spherocytic haemolytic anemia. *Lancet* B. 18 (1964).
22. HORNITZ, H. J. L-(-) Laktat-Bestimmung mit Laktat-Dehydrogenase und DPN; in BERZOWSKY's Methoden der enzymatischen Analyse, p. 706 (Verlag Chemie, 1967).
23. HORWICK, B. L. and SCHWARTZ, P. Z. 6-phosphogluconic dehydrogenase in COLOWICK and KAPLAN's Methods in Enzymology I, p. 523 (New York Academy Press, New York 1955).
24. KORN, M. Die Reduktion des Hämoglobins. *Biochem. Z.* 376: 264 (1944).
25. KORNBERG, A. and HORWICK, B. L. Glucose-6-phosphatase dehydrogenase in COLOWICK and KAPLAN's Methods in Enzymology I, p. 523 (New York Academy Press, New York 1955).
26. KROWITZ, F. und OTT, P.: Isolierung und Kristallisation eines Gärungsfermentes aus Tumoren. *Biochem. Z.* 314: 94 (1943).
27. LEE, R. H., BYRNE, W. L. and LADD, H. A. Phosphobenzokinase in COLOWICK and KAPLAN's Methods of Enzymology I, p. 306 (New York Academy Press, New York 1955).
28. LÖW, G. W. und GROSSMANN, F. Zt. u. LÖW, G. W. und WALLER, H. D. Zur Biochemie einiger angeborener hämolytischer Anämien. *Fol. haemat. N. F.* 8: 377 (1963).
29. LÖW, G. W. und WALLER, H. D. Zur Biochemie einiger angeborener hämolytischer Anämien. *Fol. haemat. N. F.* 8: 377 (1963).
30. MALANOR, B.; BELCHER, E. H., GYLLARI, E. and BOHOPOLLOS, D.. Spontaneous radioactive tracer studies of erythropoiesis and red cell destruction in thalassemia. *Brit. J. Haemat.* 7: 411 (1961).
31. PEARSON, H. A., McFARLAND, W., KORN, E. R. and BERNARD, M. D. Erythrokinetic studies in thalassemia trait. *J. lab. clin. Med.* 56: 866 (1960).
32. POPE, R. L., MURPHY, C. R., KOSKOVSKI, C. R. and ALMAGUER, C. D. Membrane adenosin triphosphate as participant in the active transport of sodium and potassium in the human erythrocyte. *J. biol. Chem.* 235: 1796 (1960).
33. RACKER, E. Glutathionreductase (liver and yeast) in COLOWICK and KAPLAN's Methods in Enzymology I, p. 772 (New York Academy Press, New York 1955).
34. RITTEL, F. Haemolytic anemias with increased osmotic resistance of the erythrocytes. *Acta med. scand.* 125: 451 (1946).
35. RODWICK, S.; VANCE, T.; DUBOWSKI, J. and SCHUM, R. Jaundice in thalassemia minor: A consequence of ineffective erythropoiesis. *N. Engl. J. Med.* 267: 523 (1962).
36. SEX, A. K. and POPE, R. L. Stoichiometry and localization of adenosin triphosphate dependent sodium and potassium transport in the erythrocyte. *J. biol. Chem.* 239: 345 (1964).
37. STOD, J. C. Preparation from mammalian brain and kidney of the enzyme system involved in active transport of Na<sup>+</sup> and K<sup>+</sup>. *Biochim. Biophys. Acta* 58: 314 (1962).
38. SCHWARTZ, M. W. Phosphobenzokinase from muscle in COLOWICK and KAPLAN's Methods in Enzymology I, p. 299 (New York Academy Press, New York 1955).
39. SCHWARTZ, P. and FOSCH, C. H. Erythrokinetics in Cooley's anemia. *Blood* 12: 64 (1957).
40. WAKESCH, O. Über den Stoffwechsel der Tumoren (Berlin 1926).
41. ZILBERMAN, C.; LOOS, J. A. and PAPPE, H. K. Hereditary high ATP content of human erythrocytes. *Proc. 10th Congr. Int. Soc. Blood Transf., Stockholm 1964*, p. 549 (1965).

Adresse der Autoren: DR. N. HORNITZ, K. MOSER, E. NEUHÄUSER und H. SCHWEIL, I. Med. Universitätsklinik, Wien (Österreich).

Departments of Medicine and Pathology, University of California Center for the Health Sciences, Los Angeles, Cal., Laboratory Service, Walterworth Hospital, Veterans Administration Center, Los Angeles, Cal.

## An Unusual Hematological Syndrome with Pyruvate-Kinase Deficiency and Thalassemia minor in the Kindreds

MARJORIE A. BAUGHAN, D. E. PAOLIA, A. S. SCHNEIDER  
and W. V. VALENTINE

Hereditary hemolytic anemia secondary to erythrocyte pyruvate kinase deficiency is now a well established clinical entity. Several examples of this disorder have been observed in our laboratory in addition to the original 7 cases [1-2] and there have been numerous reports from other laboratories [3-10]. From these reports a fairly consistent clinical pattern has emerged which characteristically includes three prominent features. First, there is a chronic hemolytic anemia which usually responds minimally to splenectomy. Second, erythrocyte morphological changes are usually nondescript with only slight macrocytosis and occasional irregularly contracted cells. And, finally, erythrocyte autohemolysis is enhanced by sterile incubation and usually not corrected by the addition of glucose.

Recently we have observed a patient with a hemolytic syndrome who exhibited at least a partial deficiency of erythrocyte pyruvate kinase. There were however many atypical features, including apparent major benefit from splenectomy, prominent erythrocyte shape changes with many cells resembling acanthocytes, and a pattern of autohemolysis distinctly different from that usually noted in pyruvate kinase deficiency. Although numerous authors have commented upon erythrocyte morphologic abnormalities in pyruvate kinase deficiency, such changes have generally

---

This work was supported by USPHS Grant Nos. TL-AM 5112-09 and HE 1029



not been very prominent. A notable exception is the case reported by Oski *et al.* [11]. Because of the clinical pattern, it was suspected that a second hematologic abnormality in addition to pyruvate kinase deficiency might be present. To investigate this possibility family studies were performed and  $\beta$ -thalassemia ( $\beta$ -thalassemia) minor in addition to pyruvate kinase deficiency was found in the kindred. The hematologic, biochemical and genetic studies of this patient and his family constitute the subject of this report.

### Materials and Methods

Routine hematologic studies were performed by standard methods. The autohemolysis test was done on defibrinated blood as previously described. Osmotic fragility was tested by the method outlined by Dacie [12]. The activities of erythrocyte hexokinase, glucose-phosphatase isomerase, phosphofructokinase, fructose-diphosphate aldolase, glyceraldehyde-phosphate dehydrogenase, triosephosphate isomerase, phosphoglycerate kinase, phosphoglyceromutase, phosphopyruvate hydratase, pyruvate kinase, lactate dehydrogenase, glucose-6-phosphate dehydrogenase, phosphogluconate dehydrogenase, and glutathione reductase were assayed as previously noted [2, 13-15].

Glutathione stability was performed essentially as described by Beutler [16] with quantitation of the reduced glutathione by a slight modification of the 5,5'-dithiobis (2-nitrobenzoic acid) method of Beutler, Doran and Kelly [17].

Hemolysis induction was quantitated as described by Beutler, Drenth and Alving [18].

Vertical descending starch block electrophoresis was done according to the method by Sorenson [19] using a phosphate buffer system at pH 7.0 according to the method of Garavito, Hutcheson, Sawcotte and Gerald [20].

Lactate production from several different glycolytic intermediate compounds was evaluated by the addition of the separate intermediates to erythrocyte hemolysate. Requisite co-factors were added when needed. The lactate generated after a period of incubation was quantitated enzymatically [21] with lactate dehydrogenase.

Hemoglobin  $A_2$  was determined electrophoretically on cellulose acetate. Fetal hemoglobin was determined by the alkali denaturation method of Sowers, Crutcher and Sowers [22].

### Case Report

The patient, S. R., caucasian male student of partial Italian ancestry was first studied in our laboratory at 17 years of age. No abnormalities were noted at birth and he remained in excellent health throughout childhood. At 14 years of age tonsillectomy was performed because of repeated episodes of pharyngitis. At this time he was found to be anemic with hemoglobin concentration of 10.5 g/100 ml. At age 18, during an acute febrile illness, he was seen by a physician who noted splenomegaly. Except for prominent frontal bossing, the physical examination was otherwise unremarkable. Hemoglobin concentration varied from 8.1 to 10.5 g/100 ml, and reticulocyte count was 2.8%. Peripheral blood many acanthocyte-like erythrocytes there was normoblastic erythroid hyperplasia of the bone marrow. Because of the history of abdominal trauma during a


football game four weeks earlier. Splenectomy was performed because of the possibility of splenic hematoma. The spleen was enlarged to four times normal size; there was no evidence of hematoma. Microscopically: Chronic congestion with moderate amount of hemosiderin deposition, thickening of the cords and rarefaction of the white pulp.

Following splenectomy the hemoglobin concentration increased and varied from 13.6 to 15.0 g/100 ml. The reticulocyte count varied from 0.7 to 1.1%. The red cell indices were consistent with slight macrocytosis. Examination of the Wright-stained smear of the peripheral blood (Fig. 1) showed persistence of the morphologic abnormalities present prior to splenectomy with approximately 75% of the erythrocytes showing contraction with numerous irregular blunted projections similar to crenocytes. When erythrocyte shape was fixed by adding whole blood to formalized saline immediately after withdrawal from the antecubital vein, according to modification of the STRAUMER [23], 42% of the patient's erythrocytes and less than 1% of the normal control erythrocytes showed abnormal spiculation. If, however, the erythrocyte shape fixation were not performed for 15 min or 2 h after withdrawal from the vein, the percentage of observed spiculation sharply increased in the patient whereas there was no increase in the normal blood. It is clear that the shape abnormality observed in the patient was present immediately after the blood was removed from the vein and increased rapidly thereafter. In addition to the marked anisopoikilocytosis, there was marked macrocytosis, slight microspherocytosis, and occasional ovalocytes, target cells and tailed poikilocytes. The cells were essentially normochromic with minimal polychromatophilia, rare basophilic stippling and numerous Howell-Jolly bodies present. The leukocyte count was 10,900/mm<sup>3</sup> with 2 neutrophilic bands, 38 segmented neutrophils, 1 basophil, 3 eosinophils, 42 small lymphocytes, and 14 monocytes. The platelet count was 698,000/mm<sup>3</sup>. Hemoglobin electrophoresis showed an AA pattern, and the A<sub>2</sub> fraction was 3.5%. The fetal hemoglobin was 2.3%. Starch block electrophoresis using phosphate buffer 0.054 M, pH 7.0, showed no migration toward the anode such as seen with hemoglobin H or Bart's hemoglobin. No inclusion bodies were noted on incubation with brilliant cresyl blue. Direct and indirect Coombs tests were negative; the serum haptoglobin was 86 mg%, and the total bilirubin was 0.35 mg% with direct value of 0.09 mg%. Serum iron was 129 mg% and total iron-binding capacity was 388 mg% with 33% saturation. Serum protein electrophoresis revealed no abnormalities, the cholesterol was 178 mg% and the alkaline phosphatase was 4.6 Shomura Units (Normal 2-9 Units). The serum beta-lipoprotein was found to be within normal limits. Red cell stromal lipid analysis (total lipid, lipid phosphorus, cholesterol, phospholipid fractionation, and the pattern of phospholipid fatty acids) was found to be within normal limits.

### Results

All the erythrocyte glycolytic enzymes mentioned under Materials and Methods were assayed on the patient, parents, siblings, maternal grandparents, paternal grandmother and paternal aunt. Pyruvate kinase activity was found to be deficient and the results are shown in table I. However the degree of deficiency in the proband was less marked than that usually observed in homozygous pyruvate kinase deficiency [2].

We thank Dr. ROBERT C. NEERHOUT, Department of Pediatrics, UCLA for doing these assays.



*Fig 1* Photomicrographs of blood smear from the patient and his parents. ( ) Propositus, (b) Father ( ) Mother




Fig. 2. Graphic representation of family studies.

Table 1. Pyruvate kinase activity of erythrocytes and leucocytes of the patient and his family members

Subject	Enzyme Activity ( $\mu$ moles of substrate utilized, $\text{min}^{-1}$ $10^6$ cells)	
	Erythrocytes	Leucocytes
Normal range	2.0-3.4	944-1436
Patient (3 determinations)	0.76	1743
Father	1.83	1118
Mother	1.48	1118
Sister	2.83	1444
Half-brother	1.03	1303
Maternal Grandfather	2.24	1431
Maternal Grandmother	1.30	1444
Paternal Grandmother	1.09	1473
Paternal aunt	0.77	1293
Paternal first cousin	1.94	1123
Paternal great aunt	3.17	
Paternal first cousin	2.46	

Data previously published. Erythrocyte pyruvate kinase activities below 1.73 units are characteristic of heterozygous enzyme deficiency.

### Family Studies

The results of family studies are summarized graphically in figure 2. Parents The father was of Italian ancestry. Physical examination revealed splenomegaly. Anemia was present with a hemoglobin concentration of 10.6 g/100 ml and the volume of packed cells was 37%. Red cell count was relatively increased to 5.69 million/ $\text{mm}^3$ . The mean corpuscular volume was 65  $\mu\text{m}^3$ , the mean corpuscular hemoglobin was 18.6 pg and the mean corpuscular hemoglobin

Table II. Autohemolysis studies of the red blood cells of the patient and his family members

Additive final concentration (M)	None	Glucose	Adenosine	Adenosine triphosphate
	—	0.26	0.02	0.02
Normal mean % autohemolysis	1.7	0.2	0.2	0.2
Patient	10.6	0.8	0.1	0.2
Father	2.4	0.4	0.6	0.6
Mother	1.0	0.0	0.0	0.6
Sister	1.2	0.1	0.1	0.5
Half-brother	0.7	0.1	0.1	0.8

city were noted and linearized on Lineweaver-Burk plot with the Michaelis-Menten constant calculated from the point of intersection with the abscissa ( $1/K_m$ ). No difference was noted in the  $K_m$  value for the patient's erythrocytes and leukocytes as compared with the normal controls.

### Other Studies

**Autohemolysis** (table II) There was marked autohemolysis of the patient's erythrocytes with almost complete correction by glucose, adenosine and adenosine triphosphate. These findings are in contrast to those usually noted in pyruvate kinase deficiency hemolytic anemia in which marked autohemolysis is not corrected by glucose or adenosine, but only by adenosine triphosphate. The pattern of autohemolysis observed in this patient is similar to that observed in hereditary spherocytosis, but the lack of characteristic findings in either parent, the absence of prominent spherocytes, and the osmotic fragility studies all rule strongly against this entity as a diagnostic consideration. The pattern of autohemolysis in diverse hemolytic states is of interest, however. It seems quite clear that characteristic differences can be correlated with the various sites of metabolic impairment when they are known. Thus, chronic hemolytic anemia with hexokinase deficiency [15] and usually with glucose-6-phosphate dehydrogenase deficiency are associated with a very slight increase in autohemolysis which is partially corrected by glucose. Classic pyruvate kinase deficiency hemolytic anemia is characterized by marked autohemolysis usually uncorrected by glucose, and triosephosphate isomerase hemolytic anemia [14] by marked autohemolysis with complete correction by glucose. The finding of a deviant pattern of autohemolysis in our patient thus




Fig 3. Erythrocyte osmotic fragility of the patient and his mother

Normal control	fresh defibrinated blood	●—●
	24 h incubation	●— — —●
Patient:	fresh defibrinated blood	—x—
	24 h incubation	—
Patient's mother:	fresh defibrinated blood	○—○
	24 h incubation	○— — —○

suggests a variation in the mechanism of impairment of erythrocyte viability. The nature of these altered mechanisms remains obscure. Slight autohemolysis was noted in the erythrocytes of the father and paternal aunt and was correctible by additives of glucose, adenosine and adenosine triphosphate. Autohemolysis was within normal limits in all other family members studied.

*Erythrocyte osmotic fragility* (fig 3 and 4) Osmotic fragility was quantitated on erythrocytes from the patient and his immediate family members, as well as on red cells from several of the paternal relatives. There was a clear increase in resistance to osmotic lysis in red cells from the father and from other family members with thalassemia. A marked further increase in osmotic resistance was noted after sterile incubation (fig 4). We have observed similar alterations on several occasions with erythrocytes from patients with  $\beta$  thalassemia minor. Erythrocytes from the mother (fig 3) and the patient's siblings failed to reveal any abnormalities in




Fig 4 Erythrocyte osmotic fragility of family members with thalassemia (the father, paternal grandmother and paternal great aunt).

Normal control:	fresh defibrinated blood	●-----●
	24 h incubation	●-----●
Father	fresh defibrinated blood	○-----○
	24 h incubation	○-----○
Paternal grandmother	fresh defibrinated blood	○-----○
	24 h incubation	○-----○
Paternal great aunt	fresh defibrinated blood	x-----x
	24 h incubation	x-----x

osmotic fragility when studies were performed on fresh defibrinated blood. After sterile incubation, however, a slight tail of osmotically resistant red cells appeared in the curves obtained from each of these individuals. A more marked degree of flattening of the curve was noted in studies of incubated erythrocytes from the patient with findings somewhat intermediate between those of the parents.

### Discussion

The data demonstrated the presence of both heterozygous pyruvate kinase deficiency and thalassemia in the kindreds studied. The patient's mother and her family members exhibited heterozygous pyruvate kinase deficiency only, the father and several of his family members were shown to have both heterozygous pyruvate kinase deficiency and heterozygous beta thalassemia.

Heterozygous pyruvate kinase deficiency has uniformly been found in both parents in all cases of homozygous pyruvate kinase deficiency hemolytic anemia when the parents were available for study. Thus the presence of heterozygous enzyme deficiency in both parents suggests that our patient may be affected by the homozygous form of the enzyme deficiency. In our laboratory, however, erythrocyte pyruvate kinase activity has generally been much lower in patients homozygous for the enzyme deficiency. Activity has varied in our experience from 0.00–0.83 units, but the higher values have been observed only in subjects in whom recently transfused normal erythrocytes were present. Enzyme activity in heterozygous family members has varied from 0.63–1.73 units [25]. It is thus apparent that our patient with an erythrocyte enzyme activity averaging 0.76 units falls into an indeterminate range consistent with either the heterozygous or homozygous form of the deficiency state. It should be emphasized that there is no quantitative relationship between the degree of enzyme deficiency and the severity of the clinical findings in patients with homozygous pyruvate kinase deficiency. The principal clinical application of enzyme activity quantitation is to establish the genetic status of the individual. In our patient it was not possible to clearly resolve the question of heterozygosity or homozygosity by this criterion.

In previously observed instances of indeterminate enzyme levels, both clinical and genealogic characteristics have generally permitted conclusions regarding the patient's genetic status. Since apparently only persons with the homozygous form of pyruvate kinase deficiency exhibit signs of impairment of erythrocyte viability, the history of hemolytic anemia prior to splenectomy is itself suggestive of the homozygous state. It should be emphasized, however, that patients with typical homozygous deficiency generally exhibit only minor improvement after splenectomy. Bowman's patients [5] are a conspicuous exception, and some others have exhibited modest improvement.

One of the most striking features of this case was the prominence of erythrocyte shape changes, especially the many acanthocyte-like forms. Somewhat similar changes have been observed in some cases of liver disease, uremia and various malignant tumors. In addition, acanthocytes are uniformly found in congenital beta-lipoprotein deficiency. There were no findings consistent with any of these conditions in our patient. Variable numbers of irregularly contracted



red cells have been noted previously in pyruvate kinase deficiency hemolytic anemia but, except for one case with a very severe hemolytic anemia [11] these have never been as striking as in this patient. It appears unlikely that the observed morphologic changes simply represent an exaggeration of those commonly seen.

In a recent case reported by Hsu, ROBINSON and ZUELZER [26] a family was found in which certain members exhibited very low pyruvate kinase activity but only extremely mild hematological abnormalities. This was thought to result from double heterozygosity from two interacting genes associated with pyruvate kinase deficiency. However no substantial erythrocyte morphological abnormalities similar to those in our case were described. The existence of a variant of pyruvate kinase is, of course, a possibility that cannot be ruled out.

The paternal kindred exhibited evidence of heterozygous thalassemia in addition to heterozygous pyruvate kinase deficiency. In addition to anemia, microcytosis, poikilocytosis and relative erythrocytosis, elevation of  $A_2$  hemoglobin was observed in affected family members, consistent with beta-thalassemia.

It would be attractive to hypothesize that the unusual hematologic syndrome manifested by this case is the result of combined inheritance of both pyruvate kinase deficiency and beta thalassemia. While it has been established clearly that the heterozygous form of both of these disorders is present in the patient's kindred, it has not been possible to define inheritance of beta thalassemia in the patient himself. Just as there is some uncertainty as to the patient's genetic status with regard to pyruvate kinase deficiency there is no direct evidence that he has inherited the thalassemic trait despite its presence in the paternal kindreds. The patient had no elevation of  $A_2$  hemoglobin, even though such elevations were uniformly noted in paternal family members with thalassemia, and there was no microcytosis or relative erythrocytosis. Also, it is somewhat difficult to conceptualize the mechanisms of interaction between a trait affecting hemoglobin synthesis and another concerned with energy metabolism.

### *Acknowledgments*

The authors wish to thank Dr. RICHARD W. OFFELL for referring the patient to us for study. Dr. NORMAN SMOKE and Dr. WILLIAM R. BERGERON for obtaining the hemoglobin  $A_2$

and fetal hemoglobin determinations, and Dr ROBERT C. NEERHOFF for doing the red cell stromal lipid analysis.

The technologic assistance of Mrs. P. GABOR, Mr. A. KUNSCHEIDT, Miss M. L. WEAVER, and Mrs. E. WITTENBERG is gratefully acknowledged.

### Summary

An unusual hemolytic syndrome with pyruvate kinase deficiency was observed in patient of partial Italian ancestry. Erythrocyte shape changes were prominent both before and after splenectomy with substantial improvement following the latter. Auto-hemolysis was corrected by glucose and adenosine findings dissimilar from those commonly observed in pyruvate kinase deficiency hemolytic anemia. Heterozygous pyruvate kinase activity was clearly demonstrated in the mother and father as well as in certain relatives on both sides of the family. In addition, beta-thalassemia was found in the father and certain paternal family members. The possibility of joint inheritance of heterozygous pyruvate kinase deficiency and beta-thalassemia was considered, but it was not possible to demonstrate this with any certainty in the affected propositus.

### References

1. VALENTINI, W. V.; TANAKA, K. R. and MIWA, S. A specific erythrocyte glycolytic enzyme defect (pyruvate kinase) in three subjects with congenital non-spherocytic hemolytic anemia. *Trans. Am. Amer. Physicians* 74: 100 (1961).
2. TANAKA, K. R.; VALENTINI, W. V. and MIWA, S. Pyruvate Kinase (PK) deficiency hereditary nonspherocytic hemolytic anemia. *Blood* 19: 267 (1962).
3. GENCIS, A. J.; MINKLER, A. and DACE, J. V. Hereditary non-spherocytic hemolytic anemia. A study of red-cell carbohydrate metabolism in twelve cases of pyruvate-kinase deficiency. *Brit. J. Haemat.* 10: 403 (1964).
4. OMEL, F. A. and DRAMOV, L. K. Erythrocyte pyruvate kinase deficiency. Report of three cases. *New Engl. J. Med.* 269: 763 (1963).
5. BOWMAN, H. S. and PROCOPIO, F. Hereditary non-spherocytic hemolytic anemia of pyruvate kinase deficient type. *Ann. Intern. Med.* 59: 67 (1963).
6. BOWDLES, A. J. and FRANKEL, T. A. J. Studies in congenital non-spherocytic hemolytic anemias with specific enzyme defects. *Acta haemat., Basel* 57: 63 (1964).
7. BERNOTTI, P.; FLUXEDOU, A.; NEMES, G. and MANSOURIS, Z. Congenital non-spherocytic haemolytic anaemia due to pyruvate-kinase deficiency. *Acta haemat., Basel* 30: 68 (1963).
8. LÖNN, G. W. und WALLER, H. D. Zur Biochemie einiger angeborener hämolytischer Anämien. *Folia Haemat.* 2: 377 (1963).
9. LODGE, P. B. and McGROVER, G. C. Red-cell enzymes and co-enzymes in non-spherocytic congenital hemolytic anemias. *Brit. J. Haemat.* 11: 21 (1963).
10. MIWA, S. and NAGATA, M. Pyruvate kinase deficiency hemolytic anemia. Report of 2 cases in Japanese family and review of literature. *Acta Haemat., Jap.* 36: 1 (1963).
11. OMEL, F. A.; NATHAN, D. G.; SIEDEL, V. W. and DRAMOV, L. K. Extreme hemolysis and red-cell distortion in erythrocyte pyruvate kinase deficiency. I. Morphology, erythrokinetics and family enzyme studies. *New Engl. J. Med.* 270: 229 (1963).
12. DACE, J. V. and LEWIS, S. M. Osmotic fragility. *Practical Haematology* Third Edition, pp. 135-140 (Grune & Stratton, New York 1963).
13. KOUTERAS, G. A.; HATTORI, M.; SCHNEIDER, A. S.; EADON, F. G. J. and VALKYMIS, W. V. Studies on chromated erythrocytes: effect of sodium chromate on erythrocyte glutathione reductase. *J. clin. Invest.* 43: 323 (1964).

14. SCHNEIDER, A. S., VALENTINI, W. N., HAYTON, M. and HARR, H. L., J.: Hereditary hemolytic anemia with triosephosphate isomerase deficiency. *New Engl. J. Med.* 272: 229 (1965).
15. VALENTINI, W. N.; OKEI, F. A., PAGLIA, D. E., BACONAR, M. A.; SCHNEIDER, A. S. and NADMAN, J. L.: Hereditary hemolytic anemia with hexokinase deficiency. *New Engl. J. Med.* 272: 1 (1967).
16. BEUTLER, E.: The glutathione instability of drug sensitive red cells. A new method for the *in vitro* detection of drug sensitivity. *J. lab. clin. Med.* 61: 882 (1963).
17. BEUTLER, E., DUNSON, O. and KELLY, B. M.: Improved method for the determination of blood glutathione. *J. lab. clin. Med.* 61: 882 (1963).
18. BEUTLER, E., DEAN, R. J. and ALVINO, A. S.: The hemolytic effect of primaquine. VI. An *in vitro* test for sensitivity of erythrocytes to primaquine. *J. lab. clin. Med.* 45: 40 (1955).
19. SERRAVALLO, O.: An improved procedure for starch-gel electrophoresis. Further variations in the serum proteins of normal individuals. *Biochem. J.* 71: 585 (1959).
20. GANDHACK, D. B.; HENDERSON, K. R., SMOOTHER, E. M. and GERRARD, P. S.: Identification of the abnormal polypeptide of haemoglobin Gaa. *J. molec. Biol.* 2: 573 (1960).
21. WRIGHT, K. and BERKE, D.: Use of tris buffer in the optical enzymatic determinations of L (+) lactic acid. *Fed. Proc.* 21: 85 (1962).
22. SEWELL, K.; CARRISBOY, A. I. and SEWELL, L.: Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* 6: 413 (1951).
23. MIALLE, J. B.: *SERENUS test, Laboratory Medicine-Hematology* Second edition, pp. 816-817 (Mosby St. Louis 1962).
24. MIWA, S., TAKAKA, K. R. and VALENTINI, W. N.: Erythrocytic and leukocyte glycolytic enzyme studies in hematologic and non-hematologic diseases. *Acta Haemat., Jap.* 25: 12 (1962).
25. TAKAKA, K. R., VALENTINI, W. N. and SCHNEIDER, A. S.: Pyruvate kinase deficiency in hereditary non-spherocytic hemolytic anemia: an inborn error of metabolism. 9th Congr. Europ. Soc. Haemat., Lisbon, pp. 739-744 (Karger Basel/New York 1964).
26. Hsu, T. H. J.; ROBINSON, A. R. and ZOLLNER, W. W.: Genetic polymorphism of hemolytic anemias associated with erythrocyte pyruvic kinase deficiency. *American Society Hematology 9th Annual Meeting, Abstracts*, p. 23, Dec. 1966.

Authors' addresses: MARJORIE A. BACONAR, M.D. Assistant Professor of Medicine UCLA Center for the Health Sciences, Los Angeles, Cal., DONALD E. PAGLIA, M.D. Postgraduate Research Hematologist, UCLA Center for the Health Sciences, Los Angeles, Cal.; ARTHUR S. SCHNEIDER, M.D. Chief, Clinical Laboratory Section, Wadsworth Hospital, Veterans Administration Center Los Angeles, Cal., and Assistant Professor of Medicine and Pathology UCLA Center for the Health Sciences, Los Angeles, Cal., WILLIAM N. VALENTINI, M.D., Professor and Chairman, Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, Cal. (USA)

Roswell Park Memorial Institute and State University of New York at Buffalo, Buffalo,  
N.Y.

## Extra Renal Production of Erythropoietin in Man

E. A. MIRAND, G. P. MURPHY, R. A. STEEVER, H. W. WEBER and  
F. P. RETTER

### *Introduction*

Erythropoietin (ESF) is a hormone active in the regulation of erythropoiesis and is activated or produced in response to hypoxia [3-9]. Although the kidney has been postulated as the sole source of the production of this hormone [5], work by others has confirmed that there is experimental evidence for an extra-renal source [1, 2, 7, 8, 9, 13]. This report confirms for the first time the presence of ESF release in an anephric human prior to renal homotransplantation.

### *Clinical History*

The patient, a 10-year-old male, J. v. W., was admitted to the Karl Bremer Hospital in a terminal uremic state with glomerulonephritis in a solitary left kidney. Following initial peritoneal dialysis, abdominal exploration and left nephrectomy were undertaken. A thorough examination of the abdomen and pelvis confirmed the complete absence of the right kidney as was suggested by roentgenography and cystoscopic examinations. Hemodialysis was continued on a bi weekly schedule. A human cadaver renal homotransplant was performed after 66 days of the renoprival state. The kidney obtained from a patient also used as a human heart transplant donor was severely ischemic although some recovery was evident after the 13th postoperative day.

### Methods

*Erythropoietin assay* Plasmas from the patient were collected and frozen. All specimens were assayed at the same time in adult Hs/ICR Swiss mice rendered polycythemic [6, 10]. Four to seven mice were used to determine the ESF activity for each plasma sample. Each test mouse received subcutaneous injections of 0.5 ml of plasma daily for 3 successive days. On the 4th day they were injected intravenously with 1  $\mu$ g of  $^{59}\text{Fe}$  in 0.5 ml saline. Twenty-four hours later they were bled from the dorsal aorta, and the radio-activity of the blood sample was measured in a well-type scintillation counter. The percentage incorporation of radio-active iron into the circulating red cells was then calculated [11]. Assays from mice with hematocrit levels of less than 60% at the end of the experiment were discarded.

### Results

*Erythropoietin levels* Serial alterations in erythropoietin (ESF) are shown in tables I and II. Plasma ESF levels obtained on the patient while in an anephric state for 66 days are higher than the range observed for the 24 hour  $^{59}\text{Fe}$  uptake in control uninoculated polycythemic mice (2.6%) (table I). During the renoprival state the ESF levels in the patient ranged from 6.9 to 25.2%. It is interesting that the highest ESF level was obtained while the patient was anephric and that during this time the lowest hemoglobin level was recorded. Moreover the patient went over 25 days without blood transfusion during which time the highest level of ESF was reported (table I).

Table II shows ESF levels in the patient at various days post homotransplantation. Consistent high levels of ESF were observed during this period.

No correlation was noted between the level of azotemia and the degree of ESF response in the renoprival state as is usually seen in patients with kidneys in a state of acute or chronic dysfunction (tables I and II).

*Hematological observations* The patient maintained a normochromic microcytic anemia with minimal schistocytes, occasional burr cells, but normal platelet counts. Repeated transfusions were necessary to correct a rapidly falling hemoglobin, at least partially due to hemolysis of infection and glomerulonephritis. Before nephrectomy the reticulocyte counts varied between 1.5 and 9.1%, and after nephrectomy they ranged from 0.3 to 2.5%. It was difficult to assess bone marrow potential in the clinically complicated anephric state, but bone marrow aspirate obtained shortly after renal transplantation was normocellular with a M:E ratio of 3:1 and no other gross abnormalities were observed.



transplants, we noted release of ESF in response to acute ischemic and cellular destruction [12]. Such may therefore, be the case in this patient.

Although it appears that an extra renal site, or sites, of ESF production does exist, this may be brought into play only after an animal or man has been nephrectomized. This might be analogous to the increased production of sex steroids by the adrenals of castrated animals and to the compensatory hypertrophy of the reticulo-endothelial system that follows splenectomy. Where the extra-renal site or sites for ESF production might be is unknown at this time, but perhaps the liver is one site. Despite our lack of knowledge of the site or sites, one can conclude that extra-renal production of ESF does occur in man as well as in other animals.

### *Acknowledgement*

These studies were supported in part by the US Public Health Service (CA-06847 and CA-07745) the John A. Hartford Foundation, Inc., the University of Stellenbosch, the Cape Provincial Administration, the Council for Scientific and Industrial Research, and the Brady Urological Institute of The Johns Hopkins Hospital.

The assistance of ANDRÉS BELLA, EDWARD DYWIDETZ, JOYCE JYRIDEK, ALBERT MIRAND, Dr. PAUL TRIDDEL and Mrs. WILMA TRIDDEL is greatly appreciated.

### *Summary*

Erythropoietin (ESF) is a hormone active in the regulation of red blood cell formation. It has been commonly thought to originate only in the kidney and was believed to be activated or produced in the kidney in response to hypoxia. The human renal homo-transplant patient described herein demonstrated that ESF activity occurs in the renoperivascular state. This observation in human confirms previous experimental evidence that extra-renal source of ESF does exist. Where this extra-renal source is located has not been determined either in animals or in man.

### *References*

1. BACIG, L.; OYRINI, C.; DOROWITZ, M.; ROSENFIELD, E.; RUBIN, M. et CARRASQUINO, C. Le rein et la production de l'erythropoietine. *J Physiol* 33: 55 (1963).
2. GALLAGHER, M. L.; MCCARTHY, J. J. and LAWSON, R. D. Erythropoietin production in uremic rabbits. *J lab. clin. Med.* 57: 281 (1961).
3. GORDON, A. S. Hemopoietine. *Physiol. Rev.* 1: 39 (1939).
4. GORDON, A. S., COOPER, G. W. and ZANJANI, E. D. The kidney and erythropoiesis. *Sci. Hemat.* 4: 337 (1967).
5. JACOBSON, L. O., GOLDWASSER, E.; FRIED, W. and FLEAS, L. Role of the kidney in erythropoiesis. *Nature, Lond.* 173: 633 (1957).
6. LAWSON, R. D., SIMMONS, M. L. and DIBLASSO, N. R. Polycythemic mice produced by hypoxia in silicone rubber membrane enclosures. A new technique. *Proc. Soc. exp. Biol., N. Y.* 122: 761 (1966).
7. MIRAND, E. A. and FRIEDTGER, T. C. Presence of plasma erythropoietin in hypoxic

- rats with or without kidney( ) and/or spleen. *Proc. Soc. exp. Biol., N.Y.* 9: 49 (1957).
8. MIRANO, E. A.; PRENTICE, T. C. and SACHSWEITZ, W. T.: Current studies on the role of erythropoietin on erythropoiesis. *Ann. N.Y. Acad. Sci.* 77: 677 (1959).
  9. MIRANO, E. A.: Studies on erythropoietin in tamarins. *Invest. Urol.* 2: 579 (1965).
  10. MIRANO, E. A.; GORDON, A. S. and WISMA, J.: Mechanism of testosterone action in erythropoiesis. *Nature Lond.* 195: 270 (1965).
  11. MIRANO, E. A.; WENTRATH, H. H.; GORDON, A. S.; PRENTICE, T. C. and GRACE, J. T. Jr.: Erythropoietic activity of untreated and deproteinized normal human plasma. *Proc. Soc. exp. Biol., N.Y.* 118: 823 (1965).
  12. MIRANO, E. A.; JONCHTOW, O. S.; HICHER, H. J. and MCKENRY G. P.: Renal transplantation in the rhesus monkey V Alterations in erythropoietin activity. *Invest. Urol.* 2: 574 (1965).
  13. PULIZO S. J.; MENDICI, P. T. and GORDON, A. S.: Production of the circulating erythropoietic factor in hypoxic endocrine-deficient rats. *Proc. 7th Congr. Int. Soc. Haemat.*, Vol. 2, p. 1 (Karger Basel/New York 1958).
  14. WENTERMAN, M.; JARVIS, J. L.; DUBNER, A.; KRECHMER, J. A. and FINKEL, B.: Significance of erythrocytosis and increased erythropoietin secretion after renal transplantation. *Lancet* ii: 755 (1967).

Authors' addresses: Prof. E. A. MIRANO and Dr. R. A. STEVENS, Rowell Park Memorial Institute, State University of New York at Buffalo, Buffalo, N. Y. 14203. Dr. G. P. MCKENRY, Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Md. 21205 (USA). Drs. H. W. WISMA and F. P. RUTHER, University of Stellenbosch, Faculty of Medicine, The Karl Bremer Hospital, Bellville, Cape Province (South Africa).






Abb. 1. Veränderung der Retikulozytenzahl im Schwanzvenenblut nach Testosteron-Injektion allein oder nach Testosteron-Injektion und hypoxischer Stimulation.

festgestellt. Bei allen Versuchstieren war die erythropoetische Reaktion höher als die Summe der Reaktionen, die jeder der Reize einzeln ergeben hatte. Die stärkste Reaktion wurde bei den Ratten beobachtet, die Testosteron 72 li vor der Hypoxie bekommen hatten, während die geringste Wirkung bei den Ratten auftrat, auf die beide Reize simultan einwirkten.

### Diskussion

Es wurde festgestellt, dass die erythropoetische Reaktion auf kombinierte Reizung durch Testosteron und Hypoxie bei plethorischen Ratten, ausgedrückt durch den Anstieg der Retikulozytenzahl, die Summe der Einzelwirkungen beider Reize beträchtlich übertraf, ausgenommen die Ratten, die weniger als 0,5 mg Testosteron bekommen hatten. Dieses Ergebnis könnte als Beweis dafür interpretiert werden, dass Kombination von Hypoxie und Testosteron die Erythropoese verstärkt.

Es ist dabei von Interesse, dass diese synergistische Wirkung am deutlichsten dann erzielt wurde, wenn die Hypoxie 3 Tage nach der Testosteron Injektion einsetzte, während sie am wenigsten evident




Abb. 2. Veränderung der Reticulocytenzahl bei Ratten der Gruppen IV VI VII nach Testosteron-Injektion und hydriischer Stimulation.

war bei den Ratten, die beide Reize gleichzeitig empfangen hatten. Der Anstieg der Reticulocytenzahl 48 h nach einer Einzeldosis von 50 mg langwirkendem Testosteron war klar erkennbar und erreichte sein Maximum nach 96 h. Von da an blieb die Reticulocytenzahl während der restlichen Versuchsdauer erhöht. Diese Ergebnisse zeigen, dass das Testosteron ziemlich schnell vom Injektionsort aus freigesetzt wird und seine stimulierende Wirkung auf die Erythropoese während der ganzen Beobachtungszeit behält. Es ist bekannt, dass Testosteron die Erythropoese bei verschiedenen Versuchstieren verstärkt, indem es die Bildung von Erythropoetin anregt [1-4].

Tabelle I Retikuloxytreaktion auf Hypophyse, Testosteron oder beide

Versuchsgruppe	Zahl der untersuchten Tier	Behandlung	Testosteron-Dosis, mg	Tage zwischen Testosteron-Inj. und hypost. Strikal.	Maximale Retikuloxytreaktbl. % <sup>1</sup>	P
V	5	Sennol	0		0,20 ± 0,08	-
V	5	Testosteron	0,5		0,32 ± 0,08	-
VI	5	Testosteron	1,0		0,49 ± 0,06	< 0,01
VII	5	Testosteron	5,0		0,79 ± 0,15	< 0,001
VIII	5	Testosteron	5,0		0,79 ± 0,08	< 0,001
IX	5	Sennol + Hypophyse	0	3	1,32 ± 0,56	
I	5	Testosteron + Hypophyse	0,5	3	1,98 ± 0,28	n. s.
II	5	Testosteron + Hypophyse	1,0	3	3,25 ± 0,34	< 0,001
III	5	Testosteron + Hypophyse	5,0	3	4,80 ± 0,91	< 0,001
IV	5	Testosteron + Hypophyse	5,0	3	4,70 ± 0,70	< 0,001
VI	5	Testosteron + Hypophyse	5,0	0	2,20 ± 0,49	-
XII	5	Testosteron + Hypophyse	5,0	7	3,40 ± 0,48	< 0,01
XIII	5	Testosteron + Hypophyse	5,0	10	3,98 ± 0,42	< 0,001
XIV	5	Testosteron + Hypophyse	5,0	14	3,06 ± 0,45	< 0,05

Mittelwert Statistische Signifikanz zur Sennol-Kontrollgruppe, zur Sennol- und Hypophyse-Kontrollgruppe oder zur Testosteron- und Hypophyse-Kontrollgruppe

n. s. nicht signifikant

+ mit bzw. Standardabweichung des Mittelwertes

Die synergistische Wirkung von Testosteron und Hypoxie auf die Erythropoese ist an Mäusen schon von GURNEY und FRIED [3] nachgewiesen worden. Diese Autoren haben ausserdem berichtet, dass der synergistische Effekt zweier kleiner aufeinanderfolgender Dosen von Erythropoetin grösser ist als dies von den Einzeldosen zu erwarten wäre. Es könnte sich hier um einen synergistischen Effekt von Testosteron und Hypoxie auf die Blutbildung handeln. Die Autoren haben jedoch an anderer Stelle [4] darauf hingewiesen, dass männliche Mäuse aufgrund ihrer höheren Produktion an endogenem Testosteron nach hypoxischer Stimulierung mehr Erythropoetin bilden. Sie folgerten daraus, dass Testosteron Veränderung an den Nieren bewirken müsse, wodurch diese während der Dauer der Hypoxie mehr Erythropoetin als unter normalen Bedingungen ausscheiden. Es ist jedoch möglich, dass die Reaktion des Knochenmarkes auf die Hypoxie durch Testosteron verändert wird. Der Synergismus könnte durch eine komplexe Wechselwirkung von Testosteron und Hypoxie bedingt sein. Es bedarf weiterer Untersuchungen, um den dabei wirksamen Mechanismus aufzufinden.

Der Autor ist Herrn Doz. Dr. H. ALUFF und Herrn Dr. R. ENGELHORN sehr verpflichtet und dankt für die Erlaubnis zu dieser Arbeit, ebenso Herrn E. WALLER für seine erfahrene technische Assistenten.

### *Zusammenfassung*

Der synergistische Einfluss von Testosteron und Hypoxie auf die Erythropoese wurde an plethorischen Ratten bestätigt. Ein maximaler Anstieg der Reticulocyten im peripheren Blut als Folge der Hypoxie wurde bei Ratten beobachtet, denen 72 Stunden zuvor Testosteron injiziert worden war. Dabei war die Reticulocytenreaktion proportional der Menge von Testosteron.

### *Summary*

A synergistic effect of testosterone and hypoxia on erythropoiesis was confirmed in plethoric rats. A maximal increase of reticulocytes in peripheral blood following hypoxia was observed in the rats injected with testosterone 72 h previously. In this case, the reticulocyte response was proportional to the amount of testosterone injected.

### *Literatur*

1. MILARD, E. A., GORDON, A. S. and WYGO, J. Mechanism of testosterone action in erythropoiesis. *Nature, Lond.* 206: 270-272 (1965).
2. FRIED, W. and GURNEY, C. W. Mechanism of the erythropoietic effect of testosterone. *Nature, Lond.* 206: 1160-1161 (1965).
3. GURNEY, C. W. and FRIED, W. Further studies on the erythropoietic effect of androgens. *J. Lab. clin. Med.* 63: 775-782 (1963).

4. FALLO W and GURNEY C. W : The erythropoietic response to testosterone in male and female mice. *J. Lab. clin. Med.* **67** 420-426 (1966).
5. SHIRAKURA, T, AZUMA, M and MAKIYAMA, T : Studies on erythropoietic action of testosterone. *Arch. haemat., Basel* **38** 49-56 (1967)

Adresse des Autors: Dr TARUO SHIRAKURA, Medizinische Klinik der Universität Gießen, Stohrs-machi 3, *Masabuchi* (Japan)

Department of Medicine Harvard Medical School and Medical Services,  
Gastrointestinal Unit, Massachusetts General Hospital, Boston, Mass.

## Blastoid Transformation of Rabbit Peripheral Lymphocytes by Phytohemagglutinin Using a Microculture Technique

S. M. SABERIN

The potentiality of the mammalian small lymphocyte for growth and differentiation has been the object of considerable recent investigation [1]. Studies with human peripheral lymphocytes have now repeatedly demonstrated that such cells may be transformed into cytologically immature blastoid cells capable of RNA and DNA synthesis and mitotic division when grown in suspension culture with phytohemagglutinin [2, 3, 4]. Recent reports [5, 6, 7, 8] indicate that other agents, presumably acting as antigens, can also induce blastoid transformation in peripheral lymphocytes provided the cells have been obtained from specifically immunized donors.

The phenomenon of blastoid transformation thus provides a unique opportunity for investigating those factors which control the growth and differentiation of small lymphocytes and for studying the role of these cells in immune phenomena. Furthermore the recent observation [9, 10] that peripheral lymphocytes from mammalian species, other than man, may also be transformed into blastoid cells by PHA affords a means of designing experimental animal models for the study of lymphocyte differentiation.

Studies of blastogenesis in man and other species has usually involved the separation of lymphocytes from relatively large volumes of peripheral blood (30-100 ml). Whereas such quantities can easily be obtained from human subjects this requirement places a severe limitation on experiments involving small animals. Thus in our experience [9] sufficient blood for certain studies in the guinea pig could only be obtained by exsanguination thereby obviating the possibility of repeated cultures from the same donor.

Attempts to utilize small quantities of blood for cytogenetic analysis were reported by EDWARDS and YOUNG [11] EDWARDS [12] and FROLAND [13]. In these studies adequate mitotic activity for cytogenetic analysis was obtained with as little as 0.1 ml of blood; however, the methods described involved the separation of leukocytes from whole blood by phytohemagglutinin (PHA) or dextran sedimentation of erythrocytes prior to the start of culture. The separatory procedures are time consuming but even more important do not allow for the complete use of the lymphoid population in the culture inocula since complete harvesting of the leukocytes cannot be obtained by erythrocyte sedimentation. Furthermore in certain mammalian species it is difficult, if not impossible, to obtain adequate erythrocyte sedimentation by ordinary methods.

In 1963 ARAKAKI and SPARKS [14] described a technique for culturing leukocytes from heparinized whole blood using minute samples of blood (0.05–0.1 ml). This method yielded satisfactory metaphase figures for complete chromosome analysis and there was no apparent modification of chromosome morphology due to the presence of whole blood elements throughout the period of culture.

In the present study lymphocyte blastogenesis, induced by PHA, was studied in microcultures of whole blood using a technique similar to that described by ARAKAKI and SPARKS [14]. The efficacy of the method was evaluated by comparing blastoid transformation, and the kinetics of RNA and DNA synthesis in the microcultures with that obtained in lymphocyte cultures prepared from large volumes of blood by the usual techniques [15].

### *Materials and Methods*

In these experiments lymphocytes were cultured by the micro and standard techniques from the same sample of blood. For this reason large volumes (30 ml) of blood was drawn into heparinized collecting syringe by cardiac puncture of New Zealand white rabbits. The microcultures were seeded by dispensing three drops of heparinized blood, directly from the collecting syringe into 16 × 125 mm screw-topped culture tubes previously prepared with 4 ml of complete culture media. The complete media was composed of Eagle's minimal essential medium, modified for suspension culture, supplemented with 20% fetal calf serum and 1% L-glutamine 200 mM. Phytohemagglutinin (0.1 ml) Type M, Difco Labs, Detroit, Mich., was immediately added to each tube which were then tightly sealed and incubated vertically without agitation at 37°C. Alternatively the tops were loosely capped and the cultures incubated in humidified atmosphere of 5% carbon dioxide in air at 37°C. In this manner multiple replicates could be easily and very rapidly cultured from small volume of blood.

For the routine cultures 30 ml of heparinized blood was transferred to 45 ml centrifuge tube and incubated with one-half volume high molecular weight dextran

(250,000 m.w.) for about 20 min. at 37°C to insure adequate erythrocyte sedimentation. The supernatant leukocyte-rich plasma was separated, centrifuged at 800 rpm for 10 min, washed twice with minimal essential medium and diluted with complete medium to final concentration of  $7.5 \times 10^5$  lymphocytes/ml. Four ml aliquots were inoculated into 16 x 125 mm screw cap culture tubes, 0.1 ml PHA, Type M added and the tubes incubated without agitation at 37°C.

To study the sequential morphological changes induced by PHA, replicate micro and regular cultures were incubated for 2, 4, 18, 24, 48 and 72 h either with 0.1 ml PHA or in its absence. The cultures were harvested by gentle centrifugation (800 rpm for 10 min) and the pellets resuspended in 1% sodium citrate for 2 min. The cells were then fixed in mixture of bockite methanol and glacial acetic acid (3:1) for 10 min, centrifuged again and then finally suspended in small volume of fixative. Air dried slides were stained with 1.0% acetic-orcein and examined by phase contrast microscopy. The percent of cytologically transformed cells and small lymphocytes at each interval of culture was determined by averaging the differential counts of at least 1000 cells from each of two or more replicate cultures.

DNA and RNA synthesis were studied by autoradiography with  $^3\text{H}$ -thymidine and  $^3\text{H}$ -cytidine respectively. Duplicate cultures at each time interval were gently agitated and then incubated for 2 h at 37°C with either  $^3\text{H}$ -thymidine 6.7  $\mu\text{Ci}/\text{ml}$  or  $^3\text{H}$ -cytidine 2.68  $\mu\text{Ci}/\text{ml}$  (New England Nuclear Corp., Boston, Mass.) added to the culture tubes at final concentration of 1.25  $\mu\text{Ci}/\text{ml}$ .


The cells were then washed three times in phosphate buffered saline and fixed ten minutes with bockite methanol and glacial acetic acid (3:1). The slides were coated with Kodak NTB2 Nuclear Track Emulsion and stored for two weeks at 4°C. The autoradiographs were developed in D-72 Kodak developer and stained with Jenner Giemsa. The percent of labelled mononuclear cells in sample of 1000 cells on each slide was then determined.

### Results and Discussion


In Table I the percent blastoid cells and the percent of lymphocytes labelled with  $^3\text{H}$  thymidine in the micro and routine cultures are compared at intervals throughout the 72 h of incubation. At the beginning of culture the lymphoid cells in the inoculum of the microcultures were almost all typical small lymphocytes (fig 1) except for 0.4-1.5% larger cells which could be distinguished not only by size but also by their cytologically immature nuclei. Using phase contrast it was possible to distinguish extremely early blastoid transformation characterized by a change in appearance of the nuclear chromatin which assumed a delicate finely reticulated pattern in contrast to the dense clumped chromatin in the typical small lymphocyte.

Evidence of blastoid transformation was apparent in the phytohemagglutinin stimulated micro and routine cultures within the first 24 h of incubation. As early as the 18th hour of culture there was a definite increase in the percentage of blastoid cells which now comprised 7.2-18.0% of the lymphocytes compared with





1



2

*Fig. 1* Phase contrast micrograph of the cellular inoculum at the beginning of macroculture. This field is composed predominantly of typical small lymphocytes which can be distinguished easily from the occasional larger lymphocyte by their uniform small size, scant cytoplasm and deeply staining nuclear chromatin.

*Fig. 2* Phase contrast micrograph of lymphoid aggregate 18 h after the addition of phytohemagglutinin to the macrocultures. Even by this time evidence of blastoid transformation is apparent in many lymphocytes characterized by nuclear and cytoplasmic enlargement, prominent nucleoli and pale-staining delicately reticulated nuclear chromatin.

0.9-2.0% in the cultures grown without PHA. In addition to the increase in the percent of transformed cells the lymphocytes were beginning to aggregate into small clusters and it was in these lymphoid foci that the earliest conclusive evidence of transformation could be detected (fig. 2).

Autoradiography with  $^3\text{H}$  thymidine disclosed that blastoid transformation preceded active DNA synthesis. There was only a slight increase in the number of lymphocytes labelled with  $^3\text{H}$  thymidine at 24 h (1.5-2.0%) over that obtained in the first 4 h of culture (0.6-1.0%). In contrast RNA synthesis was active even in the small lymphocytes, throughout the entire duration of culture. Within the first few hours of incubation up to 91% of the cells were labelled with  $^3\text{H}$ -cytidine and when the cultures were terminated at 72 h between 92 and 98% were labelled.


The blastoid response proceeded vigorously after the first 24 h and by the end of the second day of incubation between 53 and 68% of the cells had been transformed into blastoid cells compared with 0.8-4.0% in the controls (table I).

Although there was a modest increase in the percentage of cells labelled with  $^3\text{H}$ -thymidine at 48 h DNA synthesis could not be considered a prerequisite for transformation since only 4 to 8% of

Table I Blastoid transformation and DNA synthesis in micro and routine cultures of rabbit peripheral lymphocytes

Hours of incubation	Percent blastoid cells		Percent cells labelled $^3\text{H}$ -thymidine	
	Microcultures	Routine	Microcultures	Routine
0	0.4- 1.5	0.5- 2.4	0.2- 0.8	0.2- 0.5
2	0.4- 1.8	0.5- 2.1	0.8- 1.0	0.2- 0.9
4	1.0- 2.1	2.1- 2.3	0.6- 1.0	0.4- 0.5
18	7.2-18.0	17.0-20.0	0.2- 2.0	0.5- 2.4
24	18.0-33.0	17.0-30.0	1.5- 2.0	1.5- 2.8
48	53.0-68.0	60.0-75.0	4.2- 8.0	5.0- 8.0
72	71.0-80.0	60.0-88.0	15.0-30.0	15.0-40.0

Effect of phytohemagglutinin (PHA) on rabbit peripheral lymphocytes in micro and routine cultures. The data represent the range of values obtained for blastoid transformation and  $^3\text{H}$ -thymidine incorporation at each interval of culture. Cultures for radioautography were incubated for 2 h with  $^3\text{H}$ -thymidine specific activity 57 c/mg at final concentration of 125  $\mu\text{Ci/ml}$ . Autoradiographs were exposed for 14 days with Kodak NTB2 Nuclear Track emulsion.



*Fig. 3. Phase contrast micrograph showing extensive blastoid transformation and mitosis in microculture 22 h after the addition of phytohemagglutinin.*

the cells had incorporated the label at this time. When the cultures were terminated at 72 h between 71 and 80% of the cells were blastoid and now autoradiography disclosed a substantial increase in DNA synthesis with 15 to 30% labelled cells after a 2 hour incubation with  $^3\text{H}$  thymidine. At 72 h control cultures contained 5.6–10.0% blastoid cells and of these 0.5–1.5% were labelled with  $^3\text{H}$  thymidine.

At 72 h the small lymphoid aggregates in which transformation was first noted, had enlarged and mitotic figures were evident (fig 3). The transformed cells showed considerable variation in size but were readily distinguished from the small lymphocytes by their prominent nucleoli and pale staining delicately reticulated nuclear chromatin.

The transformed cells in the microcultures were similar cytologically to the blastoid cells obtained in cultured peripheral lymphocytes grown at a concentration of  $7.5 \times 10^5$  lymphocytes/ml. Furthermore the sequential cytological alterations induced by PHA and the kinetics of RNA and DNA synthesis in the transforming cells were approximately equivalent with both methods of culture (table I). In each instance significant blastoid transformation was evident by 24 h and this cytological alteration was not dependent upon prior DNA synthesis.

These studies indicate the feasibility of utilizing extremely small quantities of heparinized whole blood for studying lymphocyte blastogenic transformation. Our comparison of the microculture technique with replicate cultures prepared from the same sample of blood by the conventional technique suggests that under these cultural conditions the sequential transformation of small lymphocytes into blastoid cells capable of RNA and DNA synthesis and mitotic division is not affected by the presence in the inoculum of polymorphonuclear leukocytes, erythrocytes or other blood elements. These results confirm the previously published report of ARAKAKI and SPARKS [14] who devised the method of microculture for use with heparinized whole blood obtained from mice.

The microculture technique affords an extremely rapid and simple means of culturing peripheral blood lymphocytes but should find its greatest potential usefulness in experimental situations in which repeated cultures from the same donor are required.

### *Acknowledgment*

This work was supported in part by grants from the National Institutes of Health (AM-03014 and AM-4501) and the Medical Foundation, Boston, Mass.

### *Summary*

A microculture technique is described for studying the blastoid transformation of peripheral blood lymphocytes utilizing 0.1 ml quantities of heparinized whole blood. This technique was compared with routine lymphocyte cultures using  $3 \times 10^6$  lymphocytes/tube obtained by partial purification of dextran-sedimented whole blood. Blastoid transformation, RNA and DNA synthesis were compared in the microcultures and in routine cultures seeded with lymphocytes obtained from the same blood specimens. The kinetics of RNA and DNA synthesis and the sequential cytological transformation of small lymphocytes by phytohemagglutinin was essentially the same in both methods of culture. Microcultures thus provide a simple and rapid technique for *in vitro* studies of lymphocyte growth and differentiation.

### *References*

1. ROBINSON, J. H. Tissue culture studies of the human lymphocyte. *Science* **145**, 1648 (1963).
2. MACKENZIE, A. A. J., STOKELMAN, F. J. and BRECHER, G. The kinetics of cell proliferation in cultures of human peripheral blood. *Blood* **29**, 349 (1967).
3. EVERTZ, L. B. and STOKELMAN, F. J. RNA synthesis in cultures of normal human peripheral blood. *Blood* **29**, 69 (1964).
4. McINTYRE, O. R. and ERADOM, F. G. The effect of phytohemagglutinin on leukocyte cultures as measured by  $p^{32}$  incorporation in the DNA, RNA, and acid soluble fractions. *Blood* **29**, 443 (1967).

5. PERMAN, G., LYCETTE, R. R. and FITZGERALD, P. H. Tuberculin-induced mitosis in peripheral blood leukocytes. *Lancet* *i*: 637 (1963).
6. MARSHALL, W. H. and ROBERTS, K. B. Tuberculin-induced mitosis in peripheral blood leukocytes. *Lancet* *i*: 773 (1963).
7. ELYER, M. W., ROATH, S. and ISRAELS, M. C. G. The response of lymphocytes to antigen challenge *in vitro*. *Lancet* *i*: 806 (1963).
8. HIRSCHMAN, K.; BACH, F., KOLONOV, R. L., FINKELDEY, I. L. and HANSEN, N.: Immune response and mitosis of human peripheral blood lymphocytes *in vitro*. *Science* *122*: 1165 (1963).
9. SARNEY, S. M. Blastoid transformation of rabbit and guinea pig peripheral lymphocytes by phytohemagglutinin. *Proc. Soc. exp. Biol., N.Y.* *122*: 351 (1966).
10. SELL, S. and GELL, P. G. H. Studies on rabbit lymphocytes *in vitro*. I. Stimulation of blast transformation with an antiallotype serum. *J. exp. Med.* *122*: 423 (1965).
11. EDWARDS, J. H. Chromosome analysis from capillary blood. *Cytogenetics* *1*: 90 (1962).
12. EDWARDS, J. H. and YOUNG, R. B. Chromosome analysis from small volumes of blood. *Lancet* *ii*: 48 (1961).
13. FRELAND, A. A micro-method for chromosome analysis of peripheral blood cultures. *Lancet* *ii*: 48 (1961).
14. ARAKAKI, D. T. and SPARKES, R. S. Microtechnique for culturing leukocytes from whole blood. *Cytogenetics* *2*: 37 (1963).
15. SARNEY, S. M. Lymphocytes of small mammals: Spontaneous transformation in culture to blastoids. *Science* *149*: 1385 (1965).

Author's address: Dr SETMOOR M. SARNEY, Department of Medicine, Massachusetts General Hospital, Boston, Mass. (USA).

**Strahlenchillen und Strahlenhämatalogie** Vorträge aus einem Fortbildungsgelgang der Deutschen Akademie für Ärztliche Fortbildung 1964 bearbeitet von A. MÖRZEL. Schriftenreihe der Ärztlichen Fortbildung, Band 31 herausgegeben von H. RADTZYK und H. T. MALL. VEB Verlag Volk und Gesundheit, Berlin 1965. 166 S., 70 Abb., 9 Tab. Preis DM 25.

Der Begriff der Strahlenhämatalogie umschreibt einerseits Entwicklungen ionisierender Strahlen auf die Blutzirkulation und -zellen, andererseits die Anwendung radioaktiver Isotope in der Hämatalogie für Diagnostik, Therapie und Forschung. Im vorliegenden Band finden sich Übersichtsreferat über diese beiden Aspekte welche in ihrer Gestaltung einem kurzgefassten Lehrgang für Mediziner und Biologen entsprechen. Einzelne Interessierte beanspruchen eigene Beobachtungen von K. H. ALBRECHT und in einem weiteren Kapitel von A. MÖRZEL über hämatologische Veränderungen bei therapeutisch bestrahlten Patienten. Die Diskussion der Behandlung der Polyrhythmie mit Radionuklidphosphor basiert teilweise ebenfalls auf eigenen Untersuchungen von E. W. DÖRFFEL, S. MÖRZEL und R. VOLLMER. Die Autoren schätzen das Risiko dieser Behandlung als gering ein; sie beobachteten beispielsweise in einer Serie von 251 mit Radionuklidphosphor behandelten Patienten nur 5 Fälle welche in eine Leukämie übergingen. Die Referate über das akute Strahlensyndrom, die Überwachung von strahlenexponierten Personen und die Anwendung radioaktiver Nuklide für diagnostische Zwecke enthalten nur wenig Angaben, welche nicht ausführlicher in den neueren Lehrbüchern der Nuklearmedizin auffindbar wären.

E. BUCK, Basel

J. E. CLEAVER. *Thymidine Metabolism and Cell Kinetics*, in *Frontiers of Biology* Vol. 6. North. Holland Publ. Co., Amsterdam 1967. 259 S. Preis Hfl. 43.

This book is an excellent example of the value of the introduction of a new basic method in the field of biology. Owing to the specificity of Thymidine for DNA, tremendous advances were made in the study of the kinetics of cell population by using radioactive derivatives of Thymidine. After introduction on the preparation, stability and detection of labelled thymidine the author presents detailed data on the metabolism of thymidine: the basic problems of cell kinetics with particular emphasis on the behaviour of chromosomal DNA. The book will serve as a valuable textbook and a very complete reference on this basic topic.

P. FALCK, Zürich

**Automation in Haematology** Proceedings of a symposium held at the 11th Congress of the International Society of Haematology Brit. J. Haemat., supplementum ad vol. 11 April 1967 Hrg. S. M. LARSEN. 73 Seiten. Preis 21 sh.

Nachdem automatisierte Methoden in zunehmendem Masse auch in hämatologischen Laboratorien Anwendungsbereiche finden und propagiert werden, erscheint eine kritische Standortbestimmung heute besonders wertvoll. Die vorliegende Zusammenstellung enthält Übersichtsreferat über die Planung Standardisierung und praktische Anwendung, aber auch erst Ergebnisse automatisierter Methoden, beispielsweise in der Blutgruppenserologie. Die Beiträge dieser kleinen Monographie können gewinnhaft gewürdigt werden: sie zeigen in klarer Form, dass eine gewisse Automatisierung in der klinisch orientierten und experimentellen Hämatologie in naher Zukunft unentbehrlich sein wird: sie wird, bei sachgerechter und kritischer Anwendung, repetitive Arbeitsgänge rationalisieren, die qualitativen Reproduzierbarkeit erhöhen und vor allem geschultes Personal zugunsten produktiverer Arbeit entlasten.

Die Automatisierung wird dann ihre volle Wirksamkeit erreichen, wenn sie nicht nur eine Rationalisierung der Arbeitsmethoden, sondern auch die Möglichkeit einer internationalen Standardisierung hämatologischer Untersuchungsmethoden mit sich bringt. Die in dem vorliegenden Heft enthaltenen Empfehlungen des International Committee for Standardization in Haematology sind richtungsgewand.

E. BUCK, Basel

---

## Varia

---

### International Council of Nurses

Since August 1966, Geneva has been the headquarters of the International Council of Nurses, a world-wide organization to which 63 national nurses associations are affiliated. The Council decided to transfer its headquarters from London to Geneva so as to maintain closer relations with the World Health Organization and similar international organizations with nursing interests.

The publication of the *International Nursing Review*, official journal of the International Council of Nurses, is one of the Council's principle undertakings. Other publications include *ICN Calling* (the ICN news letter containing news of topical interest) and information leaflets in three languages, and other publications of professional interest.

In 1969 the International Council of Nurses - possibly the largest women professional association in existence - is holding an international congress in Montreal, which nearly 12,000 nurses from most parts of the world are expected to attend.

### Deutsche Gesellschaft für Hämatologie

Auf der 13. Tagung der Deutschen Gesellschaft für Hämatologie in Ulm/Donau wurde Prof. Dr. K. Lison (Kiel) zum neuen Kongress-Präsidenten für 1969 gewählt. Die nächste Tagung der Gesellschaft wird in der ersten Septemberwoche 1969 in Kiel stattfinden. Prof. Dr. W. Siron (München) wurde für die Zeit von 1968-1970 zum Vorsitzenden der Gesellschaft wiedergewählt. Dr. R. G. von Bonhoff (Freiburg/Breisgau) wurde zum neuen Sekretar der Gesellschaft gewählt.

Auf der Tagung wurde außerdem ein Ausschuss für die Vorbereitung des XIII. Kongresses der Internationalen Gesellschaft für Hämatologie gebildet, der 1970 in München unter dem Präsidium von Prof. Dr. L. Hestmark (Ulm) stattfinden wird.

### II. International Symposium on Foeto-Maternal Incompatibility

Bruscha, November 15 and 16, 1968

Round table on the Prophylaxis of Rhesus(D)-immunisation by pregnancy with immunoglobulin.

Plenary session, subjects: 1 Analysis of amniotic fluid (bilirubin, hormones, cells, proteins, etc.) 2 Differential diagnosis of neonatal icterus (blood group incompatibility, breast feeding-icterus, erythrocyte anomalies, etc.)

Symposium Secretariat: Dr. C. Vismeyer, Blood Transfusion Centre, O-L. Viersmastraat 42, Leuven, Belgium.

# Index rerum ad Vol.39

Bearbeitet von G. Böttger, Basel

(B) = Book review · Buchbesprechungen · Livres revus

ABO blood group decreased formation of erythrocyte antigen A and constant chromosome abnormality in patient with myelomonocytic leukaemia, 309

ABO hemolytic disease; differences between the red cell acetylcholinesterase defects of paroxysmal nocturnal hemoglobinuria and of ABO hemolytic disease 85

Acetylcholinesterase; differences between the red cell acetylcholinesterase defects of paroxysmal nocturnal hemoglobinuria and of ABO hemolytic disease 85

Acide folique Folique acide

Actualités hématologiques, 62 (B)

Advance, Transplantation

Agglutination, v. Physikemagglutination

AHF (= Antihæmophilic factor = AHG A) Factor VIII

Algeria (= *Portuguese province*) hæmoglobin J Paris in the South of *Portugal (Algeria)* 291

Alkaline phosphatase activity in leukocytes of some animal species, 51

Alpha-chain synthesis hæmoglobin H as an acquired defect of alpha-chain synthesis (Report of two cases) 81

Alpha-naphthyl- $\beta$ -acetate Monocytes

Alpha-Thalassaemia G-5-PD-Mangel mit Hämoglobinsynthese und alpha-Thalassaemia 167

Aminocaproic acid ( $\alpha$ -aminocaproic acid) Fibrinolysin, Fibrinolysin inhibitors

p-Aminomethylbenzoic acid, Fibrinolysin

Aminomethyl- $\beta$ -cyanoheptano-carboxylic acid, Fibrinolysin, Fibrinolysin inhibitors

Anemia, aplastic, and myelocytosis,  $Fe^{59}$  and  $Cr^{51}$  studies, 159

Anemia, megaloblastic, of children, chromosomal study 29

Anemia mediterranea, Alpha Thalassaemia Beta-thalassaemia, Thalassaemia minor

Anemia Erythroblastopénie

Anémie Erythroblastopénie

Anephric state Erythropoietin

Animal species; alkaline phosphatase activity in leukocytes of some animal species, 51

Antibody and DNA synthesis in vitro, following antigenic stimulus (Studies in rabbit peripheral lymphocytes I.) 223

Blast transformation, Blastoid transformation, Lymphocytransformation

Anticoagulants, circulating investigation of circulating anticoagulants against AHF (= factor VIII) in three patients with hæmophilia A, 214

Anticoagulant drug therapy Erythroblastopénie

Antigenic stimulus; DNA and antibody synthesis in vitro, following antigenic stimulus (Studies in rabbit peripheral lymphocytes I.) 223

Blast transformation, Blastoid transformation, Lymphocytransformation

Antihæmophilic factor (= AHF = AHG A) Factor VIII



Antihæmophilic globulin B (= Factor IX = PTC) v Christmas factor

Antihæparin activity v Christmas factor

Antistreptolysin Untersuchungen zur Korrelation von Lymphocyten-transformation durch Streptolysin O in vitro und Antistreptolysin 276

→ v Antibody 'Blast transformation, Blastoid transformation

Aplastic anaemia and myelocytosis, Fe<sup>59</sup> and Cr<sup>51</sup> studies, 139

Autohaemolysis, v Haemolytic syndrome, unusual

Automation in hematology (Symposium at the VI Congress of the International Society of Haematology) 381 (B)

Autoradiographic Technik, 127 (B)

→ Erythroblast

Avitaminosis B<sub>12</sub>, Baboons

Baboons isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 118

Baboon, Baboons

Basic lymphology, new trends (Symposium t Charleroi, 1966) 362 (B)

Basophile Zellen zur Natur der stark basophilen Zellen in der Doctus thoracicus-Lympho 282

Beta-thalassemia, heterozygous, and hereditary spherocytosis (A family study) 183

Pyruvate-kinase deficiency

Biological fluids, protides, Protides

Blast transformation of lymphocytes cells of human lymphocyte blast transformation by homologous RNA, 270

Antibody Blast transformation, Lymphocyten transformation

Blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 373

Antibody 'Blast transformation Lymphocyten transformation

Bleeding, Thrombocytosis, posthaemorrhagic

Blood B<sub>12</sub> cytochemical demonstration of dihydroorotic dehydrogenase in blood and bone marrow cells, 203

Blood coagulation, v Christmas factor Factor VIII Fibrinolysis, Fibrinolysis inhibitors, Hageman factor deficiency

Blood groups an introduction to blood group serology (3rd ed.) 127 (B)

→ v ABO group, ABO hemolytic disease

Blutfremde Zellen im strömenden Blut (Leberparenchymzellen) 243

Blutplättchen, Platelets

Bone marrow cytochemical demonstration of dihydroorotic dehydrogenase in blood and bone marrow cells, 203

→ isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 118

v Erythroblast, Erythroid hyperplasia, Monocytes, Myelocytosis

Calcium chloride density gradient centrifugation, v DNA, satellite

Cancer the inheritance of leukaemia and cancer 174

Cancer chemotherapy two week course (Houston, Texas, 13-14th May 1968) 23

Celis familiaris, v Dog

Carbamazepine Carbamazepin

Carbamyl-5H-dibenz(h,f)azepin (= Tégretol®), Erythroblastopenic Cell, v Elektrolyte (B)

Cell cultures, v Antibody 'Blast transformation, Blastoid transformation, Lymphocyten transformation

Cell kinetics and thymidine metabolism (Frontiers in biology vol. 6), 381 (B)

Chains, polypeptide chains, Haemoglobin H

Chemotherapy: two week course in cancer chemotherapy (Houston, Texas 13-24th May 1968), 23

Chien, v Dog

Children chromosomal study in megaloblastic anaemia of children, 29

→ v Erythrocytosis

Christmas factor the clotting activity of congenital factor IX deficient (Christmas) serum, 13

Chrom Aplastic anaemia, Thalassemia minor

Chromosomal study in megaloblastic anaemia of children, 29

- Chromosome abnormality decreased formation of erythrocyte antigen A and consistent chromosome abnormality in patient with myelomonocytic leukaemia 309
- Chromosome studies, v Haemoglobin H
- Chromosomes multiple chromosomal aberrations in a case of malignant myelodysplasia, 299
- ; Ph<sup>1</sup>-theory and prognosis in chronic myelogenous leukaemia, 102
- Chronic lymphocytic leukaemia the inheritance of leukaemia and cancer 174
- Circulating anticoagulants Investigation of circulating anticoagulants against APTT (= factor VIII) in three patients with haemophilia A, 214
- Clotting activity of protein fractions of congenital factor IX deficient (Christmas) serum, 15
- Coagulation of blood, v Christmas factor Factor VIII, Fibrinolysis, Fibrinolysis inhibitors, Hageman factor deficiency
- Colloquium, XVIII, Brugis (Problems of the biological fluids) May 1-3, 1968, 192
- Come for over 5 weeks, 320
- Conference Colloquium
- Congenital erythrocytosis, Erythrocytosis
- Congenital factor IX deficient (Christmas) serum, clotting activity of protein fractions, 15
- Congress, XIIth, of the International Society of Haematology (New York, September 1-6, 1968) 320
- Congress, Colloquium, Microcirculation, Symposium
- Cootner's anaemia, Alpha-Thalassaemia Beta-Thalassaemia
- Cr<sup>51</sup> and Fe<sup>59</sup> studies in aplastic anaemia and myelodysplasia, 179
- Cr<sup>51</sup> v Thalassaemia minor
- CsCl (density gradient centrifugation) DNA, satellite
- Culture des cellules, Antibody Blast transformation, Blastoid transformation, Lymphocyten transformation
- Culture des tumeurs, Culture des cellules
- Cytidine (H<sup>3</sup>-cytidine), v Blastoid transformation
- Cytochemical demonstration of dehydroarotic dehydrogenase in blood and bone marrow cells, 203
- Cytochemistry v Acetylcholinesterase Alkaline phosphatase, Driscoll's cells G-6-PD<sup>+</sup>, Monocytes, Myelodysplasia
- Cytogenetic study Haemoglobin H, Megaloblastic anaemia, Myelodysplasia
- Cytological and isotopic estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 118
- Cytologie; étude cytologique de la transformation aigue d'une leucémie myélocytair chronique, 249
- Cyto<sup>+</sup>, v Zyto<sup>+</sup>
- Deoxyribonucleic acid, v DNA, Erythroblast, Thymidine metabolism (B)
- Deoxyribonucleic acid, satellite DNA, satellite
- Density gradient centrifugation, analytical, v DNA, satellite
- Deoeculation of the erythroblast, studies on the mechanism, 193
- De Goozeno syndrome, v Haemoglobin H
- Dehydroarotic acid dehydrogenase, cytochemical demonstration in blood and bone marrow cells, 203
- DNA (= deoxyribonucleic acid) and antibody synthesis in vitro, following antigenic stimulus (Studies on rabbit peripheral lymphocytes L) 223
- Blast transformation, Blastoid transformation, Lymphocyten transformation
- DNA, satellite; presence of satellite DNA (= deoxyribonucleic acid) in normal and leukemic human thymus, 75
- Dog; effect of erythroid hyperplasia on the disappearance rate of erythropoietin in the dog, 42
- Driscoll's cells, Zytotechnik 237
- Ductus thoracicus-Lymph; zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymph, 282
- Elena, v Aplastic anaemia, Baboon, Erythropoietin, Haemoglobin H, Thalassaemia minor

Electron microscope, v Basophile Zellen

Electrophoresis, v Alpha Thalassemie, Haemoglobin D Haemoglobin H, Haemoglobin J Paris, Spherocytosis

Elektrolyte intrazelluläre, Transport und Funktion (Symposium, Schüren, 1967) 382 (B)

Enfants, v Erythrocytosis, Megaloblastic anaemia

Entkernung der Erythroblasten v Erythroblast

Enzymes, v Ferments

Épileptique: érythroblastopénie non mégaloocytaire et sensible à l'acide folique chez un épileptique 159

Epsilon-aminocaproic acid, v Fibrinolysis, Fibrinolysis inhibitors

Erythroblast studies on the mechanism of demarcation of the erythroblast, 183

Erythroblastopénie non mégaloocytaire et sensible à l'acide folique chez un épileptique, 159

Erythrocyte antigen A, decreased formation, and consistent chromosome abnormality in a patient with myelomonocytic leukaemia, 309

Erythrocytenstoffwechsel und Erythrokinetik bei Thalassemia minor Untersuchungen 333

Erythrocyten (Stoffwechsel und Membranpermeabilität) v Symposium

Erythrocytes - differences between the red cell acetylcholinesterase defects of paroxysmal nocturnal hemoglobinuria and of ABO hemolytic disease, 85

- transketolase activity of red blood cells in conditions of haematological interest, 321

Erythroblast, G-6-PD-, Pyruvatekinase deficiency Spherocytosis

Erythrocytosis, familial (A report of two cases, and review) 65

Erythroid activity of bone marrow v Erythropoiesis

Erythroid hyperplasia, effect on the disappearance rate of erythropoietin in the dog, 42

Erythrokinetik und Erythrozytenstoffwechsel bei Thalassemia minor Untersuchungen, 333

Erythroleukaemia Haemoglobin H

Erythropoiesis zur erythropoetischen Wirkung von Testosteron, 366

-; isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 118

Erythropoiesis, disturbance Haemoglobin H

Erythropoietin effect of erythroid hyperplasia on the disappearance rate of erythropoietin in the dog, 42

- extra-renal production of erythropoietin in man, 359

Espèces d'animaux (phosphatase des leukocytes), v Animal species

Extense non-specific (NaF sensitive), v Monocytes

European Society of Haematology Xth Congress, Strasbourg, 1963, proceedings (Part I and II) 362 (B)

European Society for Microcirculation, 5th Conference (as an International Conference) Gothenburg, June 24-29, 1968, 192

Expiration du rein, Erythropoietin

Extra-renal production of erythropoietin in man, 359

Extension of the model, v Erythroblast

Factor VIII (= AHF = AHG A) investigation of circulating anticoagulants against AHF (= Factor VIII) in three patients with haemophilia A, 214

Factor IX; the clotting activity of protein fractions of congenital factor IX deficient (Christmas) serum, 13

Factor XII; Hageman factor deficiency (Report of case found in Japanese girl), 86

Familial erythrocytosis (A report of two cases, and review) 65

Families, Alpha Thalassemie, Factor XII, Haemoglobin J Paris, Pyruvatekinase deficiency Spherocytosis

Favismus, v Alpha-Thalassemie

Fe<sup>59</sup> and Cr<sup>51</sup> studies in aplastic anaemia and myelodysplasia, 139

Fe<sup>59</sup> Baboons, Erythroid hyperplasia, Erythropoietin, Haemoglobin H, Thalassemia minor

Feinstruktur v Basophile Zellen

Fer v Aplastic anaemia, Baboons, Erythropoietin, Haemoglobin H, Thalassemia minor

- Ferments, v. Acetylcholinesterase Alkaline phosphatase Dihydroxyotic acid dehydrogenase Drüsenfieberzellen, Glucose-6-phosphatdehydrogenase-Mangel, G-6-PD—, Monocytes, Nitrocatecholoxidase Thalassemia minor Transketolase Pyruvate-kinase deficiency
- Ferrokinetic studies, v. Haemoglobin H
- Fibrinolysis; comparative studies on inhibitors of fibrinolysis in vitro and in vivo, 1
- Fibrinolysis inhibitors high obstruction of urine flow as complication of the treatment with fibrinolysis inhibitors of haematuria in haemophilias, 237
- Fine structure, v. Basophile Zellen
- 'Flager priaz' Alpha-Thalassaemia, Haemoglobin J Paris
- Foie, Leberparenchymzellen
- Foetus, acide; erythroblastopénie non mégalocytaire et sensible à l'acide folique chez un épileptique, 159
- Funktion und Transport intrazellulärer Elektrolyte (Symposium, Schöden, 1967) 382 (B)
- Genetics, Alpha-Thalassaemia, Erythrocytosis, Haemoglobin D Haemoglobin J Paris, Hageman factor deficiency Pyruvate-kinase deficiency Spherocytosis
- Gesellschaft, v. Microcirculation
- Gewebekultur Antibody Tissue transformation, Mastoid transformation, Lymphocytestransformation
- Glucose-6-phosphatdehydrogenase Mangel mit Hämoglobinopathie und alpha-Thalassaemia, 167
- Glucose-6-phosphat dehydrogenase, Acetylcholinesterase
- G-6-PD (= Glucose-6-phosphat dehydrogenase) - Mangel mit Hämoglobinopathie und alpha-Thalassaemia, 167
- Grupe, RUTTER—
- Groupes sanguins, ABO blood group, ABO hemolytic disease, Blood groups
- Haematological disease, unusual, an unusual haematological syndrome with pyruvate-kinase deficiency and thalassemia minor in the kindreds, 345
- Haematological diseases; transketolase activity of red blood cells in conditions of haematological interest, 321
- Hämatologie; Strahlenschäden und Strahlenhämatologie (Schriftenreihe der Ärztlichen Fortbildung, Bd. 31) 381 (B)
- Hématologie (B)
- Haematology; automation in haematology (Symposium at the XIth Congress of the International Society of Haematology) 381 (B)
- ; XIIth Congress of the International Society of Haematology (New York, September 1-5, 1968) 320
- proceedings of the XIth Congress of the European Society of Haematology Strasbourg, 1963 (Part I and II), 382 (B)
- Haematopoietic cells, Bone marrow cells
- Hämatopoietin v. Erythropoietin
- Hämaturopa; high obstruction of urine flow as complication of the treatment with fibrinolysis inhibitors of haematuria in haemophilias, 237
- Haemoglobin E & Los Angeles (D Punjab,  $\alpha_2\beta_2$  121 Glu NH<sub>2</sub>) in Thai family 151
- Haemoglobin H as an acquired defect of alpha-chain synthesis (Report of two cases) 91
- Haemoglobin H, Alpha-Thalassaemia
- Haemoglobin J Paris in the South of Portugal (Algarve) 291
- 'Haemoglobin Koefiker'; remarks on the so-called 'Haemoglobin Koefiker' 60
- answer to the remarks on 'Haemoglobin Koefiker' of Benini, Filippi, Cacci and Maggioni, 61
- Haemoglobin plasma modified (HbPM), 'Haemoglobin Koefiker'
- Haemoglobin Typ Mexico Alpha-Thalassaemia
- Hämoglobinopathie; G-6-PD-Mangel mit Hämoglobinopathie und alpha-Thalassaemia, 167
- Haemoglobinuria, paroxysmal, nocturnal, v. Paroxysmal nocturnal hemoglobinuria
- Haemolysis, ABO hemolytic disease
- Haemolytic syndrome, unusual, an

- unusual haematological syndrome with pyruvate-kinase deficiency and thalassaemia minor in the kindreds, 345
- Haemophilia; World Federation of Hemophilia. International Symposium (Montreal, 26-28th August 1968) 63
- Haemophilia A. Investigation of circulate log anticoagulants against AHP (= factor VIII) in three patients with haemophilia A, 214
- Haemophilias; high obstruction of urine flow as a complication of the treatment with fibrinolytic inhibitors of haematuria in haemophilias, 237
- Haemorrhage v Thrombocytosis, post haemorrhagic
- Hageman factor (= Factor XII) deficiency (Report of a case found in Japanese girl) 36
- H antigen, v ABO blood group
- Hb D v Haemoglobin D
- Hb H, v Haemoglobin H
- Hb J Paris, v Haemoglobin J Paris
- Hb Koelliker v 'Haemoglobin Koelliker'
- HbPM, v Haemoglobin plasma modified
- Hb 'Typ Mexico' v Haemoglobin 'Typ Mexico'
- H<sup>3</sup>-cytidine, v Blastoid transformation
- Hématologie actualités hématologiques, 62 (B)
- Hemoglobin H as an acquired defect of alpha-chain synthesis (Report of two cases) 91
- Hemoglobin H v Haemoglobin H
- Hemophilia, v Haemophilia
- Hepar v Leberparenchymzellen
- Heparin (antibeparin activity) v Christmas factor
- Hereditary spherocytosis and heterozygous beta-thalassaemia (A family study) 183
- Hereditary Alpha-Thalassaemic, Beta-thalassaemia, Christmas factor Erythrocytosis, Haemoglobin D Haemoglobin J Paris, Hageman factor deficiency H hereditary spherocytosis, Pyruvate-kinase deficiency Thalassaemia
- Heterozygous beta-thalassaemia, v Hereditary spherocytosis
- Histochemistry v Acetylcholinesterase, Alkaline phosphatase, Dihydroorotic acid dehydrogenase, Drüsenfächerzellen, G-6-PD..., Monocytes
- Homologous RNA, v Ribonucleic acid, homologous
- Homotransplantation, v Erythropoietin (extra-renal)
- Homotransplantation reactions, v Lymphocytes
- Hormones, v Erythropoiesis, Erythropoietin
- H<sup>3</sup>-thymidine, v Blastoid transformation, Erythroblast, Thymidine metabolism (B)
- Human blood platelets, nitrocatechol-sulfatase, 129
- Human lymphocyte; delay of human lymphocyte blast transformation by homologous RNA, 270
- v Antibody Blastoid transformation, Lymphocytestransformation
- Human thymus (normal and leukemic), v DNA, satellite
- Hund, v Dog
- Hypoxia, v Erythropoiesis
- Immunoblasts, v Lymphocytestransformation
- Immunological activities, v Lymphocytes
- Infectious mononucleosis, v Mononucleosis infection
- Inheritance of leukaemia and cancer 174
- Inhibitors of fibrinolysis in vivo and in vivo, comparative studies, 1
- International Conference on Microcirculation (3th Conference of the European Society for Microcirculation) Gothenburg, June 24-29, 1968, 192
- International Congress, 1st, of the Transplantation Society 1967 proceedings (Advance in transplantation) 383 (B)
- International Council of Nurses, 384
- International Society of Haematology XIIth Congress (New York, September 1-6, 1968) 320
- International Symposium on Hemophilia, Montreal, 26-28th August

- 1968 (World Federation of Hemophilia) 611
- Internationales, (I.) Symposium über Stoffwechsel und Membranpermeabilität von Erythrocyten und Thrombocyten, Wien 17-20. Juni 1968, 63
- Intrazelluläre Elektrolyte v. Elektrolyte (B)
- Introduction to blood group serology (3rd ed.) 127 (B)
- Iode, radioactive Fibrinolyse
- Iron, Aplastic anaemia, Baboon, Erythroid hyperplasia, Erythropoietin, Haemoglobin H, Thalassemia minor
- Irradiation, v. Strahlenschäden (B)
- Isotope, radioactive, Aplastic anaemia, Autoradiographie (B), Baboon, Blastoid transformation, Erythroblast, Erythroid hyperplasia, Erythropoietin, Fibrinolyse, Haemoglobin H, Thalassemia minor
- Isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 118
- Jakob's anomaly (partial) Pyruvate-kinase deficiency
- J<sup>m</sup> Fibrinolyse
- Japanese girl, v. Hageman factor deficiency
- JULLARD JEAN JULLARD prize, 320
- Kanischen, Rabbit
- Karyogram, Megaloblastic anaemia, Myelomonocytic leukaemia Myelocytosis
- Kerne, Karyogram
- Kerne (Eosinophilie der Erythroblasten) Erythroblast
- Kidney v. Erythropoietin (extra-renal)
- Kidney blockade, Fibrinolyse labilizers
- Kinder Erythrocytosis, Megaloblastic anaemia
- Kindred, Pyruvate-kinase deficiency
- Knochenmark, Bone marrow Erythroblast, Erythroid hyperplasia, Monocytes, Myelocytosis
- Korea, Coon
- Kongenital, Congenital
- Kongress, Colloquium, Congress, Microcirculation, Symposium
- Lapin, Rabbit
- Lebensdauer der Erythrocyten v. Erythrokinetik
- Leberparenchymzellen im Leukocytenkonzentrat, Blutfremde Zellen im strömenden Blut, 243
- Letter to the editor (Haemoglobin Koefiker) 60
- Leucémie, myélocytair; étude cytologique de la transformation aiguë d'une leucémie myélocytair chronique, 249
- Leukemia preleukemia (A report of four cases) 20
- process of satellite DNA in normal and leukemic human tissues, 75
- Leukemia, lymphocytic, chronic the inheritance of leukemia and cancer 174
- Leukemia, myeloblastic, v. Myelocytosis
- Leukemia, myelogenous, chronic; Philadelphia and prognosis in chronic myelogenous leukemia, 102
- Leukemia, myeloid, chronic, Leucémie myélocytair
- Leukemia, myelomonocytic decreased formation of erythrocyte antigen A and consistent chromosome abnormality in patient with myelomonocytic leukemia, 309
- Leukocytes of some animal species, activity of alkaline phosphatase, 31
- Leukocytenkonzentrat; blutfremde Zellen im strömenden Blut (Leberparenchymzellen) 243
- Libri, 62 (B) 127 (B) 381 383 (B)
- Liver Leberparenchymzellen
- Los Angeles, Haemoglobin D
- Lymph des Ductus thoracicus zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymph, 282
- Lymphocyte culture delay of human lymphocyte "blast" transformation by homologous RNA, 270
- Antibody Blastoid transformation, Lymphocytentransformation
- Lymphocytenzahl methode bei Streptococcus (I) (II) mit Antistreptolysin Ureter hängen zu deren Aussehen 270
- Lymphocyte line human Lymphocytes, 174

- Lymphocytes, 'blast' transformation; delay of human lymphocyte 'blast' transformation by homologous RNA, 270
- v Antibody- Lymphocytes, blastoid transformation Lymphocytentransformation
- Lymphocytes, blastoid transformation; blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 373
- v Antibody- Lymphocytes, 'blast' transformation Lymphocytentransformation
- Lymphocytes, peripheral blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using a microculture technique, 373
- v Antibody- Lymphocytes, 'blast' transformation Lymphocytentransformation
- Lymphocytes, peripheral, of rabbit, studies (L: DNA and antibody synthesis in vitro, following antigenic stimulus) 223
- v 'Blast' transformation, Blastoid transformation, Lymphocytentransformation
- Lymphocytes, v Drüsenfieberzellen
- Lymphocytic leukaemia, chronic the inheritance of leukaemia and cancer 174
- Lymphology: new trends in basic lymphology (Symposium at Charleroi, 1966) 382 (B)
- Malignant myelocytosis multiple chromosomal aberrations in case of malignant myelocytosis, 299
- Man extra-renal erythropoietin production in man, 339
- v Human lymphocyte, Platelets
- MARCHAFAVA-MICHELLI, Paroxysmal nocturnal hemoglobinuria
- Marrow fibroblast activity in normal and riboflavin deficient baboons, isotopic and cytological estimations, 118
- Maturation of erythrocytes, v Erythroblast
- Maus, Mice
- Mechanism of denudation of the erythroblast studies 193
- Mediterranean anaemia, Alpha-Thalassaemia, Beta-thalassaemia, Thalassaemia minor
- Medulla osseum, v Bone marrow Erythroblast, Erythroid hyperplasia, Monocytes, Myelocytosis
- Megakaryocyte response in posthaemorrhagic thrombocytosis of mice, 112
- Megaloblastic anaemia of children, chromosomal study 29
- Megalocytes, v Erythroblastopóide
- Membranpermeabilität (Erythrocytes und Thrombocyten) v Symposium
- Metabolismus, v Erythrocyten (Stoffwechsel-) Erythrocytenstoffwechsel
- Methode, Autorisation (B), Autoradiographie (B) Blastoid transformation (microculture)
- Mice megakaryocyte response in post haemorrhagic thrombocytosis of mice, 112
- MICHELLI, v MARCHAFAVA...
- MICHELLI, v BRETTE...
- Microautoradiographie, Autoradiographie (B) Erythroblast
- Microcirculation European Society for Microcirculation, 5th Conference (as an International Conference) Gothenburg, June 24-29 1968, 182
- Microculture; blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 373
- v Antibody Blast transformation, Lymphocytentransformation
- Microscope électronique, Basophile Zellen
- Mocle osseum, v Bone marrow Erythroblast, Erythroid hyperplasia, Monocytes, Myelocytosis
- Monocytes on the origin of monocytes, 177
- Monocytic leukaemia, v Myelomonocytic leukaemia
- Mononucleosis infection; zur Zytochemie der Drüsenfieberzellen, 257
- Mouse, v Mice
- Mus musculus, v Mice
- Myeloblastic leukaemia, v Myelocytosis
- Myeloid leukaemia, v Leucämie, myelocytäre

- Myelogenous leukaemia, chronic Ph<sup>1</sup>-disomy and prognosis in chronic myelogenous leukaemia, 102
- Myelomonocytic leukaemia decreased formation of erythrocyte antigen A and consistent chromosome abnormality in patient with myelomonocytic leukaemia, 309
- Myeloclerosis and phagocytosis, Fe<sup>59</sup> and Cr<sup>51</sup> studies, 139
- Myeloclerosis, malignant; multiple chromosomal aberrations in case of malignant myeloclerosis, 299
- NaF sensitive esterase, v Monocytes
- Naphthol-AS-LC-acetate v Monocytes
- Natriumfluorid, Esterasehemmung, v Monocytes
- Nephrectomy v Erythropoietin
- Neutrophils, v ABO hemolytic disease
- Neutrophils, Animal species
- Newborn, v ABO hemolytic disease
- Niere, Erythropoietin (extra-renal)
- Niere, Blockierung, Fibrinolyse-Inhibitoren
- Nierenextirpation, v Erythropoietin (extra-renal)
- Nitrocatechololactase in human blood platelets, 129
- Nocturnal haemoglobinuria, paroxysmal, v Paroxysmal nocturnal haemoglobinuria
- Nouveau-né, ABO hemolytic disease
- Noyau, v Karyogram
- Noyau (erythroblasts) Nuclei
- Nuclei, studies on the development of the erythroblast, 193
- Karyogram
- Nurses International Council of Nurses, 384
- Origin of monocytes, 177
- Orotic acid, v Dihydroorotic acid dehydrogenase
- Oryctolagus cuniculus, Rabbit
- Osmotic fragility v Spherocytosis
- Papio cynocephalus, Baboons
- Paroxysmal nocturnal haemoglobinuria differences between the red cell acetylcholinesterase defects of paroxysmal nocturnal haemoglobinuria and of ABO hemolytic disease, 65
- Paran, Baboons
- Peripheral lymphocytes, Lymphocytes, blastoid transformation
- Peripheres Blut, v Leberparenchymzellen
- Ph<sup>1</sup> chromosomes Ph<sup>1</sup>-disomy and prognosis in chronic myelogenous leukaemia, 102
- ; v Myeloclerosis
- Philadelphia chromosomes, v Ph<sup>1</sup> chromosomes
- Phosphatase alkaline activity in leukocytes of some animal species, 51
- Phytohemagglutinin (= PHA); blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 373
- Antibody Blast transformation, Lymphocytentransformation
- Plaquettes sanguines, Platelets, Thrombocytes
- Plasma (Plasminogen) v Fibrinolysis
- Plasminogen activation, inhibitors, v Fibrinolysis inhibitors
- Platelets nitrocatechololactase in human blood platelets, 129
- v Thrombocytes
- Polycythemia vera, v Erythrocytosis
- Polypeptide chains, v Haemoglobin H
- Portugal haemoglobin J Para in the South of Portugal (*Agave*) \*91
- Preleukemia (A report of four cases) 20
- Prêtre JEAN JERLEARD prêtre, 370
- Proceedings of the Xth Congress of the European Society of Haematology Strasbourg, 1965 (Part I and II), 382 (B)
- Proceedings of the 1st International Congress of the Transplantation Society 1967 (Advances in transplantation), 383 (B)
- Protein fractions, clotting activity of congenital factor IX deficient (Christmas) serum, 13
- Problems of the biological fluids XVth Colloquium, Bruges, May 1-3, 1968, 192
- PTC (= Plasma thrombopoietic component = Antithrombophilic globulin B = Factor IX), Christmas factor
- Purgab, Haemoglobin D
- Pyronucleophil Zellen, Neutrophile Zellen
- Pyruvate-Masse deficiency; an unusual haematological syndrome with py-



- ruvate-kinase deficiency and thalassemia minor in the kindreds, 345
- Rabbit; blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using a microculture technique, 373
- v Antibody 'Blast' transformation, Lymphocyten transformation
- Rabbit peripheral lymphocytes, studies (I. DNA and antibody synthesis *in vitro*, following antigenic stimulus) 223
- v 'Blast' transformation, Blastoid transformation, Lymphocyten transformation
- Radiation, v Strahlenschäden (B)
- Radioautography v Autoradiography (B) Erythroblast
- Radio-chrome, v Aplastic anaemia, Thalassemia minor
- Radio-iods v Fibrinolyse
- Radio-tron, v Aplastic anaemia, Baboon, Erythroid hyperplasia Erythropoietin, Haemoglobin H, Thalassemia minor
- Red cell acetylcholinesterase defects of paroxysmal nocturnal hemoglobinuria and of ABO hemolytic disease, differences, 85
- Red cells; transketolase activity of red blood cells in conditions of haematological interest, 321
- Ren extra-renal production of erythropoietin in man, 359
- v Fibrinolysis inhibitors
- Renoprilal state, v Ren
- Riboflavin isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 118
- Ribonucleic acid (= RNA) homologous; delay of human lymphocyte 'blast' transformation by homologous RNA, 270
- Antibody Blastoid transformation, Lymphocyten transformation
- RITA-GREEN-MISCALI, Thalassemia minor
- Sardinian families, v G-6-PD...
- Satellite DNA presence of satellite DNA in normal and leukemic human tissues, 75

- Serology: an introduction to blood group serology (3rd ed.) 127 (B)
- Sitzungsberichte v Proceedings (B)
- Society XIIth Congress of the International Society of Haematology (New York, September 1-6, 1968), 320
- of Haematology European, Xth Congress, Strasbourg, 1963, proceedings (Part I and II) 362 (B)
- ; Transplantation Society 1st International Congress, 1967 proceedings (Advance in transplantation), 363 (B)
- v Microcirculation
- Sodium fluoride sensitive esterase, Monocytes
- Souris, v Mice
- Southern Portugal v Portugal
- Species, animal, Animal species
- Spherocytosis, hereditary and heterozygous beta-thalassemia (A family study) 163
- Statistische Anwertung, v ABO hemolytic disease, Erythroid hyperplasia, Lymphocyten transformation, Transketolase
- Steroide, v Testosteron
- Stoffwechsel, Erythrocytenstoffwechsel
- Stoffwechsel (Erythrocytes and Thrombocytes) v Symposium
- Strahlentherapie, Strahlenschäden (B)
- Strahlenschäden und Strahlenbiologie (Schriftenreihe der Statistischen Fortbildung Bd. 31) 361 (B)
- Streptokinase Fibrinolyse
- Streptolysin O; Untersuchungen zur Korrelation von Lymphocyten transformation durch Streptolysin O *in vitro* und Antistreptolysin 278
- v Antibody 'Blast' transformation, Blastoid transformation
- Submicroscopical structure, v Eosinophile Zellen
- Sulfatase, v Nucleosidphosphatase
- Survival time, Erythroblastik
- Symposium, International, on Hemophilia, Montreal, 25-28th August 1968 (World Federation of Hemophilia) 63
- I. Internationales Symposium über Stoffwechsel und Membranprote-

- blüht von Erythrocyten und Thrombocyten (Wien, 17.-20. Juni 1968)  
63
- Automation (B) Elektrolyte (B)  
Lymphology (B)
- Technik der Autoradiographie 127 (B)
- Technique v. Automation (B)
- Tégretol® v. Erythroblastopénie
- Testosteron zur erythropoetischen  
Wirkung von Testosteron, 366
- Thal family; haemoglobin D Los  
Angeles (D Punjab, 121 Glu NH<sub>2</sub>)  
in Thal family 151
- Thalassemia hereditary spherocyto-  
sis and heterozygous beta-thalae-  
mia (A family study) 183
- Thalassemia minor; Untersuchungen  
über Erythrokinetik und Erythro-  
zytenstoffwechsel bei Thalassemia  
minor 333
- ; as unusual haematological syndrome  
with pyruvate-kinase deficiency and  
thalassaemia minor in the kindreds,  
345
- Thalassaemie G-6-PD-Mangel mit Hä-  
moglobinopathie und alpha-Thalae-  
sämie, 167
- Therapy v. Erythroblastopénie
- Thrombocytes (Stoffwechsel und Mem-  
branpermeabilität) v. Symposium
- Thrombocytes, Platelets
- Thrombocytosis, posthaemorrhagic in  
mice, megakaryocyt response, 112
- Thrombopoietin, Thrombocytosis,  
posthaemorrhagic
- Thymidine metabolism and cell kinet-  
ics (Frontiers in biology vol. 6)  
381 (B)
- Thymidine (H<sup>3</sup>-thymidine) Blastoid  
transformation, Erythroblast
- Tierarten (Phosphatase in Leukocyten)  
Animal species
- Tissue cultures, Antibody Blast  
transformation, Blastoid transforma-  
tion, Lymphocytentransformation
- Trapaic acid (= active isomer of  
aminomethylcyclobutane-carboxylic  
acid) Fibrinolysis, Fibrinolysis in-  
hibitors
- Transactions, v. Proceedings (B)
- Transketolase activity of red blood cells  
in conditions of haematological inter-  
est, 321
- Transplantation, advance (Proceedings  
of the 1st International Congress of  
the Transplantation Society 1967)  
383 (B)
- Transplantation, Erythropoietin (ex-  
tra-renal)
- Transplantation reactions, Lympho-  
cytes
- Transport und Funktion intrazellulärer  
Elektrolyt (Symposium, Schürer,  
1967) 382 (B)
- Trasykol® Fibrinolysis
- Triphenyl, v. Oxydine, Thymidine
- Tumors, v. Cancer Cancer chemo-  
therapy
- Turtis family v. Spherocytosis
- Ultracentrifuge, analytical, DNA,  
enzymes
- Ultrastructure Basophile Zellen
- Unusual haemolytic syndrome, Hae-  
molytic syndrome unusual
- Urine flow obstruction; high obstruc-  
tion of urine flow as complication  
of the treatment with fibrinolysis in-  
hibitors of haematoma in haemo-  
philics, 237
- Vague's disease, Erythrocytosis
- Varia, 63 192, 320, 384
- Verhandlungsberichte, Proceedings (B)
- Vitamin B<sub>12</sub>, Riboflavin
- World Federation of Hemophilia (Inter-  
national Symposium, Montreal, 26-  
28th August 1968) 63
- Zellen, Elektrolyte (B)
- Zellkultur Antibody Blast trans-  
formation Blastoid transformation,  
Lymphocytentransformation
- Zellkerne, Karyogramm
- Zellkerne (der Erythroblasten) Nuclei
- Zell-, Cell-
- Zytochemie der Drüsenfibroblasten, 237
- Zyto-, Cyto-

# Index autorum ad Vol. 39

(B) = Book reviews - Buchbesprechungen - Livres nouveaux

Abbott, C.R., v Roberts, B.E.  
 Abney M., and Erdem, S., 183  
 Alessio, L., v Sofia, E.  
 Alexiou-Tertaki, V., Kome Elias, M.  
 Antoniou, J.L., v Ragen, P.A.  
 Asai, I., v Miwa, S.  
 Awai, M., Okada, S., Takabayashi, J.  
 Kubo, T., Inoue, M., and Sano, S.,  
 193  
 Bach, C., Bona, A.M., Sartoris, S.,  
 Vergnano, F., and Fazio, M., 270  
 Basti-Masomi, B., v Matranikola, N.  
 Baughan, Marjorie A., Paglia, D.E.,  
 Schneider A.S., and Valentine,  
 W.N., 343  
 Beale, D., v Marti, H.R.  
 Beale, D., Waid, P.  
 Beck, E., 331 332 (B)  
 Bernard, J. 62 (B)  
 Boorman, Kathleen E., and Dodd,  
 Barbara E., 127 (B)  
 Borion, E., Filippi, G., Cozzi, F., and  
 Maggioni, G., 60  
 Braumstetter H., v Schmahl, F.  
 Bucher U. 62 (B)  
 Bona, M., v Bach, C.  
 Castaldi, G.L., Yam, L.T., and Miwa,  
 W.J. 203  
 Cress, M., v Schmahl, F.  
 Cleaver J.E., 331 (B)  
 Collette, M., Jantet, G., and Schofle-  
 rick, E., 332 (B)  
 Corneo, G., Gostelli, E., and Poffi, E., 75  
 Cozzi, F., v Bortum, E.  
 Crevel, S. van, v van Crevel, S.  
 Drauzet, J., Hamburger J., and Maibe,  
 G. (Editors) 333 (B)  
 Davey M.G., Lawrence, J.R., Lander  
 H., and Robson, H.N., 63

de Melo, J. Martins, v Martins de  
 Melo, J.  
 Deutsch, E., and Fischer, M., 1  
 Dewhurst, F., and Poffi, L., 13  
 Dodd, Barbara E., v Boorman, Kath-  
 leen E.  
 Dubois-Ferrière, H., 249  
 Erdem, S., v Abney M.  
 Fazio, M., v Bach, C.  
 Filippi, G., v Bottini, E.  
 Floch, C.A., v Rosenzweig, A.I.  
 Fiorilli, G., v Sofia, E.  
 Fischer, M., v Deutsch, E.  
 Forti, R.W., v Roberts, B.E.  
 Foy H., Koufi, Athena, Harris  
 Ellen B., and Preston, J.K., 113  
 Frick, P., 331 332 (B)  
 Gergely G., v Krausz, F.  
 Germano, G.H., et Scholer Y. 139  
 Giusti, E., v Corneo, G.  
 Girard, J.-P., 223  
 Götz, E., und Viet, L., 243  
 Gyftaki, E., v Kome-Elias, M.  
 Hamburger J., v Drauzet, J.  
 Harris, Ellen B., v Foy H.  
 Heine, K.M., Stobbe, H., Hermann,  
 H., und Hofer E., 276  
 Herrmann, H., v Heine K.M.  
 Herz, F., Kaplan, Eugene, and Schre,  
 Elie S., 85  
 Heywood, J.D., v Rosenzweig, A.I.  
 Hofer E., v Heine, K.M.  
 Honetz, N., Moser K., Wurmata, E.,  
 und Seipel, H., 333  
 Inoue, M., v Awai, M.  
 Isterbeck, H. van, v van Isterbeck, H.  
 Jain, N.C., 51  
 Jantet, G., v Collette M.  
 Kaplan, Eugene, v Herz, F.

- Kemmer G., 127 (B)  
 Kerkecoester L., van Grevel, S.  
 Kome-Elias, M., Gyftaki, E., Alevisou-  
 Terzaki, V. and Malamou, B., 139  
 Khan, M.H., and Martin H., 299  
 Kionoglou, K.A., v Matsankotis, N.  
 Koudi, Athena, Foy H  
 Kriza, F. Gergely G., and Rák, K.,  
 112  
 Kröck, F. (Editor) 382 (B)  
 Kubo, T., Awal, M.  
 Lauder H., Davey M.G.  
 Lawrence J.R., Davey M.G.  
 Lehmann, H., Marti, H.R.  
 Lehmann, H. Trincão, C.  
 Lehmann, H., Wasil, P.  
 Lewis, S.M. (Editor), 381 (B)  
 Lorkin, P.A., Trincão, C.  
 Maggiori, G., Bocini, E.  
 Malamou, B., Kome-Elias, M.  
 Mazonis, F. Matsankotis, N.  
 Markkanen, T., 321  
 Marti, H.R., Lehmann, H., and Brak  
 D., 61  
 Martin, H., Khan M.H.  
 Martins de Melo, J. v Trincão, C.  
 Marbe, G., v Daumet, J.  
 Matsankotis, N. Kionoglou, K.A.,  
 Mazonis, F. and Banti-Mazonis, B., 29  
 McGuire, Patricia, Ragen, P.A.  
 Melo, J. Martins de Martins de  
 Melo, J.  
 Meulen, van der., v Moll van Cha-  
 ranke-van der Meulen, C.G.  
 Mirand, E.A., Murphy G.P., Steeves,  
 R.A., Weber H.W. and Rietig,  
 F.P. 359  
 Mitus, W. J., v Castaldi, G.L.  
 Miwa, S., Asai, I., Tinkada, T., Shi-  
 mizu, M., Teramura, A., and Su-  
 naga, Y., 36  
 Moll van Charante-van der Meulen,  
 C.G., van Grevel, S.  
 Mochtar I.A., van Grevel, S.  
 Moser K., Honetz, N.  
 Motobsky A.G., Rosenzweig, A.I.  
 Murphy G.P. Mirand, E.A.  
 Muts, J.P. and Watek, M., 42  
 Na-Nakorn, S., Wasil, P.  
 Neumann, E., Honetz, N.  
 Ohada, S., Awal, M.  
 Pabis, A., Salla, E.  
 Pagin, D.E., Baughman, Marjorie A.  
 Pascha G.N. v van Grevel, S.  
 Pedersen, B., 102  
 Pollick, J. v Rotreckl, B.  
 Poller L., v Dewhurst, F.  
 Poll, E., v Cornes, G.  
 Postakul, S., Wasil, P.  
 Preston J.H., Foy H  
 Pyrah, R.D. v Roberts, B.E.  
 Rák, K., v Kriza, F.  
 Ragen, P.A., McGuire, Patricia, and  
 Antonius, J.L., 309  
 Redetzky H., und Thiele, H. (Edi-  
 tors) 381 (B)  
 Rietig, F.P. Mirand, E.A.  
 Roberts, B.E., Abbott, C.R., Fort  
 R.W., and Pyrah, R.D., 20  
 Robson H.N. Davey M.G.  
 Rogers, A.W. 127 (B)  
 Rosenzweig, A.I., Heywood, J.D.,  
 Motobsky A.G., and Finch, C.A., 91  
 Rotreckl, B., and Pollick, J. 129  
 Sabesin, S.M., 373  
 Sartoris, S., Bachi, C.  
 Scheyr Elias S., v Herz, F.  
 Schmahl, F. and Brausteiner H., 177  
 Schmahl, F. Ceresa, M. and Braun-  
 steiner H., 257  
 Schnappauf, H., und Schmorl B., 282  
 Schneider, A.S., Baughman, Marjorie A.  
 Schmorl B., v Schnappauf, H.  
 Schoofenich, E., v Colette M.  
 Scholer Y. v Germino, G.  
 Seipel, H., Honetz, N.  
 Sero, S., Awal, M.  
 Shimizu, M., v Miwa, S.  
 Shirakura, T. 366  
 Steeves, R.A., Mirand, E.A.  
 Seibbe, J., van Grevel, S.  
 Seobbe, H., Heine, K.M.  
 Salla, E., Florell, G., Akaso, L., and  
 Pabis, A., 167  
 Sunaga, Y. Miwa, S.  
 Sussman, L., 127 (B)  
 Takebayashi, J. Asai, M.  
 Teramura, K., v Miwa, S.  
 Thiele, H., Redetzky H.  
 Thölen, H., 362, 383 (B)  
 Traill, M.A., 174  
 Trincão, C., Martins de Melo, J.,  
 Lorkin, P.A., and Lehmann, H., 291  
 Tinkada, T. Miwa, S.  
 Valentine, W.N., Baughman, Marjo-  
 rie A.

- van Aakst., v Vedder-van Aakst, G.D.  
 van Creveld, S., Mochtar J.A., Moll  
 van Charante-van der Meulen, C.C.,  
 Pascha, C.N. and Seibbe, J. (and  
 Kerkmeester L., and Vedder-van  
 Aakst, G.D.), 214  
 van der Meulen, C.C. Moll van Cha-  
 rante-van der Meulen, v Moll van  
 Charante-van der Meulen, C.C.  
 van Iitterbeck, H., Vermeyken, J., and  
 Verstraete, M., 237
- Vedder-van Aakst, G.D., v van Cre-  
 veld, S.  
 Vergnano, F., v Bachl, C.  
 Vermeyken, J. v van Iitterbeck, H.  
 Verstraete, M., v van Iitterbeck, H.  
 Vitez, L., v Götz, E.  
 Was, P., Pootrakul, S., Na-Nakorn, S.,  
 Beale, D. and Lehmann, H., 151  
 Weber H.W., v Mirand, E.A.  
 Witzel, M., v Naetz, J.P.  
 Yam, L.T. v Castaldi, G.L.

